FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Levi, JE
   Telles, PR
   Scrivani, H
   Campana, G
AF Levi, Jose Eduardo
   Telles, Paulo Roberto
   Scrivani, Hommenig
   Campana, Gustavo
TI Lack of association between ABO blood groups and susceptibility to
   SARS-CoV-2 infection
SO VOX SANGUINIS
LA English
DT Letter; Early Access
C1 [Levi, Jose Eduardo; Telles, Paulo Roberto; Scrivani, Hommenig; Campana, Gustavo] Dasa Labs, Barueri, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Trop Med Inst, Sao Paulo, Brazil.
   [Telles, Paulo Roberto] Univ Fed Fluminense, Dept Epidemiol & Biostat, Rio De Janeiro, Brazil.
RP Levi, JE (corresponding author), Dasa Labs, Barueri, Brazil.; Levi, JE (corresponding author), Dasa Labs, Res & Dev, Rua Gilberto Sabino,215 Pinheiros, BR-05425020 Sao Paulo, SP, Brazil.
EM jose.levi.ext@dasa.com.br
CR Dzik S, 2020, TRANSFUSION, V60, P1883, DOI 10.1111/trf.15946
   Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283
   Focosi D, 2020, BRIT J HAEMATOL, V190, pE148, DOI 10.1111/bjh.16932
   Gerard C, 2020, BRIT J HAEMATOL, V190, pE93, DOI 10.1111/bjh.16884
   Leaf RK, 2020, BRIT J HAEMATOL, V190, pE204, DOI 10.1111/bjh.16984
NR 5
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0042-9007
EI 1423-0410
J9 VOX SANG
JI Vox Sang.
DI 10.1111/vox.13015
EA OCT 2020
PG 2
WC Hematology
SC Hematology
GA OH3ES
UT WOS:000582451900001
PM 33103769
OA Bronze
DA 2020-11-30
ER

PT J
AU Buss, LF
   Levi, JE
   Longatto, A
   Cohen, DD
   Cury, L
   Martins, TR
   Fuza, LM
   Villa, LL
   Eluf-Neto, J
AF Buss, Lewis F.
   Levi, Jose E.
   Longatto-Filho, Adhemar
   Cohen, Diane D.
   Cury, Lise
   Martins, Toni R.
   Fuza, Luiz M.
   Villa, Luisa L.
   Eluf-Neto, Jose
TI Attendance for diagnostic colposcopy among high-risk human
   papillomavirus positive women in a Brazilian feasibility study
SO INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
LA English
DT Article; Early Access
DE Adherence; Brazil; Cervical cancer; Colposcopy; Follow-up; HPV-DNA;
   Screening
AB Objective To investigate factors associated with colposcopy attendance in HPV-positive women in Sao Paulo, Brazil. Methods We analyzed data from a prospective cohort of women positive for high-risk HPV (hr-HPV) undergoing cervical cancer screening in primary care services in Sao Paulo, Brazil. Non-pregnant women attending routine screening between December 2014 and March 2016 were offered an hr-HPV test, and those testing positive and aged 25 years or older were invited for colposcopy. Sociodemographic information was recorded at study enrollment. We compared variables between women who did and did not attend colposcopy within a logistic regression framework. Results Of 1537 hr-HPV-positive women, 1235 (80.4%) attended for colposcopy, with a median time from primary test to colposcopy of 132 days. Younger age (P<0.001) and concurrent negative cytology results (P=0.025) were associated with lower attendance. Women registered at units providing both the primary test and colposcopy were more likely to attend than those at units making external referrals (788/862 [91.4%] versus 447/675 [66.2%],P<0.001). Conclusion Non-attendance for colposcopy may limit the success of future screening programs based on hr-HPV testing in Brazil. Transfer of colposcopy services to primary care is a simple and effective facilitator of attendance.
C1 [Buss, Lewis F.; Longatto-Filho, Adhemar; Villa, Luisa L.; Eluf-Neto, Jose] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Levi, Jose E.; Martins, Toni R.] Univ Sao Paulo, Virol Lab LIM 52, Inst Med Trop, Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal.
   [Longatto-Filho, Adhemar] Univ Minho, Sch Med, Life & Hlth Sci Res Inst ICVS, Braga, Portugal.
   [Longatto-Filho, Adhemar] Barretos Canc Hosp, Mol Oncol Res Ctr, Sao Paulo, Brazil.
   [Cohen, Diane D.; Cury, Lise; Fuza, Luiz M.; Eluf-Neto, Jose] Fundacao Oncoctr Sao Paulo, Sao Paulo, Brazil.
   [Villa, Luisa L.] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil.
RP Buss, LF (corresponding author), Univ Sao Paulo, Dept Med Prevent, Sao Paulo, Brazil.
EM lewisbuss@usp.br
RI longatto-filho, adhemar/D-7039-2013
OI longatto-filho, adhemar/0000-0002-5779-9752
FU National Research Council [573799/2008-3]; Sao Paulo Research
   FoundationFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2008/57889-1]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior-BrasilCAPES
FX Funding was provided by the National Research Council Grant no.
   573799/2008-3, Sao Paulo Research Foundation Grant no. 2008/57889-1. LB
   received a grant from the Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior-Brasil. Becton Dickinson provided all the equipment and
   reagents for this study at no charge. They had no role in the study
   design, data analysis, or writing of the manuscript.
CR Arbyn M, 2014, LANCET ONCOL, V15, P172, DOI 10.1016/S1470-2045(13)70570-9
   Barata RB, 2011, CAD SAUDE PUBLICA, V27, pS164, DOI 10.1590/S0102-311X2011001400005
   Barbosa IR, 2017, REV BRAS GINECOL OBS, V39, P480, DOI 10.1055/s-0037-1604481
   Barbosa IR, 2016, CIENC SAUDE COLETIVA, V21, P253, DOI 10.1590/1413-81232015211.03662015
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Castanon A, 2013, BRIT J CANCER, V109, P35, DOI 10.1038/bjc.2013.322
   Castle PE, 2019, CANCER PREV RES, V12, P159, DOI 10.1158/1940-6207.CAPR-18-0419
   Curry SJ, 2018, JAMA-J AM MED ASSOC, V320, P674, DOI 10.1001/jama.2018.10897
   Douglas E, 2015, BRIT J CANCER, V113, P119, DOI 10.1038/bjc.2015.176
   Fonseca Luiz Augusto Marcondes, 2004, Cad. Saúde Pública, V20, P136, DOI 10.1590/S0102-311X2004000100029
   FundacAo Sistema Estadual de Analise de Dados, 2013, IND PAUL VUN SOC IPV
   Instituto Nacional de Cancer Jose Alencar Gomes da Silva, 2016, DIR BRAS RASTR CANC
   Khanna N, 2001, J Am Board Fam Pract, V14, P123
   Levi JE, 2019, CANCER PREV RES, V12, P539, DOI 10.1158/1940-6207.CAPR-19-0076
   Linde DS, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024011
   Macinko J, 2015, NEW ENGL J MED, V372, P2177, DOI 10.1056/NEJMp1501140
   Nascimento C M, 1996, Bull Pan Am Health Organ, V30, P302
   Nayar R, 2015, BETHESDA SYSTEM REPO
   Palmer T., 2019, BMJ, V365
   Rama CH, 2010, BMC WOMENS HEALTH, V10, DOI 10.1186/1472-6874-10-35
   Santos M de O, 2018, REV BRASILEIRA CANCE, V64, P119, DOI DOI 10.32635/2176-9745.RBC.2018v64n1.115
   Schiffman M, 2011, JNCI-J NATL CANCER I, V103, P368, DOI 10.1093/jnci/djq562
   Speck NMG, 2018, DOSSIE ESTRATEGIAS R
   Torres KL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201262
   Zeferino LC, 2018, REV BRAS GINECOL OBS, V40, P360, DOI 10.1055/s-0038-1657754
NR 25
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7292
EI 1879-3479
J9 INT J GYNECOL OBSTET
JI Int. J. Gynecol. Obstet.
DI 10.1002/ijgo.13362
EA OCT 2020
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA NX1XK
UT WOS:000575509600001
PM 33026115
DA 2020-11-30
ER

PT J
AU Candido, DS
   Claro, IM
   de Jesus, JG
   Souza, WM
   Moreira, FRR
   Dellicour, S
   Mellan, TA
   du Plessis, L
   Pereira, RHM
   Sales, FCS
   Manuli, ER
   Theze, J
   Almeida, L
   Menezes, MT
   Voloch, CM
   Fumagalli, MJ
   Coletti, TM
   Silva, CAM
   Ramundo, MS
   Amorim, MR
   Hoeltgebaum, HH
   Mishra, S
   Gill, MS
   Carvalho, LM
   Buss, LF
   Prete, CA
   Ashworth, J
   Nakaya, HI
   Peixoto, PS
   Brady, OJ
   Nicholls, SM
   Tanuri, A
   Rossi, TD
   Braga, CKV
   Gerber, AL
   Guimaraes, APD
   Gaburo, N
   Alencar, CS
   Ferreira, ACS
   Lima, CX
   Levi, JE
   Granato, C
   Ferreira, GM
   Francisco, RS
   Granja, F
   Garcia, MT
   Moretti, ML
   Perroud, MW
   Castineiras, TMPP
   Lazari, CS
   Hill, SC
   Santos, AAD
   Simeoni, CL
   Forato, J
   Sposito, AC
   Schreiber, AZ
   Santos, MNN
   de Sa, CZ
   Souza, RP
   Resende-Moreira, LC
   Teixeira, MM
   Hubner, J
   Leme, PAF
   Moreira, RG
   Nogueira, ML
   Ferguson, NM
   Costa, SF
   Proenca-Modena, JL
   Vasconcelos, ATR
   Bhatt, S
   Lemey, P
   Wu, CH
   Rambaut, A
   Loman, NJ
   Aguiar, RS
   Pybus, OG
   Sabino, EC
   Faria, NR
AF Candido, Darlan S.
   Claro, Ingra M.
   de Jesus, Jaqueline G.
   Souza, William M.
   Moreira, Filipe R. R.
   Dellicour, Simon
   Mellan, Thomas A.
   du Plessis, Louis
   Pereira, Rafael H. M.
   Sales, Flavia C. S.
   Manuli, Erika R.
   Theze, Julien
   Almeida, Luiz
   Menezes, Mariane T.
   Voloch, Carolina M.
   Fumagalli, Marcilio J.
   Coletti, Thais M.
   Silva, Camila A. M.
   Ramundo, Mariana S.
   Amorim, Mariene R.
   Hoeltgebaum, Henrique H.
   Mishra, Swapnil
   Gill, Mandev S.
   Carvalho, Luiz M.
   Buss, Lewis F.
   Prete Jr, Carlos A.
   Ashworth, Jordan
   Nakaya, Helder, I
   Peixoto, Pedro S.
   Brady, Oliver J.
   Nicholls, Samuel M.
   Tanuri, Amilcar
   Rossi, Atila D.
   Braga, Carlos K., V
   Gerber, Alexandra L.
   Guimaraes, Ana Paula de C.
   Gaburo Jr, Nelson
   Alencar, Cecila Salete
   Ferreira, Alessandro C. S.
   Lima, Cristiano X.
   Levi, Jose Eduardo
   Granato, Celso
   Ferreira, Giulia M.
   Francisco Jr, Ronaldo S.
   Granja, Fabiana
   Garcia, Marcia T.
   Moretti, Maria Luiza
   Perroud Jr, Mauricio W.
   Castineiras, Terezinha M. P. P.
   Lazari, Carolina S.
   Hill, Sarah C.
   de Souza Santos, Andreza Aruska
   Simeoni, Camila L.
   Forato, Julia
   Sposito, Andrei C.
   Schreiber, Angelica Z.
   Santos, Magnun N. N.
   de Sa, Camila Zolini
   Souza, Renan P.
   Resende-Moreira, Luciana C.
   Teixeira, Mauro M.
   Hubner, Josy
   Leme, Patricia A. F.
   Moreira, Rennan G.
   Nogueira, Mauricio L.
   Ferguson, Neil M.
   Costa, Silvia F.
   Proenca-Modena, Jose Luiz
   Vasconcelos, Ana Tereza R.
   Bhatt, Samir
   Lemey, Philippe
   Wu, Chieh-Hsi
   Rambaut, Andrew
   Loman, Nick J.
   Aguiar, Renato S.
   Pybus, Oliver G.
   Sabino, Ester C.
   Faria, Nuno Rodrigues
CA Brazil-UK Ctr Arbovirus Discovery
TI Evolution and epidemic spread of SARS-CoV-2 in Brazil
SO SCIENCE
LA English
DT Article
ID CORONAVIRUS; ACCURATE
AB Brazil currently has one of the fastest-growing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemics in the world. Because of limited available data, assessments of the impact of nonpharmaceutical interventions (NPIs) on this virus spread remain challenging. Using a mobility-driven transmission model, we show that NPIs reduced the reproduction number from >3 to 1 to 1.6 in Sao Paulo and Rio de Janeiro. Sequencing of 427 new genomes and analysis of a geographically representative genomic dataset identified >100 international virus introductions in Brazil. We estimate that most (76%) of the Brazilian strains fell in three clades that were introduced from Europe between 22 February and 11 March 2020. During the early epidemic phase, we found that SARS-CoV-2 spread mostly locally and within state borders. After this period, despite sharp decreases in air travel, we estimated multiple exportations from large urban centers that coincided with a 25% increase in average traveled distances in national flights. This study sheds new light on the epidemic transmission and evolutionary trajectories of SARS-CoV-2 lineages in Brazil and provides evidence that current interventions remain insufficient to keep virus transmission under control in this country.
C1 [Candido, Darlan S.; du Plessis, Louis; Hill, Sarah C.; Pybus, Oliver G.] Univ Oxford, Dept Zool, Oxford, England.
   [Candido, Darlan S.; Claro, Ingra M.; de Jesus, Jaqueline G.; Sales, Flavia C. S.; Manuli, Erika R.; Coletti, Thais M.; Silva, Camila A. M.; Ramundo, Mariana S.; Buss, Lewis F.; Costa, Silvia F.; Faria, Nuno Rodrigues] Univ Sao Paulo, Fac Med, Inst Med Trop, Sao Paulo, Brazil.
   [Claro, Ingra M.; de Jesus, Jaqueline G.; Sales, Flavia C. S.; Manuli, Erika R.; Coletti, Thais M.; Silva, Camila A. M.; Ramundo, Mariana S.; Costa, Silvia F.; Sabino, Ester C.] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitaries, Sao Paulo, Brazil.
   [Souza, William M.; Fumagalli, Marcilio J.] Fac Med Ribeirao Preto, Ctr Pesquisa Virol, Ribeirao Preto, Brazil.
   [Moreira, Filipe R. R.; Menezes, Mariane T.; Voloch, Carolina M.; Tanuri, Amilcar; Rossi, Atila D.] Univ Fed Rio de Janeiro, Dept Genet, Inst Biol, Rio De Janeiro, Brazil.
   [Dellicour, Simon] Univ Libre Bruxelles, Spatial Epidemiol Lab, Brussels, Belgium.
   [Dellicour, Simon; Gill, Mandev S.; Lemey, Philippe] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Rega Inst, Leuven, Belgium.
   [Mellan, Thomas A.; Mishra, Swapnil; Ferguson, Neil M.; Bhatt, Samir; Faria, Nuno Rodrigues] Imperial Coll London, MRC Ctr Global Infect Dis Anal, J IDEA, London, England.
   [Pereira, Rafael H. M.; Braga, Carlos K., V] Inst Appl Econ Res, Brasilia, DF, Brazil.
   [Theze, Julien] Univ Clermont Auvergne, VetAgro Sup, INRAE, UMR EPIA, St Genes Champanelle, France.
   [Almeida, Luiz; Gerber, Alexandra L.; Guimaraes, Ana Paula de C.; Francisco Jr, Ronaldo S.; Vasconcelos, Ana Tereza R.] Lab Bioinformat, Lab Natl Comp Cient, Petropolis, Brazil.
   [Amorim, Mariene R.; Granja, Fabiana; Simeoni, Camila L.; Forato, Julia; Proenca-Modena, Jose Luiz] Univ Estadual Campinas, Dept Genet Evolucao Microbiol & Imunol, Inst Biol, Campinas, Brazil.
   [Hoeltgebaum, Henrique H.] Imperial Coll London, Dept Math, London, England.
   [Carvalho, Luiz M.] Fundacao Getalio Vargas, Escola Matemat Aplicada EMAp, Rio De Janeiro, Brazil.
   [Prete Jr, Carlos A.] Univ Sao Paulo, Dept Elect Syst Engn, Sao Paulo, Brazil.
   [Ashworth, Jordan] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland.
   [Nakaya, Helder, I] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, Brazil.
   [Peixoto, Pedro S.] Univ Sao Paulo, Inst Matemat & Estat, Dept Matemat Aplicada, Sao Paulo, Brazil.
   [Brady, Oliver J.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Fac Epidemiol & Populat Hlth, London, England.
   [Brady, Oliver J.] London Sch Hyg & Trop Med, Ctr Math Modelling Infect Dis, London, England.
   [Nicholls, Samuel M.; Loman, Nick J.] Univ Birmingham, Inst Microbiol & Infect, Birmingham, W Midlands, England.
   [Gaburo Jr, Nelson] DB Diagnost Brasil, Sao Paulo, Brazil.
   [Alencar, Cecila Salete] Univ Sao Paulo, LIM Lab Med Lab 03, Hosp Clin, Fac Med, Sao Paulo, Brazil.
   [Ferreira, Alessandro C. S.] Inst Hermes Pardini, Belo Horizonte, MG, Brazil.
   [Lima, Cristiano X.] Univ Fed Minas Gerais, Fac Med, Dept Cirurgia, Belo Horizonte, MG, Brazil.
   [Lima, Cristiano X.] Simile Inst Imunol Aplicada Ltda, Belo Horizonte, MG, Brazil.
   [Levi, Jose Eduardo] Lab DASA, Sao Paulo, Brazil.
   [Granato, Celso] Lab Fleury, Sao Paulo, Brazil.
   [Ferreira, Giulia M.] Univ Fed Uberlandia, Inst Glandes Biomed, Lab Virol, Uberlandia, MG, Brazil.
   [Granja, Fabiana] Univ Fed Roraima, Ctr Estudos Biodiversidade, Boa Vista, Parana, Brazil.
   [Garcia, Marcia T.; Moretti, Maria Luiza] Univ Estadual Campinas, Fac Ciencias Med, Div Doences Infecciacas, Campinas, SP, Brazil.
   [Perroud Jr, Mauricio W.] Univ Estadual Campinas, Hosp Estadual Sumare, Campinas, SP, Brazil.
   [Castineiras, Terezinha M. P. P.] Univ Fed Rio de Janeiro, Fac Med, Dept Doencas Infeccioses & Parasitarias, Rio De Janeiro, Brazil.
   [Lazari, Carolina S.] Univ Sao Paulo, Cent Hosp Clin, Fac Med, Div Lab, Sao Paulo, Brazil.
   [Hill, Sarah C.] Royal Vet Coll, Dept Pathobiol & Populat Sci, Hatfield, Herts, England.
   [de Souza Santos, Andreza Aruska] Univ Oxford, Latin Amer Ctr, Oxford Sch Global & Area Studies, Oxford, England.
   [Sposito, Andrei C.] Univ Estadual Campinas, Fac Ciencias Med, Dept Clin Med, Campinas, SP, Brazil.
   [Schreiber, Angelica Z.; Santos, Magnun N. N.] Univ Estadual Campinas, Dept Patol, Fac Ciencias Med, Campinas, SP, Brazil.
   [de Sa, Camila Zolini; Souza, Renan P.; Aguiar, Renato S.] Univ Fed Minas Gerais, Dept Genet Ecol & Evolucao, Inst Ciencias Biol, Belo Horizonte, MG, Brazil.
   [Resende-Moreira, Luciana C.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bot, Belo Horizonte, MG, Brazil.
   [Teixeira, Mauro M.] Univ Fed Minas Gerais, Dept Bioquim & Imunol, Belo Horizonte, MG, Brazil.
   [Hubner, Josy] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Biol Celular, Belo Horizonte, MG, Brazil.
   [Leme, Patricia A. F.] Univ Estadual Campinas, Ctr Saude Comunidade, Campinas, SP, Brazil.
   [Moreira, Rennan G.] Univ Fed Minas Gerais, Ctr Labs Multiusuarios, Inst Ciencias Biol, Belo Horizonte, MG, Brazil.
   [Nogueira, Mauricio L.] Fac Med Sao Jose do Rio Preto, Lab Pesquisas Virol, Sao Jose Do Rio Preto, SP, Brazil.
   [Wu, Chieh-Hsi] Univ Southampton, Math Sci, Southampton, Hants, England.
   [Rambaut, Andrew] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh, Midlothian, Scotland.
RP Sabino, EC (corresponding author), Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitaries, Sao Paulo, Brazil.; Faria, NR (corresponding author), Imperial Coll London, MRC Ctr Global Infect Dis Anal, J IDEA, London, England.
EM sabinoec@usp.br; nfaria@ic.ac.uk
RI Nogueira, Mauricio L/B-7599-2012; Rossi, Atila Duque/AAV-6079-2020;
   Pybus, Oliver G/B-2640-2012; Souza, Renan P/G-8394-2011; Cardoso,
   Cynthia/K-5824-2012; Mishra, Swapnil/AAT-3955-2020; Severo,
   Mariana/ABD-4674-2020; Peixoto, Pedro S/I-7243-2013; Sposito, Andrei
   C/G-4116-2013; Proenca-Modena, Jose Luiz/AAU-7622-2020; Fumagalli,
   Marcilio/ABE-1183-2020; Almeida, Luiz GP/G-5829-2012; Bhatt,
   Samir/ABE-7938-2020; Brady, Oliver/P-9421-2019; Dellicour,
   Simon/AAE-9054-2020; Perroud Junior, Mauricio/C-7060-2015; du Plessis,
   Louis/K-1667-2013; Souza, William/D-3044-2017; Faria, Nuno
   Rodrigues/I-2975-2012
OI Nogueira, Mauricio L/0000-0003-1102-2419; Rossi, Atila
   Duque/0000-0001-6235-8807; Pybus, Oliver G/0000-0002-8797-2667; Souza,
   Renan P/0000-0002-9479-4432; Cardoso, Cynthia/0000-0003-0565-7047;
   Mishra, Swapnil/0000-0002-8759-5902; Peixoto, Pedro
   S/0000-0003-2358-3221; Sposito, Andrei C/0000-0001-7127-2052;
   Proenca-Modena, Jose Luiz/0000-0002-4996-3153; Fumagalli,
   Marcilio/0000-0002-0207-5423; Almeida, Luiz GP/0000-0002-7124-2715;
   Brady, Oliver/0000-0002-3235-2129; Dellicour, Simon/0000-0001-9558-1052;
   Hill, Sarah/0000-0002-2995-2596; Perroud Junior,
   Mauricio/0000-0001-5984-9947; Theze, Julien/0000-0001-8188-9494; De
   Jesus, Jaqueline/0000-0002-5404-272X; du Plessis,
   Louis/0000-0003-0352-6289; Souza, William/0000-0002-0025-8293; Lopes
   Simeoni, Camila/0000-0003-2288-5500; Ashworth,
   Jordan/0000-0003-1740-7475; Faria, Nuno Rodrigues/0000-0001-8839-2798;
   Zolini de Sa, Camila/0000-0002-9394-8807; da Silva Sales, Flavia
   Cristina/0000-0002-9048-0030; Mellan, Thomas/0000-0003-4185-9930; da
   Silva Francisco Junior, Ronaldo/0000-0001-7419-3907
FU Medical Research Council-Sao Paulo Research Foundation (FAPESP) CADDE
   partnership award [MR/S0195/1, FAPESP 18/14389-0]; FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2018/17176-8,
   2019/12000-1, 18/14389-0, 2018/25468-9, 2017/13981-0, 2019/24251-9,
   2018/09383-3, 2019/07544-2, 2019/21301-5, 2018/14933-2, 16/18445-7,
   20/04836-0, 2020/04558-0, 2016/00194-8]; Wellcome TrustWellcome Trust
   [204311/Z/16/Z]; Royal Society Sir Henry Dale Fellowship
   [204311/Z/16/Z]; Clarendon Fund; Department of Zoology, University of
   Oxford; Fonds National de la Recherche Scientifique (FNRS, Belgium)Fonds
   de la Recherche Scientifique - FNRS; European UnionEuropean Union (EU)
   [874850]; CNPqNational Council for Scientific and Technological
   Development (CNPq) [303170/2017-4, 312688/2017-2, 439119/2018-9,
   310627/2018-4, 408338/2018-0]; FAPERJCarlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
   [E-26/202.826/2018, 202.922/2018]; CAPESCAPES; Sir Henry Wellcome
   Fellowship - Wellcome TrustWellcome Trust [206471/Z/17/Z]; FAPEMIGMinas
   Gerais State Research Foundation (FAPEMIG) [APQ-00475-20]; Instituto
   Nacional de Ciancia e Tecnologia em Dengue (INCT Dengue)
   [465425/2014-3]; FINEPCiencia Tecnologia e Inovacao (FINEP)
   [01.16.0078.00]; Wellcome Trust ARTIC network [206298/Z/17/Z]; European
   Research CouncilEuropean Research Council (ERC) [725422]; Oxford Martin
   School; U.K. Medical Research CouncilMedical Research Council UK (MRC);
   U.K. Department for International Development; NIHR Health Protection
   Research Unit in Modelling Methodology; Community Jameel; FMUSP
FX This project was supported by a Medical Research Council-Sao Paulo
   Research Foundation (FAPESP) CADDE partnership award (MR/S0195/1 and
   FAPESP 18/14389-0) (http://caddecentre.org/).FAPESP further supports
   I.M.C. (2018/17176-8 and 2019/12000-1), J.G.J. (2018/17176-8 and
   2019/12000-1, 18/14389-0), F.C.S.S. (2018/25468-9), W.M.S.
   (2017/13981-0, 2019/24251-9), M.F. (2018/09383-3), T.M.C.
   (2019/07544-2), C.A.M.S. (2019/21301-5), H.I.N. (2018/14933-2), P.S.P.
   (16/18445-7), M.L.N. (20/04836-0), and J.L.M. (2020/04558-0 and
   2016/00194-8). N.R.F. is supported by a Wellcome Trust and Royal Society
   Sir Henry Dale Fellowship (204311/Z/16/Z). D.S.C. is supported by the
   Clarendon Fund and by the Department of Zoology, University of Oxford.
   S.D. is supported by the Fonds National de la Recherche Scientifique
   (FNRS, Belgium). J.T. and P.L. are supported by European Union's Horizon
   2020 project MOOD (874850). This project was supported by CNPq (M.T.M.,
   M.L.N., and A.T.R.V.: 303170/2017-4; R.S.A.: 312688/2017-2 and
   439119/2018-9; R.P.S.: 310627/2018-4; and W.M.S.: 408338/2018-0), FAPERJ
   (A.T.R.V.: E-26/202.826/2018 and R.S.A.: 202.922/2018). M.S.R. is
   supported by FMUSP. C.A.P., G.M.F., J.H., and M.R.A. are supported by
   CAPES. O.J.B. is supported by a Sir Henry Wellcome Fellowship funded by
   the Wellcome Trust (206471/Z/17/Z). R.P.S. is supported by FAPEMIG
   (APQ-00475-20). M.M.T. is supported by Instituto Nacional de Ciancia e
   Tecnologia em Dengue (INCT Dengue 465425/2014-3). A.T.R.V. is supported
   by FINEP 01.16.0078.00). P.L. and N.J.L. are supported by the Wellcome
   Trust ARTIC network (collaborators award no. 206298/Z/17/Z). P.L. and
   A.R. are supported by the European Research Council (grant no. 725422
   -ReservoirDOCS). O.G.P., N.R.F., and L.d.P. are supported by the Oxford
   Martin School. This work received funding from the U.K. Medical Research
   Council under a concordat with the U.K. Department for International
   Development. We additionally acknowledge support from Community Jameel
   and the NIHR Health Protection Research Unit in Modelling Methodology.
CR Aktay A., 2020, ARXIV200404145CSCR
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Ayres DL, 2012, SYST BIOL, V61, P170, DOI 10.1093/sysbio/syr100
   Brazilian Ministry of Health, 2020, PAIN CAS DOENC PEL C
   Bruen TC, 2006, GENETICS, V172, P2665, DOI 10.1534/genetics.105.048975
   Buss LF, 2020, EPIDEMIOLOGICAL CLIN, DOI [10.1101/2020.04.25.20077396, DOI 10.1101/2020.04.25.20077396]
   Candido D. S., 2020, DRYAD, DOI [10.5061/dryad.rxwdbrv5z., DOI 10.5061/DRYAD.RXWDBRV5Z]
   Candido DD, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa042
   Centers for Disease Control and Prevention, 2020, RES US ONL 2019 NOV
   Centre for Genomic Pathogen Surveillance Imperial College London, 2020, 427 CTR GEN PATH SUR
   Centre for Genomic Pathogen Surveillance Imperial College London, 2020, 427 CTR GEN PATH SUR
   Chinese National Institute for Viral Disease Control and Prevention, 2020, SPEC PRIM PROB DET 2
   CORMAN V, 2020, EUROSURVEILLANCE, V25, DOI 10.2807/1560-7917.ES
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cotten M, 2014, MBIO, V5, DOI 10.1128/mBio.01062-13
   Cotten M, 2013, LANCET, V382, P1993, DOI 10.1016/S0140-6736(13)61887-5
   Croda J, 2020, REV SOC BRAS MED TRO, V53, DOI 10.1590/0037-8682-0167-2020
   de Jesus JG, 2020, REV INST MED TROP SP, V62, DOI [10.1590/s1678-9946202062030, 10.1590/S1678-9946202062030]
   de Souza WM, 2020, NAT HUM BEHAV, V4, P856, DOI 10.1038/s41562-020-0928-4
   Dellicour S, 2020, BIORXIV, DOI [10.1101/2020.05.05.078758, DOI 10.1101/2020.05.05.078758]
   Dellicour S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03763-2
   Dellicour S, 2016, BIOINFORMATICS, V32, P3204, DOI 10.1093/bioinformatics/btw384
   Duchene S, 2020, BIORXIV, DOI [DOI 10.1101/2020.05.04.077735, 10.1101/2020.05.04.077735]
   Dudas G, 2018, ELIFE, V7, DOI [10.7554/eLife.31257, 10.7554/eLife.37324, 10.7554/elife.37324]
   Faria NR, 2014, SCIENCE, V346, P56, DOI 10.1126/science.1256739
   Ferreira MAR, 2008, CAN J STAT, V36, P355, DOI 10.1002/cjs.5550360302
   Ferretti L, 2020, SCIENCE, V368, P619, DOI 10.1126/science.abb6936
   Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7
   Gill MS, 2013, MOL BIOL EVOL, V30, P713, DOI 10.1093/molbev/mss265
   HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694
   HKU Med LKS Faculty of Medicine School of Public Health, 2020, DET 2019 NOV COR 201
   Huson DH, 2006, MOL BIOL EVOL, V23, P254, DOI 10.1093/molbev/msj030
   Katoh K, 2014, METHODS MOL BIOL, V1079, P131, DOI 10.1007/978-1-62703-646-7_8
   Kissler SM, 2020, REDUCTIONS COMMUTING
   Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218
   Lavezzo E, 2020, NATURE, V584, P425, DOI 10.1038/s41586-020-2488-1
   Lemey P, 2010, MOL BIOL EVOL, V27, P1877, DOI 10.1093/molbev/msq067
   Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Lu J, 2020, CELL, V181, P997, DOI 10.1016/j.cell.2020.04.023
   Martin DP, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev003
   Mellan T. A., 2020, ESTIMATING COVID 19, DOI [10.25561/78872., DOI 10.25561/78872]
   Milne I, 2010, BIOINFORMATICS, V26, P401, DOI 10.1093/bioinformatics/btp666
   Minh BQ, 2020, MOL BIOL EVOL, V37, P1530, DOI 10.1093/molbev/msaa015
   Minin VN, 2008, PHILOS T R SOC B, V363, P3985, DOI 10.1098/rstb.2008.0176
   Minin VN, 2008, J MATH BIOL, V56, P391, DOI 10.1007/s00285-007-0120-8
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Nao N, 2020, DETECTION 2 CASE 201
   Nascimento V. A., 2020, MEMOIRS OSWALDO CRUZ, DOI [10.1590/0074-02760200310, DOI 10.1590/0074-02760200310]
   Northill J., 2020, WUHAN CORONAVIRUS 20
   O'Brien JD, 2009, MOL BIOL EVOL, V26, P801, DOI 10.1093/molbev/msp003
   Paco M, 2020, EUR J PUBLIC HEALTH, V30
   Peixoto PS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235732
   Quick J, 2017, NAT PROTOC, V12, P1261, DOI 10.1038/nprot.2017.066
   Rambaut A., 2020, NAT MICROBIOL
   Rambaut Andrew, 2020, Nat Microbiol, V5, P1403, DOI 10.1038/s41564-020-0770-5
   Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Resende P, 2020, 0200617158006 BIORXI, DOI [10.1101/2020.06.17.158006, DOI 10.1101/2020.06.17.158006]
   Croda JHR, 2020, EPIDEMIOL SERV SAUDE, V29, DOI [10.5123/s1679-49742020000100021, 10.5123/S1679-49742020000100021]
   Russell Timothy W, 2020, Euro Surveill, V25, DOI 10.2807/1560-7917.ES.2020.25.12.2000256
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Singer J., 2020, COV GLUE WEB APPL TR, DOI [10.20944/preprints202006.0225.v1, DOI 10.20944/PREPRINTS202006.0225.V1, 10.20944/preprints202006.0225.v1.]
   Suchard MA, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey016
   Thailand Ministry of Public Health, 2020, DIAGN DET NOV COR 20
   Tian HY, 2020, SCIENCE, V368, P638, DOI 10.1126/science.abb6105
   Thao TTN, 2020, NATURE, V582, P561, DOI 10.1038/s41586-020-2294-9
   Unwin H. J. T., 2020, 23 IMP COLL LOND, DOI [10.25561/79231, DOI 10.25561/79231]
   Unwin H. J. T., 2020, 23 IMP COLL LOND, DOI [10.25561/79231, DOI 10.25561/79231.]
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Waggoner JJ, 2020, EMERG INFECT DIS, V26, P1633, DOI 10.3201/eid2607.201285
   WHO, 2020, COR DIS COVID 19 SIT
   World Health Organisation, 2020, COR DIS COVID 2019 S
   World Health Organization, 2020, 72 WHO
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Xavier J., 2020, 20202005200520091611, DOI [10.1101/2020.05.05.20091611, DOI 10.1101/2020.05.05.20091611]
   Xavier J, 2020, EMERG MICROBES INFEC, V9, P1824, DOI 10.1080/22221751.2020.1803146
   YANG ZH, 1994, J MOL EVOL, V39, P306, DOI 10.1007/BF00160154
   Zhang Y- Z., 2020, VIROLOGICAL
   Zhao ZM, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-21
NR 83
TC 8
Z9 9
U1 5
U2 5
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD SEP 4
PY 2020
VL 369
IS 6508
SI SI
BP 1255
EP +
DI 10.1126/science.abd2161
PG 43
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NL6LT
UT WOS:000567525400055
PM 32703910
OA Green Published, Green Accepted, Other Gold
DA 2020-11-30
ER

PT J
AU Martins, VCA
   Cunha, IW
   Figliuolo, G
   Rondon, HHDF
   de Souza, PM
   Silva, FLT
   Silva, GLT
   Bastos, MD
   de Castro, DB
   Santana, MF
   Ramasawmy, R
   Levi, JE
   Torres, KL
AF Alves Martins, Valquiria Carmo
   Cunha, Isabela Werneck
   Figliuolo, Giuseppe
   de Melo Farah Rondon, Heidy Halanna
   de Souza, Paloma Menezes
   Torres Silva, Felipe Luz
   Torres Silva, Guilherme Luz
   Bastos, Michele de Souza
   de Castro, Daniel Barros
   Santana, Monique Freire
   Ramasawmy, Rajendranath
   Levi, Jose Eduardo
   Torres, Katia Luz
TI Presence of HPV with overexpression of p16(INK4a) protein and EBV
   infection in penile cancer-A series of cases from Brazil Amazon
SO PLOS ONE
LA English
DT Article
ID EPSTEIN-BARR-VIRUS; HUMAN-PAPILLOMAVIRUS DNA; SQUAMOUS-CELL CARCINOMA;
   IN-SITU; PREVALENCE; CLASSIFICATION; EXPRESSION; TUMORS; P53;
   AMPLIFICATION
AB Background
   In Brazil, penile cancer (PC) is not uncommon. The highest incidence of PC is in the North and Northeast of the country. In addition to phimosis, the Human Papillomavirus (HPV) and Epstein-Baar Virus (EBV) infections are also related as risk factors for PC. The overexpression of p16(INK4a) is a surrogate sensitive marker of HPV infection in PC.
   Objectives
   To correlate p16(INK4a) overexpression and HPV infection status with EBV infection in a series of PC patients from the Amazon region.
   Methods
   Tumor tissues from 47 PC cases were analyzed for the presence of HPV and EBV DNA by PCR. All PC patients were diagnosed between 2013 and 2018 at a public reference cancer center hospital in Manaus, Amazonas-Brazil. HPV was genotyped using E7 HPV16/HPV18 type-specific real-time PCR and the PapilloCheck (R) HPV-Screening assay. p16INK4a expression was evaluated by immunohistochemistry using the automated Ventana (R) BenchMark Ultra.
   Results
   The mean age of patients at the time of diagnosis was 57.4 years +/- SD 17.8 ranging from 20 to 90 years old. Most of the patients (64%) came from rural areas of the Amazonas State. Thirty patients had phimosis (64%). Among the patients with phimosis, 43% (13/30) underwent circumcision, three during childhood and 10 in adulthood. 60% of the patients were smokers or ex-smokers. HPV infection was observed in 45% (21/47) of cases. HPV16 was detected in 13 patients (61%). Other HPV types detected were HPV 6, 11, 42, 51, 53, 68 and 44/55. EBV infection was observed in 30% (14/47) of the patients with PC. Co-infection with HPV and EBV was observed in 28% (6/21) cases. p16(INK4a) was only investigated in 26 samples. The p16(INK4a) overexpression was observed exclusively in HPV 16 positive cases and four HPV negative cases. In the survival analysis, the follow-up time was 35.4 months/patient. The mortality rate during the follow up time was 38%.
   Conclusions
   p16(INK4a) positivity presented a high correlation to HPV 16 DNA detection, reinforcing its use as a surrogate marker for HPV-driven cancers. Infection with EBV was quite frequent and its role in epithelial penile oncogenesis needs to be demonstrated.
C1 [Alves Martins, Valquiria Carmo; Figliuolo, Giuseppe; Santana, Monique Freire; Torres, Katia Luz] Fundacao Ctr Controle Oncol Estado Amazonas, Dept Educ & Res, Manaus, Amazonas, Brazil.
   [Alves Martins, Valquiria Carmo; de Melo Farah Rondon, Heidy Halanna; Torres Silva, Felipe Luz; Torres, Katia Luz] Univ Fed Amazonas, Manaus, Amazonas, Brazil.
   [Alves Martins, Valquiria Carmo; de Castro, Daniel Barros; Ramasawmy, Rajendranath; Torres, Katia Luz] Genom Hlth Surveillance Network Optimizat Assista, Manaus, Amazonas, Brazil.
   [Cunha, Isabela Werneck] AC Camargo Canc Ctr, Dept Pathol, Sao Paulo, Brazil.
   [Cunha, Isabela Werneck] Rede DOR Sao Luiz, Dept Pathol, Sao Paulo, Brazil.
   [Figliuolo, Giuseppe; de Souza, Paloma Menezes; Torres Silva, Guilherme Luz] Univ Estado Amazonas, Manaus, Amazonas, Brazil.
   [Bastos, Michele de Souza; Santana, Monique Freire; Ramasawmy, Rajendranath] Fundacao Med Trop Heitor Vieira Dourado, Dept Virol, Manaus, Amazonas, Brazil.
   [de Castro, Daniel Barros] Fundacao Vigilancia Saude Amazonas, Tech Advisory, Manaus, Amazonas, Brazil.
   [Ramasawmy, Rajendranath] Univ Nilton Lins, Fac Med, Manaus, Amazonas, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop, Sao Paulo, Brazil.
RP Martins, VCA (corresponding author), Fundacao Ctr Controle Oncol Estado Amazonas, Dept Educ & Res, Manaus, Amazonas, Brazil.; Martins, VCA (corresponding author), Univ Fed Amazonas, Manaus, Amazonas, Brazil.; Martins, VCA (corresponding author), Genom Hlth Surveillance Network Optimizat Assista, Manaus, Amazonas, Brazil.
EM alvesvalquiria@yahoo.com.br
RI Bastos, Michele/AAS-7386-2020; Barros de Castro, Daniel/J-9358-2016
OI Bastos, Michele/0000-0003-3450-666X; Martins,
   Valquiria/0000-0003-1259-9738; Barros de Castro,
   Daniel/0000-0001-5969-544X
FU Fundacao de Amparo a Pesquisa do Estado do Amazonas-FAPEAM
   [021/2011-FAPEAM, 020/2013 FAPEAM, 05/2019 FAPEAM, 002./2008-FAPEAM]
FX This work was supported by The Fundacao de Amparo a Pesquisa do Estado
   do Amazonas-FAPEAM for financial support (PROGRAMA UNIVERSAL AMAZONAS
   N.021/2011-FAPEAM; PROGRAMA PAPAC N.020/2013 FAPEAM; PROGRAMA PAPAC
   N.05/2019 FAPEAM and PROGRAMA PRo ' ESTADO N.002./2008-FAPEAM). The Rede
   D'OR-Sao Luiz provided support in the form of a salary for author
   Isabela Werneck Cunha IW, but did not have any additional role in the
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript. The specific roles of this author is
   articulated in the `author contributions' section. The Genomic Health
   Surveillance Network: Optimization of Assistance and Research in the
   State of Amazonas -REGESAM is not a funder but a network of researchers
   in the Genomic field on the State of Amazonas.
CR Afonso LA, 2017, J MED VIROLOGY
   Afonso LA, 2012, MEM I OSWALDO CRUZ, V107, P18, DOI 10.1590/S0074-02762012000100003
   Alemany L, 2016, EUR UROL, V69, P953, DOI 10.1016/j.eururo.2015.12.007
   Alves G, 2004, CANCER LETT, V215, P79, DOI 10.1016/j.canlet.2004.04.025
   Backes DM, 2009, CANCER CAUSE CONTROL, V20, P449, DOI 10.1007/s10552-008-9276-9
   BARBOSA AD, 1984, REV SAUDE PUBL, V18, P429
   Bethune G, 2012, UROLOGY, V79, P1092, DOI 10.1016/j.urology.2011.12.048
   Bezerra ALR, 2001, CANCER, V91, P2315, DOI 10.1002/1097-0142(20010615)91:12<2315::AID-CNCR1263>3.0.CO;2-C
   Bezerra SM, 2015, HUM PATHOL, V46, P532, DOI 10.1016/j.humpath.2014.12.004
   Bleeker MCG, 2009, WORLD J UROL, V27, P141, DOI 10.1007/s00345-008-0302-z
   de Sousa IDB, 2015, BMC UROL, V15, DOI 10.1186/s12894-015-0007-8
   Calmon MF, 2011, THESCIENTIFICWORLDJO, V11, P269, DOI 10.1100/tsw.2011.24
   Chalya PL, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0482-0
   Chipollini J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081777
   Christodoulidou M, 2015, CURR PROB CANCER, V39, P126, DOI 10.1016/j.currproblcancer.2015.03.010
   Cubilla AL, 2011, AM J SURG PATHOL, V35, P253, DOI 10.1097/PAS.0b013e318203cdba
   Daling JR, 2005, INT J CANCER, V116, P606, DOI 10.1002/ijc.21009
   de Araujo LA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199557
   de Lima MAP, 2006, REV BRASILEIRA CANCE, V52, P87
   Djajadiningrat RS, 2015, J UROLOGY, V193, P1245, DOI 10.1016/j.juro.2014.11.057
   do Couto TC, 2014, INT BRAZ J UROL, V40, P738, DOI 10.1590/S1677-5538.IBJU.2014.06.04
   Dorfman S, 2006, TROP DOCT, V36, P232, DOI 10.1258/004947506778604896
   Favorito LA, 2008, INT BRAZ J UROL, V34, P587, DOI 10.1590/S1677-55382008000500007
   Ferrandiz-Pulido C, 2015, GENE CHROMOSOME CANC, V54, P629, DOI 10.1002/gcc.22274
   Ferreux E, 2003, J PATHOL, V201, P109, DOI 10.1002/path.1394
   FIGLIUOLO G, 2015, REV BRASILEIRA ONCOL, V11
   Fonseca AG, 2010, REV PAN AMAZ SAUDE, V1, P85
   Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
   Guidry JT, 2017, VIRUS RES, V231, P139, DOI 10.1016/j.virusres.2016.11.002
   Heard I, 2016, J CLIN VIROL, V81, P6, DOI 10.1016/j.jcv.2016.05.004
   Hernandez BY, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00009
   LAM KY, 1995, CANCER-AM CANCER SOC, V76, P658, DOI 10.1002/1097-0142(19950815)76:4<658::AID-CNCR2820760418>3.0.CO;2-B
   Larke NL, 2011, CANCER CAUSE CONTROL, V22, P1097, DOI 10.1007/s10552-011-9785-9
   Levi JE, 1998, INT J CANCER, V76, P779, DOI 10.1002/(SICI)1097-0215(19980610)76:6<779::AID-IJC1>3.0.CO;2-V
   Markoulatos P, 2001, J CLIN MICROBIOL, V39, P4426, DOI 10.1128/JCM.39.12.4426-4432.2001
   Martinez-Bailon C, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4696-6
   Martins VD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205350
   Micali G, 2006, J AM ACAD DERMATOL, V54, P369, DOI 10.1016/j.jaad.2005.05.007
   Michels KB, 2009, LANCET, V374, P268, DOI 10.1016/S0140-6736(09)61247-2
   Miralles-Guri C, 2009, J CLIN PATHOL
   Moch H, 2016, EUR UROL, V70, P93, DOI 10.1016/j.eururo.2016.02.029
   Cardona CEM, 2017, REV PANAM SALUD PUBL, V41, DOI 10.26633/RPSP.2017.117
   Mosconi AM, 2005, CRIT REV ONCOL HEMAT, V53, P165, DOI 10.1016/j.critrevonc.2004.09.006
   Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641
   Nd Melo MCBd, 2009, REV SBPH, V12, P99
   Olesen TB, 2019, LANCET ONCOL, V20, P145, DOI 10.1016/S1470-2045(18)30682-X
   Paner GP, 2018, EUR UROL, V73, P560, DOI 10.1016/j.eururo.2017.12.018
   Parkin DM, 2010, INT J CANCER, V127, P2918, DOI 10.1002/ijc.25517
   Pow-Sang Mariela R, 2002, Cancer Control, V9, P305
   Prue G, 2017, ORAL DIS, V23, P726, DOI 10.1111/odi.12562
   Reddy JP, 2017, BJU INT, V119, P591, DOI 10.1111/bju.13686
   Rubin MA, 2001, AM J PATHOL, V159, P1211, DOI 10.1016/S0002-9440(10)62506-0
   SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
   Salvioni R, 2009, PENILE CANC, P677
   Schabath MB, 2011, CANC EPIDEMIOLOGY PR
   Scheiner MA, 2008, INT BRAZ J UROL, V34, P467, DOI 10.1590/S1677-55382008000400009
   Schiffman M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.86
   Senba M, 2006, J MED VIROL, V78, P1341, DOI 10.1002/jmv.20703
   Soufir N, 2007, BRIT J DERMATOL, V156, P448, DOI 10.1111/j.1365-2133.2006.07604.x
   Spiess PE, 2016, CA-CANCER J CLIN, V66, P482, DOI 10.3322/caac.21354
   Stratton KL, 2016, ONCOLOGY-NY, V30, P245
   Szostek S, 2009, ACTA BIOCHIM POL, V56, P337
   Tang DH, 2015, J UROLOGY, V193, P519, DOI 10.1016/j.juro.2014.08.120
   Torres KL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201262
   Veo CAR, 2015, TUMOR BIOL, V36, P5399, DOI 10.1007/s13277-015-3205-9
   Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556
   Zargar-Shoshtari K, 2016, CLIN GENITOURIN CANC, V14, P346, DOI 10.1016/j.clgc.2015.12.019
NR 67
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 6
PY 2020
VL 15
IS 5
AR e0232474
DI 10.1371/journal.pone.0232474
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA LT7ZB
UT WOS:000537283500037
PM 32374757
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Luna, EJA
   Figueiredo, GM
   Levi, JE
   Campos, SRSLC
   Felix, AC
   Souza, NSE
   Figueiredo, WM
   Costa, AA
   Cardoso, MRA
   Pannuti, CS
AF Luna, Expedito J. A.
   Figueiredo, Gerusa M.
   Levi, Jose E.
   Campos, Sergio R. S. L. C.
   Felix, Alvina Clara
   Santiago E Souza, Nathalia
   Figueiredo, Walter M.
   Costa, Angela A.
   Cardoso, Maria R. A.
   Pannuti, Claudio S.
TI A cohort study to assess the incidence of dengue, Brazil, 2014-2018
SO ACTA TROPICA
LA English
DT Article
ID RISK-FACTORS; INFECTION; CHILDREN; EFFICACY; VACCINE; VIRUS; PCR
AB The present cohort study was set up with the aim of determining the incidence of dengue among children and adolescents, from 2 to 16 years of age, living in Araraquara, South-Eastern Brazil, a city classified as a mid-level endemicity location for dengue.
   Enrollment took place from September 2014 to March 2015. Baseline socio-demographic data were collected, and a blood sample from the participant was drawn, for dengue serology. Families were contacted weekly for fever surveillance. If the child developed fever, a nurse visited the household to collect a blood sample. PCR, NS1 and IgM were used for dengue diagnosis. Parents or legal guardians of participating children provided a written informed consent.
   3,514 children and adolescents were enrolled in the cohort. Dengue baseline seroprevalence was 12.2% (95%CI: 11.1 - 13.3). The incidence density of symptomatic dengue was 8.94 per 100 person/years in the first year of follow-up, 0.58 in the second, and 0.19 in the fourth. No cases were confirmed in the third year. Incidence was associated with age, sex, baseline seroprevalence and with living in a house as opposed to an apartment.
   This study provides relevant information on the epidemiology of dengue in mid-level transmission settings that may be useful to policymakers in the evaluation of control strategies.
C1 [Luna, Expedito J. A.; Figueiredo, Gerusa M.; Levi, Jose E.; Campos, Sergio R. S. L. C.; Felix, Alvina Clara; Santiago E Souza, Nathalia; Pannuti, Claudio S.] Univ Sao Paulo, Fac Med, Inst Med Trop, Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
   [Figueiredo, Walter M.; Costa, Angela A.] Univ Sao Paulo, Serv Especial Saude Araraquara, Rua Italia 1617, BR-14801360 Araraquara, SP, Brazil.
   [Cardoso, Maria R. A.] Univ Sao Paulo, Fac Saude Publ, Av Dr Arnaldo 715, BR-01246904 Sao Paulo, SP, Brazil.
RP Luna, EJA (corresponding author), Univ Sao Paulo, Fac Med, Inst Med Trop, Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
EM eluna@usp.br
OI Campos, Sergio/0000-0002-1048-8332
FU Sanofi-Pasteur
FX The authors are thankful to the participants and their families and also
   to the field teams in Araraquara, who participated in data and
   biological samples collection. This study was supported by
   Sanofi-Pasteur (Grant no. DNG28). The sponsor had no role in the study
   design, collection, analysis and interpretation of data, preparation of
   the manuscript, nor in the decision to submit it for publication.
CR Argolo AFLT, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-254
   Balmaseda A, 2010, J INFECT DIS, V201, P5, DOI 10.1086/648592
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Biswal S, 2019, NEW ENGL J MED, V381, P2009, DOI 10.1056/NEJMoa1903869
   Braga C, 2010, ACTA TROP, V113, P234, DOI 10.1016/j.actatropica.2009.10.021
   Brasil, 2019, GUIA VIG SAUD
   Callahan JD, 2001, J CLIN MICROBIOL, V39, P4119, DOI 10.1128/JCM.39.11.4119-4124.2001
   Castanha PMS, 2017, EPIDEMIOL INFECT, V145, P2971, DOI [10.1017/S095026881700214X, 10.1017/s095026881700214x]
   Diaz-Quijano FA, 2019, T ROY SOC TROP MED H, V113, P212, DOI 10.1093/trstmh/try135
   GIESECKE J, 2002, MODERN INFECT DIS EP
   Gordon A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002462
   Huang SY, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0623-z
   Huhtamo E, 2010, J CLIN VIROL, V47, P49, DOI 10.1016/j.jcv.2009.11.001
   L'Azou M, 2016, NEW ENGL J MED, V374, P1155, DOI 10.1056/NEJMoa1503877
   Lima V.L.C., 2007, DENGUE INQUERITO POP, P669, DOI DOI 10.1590/S0102-311X2007000300025.
   Cunha MDM, 2008, EPIDEMIOL SERV SAUDE, V17, P217
   MASCIADRI V, 2019, REV PANAM SALUD PUBL, V43, DOI DOI 10.26633/RPSP.2019.11.ECOLLECTION2019
   Morrison AC, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000670
   Perez F, 2019, TROP MED INT HEALTH, V24, P442, DOI 10.1111/tmi.13200
   Rojas DP, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006847
   Sarti E, 2016, INT J INFECT DIS, V44, P44, DOI 10.1016/j.ijid.2016.01.015
   Siqueira JB, 2004, AM J TROP MED HYG, V71, P646, DOI 10.4269/ajtmh.2004.71.646
   Teixeira MG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002520
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   World Health Organization, 2009, DENG GUID DIAGN TREA
NR 25
TC 1
Z9 1
U1 1
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0001-706X
EI 1873-6254
J9 ACTA TROP
JI Acta Trop.
PD APR
PY 2020
VL 204
AR 105313
DI 10.1016/j.actatropica.2019.105313
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA LD1NP
UT WOS:000525798800023
PM 31863736
DA 2020-11-30
ER

PT J
AU Romano, CM
   Chebabo, A
   Levi, JE
AF Romano, C. M.
   Chebabo, A.
   Levi, J. E.
TI Past, present, and future of COVID-19: a review
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Review
DE SARS-CoV-2; COVID-19; RT-PCR; Diagnosis; Origin; Treatment
ID SARS
AB SARS-CoV-2 has recently emerged, becoming a global threat, affecting directly all human beings owing to its morbidity and mortality and indirectly, due to the enormous economic and psychological impact produced by social isolation, the most effective measure so far, but unsustainable for a long period. The scientific effort to understand and control SARS-CoV-2 transmission and clinical impact has been huge, and important achievements are highlighted in this review. Diagnosis is central and is the first step in recognizing and fighting any infectious agent. Instrumental to that is the quality of the data, relying on serological and molecular surveys in addition to trustworthy clinical records. However, the fast spread of a virus adapted for human-to-human respiratory transmission raised a demand for millions of molecular tests that are simply not available. Several candidate drugs are under evaluation in clinical trials. Those with an already recognized safety profile are more auspicious, since, if proven effective, can cut several steps of production and phase 2 and 3 trials. More than one hundred vaccine prototypes are in different stages of development, however, safety and efficacy evaluations cannot be obviated, implicating, most optimistically, in at least months for us to have an effective immunization, the definite measure to allow a safe return to the pre-pandemic lifestyle. Science has never been more necessary and present in daily life. Relying on the best of human wit is the only way out to this pandemic, saving as many lives as possible.
C1 [Romano, C. M.] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP LIM52, Sao Paulo, SP, Brazil.
   [Chebabo, A.] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, RJ, Brazil.
   [Chebabo, A.; Levi, J. E.] Lab Dasa, Sao Paulo, SP, Brazil.
   [Levi, J. E.] Univ Sao Paulo, Inst Med Trop, Lab Virol, Sao Paulo, SP, Brazil.
RP Levi, JE (corresponding author), Lab Dasa, Sao Paulo, SP, Brazil.; Levi, JE (corresponding author), Univ Sao Paulo, Inst Med Trop, Lab Virol, Sao Paulo, SP, Brazil.
EM dudilevi@usp.br
RI Romano, Camila/ABC-2883-2020
OI Romano, Camila/0000-0003-4550-1987
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2020, CORONAVIRUS DIS COVI
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bhattacharyya C, 2020, GLOBAL SPREAD SARS C, DOI DOI 10.1101//2020.05.04.075911
   Bohmer MM, 2020, LANCET INFECT DIS, V20, P920, DOI 10.1016/S1473-3099(20)30314-5
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Broughton JP, 2020, NAT BIOTECHNOL, V38, P870, DOI 10.1038/s41587-020-0513-4
   Candido DS, 2020, EVOLUTION EPIDEMIC S, DOI [10.1101/2020.06.11.20128249, DOI 10.1101/2020.06.11.20128249]
   Cariou B, 2020, DIABETOLOGIA, V63, P1500, DOI 10.1007/s00125-020-05180-x
   CDC, COR DIS 2019 COVID 1
   Chong YM, 2020, MICROBIOL RESOUR ANN, V9, DOI 10.1128/MRA.00383-20
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Domingo E, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008271
   Edridge A. W., 2020, CORONAVIRUS PROTECTI, DOI [10.1101/2020.05.11.20086439, DOI 10.1101/2020.05.11.20086439]
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   Gandhi RT, 2020, NEW ENGL J MED, V383, P1757, DOI 10.1056/NEJMcp2009249
   Gonzalez-Reiche AS, 2020, SCIENCE, V369, P297, DOI 10.1126/science.abc1917
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Nunes PCG, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6641-4
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kang HYJ, 2020, J MED VIROL, V92, P2263, DOI 10.1002/jmv.26114
   Kellam P, 2020, J GEN VIROL, V101, P791, DOI 10.1099/jgv.0.001439
   Khailany RA, 2020, GENE REP, V19, DOI 10.1016/j.genrep.2020.100682
   Kirkcaldy RD, 2020, JAMA-J AM MED ASSOC, V323, P2245, DOI 10.1001/jama.2020.7869
   Kohmer N, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104480
   Korber B., 2020, SPIKE MUTATION PIPEL, DOI [10.1101/2020.04.29.069054, DOI 10.1101/2020.04.29.069054]
   Leguia M, 2020, J INFECT DIS, V221, pS289, DOI 10.1093/infdis/jiz424
   Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1070, DOI 10.1515/cclm-2020-0285
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31180-6, 10.1016/S0140-6736(20)31324-6]
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Merindol N, 2020, J CLIN VIROL, V128
   Okada P, 2020, EUROSURVEILLANCE, V25, P6, DOI 10.2807/1560-7917.ES.2020.25.8.2000097
   Panigrahy D, 2020, CANCER METAST REV, V39, P1, DOI 10.1007/s10555-020-09862-1
   Penarrubia L, 2020, INT J INFECT DIS, V97, P225, DOI 10.1016/j.ijid.2020.06.027
   Peng ZH, 2020, FRONT MED-PRC, V14, P623, DOI 10.1007/s11684-020-0788-3
   Pillonel T, 2020, EUROSURVEILLANCE, V25, P33, DOI 10.2807/1560-7917.ES.2020.25.21.2000880
   Possas C, 2018, MEM I OSWALDO CRUZ, V113, P1, DOI 10.1590/0074-02760170361
   Rambaut A., 2020, PHYLODYNAMIC ANAL 17
   Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012
   Romano M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051267
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Stefanelli P, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.13.2000305
   Stringhini S, 2020, LANCET, V396, P313, DOI 10.1016/S0140-6736(20)31304-0
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Theel ES, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00136-20
   van Dorp L, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104351
   van Kampen JJA, 2020, SHEDDING INFECT VIRU, DOI [10.1101/2020.06.08.20125310, DOI 10.1101/2020.06.08.20125310]
   Viner RM, 2020, LANCET, V395, P1741, DOI 10.1016/S0140-6736(20)31129-6
   Vogels CBF, 2020, ANAL SENSITIVITY EFF, DOI [10.1101/2020.03.30.20048108, DOI 10.1101/2020.03.30.20048108]
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Woloshin S, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2015897
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yadav Pragya D, 2020, Indian J Med Res, V151, P200, DOI 10.4103/ijmr.IJMR_663_20
   Yan C, 2020, CLIN MICROBIOL INFEC, V26, P773, DOI 10.1016/j.cmi.2020.04.001
   Yan L, 2020, NAT MACH INTELL, V2, P183
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang T, 2020, CURR BIOL, V30, P1578, DOI 10.1016/j.cub.2020.03.063
NR 70
TC 0
Z9 0
U1 1
U2 1
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PY 2020
VL 53
IS 9
AR e10475
DI 10.1590/1414-431X202010475
PG 8
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA MX5YG
UT WOS:000557797700001
PM 32725080
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Benvenuti, LA
   Roggerio, A
   Nishiya, AS
   Mangini, S
   Levi, JE
AF Benvenuti, Luiz Alberto
   Roggerio, Alessandra
   Nishiya, Anna Shoko
   Mangini, Sandrigo
   Levi, Jose Eduardo
TI Sequential measurement of Trypanosoma cruzi parasitic load in
   endomyocardial biopsies for early detection and follow-up of Chagas
   disease reactivation after heart transplantation
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE chagas disease reactivation; endomyocardial biopsy; heart
   transplantation; polymerase chain reaction; Trypanosoma cruzi
ID POLYMERASE-CHAIN-REACTION; SOLID-ORGAN; DIAGNOSIS
AB Background Reactivation of Chagas disease after heart transplantation is characterized by proliferation and dissemination of Trypanosoma cruzi parasites to several organs. Reactivation affecting the allograft can simulate acute cellular rejection, from which it should be distinguished through the analysis of endomyocardial biopsies (EMB). Methods We evaluated retrospectively 100 EMB collected in the first year of follow-up from 13 heart-transplanted, chagasic patients who presented reactivation and were successfully treated. Additionally, 37 EMB from 8 patients who did not present reactivation constituted the control group. We reviewed histopathology and performed a real-time PCR-based assay in order to evaluate the T cruzi parasitic load of each EMB. Results The parasitic load of the EMB at the time of reactivation ranged from 22.80 to 190 000/10(6) cells (median: 1555). In 6 patients, none of the EMB obtained prior to reactivation amplified T cruzi DNA. On the other hand, 10 EMB from 7 patients, obtained 9-105 days before reactivation (median: 26 days), showed parasitic load ranging from 8.25 to 625/10(6) cells (median: 167.55). In all patients, the parasitic load increased at the time of reactivation, usually sharply. After initiation of treatment, all patients showed negative PCR or a dramatic reduction of the parasitic load in the following EMB. None of the EMB from the control group amplified T cruzi DNA. Conclusions Sequential measurement of T cruzi parasitic load in EMB is useful for monitoring Chagas disease reactivation after heart transplantation. Its increase suggests imminent reactivation and its decrease after treatment indicates favorable evolution for cure of the episode of reactivation.
C1 [Benvenuti, Luiz Alberto; Roggerio, Alessandra; Mangini, Sandrigo] Univ Sao Paulo, Heart Inst InCor, Hosp Clin HCFMUSP, Fac Med, Sao Paulo, SP, Brazil.
   [Nishiya, Anna Shoko] Univ Sao Paulo, Fundacao Prosangue, Hosp Clin HCFMUSP, Fac Med,Hemoctr Sao Paulo, Sao Paulo, SP, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop, Sao Paulo, SP, Brazil.
RP Benvenuti, LA (corresponding author), Heart Inst InCor, Av Dr Eneas Carvalho Aguiar 44, BR-05403904 Sao Paulo, SP, Brazil.
EM anpluiz@incor.usp.br
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2017/07946-8]
FX This study was financially supported by grant #2017/07946-8, Sao Paulo
   Research Foundation (FAPESP).
CR [Anonymous], 2012, Wkly Epidemiol Rec, V87, P519
   Bacal F, 2010, CLIN TRANSPLANT, V24, pE29, DOI 10.1111/j.1399-0012.2009.01202.x
   Benatti RD, 2017, J HEART LUNG TRANSPL, V36, P597, DOI 10.1016/j.healun.2017.02.006
   Benvenuti LA, 2017, TRANSPL INFECT DIS, V19, DOI 10.1111/tid.12783
   Benvenuti LA, 2011, J HEART LUNG TRANSPL, V30, P799, DOI 10.1016/j.healun.2011.02.012
   Benvenuti LA, 2017, J HEART LUNG TRANSPL, V36, P1360, DOI 10.1016/j.healun.2017.08.007
   Campos SV, 2008, J HEART LUNG TRANSPL, V27, P597, DOI 10.1016/j.healun.2008.02.017
   da Costa PA, 2017, J HEART LUNG TRANSPL, V36, P797, DOI 10.1016/j.healun.2017.02.018
   Diez M, 2007, AM J TRANSPLANT, V7, P1633, DOI 10.1111/j.1600-6143.2007.01820.x
   Fiorelli AI, 2011, TRANSPL P, V43, P220, DOI 10.1016/j.transproceed.2010.12.046
   Gray EB, 2018, TRANSPL INFECT DIS, V20, DOI 10.1111/tid.12996
   Kransdorf EP, 2013, AM J TRANSPLANT, V13, P3262, DOI 10.1111/ajt.12507
   Kransdorf EP, 2014, CURR OPIN INFECT DIS, V27, P418, DOI 10.1097/QCO.0000000000000088
   Melo MF, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0770-0
   Montgomery SP, 2014, AM J TROP MED HYG, V90, P814, DOI 10.4269/ajtmh.13-0726
   Piron M, 2007, ACTA TROP, V103, P195, DOI 10.1016/j.actatropica.2007.05.019
   Ramalho AR, 2017, REV PORT CARDIOL, V36, P869, DOI 10.1016/j.repc.2016.08.015
   Salvador F, 2018, AM J TROP MED HYG, V98, P742, DOI 10.4269/ajtmh.17-0735
NR 18
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD FEB
PY 2020
VL 22
IS 1
AR e13209
DI 10.1111/tid.13209
EA NOV 2019
PG 6
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA KQ8QD
UT WOS:000497564700001
PM 31698532
DA 2020-11-30
ER

PT J
AU Rocha, DAP
   Azevedo, MJN
   Batista, SJS
   Beltrao, ES
   Moraes, CO
   Araujo, AF
   Reis, RS
   Torres, KL
   Levi, JE
   Marino, JM
AF Rocha, Danielle A. P.
   Azevedo, Maria Joana N.
   Batista, Savio Jose S.
   Beltrao, Emille S.
   Moraes, Cassia O.
   Araujo, Adriene F.
   Reis, Renato S.
   Torres, Katia L.
   Levi, Jose Eduardo
   Marino, Josiane M.
TI T. vaginalis in riverside women in Amazonia, Brazil: an experience using
   the EVALYN (R) BRUSH vaginal self-collection device
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE Trichomonas vaginalis; Amazonas; self-collection
ID TRICHOMONAS-VAGINALIS; CHLAMYDIA-TRACHOMATIS; PERFORMANCE
AB Introduction: The challenges related to the diagnosis of sexually transmitted infections present more complex factors in remote and hard-toreach areas. The use of self-collection devices that facilitate the obtaining of a biological sample with high quality for sensitive molecular tests have been examined. This study aimed to evaluate the performance and acceptance of the Evalyn (R) Brush (Rovers (R) Medical Devices) for detection of T. vaginalis among women living in the riverside communities of Amazonas, Brazil.
   Methodology: The study included 300 riverside women. They received instructions for self-collection, carried out the task, and then answered a questionnaire on the use of the device. T. vaginalis was detected by Polymerase Chain Reaction, using primers TVK3/TVK7.
   Results: The mean age of the women was 35.8 years, and most of them presented low schooling, low income, agricultural activity and lived in a marital union. All samples were positive for human genomic DNA (100%) and the prevalence of T. vaginalis infection was 5.6% (n = 17). Of the 300 women, 293 (97.7%) indicated that they liked the use of the device, 287 (95.7%) reported having had no difficulty in handling it, 265 (88.3%) did not feel any type of discomfort and 228 (76%) said they preferred the self-collection to the collection made by the professional, mainly due to privacy and comfort.
   Conclusions: The Evalyn (R) Brush proved reliable as a device for the collection of biological samples for molecular analysis and was well-accepted by women. Its use can be indicated in remote and hard to reach places.
C1 [Rocha, Danielle A. P.; Azevedo, Maria Joana N.; Batista, Savio Jose S.; Beltrao, Emille S.; Moraes, Cassia O.; Araujo, Adriene F.; Reis, Renato S.; Marino, Josiane M.] Univ Fed Amazonas UFAM, ISB, Coari, Amazonas, Brazil.
   [Torres, Katia L.] Fundacao Ctr Controle Oncol Estado Amazonas FCECO, Manaus, Amazonas, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, IMT, Sao Paulo, SP, Brazil.
RP Rocha, DAP (corresponding author), Univ Fed Amazonas, Inst Saude & Biotecnol, Estr Coari Mamia 305, BR-69460000 Espirito Santo, Coari Amazonas, Brazil.
EM dannyodonto@hotmail.com
FU "Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior"
   (CAPES)CAPES
FX The authors thank "Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior" (CAPES) for financially supporting the "Programa de
   Pos-graduacao Mestrado em Ciencias da Saude" (PPGMCS) (Universidade
   Federal do Amazonas).
CR Ambrozio CL, 2016, REV INST MED TROP SP, V58, P1
   Amorim AT, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2835-5
   Arias M, 2016, SEX TRANSM DIS, V43, P125, DOI 10.1097/OLQ.0000000000000406
   Costa-Lira E, 2017, GENET MOL RES, V16, DOI 10.4238/gmr16029626
   Crucitti T, 2003, SEX TRANSM INFECT, V79, P393, DOI 10.1136/sti.79.5.393
   Gatti FAD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173604
   Ejegod DM, 2018, PAPILLOMAVIRUS RES, V5, P192, DOI 10.1016/j.pvr.2018.04.005
   Evans DB, 2013, B WORLD HEALTH ORGAN, V91, P10
   Silva LCF, 2013, BRAZ J INFECT DIS, V17, P701, DOI 10.1016/j.bjid.2013.03.006
   Fraxe T, 2007, AMAZON RIVER COMMUNI
   Gama ASM, 2018, CAD SAUDE PUBLICA, V34, P1
   Garrett NJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196209
   Gaydos CA, 2017, SEX TRANSM INFECT, V93, pS31, DOI 10.1136/sextrans-2016-053063
   Gopalkrishna V, 2000, CLIN MICROBIOL INFEC, V6, P88, DOI 10.1046/j.1469-0691.2000.00024.x
   Gumbo FZ, 2010, J PERINATOL, V30, P717, DOI 10.1038/jp.2010.31
   Jones HE, 2013, J CLIN MICROBIOL, V51, P1037, DOI 10.1128/JCM.01547-12
   Kissinger P, 2013, SEX TRANSM INFECT, V89, P426, DOI 10.1136/sextrans-2012-051005
   Luppi Carla Gianna, 2011, Rev. bras. epidemiol., V14, P467, DOI 10.1590/S1415-790X2011000300011
   Menezes CB, 2016, MICROB CELL, V3, P404, DOI 10.15698/mic2016.09.526
   Paudyal P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124310
   Rocha DAP, 2014, INT J STD AIDS, V25, P878, DOI 10.1177/0956462414523742
   Poole DN, 2013, SEX TRANSM INFECT, V89, P418, DOI 10.1136/sextrans-2013-051075
   Price CM, 2018, SEX TRANSM DIS, V45, P332, DOI 10.1097/OLQ.0000000000000756
   Santos João Rocha, 2016, Nascer e Crescer, V25, P163
   Schnippel K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119236
   Shafir SC, 2009, CLIN MICROBIOL REV, V22, P37, DOI 10.1128/CMR.00002-08
   Silver BJ, 2014, SEX TRANSM DIS, V41, P369, DOI 10.1097/OLQ.0000000000000134
   Snijders PJF, 2013, INT J CANCER, V132, P2223, DOI 10.1002/ijc.27790
   Souza RP, 2013, AM J TROP MED HYG, V89, P1199, DOI 10.4269/ajtmh.13-0315
   Torres KL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201262
   Tranberg M, 2018, BMC INFECT DIS, V181, P4
   Tranberg M, 2018, CLIN EPIDEMIOL, V10, P1027, DOI 10.2147/CLEP.S164826
   von Glehn MD, 2017, J INFECT DEV COUNTR, V11, P269, DOI 10.3855/jidc.8143
NR 33
TC 0
Z9 0
U1 0
U2 0
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD NOV
PY 2019
VL 13
IS 11
BP 1029
EP 1037
DI 10.3855/jidc.11385
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA JT3XR
UT WOS:000500926600011
PM 32087075
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Tedder, RS
   Dicks, S
   Ijaz, S
   de Souza, NCS
   de Paula, AV
   Levy, F
   Medialdea-Carrera, R
   Levi, JE
   Pannuti, CS
   de Sequeira, PC
   Brown, DWG
   Lumb, IU
AF Tedder, Richard S.
   Dicks, Steve
   Ijaz, Samreen
   Santiago de Souza, Nathalia Caroline
   de Paula, Anderson Vincente
   Levy, Flavia
   Medialdea-Carrera, Raquel
   Levi, Jose Eduardo
   Pannuti, Claudio S.
   de Sequeira, Patricia Carvalho
   Brown, David W. G.
   Lumb, Ines Ushiro
TI Modulated Zika virus NS1 conjugate offers advantages for accurate
   detection of Zika virus specific antibody in double antigen binding and
   Ig capture enzyme immunoassays
SO PLOS ONE
LA English
DT Article
ID TRANSMISSION; INFECTION; DISEASE; ASSAY
AB The accurate diagnosis and seroprevalence investigations of Zika virus (ZKV) infections remain complex due to cross reactivity with other flaviviruses. Two assay formats, both using labelled Zika virus NS1 antigen as a revealing agent (a double antigen binding assay, DABA, and an immunoglobulin Ig capture assay, G capture) were initially developed and compared with the indirect EuroimmunZ assay for the detection of anti-Zika antibody. Of 147 pre-Zika period serum samples, 39 (27%) were reactive in the EuroimmunZ or the DABA assays, 28 sera concordantly so. Such false reactivity was influenced by the serotype of Dengue virus (DV) to which individuals had been exposed to. Thus, of sera from patients undergoing secondary Dengue virus infection of known serotype, 91%, 45% and 28% of Dengue virus serotype 2, 3 and 4 respectively were reactive in one or more of the three assays. A novel method of quenching false sero-reactivity was therefore developed for the DABA and G capture assays. Initial addition of a single homologous Dengue virus serotype 3 NS1Ag quench significantly ablated false reactivities in the pre-Zika period sera. An equipotent quadrivalent quench comprising homologous Dengue virus serotypes 1 to 4 NS1Ag was shown to be optimum yet retained sensitivity for the detection of specific anti-Zika antibody. Comparing DABA and G capture assays using quenched and unquenched conjugates in comparison with EuroimmunZ early in the course of PCR-confirmed infection indicated that a significant component of the apparent early anti-ZIKA antibody response is likely to be due to a Zika virus-driven anamnestic anti-Dengue virus response. The increased specificity provided by homologous antigen quenching is likely to provide a significant improvement in sero-diagnostics and to be of clinical value.
C1 [Tedder, Richard S.; Dicks, Steve; Ijaz, Samreen; Brown, David W. G.; Lumb, Ines Ushiro] Publ Hlth England, Blood Borne Virus Unit, Virus Reference Dept, London, England.
   [Tedder, Richard S.; Dicks, Steve; Lumb, Ines Ushiro] NHS Blood & Transplant, Microbiol Serv, London, England.
   [Tedder, Richard S.] UCL, London, England.
   [Santiago de Souza, Nathalia Caroline; de Paula, Anderson Vincente; Levi, Jose Eduardo; Pannuti, Claudio S.] Univ Sao Paulo, Inst Med Trop, Virol Lab LIM HCFMUSP, Sao Paulo, Brazil.
   [Levy, Flavia; de Sequeira, Patricia Carvalho; Brown, David W. G.] Fiocruz MS, Flavivirus Reference Lab, IOC, Rio De Janeiro, Brazil.
   [Medialdea-Carrera, Raquel] Univ Liverpool, Natl Inst Hlth Res, Hlth Protect Res Unit Emerging & Zoonot Infect, Liverpool, Merseyside, England.
   [Tedder, Richard S.] Imperial Coll London, Fac Med, Dept Infect Dis, London, England.
RP Ijaz, S (corresponding author), Publ Hlth England, Blood Borne Virus Unit, Virus Reference Dept, London, England.
EM samreen.ijaz@phe.gov.uk
OI Tedder, Richard/0000-0002-9672-5721; Medialdea-Carrera,
   Raquel/0000-0002-0371-5138; Ijaz, Samreen/0000-0001-6658-3542
FU Medical Research Council Zika Rapid Response award [MC_PC_15093]; Public
   Health England Pipeline fund [PLF 1819-115/RA]; European Union's horizon
   2020 research and innovation programme [734857]; Zikaction; Zikaplan
   [734584]
FX This work was supported by Medical Research Council Zika Rapid Response
   award (MC_PC_15093) to RST, SI, DWGB, IUL, https://mrc.ukri.org/; Public
   Health England Pipeline fund (PLF 1819-115/RA) to RST, SI,
   https://www.gov.uk/government/organisations/public-health-england. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; We would like to
   thank colleagues in Diasorin for the kind gift of the conjugate diluent.
   DB is partially funded by European Union's horizon 2020 research and
   innovation programme (grant agreement no. 734857), Zikaction and
   Zikaplan consortia (grant agreement 734584). RMC is affiliated to the
   NIHR HPRU in Emerging and Zoonotic Infections at University of Liverpool
   in partnership with PHE, in collaboration with LSHTM.
CR Balmaseda A, 2017, P NATL ACAD SCI USA, V114, P8384, DOI 10.1073/pnas.1704984114
   Barjas-Castro ML, 2016, TRANSFUSION, V56, P1684, DOI 10.1111/trf.13681
   Bingham AM, 2016, MMWR-MORBID MORTAL W, V65, P475, DOI 10.15585/mmwr.mm6518e2
   BROWN DWG, 1994, BRIT MED J, V308, P1015, DOI 10.1136/bmj.308.6935.1015
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Glynn JR, 2017, LANCET INFECT DIS, V17, P645, DOI 10.1016/S1473-3099(17)30111-1
   HALSTEAD SB, 1983, AM J TROP MED HYG, V32, P154, DOI 10.4269/ajtmh.1983.32.154
   Hills SL, 2016, MMWR-MORBID MORTAL W, V65, P215, DOI 10.15585/mmwr.mm6508e2
   Kindhauser MK, 2016, B WORLD HEALTH ORGAN, V94, P675, DOI 10.2471/BLT.16.171082
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Mead PS, 2016, NEW ENGL J MED, V378, P1377
   Moghadas SM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05013-9
   MOORE DL, 1975, ANN TROP MED PARASIT, V69, P49, DOI 10.1080/00034983.1975.11686983
   Motta IJF, 2016, NEW ENGL J MED, V375, P1101, DOI 10.1056/NEJMc1607262
   Musso D, 2017, CLIN MICROBIOL INFEC, V23, DOI 10.1016/j.cmi.2017.07.006
   Priyamvada L, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.42
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Tedder RS, 2018, TRANSFUSION, V58, P1289, DOI 10.1111/trf.14580
NR 19
TC 0
Z9 0
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 2
PY 2019
VL 14
IS 8
AR e0215708
DI 10.1371/journal.pone.0215708
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA IW5AR
UT WOS:000484991500001
PM 31374094
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Levi, JE
   Martins, TR
   Longatto, A
   Cohen, DD
   Cury, U
   Fuza, LM
   Villa, LL
   Eluf-Neto, J
AF Levi, Jose Eduardo
   Martins, Toni Ricardo
   Longatto-Filho, Adhemar
   Cohen, Diane Dede
   Cury, Use
   Fuza, Luiz Mario
   Villa, Luisa L.
   Eluf-Neto, Jose
TI High-Risk HPV Testing in Primary Screening for Cervical Cancer in the
   Public Health System, Sao Paulo, Brazil
SO CANCER PREVENTION RESEARCH
LA English
DT Article
ID WOMEN; NEOPLASIA
AB Every year there are approximately 16,000 new cases of cervical cancer in Brazil. Novel screening technologies may reduce this number by expanding the population coverage but also by improving the detection rate of precursor lesions. We aimed to evaluate human papillomaviruses (HPV)-DNA testing in the context of routine cervical cancer screening in the public health system of the city of Sao Paulo, Brazil. Women participating in the primary screening program were invited to enroll. Liquid-based cytology samples were collected and cytology and Hr-HPV DNA testing were performed in parallel. Cytologists were blind to I IPV results. Women older than 24 years with a positive high-risk HPV test and/or cytology class >= ASC-US were referred to colposcopy. From December 2014 to December 2016, 16,102 women joined the study. High-risk human papillomavirus (HR HPV) DNA prevalence was 14.9%, whereas cytologic abnormalities were found in 7,2% of the women. Per protocol, 1,592 Hr-HPV+ women, in addition to 72 patients with cytologic classification > low-grade squamous intraepithelial lesion (LSIL) were referred. A total of 80 cervical intraepithelial neoplasia (CIN2(+)) cases were diagnosed, 79 were Hr-HPV DNA(+) and 18 had normal cytology. Hr-HPV DNA detected a significant number of patients with premalignant lesions missed by cytology and all 16 CIN3(+) cases were Hr-HPV DNA(+). HPV genotyping may be useful in the management of Hr-HPV+ women, reducing the burden of colposcopic referral for those harboring genotypes with a weaker association to CIN3(+). Use of HPV-DNA testing was shown to be feasible and advantageous over current cytologic screening in the public health system.
C1 [Levi, Jose Eduardo; Martins, Toni Ricardo; Fuza, Luiz Mario] Univ Sao Paulo, Inst Med Trop, Virol Lab LIM 52, Sao Paulo, Brazil.
   [Martins, Toni Ricardo; Longatto-Filho, Adhemar; Villa, Luisa L.; Eluf-Neto, Jose] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal.
   [Longatto-Filho, Adhemar] Univ Minho, Sch Med, Life & Hlth Sci Res Inst ICVS, Braga, Portugal.
   [Longatto-Filho, Adhemar] Barretos Canc Hosp, Mol Oncol Res Ctr, Sao Paulo, Brazil.
   [Cohen, Diane Dede; Cury, Use; Fuza, Luiz Mario; Eluf-Neto, Jose] Fundacao Oncoctr Sao Paulo, Sao Paulo, Brazil.
   [Villa, Luisa L.] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil.
RP Levi, JE (corresponding author), Univ Sao Paulo, R Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM dudilevi@usp.br
RI VILLA, LUISA/AAH-4761-2019; Eluf-Neto, Jose/B-2522-2009; Longatto-Filho,
   Adhemar/N-3397-2019
OI VILLA, LUISA/0000-0003-4074-2335; Eluf-Neto, Jose/0000-0001-7504-2115;
   Longatto-Filho, Adhemar/0000-0002-5779-9752
FU National Research Council (CNPq)National Council for Scientific and
   Technological Development (CNPq) [573799/2008-3]; Sao Paulo Research
   Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2008/57889-1]
FX We would like to acknowledge the invaluable work of the three
   colposcopists Dr. Monica Christina Rial (Hospital e Maternidade
   Interlagos), Vivian R. M. de Souza Silva (UBS Vila Sonia), and Noely
   Paula Cristina Lorenzi (Hospital Universitario). National Research
   Council (CNPq) grant no. 573799/2008-3, Sao Paulo Research Foundation
   (FAPESP) grant no. 2008/57889-1.
CR Costa RFA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138945
   Arbyn M, 2015, CLIN MICROBIOL INFEC, V21, P817, DOI 10.1016/j.cmi.2015.04.015
   Silva GAE, 2010, CAD SAUDE PUBLICA, V26, P2398
   Cuschieri K, 2018, INT J CANCER, V143, P735, DOI 10.1002/ijc.31261
   Diaz RS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139677
   Ejegod D, 2016, J CLIN MICROBIOL, V54, P2267, DOI 10.1128/JCM.00508-16
   Flores YN, 2011, CANCER CAUSE CONTROL, V22, P261, DOI 10.1007/s10552-010-9694-3
   Forman D, 2013, CANC INCIDENCE 5 CON, VX
   Gultekin M, 2018, INT J CANCER, V142, P1952, DOI 10.1002/ijc.31212
   Instituto Nacional de Cancer (Brasil), 2011, COORD GER AC ESTR
   Instituto Nacional de Cancer Jose Alencar Gomes da Silva, 2016, COORDENACAO DE PREVE
   Jeronimo J, 2016, J CLIN VIROL, V76, pS69, DOI 10.1016/j.jcv.2015.11.035
   Kurman RJ, 2014, WHO CLASSIFICATION T, P2
   Lew JB, 2017, LANCET PUBLIC HEALTH, V2, pE96, DOI 10.1016/S2468-2667(17)30007-5
   Longatto A, 2015, ACTA CYTOL, V59, P273, DOI 10.1159/000435801
   Martins TR, 2018, AM J CLIN PATHOL, V149, P316, DOI [10.1093/AJCP/AQX163, 10.1093/ajcp/aqx163]
   Nayar R, 2015, CANCER CYTOPATHOL, V123, P271, DOI 10.1002/cncy.21521
   Rocha D, 2018, TRANSFUSION, V58, P862, DOI 10.1111/trf.14478
   Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7
   Schiffman M, 2011, CANCER EPIDEM BIOMAR, V20, P1398, DOI 10.1158/1055-9965.EPI-11-0206
   Smelov V, 2015, INT J CANCER, V136, P1171, DOI 10.1002/ijc.29085
   Speck NMG, 2018, DOSSIE ESTRATEGIAS R
   Stoler MH, 2018, GYNECOL ONCOL, V149, P498, DOI 10.1016/j.ygyno.2018.04.007
   Thomsen LT, 2015, INT J CANCER, V137, P193, DOI 10.1002/ijc.29374
   Torres KL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201262
   Wentzensen N, 2017, INT J CANCER, V140, P2192, DOI 10.1002/ijc.30579
   Wright TC, 2015, GYNECOL ONCOL, V136, P189, DOI 10.1016/j.ygyno.2014.11.076
   Wright TC, 2011, AM J CLIN PATHOL, V136, P578, DOI 10.1309/AJCPTUS5EXAS6DKZ
NR 28
TC 3
Z9 3
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1940-6207
EI 1940-6215
J9 CANCER PREV RES
JI Cancer Prev. Res.
PD AUG
PY 2019
VL 12
IS 8
BP 539
EP 546
DI 10.1158/1940-6207.CAPR-19-0076
PG 8
WC Oncology
SC Oncology
GA IM5EB
UT WOS:000478016000005
PM 31189569
OA Bronze
DA 2020-11-30
ER

PT J
AU Kallas, EG
   Zanella, LGFABD
   Moreira, CHV
   Buccheri, R
   Diniz, GBF
   Castineiras, ACP
   Costa, PR
   Dias, JZC
   Marmorato, MP
   Song, ATW
   Maestri, A
   Borges, IC
   Joelsons, D
   Cerqueira, NB
   Souza, NCSE
   Claro, IM
   Sabino, EC
   Levi, JE
   Avelino-Silva, VI
   Ho, YL
AF Kallas, Esper G.
   D'Elia Zanella, Luiz Gonzaga F. A. B.
   Moreira, Carlos Henrique, V
   Buccheri, Renata
   Diniz, Gabriela B. F.
   Castineiras, Anna Carla P.
   Costa, Priscilla R.
   Dias, Juliana Z. C.
   Marmorato, Mariana P.
   Song, Alice T. W.
   Maestri, Alvino
   Borges, Igor C.
   Joelsons, Daniel
   Cerqueira, Natalia B.
   Santiago e Souza, Nathalia C.
   Claro, Ingra Morales
   Sabino, Ester C.
   Levi, Jose Eduardo
   Avelino-Silva, Vivian, I
   Ho, Yeh-Li
TI Predictors of mortality in patients with yellow fever: an observational
   cohort study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID VIRUS OUTBREAK; ZIKA VIRUS; PCR; RESURGENCE; SPREAD; ANGOLA
AB Background Yellow fever virus infection results in death in around 30% of symptomatic individuals. The aim of this study was to identify predictors of death measured at hospital admission in a cohort of patients admitted to hospital during the 2018 outbreak of yellow fever in the outskirts of Sao Paulo city, Brazil.
   Methods In this observational cohort study, we enrolled patients with yellow fever virus from two hospitals in Sao Paolo-the Hospital das Clinicas, University of Sao Paulo and the Infectious Diseases Institute "Emilio Ribas". Patients older than 18 years admitted to hospital with fever or myalgia, headache, arthralgia, oedema, rash, or conjunctivitis were consecutively screened for inclusion in the present study. Consenting patients were included if they had travelled to geographical areas in which yellow fever virus cases had been previously confirmed. Yellow fever infection was confirmed by real-time PCR in blood collected at admission or tissues at autopsy. We sequenced the complete genomes of yellow fever virus from infected individuals and evaluated demographic, clinical, and laboratory findings at admission and investigated whether any of these measurements correlated with patient outcome (death).
   Findings Between Jan 11, 2018, and May 10, 2018, 118 patients with suspected yellow fever were admitted to Hospital das Clinicas, and 113 patients with suspected yellow fever were admitted to Infectious Diseases Institute "Emilio Ribas". 95 patients with suspected yellow fever were included in the study, and 136 patients were excluded. Three (3%) of 95 patients with suspected yellow fever who were included in the study were excluded because they received a different diagnosis, and 16 patients with undetectable yellow fever virus RNA were excluded. Therefore, 76 patients with confirmed yellow fever virus infection, based on detectable yellow fever virus RNA in blood (74 patients) or yellow fever virus confirmed only at the autopsy report (two patients), were included in our analysis. 27 (36%) of 76 patients died during the 60 day period after hospital admission. We generated 14 complete yellow fever virus genomes from the first 15 viral load-detectable samples. The genomes belonged to a single monophyletic clade of the South America I genotype, sub-genotype E. Older age, male sex, higher leukocyte and neutrophil counts, higher alanine aminotransferase, aspartate transaminase (AST), bilirubin, and creatinine, prolonged prothrombin time, and higher yellow fever virus RNA plasma viral load were associated with higher mortality. In a multivariate regression model, older age, elevated neutrophil count, increased AST, and higher viral load remained independently associated with death. All 11 (100%) patients with neutrophil counts of 4000 cells per mL or greater and viral loads of 5.1 log(10) copies/mL or greater died (95% CI 72-100), compared with only three (11%) of 27 (95% CI 2-29) among patients with neutrophil counts of less than 4000 cells per mL and viral loads of less than 5.1 log(10) copies/mL.
   Interpretation We identified clinical and laboratory predictors of mortality at hospital admission that could aid in the care of patients with yellow fever virus. Identification of these prognostic markers in patients could help clinicians prioritise admission to the intensive care unit, as patients often deteriorate rapidly. Moreover, resource allocation could be improved to prioritise key laboratory examinations that might be more useful in determining whether a patient could have a better outcome. Our findings support the important role of the virus in disease pathogenesis, suggesting that an effective antiviral could alter the clinical course for patients with the most severe forms of yellow fever.
C1 [Kallas, Esper G.; D'Elia Zanella, Luiz Gonzaga F. A. B.; Moreira, Carlos Henrique, V; Costa, Priscilla R.; Dias, Juliana Z. C.; Marmorato, Mariana P.; Song, Alice T. W.; Maestri, Alvino; Borges, Igor C.; Joelsons, Daniel; Cerqueira, Natalia B.; Claro, Ingra Morales; Sabino, Ester C.; Avelino-Silva, Vivian, I; Ho, Yeh-Li] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, BR-01246903 Sao Paulo, Brazil.
   [D'Elia Zanella, Luiz Gonzaga F. A. B.; Moreira, Carlos Henrique, V; Buccheri, Renata; Diniz, Gabriela B. F.; Castineiras, Anna Carla P.] Infect Dis Inst Emilio Ribas, Sao Paulo, Brazil.
   [Santiago e Souza, Nathalia C.; Levi, Jose Eduardo] Univ Sao Paulo, Trop Med Inst, Sao Paulo, Brazil.
RP Kallas, EG (corresponding author), Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, BR-01246903 Sao Paulo, Brazil.
EM esper.kallas@usp.br
RI Marmorato, Mariana/V-5375-2018; Avelino-Silva, Vivian I/L-2640-2013;
   Castineiras, Anna/AAB-6754-2019; Sabino, Ester Cerdeira/F-7750-2010;
   Borges, Igor Carmo/AAG-8531-2019
OI Marmorato, Mariana/0000-0002-0644-0862; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; Castineiras, Anna/0000-0003-2503-9414; Sabino,
   Ester Cerdeira/0000-0003-2623-5126; Carmo Borges,
   Igor/0000-0003-2749-0313; Kallas, Esper/0000-0003-2026-6925; Moreira,
   Carlos Henrique Valente/0000-0002-4187-5482; Barros D'Elia Zanella, Luiz
   Gonzaga Francisco de Assis/0000-0002-3166-5633
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP)
FX Sao Paulo Research Foundation (FAPESP).
CR Aguiar BS, 2018, INT J INFECT DIS, V70, P20, DOI 10.1016/j.ijid.2018.02.007
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P442
   Bae HG, 2003, J VIROL METHODS, V110, P185, DOI 10.1016/S0166-0934(03)00129-0
   BEEUWKES Henry, 1936, Transactions of the Royal Society of Tropical Medicine and Hygiene, V30, P61, DOI 10.1016/S0035-9203(36)90014-7
   Blake LE, 2014, MBIO, V5, DOI 10.1128/mBio.01253-14
   de Rezende IM, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006538
   Dick OB, 2012, AM J TROP MED HYG, V87, P584, DOI 10.4269/ajtmh.2012.11-0770
   Engelmann F, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003295
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Fernandes-Monteiro AG, 2015, HUM VACC IMMUNOTHER, V11, P1865, DOI 10.4161/21645515.2014.990854
   Fischer C, 2017, EMERG INFECT DIS, V23, P1867, DOI 10.3201/eid2311.171131
   Gomez MM, 2018, J GEN VIROL, V99, P536, DOI 10.1099/jgv.0.001033
   Grobbelaar AA, 2016, EMERG INFECT DIS, V22, P1854, DOI 10.3201/eid2210.160818
   Halai UA, 2017, CLIN INFECT DIS, V65, P877, DOI 10.1093/cid/cix472
   Hughes HR, 2018, EMERG INFECT DIS, V24, P1598, DOI 10.3201/eid2408.180588
   Julander JG, 2014, ANTIVIR RES, V103, P32, DOI 10.1016/j.antiviral.2013.12.011
   Kraemer MUG, 2017, LANCET INFECT DIS, V17, P330, DOI [10.1016/s1473-3099(16)30513-8, 10.1016/S1473-3099(16)30513-8]
   Lindsey NP, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay108
   Massad E, 2018, EPIDEMIOL INFECT, V146, P1219, DOI [10.1017/S0950268818001334, 10.1017/s0950268818001334]
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   Monath TP, 2005, EXPERT REV VACCINES, V4, P553, DOI 10.1586/14760584.4.4.553
   Monath TP, 2003, ADV VIRUS RES, V60, P343, DOI 10.1016/S0065-3527(03)60009-6
   Nunes PCG, 2018, VIRUSES, V10, pE236
   Plotkin SA, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay130
   Quaresma JAS, 2013, REV MED VIROL, V23, P305, DOI 10.1002/rmv.1752
   Quick J, 2017, NAT PROTOC, V12, P1261, DOI 10.1038/nprot.2017.066
   Rowe EK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002777
   Secretary of Health State of Sao Paulo, 2018, B EP FEBR AM
   Shearer FM, 2017, LANCET INFECT DIS, V17, P1209, DOI 10.1016/S1473-3099(17)30419-X
   Song ATW, 2019, HEPATOLOGY, V69, P1349, DOI 10.1002/hep.30273
   ter Meulen J, 2004, J INFECT DIS, V190, P1821, DOI 10.1086/425016
   Tuboi SH, 2007, T ROY SOC TROP MED H, V101, P169, DOI 10.1016/j.trstmh.2006.04.001
   van de Weg CAM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002236
   Weaver SC, 2015, NEW ENGL J MED, V372, P1231, DOI 10.1056/NEJMra1406035
   Wilder-Smith A, 2017, J TRAVEL MED, V24, P1
NR 35
TC 13
Z9 13
U1 3
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JUL
PY 2019
VL 19
IS 7
BP 750
EP 758
DI 10.1016/S1473-3099(19)30125-2
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA IF1DQ
UT WOS:000472818900035
PM 31104909
DA 2020-11-30
ER

PT J
AU Levi, JE
AF Levi, Jose Eduardo
TI Comment to: Test seeking: are health care professionals referring people
   to the blood centers for infectious markers testing?
SO HEMATOLOGY TRANSFUSION AND CELL THERAPY
LA English
DT Editorial Material
ID DONORS; BEHAVIORS; DONATION
C1 [Levi, Jose Eduardo] Univ Sao Paulo IMTSP USP, Inst Med Trop, Sao Paulo, SP, Brazil.
   [Levi, Jose Eduardo] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil.
RP Levi, JE (corresponding author), Univ Sao Paulo, Trop Med Inst, Virol Lab, Rua Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM dudilevi@usp.br
CR Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010
   Donnell D, 2017, AIDS, V31, P2007, DOI [10.1097/qad.0000000000001577, 10.1097/QAD.0000000000001577]
   Goncalez TT, 2006, VOX SANG, V90, P170, DOI 10.1111/j.1423-0410.2006.00743.x
   Grinsztejn B, 2018, LANCET HIV, V5, pE136, DOI 10.1016/S2352-3018(18)30008-0
   Lau JTF, 2002, AIDS CARE, V14, P481, DOI 10.1080/09540120208629667
   Miranda C, 2014, VOX SANG, V106, P344, DOI 10.1111/vox.12114
   Moreno EC, 2019, HEMATOL TRANSF CELL
   Raimondo M, 2016, VOX SANG, V110, P134, DOI 10.1111/vox.12328
   Sykes W, 2019, J INFECT DIS
NR 9
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2531-1379
J9 HEMATOL TRANSF CELL
JI Hematol. Transf. Cell Ther.
PD JUL-SEP
PY 2019
VL 41
IS 3
BP 197
EP 198
DI 10.1016/j.htct.2019.07.001
PG 2
WC Oncology; Hematology
SC Oncology; Hematology
GA NN3JY
UT WOS:000568688800003
PM 31383586
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Dezan, MR
   Costa-Neto, A
   Gomes, CN
   Ribeiro, IH
   Oliveira, VB
   Conrado, MCAV
   Oliveira, TGM
   Carvalho, MLP
   Aranha, AF
   Bosi, SRA
   Salles, NA
   Krieger, JE
   Pereira, AC
   Sabino, EC
   Rocha, V
   Mendrone, A
   Dinardo, CL
   Levi, JE
AF Dezan, Marcia Regina
   Costa-Neto, Abel
   Gomes, Carolina Nunes
   Ribeiro, Ingrid Helena
   Oliveira, Valeria Brito
   Conrado, Marina C. A., V
   Oliveira, Theo Gremen M.
   Carvalho, Mariana L. P.
   Aranha, Aline Fernanda
   Bosi, Silvia R. A.
   Salles, Nanci A.
   Krieger, Jose Eduardo
   Pereira, Alexandre Costa
   Sabino, Ester Cerdeira
   Rocha, Vanderson
   Mendrone-Junior, Alfredo
   Dinardo, Carla Luana
   Levi, Jose Eduardo
TI SMIM1 intron 2 gene variations leading to variability in Vel antigen
   expression among Brazilian blood donors
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Article
AB Background: There is a significant inter-individual heterogeneity of Vel antigen expression which can lead to inaccuracies on Vel phenotyping of blood donors and, potentially, to hemolytic post-transfusion reactions. Our aim was to evaluate the impact of genetic variants in the SMIM1 intron 2 on the expression of Vel antigen among Brazilian blood donors harboring the c.64_80del17 deletion in heterozygosity.
   Methods: Donors presenting the SMIM1 c.64_80del17 in heterozygosity were included in the study and subjected to SMIM1 intron 2 direct sequencing aiming to genotype the following polymorphisms: rs143702418, rs1181893, rs191041962, rs6673829, rs1175550 and rs9424296.
   Results: SMIM1 intron 2 sequencing was performed on two hundred donors presenting one c.64_80del17 allele. The rs1175550 polymorphism significantly impacted on Vel antigen expression. Variations in the strength of agglutination on Vel phenotyping were also observed according to the rs6673829 genotype, but this difference did not persist with statistical relevance after multivariate analysis.
   Conclusion: The presence of the rs1175550A allele of SMIM1 is significantly and independently associated with a decrease in Vel antigen expression. Even though the population in Brazil is intensely mixed, the allele frequencies obtained in the current study were very similar to that reported for Europeans.
C1 [Dezan, Marcia Regina; Gomes, Carolina Nunes; Ribeiro, Ingrid Helena; Oliveira, Valeria Brito; Conrado, Marina C. A., V; Oliveira, Theo Gremen M.; Bosi, Silvia R. A.; Salles, Nanci A.; Rocha, Vanderson; Mendrone-Junior, Alfredo; Dinardo, Carla Luana] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Dezan, Marcia Regina; Sabino, Ester Cerdeira; Dinardo, Carla Luana; Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop, Sao Paulo, Brazil.
   [Costa-Neto, Abel; Rocha, Vanderson] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med Disciplina Hematol, Sao Paulo, Brazil.
   [Rocha, Vanderson] Univ Oxford, Churchill Hosp, NHSBT, Oxford, England.
   [Oliveira, Theo Gremen M.; Carvalho, Mariana L. P.; Aranha, Aline Fernanda; Krieger, Jose Eduardo; Pereira, Alexandre Costa] Univ Sao Paulo, Lab Genet & Mol Cardiol, Heart Inst InCor, Sch Med, Sao Paulo, SP, Brazil.
RP Dinardo, CL (corresponding author), Rua Dr Eneas Carvalho Aguiar 155,1 Andar, BR-05403000 Sao Paulo, SP, Brazil.
EM mrdezan@prosangue.sp.gov.br; cldinardo@prosangue.sp.gov.br
RI Sabino, Ester Cerdeira/F-7750-2010; Rocha, Vanderson/AAO-1691-2020
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; Gremen Mimary Oliveira,
   Theo/0000-0001-9892-7485
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2015/095403]
FX Supported by the Sao Paulo Research Foundation (FAPESP), Grant
   2015/095403 (to MRD).
CR Arnoni CP, 2019, BLOOD TRANSFUS-ITALY, V17, P60, DOI 10.2450/2018.0192-17
   Ballif BA, 2013, EMBO MOL MED, V5, P751, DOI 10.1002/emmm.201302466
   Christophersen MK, 2017, SCI REP-UK, V7, DOI 10.1038/srep40451
   Cvejic A, 2013, NAT GENET, V45, P542, DOI 10.1038/ng.2603
   Dezan MR, 2019, TRANSFUSION, V59, P428, DOI 10.1111/trf.15059
   Dezan MR, 2016, TRANSFUSION, V56, P1430, DOI 10.1111/trf.13572
   Fehrmann RSN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002197
   Grossman B., 2014, TECHNICAL MANUAL
   Haer-Wigman L, 2015, TRANSFUSION, V55, P1457, DOI 10.1111/trf.13014
   Jongruamklang P, 2018, TRANSFUSION, V58, P1752, DOI 10.1111/trf.14624
   Storry JR, 2013, NAT GENET, V45, P537, DOI 10.1038/ng.2600
   Wieckhusen C, 2015, TRANSFUS MED HEMOTH, V42, P356, DOI 10.1159/000440791
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
EI 1096-0961
J9 BLOOD CELL MOL DIS
JI Blood Cells Mol. Dis.
PD JUL
PY 2019
VL 77
BP 23
EP 28
DI 10.1016/j.bcmd.2019.03.006
PG 6
WC Hematology
SC Hematology
GA HX6UD
UT WOS:000467537900005
PM 30939337
DA 2020-11-30
ER

PT J
AU Souza, NCSE
   Felix, AC
   de Paula, AV
   Levi, JE
   Pannuti, CS
   Romano, CM
AF Santiago e Souza, Nathalia Caroline
   Felix, Alvina Clara
   de Paula, Anderson Vicente
   Levi, Jose Eduardo
   Pannuti, Claudio Sergio
   Romano, Camila Malta
TI Evaluation of serological cross-reactivity between yellow fever and
   other flaviviruses
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Serological tests; Yellow fever; Dengue; Zika; Cross-reactivity
AB Objectives: This study was performed to determine whether neutralizing antibodies against yellow fever virus (YFV) generated by YFV vaccine could interfere in the specificity of dengue virus (DENV) and Zika virus (ZIKV) IgG ELISA tests.
   Methods: Seventy-nine pairs of serum samples (pre- and post-vaccination), collected during the years 1997-1998 from children with no history of yellow fever disease who had been vaccinated against YFV, were tested. The seroconversion post-vaccination was evaluated through plaque reduction neutralization test (PRNT), and four different commercial ELISA kits were used for the detection of DENV and ZIKV IgG antibodies.
   Results: A cross-reactivity rate of 3.9% with DENV IgG antibodies was found only with the Dengue Virus IgG Dx Select kit (Focus Diagnostics).
   Conclusions: As several countries have local transmission of multiple arboviruses, the absence of cross-reactivity or minimum cross-reactivity of YFV neutralizing antibodies with DENV and ZIKV antigens is a relevant finding, since the interpretation of sero-epidemiological investigations would be seriously impacted in many regions where YFV vaccination is mandatory. (C) 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Santiago e Souza, Nathalia Caroline; Felix, Alvina Clara; de Paula, Anderson Vicente; Levi, Jose Eduardo; Pannuti, Claudio Sergio; Romano, Camila Malta] Univ Sao Paulo, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   [Santiago e Souza, Nathalia Caroline] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, Brazil.
   [Romano, Camila Malta] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP LIM52, Sao Paulo, Brazil.
RP Romano, CM (corresponding author), Inst Med Trop SP, Ave Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
EM cmromano@usp.br
RI Romano, Camila/ABC-2883-2020; Romano, Camila M/C-8185-2013
OI Romano, Camila/0000-0003-4550-1987; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2016/16069-8,
   2012/15381-7]; Programa de fomento as atividades de liderancas
   cientificas dos LIMs do Hospital das Clinicas da FMUSP (PROFAP-LIM /
   HCFMUSP) [02/2019]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) grant numbers 2016/16069-8 and 2012/15381-7; and by
   the Programa de fomento as atividades de liderancas cientificas dos LIMs
   do Hospital das Clinicas da FMUSP (PROFAP-LIM / HCFMUSP) number 02/2019.
CR Faria NR, 2018, SCIENCE, V361, P894, DOI 10.1126/science.aat7115
   Saude MD, 2018, MON PER SAZ FEBR AM
   Saude MD, 2018, OR QUANT VAC FEBR AM
   Stefano I, 1999, VACCINE, V17, P1042, DOI 10.1016/S0264-410X(98)00320-X
NR 4
TC 3
Z9 3
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD APR
PY 2019
VL 81
BP 4
EP 5
DI 10.1016/j.ijid.2019.01.023
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA HS5DB
UT WOS:000463889700002
PM 30660799
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Benvenuti, LA
   Roggerio, A
   Nishiya, AS
   Mangini, S
   Levi, JE
AF Benvenuti, L. A.
   Roggerio, A.
   Nishiya, A. S.
   Mangini, S.
   Levi, J. E.
TI Sequential Measurement of Trypanosoma cruzi Parasitic Load in
   Endomyocardial Biopsies for Early Detection and Follow-up of Chagas
   Disease Reactivation After Heart Transplantation
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Meeting Abstract
CT 39th Annual Meeting and Scientific Sessions of the
   International-Society-for-Heart-and-Lung-Transplantation (ISHLT)
CY APR 03-06, 2019
CL Orlando, FL
SP Int Soc Heart & Lung Transplantat
C1 [Benvenuti, L. A.; Roggerio, A.; Mangini, S.] FMUSP, Heart Inst InCor, Hosp Clin, Sao Paulo, Brazil.
   [Nishiya, A. S.; Levi, J. E.] FMUSP, Fundacao Prosangue, Hosp Clin, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1053-2498
EI 1557-3117
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD APR
PY 2019
VL 38
IS 4
SU S
MA 33
BP S23
EP S24
DI 10.1016/j.healun.2019.01.042
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
   Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
   Transplantation
GA HP0OJ
UT WOS:000461365100033
DA 2020-11-30
ER

PT J
AU Rocha, DAP
   Moraes, CD
   Araujo, AF
   Beltrao, ED
   Dos Santos, LC
   da Mata, LM
   Xavier, ANN
   Reis, RD
   Soares, SCC
   Torres, KL
   Levi, JE
   Marino, JM
AF Rocha, Danielle A. P.
   Moraes, Cassia de Oliveira
   Araujo, Adriene F.
   Beltrao, Emille dos Santos
   dos Santos, Lainara Castelo
   da Mata, Ligia Menezes
   Xavier, Antonio N. N.
   Reis, Renato dos Santos
   Soares, Silvia C. C.
   Torres, Katia L.
   Levi, Jose E.
   Marino, Josiane M.
TI Chlamydia trachomatis infection in women living in remote areas in
   Amazonas, Brazil-a self-collection screening experience
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE Chlamydia (Chlamydia trachomatis); South America; epidemiology
ID NEISSERIA-GONORRHOEAE; SPECIMENS; URINE; PREVALENCE; DIAGNOSIS
AB Chlamydia trachomatis infection is the most common sexually transmitted bacterial infection among women. In Brazil, there is no organized screening program for C. trachomatis, and the actual prevalence of infection is unknown. This study aimed to determine the prevalence of C. trachomatis infection in women living in riverside communities in the Amazon, using self-collection employing the Evalyn (R) Brush and polymerase chain reaction. A total of 299 riverine women aged 18-81 years, mean age 35.7 (+/- 12.8) years, predominantly agricultural workers, with low schooling and living with a partner, participated in this study. The prevalence of C. trachomatis infection was found to be 3.7% (95% CI 1.8-6.5), most of them being symptomatic. The mean age of the first sexual intercourse reported by women was 15.2 (+/- 2.3) years, and the majority reported having had none or only one partner in the last 12 months, with very low adherence to consistent condom use (15.4%). Most women (98.3%) reported having approved using the vaginal self-collecting brush, and only 4.7% reported having difficulty in handling the brush. We consider that a vaginal self-collecting device is adequate for diagnosing C. trachomatis infection in women living in remote, hard-to-reach areas.
C1 [Rocha, Danielle A. P.; Moraes, Cassia de Oliveira; Araujo, Adriene F.; Beltrao, Emille dos Santos; dos Santos, Lainara Castelo; da Mata, Ligia Menezes; Xavier, Antonio N. N.; Reis, Renato dos Santos; Soares, Silvia C. C.; Marino, Josiane M.] Univ Fed Amazonas, Manaus, Amazonas, Brazil.
   [Torres, Katia L.] Oncol Control Ctr Fdn State Amazonas, Manaus, Amazonas, Brazil.
   [Levi, Jose E.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
RP Rocha, DAP (corresponding author), Univ Fed Amazonas, Es Coari Mamia 305, BR-69460000 Coari, AM, Brazil.
EM dannyodonto@hotmail.com
OI Rocha, Danielle Albuquerque Pires/0000-0002-9317-168X
CR Barcelos MRB, 2008, REV BRAS GINECOL OBS, V30, P3
   BEbEar C, 2009, CLIN MICROBIOL INFEC, V15, P4, DOI 10.1111/j.1469-0691.2008.02647.x
   Brasiliense DM, 2016, J INFECT DEV COUNTR, V10, P134, DOI 10.3855/jidc.6474
   Cevenini R, 2002, BEST PRACT RES CL OB, V16, P761, DOI 10.1053/beog.2002.0323
   Chernesky M, 2014, J CLIN MICROBIOL, V52, P2305, DOI 10.1128/JCM.03552-13
   Conejero C, 2013, REV CHIL INFECTOL, V30, P489, DOI 10.4067/S0716-10182013000500004
   Machado MSC, 2012, BRAZ J INFECT DIS, V16, P188, DOI 10.1590/S1413-86702012000200015
   de Codes Jose Santiago, 2006, Cad Saude Publica, V22, P325
   Ejegod DM, 2018, PAPILLOMAVIRUS RES, V5, P192, DOI 10.1016/j.pvr.2018.04.005
   Elwell C, 2016, NAT REV MICROBIOL, V14, P385, DOI 10.1038/nrmicro.2016.30
   Falk L, 2010, INT J STD AIDS, V21, P283, DOI 10.1258/ijsa.2009.009440
   Fang JY, 2008, J PEDIATR ADOL GYNEC, V21, P355, DOI 10.1016/j.jpag.2008.03.010
   Fernandes AMS, 2009, REV BRAS GINECOL OBS, V31, P1
   Fonseca AJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133635
   Gama ASM, 2018, CAD SAUDE PUBLICA, V34, P1
   Gopalkrishna V, 2000, CLIN MICROBIOL INFEC, V6, P88, DOI 10.1046/j.1469-0691.2000.00024.x
   Guimaraes EMB, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-8
   INCA. Instituto Nacional do Cancer Jose Gomes Alencar da Silva, 2016, EST 2016 INC CANC BR, P124
   Jalil EM, 2008, REV BRAS GINECOL OBS, V30, P1
   Luppi Carla Gianna, 2011, Rev. bras. epidemiol., V14, P467, DOI 10.1590/S1415-790X2011000300011
   Mishori R, 2012, AM FAM PHYSICIAN, V86, P1127
   Neves D, 2016, CAD SAUDE PUBLICA, V32, DOI 10.1590/0102-311X00101015
   Piazzetta RCPS, 2011, REV BRAS GINECOL OBS, V33, P328, DOI 10.1590/S0100-72032011001100002
   Paudyal P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124310
   Rocha DAP, 2014, INT J STD AIDS, V25, P878, DOI 10.1177/0956462414523742
   Price MJ, 2016, HEALTH TECHNOL ASSES, V20, P282
   Santos Cristina, 2003, Braz J Infect Dis, V7, P91, DOI 10.1590/S1413-86702003000200001
   Schachter J, 2003, J CLIN MICROBIOL, V41, P3784, DOI 10.1128/JCM.41.8.3784-3789.2003
   Snijders PJF, 2013, INT J CANCER, V132, P2223, DOI 10.1002/ijc.27790
   Tranberg M, 2018, CLIN EPIDEMIOL, V10, P1027, DOI 10.2147/CLEP.S164826
   Tranberg M, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3254-y
   Witkin SS, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00203-17, 10.1128/cvi.00203-17]
NR 32
TC 0
Z9 0
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD MAR
PY 2019
VL 30
IS 4
BP 336
EP 343
DI 10.1177/0956462418809297
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA HR3HS
UT WOS:000463028000004
PM 30486765
DA 2020-11-30
ER

PT J
AU Luna, EJ
   Figueiredo, GM
   Campos, SR
   Levi, JE
   Figueiredo, WM
   Costa, AA
   Felix, AC
   Souza, NS
   Pannuti, CS
AF Luna, Expedito J.
   Figueiredo, Gerusa M.
   Campos, Sergio R.
   Levi, Jose E.
   Figueiredo, Walter M.
   Costa, Angela A.
   Felix, Alvina C.
   Souza, Nathalia S.
   Pannuti, Claudio S.
TI RE-EMERGENCE OF DENV-2 IN THE STATE OF SAO PAULO, BRAZIL
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 68th Annual Meeting of the
   American-Society-for-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 20-24, 2019
CL National Harbor, MD
SP Amer Soc Trop Med & Hyg, Bill & Melinda Gates Fdn, Bavarian Nord, GSK, Takeda, Integrum Sci, Celgene, Vulcan, Plos Neglected Trop Dis, Elsevier
C1 [Luna, Expedito J.; Figueiredo, Gerusa M.; Campos, Sergio R.; Levi, Jose E.; Figueiredo, Walter M.; Costa, Angela A.; Felix, Alvina C.; Souza, Nathalia S.; Pannuti, Claudio S.] Univ Sao Paulo, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2019
VL 101
SU 5
MA 821
BP 251
EP 251
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA KC7PF
UT WOS:000507364503174
DA 2020-11-30
ER

PT J
AU Tozetto-Mendoza, TR
   Avelino-Silva, VI
   Fonseca, S
   Claro, IM
   de Paula, AV
   Levin, AS
   Sabino, EC
   Mendes-Correa, MC
   Figueiredo, WM
   Felix, AC
   Souza, NCS
   Costa, AA
   Inenami, M
   da Silva, RMG
   Levi, JE
   Romano, CM
   Paranhos-BaccalA, G
   Segurado, AC
   Mayaud, P
AF Tozetto-Mendoza, Tania Regina
   Avelino-Silva, Vivian Iida
   Fonseca, Silvia
   Claro, Ingra Morales
   de Paula, Anderson Vicente
   Levin, Anna Sara
   Sabino, Ester Cerdeira
   Mendes-Correa, Maria Cassia
   Figueiredo, Walter Manso
   Felix, Alvina Clara
   Santiago Souza, Nathalia C.
   Costa, Angela Aparecida
   Inenami, Maria
   Gasparetto da Silva, Rosangela M.
   Levi, Jose Eduardo
   Romano, Camila Malta
   Paranhos-BaccalA, Glaucia
   Segurado, Aluisio Cotrim
   Mayaud, Philippe
TI Zika virus infection among symptomatic patients from two healthcare
   centers in Sao Paulo State, Brazil: prevalence, clinical
   characteristics, viral detection in body fluids and serodynamics
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE Zika virus; Differential diagnosis; Kinetics; Body fluids; Polymerase
   chain reaction; Real-Time Polymerase Chain Reaction; Serology; Brazil
ID MALE SEXUAL TRANSMISSION; TIME RT-PCR; DENGUE; EPIDEMIC
AB Zika virus (ZIKV) clinical presentation and frequency/duration of shedding need further clarification. Symptomatic ZIKV-infected individuals identified in two hospitals in Sao Paulo State, Brazil, were investigated regarding clinical characteristics, shedding in body fluids, and serodynamics. Ninety-four of 235 symptomatic patients (Site A: 58%; Site B: 16%) had Real-Time PCR-confirmed ZIKV infection; fever, headache and gastrointestinal symptoms were less frequent, and rash was more frequent compared to ZIKV-negative patients. Real-Time PCR in serum had worse performance compared to plasma, while urine had the highest sensitivity. Shedding in genital fluids and saliva was rare. IgM positivity was the highest <14 days after the symptoms onset (86%), decreasing >28 days (24%); IgG positivity increased >14 days (96%) remaining positive in 94% of patients >28 days. ZIKV prevalence varied importantly in two neighboring cities during the same transmission season. Urine Real-Time PCR can improve diagnostic sensitivity; serum testing is less useful. Accurate serological tests are needed to improve diagnosis and surveillance.
C1 [Tozetto-Mendoza, Tania Regina; de Paula, Anderson Vicente; Levin, Anna Sara; Sabino, Ester Cerdeira; Mendes-Correa, Maria Cassia; Felix, Alvina Clara; Santiago Souza, Nathalia C.; Levi, Jose Eduardo; Romano, Camila Malta; Paranhos-BaccalA, Glaucia; Segurado, Aluisio Cotrim; Mayaud, Philippe] Univ Sao Paulo, Inst Med Trop Sao Paulo, Sao Paulo, SP, Brazil.
   [Avelino-Silva, Vivian Iida; Claro, Ingra Morales; Levin, Anna Sara; Sabino, Ester Cerdeira; Mendes-Correa, Maria Cassia; Segurado, Aluisio Cotrim] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, SP, Brazil.
   [Fonseca, Silvia] Hosp Sao Francisco, Ribeirao Preto, SP, Brazil.
   [Figueiredo, Walter Manso; Costa, Angela Aparecida; Inenami, Maria; Gasparetto da Silva, Rosangela M.] Univ Sao Paulo, Fac Saude Publ, Serv Especial Saude Araraquara, Araraquara, SP, Brazil.
   [Paranhos-BaccalA, Glaucia] BioMerieux SA, Med Diagnost Discovery Dept MD3, Marcy Letoile, France.
   [Mayaud, Philippe] Fac Infect & Trop Dis, London Sch Hyg & Trop Med, London, England.
RP Avelino-Silva, VI (corresponding author), Univ Sao Paulo, Inst Med Trop Sao Paulo, Av Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
EM viviansilva87@gmail.com
RI Romano, Camila/ABC-2883-2020; Levin, Anna S/C-8831-2012; Avelino-Silva,
   Vivian I/L-2640-2013; Sabino, Ester Cerdeira/F-7750-2010; Romano, Camila
   M/C-8185-2013; Segurado, Aluisio C/K-2229-2012
OI Romano, Camila/0000-0003-4550-1987; Levin, Anna S/0000-0003-2427-8368;
   Avelino-Silva, Vivian I/0000-0002-6660-3088; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Segurado, Aluisio C/0000-0002-6311-8036
FU European Union's Horizon 2020 Research and Innovation Programme under
   ZIKAlliance [734548]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES -Ministry of Education, Brazil)CAPES
   [CSF-PVE-S-88887.122640/2016-00, CSF-PVE-S-88881.068160/2014-01];
   bioMerieux Corporation
FX This work was supported by the European Union's Horizon 2020 Research
   and Innovation Programme under ZIKAlliance Grant Agreement No 734548,
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES
   -Ministry of Education, Brazil, grants No CSF-PVE-S-88887.122640/2016-00
   [VAS support] and CSF-PVE-S-88881.068160/2014-01 [ASL, ACS and PM
   support]) and bioMerieux Corporation. The funders had no role in the
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Avelino-Silva VL, 2018, REV INST MED TROP SP, V60, DOI [10.1590/S1678-9946201860064, 10.1590/s1678-9946201860064]
   Bogoch II, 2016, LANCET, V387, P335, DOI 10.1016/S0140-6736(16)00080-5
   Bonaldo MC, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004816
   Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636
   Calvet GA, 2016, J CLIN VIROL, V74, P1, DOI 10.1016/j.jcv.2015.11.014
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Cecilia D, 2015, ARCH VIROL, V160, P323, DOI 10.1007/s00705-014-2217-x
   Colombo TE, 2017, J CLIN VIROL, V96, P20, DOI 10.1016/j.jcv.2017.09.002
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P716, DOI 10.15585/mmwr.mm6528e2
   Deckard DT, 2016, MMWR-MORBID MORTAL W, V65, P372, DOI 10.15585/mmwr.mm6514a3
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Faye O, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-311
   Felix AC, 2017, J MED VIROL, V89, P1477, DOI 10.1002/jmv.24789
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Frank C, 2016, EUROSURVEILLANCE, V21, P13, DOI 10.2807/1560-7917.ES.2016.21.23.30252
   Freour T, 2016, EUROSURVEILLANCE, V21, P10, DOI 10.2807/1560-7917.ES.2016.21.23.30254
   Huhtamo E, 2010, J CLIN VIROL, V47, P49, DOI 10.1016/j.jcv.2009.11.001
   Huzly D, 2016, EUROSURVEILLANCE, V21, P9, DOI 10.2807/1560-7917.ES.2016.21.16.30203
   Joguet G, 2017, LANCET INFECT DIS, V17, P1200, DOI 10.1016/S1473-3099(17)30444-9
   Kim CR, 2018, LANCET GLOB HEALTH, V6, pE24, DOI 10.1016/S2214-109X(17)30419-9
   L'Huillier AG, 2017, J CLIN MICROBIOL, V55, P2462, DOI 10.1128/JCM.00442-17
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Li Jiandong, 2016, Zhonghua Liu Xing Bing Xue Za Zhi, V37, P329, DOI 10.3760/cma.j.issn.0254-6450.2016.03.007
   Mecharles S, 2016, LANCET, V387, P1481, DOI 10.1016/S0140-6736(16)00644-9
   Pasquier C, 2018, DIAGN MICR INFEC DIS, V90, P26, DOI 10.1016/j.diagmicrobio.2017.09.001
   Paz-Bailey G, 2018, NEW ENGL J MED, V379, P1234, DOI 10.1056/NEJMoa1613108
   Prisant N, 2017, CLIN INFECT DIS, V64, P107, DOI 10.1093/cid/ciw669
   Prisant N, 2016, LANCET INFECT DIS, V16, P1000, DOI 10.1016/S1473-3099(16)30193-1
   Safronetz D, 2017, EMERG INFECT DIS, V23, P1577, DOI 10.3201/eid2309.162043
   Sanchez-Montalva A, 2018, TROP MED INT HEALTH, V23, P92, DOI 10.1111/tmi.13019
   Teixeira MG, 2016, AM J PUBLIC HEALTH, V106, P601, DOI 10.2105/AJPH.2016.303113
   Turmel JM, 2016, LANCET, V387, P2501, DOI 10.1016/S0140-6736(16)30775-9
   Venturi G, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.8.30148
   Visseaux B, 2016, LANCET INFECT DIS, V16, P1220, DOI 10.1016/S1473-3099(16)30387-5
   Vranjac Alexandre, 2016, DISTRIBUICAO CASOS C
   Vranjac Alexandre, 2016, DISTRIBUICAO CASOS D
   Vranjac Alexandre, 2016, DISTRIBUICAO CASOS Z
   World Health Organization, WHO DIR GEN SUMM OUT
NR 40
TC 4
Z9 4
U1 0
U2 2
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
EI 1678-9946
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PY 2019
VL 61
AR e19
DI 10.1590/S1678-9946201961019
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA HS4BZ
UT WOS:000463808000002
PM 30970110
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-11-30
ER

PT J
AU Dezan, MR
   Dinardo, CL
   Rocha, V
   Mendrone, A
   Levi, JE
AF Dezan, Marcia R.
   Dinardo, Carla L.
   Rocha, Vanderson
   Mendrone-Junior, Alfredo
   Levi, Jose E.
TI Prevalence of SMIM1 c.64_80del17 homozygotes in southeastern Brazil: the
   Vel-negative phenotype
SO TRANSFUSION
LA English
DT Letter
ID BLOOD-GROUP; DONORS
C1 [Dezan, Marcia R.; Dinardo, Carla L.; Rocha, Vanderson; Mendrone-Junior, Alfredo] Fundacao Prosangue Hemoctr Sao Paulo, Immunohematol, Sao Paulo, Brazil.
   [Dezan, Marcia R.; Dinardo, Carla L.; Levi, Jose E.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   [Rocha, Vanderson] Univ Sao Paulo, Sch Med, Discipline Hematol, Sao Paulo, Brazil.
   [Rocha, Vanderson] Univ Oxford, Churchill Hosp, NHSBT, Oxford, England.
RP Dezan, MR (corresponding author), Fundacao Prosangue Hemoctr Sao Paulo, Immunohematol, Sao Paulo, Brazil.; Dezan, MR (corresponding author), Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
EM dezan.marcia@gmail.com
RI Rocha, Vanderson/AAO-1691-2020; DINARDO, CARLA LUANA/A-1062-2013
OI DINARDO, CARLA LUANA/0000-0002-0453-7863
CR Ballif BA, 2013, EMBO MOL MED, V5, P751, DOI 10.1002/emmm.201302466
   Cvejic A, 2013, NAT GENET, V45, P542, DOI 10.1038/ng.2603
   Dezan MR, 2016, TRANSFUSION, V56, P1430, DOI 10.1111/trf.13572
   Storry JR, 2010, TRANSFUSION, V50, p28A
   Storry JR, 2013, NAT GENET, V45, P537, DOI 10.1038/ng.2600
   Wieckhusen C, 2015, TRANSFUS MED HEMOTH, V42, P356, DOI 10.1159/000440791
NR 6
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD JAN
PY 2019
VL 59
IS 1
BP 428
EP 428
DI 10.1111/trf.15059
PG 1
WC Hematology
SC Hematology
GA HG8WJ
UT WOS:000455286500051
PM 30615815
DA 2020-11-30
ER

PT J
AU Viana, JD
   Ferreira, SC
   Matana, SR
   Rossi, F
   Patel, P
   Garson, JA
   Rocha, V
   Tedder, R
   Mendrone-Junior, A
   Levi, JE
AF Viana, J. D.
   Ferreira, S. C.
   Matana, S. R.
   Rossi, F.
   Patel, P.
   Garson, J. A.
   Rocha, V.
   Tedder, R.
   Mendrone-Junior, A.
   Levi, J. E.
TI Detection of bacterial contamination in platelet concentrates from
   Brazilian donors by molecular amplification of the ribosomal 16S gene
SO TRANSFUSION MEDICINE
LA English
DT Article
DE 16S; bacterial contamination; platelet concentrates; real-time PCR;
   transfusional risk; universal bacterial PCR
ID POLYMERASE-CHAIN-REACTION; REAL-TIME PCR; REACTION ASSAY; BLOOD
   COMPONENTS; DETECTION SYSTEM; RESIDUAL RISK; EXPERIENCE; DNA; DONATIONS;
   STORAGE
AB Objective The aim of our work was to establish a semi-automated high-throughput DNA amplification method for the universal screening of bacteria in platelet concentrates (PCs). Background Among cases of transfusion transmission of infectious agents, bacterial contamination ranks first in the number of events, morbidity and mortality. Transmission occurs mainly by transfused PCs. Automated culture is adopted by some blood banks for screening of bacterial contamination, but this procedure is expensive and has a relatively long turnaround time. Methods PCs were spiked with suspensions of five different bacterial species in a final concentration of 1 and 10 colony-forming units (CFU) per millilitre. After incubation, the presence of bacteria was investigated by real-time polymerase chain reaction (PCR) and by the Enhanced Bacterial Detection System (eBDS, Pall) assay as a reference method. Real-time PCR amplification was performed with a set of universal primers and probes targeting the 16S rRNA gene. Co-amplification of human mitochondrial DNA served as an internal control. Results Using the real-time PCR method, it was possible to detect the presence of all bacterial species tested with an initial concentration of 10 CFU mL(-1) 24 h after contamination, except for Staphylococcus hominis. The PCR assay also detected, at 24 h, the presence of Serratia marcescens and Enterobacter cloacae with an initial concentration of 1 CFU mL(-1). Conclusions The real-time PCR assay may be a reliable alternative to conventional culture methods in the screening of bacterial contamination of PCs, enabling bacterial detection even with a low initial concentration of microorganisms.
C1 [Viana, J. D.; Ferreira, S. C.; Matana, S. R.; Rocha, V.; Mendrone-Junior, A.; Levi, J. E.] Fundacao Prosangue Hemoctr Sao Paulo, Rua Dr Eneas Carvalho Aguiar 155,1 Andar B4, BR-05403000 Sao Paulo, SP, Brazil.
   [Rossi, F.] Univ Sao Paulo, Fac Med, Hosp Clin, Dept Microbiol,Lab Cent, Sao Paulo, Brazil.
   [Patel, P.; Garson, J. A.; Tedder, R.] NHS Blood & Transplant, Microbiol Serv, London, England.
   [Garson, J. A.; Tedder, R.] UCL, Div Infect & Immun, London, England.
RP Viana, JD (corresponding author), Fundacao Prosangue Hemoctr Sao Paulo, Rua Dr Eneas Carvalho Aguiar 155,1 Andar B4, BR-05403000 Sao Paulo, SP, Brazil.
EM jacquelinedviana@gmail.com
RI Garson, Jeremy A/C-5357-2008; Rocha, Vanderson/AAO-1691-2020
OI Garson, Jeremy/0000-0003-0553-0126; Tedder, Richard/0000-0002-9672-5721;
   Viana, Jacqueline/0000-0003-1044-5348
FU Roche Diagnostica Brasil Ltda; FundacAo de Amparo a Pesquisa do Estado
   de SAo Paulo, BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2012/51712-8]
FX We thank Marli Foglietto, from Roche Diagnostica Brasil Ltda, for
   assistance. We also thank the participating laboratories that were
   involved in the study. The research study was designed by J. E. L. and
   A. M.-J. P. P., J. A. G. and R. T. taught the techniques used in the
   study. J. D. V. performed the assays with S.C. F. collaboration. S. R.
   M. and F. R. contributed with essential reagents and tools. V. R.
   reviewed the manuscript and supervised the work. All the authors
   contributed to the research and the paper elaboration. This work was
   supported by the FundacAo de Amparo a Pesquisa do Estado de SAo Paulo,
   Brazil, Grant #2012/51712-8.
CR Alhumaidan H, 2011, AM J CLIN PATHOL, V136, P638, DOI 10.1309/AJCPFD87THDWCSVA
   Benjamin RJ, 2007, TRANSFUSION, V47, P1381, DOI 10.1111/j.1537-2995.2007.01326.x
   Blajchman MA, 2004, VOX SANG, V87, P98, DOI 10.1111/j.1741-6892.2004.00441.x
   Brecher ME, 2005, CLIN MICROBIOL REV, V18, P195, DOI 10.1128/CMR.18.1.195-204.2005
   Chavan PD, 2012, INDIAN J MED MICROBI, V30, P212, DOI 10.4103/0255-0857.96695
   de Korte D, 2011, TRANSFUS MED HEMOTH, V38, P251, DOI 10.1159/000330312
   Dierkes C, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-126
   Drancourt M, 2000, J CLIN MICROBIOL, V38, P3623, DOI 10.1128/JCM.38.10.3623-3630.2000
   Dreier J, 2008, VOX SANG, V95, P181, DOI 10.1111/j.1423-0410.2008.01087.x
   Eder AF, 2007, TRANSFUSION, V47, P1134, DOI 10.1111/j.1537-2995.2007.01248.x
   Garson JA, 2014, TRANSFUSION, V54, P870, DOI 10.1111/trf.12256
   Harm SK, 2013, TRANSFUSION, V53, P843, DOI 10.1111/j.1537-2995.2012.03818.x
   Hillyer Christopher D, 2003, Hematology Am Soc Hematol Educ Program, P575
   Hourfar MK, 2008, TRANSFUSION, V48, P1558, DOI 10.1111/j.1537-2995.2008.01718.x
   Larsen CP, 2005, VOX SANG, V88, P93, DOI 10.1111/j.1423-0410.2005.00596.x
   Lehmann LE, 2010, INTENS CARE MED, V36, P49, DOI 10.1007/s00134-009-1608-z
   McDonald CP, 2006, TRANSFUSION MED, V16, P381, DOI 10.1111/j.1365-3148.2006.00697.x
   McDonald CP, 2005, TRANSFUSION MED, V15, P259, DOI 10.1111/j.0958-7578.2005.00587.x
   Millar BC, 2002, J CLIN MICROBIOL, V40, P1575, DOI 10.1128/JCM.40.5.1575-1580.2002
   Mohammadi T, 2003, J CLIN MICROBIOL, V41, P4796, DOI 10.1128/JCM.41.10.4796-4798.2003
   Mohammadi T, 2005, TRANSFUSION, V45, P731, DOI 10.1111/j.1537-2995.2005.04258.x
   Mohr H, 2006, TRANSFUSION, V46, P949, DOI 10.1111/j.1537-2995.2006.00827.x
   Ness P, 2001, TRANSFUSION, V41, P857, DOI 10.1046/j.1537-2995.2001.41070857.x
   Ortolano GA, 2003, TRANSFUSION, V43, P1276, DOI 10.1046/j.1537-2995.2003.00487.x
   Palavecino EL, 2010, TRANSFUS APHER SCI, V42, P71, DOI 10.1016/j.transci.2009.10.009
   Patel P, 2012, TRANSFUSION, V52, P1423, DOI 10.1111/j.1537-2995.2011.03484.x
   Pietersz RNI, 2014, VOX SANG, V106, P256, DOI 10.1111/vox.12098
   Reier-Nilsen T, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-5
   Rock G, 2004, TRANSFUSION, V44, P337, DOI 10.1111/j.1537-2995.2003.00670.x
   Rood IGH, 2010, TRANSFUSION, V50, P1352, DOI 10.1111/j.1537-2995.2009.02580.x
   Schmidt M, 2007, VOX SANG, V92, P15, DOI 10.1111/j.1423-0410.2006.00850.x
   Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601
   Schrezenmeier H, 2010, VOX SANG, V99, P1, DOI 10.1111/j.1423-0410.2009.01295.x
   Stormer M, 2007, TRANSFUSION MED, V17, P61, DOI 10.1111/j.1365-3148.2006.00710.x
   Stormer M, 2014, TRANSFUS MED HEMOTH, V41, P19, DOI 10.1159/000357651
   Tsalik EL, 2010, J CLIN MICROBIOL, V48, P26, DOI 10.1128/JCM.01447-09
   Yang S, 2002, J CLIN MICROBIOL, V40, P3449, DOI 10.1128/JCM.40.9.3449-3454.2002
NR 37
TC 0
Z9 0
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0958-7578
EI 1365-3148
J9 TRANSFUSION MED
JI Transfus. Med.
PD DEC
PY 2018
VL 28
IS 6
BP 420
EP 426
DI 10.1111/tme.12561
PG 7
WC Hematology
SC Hematology
GA HE3VF
UT WOS:000453289300003
PM 30304760
DA 2020-11-30
ER

PT J
AU Musso, D
   Rodriguez-Morales, AJ
   Levi, JE
   Cao-Lormeau, VM
   Gubler, DJ
AF Musso, Didier
   Rodriguez-Morales, Alfonso J.
   Levi, Jose Eduardo
   Cao-Lormeau, Van-Mai
   Gubler, Duane J.
TI Unexpected outbreaks of arbovirus infections: lessons learned from the
   Pacific and tropical America
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID ROSS RIVER VIRUS; WEST-NILE-VIRUS; ZIKA VIRUS; YELLOW-FEVER; CHANGING
   EPIDEMIOLOGY; AEDES-AEGYPTI; KUNJIN VIRUS; MAYARO VIRUS; DENGUE;
   CHIKUNGUNYA
AB Pandemic arboviruses have emerged as a major global health problem in the past four decades. Predicting where and when the next arbovirus epidemic will occur is a challenge, but history suggests that arboviral black swan events (epidemics that are difficult to predict and that have an extreme effect) will continue to occur as urban growth and globalisation expand. We briefly review unexpected arbovirus epidemics that have occurred in the past 50 years, with emphasis on the American and Pacific regions, to illustrate their unpredictability, and to highlight the need for improved global preparedness, including laboratory-based surveillance, prevention, and control programmes.
C1 [Musso, Didier; Cao-Lormeau, Van-Mai] Inst Louis Malarde, Unit Emerging Infect Dis, F-98713 Tahiti, French Polynesi, France.
   [Musso, Didier; Cao-Lormeau, Van-Mai] Aix Marseille Univ, Unite Mixte Rech Vecteurs Infect Trop & Mediterra, Inst Hosp Univ Mediterranee Infect, AP HP,Inst Rech Dev,Serv Sante Armees, Marseille, France.
   [Rodriguez-Morales, Alfonso J.] Univ Tecnol Pereira, Fac Hlth Sci, Publ Hlth & Infect Res Grp, Pereira, Colombia.
   [Rodriguez-Morales, Alfonso J.] Colombian Collaborat Network Res Zika & Other Arb, Pereira, Colombia.
   [Levi, Jose Eduardo] Univ Sao Paulo, Trop Med Inst, Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Gubler, Duane J.] Duke NUS Med Sch, Programme Emerging Infect, Singapore, Singapore.
RP Musso, D (corresponding author), Inst Louis Malarde, Unit Emerging Infect Dis, F-98713 Tahiti, French Polynesi, France.
EM dmusso@ilm.pf
RI Musso, Didier/AAO-8178-2020; Musso, Didier/P-7809-2016; Cao-Lormeau,
   Van-Mai/H-4879-2018
OI Musso, Didier/0000-0002-9226-0971; Musso, Didier/0000-0002-9226-0971;
   Cao-Lormeau, Van-Mai/0000-0001-5606-7480
CR Arechiga-Ceballos N, 2015, REV SCI TECH OIE, V34, P491, DOI 10.20506/rst.34.2.2374
   Artsob H, 2009, ZOONOSES PUBLIC HLTH, V56, P357, DOI 10.1111/j.1863-2378.2008.01207.x
   Aubry M, 2015, INT J INFECT DIS, V37, P19, DOI 10.1016/j.ijid.2015.06.005
   Aubry M, 2015, EMERG INFECT DIS, V21, P724, DOI 10.3201/eid2104.141741
   Barber B, 2009, AUST FAM PHYSICIAN, V38, P586
   Barboza P, 2008, MED MALADIES INFECT, V38, P513, DOI 10.1016/j.medmal.2008.06.011
   Baud D, 2017, LANCET, V390, P2099, DOI [10.1016/S0140-6736(17)31450-2, 10.1016/s0140-6736(17)31450-2]
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Brault AC, 2007, NAT GENET, V39, P1162, DOI 10.1038/ng2097
   Campbell GL, 2002, LANCET INFECT DIS, V2, P519, DOI 10.1016/S1473-3099(02)00368-7
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cao-Lormeau VM, 2014, LANCET, V384, P1571, DOI 10.1016/S0140-6736(14)61977-2
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Cao-Lormeau VM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029555
   Carrera JP, 2013, NEW ENGL J MED, V369, P732, DOI 10.1056/NEJMoa1212628
   Chen RB, 2016, J VIROL, V90, P10600, DOI 10.1128/JVI.01166-16
   Couto-Lima D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05186-3
   Cui SJ, 2017, INT J INFECT DIS, V60, P93, DOI 10.1016/j.ijid.2017.05.001
   de Figueiredo ML, 2014, J ADV MICROBIOL, V4, P955, DOI [DOI 10.4236/AIM.2014.413106, DOI 10.4236/aim.2014.413106]
   de Oliveira WK, 2017, NEW ENGL J MED, V376, P1591, DOI 10.1056/NEJMc1608612
   Dick OB, 2012, AM J TROP MED HYG, V87, P584, DOI 10.4269/ajtmh.2012.11-0770
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   de Figueiredo MLG, 2014, REV SOC BRAS MED TRO, V47, P677, DOI 10.1590/0037-8682-0246-2014
   Gubler D. J., 1998, Annals Academy of Medicine Singapore, V27, P227
   GUBLER DJ, 1989, AM J TROP MED HYG, V40, P571
   GUBLER DJ, 1981, AM J TROP MED HYG, V30, P1303, DOI 10.4269/ajtmh.1981.30.1303
   GUBLER DJ, 1993, INFECT AGENT DIS, V2, P383
   Gubler DJ, 2004, COMP IMMUNOL MICROB, V27, P319, DOI 10.1016/j.cimid.2004.03.013
   Gubler DJ, 2002, ARCH MED RES, V33, P330, DOI 10.1016/S0188-4409(02)00378-8
   Gubler DJ, 2007, CLIN INFECT DIS, V45, P1039, DOI 10.1086/521911
   Gubler DJ, 2017, J INFECT DIS, V216, pS860, DOI 10.1093/infdis/jix451
   Gubler DJ, 2014, DENGUE AND DENGUE HEMORRHAGIC FEVER, 2ND EDITION, P1, DOI 10.1079/9781845939649.0001
   Gubler Duane J, 2011, Trop Med Health, V39, P3, DOI 10.2149/tmh.2011-S05
   Guillaumot Laurent, 2005, Pac Health Dialog, V12, P45
   Hall RA, 2001, ANN NY ACAD SCI, V951, P153
   Harley D, 2001, CLIN MICROBIOL REV, V14, P909, DOI 10.1128/CMR.14.4.909-932.2001
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536
   Kuno G, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9070185
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanciotti RS, 1999, SCIENCE, V286, P2333, DOI 10.1126/science.286.5448.2333
   Ledermann JP, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003188
   Lednicky J, 2016, EMERG INFECT DIS, V22, P2000, DOI 10.3201/eid2211.161015
   Mackay IM, 2016, MICROBES INFECT, V18, P724, DOI 10.1016/j.micinf.2016.10.007
   Misra UK, 2010, PROG NEUROBIOL, V91, P108, DOI 10.1016/j.pneurobio.2010.01.008
   Figueiredo LTM, 2007, REV SOC BRAS MED TRO, V40, P224, DOI 10.1590/S0037-86822007000200016
   Morales MA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005351
   Musso D, 2018, CLIN MICROBIOL INFEC, V24, P566, DOI 10.1016/j.cmi.2018.03.007
   Musso D, 2018, LANCET INFECT DIS, V18, pE172, DOI 10.1016/S1473-3099(17)30446-2
   Musso D, 2017, LANCET INFECT DIS, V17, P255, DOI 10.1016/S1473-3099(17)30070-1
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Musso D, 2015, LANCET, V386, P243, DOI 10.1016/S0140-6736(15)61273-9
   Nhan TX, 2015, CLIN MICROBIOL INFEC, V21, pE47, DOI 10.1016/j.cmi.2015.02.018
   Ometto T, 2013, T ROY SOC TROP MED H, V107, P723, DOI 10.1093/trstmh/trt081
   Ortiz-Martinez Yeimer, 2017, F1000Res, V6, P398, DOI 10.12688/f1000research.11280.2
   Pan American Health Organization/World Health Organization Regional Office for the Americas, 2017, REG ZIK EP UPD AM
   Prow NA, 2013, INT J ENV RES PUB HE, V10, P6255, DOI 10.3390/ijerph10126255
   Raoult D, 2016, INT J ANTIMICROB AG, V47, P249, DOI 10.1016/j.ijantimicag.2016.01.013
   Richard V, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005024
   Richard V, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004694
   ROSEN L, 1981, AM J TROP MED HYG, V30, P1294, DOI 10.4269/ajtmh.1981.30.1294
   ROSEN L, 1954, AM J TROP MED HYG, V3, P878, DOI 10.4269/ajtmh.1954.3.878
   Rossetto EV, 2017, REV INST MED TROP SP, V59, DOI [10.1590/S1678-9946201759017, 10.1590/s1678-9946201759017]
   Roth A, 2014, EMERG INFECT DIS, V20
   Selvey LA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002656
   Silva JR, 2014, REV SOC BRAS MED TRO, V47, P414, DOI 10.1590/0037-8682-0117-2014
   Steel A, 2010, VIROLOGY, V405, P505, DOI 10.1016/j.virol.2010.05.033
   da Rosa JFT, 2017, AM J TROP MED HYG, V96, P1019, DOI 10.4269/ajtmh.16-0672
   Cao-Lormeau VM, 2016, EMERG INFECT DIS, V22, P913, DOI 10.3201/eid2205.150547
   Vezzani D, 2008, MEM I OSWALDO CRUZ, V103, P66, DOI 10.1590/S0074-02762008005000003
   Vieira MACS, 2015, AM J TROP MED HYG, V93, P377, DOI 10.4269/ajtmh.15-0170
   Weaver SC, 2004, ANNU REV ENTOMOL, V49, P141, DOI 10.1146/annurev.ento.49.061802.123422
   Weaver SC, 2015, NEW ENGL J MED, V372, P1231, DOI 10.1056/NEJMra1406035
   Weaver SC, 2010, ANTIVIR RES, V85, P328, DOI 10.1016/j.antiviral.2009.10.008
   Wilder-Smith A, 2017, LANCET INFECT DIS, V17, P1109, DOI 10.1016/S1473-3099(17)30494-2
   Wilder-Smith A, 2017, LANCET INFECT DIS, V17, P248, DOI 10.1016/S1473-3099(16)30588-6
   World Health Organization, 2018, YELLOW FEVER
   Xavier DR, 2017, CAD SAUDE PUBLICA, V33, DOI [10.1590/0102-311X00186615, 10.1590/0102-311x00186615]
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 78
TC 27
Z9 29
U1 0
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD NOV
PY 2018
VL 18
IS 11
BP E355
EP E361
DI 10.1016/S1473-3099(18)30269-X
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA GY1WF
UT WOS:000448325300003
PM 29934112
DA 2020-11-30
ER

PT J
AU Benvenuti, LA
   Roggerio, A
   Nishiya, AS
   Levi, JE
AF Benvenuti, L. A.
   Roggerio, A.
   Nishiya, A. S.
   Levi, J. E.
TI Increase of Trypanosoma cruzi parasitic load in endomyocardial biopsies
   anticipates Chagas disease reactivation after heart transplantation
SO EUROPEAN HEART JOURNAL
LA English
DT Meeting Abstract
CT European-Society-of-Cardiology Congress
CY AUG 25-29, 2018
CL Munich, GERMANY
SP European Soc Cardiol
C1 [Benvenuti, L. A.; Roggerio, A.] Univ Sao Paulo, Med Sch, Heart Inst InCor, Sao Paulo, Brazil.
   [Nishiya, A. S.; Levi, J. E.] Fundacao Pro Sangue, Sao Paulo Blood Ctr, Mol Biol Dept, Sao Paulo, Brazil.
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2017/07946-8]
FX Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESP (grant
   2017/07946-8)
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD AUG
PY 2018
VL 39
SU 1
MA P4219
BP 855
EP 856
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA HM9RZ
UT WOS:000459824002704
DA 2020-11-30
ER

PT J
AU Bidinotto, LT
   Veo, CAR
   Loaiza, EA
   Ribeiro, GG
   Lorenzi, AT
   Rosa, LAR
   de Oliveira, CM
   Levi, JE
   Scapulatempo-Neto, C
   Longatto, A
   Reis, RM
AF Bidinotto, Lucas Tadeu
   Veo, Carlos A. R.
   Loaiza, Edgar Aleman
   Ribeiro, Guilherme G.
   Lorenzi, Adriana T.
   Reis Rosa, Luciana Albina
   de Oliveira, Cristina Mendes
   Levi, Jose Eduardo
   Scapulatempo-Neto, Cristovam
   Longatto-Filho, Adhemar
   Reis, Rui Manuel
TI Loss of Raf kinase inhibitor protein expression is associated with human
   papillomavirus 16 infection in anal tumors
SO ONCOLOGY LETTERS
LA English
DT Article
DE adenocarcinoma; anal cancer; high-grade squamous intra-epithelial
   lesion; squamous-cell carcinoma; Raf kinase inhibitor protein
ID SQUAMOUS-CELL CARCINOMA; PROGNOSTIC-FACTORS; CANAL CARCINOMA;
   CERVICAL-CANCER; BIOMARKER; SURVIVAL; DISEASE; TISSUE; RKIP
AB There has been an increase in the incidence of anal cancer in the past two decades, with squamous cell carcinoma (SCC) being the most frequent histological type identified. Among the risk factors, high-risk human papillomavirus (HPV) infection is the most pervasive. Raf kinase inhibitor protein (RKIP) is expressed in a number of normal human tissues and previous studies have demonstrated the prognostic value of the loss of RKIP expression in several gastrointestinal tumors. Therefore, the present study aimed to evaluate the clinical implications of RKIP expression in a series of neoplastic lesions of the anal canal. The resected tumors of 48 patients [8 high-grade intraepithelial lesions (HSILs), 14 adenocarcinomas and 26 squamous cell carcinomas (SCCs)] were immunohistochemically evaluated for RKIP expression, and the results were correlated with clinicopathological data. The results identified a decreased 5-year overall survival rate in patients with adenocarcinoma (40.8%) compared with patients with SCC (76.7%), and a decreased 5-year disease-free survival rate in patients at clinical stages III/IV (37.3 vs. 62.5 and 82.6% for clinical stages 0 and I/II, respectively). Low RKIP expression was revealed in 62.5% of HSILs, 88.5% of SCCs and 100.0% of the adenocarcinomas. High RKIP expression was associated with patient ethnicity (37.5% in non-Caucasians vs. 7.5% in Caucasians) and patient age (33.3% in younger patients vs. 0.0% in older patients). Finally, high RKIP expression was correlated with HPV16 infection status (40% in HPV- vs. 5.3% in HPV+ patients). A correlation was identified between high RKIP expression and lesions with a generally improved prognosis, such as those diagnosed in younger patients, in situ lesions and lesions of lower clinical grades; there was also a negative correlation between high RKIP expression and HPV16 positivity in patients.
C1 [Bidinotto, Lucas Tadeu; Veo, Carlos A. R.; Loaiza, Edgar Aleman; Ribeiro, Guilherme G.; Lorenzi, Adriana T.; Scapulatempo-Neto, Cristovam; Longatto-Filho, Adhemar; Reis, Rui Manuel] Barretos Canc Hosp, Mol Oncol Res Ctr, 1331 Antenor Duarte Villela, BR-14784400 Barretos, SP, Brazil.
   [Bidinotto, Lucas Tadeu] Dr Paulo Prata FACISB, Barretos Sch Hlth Sci, Human & Expt Biol Dept, BR-14785002 Barretos, SP, Brazil.
   [Reis Rosa, Luciana Albina; de Oliveira, Cristina Mendes; Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Lab Virol, BR-05403000 Sao Paulo, SP, Brazil.
   [Scapulatempo-Neto, Cristovam] Barretos Canc Hosp, Dept Pathol, BR-14784400 Barretos, SP, Brazil.
   [Longatto-Filho, Adhemar; Reis, Rui Manuel] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst, P-4704553 Braga, Portugal.
   [Longatto-Filho, Adhemar; Reis, Rui Manuel] Portugal Govt Associate Lab, Res Grp, Biomat Biodegradables & Biomimet 3Bs, P-4806909 Braga, Portugal.
RP Reis, RM (corresponding author), Barretos Canc Hosp, Mol Oncol Res Ctr, 1331 Antenor Duarte Villela, BR-14784400 Barretos, SP, Brazil.
EM ruireis.hcb@gmail.com
RI Oliveira, Cristina M/F-7193-2012; Reis, Rui/AAD-6470-2020;
   Longatto-Filho, Adhemar/N-3397-2019; longatto-filho,
   adhemar/D-7039-2013; Reis, Rui Manuel/B-1744-2018
OI Reis, Rui/0000-0002-9639-7940; Longatto-Filho,
   Adhemar/0000-0002-5779-9752; longatto-filho,
   adhemar/0000-0002-5779-9752; Reis, Rui Manuel/0000-0002-9639-7940
FU Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2010/16795-4, 2011/08523-7]; Ministry of Science,
   Technology, Innovation and Communication [MCT/FINEP/CT-INFRA-PROINFRA
   01/2011]
FX The present study was supported by the Sao Paulo Research Foundation
   (grant nos. 2010/16795-4 and 2011/08523-7) and Ministry of Science,
   Technology, Innovation and Communication (grant no.
   MCT/FINEP/CT-INFRA-PROINFRA 01/2011).
CR Ajani JA, 2010, DIGEST DIS SCI, V55, P1098, DOI 10.1007/s10620-009-0812-6
   Ajiro M, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.62
   Bidinotto LT, 2016, MOL MED REP, V14, P3791, DOI 10.3892/mmr.2016.5684
   Bilimoria KY, 2009, DIS COLON RECTUM, V52, P624, DOI 10.1007/DCR.0b013e31819eb7f0
   Bosman FT, 2010, WHO INT AG RES CANC
   Burgos J, 2015, AIDS, V29, P695, DOI 10.1097/QAD.0000000000000603
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   DEANS GT, 1994, BRIT J SURG, V81, P500, DOI 10.1002/bjs.1800810405
   Doorbar J, 2006, CLIN SCI, V110, P525, DOI 10.1042/CS20050369
   Doorbar J, 2016, J PATHOL, V238, P166, DOI 10.1002/path.4656
   Fedchenko N, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0221-9
   Franklin RA, 2016, CLIN COLORECTAL CANC, V15, P47, DOI 10.1016/j.clcc.2015.07.007
   Hu CJ, 2011, J INT MED RES, V39, P229, DOI 10.1177/147323001103900125
   Leonard Daniel, 2011, Clin Colon Rectal Surg, V24, P54, DOI 10.1055/s-0031-1272824
   Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158
   Mai S, 2015, INT J RADIAT ONCOL, V93, P819, DOI 10.1016/j.ijrobp.2015.08.004
   Martinho O, 2016, PATHOBIOLOGY, V83, P41, DOI 10.1159/000441227
   Martinho O, 2013, ONCOL REP, V29, P690, DOI 10.3892/or.2012.2179
   Martinho O, 2009, VIRCHOWS ARCH, V455, P277, DOI 10.1007/s00428-009-0821-z
   Matalon SA, 2015, RADIOGRAPHICS, V35, P2091, DOI 10.1148/rg.2015150037
   Meulendijks D, 2015, BRIT J CANCER, V112, P1358, DOI 10.1038/bjc.2015.20
   Nelson RA, 2013, J CLIN ONCOL, V31, P1569, DOI 10.1200/JCO.2012.45.2524
   Odabaei G, 2004, ADV CANCER RES, V91, P169, DOI 10.1016/S0065-230X(04)91005-6
   Scapulatempo-Neto C, 2017, ONCOL LETT, V13, P1891, DOI 10.3892/ol.2017.5650
   Serup-Hansen E, 2014, J CLIN ONCOL, V32, P1812, DOI 10.1200/JCO.2013.52.3464
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Smaglo BG, 2015, ONCOTARGET, V6, P43594, DOI 10.18632/oncotarget.6202
   Stier EA, 2015, AM J OBSTET GYNECOL, V213, P278, DOI 10.1016/j.ajog.2015.03.034
   Vandamme Drieke, 2014, Critical Reviews in Oncogenesis, V19, P405
   Wang Y, 2015, ONCOL REP, V34, P2106, DOI 10.3892/or.2015.4157
   Yeung K, 1999, NATURE, V401, P173
   Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001
NR 32
TC 0
Z9 1
U1 0
U2 0
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD AUG
PY 2018
VL 16
IS 2
BP 1785
EP 1790
DI 10.3892/ol.2018.8828
PG 6
WC Oncology
SC Oncology
GA GT8DC
UT WOS:000444763100054
PM 30008866
OA Bronze, Green Published
DA 2020-11-30
ER

PT J
AU Luna, E
   Romano, C
   Araujo, E
   Felix, AC
   Nakasone, O
   Campos, S
   Fernandes, L
   Levi, JE
   Santiago, N
   Fernandes, J
   Fragoso, D
   Kallas, E
   Pannuti, C
AF Luna, E.
   Romano, C.
   Araujo, E.
   Felix, A. C.
   Nakasone, O.
   Campos, S.
   Fernandes, L.
   Levi, J. E.
   Santiago, N.
   Fernandes, J.
   Fragoso, D.
   Kallas, E.
   Pannuti, C.
TI Low prevalence after the first Zika virus epidemic wave in Southeastern
   Brazil
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Luna, E.; Romano, C.; Felix, A. C.; Campos, S.; Levi, J. E.; Santiago, N.; Kallas, E.; Pannuti, C.] Univ Sao Paulo, Sao Paulo, SP, Brazil.
   [Araujo, E.; Nakasone, O.; Fernandes, L.; Fernandes, J.; Fragoso, D.] Hosp Ana Costa, Santos, Brazil.
RI Luna, Expedito J A/B-7948-2012
OI Luna, Expedito J A/0000-0002-1145-9672; Campos,
   Sergio/0000-0002-1048-8332
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2016/16069-8]
FX Grant FAPESP no. 2016/16069-8
NR 0
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD AUG
PY 2018
VL 73
SU S
MA SADI 12.00
BP 17
EP 17
DI 10.1016/j.ijid.2018.04.3464
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA GO8MP
UT WOS:000440345100030
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Torres, KL
   Marino, JM
   Rocha, DAP
   de Mello, MB
   Farah, HHD
   Reis, RD
   Alves, VDR
   Gomes, E
   Martins, TR
   Soares, AC
   de Oliveire, CM
   Levi, JE
AF Torres, Katia Luz
   Marino, Josiane Montanho
   Pires Rocha, Danielle Albuquerque
   de Mello, Monica Bandeira
   de Melo Farah, Heydy Halanna
   Reis, Renato dos Santos
   Rodrigues Alves, Valquiria do Carmo
   Gomes, Edson
   Martins, Toni Ricardo
   Soares, Ana Carolina
   de Oliveire, Cristina Mendes
   Levi, Jose Eduardo
TI Self-sampling coupled to the detection of HPV 16 and 18 E6 protein: A
   promising option for detection of cervical malignancies in remote areas
SO PLOS ONE
LA English
DT Article
ID CANCER SCREENING-PROGRAM; HUMAN-PAPILLOMAVIRUS; LATIN-AMERICA; RURAL
   CHINA; METAANALYSIS; IMPLEMENTATION; COLLECTION; TRIALS; TESTS; WOMEN
AB Objective
   To evaluate both the performance and acceptability of a method coupling self-sampling with detection of cervical malignancy via elevated HPV 16 and 18 E6 oncoproteins (OncoE6((TM)) Cervical Test) in remote areas in Brazil.
   Methods
   Women living in rural villages in proximity to Coari city, Amazonas, Brazil were invited to participate in a cervical cancer screening study. 412 subjects were enrolled; there were no refusals. In addition to E6 protein detection, DNA was extracted from the brushes and evaluated for HPV genotypes by PCR (PGMY09/11), followed by typing by the Papillocheck (TM) if positive. Subjects who were found to be positive for OncoE6 or HPV-DNA were referred for colposcopy.
   Results
   For 110 subjects (27%) this was the first cervical cancer exam. Overall the HPV-DNA prevalence was 19.1% (n = 79); 1.4% (n = 6) were positive by the OncoE6 Test. Fifty-six women attended the invitation for colposcopy where nine had an abnormal cervix and were subsequently biopsied. Histopathological analysis revealed 2 CIN3, 2 carcinomas and 5 CIN1. OncoE6 called two out of the three HPV 16 or 18 associated CIN3+ lesions.
   Conclusions
   The findings suggest that self-administered sample collection in combination with OncoE6 Test is feasible in this population. This could enable expanded screening coverage while ensuring a high specificity which is imperative given the remote geographic location, since women bearing abnormal test results would necessitate travel and logistical burden to access colposcopy and treatment.
C1 [Torres, Katia Luz; Pires Rocha, Danielle Albuquerque] Univ Fed Amazonas UFAM, Programa Posgrad Ciencias Saude, Manaus, Amazonas, Brazil.
   [Torres, Katia Luz; de Melo Farah, Heydy Halanna; Rodrigues Alves, Valquiria do Carmo] Univ Fed Amazonas UFAM, Programa Posgrad Imunol Basica & Aplicada, Manaus, Amazonas, Brazil.
   [Torres, Katia Luz; de Mello, Monica Bandeira; Rodrigues Alves, Valquiria do Carmo] Fundacao Ctr Oncol Estado Amazonas FCECON, Manaus, Amazonas, Brazil.
   [Marino, Josiane Montanho; Pires Rocha, Danielle Albuquerque; Reis, Renato dos Santos] Univ Fed Amazonas UFAM, Coari, Amazonas, Brazil.
   [Gomes, Edson] Lab Sebastiao Marinho, Manaus, Amazonas, Brazil.
   [Martins, Toni Ricardo; Soares, Ana Carolina; de Oliveire, Cristina Mendes; Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop, Sao Paulo, Brazil.
RP Levi, JE (corresponding author), Univ Sao Paulo, Inst Med Trop, Sao Paulo, Brazil.
EM dudilevi@usp.br
RI Gomes, Edson/AAB-5618-2020
FU FAPEAM Grant [062.00650/2015]
FX This study was sponsored by FAPEAM Grant# 062.00650/2015. The funder had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Costa RFA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138945
   Arbyn M, 2014, LANCET ONCOL, V15, P172, DOI 10.1016/S1470-2045(13)70570-9
   Arrossi S, 2015, INT J CANCER, V137, P1709, DOI 10.1002/ijc.29530
   Arrossi S, 2015, LANCET GLOB HEALTH, V3, pE85, DOI 10.1016/S2214-109X(14)70354-7
   Bruinsma FJ, 2011, BJOG-INT J OBSTET GY, V118, P1031, DOI 10.1111/j.1471-0528.2011.02944.x
   Bychkovsky BL, 2016, CANCER-AM CANCER SOC, V122, P502, DOI 10.1002/cncr.29813
   Carozzi FM, 2016, J CLIN VIROL, V76, pS22, DOI 10.1016/j.jcv.2015.10.025
   Derchain S, 2016, REV BRAS GINECOL OBS, V38, P161, DOI 10.1055/s-0036-1582399
   Diaz RS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139677
   Enerly E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151978
   Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
   Jeronimo J, 2016, J CLIN VIROL, V76, pS69, DOI 10.1016/j.jcv.2015.11.035
   Lazcano-Ponce E, 2014, INT J CANCER, V135, P109, DOI 10.1002/ijc.28639
   Mariano VS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164892
   Ministerio da Saude (BR). Instituto Nacional de Cancer Jose Alencar Gomes da Silva, 2017, COORD PREV VIG EST 2
   Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7
   Rossi PG, 2015, BRIT J CANCER, V112, P667, DOI 10.1038/bjc.2015.11
   SIM-Sistema de Informac E sobre Mortalidade, DATASUS MIN SAUD
   Subramaniam A, 2011, J LOW GENIT TRACT DI, V15, P110, DOI 10.1097/LGT.0b013e3181f515a2
   Valdez M, 2016, INT J CANCER, V138, P1453, DOI 10.1002/ijc.29877
   Verdoodt F, 2015, EUR J CANCER, V51, P2375, DOI 10.1016/j.ejca.2015.07.006
   Zhao FH, 2013, CANCER PREV RES, V6, P938, DOI 10.1158/1940-6207.CAPR-13-0091
NR 22
TC 10
Z9 10
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 23
PY 2018
VL 13
IS 7
AR eO201262
DI 10.1371/journal.pone.0201262
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GN8PM
UT WOS:000439429200033
PM 30036381
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Brunialti, MKC
   Cerqueira, N
   Maestri, A
   Chaves, L
   Levi, JE
   Pannuti, CS
   Kallas, EG
   Burattini, MN
   Salomao, R
AF Brunialti, Milena K. C.
   Cerqueira, Natalia
   Maestri, Alvino
   Chaves, Lucas
   Levi, Jose E.
   Pannuti, Claudio S.
   Kallas, Esper G.
   Burattini, Marcelo N.
   Salomao, Reinaldo
TI TOLL-LIKE RECEPTOR SIGNALING PATHWAY IS DIFFERENTIALLY MODULATED IN
   PATIENTS WITH DENGUE WITHOUT WARNING SIGNS AND DENGUE WITH WARNING SIGNS
SO SHOCK
LA English
DT Meeting Abstract
CT 41st Annual Conference on Shock
CY JUN 09-12, 2018
CL Scottsdale, AZ
SP Shock Soc
C1 [Brunialti, Milena K. C.; Burattini, Marcelo N.; Salomao, Reinaldo] Univ Fed Sao Paulo, Hosp Sao Paulo, Div Infect Dis, Escola Paulista Med, Sao Paulo, Brazil.
   [Cerqueira, Natalia; Maestri, Alvino; Chaves, Lucas; Kallas, Esper G.] Univ Sao Paulo, Hosp Clin, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Levi, Jose E.; Pannuti, Claudio S.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
RI Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD JUN
PY 2018
VL 49
IS 6
SU 1
MA P120
BP 90
EP 91
PG 2
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA GQ0XL
UT WOS:000441343800190
DA 2020-11-30
ER

PT J
AU Musso, D
   Bossin, H
   Mallet, HP
   Besnard, M
   Broult, J
   Baudouin, L
   Levi, JE
   Sabino, EC
   Ghawche, F
   Lanteri, MC
   Baud, D
AF Musso, Didier
   Bossin, Herve
   Mallet, Henri Pierre
   Besnard, Marianne
   Broult, Julien
   Baudouin, Laure
   Levi, Jose Eduardo
   Sabino, Ester C.
   Ghawche, Frederic
   Lanteri, Marion C.
   Baud, David
TI Zika virus in French Polynesia 2013-14: anatomy of a completed outbreak
SO LANCET INFECTIOUS DISEASES
LA English
DT Review
ID GUILLAIN-BARRE-SYNDROME; MALE SEXUAL TRANSMISSION; ROSS RIVER VIRUS;
   CHIKUNGUNYA VIRUS; MOSQUITO-BORNE; DIPTERA-CULICIDAE; DENGUE VIRUSES;
   PREGNANT-WOMEN; AEDES-AEGYPTI; NEW-CALEDONIA
AB The Zika virus crisis exemplified the risk associated with emerging pathogens and was a reminder that preparedness for the worst-case scenario, although challenging, is needed. Herein, we review all data reported during the unexpected emergence of Zika virus in French Polynesia in late 2013. We focus on the new findings reported during this outbreak, especially the first description of severe neurological complications in adults and the retrospective description of CNS malformations in neonates, the isolation of Zika virus in semen, the potential for blood-transfusion transmission, mother-to-child transmission, and the development of new diagnostic assays. We describe the effect of this outbreak on health systems, the implementation of vector-borne control strategies, and the line of communication used to alert the international community of the new risk associated with Zika virus. This outbreak highlighted the need for careful monitoring of all unexpected events that occur during an emergence, to implement surveillance and research programmes in parallel to management of cases, and to be prepared to the worst-case scenario.
C1 [Musso, Didier] Inst Louis Malarde, Pole Rech & Veille Malad Infect Emergentes, F-98713 Tahiti, French Polynesi, France.
   [Bossin, Herve] Inst Louis Malarde, Unite Entomol Med, Tahiti, French Polynesi, France.
   [Mallet, Henri Pierre] Direct Sante Papeete, Bur Veille Sanit, Tahiti, French Polynesi, France.
   [Besnard, Marianne] Ctr Hosp Taaone, Serv Reanimat Neonatale, Tahiti, French Polynesi, France.
   [Broult, Julien] Ctr Hosp Taaone, Ctr Transfus Sanguine, Tahiti, French Polynesi, France.
   [Ghawche, Frederic] Ctr Hosp Taaone, Serv Neurol, Tahiti, French Polynesi, France.
   [Levi, Jose Eduardo; Sabino, Ester C.] Univ Sao Paulo, Trop Med Inst, Sao Paulo, Brazil.
   [Sabino, Ester C.] Univ Sao Paulo, Dept Infect Dis, Med Sch, Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Lanteri, Marion C.] Blood Syst Res Inst, San Francisco, CA USA.
   [Lanteri, Marion C.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   [Lanteri, Marion C.] Cerus Corp, Concord, CA USA.
   [Baud, David] Univ Hosp, Dept Femme Mere Enfant, Maternofetal & Obstet Res Unit, Lausanne, Switzerland.
RP Musso, D (corresponding author), Inst Louis Malarde, Pole Rech & Veille Malad Infect Emergentes, F-98713 Tahiti, French Polynesi, France.
EM dmusso@ilm.pf
RI Sabino, Ester Cerdeira/F-7750-2010; Musso, Didier/AAO-8178-2020; amsalu,
   ribka/G-8780-2019; Musso, Didier/P-7809-2016
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; Musso,
   Didier/0000-0002-9226-0971; Musso, Didier/0000-0002-9226-0971; Baud,
   David/0000-0001-9914-6496
CR AASKOV JG, 1981, AM J TROP MED HYG, V30, P1053, DOI 10.4269/ajtmh.1981.30.1053
   Abraham Alon, 2011, J Clin Neuromuscul Dis, V12, P113, DOI 10.1097/CND.0b013e318209ef9a
   American Association of Blood Banks, 2016, AM ASS BLOOD BANKS A
   Aubry M, 2017, EMERG INFECT DIS, V23, P669, DOI 10.3201/eid2304.161549
   Aubry M, 2016, TRANSFUSION, V56, P33, DOI 10.1111/trf.13271
   Aubry M, 2015, INT J INFECT DIS, V41, P11, DOI 10.1016/j.ijid.2015.10.005
   Aubry M, 2015, INT J INFECT DIS, V37, P19, DOI 10.1016/j.ijid.2015.06.005
   Aubry M, 2015, EMERG INFECT DIS, V21, P724, DOI 10.3201/eid2104.141741
   Barber B, 2009, AUST FAM PHYSICIAN, V38, P586
   Barjas-Castro ML, 2016, TRANSFUSION, V56, P1684, DOI 10.1111/trf.13681
   Baronti C, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.00500-14
   Baud D, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5319
   Baud D, 2016, LANCET INFECT DIS, V16, P523, DOI 10.1016/S1473-3099(16)30008-1
   Bel M., 2007, ZIKA VIRUS PRELIMINA
   Belkin J.N., 1962, MOSQUITOES S PACIFIC, V1
   Besnard M, 2016, EUROSURVEILLANCE, V21, P22, DOI 10.2807/1560-7917.ES.2016.21.13.30181
   Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Besnard M, 2017, EMERG INFECT DIS, V23, P1421, DOI 10.3201/eid2308.170198
   Bingham AM, 2016, MMWR-MORBID MORTAL W, V65, P475, DOI 10.15585/mmwr.mm6518e2
   Boccolini D, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.35.30328
   Bourtzis K, 2014, ACTA TROP
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636
   Brooks RB, 2016, MMWR-MORBID MORTAL W, V65, P915, DOI 10.15585/mmwr.mm6534e2
   Callaway E, 2016, NATURE, V539, P17, DOI 10.1038/nature.2016.20878
   Calvez E, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004374
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cao-Lormeau VM, 2014, LANCET, V384, P1571, DOI 10.1016/S0140-6736(14)61977-2
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Dutra HLC, 2016, CELL HOST MICROBE, V19, P771, DOI 10.1016/j.chom.2016.04.021
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Cauchemez S, 2016, LANCET, V387, P2125, DOI 10.1016/S0140-6736(16)00651-6
   Champagne C, 2016, ELIFE, V5, DOI [10.7554/eLife.19874, 10.7554/eLife.19874.001]
   Chraibi S, 2016, J CLIN VIROL, V83, P61, DOI 10.1016/j.jcv.2016.08.299
   Coelho FC, 2016, INT J INFECT DIS, V51, P128, DOI 10.1016/j.ijid.2016.08.023
   Cressey D, 2015, NATURE, V517, P255, DOI 10.1038/517255a
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P716, DOI 10.15585/mmwr.mm6528e2
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Deckard DT, 2016, MMWR-MORBID MORTAL W, V65, P372, DOI 10.15585/mmwr.mm6514a3
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Dickens BL, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw103
   Dirlikov E, 2016, MMWR-MORBID MORTAL W, V65, P910, DOI 10.15585/mmwr.mm6534e1
   dos Santos T, 2016, NEW ENGL J MED, V375, P1598, DOI 10.1056/NEJMc1609015
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Duggal NK, 2017, CELL REP, V18, P1751, DOI 10.1016/j.celrep.2017.01.056
   Dupont-Rouzeyrol M, 2015, EMERG INFECT DIS, V21, P381, DOI 10.3201/eid2102.141553
   Dupont-Rouzeyrol M, 2012, VECTOR-BORNE ZOONOT, V12, P1036, DOI 10.1089/vbz.2011.0937
   ECDC, 2016, ZIK VIR SAF SUBST HU
   Esack A, 1999, W INDIAN MED J, V48, P36
   European Centre for Disease Prevention and Control, 2014, MON CURR THREATS ECD
   European Centre for Disease Prevention and Control, 2015, RAP RISK ASS MICR BR
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   FDA, 2016, REV REC RED RISK ZIK
   Fernandes RS, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004993
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Furtado JM, 2016, NEW ENGL J MED, V375, P394, DOI 10.1056/NEJMc1603618
   Gao DZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep28070
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   Gubler DJ, 2007, FIELDS VIROLOGY, P1155
   Guillaumot Laurent, 2005, Pac Health Dialog, V12, P45
   Gulland A, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i657
   Hamer DH, 2017, CURR INFECT DIS REP, V19, DOI 10.1007/s11908-017-0571-z
   Hapairai LK, 2013, J MED ENTOMOL, V50, P965, DOI 10.1603/ME12246
   Hapairai LK, 2013, J MED ENTOMOL, V50, P731, DOI 10.1603/ME12270
   Huang YJS, 2016, VECTOR-BORNE ZOONOT, V16, P673, DOI 10.1089/vbz.2016.2058
   Jimenez A, 2017, TRANSFUS MED REV, V31, P1, DOI 10.1016/j.tmrv.2016.08.001
   Johansson MA, 2016, NEW ENGL J MED, V375, P1, DOI 10.1056/NEJMp1605367
   Kessler CM, 2016, CLIN ADV HEMATOL ONC, V14, P677
   Kucharski AJ, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004726
   Kutsuna S, 2014, EUROSURVEILLANCE, V19, P8, DOI 10.2807/1560-7917.ES2014.19.4.20683
   Kutsuna S, 2017, J INFECT CHEMOTHER, V23, P114, DOI 10.1016/j.jiac.2016.08.003
   Laigret J, 1967, Bull Soc Pathol Exot Filiales, V60, P339
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanteri MC, 2016, TRANSFUSION, V56, P1907, DOI 10.1111/trf.13677
   Lardeux F, 2002, ANN TROP MED PARASIT, V96, pS105, DOI 10.1179/000349802125002455
   Laughhunn A, 2017, TRANSFUSION, V57, P779, DOI 10.1111/trf.13993
   Lebrun G, 2009, EMERG INFECT DIS, V15, P495, DOI 10.3201/eid1503.071482
   Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017
   Lustig Y, 2016, EUROSURVEILLANCE, V21, P7, DOI 10.2807/1560-7917.ES.2016.21.26.30269
   Mallet H-P, 2016, B EPIDEMIOLOGIQUE HE, V2016, P20
   Mallet HP, 2015, BISES B INFORM SANIT, V13, P1
   Mansuy JM, 2017, EMERG INFECT DIS, V23, P863, DOI 10.3201/eid2305.161631
   Mecharles S, 2016, LANCET, V387, P1481, DOI 10.1016/S0140-6736(16)00644-9
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Mercer DR, 2012, J MED ENTOMOL, V49, P51, DOI 10.1603/ME11087
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Motta IJF, 2016, NEW ENGL J MED, V375, P1101, DOI 10.1056/NEJMc1607262
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761
   Musso D, 2017, ISBT SCI SERIES, V12, P254
   Musso D, 2017, J MED VIROL, V89, P1505, DOI 10.1002/jmv.24735
   Musso D, 2016, CURR INFECT DIS REP, V18, DOI 10.1007/s11908-016-0551-8
   Musso D, 2017, BLOOD TRANSFUS-ITALY, V15, P272, DOI 10.2450/2016.0003-16
   Musso D, 2016, LANCET, V387, P1993, DOI 10.1016/S0140-6736(16)30428-7
   Musso D, 2016, LANCET, V387, P1812, DOI 10.1016/S0140-6736(16)30317-8
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Musso D, 2015, EMERG INFECT DIS, V21, P1887, DOI 10.3201/eid2110.151125
   Musso D, 2015, LANCET, V386, P243, DOI 10.1016/S0140-6736(15)61273-9
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Mysorekar IU, 2016, NEW ENGL J MED, V375, P481, DOI 10.1056/NEJMcibr1605445
   Nhan TX, 2015, CLIN MICROBIOL INFEC, V21, pE47, DOI 10.1016/j.cmi.2015.02.018
   Oehler E., 2014, Eurosurveillance, V19, P20720
   Panchaud A, 2016, LANCET INFECT DIS, V16, P995, DOI 10.1016/S1473-3099(16)30255-9
   Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564
   Pettersson JHO, 2016, MBIO, V7, DOI [10.1128/mBio.01239-16, 10.1128/mbio.01239-16]
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Ribeiro LS, 2016, CURR OPIN VIROL, V18, P76, DOI 10.1016/j.coviro.2016.04.002
   Richard V, 2017, ACTA TROP, V173, P200, DOI 10.1016/j.actatropica.2017.04.036
   Richard V, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005024
   Rodrigues LC, 2016, LANCET, V387, P2070, DOI 10.1016/S0140-6736(16)00742-X
   Roth A, 2014, EUROSURVEILLANCE, V19, P2, DOI 10.2807/1560-7917.ES2014.19.41.20929
   Roth Adam, 2014, Emerg Infect Dis, V20, DOI 10.3201/eid2008.130696
   Rubin EJ, 2016, NEW ENGL J MED, V374, P984, DOI 10.1056/NEJMe1601862
   Santa Maria F, 2016, TRANSFUSION, V56, P33
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   Sharp TM, 2016, CLIN INFECT DIS, V63, P1198, DOI 10.1093/cid/ciw476
   Singh Narendra, 2005, Pac Health Dialog, V12, P111
   Tauro LB, 2017, J MED VIROL, V89, P1, DOI 10.1002/jmv.24696
   Trosemeier J-H, 2016, GENOME ANNOUNC, V4
   Turmel JM, 2016, LANCET, V387, P2501, DOI 10.1016/S0140-6736(16)30775-9
   Uncini A, 2017, J NEUROL NEUROSUR PS, V88, P266, DOI 10.1136/jnnp-2016-314310
   Cao-Lormeau VM, 2016, EMERG INFECT DIS, V22, P913, DOI 10.3201/eid2205.150547
   Vouga M, 2016, LANCET, V387, P843, DOI 10.1016/S0140-6736(16)00383-4
   Waehre T, 2014, EMERG INFECT DIS, V20, P1412, DOI 10.3201/eid2008.140302
   Weaver SC, 2015, NEW ENGL J MED, V372, P1231, DOI 10.1056/NEJMra1406035
   WHO, 2016, MAINT SAF AD BLOOD S
   Wikan N, 2017, LANCET INFECT DIS, V17, P15, DOI 10.1016/S1473-3099(16)30525-4
   Willison HJ, 2016, LANCET, V388, P717, DOI 10.1016/S0140-6736(16)00339-1
   World Health Organization, 2009, DENG GUID DIAGN TREA
   World Health Organization, 2017, SIT REP ZIK VIR MICR
   Zammarchi L, 2015, J CLIN VIROL, V63, P32, DOI 10.1016/j.jcv.2014.12.005
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 136
TC 37
Z9 39
U1 0
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD MAY
PY 2018
VL 18
IS 5
BP E172
EP E182
DI 10.1016/S1473-3099(17)30446-2
PG 11
WC Infectious Diseases
SC Infectious Diseases
GA GD5TN
UT WOS:000430569700003
PM 29150310
DA 2020-11-30
ER

PT J
AU Fischer, C
   Pedroso, C
   Mendrone, A
   de Filippis, AMB
   Vallinoto, ACR
   Ribeiro, BM
   Durigon, EL
   Marques, ETA
   Campos, GS
   Viana, IFT
   Levi, JE
   Scarpelli, LC
   Nogueira, ML
   Bastos, MD
   Souza, NCS
   Khouri, R
   Lira, SMC
   Komninakis, SV
   Baronti, C
   Charrel, RN
   Kummerer, BM
   Drosten, C
   Brites, C
   de Lamballerie, X
   Niedrig, M
   Netto, EM
   Drexler, JF
AF Fischer, Carlo
   Pedroso, Celia
   Mendrone, Alfredo, Jr.
   Bispo de Filippis, Ana Maria
   Rosario Vallinoto, Antonio Carlos
   Ribeiro, Bergmann Morais
   Durigon, Edison Luiz
   Marques, Ernesto T. A., Jr.
   Campos, Gubio S.
   Viana, Isabelle F. T.
   Levi, Jose Eduardo
   Scarpelli, Luciano Cesar
   Nogueira, Mauricio Lacerda
   Bastos, Michele de Souza
   Santiago Souza, Nathalia C.
   Khouri, Ricardo
   Costa Lira, Sanny M.
   Komninakis, Shirley Vasconcelos
   Baronti, Cecile
   Charrel, Remi N.
   Kuemmerer, Beate M.
   Drosten, Christian
   Brites, Carlos
   de lamballerie, Xavier
   Niedrig, Matthias
   Netto, Eduardo Martins
   Drexler, Jan Felix
TI External Quality Assessment for Zika Virus Molecular Diagnostic Testing,
   Brazil
SO EMERGING INFECTIOUS DISEASES
LA English
DT Article
ID INFECTION; LOAD
AB We conducted an external quality assessment of Zika virus molecular diagnostic tests in Brazil using a new Zika virus standard. Of 15 laboratories, 73% showed limited sensitivity and specificity. Viral load estimates varied significantly. Continuous quality assurance is required for adequate estimates of Zika virus-associated disease and determination of patient care.
C1 [Fischer, Carlo; Drosten, Christian; Drexler, Jan Felix] Charite, German Ctr Infect Res, Berlin, Germany.
   [Pedroso, Celia; Brites, Carlos; Netto, Eduardo Martins] Hosp Univ Prof Edgard Santos, LAPI, Salvador, BA, Brazil.
   [Mendrone, Alfredo, Jr.; Levi, Jose Eduardo] Fdn Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Bispo de Filippis, Ana Maria] Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Rosario Vallinoto, Antonio Carlos] Fed Univ Para, Belem, Para, Brazil.
   [Ribeiro, Bergmann Morais] Univ Brasilia, Brasilia, DF, Brazil.
   [Durigon, Edison Luiz; Levi, Jose Eduardo; Santiago Souza, Nathalia C.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Marques, Ernesto T. A., Jr.; Viana, Isabelle F. T.] Fundacao Oswaldo Cruz, Pernambuco, Brazil.
   [Campos, Gubio S.] Univ Fed Bahia, Salvador, BA, Brazil.
   [Levi, Jose Eduardo; Scarpelli, Luciano Cesar] Diagnost Amer DASA, Sao Paulo, Brazil.
   [Levi, Jose Eduardo; Costa Lira, Sanny M.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Nogueira, Mauricio Lacerda] Fac Med Sao Jose do Rio Preto, Sao Jose De Rio Preto, Brazil.
   [Bastos, Michele de Souza] Fdn Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
   [Khouri, Ricardo] Fundacao Oswaldo Cruz, Salvador, BA, Brazil.
   [Komninakis, Shirley Vasconcelos] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Baronti, Cecile; Charrel, Remi N.; de lamballerie, Xavier] Aix Marseille Univ, Marseille, France.
   [Baronti, Cecile; Charrel, Remi N.; de lamballerie, Xavier] Assistance Publ Hop Marseille, Marseille, France.
   [Kuemmerer, Beate M.] Univ Bonn, Med Ctr, Bonn, Germany.
   [Niedrig, Matthias] Robert Koch Inst, Berlin, Germany.
RP Drexler, JF (corresponding author), Inst Virol, Helmut Ruska Haus, Campus Charite Mitte,Charitepl 1, D-10098 Berlin, Germany.
EM felix.drexler@charite.de
RI Khouri, Ricardo/M-3184-2018; Vallinoto, Antonio Carlos/AAL-9501-2020;
   Brites, Carlos/D-1353-2013; Netto, Eduardo/D-1432-2013; Komninakis,
   Shirley V/B-2915-2010; Marques, Ernesto T. A/L-4967-2013; Ribeiro,
   Bergmann Morais/C-7114-2015; Bastos, Michele/AAS-7386-2020; Nogueira,
   Mauricio L/B-7599-2012; Viana, Isabelle/M-4435-2017
OI Khouri, Ricardo/0000-0001-5664-4436; Vallinoto, Antonio
   Carlos/0000-0003-1135-6507; Brites, Carlos/0000-0002-4673-6991; Netto,
   Eduardo/0000-0003-1691-6761; Komninakis, Shirley V/0000-0001-7784-3418;
   Marques, Ernesto T. A/0000-0003-3826-9358; Ribeiro, Bergmann
   Morais/0000-0002-1061-196X; Bastos, Michele/0000-0003-3450-666X;
   Nogueira, Mauricio L/0000-0003-1102-2419; Drexler, Jan
   Felix/0000-0002-3509-0232; Fischer, Carlo/0000-0001-9163-2406; Viana,
   Isabelle/0000-0003-4648-6635
FU German Centre for Infection Research; European Union's Horizon research
   and innovation program (ZIKAlliance) [734548]; EVAg [653316]
FX This work was supported by the German Centre for Infection Research
   through a fast-track program for Zika virus outbreak response to J.F.D.
   and is partially supported by the European Union's Horizon 2020 research
   and innovation program (ZIKAlliance, grant agreement no. 734548 to
   X.d.L. and EVAg, grant agreement no. 653316 to C.D.).
CR Aiken ARA, 2016, NEW ENGL J MED, V375, P396, DOI 10.1056/NEJMc1605389
   Baylis SA, 2017, TRANSFUSION, V57, P748, DOI 10.1111/trf.14026
   Terzian ACB, 2017, CLIN INFECT DIS, V65, P1260, DOI 10.1093/cid/cix558
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Charrel R, 2017, J CLIN MICROBIOL, V55, P3219, DOI 10.1128/JCM.00987-17
   Corman VM, 2016, B WORLD HEALTH ORGAN, V94, P880, DOI 10.2471/BLT.16.175950
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   de Oliveira WK, 2017, LANCET, V390, P861, DOI 10.1016/S0140-6736(17)31368-5
   Domingo C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036291
   Domingo C, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000833
   Drexler JF, 2009, PLOS MED, V6, P210, DOI 10.1371/journal.pmed.1000031
   Halai UA, 2017, CLIN INFECT DIS, V65, P877, DOI 10.1093/cid/cix472
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Moreira-Soto Andres, 2017, J Infect Dis, V216, P1501, DOI 10.1093/infdis/jix539
   Niedrig M, 2006, CLIN CHEM, V52, P1851, DOI 10.1373/clinchem.2005.064451
NR 15
TC 11
Z9 11
U1 0
U2 8
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
EI 1080-6059
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD MAY
PY 2018
VL 24
IS 5
BP 888
EP 892
DI 10.3201/eid2405.171747
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA GD2TP
UT WOS:000430355500012
PM 29470164
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Martins, TR
   Longatto, A
   Cohen, D
   Viscondi, JYK
   Fuza, LM
   Cury, L
   Villa, LL
   Levi, JE
   Neto, JE
AF Martins, Toni Ricardo
   Longatto-Filho, Adhemar
   Cohen, Diane
   Kodaira Viscondi, Juliana Yukari
   Fuza, Luiz Mario
   Cury, Lise
   Villa, Luisa Lina
   Levi, Jose Eduardo
   Eluf-Neto, Jose
TI Influence of Prior Knowledge of Human Papillomavirus Status on the
   Performance of Cytology Screening
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE Cervical cytology; Screening; HPV-DNA; Papanicolaou test; Cervical
   cancer
ID LIQUID-BASED CYTOLOGY; CERVICAL-CANCER; PAP TEST; TRIAGE; ATHENA; WOMEN
AB Objectives: This study aimed to evaluate the influence of prior knowledge of human papillomavirus (HPV) status in cervical cytopathology readings.
   Methods: Participants comprised 2,376 women who underwent parallel cytology and HPV-DNA testing. Smears were read twice by the same team, first with previous knowledge of HPV-DNA status.
   Results: Overall, 239 (10.2%) smears had their cytology classification altered by the HPV-informed review. Cytology readings with prior knowledge of the HPV status revealed 10.5% of abnormal smears (atypical squamous cells of undetermined significance or higher), while without prior knowledge, this rate dropped to 7.6%. When HPV status was informed, a significant increase in all categories of altered smears was observed. Cytology with prior knowledge of HPV status detected more cervical intraepithelial neoplasia grade 2 or higher (CIN 2+) compared with blinded: 86.7% vs 60.0%.
   Conclusions: Our data indicate that cytology interpreted with prior knowledge of the HPV status provides higher sensitivity for CIN 2+ lesions while marginally reducing the overall specificity compared with HPV status blinded cytology.
C1 [Martins, Toni Ricardo; Fuza, Luiz Mario; Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] Univ Sao Paulo, Fac Med, Lab Med Invest LIM 14, Sao Paulo, Brazil.
   [Martins, Toni Ricardo] Univ Sao Paulo, Dept Infect Dis, Sch Med, Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] Pio XII Fdn, Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil.
   [Longatto-Filho, Adhemar] Univ Minho, Sch Hlth Sci, Liffe & Hlth Sci Res Inst ICVS, Braga, Portugal.
   [Longatto-Filho, Adhemar] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal.
   [Longatto-Filho, Adhemar; Villa, Luisa Lina; Levi, Jose Eduardo; Eluf-Neto, Jose] Inst Nacl Ciencia & Tecnol Doencas Papilomavirus, Sao Paulo, Brazil.
   [Cohen, Diane; Fuza, Luiz Mario; Cury, Lise; Eluf-Neto, Jose] Fundacao Oncoctr Sao Paulo, Oscar Freire St 2396, BR-05409012 Sao Paulo, SP, Brazil.
   [Kodaira Viscondi, Juliana Yukari; Eluf-Neto, Jose] Univ Sao Paulo, Fac Med, Dept Prevent Med, Sao Paulo, Brazil.
   [Villa, Luisa Lina] Univ Sao Paulo, Fac Med, Dept Radiol & Oncol, Sao Paulo, Brazil.
   [Villa, Luisa Lina] Inst Canc Estado Sao Paulo, Ctr Invest Translac Oncol, Sao Paulo, Brazil.
RP Neto, JE (corresponding author), Fundacao Oncoctr Sao Paulo, Oscar Freire St 2396, BR-05409012 Sao Paulo, SP, Brazil.
EM jelufnet@usp.br
RI Eluf-Neto, Jose/B-2522-2009; VILLA, LUISA/AAH-4761-2019; Longatto-Filho,
   Adhemar/N-3397-2019; longatto-filho, adhemar/D-7039-2013
OI Eluf-Neto, Jose/0000-0001-7504-2115; VILLA, LUISA/0000-0003-4074-2335;
   Longatto-Filho, Adhemar/0000-0002-5779-9752; longatto-filho,
   adhemar/0000-0002-5779-9752
FU Instituto Nacional de Ciencia e Tecnologia das Doencas do Papilomavirus
   Humano INCT-HPV (National Institute of Science and Technology of the
   Diseases Associated to the Papillomavirus) through CNPq [573799/2008-3];
   Instituto Nacional de Ciencia e Tecnologia das Doencas do Papilomavirus
   Humano INCT-HPV (National Institute of Science and Technology of the
   Diseases Associated to the Papillomavirus) through FAPESP [2008/57889-1]
FX We thank Becton-Dickinson (BD) for technical support, equipment, and
   reagents for the study, as well as cytologists and pathologists of the
   FOSP Laboratory. We also thank the Instituto Nacional de Ciencia e
   Tecnologia das Doencas do Papilomavirus Humano INCT-HPV (National
   Institute of Science and Technology of the Diseases Associated to the
   Papillomavirus) coordinated by Luisa Lina Villa, Sao Paulo, Brazil, for
   financial support through CNPq 573799/2008-3 and FAPESP 2008/57889-1
   grants.
CR Benoy IH, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.101
   Bergeron C, 2015, J NATL CANC I, V107
   Branca M, 2015, ACTA CYTOL, V59, P361, DOI 10.1159/000441515
   Castle PE, 2015, HPV TODAY NEWSLETTER
   Castle PE, 2013, OBSTET GYN CLIN N AM, V40, P377, DOI 10.1016/j.ogc.2013.03.002
   Dillner J, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1754
   Ejegod D, 2016, J CLIN MICROBIOL, V54, P2267, DOI 10.1128/JCM.00508-16
   El-Zein M, 2016, J CLIN VIROL, V76, pS62, DOI 10.1016/j.jcv.2015.11.020
   Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354
   Herbert A, 2017, CYTOPATHOLOGY, V28, P9, DOI 10.1111/cyt.12334
   INCA. Instituto Nacional do Cancer, 2016, MIN SAUD
   Joste N, 2013, OBSTET GYN CLIN N AM, V40, P199, DOI 10.1016/j.ogc.2013.02.001
   Kitchener HC, 2009, LANCET ONCOL, V10, P672, DOI 10.1016/S1470-2045(09)70156-1
   Lorenzi AT, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0342-0
   Nayar R, 2015, CANCER CYTOPATHOL, V123, P271, DOI 10.1002/cncy.21521
   Passamonti B, 2007, ACTA CYTOL, V51, P865, DOI 10.1159/000325862
   Poljak M, 2016, J CLIN VIROL, V76, pS1, DOI 10.1016/j.jcv.2015.11.010
   Richardson LA, 2015, CANCER CYTOPATHOL, V123, P745, DOI 10.1002/cncy.21596
   Rijkaart DC, 2012, LANCET ONCOL, V13, P78, DOI 10.1016/S1470-2045(11)70296-0
   Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7
   Stoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500
   Wentzensen N, 2016, J CLIN VIROL, V76, pS49, DOI 10.1016/j.jcv.2015.11.015
   Whitlock EP, 2011, ANN INTERN MED, V155, P687, DOI 10.7326/0003-4819-155-10-201111150-00376
   Wright TC, 2016, AM J CLIN PATHOL, V146, P391, DOI [10.1093/AJCP/AQW125, 10.1093/ajcp/aqw125]
   Wright TC, 2014, INT J CANCER, V134, P1835, DOI 10.1002/ijc.28514
   Wright TC, 2011, AM J CLIN PATHOL, V136, P578, DOI 10.1309/AJCPTUS5EXAS6DKZ
NR 26
TC 2
Z9 2
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9173
EI 1943-7722
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD APR
PY 2018
VL 149
IS 4
BP 316
EP 323
DI 10.1093/AJCP/AQX163
PG 8
WC Pathology
SC Pathology
GA GC0FU
UT WOS:000429453100005
PM 29471316
OA Bronze
DA 2020-11-30
ER

PT J
AU Levi, JE
AF Levi, Jose Eduardo
TI Emerging Infectious Agents and Blood Safety in Latin America
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE blood transfusion; arboviruses; Latin America; Zika; Dengue; Chikungunya
ID WEST NILE VIRUS; ZIKA VIRUS; DENGUE VIRUS; CHIKUNGUNYA VIRUS;
   PUERTO-RICO; TRANSFUSION; DONORS; TRANSMISSION; MULTICENTER; EXPERIENCE
AB Historically, emerging infectious agents have been an important driving force toward the enhancement of blood safety, illustrated by the sharp reduction in the transmission of infectious agents by blood transfusion after human immunodeficiency virus (HIV) epidemics. In general, Latin American (LATAM) countries have introduced screening for microorganisms with proven blood transmission with some delay in comparison to developed countries, but, nowadays, all LATAM countries comply with a minimum standard of screening which includes Hepatitis B, C, HIV, Treponema pallidum, and Trypanosoma cruzi. Noticeably, all those agents, in addition to HTLV, cause chronic infections. By contrast, in the last decade, the region has witnessed explosive outbreaks of arboviral diseases, representing a new challenge to the blood system, threatening not only blood safety but also availability. So far, the clinical impact of transfusion-transmitted Dengue, Chikungunya, or Zika has not been evident, precluding immediate reaction from the authorities. A number of other arboviruses are endemic in the region and may, unpredictably, originate new epidemics. Several measures must be taken in preparedness for the potential emergence of another arbodisease.
C1 [Levi, Jose Eduardo] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
RP Levi, JE (corresponding author), Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
EM jose.levi@einstein.br
FU Sao Paulo State Research Agency (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2014/50093-8];  [CNPq 444961/2014-3]
FX This work was partially supported by Sao Paulo State Research Agency
   (FAPESP) Grant # 2014/50093-8, and the grant CNPq 444961/2014-3.
CR Adams L, 2016, MMWR-MORBID MORTAL W, V65, P774, DOI 10.15585/mmwr.mm6530e1
   Allain JP, 2017, TRANSFUSION MED, V27, P320, DOI 10.1111/tme.12456
   Esposito DLA, 2017, BRAZ J INFECT DIS, V21, P540, DOI 10.1016/j.bjid.2017.06.002
   [Anonymous], 2016, WHOZIKVHS161
   de Brito CAA, 2017, REV SOC BRAS MED TRO, V50, P585, DOI 10.1590/0037-8682-0479-2016
   Arellanos-Soto D, 2015, TRANSFUSION MED, V25, P122, DOI 10.1111/tme.12198
   Aubry M, 2018, VOX SANG, DOI [10.1111/vox, DOI 10.1111/VOX]
   Bajak A, 2014, NATURE, V512, P124, DOI 10.1038/512124a
   Barjas-Castro ML, 2016, TRANSFUSION, V56, P1684, DOI 10.1111/trf.13681
   Bierlaire D, 2017, TRANSFUSION, V57, P729, DOI 10.1111/trf.14028
   BRAZIL, 2017, B EP MON CAS DENG FE
   BRUCECHW.LJ, 1974, B WORLD HEALTH ORGAN, V50, P337
   Chen RB, 2016, J VIROL, V90, P10600, DOI 10.1128/JVI.01166-16
   de Almeida-Neto C, 2013, VOX SANG, V105, P91, DOI 10.1111/vox.12028
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Dias LL, 2012, TRANSFUSION, V52, P1667, DOI 10.1111/j.1537-2995.2012.03729.x
   Dodd RY, 2015, TRANSFUS MED REV, V29, P153, DOI 10.1016/j.tmrv.2015.03.001
   Elizondo-Quiroga D, 2013, J GLOB INFECT DIS, V5, P168, DOI 10.4103/0974-777X.122014
   Galel SA, 2017, TRANSFUSION, V57, P762, DOI 10.1111/trf.14029
   Gallian P, 2017, BLOOD, V129, P263, DOI 10.1182/blood-2016-09-737981
   Gallian P, 2014, BLOOD, V123, P3679, DOI 10.1182/blood-2014-03-564880
   Hills SL, 2017, J INFECT DIS, V216, pS868, DOI 10.1093/infdis/jix434
   Levi JE, 2017, TRANSFUSION MED, V27, P286, DOI 10.1111/tme.12427
   Levi JE, 2016, J INFECT DIS, V213, P689, DOI 10.1093/infdis/jiv322
   Levi JE, 2015, TRANSFUSION, V55, P961, DOI 10.1111/trf.12944
   Linnen JM, 2008, TRANSFUSION, V48, P1355, DOI 10.1111/j.1537-2995.2008.01772.x
   Lye DC, 2017, LANCET, V389, P1611, DOI 10.1016/S0140-6736(17)30269-6
   Matos D, 2016, TRANSFUSION, V56, P215, DOI 10.1111/trf.13288
   Motta IJF, 2016, NEW ENGL J MED, V375, P1101, DOI 10.1056/NEJMc1607262
   Musso D, 2018, LANCET INFECT DIS, V18, pE172, DOI 10.1016/S1473-3099(17)30446-2
   Musso D, 2016, LANCET, V387, P1993, DOI 10.1016/S0140-6736(16)30428-7
   Netto EM, 2017, MBIO, V8, DOI [10.1128/mBio.01390-17, 10.1128/mbio.01390-17]
   Pealer LN, 2003, NEW ENGL J MED, V349, P1236, DOI 10.1056/NEJMoa030969
   Perkins HA, 2010, TRANSFUSION, V50, P2080, DOI 10.1111/j.1537-2995.2010.02851.x
   Sabino EC, 2016, J INFECT DIS, V213, P694, DOI 10.1093/infdis/jiv326
   Schmunis GA, 2001, AM J TROP MED HYG, V65, P924, DOI 10.4269/ajtmh.2001.65.924
   Simmons G, 2016, EMERG INFECT DIS, V22, P1221, DOI 10.3201/eid2207.160116
   Stansbury LG, 2009, TRANSFUS MED REV, V23, P232, DOI 10.1016/j.tmrv.2009.03.007
   Stone M, 2017, TRANSFUSION, V57, P734, DOI 10.1111/trf.14031
   Stramer SL, 2012, TRANSFUSION, V52, P1657, DOI 10.1111/j.1537-2995.2012.03566.x
   Nunes MRT, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0348-x
   WHO/ PAHO, 2015, SUPPL BLOOD TRANSF L
   Williamson PC, 2017, TRANSFUSION, V57, P770, DOI 10.1111/trf.14041
   Zuchi N, 2014, MEM I OSWALDO CRUZ, V109, P820, DOI 10.1590/0074-0276140108
NR 44
TC 1
Z9 1
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD MAR 14
PY 2018
VL 5
AR 71
DI 10.3389/fmed.2018.00071
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA FZ2QH
UT WOS:000427424900001
PM 29594126
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Dezan, MR
   Guardalini, LGO
   Pessoa, E
   Ribeiro, IH
   Oliveira, VB
   Luz, F
   Novac, DR
   Gallucci, A
   Bonifacio, S
   Gomes, F
   Levi, JE
   Pereira, AC
   Krieger, JE
   Mendrone, A
   Rocha, V
   Dinardo, CL
AF Dezan, Marcia Regina
   Guardalini, Luis Giovani O.
   Pessoa, Elaine
   Ribeiro, Ingrid Helena
   Oliveira, Valeria Brito
   Luz, Fabio
   Novac, Denise Rossite
   Gallucci, Antonio
   Bonifacio, Silvia
   Gomes, Francisco
   Levi, Jose E.
   Pereira, Alexandre C.
   Krieger, Jose E.
   Mendrone-Junior, Alfredo
   Rocha, Vanderson
   Dinardo, Carla Luana
TI Evaluation of the applicability and effectiveness of a molecular
   strategy for identifying weakD and DEL phenotype among D- blood donors
   of mixed origin exhibiting high frequency of RHD*
SO TRANSFUSION
LA English
DT Article
ID ANTI-D IMMUNIZATION; D-EL; VARIANTS; CELLS; IDENTIFICATION; ZYGOSITY;
   MUTATION; DISEASE; PCR; DNA
AB BACKGROUNDMolecular tests designed to detect the presence of active RHD gene among D- donors have been successfully applied in people of European ancestry, but not in admixed populations with a considerable frequency of RHD*. Our goal was to evaluate the performance of a molecular screening tool for identifying active RHD alleles among Brazilian blood donors classified as D- C+ and/or E+.
   STUDY DESIGN AND METHODSPools of five DNA samples of serologically D- C+ and/or E+ donors were checked by a RHD polymerase chain reaction (PCR) assay specific for RHD Intron 4 and Exon 7. When a pool result was positive, samples were genotyped individually for RHD Intron 4 and Exon 7, RHD*, RHCE*Cc, and RHD zygosity. Donors suspected of active RHD gene were further evaluated by whole-coding region and flanking intron direct sequencing.
   RESULTSA total of 405 donors were included. Two percent exhibited active RHD gene, codifying D-weak (38 and 45) or DEL phenotype. The most prevalent DEL allele was RHD*DEL1 (c.1227G>A), which is proven to be immunogenic. A high frequency of RHD* was detected in the donors with nondeleted RHD alleles (31%), far superior to the frequency of RHD variant alleles (15.5%). The proposed approach presented sensitivity of 100% and specificity of 85.7% for identifying active RHD gene.
   CONCLUSIONThe strategy of checking D- donors with RHD PCR followed by exclusion of RHD* allele has proved efficient in identifying weak-D and DEL phenotype in the Brazilian population.
C1 [Dezan, Marcia Regina; Guardalini, Luis Giovani O.; Pessoa, Elaine; Ribeiro, Ingrid Helena; Oliveira, Valeria Brito; Luz, Fabio; Novac, Denise Rossite; Gallucci, Antonio; Bonifacio, Silvia; Gomes, Francisco; Levi, Jose E.; Mendrone-Junior, Alfredo; Rocha, Vanderson; Dinardo, Carla Luana] Fundacao Prosangue, Immunohematol Div, Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Pereira, Alexandre C.; Krieger, Jose E.; Dinardo, Carla Luana] Univ Sao Paulo, Sch Med, Lab Genet & Mol Cardiol, Heart Inst InCor, Sao Paulo, Brazil.
   [Rocha, Vanderson] Univ Sao Paulo, Sch Med, Discipline Hematol, Sao Paulo, Brazil.
RP Dinardo, CL (corresponding author), Ave Dr Eneas de Carvalho Aguiar 155,1st Floor, Sao Paulo, SP, Brazil.
EM caludinardo@gmail.com
RI Rocha, Vanderson/AAO-1691-2020; Krieger, Jose E/C-3117-2011
OI Rocha, Vanderson/0000-0003-0094-619X
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPQ)National Council for Scientific and Technological Development
   (CNPq) [420168/2016-8]
FX This study was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPQ), Grant 420168/2016-8.
CR Chiu RWK, 2001, CLIN CHEM, V47, P667
   COLIN Y, 1991, BLOOD, V78, P2747
   Dezan M. R., 2016, ISBT SCI SERIES, V11, P132
   Dezan MR, 2017, BLOOD CELL MOL DIS, V65, P8, DOI 10.1016/j.bcmd.2017.03.014
   Flegel WA, 1998, TRANSFUSION MED, V8, P281
   Flegel WA, 2009, TRANSFUSION, V49, P465, DOI 10.1111/j.1537-2995.2008.01975.x
   Gowland P, 2014, TRANSFUS APHER SCI, V50, P163, DOI 10.1016/j.transci.2014.02.009
   Kim KH, 2009, KOREAN J LAB MED, V29, P361, DOI 10.3343/kjlm.2009.29.4.361
   Le Marechal C, 2007, TRANSFUSION, V47, P858, DOI 10.1111/j.1537-2995.2007.01200.x
   Mota M, 2012, J CLIN LAB ANAL, V26, P104, DOI 10.1002/jcla.21489
   Orzinska A, 2013, TRANSFUSION, V53, P2945, DOI 10.1111/trf.12230
   Pirelli KJ, 2010, PRENATAL DIAG, V30, P1207, DOI 10.1002/pd.2652
   Seo MH, 2016, VOX SANG, V111, P425, DOI 10.1111/vox.12450
   Shao CP, 2002, VOX SANG, V83, P156, DOI 10.1046/j.1423-0410.2002.00192.x
   Singleton BK, 2000, BLOOD, V95, P12
   Tax MGHM, 2002, TRANSFUSION, V42, P634, DOI 10.1046/j.1537-2995.2002.00096.x
   Wagner F F, 2004, Immunohematology, V20, P23
   Wagner FF, 1998, BLOOD, V91, P2157, DOI 10.1182/blood.V91.6.2157.2157_2157_2168
   Wagner FF, 2013, TRANSFUS MED HEMOTH, V40, P172, DOI 10.1159/000351604
   Wagner FF, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-10
   Wagner T, 2005, TRANSFUSION, V45, P520, DOI 10.1111/j.0041-1132.2005.04256.x
   Yang HS, 2015, ANN LAB MED, V35, P554, DOI 10.3343/alm.2015.35.5.554
   Yasuda H, 2005, TRANSFUSION, V45, P1581, DOI 10.1111/j.1537-2995.2005.00579.x
NR 23
TC 4
Z9 5
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD FEB
PY 2018
VL 58
IS 2
BP 317
EP 322
DI 10.1111/trf.14425
PG 6
WC Hematology
SC Hematology
GA FV2KJ
UT WOS:000424395000008
PM 29193119
DA 2020-11-30
ER

PT J
AU Perdomo, S
   Anantharaman, D
   Foll, M
   Abedi-Ardekani, B
   Durand, G
   Rosa, LAR
   Holmila, R
   Le Calvez-Kelm, F
   Tajara, EH
   Wunsch, V
   Levi, JE
   Vilensky, M
   Polesel, J
   Holcatova, I
   Simonato, L
   Canova, C
   Lagiou, P
   McKay, JD
   Brennan, P
AF Perdomo, Sandra
   Anantharaman, Devasena
   Foll, Matthieu
   Abedi-Ardekani, Behnoush
   Durand, Geoffroy
   Rosa, Luciana Albina Reis
   Holmila, Reetta
   Le Calvez-Kelm, Florence
   Tajara, Eloiza H.
   Wunsch-Filho, Victor
   Levi, Jose Eduardo
   Vilensky, Marta
   Polesel, Jerry
   Holcatova, Ivana
   Simonato, Lorenzo
   Canova, Cristina
   Lagiou, Pagona
   McKay, James D.
   Brennan, Paul
TI Genomic analysis of head and neck cancer cases from two high incidence
   regions
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; HUMAN-PAPILLOMAVIRUS; GENETIC LANDSCAPE; TP53
   MUTATIONS; NEGATIVE HEAD; ORAL-CANCER; SURVIVAL; HPV; PATHWAY;
   PREVALENCE
AB We investigated how somatic changes in HNSCC interact with environmental and host risk factors and whether they influence the risk of HNSCC occurrence and outcome. 180-paired samples diagnosed as HNSCC in two high incidence regions of Europe and South America underwent targeted sequencing (14 genes) and evaluation of copy number alterations (SCNAs). TP53, PIK3CA, NOTCH1, TP63 and CDKN2A were the most frequently mutated genes. Cases were characterized by a low copy number burden with recurrent focal amplification in 11q13.3 and deletion in 15q22. Cases with low SCNAs showed an improved overall survival. We found significant correlations with decreased overall survival between focal amplified regions 4p16, 10q22 and 22q11, and losses in 12p12, 15814 and 15q22. The mutational landscape in our cases showed an association to both environmental exposures and clinical characteristics. We confirmed that somatic copy number alterations are an important predictor of HNSCC overall survival.
C1 [Perdomo, Sandra; Anantharaman, Devasena; Foll, Matthieu; Abedi-Ardekani, Behnoush; Durand, Geoffroy; Holmila, Reetta; Le Calvez-Kelm, Florence; McKay, James D.; Brennan, Paul] IARC, Lyon, France.
   [Perdomo, Sandra] Univ El Bosque, Inst Nutr Genet & Metab Res, Fac Med, Bogota, Colombia.
   [Rosa, Luciana Albina Reis; Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop SP, Sao Paulo, Brazil.
   [Tajara, Eloiza H.] Sch Med Sao Jose do Rio Preto, Sao Jose Do Rio Preto, Brazil.
   [Wunsch-Filho, Victor] Univ Sao Paulo, Fac Saude PUbl, Sao Paulo, Brazil.
   [Vilensky, Marta] Inst Angel Roffo, Buenos Aires, DF, Argentina.
   [Polesel, Jerry] Aviano Natl Canc Inst, CRO, Aviano, Italy.
   [Holcatova, Ivana] Charles Univ Prague, Prague, Czech Republic.
   [Simonato, Lorenzo; Canova, Cristina] Lab Publ Hlth & Populat Studies, Padua, Italy.
   [Lagiou, Pagona] Univ Athens, Med Sch, Athens, Greece.
   [Anantharaman, Devasena] Raj Gandhi Ctr Biotechnol, Thycaud PO, Trivandrum, Kerala, India.
   [Holmila, Reetta] Wake Forest Sch Med, Mol Med Sect, Winston Salem, NC USA.
RP Brennan, P (corresponding author), IARC, Lyon, France.
EM gep@iarc.fr
RI Polesel, Jerry/AAA-5750-2019; Foll, Matthieu/A-8561-2014;
   Abedi-Ardekani, Behnoush/O-7829-2016; Filho, Victor Wunsch/C-4475-2012
OI Polesel, Jerry/0000-0001-9381-1520; Foll, Matthieu/0000-0001-9006-8436;
   Abedi-Ardekani, Behnoush/0000-0002-0980-0587; Rasul,
   holem/0000-0003-0579-9029; Le Calvez-Kelm, Florence/0000-0003-0063-5068;
   SIMONATO, LORENZO/0000-0002-9914-1000; Holmila,
   Reetta/0000-0002-2825-5676; CANOVA, CRISTINA/0000-0001-7027-7935
FU International Agency for Research on Cancer (IARC)World Health
   Organization; FAPESP (Sao Paulo Research Foundation)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [04/12054-9, 10/51168-0];
   European CommissionEuropean CommissionEuropean Commission Joint Research
   Centre
FX This work has been funded by the International Agency for Research on
   Cancer (IARC). The GENCAPO study was supported by grants from FAPESP
   (Sao Paulo Research Foundation) (04/12054-9 and 10/51168-0), which had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.; This work was undertaken
   during the tenure of a Postdoctoral Fellowship to Dr Sandra Perdomo from
   The International Agency for Research on Cancer, partially supported by
   the European Commission FP7 Marie Curie Actions-People-Co-funding of
   regional, national and international programmes (COFUND).
CR Aeberhard WH, 2014, BIOMETRICS, V70, P920, DOI 10.1111/biom.12212
   Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923
   Anantharaman D, 2017, INT J CANCER, V140, P1968, DOI 10.1002/ijc.30608
   Anantharaman D, 2013, JNCI-J NATL CANCER I, V105, P536, DOI 10.1093/jnci/djt053
   Andor N, 2015, NAT MED
   Benjamini Y., 1995, J ROYAL STAT SOC B, V57
   Castellsague X, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv403
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chatenoud L, 2014, ANN ONCOL, V25, P1843, DOI 10.1093/annonc/mdu206
   Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762
   Dai M, 2004, CANCER RES, V64, P468, DOI 10.1158/0008-5472.CAN-03-3284
   Ervik M. FL, 2016, CANC TODAY LYON FRAN
   Feenstra M, 1999, TISSUE ANTIGENS, V54, P235, DOI 10.1034/j.1399-0039.1999.540304.x
   Ferlay J, 2014, GLOBOCAN 2012 V1 0 C
   Fernandez-Cuesta L, 2016, EBIOMEDICINE
   Forman D, 2013, CANC INCIDENCE 5 CON, VX
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gatta G, 2015, EUR J CANC
   Gross AM, 2014, NAT GENET, V46, P939, DOI 10.1038/ng.3051
   Hayes DN, 2015, J CLIN ONCOL, V33, P3227, DOI 10.1200/JCO.2015.62.1086
   Hedberg ML, 2016, J CLIN INVEST, V126, P169, DOI 10.1172/JCI82066
   Herrero R, 2003, JNCI-J NATL CANCER I, V95, P1772, DOI [10.1093/jnci/djg107, 10.1093/jnci/djg/107]
   IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P1
   Imai FL, 2001, INT J MOL MED, V7, P43
   Keck MK, 2015, CLIN CANCER RES, V21, P870, DOI 10.1158/1078-0432.CCR-14-2481
   Kim KT, 2016, HEAD NECK-J SCI SPEC, V38, pE2021, DOI 10.1002/hed.24372
   Kim YH, 2010, ONCOGENE, V29, P1421, DOI 10.1038/onc.2009.437
   Kreimer AR, 2013, J CLIN ONCOL, V31, P2708, DOI 10.1200/JCO.2012.47.2738
   Lagiou P, 2009, EUR J CANCER PREV, V18, P76, DOI 10.1097/CEJ.0b013e32830c8dca
   Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129
   Le Calvez-Kelm F, 2016, ONCOTARGET, V7, P78827, DOI 10.18632/oncotarget.12386
   Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103
   MacDonald JR, 2014, NUCLEIC ACIDS RES, V42, pD986, DOI 10.1093/nar/gkt958
   Maitra A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3873
   Lopez RVM, 2014, CANCER CAUSE CONTROL, V25, P461, DOI 10.1007/s10552-014-0348-8
   Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41
   Mo QX, 2013, P NATL ACAD SCI USA, V110, P4245, DOI 10.1073/pnas.1208949110
   Morris LG, 2016, JAMA ONCOL
   Mroz EA, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001786
   Neskey DM, 2015, CANCER RES, V75, P1527, DOI 10.1158/0008-5472.CAN-14-2735
   Oh JE, 2015, J NEUROPATH EXP NEUR, V74, P952, DOI 10.1097/NEN.0000000000000238
   Pena-Alonso E, 2008, CANCER LETT, V263, P89, DOI 10.1016/j.canlet.2007.12.029
   Perez-Llamas C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019541
   Peters HL, 2011, IMMUNOL RES, V51, P39, DOI 10.1007/s12026-011-8238-6
   Pickering CR, 2013, CANCER DISCOV, V3, P770, DOI 10.1158/2159-8290.CD-12-0537
   Poeta ML, 2007, NEW ENGL J MED, V357, P2552, DOI 10.1056/NEJMoa073770
   Pulte D, 2010, ONCOLOGIST, V15, P994, DOI 10.1634/theoncologist.2009-0289
   Reddy RB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147409
   Reuschenbach M, 2008, INT J CANCER, V123, P2626, DOI 10.1002/ijc.23837
   Rodrigo JP, 2011, HEAD NECK-J SCI SPEC, V33, P1708, DOI 10.1002/hed.21661
   Scharpf RB, 2011, J STAT SOFTW, V40, P1
   Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310
   Smeets SJ, 2009, CELL ONCOL, V31, P291, DOI 10.3233/CLO-2009-0471
   Squarize C. H., 2013, J CARCINOG MUTAGE S5
   Stoepker C, 2015, CANCER RES, V75, P3543, DOI 10.1158/0008-5472.CAN-15-0528
   Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130
   Sweeny L, 2012, LARYNGOSCOPE, V122, P1539, DOI 10.1002/lary.23266
   Szymanska K, 2011, CANCER CAUSE CONTROL, V22, P1037, DOI 10.1007/s10552-011-9779-7
   Taberna M, 2017, ANN ONCOL
   Vairaktaris E, 2006, ANTICANCER RES, V26, P4217
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Yanagi H, 2012, BIOCHEM BIOPH RES CO, V418, P104, DOI 10.1016/j.bbrc.2011.12.142
   Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760
   Zhou G, 2016, J CELL BIOCHEM, V117, P2682, DOI 10.1002/jcb.25592
NR 64
TC 7
Z9 7
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 29
PY 2018
VL 13
IS 1
AR e0191701
DI 10.1371/journal.pone.0191701
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FU0AV
UT WOS:000423514700027
PM 29377909
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Jalil, EM
   Luz, PM
   Quintana, M
   Friedman, RK
   Madeira, RMDS
   Andrade, AC
   Chicarino, J
   Moreira, RI
   Derrico, M
   Levi, JE
   Russomano, F
   Veloso, VG
   Grinsztejn, B
AF Jalil, Emilia Moreira
   Luz, Paula M.
   Quintana, Marcel
   Friedman, Ruth Khalili
   Madeira, Rosa M. Domingues S.
   Andrade, Angela Cristina
   Chicarino, Janice
   Moreira, Ronaldo Isrnerio
   Derrico, Monica
   Levi, Jose Eduardo
   Russomano, Fabio
   Veloso, Valdilea Goncalves
   Grinsztejn, Beatriz
TI Hybrid capture as a tool for cervical lesions screening in HIV-infected
   women: insights from a Brazilian cohort
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HPV; HIV; Women; Cohort; Incidence
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SQUAMOUS INTRAEPITHELIAL LESIONS;
   HUMAN-PAPILLOMAVIRUS INFECTION; SEROPOSITIVE WOMEN; RISK-FACTORS;
   CYTOLOGY; PREVALENCE; ACCURACY; PERFORMANCE; PROGRESSION
AB Introduction: Cervical cancer remains an important burden for HIV-infected women in the era of combination antiretroviral therapy. Recommendations for cervical screening in these women diverge and may include high-risk HPV (HRHPV) testing. We aimed to evaluate the clinical usefulness of a single HRHPV testing for cervical screening of HIV-infected women.
   Methods: 723 HIV-infected women from a Brazilian prospective cohort were included between 1996 and 2012. Inclusion criteria were: normal cervical cytology at baseline and having a HRHPV-test at baseline. We calculated incidence rates of any squamous intraepithelial lesion (SIL) and high grade SIL+ (HSIL+) and negative predictive values (NPV) within 12 and 36 months. Hazard Ratios were obtained using Cox proportional hazards regression models.
   Results: Incidence rate for both outcomes was low (9.9 cases per 100 PY [95% CI 8.8-11.0] for any SIL and 1.3 cases per 100 PY [95% IC 0.9-1.8] for HSIL+). Women with a HRHPV positive status at baseline had 1.7-fold (95% CI 1.3-2.2) and 3.2-fold (95% CI 1.5-7.1) increased risk of presenting any SIL and HSIL+, respectively, during follow-up. Negative-HRHPV test presented high NPV for both periods and outcomes (any SIL: 92.4% [95% CI 89.7-94.6] for 12 months and 80.9% [95% CI 77.2-84.3] for 36 months; and HSIL+: 99.8% [95% CI 98.9-100.0] for 12 months and 99.0 [95% CI 97.6-99.7] for 36 months).
   Conclusions: Incidence of any and high grade cytological abnormality was significantly higher among HIV-infected women with positive-HRHPV test. A single negative-HRHPV test helped reassure follow-up free of cytological abnormalities through three years of follow-up in HIV-infected women with negative cytology. (C) 2017 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license.
C1 [Jalil, Emilia Moreira; Luz, Paula M.; Quintana, Marcel; Friedman, Ruth Khalili; Madeira, Rosa M. Domingues S.; Andrade, Angela Cristina; Chicarino, Janice; Moreira, Ronaldo Isrnerio; Derrico, Monica; Russomano, Fabio; Veloso, Valdilea Goncalves; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas INI Evandro Cha, Rio De Janeiro, RJ, Brazil.
   [Quintana, Marcel; Levi, Jose Eduardo] Univ Sao Paulo, Sao Paulo, SP, Brazil.
RP Jalil, EM (corresponding author), Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas INI Evandro Cha, Rio De Janeiro, RJ, Brazil.
EM emjalil@hotmail.com
OI Luz, Paula/0000-0001-9746-719X
FU Scientific Development and Research Funding Agency of the State of Rio
   de Janeiro (FAPERJ); Brazilian Research Council (CNPq)National Council
   for Scientific and Technological Development (CNPq); FIOCRUZ
FX The authors acknowledge Scientific Development and Research Funding
   Agency of the State of Rio de Janeiro (FAPERJ), the Brazilian Research
   Council (CNPq), and FIOCRUZ for funding this study.
CR Allison P.D., 1995, SURVIVAL ANAL USING
   Anderson JR, 2006, CLIN INFECT DIS, V42, P562, DOI 10.1086/499357
   [Anonymous], 2016, Obstet Gynecol, V127, pe1, DOI 10.1097/AOG.0000000000001263
   [Anonymous], 2016, DIRETRIZES BRASILEIR
   [Anonymous], 2014, COMPR CERV CANC CONT
   Boldrini NT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102169
   Castle PE, 2002, CANCER EPIDEM BIOMAR, V11, P1394
   Chaturvedi AK, 2009, JNCI-J NATL CANCER I, V101, P1120, DOI 10.1093/jnci/djp205
   COX DR, 1972, J R STAT SOC B, V34, P187
   Denny L, 2008, OBSTET GYNECOL, V111, P1380, DOI 10.1097/AOG.0b013e3181743327
   Denslow SA, 2014, INT J STD AIDS, V25, P163, DOI 10.1177/0956462413491735
   Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031
   Goodman A, 2000, INT J GYNECOL CANCER, V10, P27, DOI 10.1046/j.1525-1438.2000.00001.x
   GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Grinsztejn B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059768
   Harris TG, 2005, JAMA-J AM MED ASSOC, V293, P1471, DOI 10.1001/jama.293.12.1471
   Jamieson DJ, 2002, AM J OBSTET GYNECOL, V186, P21, DOI 10.1067/mob.2002.119776
   Keller MJ, 2015, CLIN INFECT DIS, V61, P1573, DOI 10.1093/cid/civ569
   Keller MJ, 2012, JAMA-J AM MED ASSOC, V308, P362, DOI 10.1001/jama.2012.5664
   Kojic EM, 2011, SEX TRANSM DIS, V38, P253, DOI 10.1097/OLQ.0b013e3181f70253
   Koliopoulos G, 2007, GYNECOL ONCOL, V104, P232, DOI 10.1016/j.ygyno.2006.08.053
   KORN AP, 1994, OBSTET GYNECOL, V83, P401
   Kreitchmann R, 2013, ARCH GYNECOL OBSTET, V288, P1107, DOI 10.1007/s00404-013-2871-3
   Levi JE, 2002, J CLIN MICROBIOL, V40, P3341, DOI 10.1128/JCM.40.9.3341-3345.2002
   MAIMAN M, 1991, OBSTET GYNECOL, V78, P84
   Maiman M, 1998, GYNECOL ONCOL, V68, P233, DOI 10.1006/gyno.1998.4938
   Massad LS, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.12.003
   Massad LS, 2013, J LOW GENIT TRACT DI, V17, pS1, DOI 10.1097/LGT.0b013e318287d329
   Cobucci RNO, 2015, J INFECT PUBLIC HEAL, V8, P1, DOI 10.1016/j.jiph.2014.08.003
   Palefsky Joel, 2007, Top HIV Med, V15, P130
   Palefsky J, 2009, CURR OPIN HIV AIDS, V4, P52, DOI 10.1097/COH.0b013e32831a7246
   Palmer TJ, 2016, BRIT J CANCER, V114, P582, DOI 10.1038/bjc.2015.474
   Peyton CL, 1998, J CLIN MICROBIOL, V36, P3248, DOI 10.1128/JCM.36.11.3248-3254.1998
   Raposo LM, 2011, CAD SAUDE PUBLICA, V27, P1281, DOI 10.1590/S0102-311X2011000700004
   Singh DK, 2009, J INFECT DIS, V199, P1851, DOI 10.1086/599123
   Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114
   Spinillo A, 1998, GYNECOL ONCOL, V69, P109, DOI 10.1006/gyno.1998.4985
   van Buuren S, 2000, MULTIVARIATE IMPUTAT
   Vanni T, 2012, INT J CANCER, V131, pE96, DOI 10.1002/ijc.26472
   WRIGHT TC, 1994, OBSTET GYNECOL, V84, P591
NR 41
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD JAN-FEB
PY 2018
VL 22
IS 1
BP 16
EP 23
DI 10.1016/j.bjid.2017.10.007
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA GG4ET
UT WOS:000432647100003
PM 29207280
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Golfetto, L
   Alves, EV
   Martins, TR
   Sincero, TCM
   Castro, JBS
   Dannebrock, C
   Oliveira, JG
   Levi, JE
   Onofre, ASC
   Bazzo, ML
AF Golfetto, L.
   Alves, E. V.
   Martins, T. R.
   Sincero, T. C. M.
   Castro, J. B. S.
   Dannebrock, C.
   Oliveira, J. G.
   Levi, J. E.
   Onofre, A. S. C.
   Bazzo, M. L.
TI PCR-RFLP assay as an option for primary HPV test
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Cervical cancer; HPV; Screening; PCR-RFLP; PapilloChecks (R) microarray
ID HUMAN-PAPILLOMAVIRUS TYPES; POLYMERASE-CHAIN-REACTION; GENOTYPE
   DISTRIBUTION; FOLLOW-UP; WOMEN; DNA; PREVALENCE; CYTOLOGY; PERSISTENCE;
   PREVENTION
AB Persistent human papillomavirus (HPV) infection is an essential factor of cervical cancer. This study evaluated the analytical performance of restriction fragment length polymorphism polymerase chain reaction (PCR-RFLP) assay compared to PapilloChecks (R) microarray to identify human papilloma virus (HPV) in cervical cells. Three hundred and twenty-five women were analyzed. One sample was used for conventional cytology and another sample was collected using BD SurePath (TM) kit for HPV tests. Eighty samples (24.6%) were positive for HPV gene by PCR-Multiplex and were then submitted to PCR-RFLP and PapilloChecks (R) microarray. There was a genotyping agreement in 71.25% (57/80) on at least one HPV type between PCRRFLP and PapilloChecks (R) microarray. In 22 samples (27.5%), the results were discordant and those samples were additionally analyzed by DNA sequencing. HPV 16 was the most prevalent HPV type found in both methods, followed by HPVs 53, 68, 18, 39, and 66 using PCR-RFLP analysis, and HPVs 39, 53, 68, 56, 31, and 66 using PapilloChecks (R) microarray. In the present study, a perfect agreement using Cohen's kappa (kappa) was found in HPV 33 and 58 (kappa=1), very good for HPV 51, and good for types 16, 18, 53, 59, 66, 68, 70, and 73. PCR-RFLP analysis identified only 25% (20/80) HPV coinfection, and PapilloChecks (R) microarray found 62.5% (50/80). Our Cohen's kappa results indicate that our in-house HPV genotyping testing (PCR-RFLP analysis) could be applied as a primary HPV test screening, especially in low income countries. If multiple HPV types are found in this primary test, a more descriptive test, such as PapilloChecks (R) microarray, could be performed.
C1 [Golfetto, L.; Alves, E. V.; Bazzo, M. L.] Univ Fed Santa Catarina, Lab Biol Mol Microbiol & Sorol, Florianopolis, SC, Brazil.
   [Martins, T. R.; Levi, J. E.] Univ Sao Paulo, Inst Med Trop, Lab Virol, Sao Paulo, SP, Brazil.
   [Sincero, T. C. M.; Onofre, A. S. C.; Bazzo, M. L.] Univ Fed Santa Catarina, Dept Anal Clin, Florianopolis, SC, Brazil.
   [Castro, J. B. S.] Secretaria Municipal Saude, Posto Cent, Sao Miguel Do Oeste, SC, Brazil.
   [Dannebrock, C.] Lab Prevent Citopatol, Sao Miguel Do Oeste, SC, Brazil.
   [Oliveira, J. G.] Fundacao Oswaldo Cruz, Inst Rene Rachou, Grp Pesquisa Imunol Celular & Mol, Belo Horizonte, MG, Brazil.
RP Bazzo, ML (corresponding author), Univ Fed Santa Catarina, Lab Biol Mol Microbiol & Sorol, Florianopolis, SC, Brazil.; Bazzo, ML (corresponding author), Univ Fed Santa Catarina, Dept Anal Clin, Florianopolis, SC, Brazil.
EM marialuizabazzo@gmail.com
RI Sincero, Thais/B-7310-2013
OI Sincero, Thais/0000-0001-8177-4195; Bazzo, Maria
   Luiza/0000-0003-1292-0974
CR Altman D.G., 1991, PRACTICAL STAT MED R
   Bernard HU, 2010, VIROLOGY, V401, P70, DOI 10.1016/j.virol.2010.02.002
   Bruford MW, 1998, MOL GENETIC ANAL POP
   Bruni L, 2015, ICO INFORM CTR HPV C
   Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321
   Bruno A, 2014, REV BRAS GINECOL OBS, V36, P416, DOI 10.1590/SO100-720320140004995
   Chatzistamatiou K, 2016, GYNECOL ONCOL, V142, P120, DOI 10.1016/j.ygyno.2016.04.027
   Coser J, 2016, BRAZ J INFECT DIS, V20, P61, DOI 10.1016/j.bjid.2015.10.008
   Cox JT, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.11.020
   Dalstein V, 2009, J VIROL METHODS, V156, P77, DOI 10.1016/j.jviromet.2008.11.002
   de Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016/S1473-3099(07)70158-5
   Felix JC, 2016, J WOMENS HEALTH, V25, P606, DOI 10.1089/jwh.2015.5708
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fernandes JV, 2009, INT J GYNECOL OBSTET, V105, P21, DOI 10.1016/j.ijgo.2008.12.004
   Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
   Green MR, 2012, ISOLATION AND QUANTI
   Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868
   Husnjak K, 2000, J VIROL METHODS, V88, P125, DOI 10.1016/S0166-0934(00)00194-4
   Isidean SD, 2016, INT J CANCER, V139, P2456, DOI 10.1002/ijc.30385
   Kitchener HC, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18230
   Kocjan BJ, 2015, CLIN MICROBIOL INFEC, V21, P808, DOI 10.1016/j.cmi.2015.05.011
   Levi JE, 2014, OJOG, V4, P470, DOI DOI 10.4236/0J0G.2014.48068
   Lim YK, 2016, J CLIN LAB ANAL, V30, P1110, DOI 10.1002/jcla.21989
   Lippman SA, 2010, INT J STD AIDS, V21, P105, DOI 10.1258/ijsa.2009.008436
   Martin P, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-316
   Martins TR, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0594-3
   Matsukura T, 2008, INT J GYNECOL CANCER, V18, P1042, DOI 10.1111/j.1525-1438.2007.01157.x
   Miranda PM, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/578276
   Moreau F, 2013, J CLIN VIROL, V56, P244, DOI 10.1016/j.jcv.2012.11.003
   Moss S, 2017, HPV PRIMARY SCREENIN
   Nobre RJ, 2008, J CLIN VIROL, V42, P13, DOI 10.1016/j.jcv.2007.11.021
   Oliveira-Silva M, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-4
   Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7
   Schiffman M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.86
   Schiffman M, 2011, JNCI-J NATL CANCER I, V103, P368, DOI 10.1093/jnci/djq562
   Schopp B, 2010, J MED VIROL, V82, P605, DOI 10.1002/jmv.21719
   Tota JE, 2017, PREV MED, V98, P5, DOI 10.1016/j.ypmed.2016.11.029
   Zhao CQ, 2016, ARCH PATHOL LAB MED, V140, P1364, DOI 10.5858/arpa.2016-0061-CP
NR 38
TC 4
Z9 4
U1 0
U2 4
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1678-4510
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PY 2018
VL 51
IS 5
AR e7098
DI 10.1590/1414-431X20177098
PG 7
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA GA8EI
UT WOS:000428570600001
PM 29590262
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Paquin-Proulx, D
   Avelino-Silva, VI
   Santos, BAN
   Barsotti, NS
   Siroma, F
   Ramos, JF
   Tonacio, AC
   Song, A
   Maestri, A
   Cerqueira, NB
   Felix, AC
   Levi, JE
   Greenspun, BC
   Rougvie, MD
   Rosenberg, MG
   Nixon, DF
   Kallas, EG
AF Paquin-Proulx, Dominic
   Avelino-Silva, Vivian I.
   Santos, Bianca A. N.
   Barsotti, Nathalia Silveira
   Siroma, Fabiana
   Ramos, Jessica Fernandes
   Tonacio, Adriana Coracini
   Song, Alice
   Maestri, Alvino
   Cerqueira, Natalia Barros
   Felix, Alvina Clara
   Levi, Jose Eduardo
   Greenspun, Benjamin C.
   Rougvie, Miguel de Mulder
   Rosenberg, Michael G.
   Nixon, Douglas F.
   Kallas, Esper G.
TI MAIT cells are activated in acute Dengue virus infection and after in
   vitro Zika virus infection
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID INVARIANT T-CELLS; TRANSMISSION; POPULATION; IMMUNITY
AB Dengue virus (DENV) and Zika virus (ZIKV) are members of the Flaviviridae and are pre-dominantly transmitted via mosquito bites. Both viruses are responsible for a growing number of infections in tropical and subtropical regions. DENV infection can cause lethargy with severe morbidity and dengue shock syndrome leading to death in some cases. ZIKV is now linked with Guillain-Barre A syndrome and fetal malformations including microcephaly and developmental disorders (congenital Zika syndrome). The protective and pathogenic roles played by the immune response in these infections is unknown. Mucosal-associated invariant T (MAIT) cells are a population of innate T cells with potent anti-bacterial activity. MAIT cells have also been postulated to play a role in the immune response to viral infections. In this study, we evaluated MAIT cell frequency, phenotype, and function in samples from subjects with acute and convalescent DENV infection. We found that in acute DENV infection, MAIT cells had elevated co-expression of the activation markers CD38 and HLA-DR and had a poor IFN gamma response following bacterial stimulation. Furthermore, we found that MAIT cells can produce IFN gamma in response to in vitro infection with ZIKV. This MAIT cell response was independent of MR1, but dependent on IL-12 and IL-18. Our results suggest that MAIT cells may play an important role in the immune response to Flavivirus infections.
C1 [Paquin-Proulx, Dominic; Greenspun, Benjamin C.; Rougvie, Miguel de Mulder; Nixon, Douglas F.] George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA.
   [Avelino-Silva, Vivian I.; Santos, Bianca A. N.; Barsotti, Nathalia Silveira; Ramos, Jessica Fernandes; Tonacio, Adriana Coracini; Song, Alice; Maestri, Alvino; Cerqueira, Natalia Barros; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Avelino-Silva, Vivian I.; Siroma, Fabiana; Ramos, Jessica Fernandes; Tonacio, Adriana Coracini; Song, Alice] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Felix, Alvina Clara; Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop Sao Paulo, Dept Molestias Infecciosas & Parasitarias LIM 52, Sao Paulo, Brazil.
   [Felix, Alvina Clara; Levi, Jose Eduardo] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Rosenberg, Michael G.] Jacobi Med Ctr, Pediat Infect Dis Dept, Bronx, NY USA.
RP Paquin-Proulx, D (corresponding author), George Washington Univ, Dept Microbiol Immunol & Trop Med, Washington, DC 20052 USA.
EM dpaquin_proulx@gwu.edu
RI Song, Alice Tung Wan/F-2494-2014; Avelino-Silva, Vivian I/L-2640-2013;
   de Mulder Rougvie, Miguel/AAG-6224-2020; Nixon, Douglas/AAU-5734-2020
OI Song, Alice Tung Wan/0000-0001-6992-9326; Avelino-Silva, Vivian
   I/0000-0002-6660-3088; de Mulder Rougvie, Miguel/0000-0002-8026-7076;
   Nixon, Douglas/0000-0002-2801-1786; Paquin Proulx,
   Dominic/0000-0003-1407-3414; Silveira Barsotti,
   Nathalia/0000-0003-3513-5258; Kallas, Esper/0000-0003-2026-6925
FU District of Columbia Center for AIDS Research, an NIH [AI117970]; GWU
   SMHS Office of International Medicine Programs
FX This research was funded in part by a pilot award, and facilities and
   services, from the District of Columbia Center for AIDS Research, an NIH
   funded program (AI117970), and from the GWU SMHS Office of International
   Medicine Programs. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Calvet GA, 2016, J CLIN VIROL, V74, P1, DOI 10.1016/j.jcv.2015.11.014
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cosgrove C, 2013, BLOOD, V121, P951, DOI 10.1182/blood-2012-06-436436
   de Matos AM, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003520
   Delvecchio R, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8120322
   Dias J, 2017, P NATL ACAD SCI US
   Dias J, 2016, J LEUKOCYTE BIOL, V100, P233, DOI 10.1189/jlb.4TA0815-391RR
   Fagundes CT, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001449
   Gold MC, 2014, J EXP MED, V211, P1601, DOI 10.1084/jem.20140507
   Hengst J, 2016, EUR J IMMUNOL, V46, P2204, DOI 10.1002/eji.201646447
   Joao Esau Custodio, 2017, Pediatr Infect Dis J, V36, P500, DOI 10.1097/INF.0000000000001482
   Kjer-Nielsen L, 2012, NATURE, V491, P717, DOI 10.1038/nature11605
   Le Bourhis L, 2010, NAT IMMUNOL, V11, P701, DOI 10.1038/ni.1890
   Leeansyah E, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005072
   Leeansyah E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4143
   Leeansyah E, 2013, BLOOD, V121, P1124, DOI 10.1182/blood-2012-07-445429
   Leeansyah E, 2013, CURR OPIN HIV AIDS, V8, P117, DOI 10.1097/COH.0b013e32835c7134
   Li J, 2016, AUSTRALAS J DERMATOL
   Loh L, 2016, P NATL ACAD SCI USA, V113, P10133, DOI 10.1073/pnas.1610750113
   Messina JP, 2016, ELIFE, V5, DOI 10.7554/eLife.15272
   Mustafa AS, 2001, FEMS IMMUNOL MED MIC, V30, P229, DOI 10.1111/j.1574-695X.2001.tb01575.x
   Pacsa AS, 2000, FEMS IMMUNOL MED MIC, V28, P151, DOI 10.1111/j.1574-695X.2000.tb01470.x
   Pal T, 2014, J CLIN VIROL, V61, P365, DOI 10.1016/j.jcv.2014.09.003
   Pang JX, 2015, AM J TROP MED HYG, V92, P1156, DOI 10.4269/ajtmh.15-0031
   Paquin-Proulx D, 2017, IMMUNOHORIZON, V1, P141
   Paquin-Proulx D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175345
   Penot P, 2017, EURO SURVEILL, V22
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Reantragoon R, 2013, J EXP MED, V210, P2305, DOI 10.1084/jem.20130958
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Salou M, 2017, CURR OPIN IMMUNOL, V48, P7, DOI 10.1016/j.coi.2017.07.009
   Tang XZ, 2013, J IMMUNOL, V190, P3142, DOI 10.4049/jimmunol.1203218
   Teunissen MBM, 2014, J INVEST DERMATOL, V134, P2898, DOI 10.1038/jid.2014.261
   Treiner E, 2003, NATURE, V422, P164, DOI 10.1038/nature01433
   Ussher JE, 2014, EUR J IMMUNOL, V44, P195, DOI 10.1002/eji.201343509
   van de Weg CAM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002236
   van de Weg CAM, 2012, J CLIN VIROL, V53, P38, DOI 10.1016/j.jcv.2011.09.028
   van Wilgenburg B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11653
   Yauch LE, 2009, J IMMUNOL, V182, P4865, DOI 10.4049/jimmunol.0801974
NR 40
TC 17
Z9 17
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JAN
PY 2018
VL 12
IS 1
AR e0006154
DI 10.1371/journal.pntd.0006154
PG 15
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA FU7HJ
UT WOS:000424022700027
PM 29357366
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Lima, GFMC
   Sanchez, MCA
   Levi, JE
   Fujimori, M
   Caramelo, LD
   Sanchez, AR
   Ramos-Sanchez, EM
   Inoue, J
   Costa-Nascimento, MD
   Mendrone, A
   Di Santi, SM
AF Lima, Giselle F. M. C.
   Arroyo Sanchez, Maria C.
   Levi, Jose E.
   Fujimori, Mahyumi
   Caramelo, Luiza da Cruz
   Sanchez, Arianni Rondelli
   Ramos-Sanchez, Eduardo M.
   Inoue, Juliana
   Costa-Nascimento, Maria de Jesus
   Mendrone Junior, Alfredo
   Di Santi, Silvia M.
TI Asymptomatic infections in blood donors harbouring Plasmodium: an
   invisible risk detected by molecular and serological tools
SO BLOOD TRANSFUSION
LA English
DT Article
DE transfusion-transmitted malaria; blood donors; asymptomatic infection;
   molecular tools; serological tools
ID TRANSFUSION-TRANSMITTED MALARIA; MEROZOITE SURFACE PROTEIN-1;
   POLYMERASE-CHAIN-REACTION; REAL-TIME-PCR; VIVAX MALARIA; NESTED-PCR;
   BRAZIL; TRANSMISSION; DIAGNOSIS; AREAS
AB Background. Transfusion-transmitted malaria due to asymptomatic Plasmodium infections is a challenge for blood banks. There is a lack of data on the prevalence of asymptomatic infected blood donors and the incidence of transfusion-transmitted malaria in low endemicity areas worldwide. We estimated the frequency of blood donors harbouring Plasmodium in an area in which asymptomatic infections have been reported.
   Material and methods. To estimate the frequency of blood donors harbouring Plasmodium we used microscopy and molecular tools. Serological tests were applied to measure the exposure of candidates to Plasmodium antigens. Venous blood was collected from 91 candidates attending the "Pro-Sangue" Blood Centre Foundation in Sao Paulo, who lived in the municipality of Juquitiba, Sao Paulo, Brazil, where sporadic autochthonous cases of malaria have been described. Blood samples were used for parasitological, molecular and serological studies.
   Results. Among the 91 samples examined, rare Plasmodium forms were observed in two donors. Genus real-time polymerase chain reaction analysis demonstrated Plasmodium amplification in three candidates and species-specific nested polymerase chain reaction identified P. malariae in two. ELISA-IgG was reactive in 42.9% of samples for P. vivax (Pv-MSP1 19) and in 6.6% for P. falciparum (Pf-Zw). ELISA-IgM was reactive in 2.2% of samples for P. vivax and in 4.4% for P. falciparum. An indirect immunofluorescence assay was reactive for P. malariae in 15.4% of cases.
   Discussion. Reservoirs of Plasmodium represent a challenge for blood banks, since studies have shown that high levels of submicroscopic infections can occur in low transmission areas. The risk of transfusion-transmitted malaria presented here points to the need to conduct molecular investigations of candidate donors with any positive malarial antibody test.
C1 [Lima, Giselle F. M. C.; Inoue, Juliana; Di Santi, Silvia M.] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Arroyo Sanchez, Maria C.; Fujimori, Mahyumi; Caramelo, Luiza da Cruz; Sanchez, Arianni Rondelli; Ramos-Sanchez, Eduardo M.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   [Levi, Jose E.; Mendrone Junior, Alfredo] Prosangue Blood Ctr Fdn, Sao Paulo, Brazil.
   [Costa-Nascimento, Maria de Jesus; Di Santi, Silvia M.] Epidem Dis Control Unit, Sao Paulo, Brazil.
RP Lima, GFMC (corresponding author), Univ Sao Paulo, IMTSP, SUCEN, Ave Doutor Eneas Carvalho Aguiar, BR-05403000 Sao Paulo, SP, Brazil.
EM santi@usp.br
RI Sanchez, Eduardo Milton M R Ramos/F-9367-2012; Di Santi,
   Silvia/D-8973-2012; Fujimori, Mahyumi/AAH-4746-2020; Sanchez, Maria
   Carmen/D-8886-2012
OI Di Santi, Silvia/0000-0001-8049-2014; Fujimori,
   Mahyumi/0000-0001-7790-9827; Arroyo Sanchez, Maria
   Carmen/0000-0003-4055-5556; Ramos-Sanchez, Eduardo
   Milton/0000-0001-8700-5469
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2012/18014-5, 2014/50093-8];
   Superintendencia de Controle de Endemias/Instituto de Medicina Tropical
   de Sao Paulo-USP; Fundacao Pro-Sangue Hemocentro de Sao Paulo; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National
   Council for Scientific and Technological Development (CNPq)
FX This work was supported by grants #2012/18014-5 and #2014/50093-8, Sao
   Paulo Research Foundation (FAPESP), Superintendencia de Controle de
   Endemias/Instituto de Medicina Tropical de Sao Paulo-USP, Fundacao
   Pro-Sangue Hemocentro de Sao Paulo and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq).
CR [Anonymous], 2014, GUID IND REC DON QUE
   Assennato SM, 2014, TRANSFUSION, V54, P2419, DOI 10.1111/trf.12650
   BRUCECHW.LJ, 1974, B WORLD HEALTH ORGAN, V50, P337
   Cerutti C, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-33
   Costa DC, 2014, MEM I OSWALDO CRUZ, V109, P21, DOI 10.1590/0074-0276140102
   Coura JR, 2006, MEM I OSWALDO CRUZ, V101, P229, DOI 10.1590/S0074-02762006000300001
   Curado I, 1997, MEM I OSWALDO CRUZ, V92, P235, DOI 10.1590/S0074-02761997000200017
   de Pina-Costa A, 2014, MEM I OSWALDO CRUZ, V109, P618, DOI 10.1590/0074-0276140228
   FERREIRA AW, 1988, REV I MED TROP, V30, P137, DOI 10.1590/S0036-46651988000300003
   Golassa L, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1070-1
   Greiner M, 2000, PREV VET MED, V45, P23, DOI 10.1016/S0167-5877(00)00115-X
   Hristov AD, 2014, MEM I OSWALDO CRUZ, V109, P1014, DOI 10.1590/0074-0276140229
   Kirchgatter K, 2005, BMJ-BRIT MED J, V331, P576
   Kitchen AD, 2014, VOX SANG, V107, P123, DOI 10.1111/vox.12142
   Lima GFMC, 2011, MEM I OSWALDO CRUZ, V106, P691, DOI 10.1590/S0074-02762011000600008
   Lindblade KA, 2013, EXPERT REV ANTI-INFE, V11, P623, DOI [10.1586/ERI.13.45, 10.1586/eri.13.45]
   Lima GFMD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150391
   Ministerio da Saude/Secretaria de Vigilancia em Saude do Brasil, 2005, MAN DIAGN LAB MAL, P166
   Ministry of Health of the People's Republic of China, 2010, GAZETTE MINISTRY HLT, P35
   Okell LC, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2241
   Owusu-Ofori AK, 2010, CLIN INFECT DIS, V51, P1192, DOI 10.1086/656806
   Reesink HW, 2010, VOX SANG, V98, P468, DOI 10.1111/j.1423-0410.2009.01301.x
   Rodrigues MHC, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-39
   Sanchez A., 2014, THESIS
   Sanchez Maria Carmen Arroyo, 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P495, DOI 10.1590/S0036-46651993000600004
   Scuracchio P, 2011, REV INST MED TROP SP, V53, P55, DOI 10.1590/S0036-46652011000100010
   Seed CR, 2005, TRANSFUS MED REV, V19, P229, DOI 10.1016/j.tmrv.2005.02.004
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B
   Soares IS, 1999, ACTA TROP, V72, P13, DOI 10.1016/S0001-706X(98)00078-3
   Vinetz JM, 1998, NEW ENGL J MED, V338, P367, DOI 10.1056/NEJM199802053380605
   Waltmann A, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003758
   Wang B, 2014, J CLIN MICROBIOL, V52, P1838, DOI 10.1128/JCM.03615-13
   World Health Organization, 2009, MAL MICR QUAL ASS MA, P149
NR 33
TC 6
Z9 6
U1 0
U2 3
PU SIMTI SERVIZI SRL
PI MILAN
PA VIA DESIDERIO 21, MILAN, 20131, ITALY
SN 1723-2007
J9 BLOOD TRANSFUS-ITALY
JI Blood Transf.
PY 2018
VL 16
IS 1
BP 17
EP 25
DI 10.2450/2016.0118-16
PG 9
WC Hematology
SC Hematology
GA FW4AR
UT WOS:000425255100004
PM 27893347
DA 2020-11-30
ER

PT J
AU Benvenuti, LA
   Roggerio, A
   Cavalcanti, MM
   Nishiya, AS
   Levi, JE
AF Benvenuti, Luiz A.
   Roggerio, Alessandra
   Cavalcanti, Marta M.
   Nishiya, Anna S.
   Levi, Jose E.
TI An autopsy-based study of Trypanosoma cruzi persistence in organs of
   chronic chagasic patients and its relevance for transplantation
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE autopsy; Chagas' disease; transplantation; Trypanosoma cruzi
ID ENDOMYOCARDIAL BIOPSIES; PARASITE PERSISTENCE; DISEASE; HEART;
   REACTIVATION; BLOOD; DNA
AB BackgroundChagas' disease (CD) is caused by infection with the protozoan Trypanosoma cruzi. The disease can affect the heart and/or the gastrointestinal (GI) tract, but around 70% of infected individuals remain asymptomatic in the chronic form. Organ transplantation from T.cruzi-infected donors is often avoided because of the risk of disease transmission, previously reported after heart, kidney, or liver transplantation.
   MethodsWe investigated by histology, immunohistochemistry, and polymerase chain reaction (PCR) the persistence of T.cruzi in samples of the heart, lung, liver, kidney, pancreas, adrenal gland, esophagus, and GI tract of 21 chronic chagasic patients.
   ResultsParasite persistence was detected in 12/21 (57.1%) heart samples, mainly by PCR-based assays. T.cruzi parasites were detected by histology and immunohistochemistry in smooth muscle cells of the central vein from 1/21 (4.8%) adrenal gland samples. No samples of the lung, liver, kidney, pancreas, esophagus, or GI tract were found to have parasites by histology, immunohistochemistry, or PCR.
   ConclusionsWe concluded that, aside from the heart, the other solid organs of T.cruzi-infected donors can be used for transplantation with a lot of caution. Such organs are not safe in the view of previous reports of CD transmission, but seem to present a low T.cruzi load compared to the heart.
C1 [Benvenuti, Luiz A.; Roggerio, Alessandra; Cavalcanti, Marta M.] Univ Sao Paulo, Heart Inst InCor, Fac Med, Hosp Clin, Sao Paulo, SP, Brazil.
   [Nishiya, Anna S.; Levi, Jose E.] Dept Mol Biol, Mol Biol Dept, Fundacao Prosangue, Sao Paulo Blood Ctr, Sao Paulo, SP, Brazil.
RP Benvenuti, LA (corresponding author), Heart Inst InCor, Pathol Lab, Sao Paulo, SP, Brazil.
EM anpluiz@incor.usp.br
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2014/04691-0]
FX This study was financially supported by grant 2014/04691-0, Sao Paulo
   Research Foundation (FAPESP).
CR [Anonymous], 2012, Wkly Epidemiol Rec, V87, P519
   Marcon GEB, 2011, MEM I OSWALDO CRUZ, V106, P85, DOI 10.1590/S0074-02762011000100014
   Benvenuti LA, 2008, ANN TROP MED PARASIT, V102, P481, DOI 10.1179/136485908X311740
   Benvenuti LA, 2005, CARDIOVASC PATHOL, V14, P265, DOI 10.1016/j.carpath.2005.06.001
   Benvenuti LA, 2014, J HEART LUNG TRANSPL, V33, P698, DOI 10.1016/j.healun.2014.01.920
   Chin-Hong PV, 2011, AM J TRANSPLANT, V11, P672, DOI 10.1111/j.1600-6143.2011.03444.x
   Cobo ED, 2012, J TROP MED-US, V2012, DOI 10.1155/2012/232646
   Cura CI, 2013, AM J TRANSPLANT, V13, P3253, DOI 10.1111/ajt.12487
   da Silveira ABM, 2005, PARASITOLOGY, V131, P627, DOI 10.1017/S0031182005008061
   Higuchi MD, 2003, CARDIOVASC RES, V60, P96, DOI 10.1016/S0008-6363(03)00361-4
   Huprikar S, 2013, AM J TRANSPLANT, V13, P2418, DOI 10.1111/ajt.12340
   JONES EM, 1993, AM J TROP MED HYG, V48, P348, DOI 10.4269/ajtmh.1993.48.348
   Kransdorf EP, 2014, CURR OPIN INFECT DIS, V27, P418, DOI 10.1097/QCO.0000000000000088
   Lages-Silva E, 2001, AM J TROP MED HYG, V65, P435, DOI 10.4269/ajtmh.2001.65.435
   Otani MM, 2009, TRANSFUSION, V49, P1076, DOI 10.1111/j.1537-2995.2009.02107.x
   Riarte A, 1999, CLIN INFECT DIS, V29, P561, DOI 10.1086/598634
   Rosen A, 2017, TRANSPL INFECT DIS, V19, DOI 10.1111/tid.12633
   Sabino EC, 2015, EUR J HEART FAIL, V17, P416, DOI 10.1002/ejhf.220
   Sartori AMC, 1998, AM J TROP MED HYG, V59, P784, DOI 10.4269/ajtmh.1998.59.784
   de Freitas VLT, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001277
   TEIXEIRA VDA, 1993, T ROY SOC TROP MED H, V87, P552
   Teixiera V. de P.A., 1991, Revista da Sociedade Brasileira de Medicina Tropical, V24, P73
NR 22
TC 6
Z9 6
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD DEC
PY 2017
VL 19
IS 6
AR e12783
DI 10.1111/tid.12783
PG 6
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA FR1LV
UT WOS:000418829500022
PM 28945308
DA 2020-11-30
ER

PT J
AU Slavov, SN
   Hespanhol, MR
   Rodrigues, ES
   Levi, JE
   Ubiali, EMA
   Covas, DT
   Kashima, S
AF Slavov, Svetoslav N.
   Hespanhol, Marta R.
   Rodrigues, Evandra S.
   Levi, Jose E.
   Ubiali, Eugenia M. A.
   Covas, Dimas T.
   Kashima, Simone
TI Zika virus RNA detection in asymptomatic blood donors during an outbreak
   in the northeast region of Sao Paulo State, Brazil, 2016
SO TRANSFUSION
LA English
DT Article
AB BACKGROUND: In 2015, there was a large Zika virus (ZIKV) outbreak in Brazil. The proportion of asymptomatic infections is very high, and it is possible for transfusion-transmitted ZIKV (TT-ZIKV) infection to occur. The prevalence of asymptomatic ZIKV infection among Brazilian blood donors during this epidemic outbreak is unknown.
   STUDY DESIGN AND METHODS: Plasma samples obtained between October 2015 and May 2016 from 1393 volunteer blood donors were tested for ZIKV RNA. The viral load was quantified using an in-house standard curve. Additionally, positive ZIKV RNA samples were tested for anti-ZIKV immunoglobulin (Ig)M and anti-ZIKV IgG.
   RESULTS: Of the 1393 blood samples, ZIKV RNA was detected in 37 (n = 37/1393; 2.7%). The median infection viral load detected was 7714 copies/mL (ranging from 135-124,220 copies/mL). The majority of the positive samples (70.3%) exhibited a viral load of approximately 10(3) copies/mL. Six samples that were positive for ZIKV RNA were also positive for anti-ZIKV IgM and IgG (n = 6/37; 13.5%).
   CONCLUSION: This is the first study evaluating the prevalence of ZIKV RNA among Brazilian blood donors, which was relatively high and might lead to TT-ZIKV infection. It is unclear whether the simultaneous presence of anti-ZIKV IgM and IgG in RNA-positive donations or the viral load influences transfusion transmission of the infection. This study also adds to the global understanding of ZIKV prevalence in blood donors during outbreaks and the transfusion impact of the infection.
C1 [Slavov, Svetoslav N.; Hespanhol, Marta R.; Rodrigues, Evandra S.; Ubiali, Eugenia M. A.; Covas, Dimas T.; Kashima, Simone] Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Sao Paulo, Brazil.
   [Levi, Jose E.] Univ Sao Paulo, Virol Lab, Inst Trop Med, Sao Paulo, Brazil.
   [Kashima, Simone] Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Sao Paulo, Brazil.
RP Slavov, SN (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Lab Mol Biol, 2501 Tenente Catao Roxo St, BR-14051140 Sao Paulo, Brazil.
EM svetoslav.slavov@hemocentro.fmrp.usp.br
RI Covas, Dimas T/C-5431-2013; Rodrigues, Evandra/L-6094-2017; N,
   Svetoslav/M-5416-2017; Kashima, Simone/G-4876-2012
OI Covas, Dimas T/0000-0002-7364-2595; Rodrigues,
   Evandra/0000-0003-0964-9554; Kashima, Simone/0000-0002-1487-0141
FU Fundacao de Amparo e Pesquisa do Estado de Sao Paulo-FAPESP, Brazil
   [2009/16623-1, CTC-2013/081352]; Conselho Nacional do Desenvolvimento
   Cientifico e Tecnologico, Brazil [INCTC-573.754/2008-0,
   INCTC-2008/57.877-3]; FINEP, BrazilCiencia Tecnologia e Inovacao (FINEP)
   [245/2016]
FX This study was supported by the Fundacao de Amparo e Pesquisa do Estado
   de Sao Paulo-FAPESP, Brazil (Grant 2009/16623-1, CTC-2013/081352); the
   Conselho Nacional do Desenvolvimento Cientifico e Tecnologico, Brazil
   (INCTC-573.754/2008-0 and INCTC-2008/57.877-3); and FINEP, Brazil
   (245/2016).
NR 0
TC 11
Z9 12
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD DEC
PY 2017
VL 57
IS 12
BP 2897
EP 2901
DI 10.1111/trf.14322
PG 5
WC Hematology
SC Hematology
GA FP5AW
UT WOS:000417630900012
PM 28921551
OA Bronze
DA 2020-11-30
ER

PT J
AU Figueiredo, GM
   Luna, EJ
   Cardoso, MR
   Levi, JE
   Felix, AC
   Souza, NCC
   Souza, AC
   Campos, SRCR
   Figueiredo, WM
   Costa, AA
   Pannuti, CS
AF Figueiredo, Gerusa M.
   Luna, Expedito J.
   Cardoso, Maria Regina
   Levi, Jose E.
   Felix, Alvina C.
   Souza, Nathalia C. C.
   Souza, Ana C.
   Campos, Sergio R. Campos R.
   Figueiredo, Walter M.
   Costa, Angela A.
   Pannuti, Claudio S.
TI ZIKA VIRUS INFECTION IN A COHORT STUDY TO ASSESS THE INCIDENCE OF
   DENGUE, STATE OF SAO PAULO, BRAZIL, 2015, 2016
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 13-16, 2016
CL Atlanta, GA
SP Amer Soc Trop Med & Hygiene, Bill & Melinda Gates Fdn, Takeda Pharamaceut Int AG, ClinicalRM, Techlab Inc, Bayer, Sanofi Pasteur, ACS Infectious Diseases, New England Biolabs
C1 [Figueiredo, Gerusa M.; Luna, Expedito J.; Levi, Jose E.; Felix, Alvina C.; Souza, Nathalia C. C.; Souza, Ana C.; Campos, Sergio R. Campos R.; Figueiredo, Walter M.; Costa, Angela A.; Pannuti, Claudio S.] Univ Sao Paulo, Inst Med Trop, Sao Paulo, Brazil.
   [Cardoso, Maria Regina] Univ Sao Paulo, Fac Saude Publ, Sao Paulo, Brazil.
RI Figueiredo, Gerusa M/B-6660-2014; Luna, Expedito J A/B-7948-2012
OI Figueiredo, Gerusa M/0000-0001-9657-9675; Luna, Expedito J
   A/0000-0002-1145-9672
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2017
VL 95
IS 5
SU S
MA 716
BP 226
EP 226
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FJ6FS
UT WOS:000412851502239
DA 2020-11-30
ER

PT J
AU Luna, EJ
   Figueiredo, GM
   Campos, SR
   Levi, JE
   Figueiredo, WM
   Costa, AA
   Felix, AC
   Souza, AC
   Souza, NC
   Cardoso, MR
   Pannuti, CS
AF Luna, Expedito J.
   Figueiredo, Gerusa M.
   Campos, Sergio R.
   Levi, Jose E.
   Figueiredo, Walter M.
   Costa, Angela A.
   Felix, Alvina C.
   Souza, Ana C.
   Souza, Nathalia C.
   Cardoso, Maria R.
   Pannuti, Claudio S.
TI INAPPARENT DENGUE VIRUS INFECTION INCIDENCE, SAO PAULO, BRAZIL,
   2014-2015
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 13-16, 2016
CL Atlanta, GA
SP Amer Soc Trop Med & Hygiene, Bill & Melinda Gates Fdn, Takeda Pharamaceut Int AG, ClinicalRM, Techlab Inc, Bayer, Sanofi Pasteur, ACS Infectious Diseases, New England Biolabs
C1 [Luna, Expedito J.; Figueiredo, Gerusa M.; Campos, Sergio R.; Levi, Jose E.; Figueiredo, Walter M.; Costa, Angela A.; Felix, Alvina C.; Souza, Ana C.; Souza, Nathalia C.; Cardoso, Maria R.; Pannuti, Claudio S.] Univ Sao Paulo, Sao Paulo, Brazil.
RI Figueiredo, Gerusa M/B-6660-2014; Luna, Expedito J A/B-7948-2012
OI Figueiredo, Gerusa M/0000-0001-9657-9675; Luna, Expedito J
   A/0000-0002-1145-9672
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2017
VL 95
IS 5
SU S
MA 717
BP 226
EP 227
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FJ6FS
UT WOS:000412851502240
DA 2020-11-30
ER

PT J
AU Lima, GF
   Levi, JE
   Wendel, S
   Sanchez, MCA
   Lucchi, NW
   Silva-Flannery, L
   Macedo-de-Oliveira, A
   Inoue, J
   Costa-Nascimento, MJ
   Udhayakumar, V
   Di Santi, S
AF Lima, Giselle F.
   Levi, Jose Eduardo
   Wendel, Silvano
   Arroyo Sanchez, Maria Carmen
   Lucchi, Naomi W.
   Silva-Flannery, Luciana
   Macedo-de-Oliveira, Alexandre
   Inoue, Juliana
   Costa-Nascimento, Maria Jesus
   Udhayakumar, Venkatachalam
   Di Santi, Silvia
TI PLATFORM FOR PLASMODIUM DETECTION IN BLOOD DONORS FROM ENDEMIC AND
   NON-ENDEMIC BRAZILIAN AREAS: PROCESSING OF POOLED SAMPLES USING
   MOLECULAR AND SEROLOGICAL MARKERS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 13-16, 2016
CL Atlanta, GA
SP Amer Soc Trop Med & Hygiene, Bill & Melinda Gates Fdn, Takeda Pharamaceut Int AG, ClinicalRM, Techlab Inc, Bayer, Sanofi Pasteur, ACS Infectious Diseases, New England Biolabs
C1 [Lima, Giselle F.; Inoue, Juliana; Di Santi, Silvia] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Wendel, Silvano] Hosp Sirio Libanes, Blood Bank, Sao Paulo, Brazil.
   [Arroyo Sanchez, Maria Carmen] Univ Sao Paulo, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   [Lucchi, Naomi W.; Silva-Flannery, Luciana; Macedo-de-Oliveira, Alexandre; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA USA.
   [Costa-Nascimento, Maria Jesus] Univ Sao Paulo, Inst Med Trop Sao Paulo, Secretaria Estado Saude Sao Paulo, Nucleo Estudos Malsria,Superintendencia Controle, Sao Paulo, Brazil.
RI Wendel, S/AAQ-9048-2020
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2017
VL 95
IS 5
SU S
MA 1515
BP 475
EP 475
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FJ6FS
UT WOS:000412851503068
DA 2020-11-30
ER

PT J
AU Sanchez, MC
   Rocha, MC
   Montenegro, C
   Fujimori, M
   Di Santi, SM
   Sanchez, AR
   Ramos-Sanchez, EM
   Mendrone, A
   Levi, JE
AF Sanchez, Maria Carmen
   Rocha, Mussya Cisotto
   Montenegro, Catarina
   Fujimori, Mahyumi
   Di Santi, Silvia Maria
   Sanchez, Arianni Rondelli
   Ramos-Sanchez, Eduardo Milton
   Mendrone Junior, Alfredo
   Levi, Jose Eduardo
TI ANTIBODIES TO PLASMODIUM VIVAX MSP1-19 RECOMBINANT ANTIGEN IN BLOOD
   DONORS FROM SAO PAULO BLOOD BANK
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 13-16, 2016
CL Atlanta, GA
SP Amer Soc Trop Med & Hygiene, Bill & Melinda Gates Fdn, Takeda Pharamaceut Int AG, ClinicalRM, Techlab Inc, Bayer, Sanofi Pasteur, ACS Infectious Diseases, New England Biolabs
C1 [Sanchez, Maria Carmen; Rocha, Mussya Cisotto; Montenegro, Catarina; Fujimori, Mahyumi; Di Santi, Silvia Maria; Sanchez, Arianni Rondelli; Ramos-Sanchez, Eduardo Milton] Univ Sao Paulo, Sao Paulo, Brazil.
   [Mendrone Junior, Alfredo; Levi, Jose Eduardo] Fundacao Pro Sangue, Hemoctr Sao Paulo, Sao Paulo, Brazil.
RI Sanchez, Eduardo Milton M R Ramos/F-9367-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD NOV
PY 2017
VL 95
IS 5
SU S
MA 1520
BP 476
EP 477
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FJ6FS
UT WOS:000412851503073
DA 2020-11-30
ER

PT J
AU Oliveira, VB
   Dezan, MR
   Gomes, FCA
   Gualandro, SFM
   Krieger, JE
   Pereira, AC
   Marsiglia, JD
   Levi, JE
   Rocha, V
   Mendrone, A
   Sabino, EC
   Dinardo, CL
AF Oliveira, V. B.
   Dezan, M. R.
   Gomes, F. C. A.
   Menosi Gualandro, S. F.
   Krieger, J. E.
   Pereira, A. C.
   Marsiglia, J. D.
   Levi, J. E.
   Rocha, V.
   Mendrone-Junior, A.
   Sabino, E. C.
   Dinardo, C. L.
TI -318C/T polymorphism of the CTLA-4 gene is an independent risk factor
   for RBC alloimmunization among sickle cell disease patients
SO INTERNATIONAL JOURNAL OF IMMUNOGENETICS
LA English
DT Article
DE alloimmunization; CTLA-4; polymorphism; sickle cell
ID RED-BLOOD-CELL; POPULATION; PROMOTER; EXON-1
AB Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) molecule is expressed on T-lymphocyte membrane and negatively influences the antigen-presenting process. Reduced expression of CTLA-4 due to gene polymorphisms is associated with increased risk of autoimmune disorders, whose physiopathology is similar to that of post-transfusion red blood cell (RBC) alloimmunization. Our goal was to evaluate if polymorphisms of CTLA-4 gene that affect protein expression are associated with RBC alloimmunization. This was a case-control study in which 134 sickle cell disease (SCD) patients and 253 non-SCD patients were included. All patients were genotyped for the polymorphisms 49A/G and -318C/T of CTLA-4 gene. The genotype frequency of -318C/T differed significantly between alloimmunized and nonalloimmunized SCD patients, irrespective of clinical confounders (p=.016). SCD patients heterozygous for -318T allele presented higher risk of alloantibody development (OR: 5.4, CI: 1.15-25.6). In conclusion, the polymorphism -318C/T of CTLA-4 gene is associated with RBC alloimmunization among SCD patients. This highlights the role played by CTLA-4 on post-transfusion alloantibody development.
C1 [Oliveira, V. B.; Dezan, M. R.; Gomes, F. C. A.; Levi, J. E.; Mendrone-Junior, A.; Dinardo, C. L.] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Menosi Gualandro, S. F.; Rocha, V.] Univ Sao Paulo, Discipline Hematol, Sch Med, Sao Paulo, Brazil.
   [Krieger, J. E.; Pereira, A. C.; Marsiglia, J. D.] Univ Sao Paulo, Lab Genet & Mol Cardiol, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
   [Sabino, E. C.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
RP Dinardo, CL (corresponding author), Fundacao Prosangue, Div Immunohematol, Sao Paulo, SP, Brazil.
EM caludinardo@gmail.com
RI Rocha, Vanderson/AAO-1691-2020; Sabino, Ester Cerdeira/F-7750-2010
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; Krieger,
   Jose/0000-0001-5464-1792; DEZAN, MARCIA REGINA/0000-0002-3760-9843
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2014/50250-6]
FX Sao Paulo Research Foundation (FAPESP), Grant/Award Number: 2014/50250-6
CR Bour-Jordan H, 2003, NAT IMMUNOL, V4, P182, DOI 10.1038/ni884
   Dezan M. R., 2016, ISBT SCI SERIES, V11, P132
   Dezan MR, 2017, BLOOD CELL MOL DIS, V65, P8, DOI 10.1016/j.bcmd.2017.03.014
   Dinardo Carla Luana, 2013, Rev. Bras. Hematol. Hemoter., V35, P414, DOI 10.5581/1516-8484.20130123
   Fasano RM, 2015, BRIT J HAEMATOL, V168, P291, DOI 10.1111/bjh.13123
   Gilson CR, 2012, TRANSFUSION, V52, P2209, DOI 10.1111/j.1537-2995.2011.03550.x
   Hendrickson JE, 2006, TRANSFUSION, V46, P1526, DOI 10.1111/j.1537-2995.2006.00946.x
   Hendrickson JE, 2012, TRANSFUSION, V52, P231, DOI 10.1111/j.1537-2995.2011.03255.x
   Higgins JM, 2008, BLOOD, V112, P2546, DOI 10.1182/blood-2008-03-146415
   Kumar N, 2015, INT J IMMUNOGENET, V42, P445, DOI 10.1111/iji.12233
   Nickel RS, 2016, TRANSFUSION, V56, P107, DOI 10.1111/trf.13379
   Noizat-Pirenne F, 2006, TRANSFUSION, V46, P1328, DOI 10.1111/j.1537-2995.2006.00900.x
   Park YJ, 2000, THYROID, V10, P453, DOI 10.1089/thy.2000.10.453
   Rodriguez S, 2009, AM J EPIDEMIOL, V169, P505, DOI 10.1093/aje/kwn359
   ROSSE WF, 1990, BLOOD, V76, P1431
   Ryder AB, 2016, BRIT J HAEMATOL, V174, P483, DOI 10.1111/bjh.13781
   Sippert EA, 2017, TRANSFUSION, V57, P379, DOI 10.1111/trf.13920
   Svahn J, 2005, BONE MARROW TRANSPL, V35, pS89, DOI 10.1038/sj.bmt.1704855
   Ting WH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154394
   Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621
   Verduin EP, 2016, TRANSFUSION, V56, P1849, DOI 10.1111/trf.13648
   Vichinsky E P, 2012, Immunohematology, V28, P20
   Vingert B, 2014, AM J HEMATOL, V89, P261, DOI 10.1002/ajh.23629
   Yu J, 2007, AM J HEMATOL, V82, P691, DOI 10.1002/ajh.20959
NR 24
TC 10
Z9 10
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-3121
EI 1744-313X
J9 INT J IMMUNOGENET
JI Int. J. Immunogenet.
PD OCT
PY 2017
VL 44
IS 5
BP 219
EP 224
DI 10.1111/iji.12334
PG 6
WC Genetics & Heredity; Immunology
SC Genetics & Heredity; Immunology
GA FG0RQ
UT WOS:000409475100003
PM 28815969
DA 2020-11-30
ER

PT J
AU Genta, MLND
   Martins, TR
   Lope, RVM
   Sadalla, JC
   de Carvalho, JPM
   Baracat, EC
   Levi, JE
   Carvalho, JP
AF Nogueira Dias Genta, Maria Luiza
   Martins, Toni Ricardo
   Mendoza Lope, Rossana V.
   Sadalla, Jose Carlos
   Mancusi de Carvalho, Joao Paulo
   Baracat, Edmund Chada
   Levi, Jose Eduardo
   Carvalho, Jesus Paula
TI Multiple HPV genotype infection impact on invasive cervical cancer
   presentation and survival
SO PLOS ONE
LA English
DT Article
ID HUMAN-PAPILLOMAVIRUS GENOTYPE; PROGNOSTIC-FACTOR; NATURAL-HISTORY;
   CARCINOMA; PREDICT; WOMEN; RISK
AB Background
   Invasive cervical cancer (ICC) is the third most common malignant neoplasm affecting Brazilian women. Little is known about the impact of specific HPV genotypes in the prognosis of ICC. We hypothesized that HPV genotype would impact ICC clinical presentation and survival.
   Methods
   Women diagnosed with ICC at the Instituto do Ca A ncer do Estado de Sao Paulo (ICESP) between May 2008 and June 2012 were included in the study and were followed until December 2015. HPV genotype was detected from formalin-fixed paraffin-embedded (FFPE) tumor tissue samples using Onclarity (TM) system (BD Viper (TM) LT automated system).
   Results
   292 patients aged 50 +/- 14 years were analyzed. HPVDNA was detected in 84% of patients. The HPV genotypes studied were: HPV16 (64%), HPV18 (10%), HPV33-58 (7%), HPV45 (5%), HPV31 (4%) and other high-risk HPV genotypes (11%). HPV genotypes showed different distributions regarding histological type and clinical stage. Patients were followed for 35-21 months. The overall survival at 5 years after diagnosis of cervical cancer was 54%. Age, clinical staging, histological type and multiple HPV genotypes infection detected in the same tumor specimen were associated with poorer overall survival on multivariate Cox proportional hazard analysis (p<0.05). No specific HPV genotype affected survival.
   Conclusion
   Multiple HPV genotype infection was associated with poorer ICC survival in our study, compared with single genotype infection. HPV genotyping from FFPE tumor tissue using an automated assay such as the Onclarity BD (TM) assay provides a simpler alternative for routine clinical use.
C1 [Nogueira Dias Genta, Maria Luiza; Sadalla, Jose Carlos; Mancusi de Carvalho, Joao Paulo; Carvalho, Jesus Paula] Univ Sao Paulo, Fac Med, ICESP, Gynecol Oncol Dept, Sao Paulo, Brazil.
   [Martins, Toni Ricardo; Levi, Jose Eduardo] Univ Sao Paulo, Virol Lab, Inst Med Trop, Sao Paulo, SP, Brazil.
   [Mendoza Lope, Rossana V.] Univ Sao Paulo, Fac Med, ICESP, Ctr Invest Translac Oncol, Sao Paulo, Brazil.
   [Baracat, Edmund Chada] Univ Sao Paulo, Fac Med, Hosp Clin, Div Gynecol Clin, Sao Paulo, Brazil.
RP Genta, MLND (corresponding author), Univ Sao Paulo, Fac Med, ICESP, Gynecol Oncol Dept, Sao Paulo, Brazil.
EM mlndias@usp.br
RI Baracat, Edmund C/H-3800-2012; Carvalho, Jesus Paula/O-7464-2019;
   CARVALHO, JESUS PAULA/G-8387-2018; Mendoza Lopez, Rossana
   Veronica/X-3968-2018
OI Baracat, Edmund C/0000-0003-0111-9030; CARVALHO, JESUS
   PAULA/0000-0003-4495-057X; Mendoza Lopez, Rossana
   Veronica/0000-0001-7993-767X
CR Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244
   Brotherton JML, 2014, J PAEDIATR CHILD H, V50, P959, DOI 10.1111/jpc.12627
   Burger RA, 1996, JNCI-J NATL CANCER I, V88, P1361, DOI 10.1093/jnci/88.19.1361
   Castellsague X, 2008, GYNECOL ONCOL, V110, pS4, DOI 10.1016/j.ygyno.2008.07.045
   Castro FA, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1281-5
   Zampronha RDC, 2013, CLINICS, V68, P809, DOI 10.6061/clinics/2013(06)14
   Correa MD, 2012, CAD SAUDE PUBLICA, V28, P2257, DOI 10.1590/S0102-311X2012001400005
   de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8
   Dizon DS, 2014, CANCER-AM CANCER SOC, V120, P2282, DOI 10.1002/cncr.28722
   Eklund C, 2014, J CLIN MICROBIOL, V52, P449, DOI 10.1128/JCM.02453-13
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gravitt PE, 2007, INT J CANCER, V121, P2787, DOI 10.1002/ijc.23012
   Huang LW, 2004, CANCER-AM CANCER SOC, V100, P327, DOI 10.1002/cncr.20003
   INCA-Instituto Nacional de Ca A ncer MdSdB, 2015, EST 2016 CANC BRAS
   Lai CH, 2007, J CLIN ONCOL, V25, P3628, DOI 10.1200/JCO.2007.11.2995
   Lai HC, 1999, INT J CANCER, V84, P553, DOI 10.1002/(SICI)1097-0215(19991222)84:6&lt;553::AID-IJC2&gt;3.0.CO;2-4
   Lau YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122557
   Lee SA, 2003, CANCER LETT, V198, P187, DOI 10.1016/S0304-3835(03)00312-4
   Levi JE, 2004, GYNECOL ONCOL, V92, P225, DOI 10.1016/j.ygyno.2003.10.004
   Liu JH, 2004, GYNECOL ONCOL, V94, P803, DOI 10.1016/j.ygyno.2004.06.005
   MEANWELL CA, 1988, BRIT MED J, V296, P386, DOI 10.1136/bmj.296.6619.386
   Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P103, DOI 10.1016/j.ijgo.2009.02.012
   Tong SY, 2007, INT J GYNECOL CANCER, V17, P1307, DOI 10.1111/j.1525-1438.2007.00933.x
   Trottier H, 2006, CANCER EPIDEM BIOMAR, V15, P1274, DOI 10.1158/1055-9965.EPI-06-0129
   Wang CC, 2012, INT J RADIAT ONCOL, V84, pE499, DOI 10.1016/j.ijrobp.2012.06.031
   Wang CC, 2010, INT J RADIAT ONCOL, V78, P1111, DOI 10.1016/j.ijrobp.2009.09.021
   Woodman CBJ, 2007, NAT REV CANCER, V7, P11, DOI 10.1038/nrc2050
   Wright TC, 2014, AM J CLIN PATHOL, V142, P43, DOI 10.1309/AJCP53KMHNRDICBL
NR 28
TC 7
Z9 7
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 22
PY 2017
VL 12
IS 8
AR e0182854
DI 10.1371/journal.pone.0182854
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FE2ZB
UT WOS:000408085100019
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Levi, JE
   Lira, SM
   Bub, CB
   Polite, MB
   Terzian, CC
   Kutner, JM
AF Levi, J. E.
   Lira, S. M.
   Bub, C. B.
   Polite, M. B.
   Terzian, C. C.
   Kutner, J. M.
TI Contrasting HCV and HIV seroepidemiology in 11 years of blood donors
   screening in Brazil
SO TRANSFUSION MEDICINE
LA English
DT Article
DE blood donors; epidemiology; HCV; HIV; incidence
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; RESIDUAL RISK;
   TRANSFUSION; TRANSMISSION; INFECTIONS; PREVALENCE; EPIDEMIOLOGY;
   RETROVIRUS; DONATIONS
AB BackgroundBlood donors are, in principle, healthy individuals who may be revealed as infectious for blood-borne agents by the laboratory screening process, depicting the asymptomatic burden of the disease. Therefore, monitoring hepatitis C virus (HCV)-infected donor and human immunodeficiency virus (HIV)-infected donor and associating to their demographical and behavioural characteristics may shed light on the dynamics and contemporary changes in these viruses' epidemiology.
   MethodsDonors presenting repeatedly reactive HCV or HIV serology/nucleic acid testing (NAT) screening results were submitted to confirmatory testing. Confirmed positive donors were invited to return to the blood bank for notification and counselling when a follow-up sample was obtained and an interview performed to eventually disclose potential risks. HCV- or HIV-infected donors identified over 11 years of screening (2004-2015) were evaluated for demographic and behavioural parameters.
   ResultsIn the period, 139 160 donations were screened, and 36 (0.025%) were found positive for HIV, stemming from 29 male and 7 female donors. Among those, eight subjects were repeat donors. A total of 95 donations were found repeatedly reactive for HCV (0.068%), obtained from 60 men and 35 women. Noticeably, in despite of a higher HCV prevalence in the donor population, the incidence of HIV among repeat donors was 10 times that of HCV (18 x 1.6/100 000 persons-year, respectively). On average, HIV-seroreactive men were found to be younger (mean = 34 years old) than women (mean = 40 years old). A total of 10 donors acknowledged sexual behaviours not previously informed, including 2 who were aware of their HIV-positive status and another 2 who admitted to be seeking HIV testing. No window period donation was verified.
   DiscussionThe majority of the HIV-infected donors are young males who deny risk factors in the interview and also ignore the confidence self-exclusion opportunity. As they may reiterate this behaviour in serial donations, use of the most sensitive laboratory testing is justified in this setting.
C1 [Levi, J. E.; Lira, S. M.; Bub, C. B.; Polite, M. B.; Terzian, C. C.; Kutner, J. M.] Hosp Israelita Albert Einstein, Hemotherapy & Cell Therapy Dept, Ave Albert Einstein 627,3 Andar,Bloco E, BR-05652000 Sao Paulo, Brazil.
RP Levi, JE (corresponding author), Hosp Israelita Albert Einstein, Hemotherapy & Cell Therapy Dept, Ave Albert Einstein 627,3 Andar,Bloco E, BR-05652000 Sao Paulo, Brazil.
EM jose.levi@einstein.br
RI Bub, Carolina B/N-8010-2018
OI Bub, Carolina B/0000-0001-5103-4970; Kutner, Jose/0000-0003-3784-6731
CR Bruhn R, 2013, TRANSFUSION, V53, P2399, DOI 10.1111/trf.12299
   Custer B, 2015, TRANSFUSION, V55, P1098, DOI 10.1111/trf.12951
   de Almeida-Neto C, 2013, TRANSFUSION, V53, P827, DOI 10.1111/j.1537-2995.2012.03840.x
   Goncalez T, 2010, TRANSFUSION, V50, P1806, DOI 10.1111/j.1537-2995.2010.02650.x
   Kleinman S, 1997, TRANSFUS MED REV, V11, P155, DOI 10.1053/tmrv.1997.0110155
   Klevens RM, 2012, CLIN INFECT DIS, V55, pS3, DOI 10.1093/cid/cis393
   Levi GC, 2002, AIDS, V16, P2373, DOI 10.1097/00002030-200212060-00001
   Levi Jose Eduardo, 2013, Rev. Bras. Hematol. Hemoter., V35, P167, DOI 10.5581/1516-8484.20130039
   Ministry of Health Brazil, 2015, CAD INF SANG HEM DAD, V9, P154
   Ministry of Health Brazil, 2015, B EP AIDS DST AN 4 N
   Nishiya AS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086413
   Pereira LMMB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-60
   Perkins HA, 2010, TRANSFUSION, V50, P2080, DOI 10.1111/j.1537-2995.2010.02851.x
   Petry A., 2015, TRANSFUSION MED, V25, P125
   Roth WK, 2012, VOX SANG, V102, P82, DOI 10.1111/j.1423-0410.2011.01506.x
   Sabino EC, 2012, TRANSFUSION, V52, P870, DOI 10.1111/j.1537-2995.2011.03344.x
   Salles NA, 2013, TRANSFUSION, V53, P2593, DOI 10.1111/trf.12316
   Vermeulen M, 2009, TRANSFUSION, V49, P1115, DOI 10.1111/j.1537-2995.2009.02110.x
   Zou SM, 2010, TRANSFUSION, V50, P1495, DOI 10.1111/j.1537-2995.2010.02622.x
NR 19
TC 2
Z9 3
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0958-7578
EI 1365-3148
J9 TRANSFUSION MED
JI Transfus. Med.
PD AUG
PY 2017
VL 27
IS 4
BP 286
EP 291
DI 10.1111/tme.12427
PG 6
WC Hematology
SC Hematology
GA FD6ZW
UT WOS:000407677400007
PM 28524366
DA 2020-11-30
ER

PT J
AU Felix, AC
   Souza, NCS
   Figueiredo, WM
   Costa, AA
   Inenami, M
   da Silva, RMG
   Levi, JE
   Pannuti, CS
   Romano, CM
AF Felix, Alvina Clara
   Santiago Souza, Nathalia C.
   Figueiredo, Walter M.
   Costa, Angela A.
   Inenami, Marta
   da Silva, Rosangela M. G.
   Levi, Jose Eduardo
   Pannuti, Claudio Sergio
   Romano, Camila Malta
TI Cross reactivity of commercial anti-dengue immunoassays in patients with
   acute Zika virus infection
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE cross reaction; dengue virus; serological tests; Zika virus
ID EPIDEMIOLOGY; BRAZIL
AB Several countries have local transmission of multiple arboviruses, in particular, dengue and Zika viruses, which have recently spread through many American countries. Cross reactivity among Flaviviruses is high and present a challenge for accurate identification of the infecting agent. Thus, we evaluated the level of cross reactivity of anti-dengue IgM/G Enzyme-Linked Immunosorbent Assays (ELISA) from three manufacturers against 122 serum samples obtained at two time-points from 61 patients with non-dengue confirmed Zika virus infection. All anti-dengue ELISAs cross reacted with serum from patients with acute Zika infection at some level and a worrisome number of seroconversion for dengue IgG and IgM was observed. These findings may impact the interpretation of currently standard criteria for dengue diagnosis in endemic regions.
C1 [Felix, Alvina Clara; Santiago Souza, Nathalia C.; Levi, Jose Eduardo; Pannuti, Claudio Sergio; Romano, Camila Malta] Univ Sao Paulo, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   [Figueiredo, Walter M.; Costa, Angela A.; Inenami, Marta; da Silva, Rosangela M. G.] Univ Sao Paulo, Fac Saude Publ, SESA, Sao Paulo, Brazil.
RP Romano, CM (corresponding author), Inst Med Trop SP, Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
EM cmromano@usp.br
RI Romano, Camila M/C-8185-2013; Romano, Camila/ABC-2883-2020
OI Romano, Camila/0000-0003-4550-1987
CR Buathong R, 2015, AM J TROP MED HYG, V93, P380, DOI 10.4269/ajtmh.15-0022
   Cabral-Castro MJ, 2016, J CLIN VIROL, V82, P108, DOI 10.1016/j.jcv.2016.07.017
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   LANCIOTTI RS, 1994, J GEN VIROL, V75, P65, DOI 10.1099/0022-1317-75-1-65
   San Martin JL, 2010, AM J TROP MED HYG, V82, P128, DOI 10.4269/ajtmh.2010.09-0346
   Figueiredo LTM, 2015, REV SOC BRAS MED TRO, V48, P233, DOI 10.1590/0037-8682-0179-2015
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Sabino EC, 2016, J INFECT DIS, V213, P694, DOI 10.1093/infdis/jiv326
   Vorou R, 2016, EUROSURVEILLANCE, V21, P27, DOI 10.2807/1560-7917.ES.2016.21.10.30161
NR 12
TC 45
Z9 46
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD AUG
PY 2017
VL 89
IS 8
BP 1477
EP 1479
DI 10.1002/jmv.24789
PG 3
WC Virology
SC Virology
GA FA2UA
UT WOS:000405295100021
PM 28229481
DA 2020-11-30
ER

PT J
AU de Moraes, RW
   de Carvalho, MHB
   de Amorim, AG
   Francisco, RPV
   Romao, RM
   Levi, JE
   Zugaib, M
AF de Moraes, Renata Wendel
   Burlacchini de Carvalho, Mario Henrique
   de Amorim-Filho, Antonio Gomes
   Vieira Francisco, Rossana Pulcineli
   Romao, Renata Moscolini
   Levi, Jose Eduardo
   Zugaib, Marcelo
TI Validation of QF-PCR for prenatal diagnoses in a Brazilian population
SO CLINICS
LA English
DT Article
DE Prenatal Diagnosis; Aneuploidy; QF-PCR; Brazilian Population
ID QUANTITATIVE FLUORESCENCE PCR; COMMON CHROMOSOME ANEUPLOIDIES;
   CONSECUTIVE CLINICAL-SAMPLES; POLYMERASE-CHAIN-REACTION; STAND-ALONE
   TEST; FETAL ANEUPLOIDIES; PERFORMANCE; EXPERIENCE; FUTURE
AB OBJECTIVES: Quantitative fluorescence polymerase chain reaction (QF-PCR) is a rapid and reliable method for screening aneuploidies, but in Brazil, it is not used in public services. We investigated the accuracy of QF-PCR for the prenatal recognition of common aneuploidies and compared these results with cytogenetic results in our laboratory.
   METHOD: A ChromoQuant QF-PCR kit containing 24 primer pairs targeting loci on chromosomes 21, 13, 18, X and Y was employed to identify aneuploidies of the referred chromosomes.
   RESULTS: A total of 162 amniotic fluid samples analyzed using multiplex QF-PCR were compared with karyotyping analysis. The QF-PCR results were consistent with the results of cytogenetic analysis in 95.4% of all samples.
   CONCLUSION: QF-PCR was demonstrated to be efficient and reliable for prenatal aneuploidy screening. This study suggests that QF-PCR can be used as a rapid diagnostic method. However, rearrangements and some mosaic samples cannot be detected with this test; thus, those exceptions must undergo cytogenetic analysis.
C1 [de Moraes, Renata Wendel; Burlacchini de Carvalho, Mario Henrique; de Amorim-Filho, Antonio Gomes; Vieira Francisco, Rossana Pulcineli; Romao, Renata Moscolini; Zugaib, Marcelo] Univ Sao Paulo, Fac Med FMUSP, Dept Ginecol & Obstet, Sao Paulo, SP, Brazil.
   [Levi, Jose Eduardo] Fundacao Prosangue, Hemoctr Sao Paulo, Sao Paulo, SP, Brazil.
RP de Carvalho, MHB (corresponding author), Univ Sao Paulo, Fac Med FMUSP, Dept Ginecol & Obstet, Sao Paulo, SP, Brazil.
EM marioburlacchini@uol.com.br
RI Francisco, Rossana PV/C-5648-2012; Zugaib, Marcelo/A-5724-2013;
   Burlacchini de Carvalho, Mario Henrique/E-7217-2013; Francisco, Rossana
   Pulcineli Vieira/AAG-7461-2020
OI Francisco, Rossana PV/0000-0002-9981-8069; Zugaib,
   Marcelo/0000-0003-1155-2671; Burlacchini de Carvalho, Mario
   Henrique/0000-0003-0599-0739; Francisco, Rossana Pulcineli
   Vieira/0000-0002-9981-8069
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2012/51806-2]; CAPESCAPES
FX This research was supported by FAPESP (2012/51806-2) to Mario Henrique
   Burlacchini de Carvalho and a Master's Scholarship supported by CAPES to
   Renata Wendel de Moraes. We are also grateful to all families who took
   part in this study and kindly donated their amniotic fluid samples.
CR Badenas C, 2010, J MOL DIAGN, V12, P828, DOI 10.2353/jmoldx.2010.090224
   Brown L, 2006, PRENATAL DIAG, V26, P1068, DOI 10.1002/pd.1558
   Cho EH, 2009, PRENATAL DIAG, V29, P213, DOI 10.1002/pd.2190
   Cirigliano V, 2004, MOL HUM REPROD, V10, P839, DOI 10.1093/molehr/gah108
   Cirigliano V, 2006, ANN NY ACAD SCI, V1075, P288, DOI 10.1196/annals.1368.039
   Cirigliano V, 2009, PRENATAL DIAG, V29, P40, DOI 10.1002/pd.2192
   Faas BHW, 2011, SEMIN FETAL NEONAT M, V16, P81, DOI 10.1016/j.siny.2011.01.003
   Guzel AI, 2012, BALK J MED GENET, V15, P11, DOI 10.2478/v10034-012-0002-2
   Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065
   Hills A, 2010, PRENATAL DIAG, V30, P509, DOI 10.1002/pd.2503
   Jain S, 2012, GENET TEST MOL BIOMA, V16, P624, DOI 10.1089/gtmb.2011.0243
   Lildballe DL, 2014, DAN MED J, V61
   Mann K, 2001, LANCET, V358, P1057, DOI 10.1016/S0140-6736(01)06183-9
   Mann K, 2012, PRENATAL DIAG, V32, P1197, DOI 10.1002/pd.3986
   Mann K, 2012, PRENATAL DIAG, V32, P309, DOI 10.1002/pd.2945
   Mann Kathy, 2008, V444, P71, DOI 10.1007/978-1-59745-066-9_6
   Muthuswamy S, 2015, GENE, V562, P55, DOI 10.1016/j.gene.2015.02.028
   Nicolini U, 2004, HUM REPROD UPDATE, V10, P541, DOI 10.1093/humupd/dmh046
   Papoulidis I, 2012, PRENATAL DIAG, V32, P680, DOI 10.1002/pd.3888
   Rostami P, 2015, ARCH IRAN MED, V18, P296, DOI 0151805/AIM.007
   Tekcan A, 2014, MOL BIOL REP, V41, P7431, DOI 10.1007/s11033-014-3630-7
   Xu AQ, 2013, GENET MOL RES, V12, P6379, DOI 10.4238/2013.December.9.1
   Zaczmanska I, 2015, GINEKOL POL, V86, P694
NR 23
TC 5
Z9 5
U1 0
U2 4
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PD JUL
PY 2017
VL 72
IS 7
BP 400
EP 404
DI 10.6061/clinics/2017(07)02
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA FD2SY
UT WOS:000407386300002
PM 28792998
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Magnani, DM
   Silveira, CGT
   Rosen, BC
   Ricciardi, MJ
   Pedreno-Lopez, N
   Gutman, MJ
   Bailey, VK
   Maxwell, HS
   Domingues, A
   Gonzalez-Nieto, L
   Avelino-Silva, VI
   Trindade, M
   Nogueira, J
   Oliveira, CS
   Maestri, A
   Felix, AC
   Levi, JE
   Nogueira, ML
   Martins, MA
   Martinez-Navio, JM
   Fuchs, SP
   Whitehead, SS
   Burton, DR
   Desrosiers, RC
   Kallas, EG
   Watkins, DI
AF Magnani, Diogo M.
   Silveira, Cassia G. T.
   Rosen, Brandon C.
   Ricciardi, Michael J.
   Pedreno-Lopez, Nuria
   Gutman, Martin J.
   Bailey, Varian K.
   Maxwell, Helen S.
   Domingues, Aline
   Gonzalez-Nieto, Lucas
   Avelino-Silva, Vivian I.
   Trindade, Mateus
   Nogueira, Juliana
   Oliveira, Consuelo S.
   Maestri, Alvino
   Felix, Alvina Clara
   Levi, Jose Eduardo
   Nogueira, Mauricio L.
   Martins, Mauricio A.
   Martinez-Navio, Jose M.
   Fuchs, Sebastian P.
   Whitehead, Stephen S.
   Burton, Dennis R.
   Desrosiers, Ronald C.
   Kallas, Esper G.
   Watkins, David I.
TI A human inferred germline antibody binds to an immunodominant epitope
   and neutralizes Zika virus
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID MEMORY B-CELLS; DENGUE VIRUS; INTERIM GUIDELINES; UNITED-STATES;
   MONOCLONAL-ANTIBODIES; SOMATIC HYPERMUTATION; PREGNANT-WOMEN; HIV-1
   VACCINE; INFECTION; RESPONSES
AB The isolation of neutralizing monoclonal antibodies (nmAbs) against the Zika virus (ZIKV) might lead to novel preventative strategies for infections in at-risk individuals, primarily pregnant women. Here we describe the characterization of human mAbs from the plasmablasts of an acutely infected patient. One of the 18 mAbs had the unusual feature of binding to and neutralizing ZIKV despite not appearing to have been diversified by affinity maturation. This mAb neutralized ZIKV (Neut(50) similar to 2 mu g/ml) but did not react with any of the four dengue virus serotypes. Except for the expected junctional diversity created by the joining of the V-(D)-J genes, there was no deviation from immunoglobulin germline genes. This is a rare example of a human mAb with neutralizing activity in the absence of detectable somatic hypermutation. Importantly, binding of this mAb to ZIKV was specifically inhibited by human plasma from ZIKV-exposed individuals, suggesting that it may be of value in a diagnostic setting.
C1 [Magnani, Diogo M.; Rosen, Brandon C.; Ricciardi, Michael J.; Pedreno-Lopez, Nuria; Gutman, Martin J.; Bailey, Varian K.; Maxwell, Helen S.; Domingues, Aline; Gonzalez-Nieto, Lucas; Martins, Mauricio A.; Martinez-Navio, Jose M.; Fuchs, Sebastian P.; Desrosiers, Ronald C.; Watkins, David I.] Univ Miami, Dept Pathol, Miami, FL 33136 USA.
   [Silveira, Cassia G. T.; Maestri, Alvino; Kallas, Esper G.] Univ Sao Paulo, Sch Med, Div Clin Immunol & Allergy, Sao Paulo, SP, Brazil.
   [Avelino-Silva, Vivian I.; Trindade, Mateus] Hosp Sirio Libanes, Sao Paulo, SP, Brazil.
   [Trindade, Mateus] Univ Sao Paulo, Sch Med, Neurol Dept, Sao Paulo, SP, Brazil.
   [Nogueira, Juliana] Adolfo Lutz Inst, Sao Paulo, SP, Brazil.
   [Oliveira, Consuelo S.] Inst Evandro Chagas, Belem, Para, Brazil.
   [Felix, Alvina Clara; Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop Sao Paulo, Dept Molestias Infecciosas & Parasitarias LIM 52, Sao Paulo, SP, Brazil.
   [Felix, Alvina Clara; Levi, Jose Eduardo] Univ Sao Paulo, Fac Med, Sao Paulo, SP, Brazil.
   [Nogueira, Mauricio L.] Fac Med Sao Jose do Rio Preto, Dept Doencas Dermatol Infecciosas & Parasitarias, Lab Pesquisas Virol, Sao Jose Do Rio Preto, SP, Brazil.
   [Whitehead, Stephen S.] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA.
   [Burton, Dennis R.] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA 92037 USA.
   [Burton, Dennis R.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Cambridge, MA USA.
RP Watkins, DI (corresponding author), Univ Miami, Dept Pathol, Miami, FL 33136 USA.
EM dwatkins@med.miami.edu
RI Avelino-Silva, Vivian I/L-2640-2013; Martins, Mauricio/AAU-9226-2020;
   Whitehead, Stephen/AAG-2787-2019; Nogueira, Mauricio L/B-7599-2012;
   amsalu, ribka/G-8780-2019; Terrassani Silveira, Cassia/M-8057-2017
OI Avelino-Silva, Vivian I/0000-0002-6660-3088; Martins,
   Mauricio/0000-0001-8336-216X; Nogueira, Mauricio L/0000-0003-1102-2419;
   Terrassani Silveira, Cassia/0000-0002-0932-7769; Kallas,
   Esper/0000-0003-2026-6925; Magnani, Diogo/0000-0002-1773-2406
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [4P01AI094420-05]; Wallace H. Coulter
   Center for Translational Research at University of Miami; Miami Clinical
   and Translational Science Institute (CTSI); NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000460,
   UL1TR000460, UL1TR000460, UL1TR000460, UL1TR000460, UL1TR000460] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [ZIAAI000891, ZIAAI000891, ZIAAI000891,
   ZIAAI000891, ZIAAI000891, ZIAAI000891, ZIAAI000891, ZIAAI000891,
   ZIAAI000891, ZIAAI000891, ZIAAI000891] Funding Source: NIH RePORTER
FX This work was supported by the NIH grant 4P01AI094420-05, the Wallace H.
   Coulter Center for Translational Research at the University of Miami
   [http://www.miami.edu/index.php/u innovation/about_us/whcc/], and the
   Miami Clinical and Translational Science Institute (CTSI) [http://
   miamictsi.org].The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938
   Bonsignori M, 2016, CELL, V165, P449, DOI 10.1016/j.cell.2016.02.022
   BOORMAN J. P. T., 1956, TRANS ROY SOC TROP MED AND HYG, V50, P238, DOI 10.1016/0035-9203(56)90029-3
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636
   Burton DR, 2016, ANNU REV IMMUNOL, V34, P635, DOI 10.1146/annurev-immunol-041015-055515
   Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5
   Corti D, 2016, SCIENCE, V351, P1339, DOI 10.1126/science.aad5224
   Davidson E, 2014, IMMUNOLOGY, V143, P13, DOI 10.1111/imm.12323
   de Alwis R, 2014, METHODS MOL BIOL, V1138, P27, DOI 10.1007/978-1-4939-0348-1_3
   de Paula Freitas B, 2016, JAMA OPHTHALMOL
   Dejnirattisai W, 2015, NAT IMMUNOL, V16, P170, DOI 10.1038/ni.3058
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Durbin AP, 2001, AM J TROP MED HYG, V65, P405, DOI 10.4269/ajtmh.2001.65.405
   Dyer O, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6983
   Eisen HN, 2014, CANCER IMMUNOL RES, V2, P381, DOI 10.1158/2326-6066.CIR-14-0029
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Fields BN, 2007, FIELDS VIROLOGY, Vxix, P3091
   Fink K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00078
   Gatherer D, 2016, J GEN VIROL, V97, P269, DOI 10.1099/jgv.0.000381
   Giudicelli Veronique, 2011, Cold Spring Harb Protoc, V2011, P695, DOI 10.1101/pdb.prot5633
   Godoy-Lozano EE, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0276-1
   HADDOW AJ, 1964, B WORLD HEALTH ORGAN, V31, P57
   Hangartner L, 2006, NAT REV IMMUNOL, V6, P231, DOI 10.1038/nri1783
   Hayes EB, 2009, EMERG INFECT DIS, V15, P1347, DOI 10.3201/eid1509.090442
   Hennessey M, 2016, MMWR-MORBID MORTAL W, V65, P55, DOI 10.15585/mmwr.mm6503e1
   Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106
   Honein MA, 2016, JAMA J AM MED ASS
   Huzly D, 2016, EURO SURVEILL, V21
   Kalinke U, 2000, P NATL ACAD SCI USA, V97, P10126, DOI 10.1073/pnas.97.18.10126
   Kalinke U, 1996, IMMUNITY, V5, P639, DOI 10.1016/S1074-7613(00)80277-0
   Kato M, 2015, J VIROL, V89, P1468, DOI 10.1128/JVI.02293-14
   KAVERI SV, 1991, CLIN EXP IMMUNOL, V86, P192
   Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144
   Klein F, 2013, CELL, V153, P126, DOI 10.1016/j.cell.2013.03.018
   Kraus AA, 2007, J CLIN MICROBIOL, V45, P3777, DOI 10.1128/JCM.00827-07
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lefranc MP, 2003, DEV COMP IMMUNOL, V27, P55, DOI 10.1016/S0145-305X(02)00039-3
   Likos A, 2016, MMWR-MORBID MORTAL W, V65, P1032, DOI 10.15585/mmwr.mm6538e1
   Martines RB, 2016, LANCET, V388, P898, DOI 10.1016/S0140-6736(16)30883-2
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65, P159, DOI 10.15585/mmwr.mm6506e1
   Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1180
   McCarthy M, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i720
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Mor G, 2016, AM J REPROD IMMUNOL, V75, P421, DOI 10.1111/aji.12505
   Oduyebo T, 2016, MMWR-MORBID MORTAL W, V65, P122, DOI 10.15585/mmwr.mm6505e2
   Oster AM, 2016, MMWR-MORBID MORTAL W, V65, P120, DOI 10.15585/mmwr.mm6505e1
   Petersen EE, 2016, MMWR-MORBID MORTAL W, V65, P30, DOI 10.15585/mmwr.mm6502e1
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   ROOST HP, 1995, P NATL ACAD SCI USA, V92, P1257, DOI 10.1073/pnas.92.5.1257
   Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Sok D, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003754
   Speer SD, 2016, SCIENCE, V353, P750, DOI 10.1126/science.aah6187
   Staples JE, 2016, MMWR-MORBID MORTAL W, V65, P63, DOI 10.15585/mmwr.mm6503e3
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Sukupolvi-Petty S, 2010, J VIROL, V84, P9227, DOI 10.1128/JVI.01087-10
   Takemori T, 2014, EUR J IMMUNOL, V44, P1258, DOI 10.1002/eji.201343716
   Thornburg NJ, 2016, J CLIN INVEST, V126, P1482, DOI 10.1172/JCI85317
   Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017
   Tiller T, 2007, IMMUNITY, V26, P205, DOI 10.1016/j.immuni.2007.01.009
   Wakerley BR, 2014, NAT REV NEUROL, V10, P537, DOI 10.1038/nrneurol.2014.138
   Wang QH, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aai8336
   West AP, 2014, CELL, V156, P633, DOI 10.1016/j.cell.2014.01.052
   Wrammert J, 2012, J VIROL, V86, P2911, DOI 10.1128/JVI.06075-11
   Xiao XD, 2009, BIOCHEM BIOPH RES CO, V390, P404, DOI 10.1016/j.bbrc.2009.09.029
   Ye J, 2013, NUCLEIC ACIDS RES, V41, pW34, DOI 10.1093/nar/gkt382
NR 72
TC 10
Z9 10
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JUN
PY 2017
VL 11
IS 6
AR e0005655
DI 10.1371/journal.pntd.0005655
PG 17
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA EZ9WL
UT WOS:000405080700038
PM 28604797
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Dezan, MR
   Ribeiro, IH
   Oliveira, VB
   Vieira, JB
   Gomes, FC
   Franco, LAM
   Varuzza, L
   Ribeiro, R
   Chinoca, KZ
   Levi, JE
   Krieger, JE
   Pereira, AC
   Gualandro, SFM
   Rocha, VG
   Mendrone, A
   Sabino, EC
   Dinardo, CL
AF Dezan, Marcia R.
   Ribeiro, Ingrid Helena
   Oliveira, Valeria B.
   Vieira, Juliana B.
   Gomes, Francisco C.
   Franco, Lucas A. M.
   Varuzza, Leonardo
   Ribeiro, Roberto
   Chinoca, Karen Ziza
   Levi, Jose Eduardo
   Krieger, Jose Eduardo
   Pereira, Alexandre Costa
   Gualandro, Sandra F. M.
   Rocha, Vanderson G.
   Mendrone-Junior, Alfredo
   Sabino, Ester Cerdeira
   Dinardo, Carla Luana
TI RHD and RHCE genotyping by next-generation sequencing is an effective
   strategy to identify molecular variants within sickle cell disease
   patients
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Article
ID TRANSFUSION THERAPY; ALLOIMMUNIZATION; PHENOTYPE; MUTATION; ALLELES
AB Background: The complexity of Rh genetic variation among sickle cell disease (SCD) patients is high. Conventional molecular assays cannot identify all genetic variants already described for the RH locus as well as foresee novel alleles. Sequencing RHD and RHCE is indicated to broaden the search for Rh genetic variants.
   Aims: To standardize the Next Generation Sequencing (NGS) strategy to assertively identify Rh genetic variants among SCD patients with serologic suspicion of Rh variants and evaluate if it can improve the transfusion support.
   Methods: Thirty-five SCD patients with unexplained Rh antibodies were enrolled. A NGS-based strategy was developed to genotype RHD and RHCE using gene-specific primers. Genotype and serological data were compared.
   Results: Data obtained from the NGS-based assay were gene-specific. Ten and 25 variant RHD and RHCE alleles were identified, respectively. Among all cases of unexplained Rh antibodies, 62% had been inaccurately classified by serological analysis and, of these, 73.1% were considered as relevant, as were associated with increased risk of hemolytic reactions and shortage of units suitable for transfusion.
   Conclusion: The NGS assay designed to genotype RH coding regions was effective and accurate in identifying variants. The proposed strategy clarified the Rh phenotype of most patients, improving transfusion support.
C1 [Dezan, Marcia R.; Ribeiro, Ingrid Helena; Oliveira, Valeria B.; Vieira, Juliana B.; Gomes, Francisco C.; Levi, Jose Eduardo; Rocha, Vanderson G.; Mendrone-Junior, Alfredo; Dinardo, Carla Luana] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Franco, Lucas A. M.; Varuzza, Leonardo; Ribeiro, Roberto; Sabino, Ester Cerdeira] Univ Sao Paulo, Dept Infect Dis, Inst Trop Med, Sao Paulo, Brazil.
   [Chinoca, Karen Ziza; Krieger, Jose Eduardo; Gualandro, Sandra F. M.; Rocha, Vanderson G.] Univ Sao Paulo, Sch Med, Discipline Hematol, Sao Paulo, Brazil.
   [Pereira, Alexandre Costa; Dinardo, Carla Luana] Univ Sao Paulo, Sch Med, Heart Inst InCor, Lab Genet & Mol Cardiol, Sao Paulo, Brazil.
RP Dinardo, CL (corresponding author), Av Dr Eneas de Carvalho Aguiar 155,1st Floor, BR-05403000 Sao Paulo, SP, Brazil.
EM cdinardo@sp.gov.br
RI Sabino, Ester Cerdeira/F-7750-2010; Rocha, Vanderson/AAO-1691-2020
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; Varuzza,
   Leonardo/0000-0002-0827-858X; Krieger, Jose/0000-0001-5464-1792; DEZAN,
   MARCIA REGINA/0000-0002-3760-9843
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2014/50250-6]
FX This work was supported by Grant #2014/50250-6, Sao Paulo Research
   Foundation (FAPESP).
CR Casas J, 2015, TRANSFUSION, V55, P1388, DOI 10.1111/trf.12987
   Chiu RWK, 2001, CLIN CHEM, V47, P667
   Chou ST, 2013, BLOOD, V122, P1062, DOI 10.1182/blood-2013-03-490623
   Chou ST, 2012, BRIT J HAEMATOL, V159, P394, DOI 10.1111/bjh.12061
   De Santis D, 2013, INT J IMMUNOGENET, V40, P72, DOI 10.1111/iji.12024
   Dezan V.B.O.M.R., 2016, ISBT SCI SER INT J I, V11, P132
   Dinardo Carla Luana, 2013, Rev. Bras. Hematol. Hemoter., V35, P414, DOI 10.5581/1516-8484.20130123
   Fichou Y, 2016, VOX SANG, V111, P418, DOI 10.1111/vox.12432
   Fichou Y, 2014, BRIT J HAEMATOL, V167, P554, DOI 10.1111/bjh.13084
   Hendrickson JE, 2007, BLOOD, V110, P2736, DOI 10.1182/blood-2007-03-083105
   Johnsen JM, 2015, HEMATOL-AM SOC HEMAT, P168, DOI 10.1182/asheducation-2015.1.168
   Legler TJ, 2001, TRANSFUSION MED, V11, P383, DOI 10.1046/j.1365-3148.2001.00327.x
   Maaskant-van Wijk PA, 1998, TRANSFUSION, V38, P1015, DOI 10.1046/j.1537-2995.1998.38111299056309.x
   Noizat-Pirenne F, 2011, TRANSFUS CLIN BIOL, V18, P527, DOI 10.1016/j.tracli.2011.09.001
   Percy MJ, 2012, AM J HEMATOL, V87, P439, DOI 10.1002/ajh.23123
   Reid ME, 2014, BLOOD CELL MOL DIS, V52, P195, DOI 10.1016/j.bcmd.2013.11.003
   Singleton BK, 2000, BLOOD, V95, P12
   Sippert E, 2015, BLOOD TRANSFUS-ITALY, V13, P72, DOI 10.2450/2014.0324-13
   Stabentheiner S, 2011, VOX SANG, V100, P381, DOI 10.1111/j.1423-0410.2010.01444.x
   Vichinsky EP, 2001, TRANSFUSION, V41, P1086, DOI 10.1046/j.1537-2995.2001.41091086.x
   Wagner FF, 1998, BLOOD, V91, P2157, DOI 10.1182/blood.V91.6.2157.2157_2157_2168
   Yazdanbakhsh K, 2012, BLOOD, V120, P528, DOI 10.1182/blood-2011-11-327361
NR 22
TC 20
Z9 20
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
EI 1096-0961
J9 BLOOD CELL MOL DIS
JI Blood Cells Mol. Dis.
PD JUN
PY 2017
VL 65
BP 8
EP 15
DI 10.1016/j.bcmd.2017.03.014
PG 8
WC Hematology
SC Hematology
GA EY1PU
UT WOS:000403738600002
PM 28388467
DA 2020-11-30
ER

PT J
AU Ziza, KC
   Liao, AW
   Dezan, M
   Dinardo, CL
   Jens, E
   Francisco, RPV
   Mendrone, A
   Zugaib, M
   Levi, JE
AF Ziza, Karen Chinoca
   Liao, Adolfo Wenjaw
   Dezan, Marcia
   Dinardo, Carla Luana
   Jens, Eduardo
   Vieira Francisco, Rossana Pulcineli
   Mendrone Junior, Alfredo
   Zugaib, Marcelo
   Levi, Jose Eduardo
TI Determination of Fetal RHD Genotype Including the RHD Pseudogene in
   Maternal Plasma
SO JOURNAL OF CLINICAL LABORATORY ANALYSIS
LA English
DT Article
DE DNA; analysis; genotyping techniques; prenatal diagnosis; methods; RhD
   Blood group system; sensitivity and specificity
ID BRAZILIAN BLOOD-DONORS; PREGNANT-WOMEN; DNA; POPULATION; IDENTIFICATION;
   METAANALYSIS; PROPHYLAXIS; EXPERIENCE; PHENOTYPES; AFRICANS
AB Objective: To examine the accuracy of fetal RHD genotype and RHD pseudogene determination in a multiethnical population. Methods: Prospective study involving D-negative pregnant women. Cell-free DNA was extracted from 1 ml of maternal plasma by an automated system (MagNA Pure Compact, Roche) and real-time PCR was performed in triplicate targeting the RHD gene exons 5 and 7. Inconclusive samples underwent RHD pseudogene testing by real-time PCR analysis employing novel primers and probe. Results: A positive result was observed in 128/185 (69.2%) samples and negative in 50 (27.0%). Umbilical cord blood phenotype confirmed all cases with a positive or negative PCR result. Seven (3.8%) cases were found inconclusive (exon 7 amplification only) and RHD pseudogene testing with both conventional and real-time PCR demonstrated a positive result in five of them, while two samples were also RHD pseudogene negative. Conclusion: Real-time PCR targeting RHD exons 5 and 7 simultaneously in maternal plasma is an accurate method for the diagnosis of fetal D genotype in our population. The RHD pseudogene real-time PCR assay is feasible and is particularly useful in populations with a high prevalence of this allele. (C) 2016 Wiley Periodicals, Inc.
C1 [Ziza, Karen Chinoca; Dezan, Marcia; Dinardo, Carla Luana; Jens, Eduardo; Mendrone Junior, Alfredo; Levi, Jose Eduardo] Fundacao Pro Sangue, Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Liao, Adolfo Wenjaw; Vieira Francisco, Rossana Pulcineli; Zugaib, Marcelo] Univ Sao Paulo, Hosp Clin, Dept Obstet & Gynecol, Sch Med, Sao Paulo, Brazil.
RP Ziza, KC (corresponding author), Fundacao Pro Sangue, Hemoctr Sao Paulo, Immunohematol, Sao Paulo, Brazil.
EM karen.chinoca26@gmail.com
RI Francisco, Rossana Pulcineli Vieira/AAG-7461-2020; Zugaib,
   Marcelo/A-5724-2013; Francisco, Rossana PV/C-5648-2012
OI Francisco, Rossana Pulcineli Vieira/0000-0002-9981-8069; Zugaib,
   Marcelo/0000-0003-1155-2671; Francisco, Rossana PV/0000-0002-9981-8069;
   DEZAN, MARCIA REGINA/0000-0002-3760-9843
CR Amaral DRT, 2011, J CLIN LAB ANAL, V25, P100, DOI 10.1002/jcla.20440
   Avent ND, 2005, TRANSFUSION, V45, P293, DOI 10.1111/j.1537-2995.2005.04470.x
   Baiochi E, 2007, REV ASSOC MED BRAS, V53, P44, DOI 10.1590/S0104-42302007000100018
   Chinen PA, 2010, AM J PERINAT, V27, P759, DOI 10.1055/s-0030-1253560
   Clausen FB, 2012, TRANSFUSION, V52, P752, DOI 10.1111/j.1537-2995.2011.03362.x
   Cruz BR, 2012, TRANSFUSION MED, V22, P84, DOI 10.1111/j.1365-3148.2011.01129.x
   Daniels G, 2010, CLIN LAB MED, V30, P431, DOI 10.1016/j.cll.2010.02.006
   Daniels G, 2009, PRENATAL DIAG, V29, P101, DOI 10.1002/pd.2172
   Daniels GL, 1998, TRANSFUSION, V38, P951, DOI 10.1046/j.1537-2995.1998.381098440860.x
   de Haas M, 2015, VOX SANG, V109, P99, DOI 10.1111/vox.12265
   Devaney SA, 2011, JAMA-J AM MED ASSOC, V306, P627, DOI 10.1001/jama.2011.1114
   ElsMessaoudi S, 2013, CLIN CHIM ACTA, V424, P222, DOI 10.1016/j.cca.2013.05.022
   Finning K, 2008, BRIT MED J, V336, P816, DOI 10.1136/bmj.39518.463206.25
   Finning KM, 2002, TRANSFUSION, V42, P1079, DOI 10.1046/j.1537-2995.2002.00165.x
   Flegel WA, 2011, TRANSFUS APHER SCI, V44, P81, DOI 10.1016/j.transci.2010.12.013
   Geifman-Holtzman O, 2006, AM J OBSTET GYNECOL, V195, P1163, DOI 10.1016/j.ajog.2006.07.033
   Grande M, 2013, PRENATAL DIAG, V33, P173, DOI 10.1002/pd.4035
   Huang DJ, 2005, CLIN CHEM, V51, P2419, DOI 10.1373/clinchem.2005.056010
   Illanes S, 2007, EARLY HUM DEV, V83, P563, DOI 10.1016/j.earlhumdev.2006.11.001
   Legler TJ, 2007, PRENATAL DIAG, V27, P824, DOI 10.1002/pd.1783
   Maaskant-van Wijk PA, 1998, TRANSFUSION, V38, P1015, DOI 10.1046/j.1537-2995.1998.38111299056309.x
   Machado Isabela Nelly, 2006, Rev. Assoc. Med. Bras., V52, P232, DOI 10.1590/S0104-42302006000400022
   Minon J-M, 2005, J Gynecol Obstet Biol Reprod (Paris), V34, P448
   Moise KJ, 2008, OBSTET GYNECOL, V112, P164, DOI 10.1097/AOG.0b013e31817d453c
   Mota M, 2012, J CLIN LAB ANAL, V26, P104, DOI 10.1002/jcla.21489
   Muller SP, 2008, TRANSFUSION, V48, P2292, DOI 10.1111/j.1537-2995.2008.01843.x
   Muller SP, 2011, PRENATAL DIAG, V31, P1300, DOI 10.1002/pd.2889
   PACHECO Cristiano de Souza Lima Pacheco, 2013, THESIS
   Rijnders RJP, 2003, PRENATAL DIAG, V23, P1042, DOI 10.1002/pd.750
   Scheffer PG, 2011, BJOG-INT J OBSTET GY, V118, P1340, DOI 10.1111/j.1471-0528.2011.03028.x
   Schmidt LC, 2014, GENET MOL RES, V13, P799, DOI 10.4238/2014.February.7.1
   Singleton BK, 2000, BLOOD, V95, P12
   Szulman A, 2012, TRANSFUS APHER SCI, V47, P289, DOI 10.1016/j.transci.2012.07.007
   Teitelbaum L, 2015, ULTRASOUND OBST GYN, V45, P84, DOI 10.1002/uog.14723
   van der Schoot CE, 2003, TRANSFUS MED REV, V17, P31, DOI 10.1053/tmrv.2003.50001
   Wagner F F, 2004, Immunohematology, V20, P23
   Wagner FF, 2000, BLOOD, V95, P3662
NR 37
TC 2
Z9 2
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0887-8013
EI 1098-2825
J9 J CLIN LAB ANAL
JI J. Clin. Lab. Anal.
PD MAY
PY 2017
VL 31
IS 3
AR e22052
DI 10.1002/jcla.22052
PG 6
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA EV1VW
UT WOS:000401538800008
PM 27595845
OA Green Published
DA 2020-11-30
ER

PT J
AU Anantharaman, D
   Abedi-Ardekani, B
   Beachler, DC
   Gheit, T
   Olshan, AF
   Wisniewski, K
   Wunsch, V
   Toporcov, TN
   Tajara, EH
   Levi, JE
   Moyses, RA
   Boccia, S
   Cadoni, G
   Rindi, G
   Ahrens, W
   Merletti, F
   Conway, DI
   Wright, S
   Carreira, C
   Renard, H
   Chopard, P
   McKay-Chopin, S
   Scelo, G
   Tommasino, M
   Brennan, P
   D'Souza, G
AF Anantharaman, Devasena
   Abedi-Ardekani, Behnoush
   Beachler, Daniel C.
   Gheit, Tarik
   Olshan, Andrew F.
   Wisniewski, Kathy
   Wunsch-Filho, Victor
   Toporcov, Tatiana N.
   Tajara, Eloiza H.
   Levi, Jose Eduardo
   Moyses, Raquel A.
   Boccia, Stefania
   Cadoni, Gabriella
   Rindi, Guido
   Ahrens, Wolfgang
   Merletti, Franco
   Conway, David I.
   Wright, Sylvia
   Carreira, Christine
   Renard, Helene
   Chopard, Priscilia
   McKay-Chopin, Sandrine
   Scelo, Ghislaine
   Tommasino, Massimo
   Brennan, Paul
   D'Souza, Gypsyamber
TI Geographic heterogeneity in the prevalence of human papillomavirus in
   head and neck cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE HPV16; oropharynx; head and neck cancer; smoking; alcohol; prevalence
ID RISK HUMAN-PAPILLOMAVIRUS; SQUAMOUS-CELL CARCINOMAS; OROPHARYNGEAL
   CANCER; TONSILLAR CARCINOMA; CAUSAL ASSOCIATION; POSITIVE HEAD;
   ORAL-CAVITY; HPV-DNA; INFECTIONS; PROGNOSIS
AB Human papillomavirus (HPV) causes oropharyngeal squamous cell carcinoma (OPSCC), although strongly divergent results have been reported regarding the prevalence of HPV16 in different countries, whether this represents important differences in etiology remains unclear. Applying rigorous protocols for sample processing, we centrally evaluated 1,420 head and neck tumors (533 oropharynx, 395 oral cavity and 482 larynx) from studies conducted in the US, Europe and Brazil for mucosal HPV DNA and p16(INK4a) expression to evaluate regional heterogeneity in the proportion of HPV16-associated OPSCC and other head and neck cancer, and to assess covariates associated with the risk of HPV16-positive OPSCC. While majority of OPSCC in the US (60%) were HPV16-positive, this proportion was 31% in Europe and only 4% in Brazil (p < 0.01). Similar differences were observed for other head and neck tumors, ranging from 7% in the US and 5% in Europe, to 0% in South America. The odds of HPV16-positive OPSCC declined with increasing pack years of smoking (OR: 0.75; 95% CI: 0.64-0.87) and drink years of alcohol use (OR: 0.64; 95% CI: 0.54-0.76). These results suggest that while the contribution of HPV16 is substantial for the oropharynx, it remains limited for oral cavity and laryngeal cancers.
C1 [Anantharaman, Devasena; Abedi-Ardekani, Behnoush; Gheit, Tarik; Carreira, Christine; Renard, Helene; Chopard, Priscilia; McKay-Chopin, Sandrine; Scelo, Ghislaine; Tommasino, Massimo; Brennan, Paul] Int Agcy Res Canc, Lyon, France.
   [Beachler, Daniel C.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
   [Olshan, Andrew F.; Wisniewski, Kathy] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA.
   [Wunsch-Filho, Victor; Toporcov, Tatiana N.] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Tajara, Eloiza H.] Univ Sao Paulo, Inst Biosci, Dept Genet & Evolutionary Biol, Sao Paulo, Brazil.
   [Tajara, Eloiza H.] Sch Med Sao Jose do Rio Preto, Dept Mol Biol, Sao Jose Do Rio Preto, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Moyses, Raquel A.] Univ Sao Paulo, Sch Med, Dept Surg, Div Head & Neck, Sao Paulo, Brazil.
   [Boccia, Stefania] Univ Cattolica Sacro Cuore, Fac Med, Sect Hyg, Inst Publ Hlth, Rome, Italy.
   [Cadoni, Gabriella] Univ Cattolica Sacro Cuore, Inst Otorhinolaryngol, Rome, Italy.
   [Rindi, Guido] Univ Cattolica Sacro Cuore, Inst Anat Pathol, Rome, Italy.
   [Ahrens, Wolfgang] Leibniz Inst Prevent Res & Epidemiology BIPS, Bremen, Germany.
   [Ahrens, Wolfgang] Univ Bremen, Inst Stat, Bremen, Germany.
   [Merletti, Franco] CeRMS, Dept Med Sci, Turin, Italy.
   [Merletti, Franco] Univ Turin, Turin, Italy.
   [Conway, David I.] Univ Glasgow, Dent Sch, Glasgow, Lanark, Scotland.
   [Wright, Sylvia] Queen Elizabeth Univ Hosp, Dept Pathol, Glasgow, Lanark, Scotland.
   [D'Souza, Gypsyamber] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Brennan, P (corresponding author), Int Agcy Res Canc, Genet Sect, 150 Cours Albert Thomas, F-69372 Lyon 08, France.
EM gep@iarc.fr
RI Filho, Victor Wunsch/C-4475-2012; Moyses, Raquel/N-4376-2015;
   Abedi-Ardekani, Behnoush/O-7829-2016; Toporcov, Tatiana/M-7729-2015;
   cadoni, gabriella/AAC-8203-2019; Ahrens, Wolfgang/A-2740-2012
OI Moyses, Raquel/0000-0002-0872-9870; Abedi-Ardekani,
   Behnoush/0000-0002-0980-0587; cadoni, gabriella/0000-0002-6239-838X;
   Ahrens, Wolfgang/0000-0003-3777-570X; Boccia,
   Stefania/0000-0002-1864-749X; Conway, David/0000-0001-7762-4063
FU European Commission's 5th Framework Program (ARCAGE study)
   [QLK1-2001-00182]; European Commission's 7th Framework Program
   [FP7-HEALTH-2011-282562]; Health General Directorate of the French
   Social Affairs and Health Ministry; Italian Association for Research on
   Cancer (AIRC)Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG
   2013 N.14220]; Fondazione VeronesiFondazione Umberto Veronesi; National
   Cancer Institute (U.S. CHANCE study) [NCI R01-CA90731]; FAPESP (Sao
   Paulo Research Foundation; GENCAPO study)Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP) [04/12054-9, 10/51168-0]
FX Grant sponsor: European Commission's 5th Framework Program (ARCAGE
   study; P.B., PI); Grant number: QLK1-2001-00182; Grant sponsor: European
   Commission's 7th Framework Program (M.T., PI); Grant number:
   FP7-HEALTH-2011-282562; Grant sponsor: Health General Directorate of the
   French Social Affairs and Health Ministry; Grant sponsor: Italian
   Association for Research on Cancer (AIRC; S.B., PI); Grant number: IG
   2013 N.14220; Grant sponsor: Fondazione Veronesi (S.B., PI); Grant
   sponsor: National Cancer Institute (U.S. CHANCE study; A.O., PI); Grant
   number: NCI R01-CA90731; Grant sponsor: FAPESP (Sao Paulo Research
   Foundation; GENCAPO study); Grant number: 04/12054-9 and 10/51168-0
CR Anantharaman D, 2014, CANCER RES, V74, P3525, DOI 10.1158/0008-5472.CAN-13-3548
   Anantharaman D, 2013, JNCI-J NATL CANCER I, V105, P536, DOI 10.1093/jnci/djt053
   Anantharaman D, 2011, ORAL ONCOL, V47, P725, DOI 10.1016/j.oraloncology.2011.05.004
   Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217
   Boing AF, 2011, J EPIDEMIOL COMMUN H, V65, P709, DOI 10.1136/jech.2009.097691
   Castellsague X, 2016, JNCI-J NATL CANCER I, P108
   Chaturvedi AK, 2008, J CLIN ONCOL, V26, P612, DOI 10.1200/JCO.2007.14.1713
   Chaturvedi AK, 2014, LANCET ONCOL, V15, P1282, DOI 10.1016/S1470-2045(14)71029-0
   Chaturvedi AK, 2013, J CLIN ONCOL, V31, P4550, DOI 10.1200/JCO.2013.50.3870
   Combes JD, 2014, ORAL ONCOL, V50, P370, DOI 10.1016/j.oraloncology.2013.11.004
   Curado MP, 2007, CANC INCIDENCE 5 CON, VIX
   Dahlstrand HM, 2005, ANTICANCER RES, V25, P4375
   Divaris K, 2010, CANCER CAUSE CONTROL, V21, P567, DOI 10.1007/s10552-009-9486-9
   Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gheit T, 2006, J CLIN MICROBIOL, V44, P2025, DOI 10.1128/JCM.02305-05
   Gheit T, 2009, VACCINE, V27, P636, DOI 10.1016/j.vaccine.2008.11.041
   Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709
   Hashibe M, 2009, BIOMARKERS PREV, V18, P5401
   Herrero R, 2003, JNCI-J NATL CANCER I, V95, P1772, DOI [10.1093/jnci/djg107, 10.1093/jnci/djg/107]
   Hoffmann M, 2010, INT J CANCER, V127, P1595, DOI 10.1002/ijc.25174
   IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007, IARC Monogr Eval Carcinog Risks Hum, V90, P1
   IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1995, IARC Monogr Eval Carcinog Risks Hum, V64, P1
   IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2012, IARC Monogr Eval Carcinog Risks Hum, V100, P1
   Koo CL, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-25
   Kreimer AR, 2005, CANCER EPIDEM BIOMAR, V14, P467, DOI 10.1158/1055-9965.EPI-04-0551
   Kuo KT, 2008, MODERN PATHOL, V21, P376, DOI 10.1038/modpathol.3800979
   Lagiou P, 2009, EUR J CANCER PREV, V18, P76, DOI 10.1097/CEJ.0b013e32830c8dca
   Licitra L, 2006, J CLIN ONCOL, V24, P5630, DOI 10.1200/JCO.2005.04.6136
   Lingen MW, 2013, ORAL ONCOL, V49, P1, DOI 10.1016/j.oraloncology.2012.07.002
   Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6
   Lopez RVM, 2014, CANCER CAUSE CONTROL, V25, P461, DOI 10.1007/s10552-014-0348-8
   Nasman A, 2009, INT J CANCER, V125, P362, DOI 10.1002/ijc.24339
   Ndiaye C, 2014, LANCET ONCOL, V15, P1319, DOI 10.1016/S1470-2045(14)70471-1
   Reimers N, 2007, INT J CANCER, V120, P1731, DOI 10.1002/ijc.22355
   Ribeiro KB, 2011, INT J EPIDEMIOL, V40, P489, DOI 10.1093/ije/dyq249
   Schmitt M, 2006, J CLIN MICROBIOL, V44, P504, DOI 10.1128/JCM.44.2.504-512.2006
   Schmitt M, 2010, J CLIN MICROBIOL, V48, P143, DOI 10.1128/JCM.00991-09
   Severino Patricia, 2008, BMC Res Notes, V1, P113, DOI 10.1186/1756-0500-1-113
   Smeets SJ, 2007, INT J CANCER, V121, P2465, DOI 10.1002/ijc.22980
NR 40
TC 47
Z9 47
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD MAY 1
PY 2017
VL 140
IS 9
BP 1968
EP 1975
DI 10.1002/ijc.30608
PG 8
WC Oncology
SC Oncology
GA ES1UR
UT WOS:000399313000003
PM 28108990
OA Bronze
DA 2020-11-30
ER

PT J
AU Scapulatempo-Neto, C
   Veo, C
   Fregnani, JHTG
   Lorenzi, A
   Mafra, A
   Melani, AGF
   Loaiza, EAA
   Rosa, LAR
   De Oliveira, CM
   Levi, JE
   Longatto, A
AF Scapulatempo-Neto, Cristovam
   Veo, Carlos
   Fregnani, Jose Humberto T. G.
   Lorenzi, Adriana
   Mafra, Allini
   Melani, Armando G. F.
   Loaiza, Edgar Antonio Aleman
   Rosa, Luciana Albina Reis
   De Oliveira, Cristina Mendes
   Levi, Jose Eduardo
   Longatto-Filho, Adhemar
TI Characterization of topoisomerase II alpha and minichromosome
   maintenance protein 2 expression in anal carcinoma
SO ONCOLOGY LETTERS
LA English
DT Article
DE anal carcinoma; p16; Ki-67; minichromosome maintenance protein 2;
   topoisomerase II alpha; human papillomavirus
ID HUMAN-PAPILLOMAVIRUS DNA; INTRAEPITHELIAL NEOPLASIA; P16; LESIONS;
   WOMEN; EPIDEMIOLOGY; BIOMARKERS; P16INK4A
AB The present study aimed to ascertain the significance of topoisomerase II alpha (TOP2A) and minichromosome maintenance protein (MCM) 2 expression in anal carcinoma. A total of 75 anal lesions were retrieved from the files of the Department of Pathology of Barretos Cancer Hospital (Barretos, Brazil) in order to verify the human papillomavirus (HPV) statuses of these lesions and characterize the immunohistochemical expression levels of TOP2A and MCM2 in anal carcinoma, as these are important markers for cervical HPV-induced lesions; their expression was also compared with respect to p16 and Ki-67. The vast majority of the cases tested positive for HPV16 (84%); 1 case tested positive for both HPV16 and HPV18. Positive HPV16 status was more frequent in early stages than in advanced stages (P=0.008). Positive immunohistochemical reactivity for MCM2 and TOP2A protein was observed in 71.6 and 100% of cases, respectively. Positive reactivity for p16 was significantly associated (P=0.001) with histological grade, and was more commonly expressed in squamous cell carcinoma than adenocarcinomas. HPV16 was strongly associated with positive p16 protein expression (76.6%). However, the high expression of Ki-67 combined with the high expression of p16 was predominantly observed in Stage III-IV cases. MCM2, TOP2A, p16 and Ki-67 exhibited intense positive staining in the anal lesions, indicating that these markers were significantly and constantly expressed in anal carcinoma.
C1 [Scapulatempo-Neto, Cristovam; Fregnani, Jose Humberto T. G.] Barretos Canc Hosp, Pio Fdn 12, Dept Pathol CSN, BR-14784400 Sao Paulo, SP, Brazil.
   [Veo, Carlos; Melani, Armando G. F.; Loaiza, Edgar Antonio Aleman] Barretos Canc Hosp, Pio Fdn 12, Dept Surg, BR-14784400 Sao Paulo, SP, Brazil.
   [Fregnani, Jose Humberto T. G.; Lorenzi, Adriana; Mafra, Allini; Longatto-Filho, Adhemar] Barretos Canc Hosp, Pio Fdn 12, Mol Oncol Res Ctr, BR-14784400 Sao Paulo, SP, Brazil.
   [Rosa, Luciana Albina Reis; De Oliveira, Cristina Mendes] Univ Sao Paulo, Inst Trop Med Sao Paulo, Virol Lab, BR-05403000 Sao Paulo, SP, Brazil.
   [Longatto-Filho, Adhemar] Univ Sao Paulo, Fac Med, Lab Med Invest 14, 455 Dr Arnaldo Ave, BR-01246903 Sao Paulo, SP, Brazil.
   [Longatto-Filho, Adhemar] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal.
   [Longatto-Filho, Adhemar] ICVS 3Bs PT Govt Associate Lab, P-4806909 Caldas Taipas Guimaraes, Portugal.
RP Longatto, A (corresponding author), Univ Sao Paulo, Fac Med, Lab Med Invest 14, 455 Dr Arnaldo Ave, BR-01246903 Sao Paulo, SP, Brazil.
EM longatto16@hotmail.com
RI longatto-filho, adhemar/D-7039-2013; Oliveira, Cristina M/F-7193-2012;
   Longatto-Filho, Adhemar/N-3397-2019; da Costa, Allini
   Mafra/AAQ-2091-2020; Melani, Armando G Franchini/Q-6498-2019; Fregnani,
   Jose H/H-4238-2012; Mafra, Allini/R-1360-2018
OI longatto-filho, adhemar/0000-0002-5779-9752; Longatto-Filho,
   Adhemar/0000-0002-5779-9752; da Costa, Allini Mafra/0000-0002-2993-7919;
   Fregnani, Jose H/0000-0002-5235-6469; Mafra, Allini/0000-0002-2993-7919;
   FRANCHINI MELANI, ARMANDO GERALDO/0000-0002-5606-9651;
   Scapulatempo-Neto, Cristovam/0000-0002-8920-6579
CR Bala R, 2013, AM J SURG PATHOL, V37, P659, DOI 10.1097/PAS.0b013e31828706c0
   Bean SM, 2007, AM J SURG PATHOL, V31, P555, DOI 10.1097/PAS.0b013e31802ca3f4
   Brown CA, 2012, J ONCOL, V2012, DOI 10.1155/2012/289315
   Firnhaber C, 2012, CURR HIV-AIDS REP, V9, P278, DOI 10.1007/s11904-012-0128-6
   Grulich AE, 2012, SEX HEALTH, V9, P504, DOI 10.1071/SH12070
   Kreuter A, 2010, J AM ACAD DERMATOL, V63, P490, DOI 10.1016/j.jaad.2009.08.043
   Legarth R, 2013, SCAND J INFECT DIS, V45, P453, DOI 10.3109/00365548.2012.737476
   Longacre TA, 2008, ADV ANAT PATHOL, V15, P263, DOI 10.1097/PAP.0b013e318183234b
   Longatto A, 2005, INT J GYNECOL PATHOL, V24, P118, DOI 10.1097/01.RCT.0000157092.44680.25
   Machalek DA, 2012, LANCET ONCOL, V13, P487, DOI 10.1016/S1470-2045(12)70080-3
   Nielsen A, 2012, INT J CANCER, V130, P1168, DOI 10.1002/ijc.26115
   Palefsky JM, 2009, OBSTET GYN CLIN N AM, V36, P187, DOI 10.1016/j.ogc.2009.02.003
   Pinto AP, 2008, MODERN PATHOL, V21, P1067, DOI 10.1038/modpathol.2008.101
   Pirog EC, 2010, AM J SURG PATHOL, V34, P1449, DOI 10.1097/PAS.0b013e3181f0f52a
   Roelens J, 2012, CANCER CYTOPATHOL, V120, P294, DOI 10.1002/cncy.21205
   SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
   Salit IE, 2009, CANCER EPIDEM BIOMAR, V18, P1986, DOI 10.1158/1055-9965.EPI-08-1141
   Serup-Hansen E, 2014, J CLIN ONCOL, V32, P1812, DOI 10.1200/JCO.2013.52.3464
   Shi J, 2007, HUM PATHOL, V38, P1335, DOI 10.1016/j.humpath.2007.01.025
   Thomas MK, 2011, VIROLOGY, V421, P114, DOI 10.1016/j.virol.2011.09.018
   Urgoiti GBR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108790
   Valari O, 2011, GYNECOL ONCOL, V122, P505, DOI 10.1016/j.ygyno.2011.05.033
   Veo CAR, 2015, TUMOR BIOL, V36, P5399, DOI 10.1007/s13277-015-3205-9
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Walts Ann E, 2008, Clin Med Pathol, V1, P7
   Wentzensen N, 2012, CLIN CANCER RES, V18, P4154, DOI 10.1158/1078-0432.CCR-12-0270
   Wong AK, 2010, MODERN PATHOL, V23, P144, DOI 10.1038/modpathol.2009.143
   Zandberg DP, 2013, CA-CANCER J CLIN, V63, P57, DOI 10.3322/caac.21167
NR 28
TC 5
Z9 5
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD MAR
PY 2017
VL 13
IS 3
BP 1891
EP 1898
DI 10.3892/ol.2017.5650
PG 8
WC Oncology
SC Oncology
GA EO9HA
UT WOS:000396998600131
PM 28454340
OA Green Published, Bronze
DA 2020-11-30
ER

PT J
AU Stone, M
   Lanteri, MC
   Bakkour, S
   Deng, XT
   Galel, SA
   Linnen, JM
   Munoz-Jordan, JL
   Lanciotti, RS
   Rios, M
   Gallian, P
   Musso, D
   Levi, JE
   Sabino, EC
   Coffey, LL
   Busch, MP
AF Stone, Mars
   Lanteri, Marion C.
   Bakkour, Sonia
   Deng, Xutao
   Galel, Susan A.
   Linnen, Jeffrey M.
   Munoz-Jordan, Jorge L.
   Lanciotti, Robert S.
   Rios, Maria
   Gallian, Pierre
   Musso, Didier
   Levi, Jose E.
   Sabino, Ester C.
   Coffey, Lark L.
   Busch, Michael P.
TI Relative analytical sensitivity of donor nucleic acid amplification
   technology screening and diagnostic real-time polymerase chain reaction
   assays for detection of Zika virus RNA
SO TRANSFUSION
LA English
DT Article
ID UPDATE INTERIM GUIDELINES; MALE SEXUAL TRANSMISSION; UNITED-STATES;
   BLOOD-TRANSFUSION; FRENCH-POLYNESIA; PREGNANT-WOMEN; BRAZIL; URINE;
   INFECTION; OUTBREAK
AB BACKGROUND Zika virus (ZIKV) has spread rapidly in the Pacific and throughout the Americas and is associated with severe congenital and adult neurologic outcomes. Nucleic acid amplification technology (NAT) assays were developed for diagnostic applications and for blood donor screening on high-throughput NAT systems. We distributed blinded panels to compare the analytical performance of blood screening relative to diagnostic NAT assays.
   STUDY DESIGN AND METHODS A 25-member, coded panel (11 half-log dilutions of a 2013 French Polynesia ZIKV isolate and 2015 Brazilian donor plasma implicated in transfusion transmission, and 3 negative controls) was sent to 11 laboratories that performed 17 assays with 2 to 12 replicates per panel member. Results were analyzed for the percentage reactivity at each dilution and by probit analysis to estimate the 50% and 95% limits of detection (LOD50 and LOD95, respectively).
   RESULTS Donor-screening NAT assays that process approximately 500 mu L of plasma into amplification reactions were comparable in sensitivity (LOD50 and LOD95, 2.5 and 15-18 copies/mL) and were approximately 10-fold to 100-fold more sensitive than research laboratory-developed and diagnostic reverse transcriptase-polymerase chain reaction tests that process from 10 to 30 mu L of plasma per amplification. Increasing sample input volume assayed with the Centers for Disease Control and Prevention reverse transcriptase-polymerase chain reaction assays increased the LODs by 10-fold to 30-fold.
   CONCLUSIONS Blood donor-screening ZIKV NAT assays demonstrate similar excellent sensitivities to assays currently used for screening for transfusion-transmitted viruses and are substantially more sensitive than most other laboratory-developed and diagnostic ZIKV reverse transcriptase-polymerase chain reaction assays. Enhancing sensitivities of laboratory-developed and diagnostic assays may be achievable by increasing sample input.
C1 [Stone, Mars; Lanteri, Marion C.; Bakkour, Sonia; Deng, Xutao; Busch, Michael P.] Univ Calif San Francisco, Blood Syst Res Inst, San Francisco, CA 94143 USA.
   [Lanteri, Marion C.; Busch, Michael P.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   [Galel, Susan A.] Roche Mol Syst Inc, Pleasanton, CA USA.
   [Linnen, Jeffrey M.] Hologic Inc, San Diego, CA USA.
   [Munoz-Jordan, Jorge L.] Ctr Dis Control & Prevent, CDC, San Juan, PR USA.
   [Lanciotti, Robert S.] Ctr Dis Control & Prevent, Ft Collins, CO USA.
   [Rios, Maria] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA.
   [Gallian, Pierre] Etab Francais Sang, St Denis, Reunion, France.
   [Gallian, Pierre] Aix Marseille Univ, Marseille, France.
   [Gallian, Pierre] Inst Hosp Univ Mediterranee Infect, INSERM, French Inst Res Dev, Unite Mixte Rech,Emergence Pathol Virales D190, Marseille, France.
   [Musso, Didier] Inst Louis Malarde, Tahiti, French Polynesi, France.
   [Levi, Jose E.] Univ Sao Paulo, Dept Biol Mol, Fundacao Prosangue, Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Sabino, Ester C.] Univ Sao Paulo, Inst Med Trop, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, Brazil.
   [Coffey, Lark L.] Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA.
RP Busch, MP (corresponding author), Blood Syst Res Inst, 270 Masonic Ave, San Francisco, CA 94118 USA.
EM mbusch@bloodsystems.org
RI Musso, Didier/AAO-8178-2020; Sabino, Ester Cerdeira/F-7750-2010; Musso,
   Didier/P-7809-2016
OI Musso, Didier/0000-0002-9226-0971; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Musso, Didier/0000-0002-9226-0971
CR Atkinson B, 2016, EMERG INFECT DIS, V22, P940, DOI 10.3201/eid2205.160107
   Aubry M, 2016, TRANSFUSION, V56, P33, DOI 10.1111/trf.13271
   Barjas-Castro ML, 2016, TRANSFUSION, V56, P1684, DOI 10.1111/trf.13681
   Baronti C, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.00500-14
   Besnard M., 2014, EURO SURVEILL, V19
   Bingham AM, 2016, MMWR-MORBID MORTAL W, V65, P475, DOI 10.15585/mmwr.mm6518e2
   Bonaldo MC, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004816
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Brasil P, 2016, LANCET INFECT DIS, V16, P1307, DOI 10.1016/S1473-3099(16)30372-3
   Campos RD, 2016, J CLIN VIROL, V77, P69, DOI 10.1016/j.jcv.2016.02.009
   Centers for Disease Control and Prevention, 2016, AR WITH ZIK
   Centers for Disease Control and Prevention, 2016, CAS COUNTS US
   Centers for Disease Control and Prevention (CDC), 2016, PREGN OUTC US DISTR
   Cunha MS, 2016, GENOME ANNOUNC, V4
   Davidson A, 2016, MMWR-MORBID MORTAL W, V65, P716, DOI 10.15585/mmwr.mm6528e2
   Deckard DT, 2016, MMWR-MORBID MORTAL W, V65, P372, DOI 10.15585/mmwr.mm6514a3
   ECDC, 2016, ZIK VIR SAF SUBST HU
   European Centre for Disease Prevention and Control (ECDC), 2014, RAP RISK ASS ZIK VIR
   Fleming-Dutra KE, 2016, MMWR-MORBID MORTAL W, V65, P182, DOI 10.15585/mmwr.mm6507e1
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Galel S, 2016, TRANSFUSION, V57
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Gulland A, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i657
   Jayakumar P, 2016, SOUTH MED J, V109, P697, DOI 10.14423/SMJ.0000000000000550
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Lanteri MC, 2016, TRANSFUSION, V56, P1907, DOI 10.1111/trf.13677
   Melo ASO, 2016, ULTRASOUND OBST GYN, V47, P6, DOI 10.1002/uog.15831
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Motta IJF, 2016, NEW ENGL J MED, V375, P1101, DOI 10.1056/NEJMc1607262
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761
   Musso D, 2016, LANCET, V387, P1993, DOI 10.1016/S0140-6736(16)30428-7
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Musso D, 2015, EMERG INFECT DIS, V21, P1887, DOI 10.3201/eid2110.151125
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Nunes ML, 2016, J PEDIAT-BRAZIL, V92, P230, DOI 10.1016/j.jped.2016.02.009
   Oduyebo T, 2016, MMWR-MORBID MORTAL W, V65, P122, DOI 10.15585/mmwr.mm6505e2
   Petersen EE, 2016, MMWR-MORBID MORTAL W, V65, P30, DOI 10.15585/mmwr.mm6502e1
   Richard V, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005024
   Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517
   Staples JE, 2016, MMWR-MORBID MORTAL W, V65, P63, DOI 10.15585/mmwr.mm6503e3
   Trosemeier J-H, 2016, GENOME ANNOUNC, V4
   U.S. Food and Drug Administration, 2016, REV REC RED RISK ZIK
   U.S. Food and Drug Administraton, EM US AUTH
   US Food and Drug Administration, 2016, REC DON SCREEN DEF P
   Wang JN, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13101031
   Weiner E, 2016, 2016 AABB ANN M OCT
   WHO, 2016, MAINT SAF AD BLOOD S
   Williamson P, 2016, TRANSFUSION, V57
   Zhang FC, 2016, LANCET INFECT DIS, V16, P641, DOI 10.1016/S1473-3099(16)30070-6
NR 51
TC 21
Z9 21
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD MAR
PY 2017
VL 57
IS 3
SI SI
BP 734
EP 747
DI 10.1111/trf.14031
PN 2
PG 14
WC Hematology
SC Hematology
GA ER1ZZ
UT WOS:000398595000003
PM 28194799
OA Bronze
DA 2020-11-30
ER

PT J
AU D'Souza, G
   Anantharaman, D
   Gheit, T
   Abedi-Ardekani, B
   Beachler, DC
   Conway, DI
   Olshan, AF
   Wunsch, V
   Toporcov, TN
   Ahrens, W
   Wisniewski, K
   Merletti, F
   Boccia, S
   Tajara, EH
   Zevallos, JP
   Levi, JE
   Weissler, MC
   Wright, S
   Scelo, G
   Mazul, AL
   Tommasino, M
   Cadoni, G
   Brennan, P
AF D'Souza, Gypsyamber
   Anantharaman, Devasena
   Gheit, Tarik
   Abedi-Ardekani, Behnoush
   Beachler, Daniel C.
   Conway, David I.
   Olshan, Andrew F.
   Wunsch-Filho, Victor
   Toporcov, Tatiana N.
   Ahrens, Wolfgang
   Wisniewski, Kathy
   Merletti, Franco
   Boccia, Stefania
   Tajara, Eloiza H.
   Zevallos, Jose P.
   Levi, Jose Eduardo
   Weissler, Mark C.
   Wright, Sylvia
   Scelo, Ghislaine
   Mazul, Angela L.
   Tommasino, Massimo
   Cadoni, Gabriella
   Brennan, Paul
TI Effect of HPV on head and neck cancer patient survival, by region and
   tumor site: A comparison of 1362 cases across three continents (vol 62,
   pg 20, 2016)
SO ORAL ONCOLOGY
LA English
DT Correction
C1 [D'Souza, Gypsyamber] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Anantharaman, Devasena; Scelo, Ghislaine; Brennan, Paul] Int Agcy Res Canc, Genet Epidemiol Grp, Lyon, France.
   [Gheit, Tarik; Tommasino, Massimo] Int Agcy Res Canc, Infect & Canc Biol Grp, Lyon, France.
   [Abedi-Ardekani, Behnoush] Int Agcy Res Canc, Genet Canc Susceptibil Grp, Lyon, France.
   [Beachler, Daniel C.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
   [Conway, David I.] Univ Glasgow, Sch Med Dent & Nursing, Glasgow, Lanark, Scotland.
   [Olshan, Andrew F.; Wisniewski, Kathy; Mazul, Angela L.] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC USA.
   [Wunsch-Filho, Victor; Toporcov, Tatiana N.] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Ahrens, Wolfgang] Leibniz Inst Prevent Res & Epidemiol BIPS, Bremen, Germany.
   [Ahrens, Wolfgang] Univ Bremen, Inst Stat, Bremen, Germany.
   [Merletti, Franco] Univ Turin, Dept Med Sci, Turin, Italy.
   [Boccia, Stefania] Univ Cattolica Sacro Cuore, Fac Med, Inst Publ Hlth, Sect Hyg, Rome, Italy.
   [Tajara, Eloiza H.] Fac Med Sao Jose do Rio Preto, Dept Mol Biol, Sao Paulo, Brazil.
   [Zevallos, Jose P.; Weissler, Mark C.] Univ North Carolina Chapel Hill, Dept Otolaryngol Head & Neck Surg, Chapel Hill, NC USA.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Wright, Sylvia] Queen Elizabeth Univ Hosp, Dept Pathol, Glasgow, Lanark, Scotland.
   [Cadoni, Gabriella] Univ Cattolica Sacro Cuore, Fdn Policlin A Gemelli, Inst Otorhinolaryngol, Head & Neck Surg Dept, Rome, Italy.
EM gdsouza2@jhu.edu; brennan@iarc.fr
RI Abedi-Ardekani, Behnoush/O-7829-2016; cadoni, gabriella/AAC-8203-2019;
   Toporcov, Tatiana/M-7729-2015; Ahrens, Wolfgang/A-2740-2012
OI Abedi-Ardekani, Behnoush/0000-0002-0980-0587; cadoni,
   gabriella/0000-0002-6239-838X; Mazul, Angela/0000-0002-1249-4613;
   Ahrens, Wolfgang/0000-0003-3777-570X; Conway, David/0000-0001-7762-4063;
   Boccia, Stefania/0000-0002-1864-749X
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01
   CA090731] Funding Source: Medline; NIEHS NIH HHSUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Environmental Health Sciences (NIEHS) [P30
   ES010126] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA090731,
   R01CA090731, R01CA090731, R01CA090731, R01CA090731] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Environmental Health
   Sciences (NIEHS) [P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126] Funding Source: NIH
   RePORTER
CR D'Souza G, 2016, ORAL ONCOL, V62, P20, DOI 10.1016/j.oraloncology.2016.09.005
NR 1
TC 0
Z9 0
U1 1
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1368-8375
EI 1879-0593
J9 ORAL ONCOL
JI Oral Oncol.
PD FEB
PY 2017
VL 65
BP E1
EP E1
DI 10.1016/j.oraloncology.2016.12.023
PG 1
WC Oncology; Dentistry, Oral Surgery & Medicine
SC Oncology; Dentistry, Oral Surgery & Medicine
GA EI6XO
UT WOS:000392641100001
PM 28043765
OA Green Accepted
DA 2020-11-30
ER

PT J
AU Luna, EJ
   Romano, CM
   Araujo, ES
   Levi, JE
   Oliveira, ON
   Fernandes, LR
   Felix, AC
   Souza, NS
   Fernandes, JH
   Campos, SR
   Fragoso, DB
   Pannuti, CS
AF Luna, Expedito J.
   Romano, Camila M.
   Araujo, Evaldo S.
   Levi, Jose E.
   Oliveira, Olimpia N.
   Fernandes, Luis R.
   Felix, Alvina C.
   Souza, Nathalia S.
   Fernandes, Joao H.
   Campos, Sergio R.
   Fragoso, Danielli B.
   Pannuti, Claudio S.
TI A COHORT STUDY TO DETERMINE THE INCIDENCE OF ZIKA VIRUS INFECTION AMONG
   NEWBORNS, SANTOS, BRAZIL, 2016-2017
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 05-09, 2017
CL Baltimore, MD
SP Amer Soc Trop Med & Hyg
C1 [Luna, Expedito J.; Romano, Camila M.; Levi, Jose E.; Felix, Alvina C.; Souza, Nathalia S.; Campos, Sergio R.; Pannuti, Claudio S.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Araujo, Evaldo S.; Oliveira, Olimpia N.; Fernandes, Luis R.; Fernandes, Joao H.; Fragoso, Danielli B.] Hosp Ana Costa, Santos, Brazil.
RI Romano, Camila/ABC-2883-2020; Luna, Expedito J A/B-7948-2012; Romano,
   Camila M/C-8185-2013
OI Romano, Camila/0000-0003-4550-1987; Luna, Expedito J
   A/0000-0002-1145-9672; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2017
VL 97
IS 5
SU S
MA 824
BP 257
EP 258
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FT5TD
UT WOS:000423215203194
DA 2020-11-30
ER

PT J
AU Luna, EJ
   Figueiredo, GM
   Campos, SR
   Levi, JE
   Figueiredo, WM
   Costa, AA
   Felix, AC
   Souza, NS
   Cardoso, MR
   Pannuti, CS
AF Luna, Expedito J.
   Figueiredo, Gerusa M.
   Campos, Sergio R.
   Levi, Jose E.
   Figueiredo, Walter M.
   Costa, Angela A.
   Felix, Alvina C.
   Souza, Nathalia S.
   Cardoso, Maria R.
   Pannuti, Claudio S.
TI ESTIMATING THE UNDERREPORTING OF DENGUE CASES, ARARAQUARA, BRAZIL, 2015
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 05-09, 2017
CL Baltimore, MD
SP Amer Soc Trop Med & Hyg
C1 [Luna, Expedito J.; Figueiredo, Gerusa M.; Campos, Sergio R.; Levi, Jose E.; Felix, Alvina C.; Souza, Nathalia S.; Cardoso, Maria R.; Pannuti, Claudio S.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Figueiredo, Walter M.; Costa, Angela A.] Univ Sao Paulo, Araraquara, Brazil.
RI Figueiredo, Gerusa M/B-6660-2014; Luna, Expedito J A/B-7948-2012
OI Figueiredo, Gerusa M/0000-0001-9657-9675; Luna, Expedito J
   A/0000-0002-1145-9672
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2017
VL 97
IS 5
SU S
MA 1400
BP 435
EP 436
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FT5TD
UT WOS:000423215204116
DA 2020-11-30
ER

PT J
AU Di Santi, SM
   Sanchez, MCA
   Mendrone, A
   Lima, GF
   Rocha, MC
   Costa-Nascimento, MJ
   Fujimori, M
   Levi, JE
AF Di Santi, Silvia M.
   Sanchez, Maria Carmen A.
   Mendrone, Alfredo, Jr.
   Lima, Giselle F.
   Rocha, Mussya C.
   Costa-Nascimento, Maria J.
   Fujimori, Mahyumi
   Levi, Jose E.
TI PREVENTION OF TRANSFUSIONAL MALARIA IN THE STATE OF SAO PAULO BRAZIL
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
CT 66th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene (ASTMH)
CY NOV 05-09, 2017
CL Baltimore, MD
SP Amer Soc Trop Med & Hyg
C1 [Di Santi, Silvia M.; Sanchez, Maria Carmen A.; Lima, Giselle F.; Rocha, Mussya C.; Fujimori, Mahyumi; Levi, Jose E.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Mendrone, Alfredo, Jr.] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Costa-Nascimento, Maria J.] Hlth Secretary Sao Paulo State, Sao Paulo, Brazil.
RI Sanchez, Maria Carmen/D-8886-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2017
VL 97
IS 5
SU S
MA 1636
BP 507
EP 508
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA FT5TD
UT WOS:000423215204351
DA 2020-11-30
ER

PT J
AU Ayres, ARG
   Azevedo e Silva, G
   Teixeira, MTB
   Duque, KDD
   Machado, MLSM
   Gamarra, CJ
   Levi, JE
AF Goncalves Ayres, Andreia Rodrigues
   Azevedo e Silva, Gulnar
   Bustamante Teixeira, Maria Teresa
   Dias Duque, Kristiane de Castro
   Salim Miranda Machado, Maria Lucia
   Gamarra, Carmen Justina
   Levi, Jose Eduardo
TI HPV in women assisted by the Family Health Strategy
SO REVISTA DE SAUDE PUBLICA
LA English
DT Article
DE Papillomaviridae; Prevalence; Mass Screening; Uterine Cervical
   Neoplasms, prevention & control; Family Health Strategy
ID HUMAN-PAPILLOMAVIRUS INFECTION; CERVICAL-CANCER; RISK-FACTORS;
   PREVALENCE SURVEYS; POOLED ANALYSIS; POPULATION; PROGRAM; BRAZIL;
   PREVENTION
AB OBJECTIVE: Estimate the prevalence of cervical HPV infection among women assisted by the Family Health Strategy and identify the factors related to the infection.
   METHODS: A cross-sectional study involving 2,076 women aged 20-59 years old residing in Juiz de Fora, State of Minas Gerais, who were asked to participate in an organized screening carried out in units were the Family Health Strategy had been implemented. Participants answered the standardized questionnaire and underwent a conventional cervical cytology test and HPV test for high oncogenic risk. Estimates of HPV infection prevalence were calculated according to selected characteristics referenced in the literature and related to socioeconomic status, reproductive health and lifestyle.
   RESULTS: The overall prevalence of HPV infection was 12.6% (95% CI 11.16-14.05). The prevalence for the pooled primer contained 12 oncogenic HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) was 8.6% (95% CI 7.3-9.77). In the multivariate analysis, it was observed that the following variables were significantly associated with a higher prevalence of HPV infection: marital status (single: adjusted PR = 1.40, 95% CI 1.07-1.8), alcohol consumption (any lifetime frequency: adjusted PR = 1.44, 95% CI 1.11-1.86) and number of lifetime sexual partners (>= 3: adjusted PR = 1.35, 95% CI 1.04-1.74).
   CONCLUSIONS: The prevalence of HPV infection in the study population ranges from average to particularly high among young women. The prevalence of HPV16 and HPV18 infection is similar to the worldwide prevalence. Homogeneous distribution among the pooled primer types would precede the isolated infection by HPV18 in magnitude, which may be a difference greater than the one observed. The identification of high-risk oncogenic HPV prevalence may help identify women at higher risk of developing preneoplastic lesions.
C1 [Goncalves Ayres, Andreia Rodrigues] Univ Fed Estado Rio de Janeiro, Hosp Univ Gaffree & Guinle, Rio De Janeiro, RJ, Brazil.
   [Azevedo e Silva, Gulnar] Univ Estado Rio de Janeiro, Inst Med Social, Dept Epidemiol, Rio De Janeiro, RJ, Brazil.
   [Bustamante Teixeira, Maria Teresa; Dias Duque, Kristiane de Castro; Salim Miranda Machado, Maria Lucia] Univ Fed Juiz de Fora, Nucl Assessoria Treinamento & Estudos Saude, Juiz De Fora, MG, Brazil.
   [Gamarra, Carmen Justina] Univ Fed Integracao Latino Amer, Fac Saude Colet, Foz Do Iguacu, PR, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop, Lab Virol, Sao Paulo, SP, Brazil.
RP Ayres, ARG (corresponding author), Hosp Univ Gaffree & Guinle, Rua Mariz & Barros 775 Tijuca, BR-20270004 Rio De Janeiro, RJ, Brazil.
EM andreiarg.ayres@unirio.br
FU Universal Edit Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq) [478949/2010-3]
FX Universal Edit Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq - Processo 478949/2010-3).
CR Alibegashvili T, 2011, CANCER EPIDEMIOL, V35, P465, DOI 10.1016/j.canep.2010.12.006
   Ayres Andréia Rodrigues Gonçalves, 2010, Rev. Saúde Pública, V44, P963
   Bardin A, 2008, EUR J CANCER, V44, P557, DOI 10.1016/j.ejca.2007.12.001
   Cuzick J, 2013, BRIT J CANCER, V108, P908, DOI 10.1038/bjc.2013.22
   Damacena GN, 2015, EPIDEMIOL SERV SAUDE, V24, P197, DOI 10.5123/S1679-49742015000200002
   Demir ET, 2012, J MED VIROL, V84, P1242, DOI 10.1002/jmv.23333
   Dondog B, 2008, CANCER EPIDEM BIOMAR, V17, P1731, DOI 10.1158/1055-9965.EPI-07-2796
   Novaes HMD, 2015, VACCINE, V33, pA135, DOI 10.1016/j.vaccine.2014.12.031
   FACINA T., 2014, REV BRASILEIRA CANCE, V60, P63
   Forman D, 2013, CANC INCIDENCE 5 CON, VX
   Girianelli VR, 2014, REV SAUDE PUBL, V48, P459, DOI 10.1590/S0034-8910.2014048005214
   Girianelli VR, 2010, REV BRAS GINECOL OBS, V32, P39, DOI 10.1590/S0100-72032010000100007
   Levi JE, 2014, OJOG, V4, P470, DOI DOI 10.4236/0J0G.2014.48068
   Malta DC, 2013, EPIDEMIOL SERV SAUDE, V22, P151, DOI 10.5123/S1679-49742013000100016
   Marcal JA, 2013, REV ELETRON ACERVO S, V5, P479
   Nunez-Troconis J, 2009, INVEST CLIN, V50, P203
   Pista A, 2012, INT J GYNECOL OBSTET, V118, P112, DOI 10.1016/j.ijgo.2012.03.028
   Rojas IQ, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.578
   Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7
   Sankaranarayanan R, 2014, ANN GLOB HEALTH, V80, P412, DOI 10.1016/j.aogh.2014.09.014
   Sarian LO, 2010, REV BRAS GINECOL OBS, V32, P363, DOI 10.1590/S0100-72032010000800001
   Sherpa ATL, 2010, CANCER CAUSE CONTROL, V21, P323, DOI 10.1007/s10552-009-9467-z
   Shin HR, 2003, INT J CANCER, V103, P413, DOI 10.1002/ijc.10825
   Silva KC, 2009, MEM I OSWALDO CRUZ, V104, P885, DOI 10.1590/S0074-02762009000600011
   Vaccarella S, 2006, CANCER EPIDEM BIOMAR, V15, P326, DOI 10.1158/1055-9965.EPI-05-0577
   Vaccarella S, 2008, INT J EPIDEMIOL, V37, P536, DOI 10.1093/ije/dyn033
   Vaccarella S, 2006, CANCER EPIDEM BIOMAR, V15, P2148, DOI 10.1158/1055-9965.EPI-06-0556
   Vaccarella S, 2013, EUR J CANCER, V49, P3262, DOI 10.1016/j.ejca.2013.04.024
   Wentzensen N, 2013, LANCET ONCOL, V14, P107, DOI 10.1016/S1470-2045(12)70568-5
   WHO/ICO Information Centre on HPV and Cervical Cancer, 2007, Vaccine, V25 Suppl 3, pC1
   Zorzi M, 2013, BJOG-INT J OBSTET GY, V120, P1260, DOI 10.1111/1471-0528.12272
NR 31
TC 3
Z9 3
U1 0
U2 3
PU REVISTA DE SAUDE PUBLICA
PI SAO PAULO
PA FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01246-904SP SAO PAULO,
   BRAZIL
SN 0034-8910
EI 1518-8787
J9 REV SAUDE PUBL
JI Rev. Saude Publica
PY 2017
VL 51
AR 92
DI 10.11606/S1518-8787.2017051000065
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA FJ5BM
UT WOS:000412759600004
PM 29020120
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Da Mota, LD
   Nishiya, AS
   Finger-Jardim, F
   Barral, MFM
   Silva, CM
   Nader, MM
   Goncalves, CV
   Da Hora, VP
   Silveira, J
   Basso, RP
   Soares, MA
   Levi, JE
   Martinez, AMB
AF Da Mota, Luisa Dias
   Nishiya, Anna S.
   Finger-Jardim, Fabiana
   Barral, Maria F. M.
   Silva, Claudio M.
   Nader, Maiba M.
   Goncalves, Carla V.
   Da Hora, Vanusa P.
   Silveira, Jussara
   Basso, Rossana P.
   Soares, Marcelo A.
   Levi, Jose E.
   Martinez, Ana M. B.
TI Prevalence of human pegivirus (HPgV) infection in patients carrying
   HIV-1C or non-C in southern Brazil
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE HPgV; human immunodeficiency virus; HPgV; HIV coinfection; HIV-1 subtype
ID GB-VIRUS-C; HEPATITIS-G VIRUS; C/HEPATITIS-G VIRUS; TRANSMISSION;
   COINFECTION; SURVIVAL; DISEASE; VIREMIA; GLYCOPROTEIN; INDIVIDUALS
AB Previous studies have demonstrated that coinfection with HPgV is a protective factor for human immunodeficiency virus (HIV)-infected patients, leading to slower disease progression, and longer survival after established disease. The present study sought to estimate the prevalence of HPgV infection and associated risk factors in patients harboring C or non-C HIV-1 subtypes followed-up at HU-FURG, southern Brazil. Samples from 347 HIV-1-infected subjects were subjected to plasma RNA extraction, cDNA synthesis, HPgV RNA detection, and HIV-1 genotyping. The overall prevalence of HPgV RNA was 34%. Individuals aged 18-30 years had higher chances of infection compared with those 50 years or older (95%CI 1.18-52.36, P=0.03). The number of sexual partner between one and three was a risk factor for HPgV infection (95%CI 1.54-10.23; P<0.01), as well as the time since diagnosis of HIV-111 years (95%CI 1.01-2.89; P=0.04). Patients infected with HIV non-C subtypes had six times more chance of being HPgV-infected when compared to subtype C-infected subjects (95%CI 2.28-14.78; P<0.01). This was the first study conducted in southern Brazil to find the circulation of HPgV. HIV/HPgV coinfection was associated with a longer survival among HIV+ patients. Of novelty, individuals infected by HIV non-C subtypes were more susceptible to HPgV infection. However, additional studies are needed to correlate the HIV-1 subtypes with HPgV infection and to clarify cellular and molecular pathways through which such associations are ruled. J. Med. Virol 88:2106-2114, 2016. (c) 2016 Wiley Periodicals, Inc.
C1 [Da Mota, Luisa Dias; Finger-Jardim, Fabiana; Barral, Maria F. M.; Silva, Claudio M.; Nader, Maiba M.; Da Hora, Vanusa P.; Silveira, Jussara; Basso, Rossana P.; Martinez, Ana M. B.] Fed Univ Rio Grande, Sch Med, Porto Alegre, RS, Brazil.
   [Nishiya, Anna S.; Levi, Jose E.] Fdn Prosangue, Sao Paulo, Brazil.
   [Soares, Marcelo A.] Natl Canc Inst INCA, Genet Program, Rio De Janeiro, Brazil.
RP Da Mota, LD (corresponding author), FAMED FURG, Lab Biol Mol, Rua Visconde Paranagua 102, BR-96200190 Rio Grande, RS, Brazil.
EM luisadias_sixcp@hotmail.com
RI Nishiya, Anna/Q-8156-2016; Soares, Marcelo A/G-5662-2010; Pousada Da
   Hora, Vanusa/C-3670-2015
FU CAPESCAPES; CNPqNational Council for Scientific and Technological
   Development (CNPq)
FX Grant sponsor: CAPES; Grant sponsor: CNPq
CR Abe K, 2001, JPN J INFECT DIS, V54, P55
   Adams MJ, 2013, ARCH VIROL, V158, P2023, DOI 10.1007/s00705-013-1688-5
   Alcalde R, 2010, VIRUS RES, V151, P148, DOI 10.1016/j.virusres.2010.04.008
   Anggorowati N, 2013, MICROBIOL IMMUNOL, V57, P298, DOI 10.1111/1348-0421.12033
   Barbosa RM, 2008, REV SAUDE PUBL, V42, P1
   Berzsenyi MD, 2006, J INFECT DIS, V194, P407, DOI 10.1086/505716
   Campos AF, 2011, INT J STD AIDS, V22, P209, DOI 10.1258/ijsa.2011.010283
   Chivero ET, 2015, J GEN VIROL, V96, P1521, DOI 10.1099/vir.0.000086
   Martínez Ana Maria Barral de, 2002, Rev. Soc. Bras. Med. Trop., V35, P471, DOI 10.1590/S0037-86822002000500008
   DEINHARDT F, 1967, J EXP MED, V125, P673, DOI 10.1084/jem.125.4.673
   Ernst D, 2014, HIV MED, V15, P245, DOI 10.1111/hiv.12094
   Feng Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021151
   Feucht HH, 1997, J CLIN MICROBIOL, V35, P767, DOI 10.1128/JCM.35.3.767-768.1997
   George SL, 2007, PLOS ONE, V7, P1
   Giret MTM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018407
   Gretch D, 2012, CLIN INFECT DIS, V55, P1020, DOI 10.1093/cid/cis591
   Hemelaar J, 2011, AIDS, V25, P679, DOI 10.1097/QAD.0b013e328342ff93
   Heringlake S, 1998, J INFECT DIS, V177, P1723, DOI 10.1086/517431
   Sanchez-Martin MJ, 2011, J COLLOID INTERF SCI, V360, P124, DOI 10.1016/j.jcis.2011.04.053
   Jung S, 2007, AIDS, V21, P645, DOI 10.1097/QAD.0b013e32803277c7
   Kaye S, 2005, CLIN INFECT DIS, V40, P876, DOI 10.1086/428123
   Lee CK, 2014, J MED VIROL, V86, P737, DOI 10.1002/jmv.23893
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   Mohr EL, 2009, J VIRAL HEPATITIS, V16, P757, DOI 10.1111/j.1365-2893.2009.01194.x
   Nie T, 2011, ANTIVIR THER, V16, P1267, DOI 10.3851/IMP1892
   Nishiya Anna S., 2003, Rev. Inst. Med. trop. S. Paulo, V45, P213, DOI 10.1590/S0036-46652003000400007
   Oliveira LA, 2002, MEM I OSWALDO CRUZ, V97, P953, DOI 10.1590/S0074-02762002000700005
   Pavesi A, 2001, J MOL EVOL, V53, P104, DOI 10.1007/s002390010198
   Quiros-Roldan E, 2002, AIDS, V16, P1430, DOI 10.1097/00002030-200207050-00019
   Ramezani A, 2008, J GASTROINTEST LIVER, V17, P269
   Ramia S, 2004, INT J STD AIDS, V15, P463, DOI 10.1258/0956462041211180
   Ribeiro-dos-Santos G, 2002, EUR J CLIN MICROBIOL, V21, P438, DOI 10.1007/s10096-002-0752-y
   Robertson DL, 2000, SCIENCE, V288, P55, DOI 10.1126/science.288.5463.55d
   Sahni H, 2014, J MED VIROL, V86, P426, DOI 10.1002/jmv.23845
   Schwarze-Zander C, 2006, J INFECT DIS, V194, P410, DOI 10.1086/505713
   Silveira J, 2012, J CLIN VIROL, V54, P36, DOI 10.1016/j.jcv.2012.01.017
   Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017
   Snoeck J, 2005, J VIROL METHODS, V128, P47, DOI 10.1016/j.jviromet.2005.04.001
   Souza AKV, 2012, AIDS RES HUM RETROV, V28, P289
   Stapleton JT, 2013, AIDS, V27, P1829, DOI 10.1097/QAD.0b013e328363089f
   Stapleton JT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050563
   Stapleton JT, 2012, ASSIGNMENT HUMAN SIM
   Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398
   Timmons CL, 2013, J INFECT DIS, V207, P1171, DOI 10.1093/infdis/jit001
   Toyoda H, 1998, J ACQ IMMUN DEF SYND, V17, P209, DOI 10.1097/00042560-199803010-00004
   Vahidnia F, 2012, CLIN INFECT DIS, V55, P1012, DOI 10.1093/cid/cis589
   Williams CF, 2004, NEW ENGL J MED, V350, P981, DOI 10.1056/NEJMoa030107
   Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364
   Xiang JH, 2012, VIROLOGY, V430, P53, DOI 10.1016/j.virol.2012.04.019
   Zhang W, 2006, HIV MED, V7, P173, DOI 10.1111/j.1468-1293.2006.00366.x
NR 50
TC 5
Z9 5
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD DEC
PY 2016
VL 88
IS 12
BP 2106
EP 2114
DI 10.1002/jmv.24574
PG 9
WC Virology
SC Virology
GA DZ3DF
UT WOS:000385724000014
PM 27171504
DA 2020-11-30
ER

PT J
AU Almeida-Nunes, J
   Marcilio, I
   Oliveira, MS
   Goncalves, EMN
   Batista, MV
   Mendrone, A
   Levi, JE
   Costa, SF
   Levin, AS
AF Almeida-Nunes, Juliana
   Marcilio, Izabel
   Oliveira, Maura S.
   Goncalves, Elenice M. N.
   Batista, Marjorie V.
   Mendrone, Alfredo, Jr.
   Levi, Jose E.
   Costa, Silvia F.
   Levin, Anna S.
TI Hospital-Acquired Vector-Transmitted Dengue Fever: An Overlooked
   Problem?
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Editorial Material
ID TRANSMISSION
C1 [Almeida-Nunes, Juliana; Marcilio, Izabel] Univ Sao Paulo, Hosp Surveillance Syst, Hosp Clin, Sao Paulo, Brazil.
   [Oliveira, Maura S.; Batista, Marjorie V.; Levin, Anna S.] Univ Sao Paulo, Infect Control Dept, Hosp Clin, Sao Paulo, Brazil.
   [Oliveira, Maura S.; Batista, Marjorie V.; Levin, Anna S.] Univ Sao Paulo, Hosp Clin, LIM54, Sao Paulo, Brazil.
   [Goncalves, Elenice M. N.] Univ Sao Paulo, Hosp Clin, Internal Commiss Accid Prevent, Sao Paulo, Brazil.
   [Mendrone, Alfredo, Jr.; Levi, Jose E.] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Costa, Silvia F.; Levin, Anna S.] Univ Sao Paulo, Dept Infect Dis, Sao Paulo, Brazil.
   [Costa, Silvia F.; Levin, Anna S.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
RP Levin, AS (corresponding author), Rua Banibas 618, BR-05460010 Sao Paulo, SP, Brazil.
EM gcih.adm@hc.fm.usp.br
RI Levin, Anna S/C-8831-2012; Costa, Silvia F/K-4768-2012; Batista,
   Marjorie V/F-2292-2011
OI Levin, Anna S/0000-0003-2427-8368; Costa, Silvia F/0000-0003-1087-752X;
   Batista, Marjorie V/0000-0003-0717-0873
CR Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Boulos M, 2015, CURRENT DENGUE SETTI
   Chen LH, 2004, CLIN INFECT DIS, V39, pE56, DOI 10.1086/423807
   Honorio NA, 2003, MEM I OSWALDO CRUZ, V98, P191, DOI 10.1590/S0074-02762003000200005
   Lee HI, 2006, J AM MOSQUITO CONTR, V22, P239, DOI 10.2987/8756-971X(2006)22[239:SOFHOC]2.0.CO;2
   Levi JE, 2015, TRANSFUSION, V55, P961, DOI 10.1111/trf.12944
   Morgan C, 2015, TRAVEL MED INFECT DI, V13, P271, DOI 10.1016/j.tmaid.2015.03.016
   Snow GE, 2014, AM J TROP MED HYG, V91, P1203, DOI 10.4269/ajtmh.14-0132
NR 8
TC 3
Z9 3
U1 0
U2 3
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0899-823X
EI 1559-6834
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD NOV
PY 2016
VL 37
IS 11
BP 1387
EP 1389
DI 10.1017/ice.2016.173
PG 3
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA EA2EA
UT WOS:000386404400019
PM 27573650
DA 2020-11-30
ER

PT J
AU D'Souza, G
   Anantharaman, D
   Gheit, T
   Abedi-Ardekani, B
   Beachler, DC
   Conway, DI
   Olshan, AF
   Wunsch, V
   Toporcov, TN
   Ahrens, W
   Wisniewski, K
   Merletti, F
   Boccia, S
   Tajara, EH
   Zevallos, JP
   Levi, JE
   Weissler, MC
   Wright, S
   Scelo, G
   Mazul, AL
   Tommasino, M
   Cadoni, G
   Brennan, P
AF D'Souza, Gypsyamber
   Anantharaman, Devasena
   Gheit, Tarik
   Abedi-Ardekani, Behnoush
   Beachler, Daniel C.
   Conway, David I.
   Olshan, Andrew F.
   Wunsch-Filho, Victor
   Toporcov, Tatiana N.
   Ahrens, Wolfgang
   Wisniewski, Kathy
   Merletti, Franco
   Boccia, Stefania
   Tajara, Eloiza H.
   Zevallos, Jose P.
   Levi, Jose Eduardo
   Weissler, Mark C.
   Wright, Sylvia
   Scelo, Ghislaine
   Mazul, Angela L.
   Tommasino, Massimo
   Cadoni, Gabriella
   Brennan, Paul
TI Effect of HPV on head and neck cancer patient survival, by region and
   tumor site: A comparison of 1362 cases across three continents
SO ORAL ONCOLOGY
LA English
DT Article
DE HPV; P16; Survival; HNSCC; Oral HPV; Non-OP; Prognostic; Risk factors;
   Brazil; Europe
ID SQUAMOUS-CELL CARCINOMA; HUMAN-PAPILLOMAVIRUS INFECTION; OROPHARYNGEAL
   CANCER; PROGNOSTIC-SIGNIFICANCE; METAANALYSIS; PREVALENCE; P16(INK4A);
   BIOMARKERS; SMOKING; EXPRESSION
AB Objectives: To explore whether HPV-related biomarkers predict oropharyngeal squamous cell cancer (OPSCC) survival similarly across different global regions, and to explore their prognostic utility among non-oropharyngeal (non-OP) head and neck cancers.
   Methods: Data from 1362 head and neck SCC (HNSCC) diagnosed 2002-2011 was used from epidemiologic studies in: Brazil (GENCAPO study, n = 388), U.S. (CHANCE study, n = 472), and Europe (ARCAGE study, n = 502). Tumors were centrally tested for p16(INK4a) and HPV16 DNA (by PCR). Risk of mortality was examined using Cox proportional hazard models.
   Results: There were 517 OPSCC and 845 non-OP HNSCC. Cases were primarily male (81%), ever smokers (91%), with median age of 58 years and median follow-up of 3.1 years (IQR = 1.4-5.9). Among OPSCC, the risk of mortality was significantly lower among 184 HPV-related (i.e., p16(+)/HPV16(+)) compared to 333 HPV-unrelated (p16-and/or HPV16-) cases (HR = 0.25, 95% CI = 0.18-0.34). Mortality was reduced among HPV-related OPSCC cases from the U.S., Europe, and Brazil (each p <= 0.01) and after adjustment, remained significantly reduced (aHR = 0.34, 95% CI = 0.24-0.49). Among non-OP HNSCC, neither p16 (aHR = 0.83, 95% CI = 0.60-1.14), HPV16 DNA (aHR = 1.20, 95% CI = 0.89-1.63), or p16+/HPV16+ (aHR = 0.59, 95% CI = 0.32-1.08) was a significantly predictor of mortality. When interaction was tested, the effect of HPV16/p16 was significantly different in OPSCC than non-OP HNSCC (p-interaction = 0.02).
   Conclusion: HPV-related OPSCCs had similar survival benefits across these three regions. Prognostic utility of HPV among non-OP HNSCC is limited so tumor HPV/p16 testing should not be routinely done among non-OP HNSCC. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [D'Souza, Gypsyamber] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Anantharaman, Devasena; Scelo, Ghislaine; Brennan, Paul] Int Agcy Res Canc, Genet Epidemiol Grp, Lyon, France.
   [Gheit, Tarik; Tommasino, Massimo] Int Agcy Res Canc, Infect & Canc Biol Grp, Lyon, France.
   [Abedi-Ardekani, Behnoush] Int Agcy Res Canc, Genet Canc Susceptibil Grp, Lyon, France.
   [Beachler, Daniel C.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
   [Conway, David I.] Univ Glasgow, Sch Med Dent & Nursing, Glasgow, Lanark, Scotland.
   [Olshan, Andrew F.; Wisniewski, Kathy; Mazul, Angela L.] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC USA.
   [Wunsch-Filho, Victor; Toporcov, Tatiana N.] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Ahrens, Wolfgang] Leibniz Inst Prevent Res & Epidemiol BIPS, Bremen, Germany.
   [Ahrens, Wolfgang] Univ Bremen, Inst Stat, Bremen, Germany.
   [Merletti, Franco] Univ Turin, Dept Med Sci, Turin, Italy.
   [Boccia, Stefania] Univ Cattolica Sacro Cuore, Fac Med, Inst Publ Hlth, Sect Hyg, Rome, Italy.
   [Tajara, Eloiza H.] Fac Med Sao Jose Rio Preto, Dept Mol Biol, Rome, Italy.
   [Zevallos, Jose P.; Weissler, Mark C.] Univ North Carolina Chapel Hill, Dept Otolaryngol Head & Neck Surg, Chapel Hill, NC USA.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Wright, Sylvia] Queen Elizabeth Univ Hosp, Dept Pathol, Glasgow, Lanark, Scotland.
   [Cadoni, Gabriella] Univ Cattolica Sacro Cuore, Fdn Policlin A Gemelli, Inst Otorhinolaryngol, Head & Neck Surg Dept, Rome, Italy.
RP D'Souza, G (corresponding author), Johns Hopkins Sch Publ Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.; Brennan, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon 08, France.
EM gdsouza2@jhu.edu; brennan@iarc.fr
RI Abedi-Ardekani, Behnoush/O-7829-2016; Mazul, Angela/J-8357-2019; cadoni,
   gabriella/AAC-8203-2019; Filho, Victor Wunsch/C-4475-2012; Toporcov,
   Tatiana/M-7729-2015; Ahrens, Wolfgang/A-2740-2012
OI Abedi-Ardekani, Behnoush/0000-0002-0980-0587; Mazul,
   Angela/0000-0002-1249-4613; cadoni, gabriella/0000-0002-6239-838X;
   Boccia, Stefania/0000-0002-1864-749X; Conway, David/0000-0001-7762-4063;
   Ahrens, Wolfgang/0000-0003-3777-570X
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); European Framework Programs; French Health Ministry;
   Italian AIRCAssociazione Italiana per la Ricerca sul Cancro (AIRC);
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, R01CA090731,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, R01CA090731, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, R01CA090731, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, R01CA090731, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   R01CA090731, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086,
   P30CA016086, P30CA016086, P30CA016086, P30CA016086, P30CA016086] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Environmental
   Health Sciences (NIEHS) [P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126, P30ES010126, P30ES010126, P30ES010126, P30ES010126,
   P30ES010126] Funding Source: NIH RePORTER
FX This work was support by FAPESP, National Cancer Institute, European
   Framework Programs, French Health Ministry, and Italian AIRC.
CR Amini A, 2016, ORAL ONCOL, V56, P1, DOI 10.1016/j.oraloncology.2016.02.011
   Anantharaman D, GEOGRAPHIC IN PRESS
   Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217
   Castellsague X, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv403
   Chaturvedi AK, 2013, J CLIN ONCOL, V31, P4550, DOI 10.1200/JCO.2013.50.3870
   Chung CH, 2014, J CLIN ONCOL, V32, P3930, DOI 10.1200/JCO.2013.54.5228
   Dahlstrom KR, 2016, J CLIN ONCOL, V34, P1848, DOI 10.1200/JCO.2015.64.6448
   Dalianis T, 2015, ORAL ONCOL, V51, P857, DOI 10.1016/j.oraloncology.2015.06.002
   Dalianis T, 2014, INT J ONCOL, V44, P1799, DOI 10.3892/ijo.2014.2355
   Evans M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-220
   Granata R, 2012, ANN ONCOL, V23, P1832, DOI 10.1093/annonc/mdr544
   Huang SH, 2015, J CLIN ONCOL, V33, P836, DOI 10.1200/JCO.2014.58.6412
   Lagiou P, 2009, EUR J CANCER PREV, V18, P76, DOI 10.1097/CEJ.0b013e32830c8dca
   Lassen P, 2014, RADIOTHER ONCOL, V113, P310, DOI 10.1016/j.radonc.2014.11.032
   Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6
   Masterson L, 2014, EUR J CANCER, V50, P2636, DOI 10.1016/j.ejca.2014.07.001
   Lopez RVM, 2014, CANCER CAUSE CONTROL, V25, P461, DOI 10.1007/s10552-014-0348-8
   Moyses RA, 2013, CLINICS, V68, P738, DOI 10.6061/clinics/2013(06)03
   Ragin CCR, 2007, INT J CANCER, V121, P1813, DOI 10.1002/ijc.22851
   Rainsbury JW, 2013, HEAD NECK-J SCI SPEC, V35, P1048, DOI 10.1002/hed.22950
   Ribeiro KB, 2011, INT J EPIDEMIOL, V40, P489, DOI 10.1093/ije/dyq249
   Rischin D, 2010, J CLIN ONCOL, V28, P4142, DOI 10.1200/JCO.2010.29.2904
   Rosenthal DI, 2015, J CLIN ONCOL
   Schmitt M, 2006, J CLIN MICROBIOL, V44, P504, DOI 10.1128/JCM.44.2.504-512.2006
   Schmitt M, 2010, J CLIN MICROBIOL, V48, P143, DOI 10.1128/JCM.00991-09
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wyss AB, 2013, CANCER EPIDEM BIOMAR, V22, P1428, DOI 10.1158/1055-9965.EPI-13-0185
   Young RJ, 2015, BRIT J CANCER, V112, P1098, DOI 10.1038/bjc.2015.59
NR 28
TC 39
Z9 39
U1 2
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1368-8375
EI 1879-0593
J9 ORAL ONCOL
JI Oral Oncol.
PD NOV
PY 2016
VL 62
BP 20
EP 27
DI 10.1016/j.oraloncology.2016.09.005
PG 8
WC Oncology; Dentistry, Oral Surgery & Medicine
SC Oncology; Dentistry, Oral Surgery & Medicine
GA EI6VL
UT WOS:000392635300006
PM 27865368
OA Green Accepted
DA 2020-11-30
ER

PT J
AU Mariano, VS
   Lorenzi, AT
   Scapulatempo, C
   Stein, MD
   Resende, JCP
   Antoniazzi, M
   Villa, LL
   Levi, JE
   Longatto, A
   Fregnani, JHTG
AF Mariano, Vania Sammartino
   Lorenzi, Adriana Tarla
   Scapulatempo-Neto, Cristovam
   Stein, Maira Degiovani
   Possati Resende, Julio Cesar
   Antoniazzi, Marcio
   Villa, Luisa Lina
   Levi, Jose Eduardo
   Longatto-Filho, Adhemar
   Tavares Guerreiro Fregnani, Jose Humberto
TI A Low-Cost HPV Immunochromatographic Assay to Detect High-Grade Cervical
   Intraepithelial Neoplasia
SO PLOS ONE
LA English
DT Article
ID HUMAN-PAPILLOMAVIRUS E6; E6/E7 MESSENGER-RNA; RURAL CHINA; DNA TEST;
   CANCER; WOMEN; CYTOLOGY; TESTS; RISK; MANAGEMENT
AB Objective
   To evaluate the reproducibility and accuracy of the HPV16/18-E6 test.
   Methods
   The study population was comprised of 448 women with a previously abnormal Pap who were referred to the Barretos Cancer Hospital (Brazil) for diagnosis and treatment. Two cervical samples were collected immediately before colposcopy, one for the hr-HPV-DNA test and cytology and the other for the HPV16/18-E6 test using high-affinity monoclonal antibodies (mAb). Women with a histologic diagnosis of cervical intraepithelial neoplasia grade 2 or 3 were considered to be positive cases. Different strategies using a combination of screening methods (HPV-DNA) and triage tests (cytology and HPV16/18-E6) were also examined and compared.
   Results
   The HPV16/18-E6 test exhibited a lower positivity rate compared with the HPV-DNA test (19.0% vs. 29.3%, p<0.001) and a moderate/high agreement (kappa = 0.68, 95% CI: 0.60-0.75). It also exhibited a significantly lower sensitivity for CIN2+ and CIN3+ detection compared to the HPV-DNA test and a significantly higher specificity. The HPV16/18-E6 test was no different from cytology in terms of sensitivity, but it exhibited a significantly higher specificity in comparison to ASCH+. A triage test after HPV-DNA detection using the HPV16/18-E6 test exhibited a significantly higher specificity compared with a triage test of ASCH+ to CIN2+ (91.8% vs. 87.4%, p = 0.04) and CIN3+ (88.6% vs. 84.0%, p = 0.05).
   Conclusion
   The HPV16/18-E6 test exhibited moderate/high agreement with the HPV-DNA test but lower sensitivity and higher specificity for the detection of CIN2+ and CIN3+. In addition, its performance was quite similar to cytology, but because of the structural design addressed for the detection of HPV16/18-E6 protein, the test can miss some CIN2/3+ lesions caused by other high-risk HPV types.
C1 [Mariano, Vania Sammartino; Lorenzi, Adriana Tarla; Longatto-Filho, Adhemar; Tavares Guerreiro Fregnani, Jose Humberto] Barretos Canc Hosp, Pio Fdn 12, Mol Oncol Res Ctr, Sao Paulo, Brazil.
   [Scapulatempo-Neto, Cristovam; Stein, Maira Degiovani] Barretos Canc Hosp, Pio Fdn 12, Dept Pathol, Sao Paulo, Brazil.
   [Possati Resende, Julio Cesar; Antoniazzi, Marcio] Barretos Canc Hosp, Pio Fdn 12, Canc Prevent Dept, Sao Paulo, Brazil.
   [Villa, Luisa Lina] Univ Sao Paulo, Fac Med, Dept Radiol & Oncol, Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, LIM 52, Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] Univ Sao Paulo, Lab Med Res Lab, Dept Pathol, Fac Med, LIM 14, Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal.
   [Longatto-Filho, Adhemar] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal.
RP Fregnani, JHTG (corresponding author), Barretos Canc Hosp, Pio Fdn 12, Mol Oncol Res Ctr, Sao Paulo, Brazil.
EM mdfregnani@terra.com.br
RI Longatto-Filho, Adhemar/N-3397-2019; Fregnani, Jose H/H-4238-2012;
   Mariano, Vania Sammartino/AAV-1851-2020; VILLA, LUISA/AAH-4761-2019;
   Mariano, Vania/O-1133-2016; longatto-filho, adhemar/D-7039-2013;
   Possati-Resende, Julio Cesar/C-8575-2016
OI Longatto-Filho, Adhemar/0000-0002-5779-9752; Fregnani, Jose
   H/0000-0002-5235-6469; Mariano, Vania Sammartino/0000-0002-5399-5676;
   VILLA, LUISA/0000-0003-4074-2335; longatto-filho,
   adhemar/0000-0002-5779-9752; Possati-Resende, Julio
   Cesar/0000-0002-7869-3885; Scapulatempo-Neto,
   Cristovam/0000-0002-8920-6579
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/51221-4,
   2008/57889-1]; CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico)National Council for Scientific and Technological
   Development (CNPq) [573799/2008-3]; CNPqNational Council for Scientific
   and Technological Development (CNPq) [573799/2008-3]; FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2008/57889-1]
FX FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo to JHGF
   2012/51221-4 and to LLV - 2008/57889-1, for HPV-DNA tests-Cobas test)
   and CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   to LLV - 573799/2008-3). Arbor Vita Corporation donated all OncoE6 tests
   and no role in decision to publish.; The authors would like to thank the
   following organizations: the Cancer Prevention Department, Center for
   the Researcher Support and Pathology Department of the Barretos Cancer
   Hospital. They would also like to thank Monique Ferreira Amendola and
   Ursula Moraes Leme for their technical laboratorial support. This study
   was supported by CNPq 573799/2008-3 and FAPESP 2008/57889-1.
CR [Anonymous], 2005, IARC HDB CANC PREV C, V10
   Benevolo M, 2011, CANCER CAUSE CONTROL, V22, P869, DOI 10.1007/s10552-011-9757-0
   Blumenthal PD, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2006.12.031
   Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
   Cattani P, 2009, J CLIN MICROBIOL, V47, P3895, DOI 10.1128/JCM.01275-09
   Cox JT, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.11.020
   Cronin AM, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-75
   Cubie HA, 2013, CYTOPATHOLOGY, V24, P289, DOI 10.1111/cyt.12083
   Cuzick J, 2013, BRIT J CANCER, V108, P908, DOI 10.1038/bjc.2013.22
   Cuzick J, 2015, INT J CANCER, V136, P2854, DOI 10.1002/ijc.29337
   Cuzick J, 2012, VACCINE, V30, pF107, DOI 10.1016/j.vaccine.2012.05.088
   Resende LSDA, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-214
   de Oliveira CM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-357
   de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Ganguly N, 2009, J BIOSCIENCES, V34, P113, DOI 10.1007/s12038-009-0013-7
   Halfon P, 2010, J CLIN VIROL, V47, P177, DOI 10.1016/j.jcv.2009.11.011
   IARC IAfRoC, 2005, IARC HDB CANC PREV C
   Jeantet D, 2009, J CLIN VIROL, V45, pS29, DOI 10.1016/S1386-6532(09)70006-X
   Kitchener HC, 2006, VACCINE, V24, P63, DOI 10.1016/j.vaccine.2006.05.113
   Litjens Rogier J N T M, 2013, Expert Opin Med Diagn, V7, P365, DOI 10.1517/17530059.2013.808621
   Longatto-Filho A, 2007, DIAGN CYTOPATHOL, V35, P672, DOI 10.1002/dc.20700
   Lorenzi AT, 2013, GYNECOL ONCOL, V131, P131, DOI 10.1016/j.ygyno.2013.07.092
   McCredie MRE, 2008, LANCET ONCOL, V9, P425, DOI 10.1016/S1470-2045(08)70103-7
   Molden T, 2005, CANCER EPIDEM BIOMAR, V14, P367, DOI 10.1158/1055-9965.EPI-04-0410
   Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004
   Munkhdelger J, 2014, DIAGN MICR INFEC DIS, V79, P422, DOI 10.1016/j.diagmicrobio.2014.04.004
   Naucler P, 2007, NEW ENGL J MED, V357, P1589, DOI 10.1056/NEJMoa073204
   Ntekim A, 2015, CANC MED
   Oliveira A, 2013, J MED VIROL, V85, P1235, DOI 10.1002/jmv.23590
   Castro SP, 2013, J MED VIROL, V85, P1063, DOI 10.1002/jmv.23544
   Qiao YL, 2008, LANCET ONCOL, V9, P929, DOI 10.1016/S1470-2045(08)70210-9
   Qiao YL, 2014, INT J CANCER, V134, P2891, DOI 10.1002/ijc.28616
   Rossi PG, 2012, AM J CLIN PATHOL, V138, P65, DOI 10.1309/AJCP6J2OEFOYTRFD
   Ruttkay-Nedecky B, 2013, INT J ONCOL, V43, P1754, DOI 10.3892/ijo.2013.2105
   Sankaranarayanan R, 2001, B WORLD HEALTH ORGAN, V79, P954
   Schiffman M, 2011, JNCI-J NATL CANCER I, V103, P368, DOI 10.1093/jnci/djq562
   Schweizer J, 2010, J CLIN MICROBIOL, V48, P4646, DOI 10.1128/JCM.01315-10
   Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114
   Sotlar K, 2004, J MED VIROL, V74, P107, DOI 10.1002/jmv.20153
   Wechsler EI, 2012, J VIROL, V86, P6358, DOI 10.1128/JVI.07069-11
   WHO/ICO Information Centre on HPV and Cervical Cancer, 2007, Vaccine, V25 Suppl 3, pC1
   Yim Eun-Kyoung, 2005, Cancer Res Treat, V37, P319, DOI 10.4143/crt.2005.37.6.319
   Zhao FH, 2013, CANCER PREV RES, V6, P938, DOI 10.1158/1940-6207.CAPR-13-0091
   Zhao FH, 2012, J NATL CANCER I, V104, P178, DOI 10.1093/jnci/djr532
NR 47
TC 7
Z9 7
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 20
PY 2016
VL 11
IS 10
AR e0164892
DI 10.1371/journal.pone.0164892
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DZ9NZ
UT WOS:000386204500077
PM 27764154
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Genta, MLND
   Levi, JE
   Martins, TR
   Sadalla, JC
   Lopez, RVM
   Carvalho, JPM
   Carvalho, JP
AF Genta, M. L. N. D.
   Levi, J. E.
   Martins, T. R.
   Sadalla, J. C.
   Lopez, R. V. M.
   Carvalho, J. P. M.
   Carvalho, J. P.
TI Human papillomavirus 16 is an independent predictor of better survival
   among patients with early cervical cancer
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
LA English
DT Meeting Abstract
C1 [Genta, M. L. N. D.; Sadalla, J. C.; Carvalho, J. P. M.; Carvalho, J. P.] ICESP, Gynecol Oncol, Sao Paulo, Brazil.
   [Levi, J. E.; Martins, T. R.] IMT, Virol, Sao Paulo, Brazil.
   [Lopez, R. V. M.] ICESP, Epiddemiol, Sao Paulo, Brazil.
RI CARVALHO, JESUS PAULA/G-8387-2018; Carvalho, Jesus Paula/O-7464-2019
OI CARVALHO, JESUS PAULA/0000-0003-4495-057X; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1048-891X
EI 1525-1438
J9 INT J GYNECOL CANCER
JI Int. J. Gynecol. Cancer
PD OCT
PY 2016
VL 26
SU 3
MA IGCS-1038
BP 345
EP 345
PG 1
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA EB1KD
UT WOS:000387109100288
DA 2020-11-30
ER

PT J
AU Costa, DC
   Dezan, M
   Santos, T
   Schinaider, AA
   Schorner, EJ
   Levi, JE
   Santos-Silva, MC
AF Costa, D. C.
   Dezan, M.
   Santos, T.
   Schinaider, A. A.
   Schorner, E. J.
   Levi, J. E.
   Santos-Silva, M. C.
TI Screening for the SMIM1*64_80 del Allele in blood donors in a population
   from Southern Brazil
SO TRANSFUSION MEDICINE
LA English
DT Article
DE blood groups; donors; genotyping; transfusion
AB Background and ObjectivesSerological screening for the Vel- phenotype is complex given the large individual variation in the levels of expression of the Vel antigen, and the polyclonal anti-human sera of immunised persons, when available, show heterogeneous reactivity levels. Studies of the SMIM1 gene have enabled the development of several molecular methodologies that will be crucially important for the screening of different populations, including Brazilians. To evaluate the deletion of 17 bp in the SMIM1 gene in a population from the south of Brazil, 448 unrelated blood donors from 7 regions comprising the haemotherapy network in the state of Santa Catarina were evaluated between August 2011 and March 2014.
   Materials and MethodsDNA samples from these donors were analysed employing a 5 nuclease real-time polymerase chain reaction (PCR) assay targeting the 17 bp deletion in the SMIM1 gene.
   ResultsAmong the 448 samples analysed, 10 (223%) harboured the 17 bp deletion of the gene SMIM1, and all were heterozygote for the SMIM1*64_80 del allele.
   ConclusionThe allelic frequency found differed from those observed in other Caucasian populations. This difference can be explained by the ethnic make-up of each Caucasian population. The data obtained are important to characterise the correct phenotype of the donor as the serological assay results are not reliable due to variations in the expression intensity of the Vel antigen in heterozygote donors for the SMIM1*64_80 del allele. Moreover, the tool used in this study is of great value for identifying a donor Vel- phenotype and supplying a possible need for transfusion.
C1 [Costa, D. C.] Univ Fed Santa Catarina, Grad Program Pharm, Florianopolis, SC, Brazil.
   [Dezan, M.; Levi, J. E.] Fundacao Prosangue Hemoctr Sao Paulo, Rua Dr Eneas Carvalho Aguiar, Sao Paulo, Brazil.
   [Santos, T.; Schinaider, A. A.; Santos-Silva, M. C.] Univ Fed Santa Catarina, Dept Clin Anal, Florianopolis, SC, Brazil.
   [Schorner, E. J.] HEMOSC, Immunohematol Lab, Santa Catarina Blood Bank, Ave Prof Othon Gama DEca, Florianopolis, SC, Brazil.
RP Santos-Silva, MC (corresponding author), Univ Fed Santa Catarina, Dept Clin Anal, Ctr Healthcare Sci, Campus Trindade, BR-88040000 Florianopolis, SC, Brazil.
EM maclau@ccs.ufsc.br
OI DEZAN, MARCIA REGINA/0000-0002-3760-9843
FU Capes - Coordenacao de Aperfeicoamento de Pessoal de Nivel
   SuperiorCAPES; Graduate Program in Pharmacy from the Federal University
   of Santa Catarina
FX We acknowledge and thank the Laboratory of Molecular Biology and
   Mycobacteria (Maria Luiza Bazzo, PhD UFSC, Department of Clinical
   Analyses) for the technical support. This research was supported by a
   scholarship for D. C. C. from Capes - Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (www.capes.gov.br). This study was done with
   partial financial support by the Graduate Program in Pharmacy from the
   Federal University of Santa Catarina. D. C. C. defined the study,
   collected and analysed the data and wrote the manuscript. J. E. L. and
   M. D analysed the data, reviewed the manuscript and provided technical
   support. A. A. S. and T. S. performed the laboratory experiments. E. J.
   S. defined the study and provided technical support. M. C. S.-S. defined
   the study, collected and analysed the data and reviewed the manuscript.
   All authors approved the final version of the article, including the
   authorship list.
CR Ballif BA, 2013, EMBO MOL MED, V5, P751, DOI 10.1002/emmm.201302466
   Carvalho-Silva DR, 2001, AM J HUM GENET, V68, P281, DOI 10.1086/316931
   Cvejic A, 2013, NAT GENET, V45, P542, DOI 10.1038/ng.2603
   Daniels G, 2013, HUMAN BLOOD GROUPS
   Manta FSD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075145
   Dezan MR, 2016, TRANSFUSION, V56, P1430, DOI 10.1111/trf.13572
   Dinardo C L, 2014, Immunohematology, V30, P1
   Guelsin G. A., 2010, REV BRAS HEMATOL HEM, V33, P21
   Haer-Wigman L, 2015, TRANSFUSION, V55, P1457, DOI 10.1111/trf.13014
   Linz W J, 2010, Immunohematology, V26, P8
   Nance ST, 2009, CURR OPIN HEMATOL, V16, P503, DOI 10.1097/MOH.0b013e3283316bed
   Parra FC, 2003, P NATL ACAD SCI USA, V100, P177, DOI 10.1073/pnas.0126614100
   Reid M.E, 2012, BLOOD GROUP ANTIGEN
   Reid ME, 2011, TRANSFUS APHER SCI, V44, P65, DOI 10.1016/j.transci.2010.12.011
   Reid ME, 2003, TRANSFUSION, V43, P1748, DOI 10.1111/j.0041-1132.2003.00597.x
   Storry JR, 2014, ISBT SCI SER, V9, P136, DOI 10.1111/voxs.12078
   Storry JR, 2013, NAT GENET, V45, P537, DOI 10.1038/ng.2600
   SUSSMAN L N, 1952, Rev Hematol, V7, P368
   van Gammeren AJ, 2008, TRANSFUSION MED, V18, P197, DOI 10.1111/j.1365-3148.2008.00863.x
   Wieckhusen C, 2015, TRANSFUS MED HEMOTH, V42, P356, DOI 10.1159/000440791
NR 20
TC 1
Z9 1
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0958-7578
EI 1365-3148
J9 TRANSFUSION MED
JI Transfus. Med.
PD OCT
PY 2016
VL 26
IS 5
BP 355
EP 359
DI 10.1111/tme.12328
PG 5
WC Hematology
SC Hematology
GA EA6SF
UT WOS:000386758500006
PM 27328373
DA 2020-11-30
ER

PT J
AU Bidinotto, LT
   Veo, CAR
   Loaiza, EA
   De Franca, APS
   Lorenzi, AT
   Rosa, LAR
   De Oliveira, CM
   Levi, JE
   Scapulatempo-Neto, C
   Longatto, A
   Reis, RM
AF Bidinotto, Lucas Tadeu
   Veo, Carlos A. R.
   Loaiza, Edgar Aleman
   Santos De Franca, Alessandra Paulino
   Lorenzi, Adriana Tarla
   Reis Rosa, Luciana Albina
   De Oliveira, Cristina Mendes
   Levi, Jose Eduardo
   Scapulatempo-Neto, Cristovam
   Longatto-Filho, Adhemar
   Reis, Rui Manuel
TI Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE anal cancer; squamous cell carcinoma; adenocarcinoma; high-grade
   squamous intra-epithelial lesion; KRAS; BRAF
ID SQUAMOUS-CELL CARCINOMA; HUMAN-PAPILLOMAVIRUS; EGFR; ANUS; EXPRESSION;
   INFECTION; RADIATION
AB Anal cancer is a rare type of digestive tract disease, which has had a crescent incidence in a number of regions. Carcinomas are most frequently found, with squamous cell carcinoma (SCC) comprising similar to 95% of all anal tumors. The major risk factor for development of this type of tumor is human papillomavirus (HPV) infection. However, previous studies have identified patients with anal cancer that are HPV-/p16-and observed that they have a poorer outcome compared with HPV+/p16+ patients. This suggests that molecular profile may drive anal cancer progression. The aim of the present study was to evaluate the mutational status of two important oncogenes, KRAS and BRAF, in a series of anal cancer lesions. Resected tumors of the anal canal (n=43) were evaluated, nine of these were high-grade squamous intra-epithelial lesion cases (HSIL), 11 were adenocarcinomas, and 23 SCCs. Direct sequencing of KRAS proto-oncogene, GTPase (KRAS; codons 12 and 13) and B-Raf proto-oncogene, serine/threonine kinase (BRAF; codon 600) was performed and associated with patient clinicopathological and molecular features. There was a trend of poorer prognosis of adenocarcinoma compared with HSIL and SCC. Analysis indicated one SCC patient (2.3%) exhibited a KRAS p.G13D mutation, and one adenocarcinoma patient (2.3%) exhibited a BRAF p.V600E mutation. It was observed that, these mutations are rare in anal tumors, and certain patients may be at a disadvantage using targeted therapies based on KRAS and BRAF mutational status. As there is a low mutation percentage in SCCs, adenocarcinomas and HSIL, there may exist other underlying molecular alterations that result in anal cancer development, which require further elucidation.
C1 [Bidinotto, Lucas Tadeu; Veo, Carlos A. R.; Loaiza, Edgar Aleman; Santos De Franca, Alessandra Paulino; Lorenzi, Adriana Tarla; Scapulatempo-Neto, Cristovam; Longatto-Filho, Adhemar; Reis, Rui Manuel] Barretos Canc Hosp, Mol Oncol Res Ctr, 1331 Rua Antenor Duarte Villela, BR-14784400 Sao Paulo, Brazil.
   [Bidinotto, Lucas Tadeu] Dr Paulo Prata FACISB, Barretos Sch Hlth Sci, BR-14785002 Sao Paulo, Brazil.
   [Reis Rosa, Luciana Albina; De Oliveira, Cristina Mendes; Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, BR-05403000 Sao Paulo, Brazil.
   [Scapulatempo-Neto, Cristovam] Barretos Canc Hosp, Dept Pathol, BR-14784400 Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar; Reis, Rui Manuel] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Hlth Sci, P-4710057 Braga, Portugal.
   [Longatto-Filho, Adhemar; Reis, Rui Manuel] ICVS 3Bs PT Govt Associate Lab, P-4710057 Braga, Portugal.
RP Reis, RM (corresponding author), Barretos Canc Hosp, Mol Oncol Res Ctr, 1331 Rua Antenor Duarte Villela, BR-14784400 Sao Paulo, Brazil.
EM ruireis.hcb@gmail.com
RI longatto-filho, adhemar/D-7039-2013; Reis, Rui/AAD-6470-2020; Reis, Rui
   Manuel/B-1744-2018; Oliveira, Cristina M/F-7193-2012; Longatto-Filho,
   Adhemar/N-3397-2019; Bidinotto, Lucas/D-3625-2012
OI longatto-filho, adhemar/0000-0002-5779-9752; Reis,
   Rui/0000-0002-9639-7940; Reis, Rui Manuel/0000-0002-9639-7940;
   Longatto-Filho, Adhemar/0000-0002-5779-9752; Bidinotto,
   Lucas/0000-0002-6909-8347; Scapulatempo-Neto,
   Cristovam/0000-0002-8920-6579
FU Sao Paulo Research FoundationFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2010/16795-4, 2011/08523-7]; Ministerio da Ciencia e
   Tecnologia/Financiadora de Estudos e Projetos [CT-INFRA-PROINFRA
   01/2011]
FX The present study was partially supported by the Sao Paulo Research
   Foundation (grant no. 2010/16795-4 to Dr Adhemar Longatto-Filho) and the
   Ministerio da Ciencia e Tecnologia/Financiadora de Estudos e Projetos
   (grant no. CT-INFRA-PROINFRA 01/2011). Dr Lucas Tadeu Bidinotto received
   a Sao Paulo Research Foundation fellowship (grant no. 2011/08523-7).
CR Bartelink H, 1997, J CLIN ONCOL, V15, P2040, DOI 10.1200/JCO.1997.15.5.2040
   Bosman FT, 2010, WHO CLASSIFICATION T
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   DEANS GT, 1994, BRIT J SURG, V81, P500, DOI 10.1002/bjs.1800810405
   Doorbar J, 2006, CLIN SCI, V110, P525, DOI 10.1042/CS20050369
   El-Deiry WS, 2015, CANCER BIOL THER, V16, P1726, DOI 10.1080/15384047.2015.1113356
   Ferreira CG, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-73
   Franceschi S, 2009, CURR OPIN HIV AIDS, V4, P57, DOI 10.1097/COH.0b013e32831b9c81
   Franklin RA, 2016, CLIN COLORECTAL CANC, V15, P47, DOI 10.1016/j.clcc.2015.07.007
   Gardini AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092071
   Gilbert DC, 2013, RADIOTHER ONCOL, V109, P146, DOI 10.1016/j.radonc.2013.08.002
   Lampejo T, 2010, BRIT J CANCER, V103, P1858, DOI 10.1038/sj.bjc.6605984
   Leonard Daniel, 2011, Clin Colon Rectal Surg, V24, P54, DOI 10.1055/s-0031-1272824
   Lukan N, 2009, ONCOLOGY-BASEL, V77, P293, DOI 10.1159/000259615
   Mai S, 2015, INT J RADIAT ONCOL, V93, P819, DOI 10.1016/j.ijrobp.2015.08.004
   Martin V, 2014, HISTOL HISTOPATHOL, V29, P513, DOI 10.14670/HH-29.10.513
   Matalon SA, 2015, RADIOGRAPHICS, V35, P2091, DOI 10.1148/rg.2015150037
   Meulendijks D, 2015, BRIT J CANCER, V112, P1358, DOI 10.1038/bjc.2015.20
   Okumura S, 2014, CLIN CANCER RES, V20, P4193, DOI 10.1158/1078-0432.CCR-13-2365
   Paliga A, 2012, BRIT J CANCER, V107, P1864, DOI 10.1038/bjc.2012.479
   Prigge ES, 2014, HUM PATHOL, V45, P2347, DOI 10.1016/j.humpath.2014.08.001
   Rousseau DL, 2005, SURG ONCOL, V14, P121, DOI 10.1016/j.suronc.2005.07.002
   Scapulatempo-Neto C, 2016, ONCOL LETT
   Serup-Hansen E, 2015, APMIS, V123, P53, DOI 10.1111/apm.12306
   Serup-Hansen E, 2014, J CLIN ONCOL, V32, P1812, DOI 10.1200/JCO.2013.52.3464
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208]
   Smaglo BG, 2015, ONCOTARGET, V6, P43594, DOI 10.18632/oncotarget.6202
   Tan C, 2012, WORLD J GASTROENTERO, V18, P5171, DOI 10.3748/wjg.v18.i37.5171
   Veo CAR, 2015, TUMOR BIOL, V36, P5399, DOI 10.1007/s13277-015-3205-9
   Yamane LS, 2014, ONCOL REP, V32, P1419, DOI 10.3892/or.2014.3338
NR 31
TC 1
Z9 1
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD OCT
PY 2016
VL 14
IS 4
BP 3791
EP 3797
DI 10.3892/mmr.2016.5684
PG 7
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA DZ1ED
UT WOS:000385580800120
PM 27573925
OA Bronze
DA 2020-11-30
ER

PT J
AU Benvenuti, LA
   Roggerio, A
   Cavalcanti, MM
   Nishyia, A
   Levi, JE
AF Benvenuti, L. A.
   Roggerio, A.
   Cavalcanti, M. M.
   Nishyia, A.
   Levi, J. E.
TI An autopsy-based study of Trypanosoma cruzi persistence in chronic
   chagasic patients
SO VIRCHOWS ARCHIV
LA English
DT Meeting Abstract
C1 [Benvenuti, L. A.] Heart Inst InCor, Dept Pathol, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0945-6317
EI 1432-2307
J9 VIRCHOWS ARCH
JI Virchows Arch.
PD SEP
PY 2016
VL 469
SU 1
MA OFP-10-003
BP S28
EP S28
PG 1
WC Pathology
SC Pathology
GA ED1OJ
UT WOS:000388614500115
DA 2020-11-30
ER

PT J
AU Martins, TR
   de Oliveira, CM
   Rosa, LR
   Centrone, CD
   Rodrigues, CLR
   Villa, LL
   Levi, JE
AF Martins, Toni Ricardo
   de Oliveira, Cristina Mendes
   Rosa, Luciana Reis
   Centrone, Cristiane de Campos
   Regina Rodrigues, Celia Luiza
   Villa, Luisa Lina
   Levi, Jose Eduardo
TI HPV genotype distribution in Brazilian women with and without cervical
   lesions: correlation to cytological data
SO VIROLOGY JOURNAL
LA English
DT Article
DE Cervical Cancer; Cytology; HPV; HPV types; PapilloCheck
ID HUMAN-PAPILLOMAVIRUS PREVALENCE; INTRAEPITHELIAL LESIONS;
   NATURAL-HISTORY; CANCER; INFECTION; DNA; NEOPLASIA; SAMPLES; NORTH;
   CLASSIFICATION
AB Background: Human Papillomavirus (HPV) genotype distribution varies according to the method of assessment and population groups. This study analyzed type-specific HPV infections among women ranging from 14-95 years old, displaying normal and abnormal cytology, from Sao Paulo and Barretos cities, Brazil.
   Methods: Women found positive for High Risk-HPVs DNA by either the Hybrid Capture 2 (HC2) or Cobas HPV Test (n = 431) plus a random sample of 223 negative by both assays and 11 samples with indeterminate results, totalizing 665 samples, were submitted to HPV detection by the PapilloCheck test. Cytological distribution included 499 women with a cytological result of Negative for Intraepithelial Lesion or Malignancy and 166 with some abnormality as follows: 54 Atypical Squamous Cells of Undetermined Significance; 66 Low-Grade Squamous Intraepithelial Lesion; 43 High-Grade Squamous Intraepithelial Lesion and 3 (0.5 %) Invasive Cervical Cancer.
   Results: From the 323 samples (48.6 %) that had detectable HPV-DNA by the PapilloCheck assay, 31 were HPV negative by the cobas HPV and HC2 assays. Out of these 31 samples, 14 were associated with HR-HPVs types while the remaining 17 harbored exclusively low-risk HPVs. In contrast, 49 samples positive by cobas HPV and HC 2 methods tested negative by the PapilloCheck assay (19.8 %). Overall, the most frequent HR-HPV type was HPV 16 (23.2 %), followed by 56 (21.0 %), 52 (8.7 %) and 31 (7.7 %) and the most frequent LR-HPV type was HPV 42 (12.1 %) followed by 6 (6.2 %). Among the HR-HPV types, HPV 56 and 16 were the most frequent types in NILM, found in 19. 1 and 17.7 % of the patients respectively while in HSIL and ICC cases, HPV 16 was the predominant type, detected in 37.2 and 66.7 % of these samples.
   Conclusions: In the population studied, HPV 16 and 56 were the most frequently detected HR-HPV types. HPV 56 was found mainly in LSIL and NILM suggesting a low oncogenic potential. HPV 16 continues to be the most prevalent type in high-grade lesions whereas HPV 18 was found in a low frequency both in NILM and abnormal smears. Surveillance of HPV infections by molecular methods is an important tool for the development and improvement of prevention strategies.
C1 [Martins, Toni Ricardo; de Oliveira, Cristina Mendes; Rosa, Luciana Reis; Centrone, Cristiane de Campos; Regina Rodrigues, Celia Luiza; Levi, Jose Eduardo] Univ Sao Paulo, Virol Lab, LIM 52, Inst Trop Med, Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
   [Martins, Toni Ricardo] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
   [Villa, Luisa Lina] Univ Sao Paulo, Sch Med, Dept Oncol & Radiol, Sao Paulo, Brazil.
   [Villa, Luisa Lina; Levi, Jose Eduardo] Natl Inst Sci & Technol, Dis Associated Papillomaviruses INCT HPV, Sao Paulo, Brazil.
RP Martins, TR (corresponding author), Univ Sao Paulo, Virol Lab, LIM 52, Inst Trop Med, Dr Eneas Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.; Martins, TR (corresponding author), Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
EM trmartins@usp.br
RI Oliveira, Cristina M/F-7193-2012; VILLA, LUISA/AAH-4761-2019
OI VILLA, LUISA/0000-0003-4074-2335
FU Sao Paulo, Brazil, through CNPq [573799/2008-3]; Sao Paulo, Brazil,
   through FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2008/57889-1]
FX The authors are grateful to the Instituto Nacional de Ciencia e
   Tecnologia das Doencas do Papilomavirus Humano INCT-HPV (National
   Institute of Science and Technology of the Diseases Associated to the
   Papillomavirus) coordinated by Luisa Lina Villa; Sao Paulo, Brazil,
   through CNPq 573799/2008-3 and FAPESP 2008/57889-1 grants.
CR Arbyn M, 2014, LANCET ONCOL, V15, P172, DOI 10.1016/S1470-2045(13)70570-9
   Argyri E, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-53
   Baldez da Silva M F P T, 2009, Genet Mol Res, V8, P1437, DOI 10.4238/vol8-4gmr677
   Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244
   Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
   Brismar-Wendel S, 2009, BRIT J CANCER, V101, P511, DOI 10.1038/sj.bjc.6605165
   Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321
   Bruno A, 2014, REV BRAS GINECOL OBS, V36, P416, DOI 10.1590/SO100-720320140004995
   Capra G, 2008, VIRUS RES, V133, P195, DOI 10.1016/j.virusres.2007.12.020
   Castellsague X, 2008, GYNECOL ONCOL, V110, pS4, DOI 10.1016/j.ygyno.2008.07.045
   Castilho JL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1486-4
   Castle PE, 2008, J CLIN MICROBIOL, V46, P2595, DOI 10.1128/JCM.00824-08
   Chatterjee A, 2014, EXPERT REV VACCINES, V13, P1279, DOI 10.1586/14760584.2014.963561
   Ciapponi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025493
   Cuzick J, 1999, EUR J CANCER, V35, P685, DOI 10.1016/S0959-8049(99)00070-2
   Cuzick J, 2006, VACCINE S3, V24, pS3/90
   Dalstein V, 2009, J VIROL METHODS, V156, P77, DOI 10.1016/j.jviromet.2008.11.002
   de Oliveira CM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-357
   de Oliveira Cristina Mendes, 2011, Gynecol Oncol Case Rep, V2, P18, DOI 10.1016/j.gynor.2011.11.004
   de Ona M, 2010, J MED VIROL, V82, P597, DOI 10.1002/jmv.21697
   de Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016/S1473-3099(07)70158-5
   de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8
   de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033
   Delgado D, 2012, ENFERM INFEC MICR CL, V30, P230, DOI 10.1016/j.eimc.2011.10.021
   ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18
   Fernandes JV, 2009, INT J GYNECOL OBSTET, V105, P21, DOI 10.1016/j.ijgo.2008.12.004
   Ferreccio C, 2013, INT J CANCER, V132, P916, DOI 10.1002/ijc.27662
   Gonzalez-Bosquet E, 2008, GYNECOL ONCOL, V111, P9, DOI 10.1016/j.ygyno.2008.06.012
   Gray SH, 2004, CURR OPIN PEDIATR, V16, P344, DOI 10.1097/01.mop.0000133078.40007.2b
   Guo M, 2004, AM J CLIN PATHOL, V122, P894, DOI [10.1309/0DGGQBDQAMJCJBXB, 10.1309/0DGGQAMJCJBXB]
   Halec G, 2014, J PATHOL, V234, P441, DOI 10.1002/path.4405
   Halfon P, 2013, ARCH VIROL, V158, P1143, DOI 10.1007/s00705-012-1584-4
   Herrero R, 2005, J INFECT DIS, V191, P1796, DOI 10.1086/428850
   Herrington CS, 1999, J PATHOL, V189, P1
   Kocjan BJ, 2015, CLIN MICROBIOL INFEC, V21, P808, DOI 10.1016/j.cmi.2015.05.011
   Levi JE, 2014, OJOG, V4, P470, DOI DOI 10.4236/0J0G.2014.48068
   Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396
   Malagon T, 2012, LANCET INFECT DIS, V12, P781, DOI 10.1016/S1473-3099(12)70187-1
   Martin P, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-316
   Matsumoto K, 2011, INT J CANCER, V128, P2898, DOI 10.1002/ijc.25630
   Mayrand M, 2007, NEW ENGL J MED, V357, P1579, DOI 10.1056/NEJMoa071430
   Mejlhede N, 2009, APMIS, V117, P108, DOI 10.1111/j.1600-0463.2008.00019.x
   Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641
   Nayar R, 2015, CANCER CYTOPATHOL, V123, P271, DOI 10.1002/cncy.21521
   Noronha V, 1999, Rev Soc Bras Med Trop, V32, P235, DOI 10.1590/S0037-86821999000300003
   Oliveira-Silva M, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-4
   Otero-Motta AP, 2011, APMIS, V119, P204, DOI 10.1111/j.1600-0463.2010.02711.x
   Peevor R, 2009, J CLIN VIROL, V44, P322, DOI 10.1016/j.jcv.2009.01.015
   Piana A, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-785
   Powell NG, 2011, INT J CANCER, V128, P1676, DOI 10.1002/ijc.25485
   Rabelo-Santos SH, 2003, MEM I OSWALDO CRUZ, V98, P181, DOI 10.1590/S0074-02762003000200003
   Ronco G, 2010, LANCET ONCOL, V11, P249, DOI 10.1016/S1470-2045(09)70360-2
   Sandri MT, 2009, J MED VIROL, V81, P271, DOI 10.1002/jmv.21382
   Sankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516
   Schiffman M, 2011, JNCI-J NATL CANCER I, V103, P368, DOI 10.1093/jnci/djq562
   Schopp B, 2010, J MED VIROL, V82, P605, DOI 10.1002/jmv.21719
   Sjoeborg KD, 2010, GYNECOL ONCOL, V118, P29, DOI 10.1016/j.ygyno.2010.03.007
   Solomon Diane, 2003, J Natl Cancer Inst Monogr, P97
   Stoler MH, 2007, AM J CLIN PATHOL, V127, P335, DOI 10.1309/RNF3C01JKADQCLKP
   Tozetti Inês Aparecida, 2006, Braz J Infect Dis, V10, P309, DOI 10.1590/S1413-86702006000500001
   Trottier H, 2006, VACCINE, V24, P4, DOI 10.1016/j.vaccine.2005.09.054
   Vidal AC, 2011, INFECT AGENTS CANCER, V6, DOI 10.1186/1750-9378-6-20
   Vieira L, 2013, EUR J MICROBIOL IMMU, V3, P61, DOI 10.1556/EuJMI.3.2013.1.9
   Wheeler CM, 2013, INT J CANCER, V132, P198, DOI 10.1002/ijc.27608
   WHO. The World Health Organization-Information Centre on HPV and Cervical Cancer (HPV Information Centre), 2014, HUM PAP REL DIS
   Wright TC, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2011.07.024
   Bosch FX, 2008, VACCINE, V26, pK1, DOI 10.1016/j.vaccine.2008.05.064
NR 67
TC 10
Z9 12
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PD AUG 12
PY 2016
VL 13
AR 138
DI 10.1186/s12985-016-0594-3
PG 9
WC Virology
SC Virology
GA DT9DZ
UT WOS:000381797100001
PM 27515763
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Orico, LD
   Fernandes, LN
   Melo, MA
   Zwarg, T
   Levi, JE
   Marrelli, MT
AF Orico, Lilian Dias
   Fernandes, Licia Natal
   Melo, Marcos Antonio
   Zwarg, Ticiana
   Levi, Jose Eduardo
   Marrelli, Mauro Toledo
TI A survey of flaviviruses in birds in green areas of Sao Paulo, Brazil
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA English
DT Article
DE Birds; Flavivirus; Green areas
ID WEST-NILE-VIRUS; ARBOVIRUS DISEASE; CULEX FLAVIVIRUS; MOSQUITOS; STRAIN
AB Introduction: This study aimed to investigate Flavivirus infection in birds captured in green areas of Sao Paulo. Methods: Oropharyngeal swabs, cloacal swabs, and blood samples from 170 birds captured in two green areas in Sao Paulo, Brazil were subjected to real time-polymerase chain reaction (RT-qPCR) analysis of Flavivirus specific NS5 gene fragment. Results: All samples were negative for the presence of viral ribonucleic acid (RNA). Conclusions: Despite the negative results, Flavivirus surveillance must be performed regularly due to favorable ecological conditions for virus circulation and transmission among birds in these areas and their close proximity to humans.
C1 [Orico, Lilian Dias; Marrelli, Mauro Toledo] Univ Sao Paulo, Fac Saude Publ, Dept Epidemiol, Sao Paulo, Brazil.
   [Fernandes, Licia Natal] Univ Sao Paulo, Inst Med Trop Sao Paulo, Lab Protozool, Sao Paulo, Brazil.
   [Melo, Marcos Antonio; Zwarg, Ticiana] Div Tecn Med Vet & Manejo Fauna Silvestre, Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop Sao Paulo, Virol Lab, Sao Paulo, Brazil.
RP Marrelli, MT (corresponding author), Univ Sao Paulo, Fac Saude Publ, Dept Epidemiol, Sao Paulo, Brazil.
EM mmarelli@usp.br
RI Fernandes, Licia N/F-9619-2016; Marrelli, Mauro/H-2568-2013
OI Marrelli, Mauro/0000-0002-0312-8777; A. Melo,
   Marcos/0000-0001-9940-8441; Natal Fernandes, Licia/0000-0001-8008-1338
FU FAPESP, BIOTA ProgramFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2010/51230-8]
FX FAPESP, BIOTA Program, Grant 2010/51230-8.
CR Almeida AF, 2007, FAUNA SILVESTRE QUEM
   Banet-Noach C, 2003, AVIAN PATHOL, V32, P489, DOI 10.1080/0307945031000154080
   Cook S, 2009, J GEN VIROL, V90, P2669, DOI 10.1099/vir.0.014183-0
   Fernandes LN, 2016, ACTA TROP, V157, P73, DOI 10.1016/j.actatropica.2016.01.026
   FIGUEIREDO M. W., 2010, THESIS
   Hubalek Z, 2004, J WILDLIFE DIS, V40, P639, DOI 10.7589/0090-3558-40.4.639
   Johnson N, 2010, VECTOR-BORNE ZOONOT, V10, P665, DOI 10.1089/vbz.2009.0210
   Komar N, 2003, EMERG INFECT DIS, V9, P311, DOI 10.3201/eid0903.020628
   LOPES OD, 1981, AM J EPIDEMIOL, V113, P122
   Medeiros-Sousa AR, 2015, ACTA TROP, V150, P200, DOI 10.1016/j.actatropica.2015.08.002
   Mello-Théry Neli Aparecida de, 2011, Estud. av., V25, P175, DOI 10.1590/S0103-40142011000100012
   Figueiredo LTM, 2015, REV SOC BRAS MED TRO, V48, P233, DOI 10.1590/0037-8682-0179-2015
   Moureau G, 2007, VECTOR-BORNE ZOONOT, V7, P467, DOI 10.1089/vbz.2007.0206
   Peterson AT, 2004, BIRD CONSERV INT, V14, P215, DOI 10.1017/S0959270904000309
   SAO PAULO, 2010, SECRETARIA MUNICIP S, V55, P1
NR 15
TC 0
Z9 0
U1 0
U2 42
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD JUL-AUG
PY 2016
VL 49
IS 4
BP 494
EP 497
DI 10.1590/0037-8682-0426-2015
PG 4
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA DU8IT
UT WOS:000382457200016
PM 27598638
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Dezan, MR
   Dinardo, CL
   Bosi, SRA
   Vega, S
   Salles, NA
   Mendrone, A
   Levi, JE
AF Dezan, Marcia R.
   Dinardo, Carla L.
   Bosi, Silvia R. A.
   Vega, Sileni
   Salles, Nanci A.
   Mendrone-Junior, Alfredo
   Levi, Jose E.
TI High-throughput strategy for molecular identification of Vel- blood
   donors employing nucleic acids extracted from plasma pools used for
   viral nucleic acid test screening
SO TRANSFUSION
LA English
DT Article
AB BACKGROUNDSerologic methods to determine the Vel- phenotype require the use of rare human antisera and do not allow for many samples to be tested simultaneously, which limits their application as a tool to search for rare donors. This study developed a low-cost molecular screening strategy using real-time polymerase chain reaction (PCR) and DNA, extracted from plasma pools for viral nucleic acid test (NAT) screening, to identify Vel- and Vel+(W) donors.
   STUDY DESIGN AND METHODSA total of 4680 blood donors from the Brazilian southeast region were genotyped through real-time PCR targeting the 17-nucleotide (c.64_80del) deletion in the SMIM1 gene, which determines the Vel- phenotype, by using remaining nucleic acid from plasma pools of six donors, routinely discarded after the release of viral NAT results.
   RESULTSTwenty pools tested reactive and individual testing of samples from reactive pools identified 19 heterozygous donors with the SMIM1*64_80del deletion (0.40%) and one homozygous donor (0.02%). Fourteen of the 19 donors were confirmed as Vel- or Vel+(W) using anti-Vel human antiserum.
   CONCLUSIONThe DNA pool genotyping strategy using real-time PCR designed to detect the deletion in the SMIM1 gene proved effective and accurate in identifying donors with the Vel- and Vel+(W) phenotypes. The fact that remaining nucleic acid from routine viral NAT screening was used makes this technique economically attractive and definitely superior to the serologic techniques available to search for this rare phenotype.
C1 [Dezan, Marcia R.; Dinardo, Carla L.; Bosi, Silvia R. A.; Vega, Sileni; Salles, Nanci A.; Mendrone-Junior, Alfredo; Levi, Jose E.] Fundacao Prosangue, Hemoctr Sao Paulo, Rua Dr Eneas de Carvalho Aguiar 155,1 Andar B4, BR-05403000 Sao Paulo, SP, Brazil.
RP Levi, JE (corresponding author), Fundacao Prosangue, Hemoctr Sao Paulo, Rua Dr Eneas de Carvalho Aguiar 155,1 Andar B4, BR-05403000 Sao Paulo, SP, Brazil.
EM jelevi@prosangue.sp.gov.br
RI Sabino, Ester Cerdeira/F-7750-2010
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; DEZAN, MARCIA
   REGINA/0000-0002-3760-9843
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2015/095403]
FX Supported by the Sao Paulo Research Foundation (FAPESP), Grant
   2015/095403 (to MRD).
CR Andrea P, 2015, TRANSFUSION MED, V25, P125, DOI 10.1111/tme.12180
   Ballif BA, 2013, EMBO MOL MED, V5, P751, DOI 10.1002/emmm.201302466
   Brecher ME, 2005, TECHNICAL MANUAL
   Cvejic A, 2013, NAT GENET, V45, P542, DOI 10.1038/ng.2603
   Daniels G, 2013, HUMAN BLOOD GROUPS
   Haer-Wigman L, 2015, TRANSFUSION, V55, P1457, DOI 10.1111/trf.13014
   Rozman P, 2000, TRANSFUSION, V40, P936, DOI 10.1046/j.1537-2995.2000.40080936.x
   Seltsam A, 2003, TRANSFUSION, V43, P1563, DOI 10.1046/j.1537-2995.2003.00565.x
   Storry JR, 2013, NAT GENET, V45, P537, DOI 10.1038/ng.2600
   Sussman LN, 1952, VEL REV HEMATOL, V7, P368
NR 10
TC 7
Z9 8
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD JUN
PY 2016
VL 56
IS 6
BP 1430
EP 1434
DI 10.1111/trf.13572
PG 5
WC Hematology
SC Hematology
GA DP5QU
UT WOS:000378553200055
PM 27060345
DA 2020-11-30
ER

PT J
AU Fernandes, LN
   de Paula, MB
   Araujo, AB
   Goncalves, EFB
   Romano, CM
   Natal, D
   Malafronte, RD
   Marrelli, MT
   Levi, JE
AF Fernandes, Licia Natal
   de Paula, Marcia Bicudo
   Araujo, Alessandra Bergamo
   Bertoletti Goncalves, Elisabeth Fernandes
   Romano, Camila Malta
   Natal, Delsio
   Malafronte, Rosely dos Santos
   Marrelli, Mauro Toledo
   Levi, Jose Eduardo
TI Detection of Culex flavivirus and Aedes flavivirus nucleotide sequences
   in mosquitoes from parks in the city of Sao Paulo, Brazil
SO ACTA TROPICA
LA English
DT Article
DE Flavivirus; Mosquitoes; Parks; Polymerase chain reaction
ID WEST-NILE-VIRUS; INSECT-SPECIFIC FLAVIVIRUS; FUSING AGENT VIRUS;
   DIPTERA-CULICIDAE; ZIKA VIRUS; YUCATAN PENINSULA; YELLOW-FEVER;
   TRANSMISSION; IDENTIFICATION; POPULATION
AB The dengue viruses are widespread in Brazil and are a major public health concern. Other flaviviruses also cause diseases in humans, although on a smaller scale. The city of Sao Paulo is in a highly urbanized area with few green spaces apart from its parks, which are used for recreation and where potential vertebrate hosts and mosquito vectors of pathogenic Flavivirus species can be found. Although this scenario can contribute to the transmission of Flavivirus to humans, little is known about the circulation of members of this genus in these areas. In light of this, the present study sought to identify Flavivirus infection in mosquitoes (Diptera: Culicidae) collected in parks in the city of Sao Paulo. Seven parks in different sectors of the city were selected. Monthly mosquito collections were carried out in each park from March 2011 to February 2012 using aspiration and traps (Shannon and CD C-CO2). Nucleic acids were extracted from the mosquitoes collected and used for reverse-transcriptase and real-time polymerase chain reactions with genus-specific primers targeting a 200-nucleotide region in the Flavivirus NS5 gene. Positive samples were sequenced, and phylogenetic analyses were performed. Culex and Aedes were the most frequent genera of Culicidae collected. Culex flavivirus (CxFV)-related and Aedes flavivirus (AEFV)- related nucleotide sequences were detected in 17 pools of Culex and two pools of Aedes mosquitoes, respectively, among the 818 pools of non-engorged females analyzed. To the best of our knowledge, this is the first report of CxFV and AEFV in the city of Sao Paulo and Latin America, respectively. Both viruses are insect- specific flaviviruses, a group known to replicate only in mosquito cells and induce a cytopathic effect in some situations. Hence, our data suggests that CxFV and AEFV are present in Culex and Aedes mosquitoes, respectively, in parks in the city of Sao Paulo. Even though Flavivirus species of medical importance were not detected, surveillance is recommended in the study areas because of the presence of vertebrates and mosquitoes that could act as amplifying hosts and vectors of flaviviruses, providing the required conditions for circulation of these viruses. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Fernandes, Licia Natal; Malafronte, Rosely dos Santos] Univ Sao Paulo, Inst Med Trop Sao Paulo, Lab Protozool, Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
   [de Paula, Marcia Bicudo; Natal, Delsio; Marrelli, Mauro Toledo] Univ Sao Paulo, Fac Saude Publ, Dept Epidemiol, Av Dr Arnaldo 715, BR-01246904 Sao Paulo, SP, Brazil.
   [Araujo, Alessandra Bergamo] Prefeitura Sao Paulo, Ctr Controle Zoonoses, Lab Fauna Sinantrop, Rua Santa Eulalia 86, BR-02031020 Sao Paulo, SP, Brazil.
   [Bertoletti Goncalves, Elisabeth Fernandes] Prefeitura Sao Paulo, Dept Parques & Areas Verdes, Ave 4 Centenario, BR-04030090 Sao Paulo, SP, Brazil.
   [Romano, Camila Malta; Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop Sao Paulo, Virol Lab, Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
   [Levi, Jose Eduardo] Fundacao Prosangue, Hemoctr Sao Paulo, Dept Biol Mol, Av Dr Eneas de Carvalho Aguiar 155, BR-05403000 Sao Paulo, SP, Brazil.
RP Fernandes, LN (corresponding author), Univ Sao Paulo, Inst Med Trop Sao Paulo, Lab Protozool, Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, SP, Brazil.
EM licianatal@usp.br
RI Romano, Camila M/C-8185-2013; Marrelli, Mauro/H-2568-2013; Fernandes,
   Licia N/F-9619-2016; Romano, Camila/ABC-2883-2020
OI Marrelli, Mauro/0000-0002-0312-8777; Romano, Camila/0000-0003-4550-1987;
   Natal Fernandes, Licia/0000-0001-8008-1338
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP: BIOTA
   Program)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2010/51230-8]
FX We would like to thank Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP: BIOTA Program: Project 2010/51230-8) for providing
   funding. Our thanks also to all the other members of the Department of
   Epidemiology in the Faculty of Public Health, University of Sao Paulo
   (especially Dr. Paulo Roberto Urbinatti and Aristides Fernandes), the
   staff at the Zoonosis Control Center/COVISA/SMS/PMSP (in particular
   Maria Helena Silva Homem de Mello and Renildo Souza Teixeira) and the
   staff at the Department of Parks and Green Spaces, SVMA-Sao Paulo, who
   helped with the field and laboratory work. Finally, we would like to
   thank Almir Robson Ferreira (Institute of Tropical Medicine, University
   of Sao Paulo) for providing the map.
CR Diaz LA, 2008, EMERG INFECT DIS, V14, P689, DOI 10.3201/eid1404.071257
   Almeida A. F., 2007, FAUN SILV QUEM OND V
   An Shu-yi, 2012, Chinese Journal of Virology, V28, P511
   Blitvich BJ, 2015, VIRUSES-BASEL, V7, P1927, DOI 10.3390/v7041927
   Blitvich BJ, 2009, J MED ENTOMOL, V46, P934, DOI 10.1603/033.046.0428
   Bolling BG, 2015, AM J TROP MED HYG, V92, P422, DOI 10.4269/ajtmh.14-0330
   Bolling BG, 2012, VIROLOGY, V427, P90, DOI 10.1016/j.virol.2012.02.016
   Bolling BG, 2011, AM J TROP MED HYG, V85, P169, DOI 10.4269/ajtmh.2011.10-0474
   Bosch I, 2007, EMERG INFECT DIS, V13, P651, DOI 10.3201/eid1304.061383
   Burivong P, 2004, VIROLOGY, V329, P261, DOI 10.1016/j.virol.2004.08.032
   Calzolari M, 2012, J GEN VIROL, V93, P1215, DOI 10.1099/vir.0.040485-0
   Calzolari M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014324
   Calzolari M, 2010, VECTOR-BORNE ZOONOT, V10, P875, DOI 10.1089/vbz.2009.0176
   CAMMISAPARKS H, 1992, VIROLOGY, V189, P511, DOI 10.1016/0042-6822(92)90575-A
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Chen YY, 2013, COMP IMMUNOL MICROB, V36, P387, DOI 10.1016/j.cimid.2013.02.001
   Christophers S., 1960, BIONOMICS STRUCTURE
   Consoli RAGB, 1994, PRINCIPAIS MOSQUITOS
   Cook S, 2006, J GEN VIROL, V87, P735, DOI 10.1099/vir.0.81475-0
   Cook S, 2006, ARCH VIROL, V151, P309, DOI 10.1007/s00705-005-0626-6
   Cook S, 2009, J GEN VIROL, V90, P2669, DOI 10.1099/vir.0.014183-0
   Crabtree MB, 2003, ARCH VIROL, V148, P1095, DOI 10.1007/s00705-003-0019-7
   Crochu S, 2004, J GEN VIROL, V85, P1971, DOI 10.1099/vir.0.79850-0
   Crockett RK, 2012, J MED ENTOMOL, V49, P165, DOI 10.1603/ME11080
   Vasconcelos PFD, 2010, REV SAUDE PUBL, V44, P1144, DOI 10.1590/S0034-89102010005000046
   de BUSTAMANTE F M, 1951, Folha Med, V32, P53
   de Carvalho GC, 2014, J VECTOR ECOL, V39, P146, DOI 10.1111/j.1948-7134.2014.12081.x
   de Paula MB, 2015, BIOTA NEOTROP, V15, DOI 10.1590/1676-0611-BN-2014-0026
   Espinoza-Gomez F, 2011, ARCH VIROL, V156, P1263, DOI 10.1007/s00705-011-0967-2
   Farfan-Ale JA, 2010, VECTOR-BORNE ZOONOT, V10, P777, DOI 10.1089/vbz.2009.0196
   Farfan-Ale JA, 2009, AM J TROP MED HYG, V80, P85, DOI 10.4269/ajtmh.2009.80.85
   Figueiredo L. T., 1998, OVERVIEW ARBOVIROLOG, P154
   Figueiredo L. T. M., 2010, Dengue Bulletin, V34, P6
   Figueiredo LTM, 2000, MICROBES INFECT, V2, P1643, DOI 10.1016/S1286-4579(00)01320-4
   Forattini O. P, 2002, CULICIDOLOGIA MED, V2
   Goenaga S, 2014, J MED ENTOMOL, V51, P900, DOI 10.1603/ME13172
   GOMES AD, 1985, REV SAUDE PUBL, V19, P190, DOI 10.1590/S0034-89101985000200009
   Grisenti M, 2015, J GEN VIROL, V96, P420, DOI 10.1099/vir.0.069625-0
   Gubler DJ, 2014, DENGUE AND DENGUE HEMORRHAGIC FEVER, 2ND EDITION, P1, DOI 10.1079/9781845939649.0001
   Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520
   Haddow AD, 2013, VIROLOGY, V440, P134, DOI 10.1016/j.virol.2012.12.008
   Hayes EB, 2006, ANNU REV MED, V57, P181, DOI 10.1146/annurev.med.57.121304.131418
   Hobson-Peters J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056534
   Hoshino K, 2007, VIROLOGY, V359, P405, DOI 10.1016/j.virol.2006.09.039
   Hoshino K, 2009, VIROLOGY, V391, P119, DOI 10.1016/j.virol.2009.06.025
   Johnson N, 2010, VECTOR-BORNE ZOONOT, V10, P665, DOI 10.1089/vbz.2009.0210
   Kent RJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000671
   Kihara Y, 2007, J VIROL METHODS, V146, P372, DOI 10.1016/j.jviromet.2007.07.008
   Kim DY, 2009, VIROLOGY, V386, P154, DOI 10.1016/j.virol.2008.12.034
   Komar N, 2006, REV PANAM SALUD PUBL, V19, P112, DOI 10.1590/S1020-49892006000200006
   Komar N, 2000, REV SCI TECH OIE, V19, P166, DOI 10.20506/rst.19.1.1201
   Kuno G, 1998, J VIROL, V72, P73, DOI 10.1128/JVI.72.1.73-83.1998
   Kuwata R, 2015, J MED ENTOMOL, V52, P222, DOI 10.1093/jme/tju059
   Laporta GZ, 2006, REV BRAS ENTOMOL, V50, P125, DOI 10.1590/S0085-56262006000100019
   Luna E. J. A., 2003, EPIDEMIOL SERV SAUDE, V12, P7
   Machado DC, 2012, INTERVIROLOGY, V55, P475, DOI 10.1159/000337166
   Marin M. S., 1995, VIROLOGY, V213, P169
   Mattar S, 2005, EMERG INFECT DIS, V11, P1497, DOI 10.3201/eid1109.050426
   Medeiros-Sousa AR, 2015, ACTA TROP, V150, P200, DOI 10.1016/j.actatropica.2015.08.002
   Medeiros-Sousa AR, 2013, J AM MOSQUITO CONTR, V29, P275, DOI 10.2987/12-6304R.1
   Melandri V, 2012, MEM I OSWALDO CRUZ, V107, P1073, DOI 10.1590/S0074-02762012000800020
   Montes J, 2005, REV SAUDE PUBL, V39, P578, DOI 10.1590/S0034-89102005000400010
   Figueiredo LTM, 2012, REV SOC BRAS MED TRO, V45, P285, DOI 10.1590/S0037-86822012000300001
   Morais Sirlei Antunes de, 2006, Rev. Bras. entomol., V50, P413, DOI 10.1590/S0085-56262006000300012
   Morales-Betoulle ME, 2008, J MED ENTOMOL, V45, P1187, DOI 10.1603/0022-2585(2008)45[1187:CFIFMI]2.0.CO;2
   Moureau G, 2007, VECTOR-BORNE ZOONOT, V7, P467, DOI 10.1089/vbz.2007.0206
   NASCI RS, 1981, MOSQ NEWS, V41, P808
   Nash D, 2001, NEW ENGL J MED, V344, P1807, DOI 10.1056/NEJM200106143442401
   NATAL D, 1984, REV SAUDE PUBL, V18, P418, DOI 10.1590/S0034-89101984000500013
   Natal D., 2002, BIOLOGICO, V62, P205
   Newman CM, 2011, VECTOR-BORNE ZOONOT, V11, P1099, DOI 10.1089/vbz.2010.0144
   Ometto T, 2013, T ROY SOC TROP MED H, V107, P723, DOI 10.1093/trstmh/trt081
   Paiva BR, 2006, ACTA TROP, V99, P252, DOI 10.1016/j.actatropica.2006.08.009
   Pauvolid-Correa A, 2011, MEM I OSWALDO CRUZ, V106, P467, DOI 10.1590/S0074-02762011000400014
   Pepin KM, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-28
   Pereira LE, 2001, REV SAUDE PUBL, V35, P119, DOI 10.1590/S0034-89102001000200003
   de Figueiredo RMP, 2008, EMERG INFECT DIS, V14, P667, DOI 10.3201/eid1404.071185
   Rizzo F, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-395
   Roiz D, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-223
   Roiz D, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-93
   Saiyasombat R, 2010, ARCH VIROL, V155, P983, DOI 10.1007/s00705-010-0665-5
   Sang RC, 2003, ARCH VIROL, V148, P1085, DOI 10.1007/s00705-003-0018-8
   Silverio ED, 2011, REV SOC BRAS MED TRO, V44, P504, DOI 10.1590/S0037-86822011000400020
   STOLLAR V, 1975, VIROLOGY, V64, P367, DOI 10.1016/0042-6822(75)90113-0
   SUNDIN DR, 1988, AM J TROP MED HYG, V38, P428, DOI 10.4269/ajtmh.1988.38.428
   Taipe-Lagos CB, 2003, REV SAUDE PUBL, V37, P275, DOI 10.1590/S0034-89102003000300002
   Tauil P L, 2001, Cad Saude Publica, V17 Suppl, P99, DOI 10.1590/S0102-311X2001000700018
   Urbinatti PR, 2001, REV SAUDE PUBL, V35, P461, DOI 10.1590/S0034-89102001000500009
   Vasconcelos Pedro Fernando da Costa, 2003, Rev. Soc. Bras. Med. Trop., V36, P275, DOI 10.1590/S0037-86822003000200012
   Vasconcelos PFC, 2003, T ROY SOC TROP MED H, V97, P60, DOI 10.1016/S0035-9203(03)90023-X
   Vasconcelos PFC, 1998, OVERVIEW ARBOVIROLOG, P19
   Vasconcelos PFC, 2005, TRATADO INFECTOLOGIA, V1, P289
   VASCONCELOS PFD, 2015, REV PAN-AMAZ SAUDE, V6, P9, DOI DOI 10.5123/S2176-62232015000200001
   Vieira MACS, 2015, AM J TROP MED HYG, V93, P377, DOI 10.4269/ajtmh.15-0170
   Wang HY, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-73
   Yamanaka A, 2013, INFECT GENET EVOL, V19, P188, DOI 10.1016/j.meegid.2013.07.012
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
NR 97
TC 8
Z9 8
U1 2
U2 98
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0001-706X
EI 1873-6254
J9 ACTA TROP
JI Acta Trop.
PD MAY
PY 2016
VL 157
BP 73
EP 83
DI 10.1016/j.actatropica.2016.01.026
PG 11
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA DH4MZ
UT WOS:000372761400009
PM 26829359
DA 2020-11-30
ER

PT J
AU Levi, JE
AF Levi, Jose Eduardo
TI Dengue Virus and Blood Transfusion
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Editorial Material
DE dengue virus; blood transfusion; mosquito bite; pathogenesis
ID OUTBREAK; MOSQUITO; DONORS; TIME
C1 [Levi, Jose Eduardo] Univ Sao Paulo, Fundacao Prosangue, Hemoctr Sao Paulo, BR-05508 Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Hosp Israelita Albert Einstein, BR-05508 Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, BR-05508 Sao Paulo, Brazil.
RP Levi, JE (corresponding author), Fundacao Prosangue, Dept Mol Biol, Rua Dr Eneas de Carvalho Aguiar 155,1 Andar, BR-05403000 Sao Paulo, SP, Brazil.
EM dudilevi@usp.br
CR Chuang Vivien W. M., 2008, Hong Kong Medical Journal, V14, P170
   Cox J, 2012, J VIROL, V86, P7637, DOI 10.1128/JVI.00534-12
   De Vlaminck I, 2013, CELL, V155, P1178, DOI 10.1016/j.cell.2013.10.034
   Felix AC, 2012, CLIN VACCINE IMMUNOL, V19, P1972, DOI 10.1128/CVI.00535-12
   Fujimoto Denys Eiti, 2014, Rev. Bras. Hematol. Hemoter., V36, P115, DOI 10.5581/1516-8484.20140027
   Gallian P, 2014, BLOOD, V123, P3679, DOI 10.1182/blood-2014-03-564880
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   Levi JE, 2015, TRANSFUSION, V55, P961, DOI 10.1111/trf.12944
   Lo YMD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001720
   Mores CN, 2014, J INFECT DIS, V209, P571, DOI 10.1093/infdis/jiu110
   Oh HB, 2015, TRANSFUSION, V55, P1655, DOI 10.1111/trf.13054
   Onlamoon N, 2010, BLOOD, V115, P1823, DOI 10.1182/blood-2009-09-242990
   Rasongles P, 2009, TRANSFUSION, V49, P1083, DOI 10.1111/j.1537-2995.2009.02111.x
   Rey FA, 2013, NATURE, V497, P443, DOI 10.1038/497443a
   Sabino EC, 2016, J INFECT DIS, V213, P694, DOI 10.1093/infdis/jiv326
   Snyder EL, 2015, NEW ENGL J MED, V372, P1882, DOI 10.1056/NEJMp1500154
   Stramer SL, 2005, NEW ENGL J MED, V353, P451, DOI 10.1056/NEJMoa044333
   Stramer SL, 2012, TRANSFUSION, V52, P1657, DOI 10.1111/j.1537-2995.2012.03566.x
   Tambyah PA, 2008, NEW ENGL J MED, V359, P1526, DOI 10.1056/NEJMc0708673
   Nunes MRT, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0348-x
NR 20
TC 10
Z9 11
U1 2
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR 1
PY 2016
VL 213
IS 5
BP 689
EP 690
DI 10.1093/infdis/jiv322
PG 2
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA DG9XY
UT WOS:000372438300001
PM 26908779
OA Bronze
DA 2020-11-30
ER

PT J
AU Santos, APD
   Levi, JE
   Lemos, MF
   Calux, SJ
   Oba, IT
   Moreira, RC
AF de Torres Santos, Ana Paula
   Levi, Jose Eduardo
   Lemos, Marcilio Figueiredo
   Calux, Samira Julien
   Oba, Isabel Takano
   Moreira, Regina Celia
TI An in-house real-time polymerase chain reaction: standardisation and
   comparison with the Cobas Amplicor HBV monitor and Cobas AmpliPrep/Cobas
   TaqMan HBV tests for the quantification of hepatitis B virus DNA
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE HBV viral load; Cobas Amplicor HBV monitor; Cobas TaqMan HBV; HBVDNA;
   in-house rtPCR
ID RESISTANCE MUTATIONS; INFECTED PATIENTS; GENOTYPE-G; PCR ASSAY;
   QUANTITATION; SEQUENCE; PROBE; GENE
AB This study aimed to standardise an in-house real-time polymerase chain reaction (rtPCR) to allow quantification of hepatitis B virus (HBV) DNA in serum or plasma samples, and to compare this method with two commercial assays, the Cobas Amplicor HBV monitor and the Cobas AmpliPrep/Cobas TaqMan HBV test. Samples from 397 patients from the state of Sao Paulo were analysed by all three methods. Fifty-two samples were from patients who were human immunodeficiency virus and hepatitis C virus positive, but HBV negative. Genotypes were characterised, and the viral load was measure in each sample. The in-house rtPCR showed an excellent success rate compared with commercial tests; inter-assay and intra-assay coefficients correlated with commercial tests (r = 0.96 and r = 0.913, p < 0.001) and the in-house test showed no genotype-dependent differences in detection and quantification rates. The in-house assay tested in this study could be used for screening and quantifying HBV DNA in order to monitor patients during therapy.
C1 [de Torres Santos, Ana Paula] Univ Sao Paulo, Fac Med, Hosp Clin, Div Lab Cent,Lab Imunol, Sao Paulo, SP, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, SP, Brazil.
   [Lemos, Marcilio Figueiredo; Calux, Samira Julien; Oba, Isabel Takano; Moreira, Regina Celia] Adolfo Lutz Inst, Ctr Virol, Nucleo Doencas Sanguineas & Sexuais, Sao Paulo, SP, Brazil.
RP Moreira, RC (corresponding author), Adolfo Lutz Inst, Ctr Virol, Nucleo Doencas Sanguineas & Sexuais, Sao Paulo, SP, Brazil.
EM regina.moreira7@gmail.com
RI Lemos, Marcilio/C-8430-2019; Moreira, Regina C/B-1488-2016
OI Lemos, Marcilio/0000-0002-5833-886X; Moreira, Regina
   C/0000-0002-8208-8776
FU PPSUS/FAPESP [09-53086-4]
FX Financial support: PPSUS/FAPESP (09-53086-4)
CR Alcalde R, 2009, REV INST MED TROP SP, V51, P269, DOI 10.1590/S0036-46652009000500006
   Alvarado-Mora MV, 2013, ANTIVIR THER, V18, P459, DOI 10.3851/IMP2599
   [Anonymous], 2003, J HEPATOL, V38, P533, DOI DOI 10.1016/S0168-8278(03)00083-7
   Aytay S, 2004, TRANSFUSION, V44, P476, DOI 10.1111/j.1537-2995.2003.03306.x
   BECKER Carlos Eduardo, 2013, Arq. Gastroenterol., V50, P219, DOI 10.1590/S0004-28032013000200039
   Bottecchia M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-11
   Carrilho FJ, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-13
   Compri AP, 2012, REV SOC BRAS MED TRO, V45, P301, DOI 10.1590/S0037-86822012000300004
   Compston LI, 2008, J VIROL METHODS, V151, P47, DOI 10.1016/j.jviromet.2008.03.023
   da Silva AC, 2010, MEM I OSWALDO CRUZ, V105, P770, DOI 10.1590/S0074-02762010000600007
   Daniel HDJ, 2009, INDIAN J MED MICROBI, V27, P111, DOI 10.4103/0255-0857.45362
   dos Santos AD, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-16
   Drosten C, 2000, TRANSFUSION, V40, P718, DOI 10.1046/j.1537-2995.2000.40060718.x
   Galli C, 2008, J MED VIROL, V80, P974, DOI 10.1002/jmv.21179
   Lu YQ, 2006, WORLD J GASTROENTERO, V12, P7365, DOI 10.3748/wjg.v12.i45.7365
   Moraes MTB, 1996, ARCH VIROL, V141, P1767, DOI 10.1007/BF01718299
   MS-Ministerio da Saude Brasil, 2010, EST PREV BAS POP INF
   MS-Ministerio da Saude Brasil, 2011, PROT CLIN DIR TER TR
   Shi M, 2008, WORLD J GASTROENTERO, V14, P479, DOI 10.3748/wjg.14.479
   Teles SA, 1999, ARTIF ORGANS, V23, P1074, DOI 10.1046/j.1525-1594.1999.06310.x
   Viana S, 2005, AM J TROP MED HYG, V73, P808, DOI 10.4269/ajtmh.2005.73.808
   Welzel TM, 2006, J CLIN MICROBIOL, V44, P3325, DOI 10.1128/JCM.00024-06
   Zhao JR, 2005, WORLD J GASTROENTERO, V11, P508, DOI 10.3748/wjg.v11.i4.508
NR 23
TC 2
Z9 3
U1 0
U2 8
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD FEB
PY 2016
VL 111
IS 2
BP 134
EP 140
DI 10.1590/0074-02760150415
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA DE3IW
UT WOS:000370522900008
PM 26872342
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU de Oliveira, CM
   Levi, JE
AF de Oliveira, Cristina Mendes
   Levi, Jose Eduardo
TI The Biological Impact of Genomic Diversity in Cervical Cancer
   Development
SO ACTA CYTOLOGICA
LA English
DT Review
DE Human papillomavirus; Cervical cancer; Genetic diversity
ID HUMAN-PAPILLOMAVIRUS TYPE-16; UPSTREAM REGULATORY REGION;
   SEQUENCE-ANALYSIS; VARIANT LINEAGES; RISK; DNA; APOBEC3; E6;
   CLASSIFICATION; POLYMORPHISMS
AB Human papillomaviruses (HPVs) are the etiologic agents of cervical cancer, the unique human neoplasia that has one single necessary cause. The diversity of HPVs is well described, with 200 HPV types existing as distinct taxonomic units and each receiving an Arabic number. On a clinical basis, they are usually grouped by their site of occurrence and disease associations. Those types inhabiting the anogenital mucosa are more intensively studied and further divided into cancer-associated HPVs, which are termed 'high risk', while those linked to benign proliferative lesions are assigned as 'low risk'. HPV16 is responsible for approximately 50% of all ICC cases, and paradoxically is one of the most prevalent types among healthy women. Longitudinal studies have shown that when an incidental HPV16 infection becomes persistent it will result in an enhanced risk for the development of high-grade lesions. However, it is unknown why some persistent, HPV16 infections (or infections by other HR-HPV types) progress to CIN3+ while most clear spontaneously. Several epidemiological investigations have focused on cofactors, from the most obvious such as cigarette and other carcinogenic exposures, to coinfections by other STDs such as chlamydia, with no significant findings. Thus, the current focus is on genomic variation from both virus and host. Such studies have been potentialized by the enormous technical advances in nucleic acid sequencing, allowing this relationship to be broadly interrogated. Corroborating subgenomic data from decades ago, an association between HPV16 lineages and carcinogenesis is being revealed. However, this effect does not seem to apply across female populations from different continents/ethnicities, again highlighting a role played by HPV16 adaptation and evasion from the host over time. (C) 2016 S. Karger AG, Basel.
C1 [de Oliveira, Cristina Mendes; Levi, Jose Eduardo] Univ Sao Paulo, Virol Lab, Inst Trop Med, Sao Paulo, Brazil.
RP de Oliveira, CM (corresponding author), Univ Sao Paulo, Virol Lab, Inst Trop Med, LIM 52, Rua Dr Eneas de Carvalho Aguiar 470,2 Andar, BR-05403000 Sao Paulo, Brazil.
EM cristina.oliveira1@gmail.com
RI Oliveira, Cristina M/F-7193-2012
CR Antonsson A, 2000, J VIROL, V74, P11636, DOI 10.1128/JVI.74.24.11636-11641.2000
   Arias-Pulido H, 2005, VIROLOGY, V338, P22, DOI 10.1016/j.virol.2005.04.022
   BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228
   Bernard HU, 2010, VIROLOGY, V401, P70, DOI 10.1016/j.virol.2010.02.002
   Berumen J, 2001, JNCI-J NATL CANCER I, V93, P1325, DOI 10.1093/jnci/93.17.1325
   Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
   Bravo IG, 2004, J VIROL, V78, P13613, DOI 10.1128/JVI.78.24.13613-13626.2004
   Bravo Ignacio G., 2015, Evolution Medicine and Public Health, P32, DOI 10.1093/emph/eov003
   Bravo IG, 2010, TRENDS MICROBIOL, V18, P432, DOI 10.1016/j.tim.2010.07.008
   Calleja-Macias IE, 2004, VIROLOGY, V319, P315, DOI 10.1016/j.virol.2003.11.009
   Chan PKS, 2002, J NATL CANCER I, V94, P1249, DOI 10.1093/jnci/94.16.1249
   Chen ZG, 2005, J VIROL, V79, P7014, DOI 10.1128/JVI.79.11.7014-7023.2005
   Chen ZG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020183
   Chen ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072565
   Chen Z, 2009, J VIROL, V83, P1443, DOI 10.1128/JVI.02068-08
   Cladel NM, 2010, VIRUS GENES, V40, P329, DOI 10.1007/s11262-010-0451-1
   Cornet I, 2013, BRIT J CANCER, V108, P240, DOI 10.1038/bjc.2012.508
   Cornet I, 2012, J VIROL, V86, P6855, DOI 10.1128/JVI.00483-12
   Cubie HA, 2013, VIROLOGY, V445, P21, DOI 10.1016/j.virol.2013.06.007
   Souza PSD, 2009, FUTURE ONCOL, V5, P359, DOI [10.2217/FON.09.8, 10.2217/fon.09.8]
   de Oliveira CM, 2015, INFECT GENET EVOL, V34, P44, DOI 10.1016/j.meegid.2015.07.002
   de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8
   de Villiers EM, 2013, VIROLOGY, V445, P2, DOI 10.1016/j.virol.2013.04.023
   DILLNER J, 1990, INT J CANCER, V46, P703, DOI 10.1002/ijc.2910460426
   DILORENZO TP, 1992, J GEN VIROL, V73, P423, DOI 10.1099/0022-1317-73-2-423
   Doorbar J, 2015, REV MED VIROL, V25, P2, DOI 10.1002/rmv.1822
   Engelmark M, 2004, HUM MOL GENET, V13, P1951, DOI 10.1093/hmg/ddh201
   Felez-Sanchez M, 2015, GENOME BIOL EVOL, V7, P2117, DOI 10.1093/gbe/evv129
   Garcia-Vallve S, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-20
   Hildesheim A, 2001, JNCI-J NATL CANCER I, V93, P315, DOI 10.1093/jnci/93.4.315
   HO L, 1991, J CLIN MICROBIOL, V29, P1765, DOI 10.1128/JCM.29.9.1765-1772.1991
   Hubert WG, 2005, J VIROL, V79, P5914, DOI 10.1128/JVI.79.10.5914-5922.2005
   Khouadri S, 2006, J INFECT DIS, V194, P886, DOI 10.1086/507431
   Kukimoto I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080583
   Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396
   Liu L, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/251364
   MARIN A, 1989, NUCLEIC ACIDS RES, V17, P6181
   Mirabello L, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw100
   Munk C, 2012, BMC EVOL BIOL, V12, DOI 10.1186/1471-2148-12-71
   MURRAY RF, 1971, NATURE, V232, P51, DOI 10.1038/232051a0
   OCONNOR M, 1995, HUMAN PAPILLOMAVIRUS
   Oliveira CM, 2012, GYNECOL ONCOL, V2, P18
   Quint W, 2012, J PATHOL, V227, P62, DOI 10.1002/path.3970
   Rector A, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r57
   Rose B, 1998, J GEN VIROL, V79, P1659, DOI 10.1099/0022-1317-79-7-1659
   Shah SD, 2010, MOL BIOL EVOL, V27, P1301, DOI 10.1093/molbev/msq015
   Sichero L, 2007, INT J CANCER, V120, P1763, DOI 10.1002/ijc.22481
   Smith B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021375
   Vartanian JP, 2008, SCIENCE, V320, P230, DOI 10.1126/science.1153201
   Villa LL, 2000, J GEN VIROL, V81, P2959, DOI 10.1099/0022-1317-81-12-2959
   VILLA LL, 1991, VIROLOGY, V181, P374
   Wang Z, 2014, J VIROL, V88, P1308, DOI 10.1128/JVI.03091-13
   Watts KJ, 2002, INT J CANCER, V97, P868, DOI 10.1002/ijc.10103
   Xi LF, 2006, J NATL CANCER I, V98, P1045, DOI 10.1093/jnci/djj297
   YAMADA T, 1995, J VIROL, V69, P7743, DOI 10.1128/JVI.69.12.7743-7753.1995
   Yuan H, 2012, NEW ENGL J MED, V367, P1220, DOI 10.1056/NEJMoa1203055
   Zhao KN, 2003, VIRUS RES, V98, P95, DOI 10.1016/j.virusres.2003.08.019
   Zoodsma M, 2005, J MED GENET, V42, DOI 10.1136/jmg.2005.031351
NR 58
TC 4
Z9 4
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0001-5547
EI 1938-2650
J9 ACTA CYTOL
JI Acta Cytol.
PY 2016
VL 60
IS 6
BP 513
EP 517
DI 10.1159/000449401
PG 5
WC Pathology
SC Pathology
GA EF9RK
UT WOS:000390667200003
PM 27771695
OA Bronze
DA 2020-11-30
ER

PT J
AU Freitas, VG
   Focchi, GR
   Pereira, ER
   Levi, JE
   Speck, NMG
   Ribalta, JC
AF Freitas, V. G.
   Focchi, G. R.
   Pereira, E. R.
   Levi, J. E.
   Speck, N. M. G.
   Ribalta, J. C.
TI HPV genotyping and p16 expression in Xingu Indigenous Park, Brazil
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE p16 protein; p16 expression; Human papillomavirus; Indigenous; Xingu;
   Genotype
ID CERVICAL INTRAEPITHELIAL NEOPLASIA; HUMAN-PAPILLOMAVIRUS GENOTYPES;
   CANCER; WOMEN; INFECTION; LESIONS; DIAGNOSIS; RISK; PREVALENCE;
   PREVENTION
AB The association between high-risk human papillomavirus (HPV) genotypes and p16 expression in indigenous women from the Xingu Indigenous Park, Brazil, was unknown. This study evaluated p16 expression in women with a histological diagnosis of cervical intraepithelial neoplasia (CIN) 3 or higher and correlated this expression with HPV genotypes to determine possible discrepancies in the expression of this marker. We evaluated 37 previously collected samples with different HPV genotypes and high-grade lesions diagnosed based on cytology, histology, and colposcopy. Immunohistochemical analysis was performed using paraffin-embedded tissue sections and the CINtec (R) Histology Kit. p16 protein expression was investigated by immunostaining with an anti-p16 antibody. HPV genotyping was performed by reverse hybridization. The age of the study population ranged from 22-75 years (43.81 +/- 15.89 years) and parity ranged from 1-11 (5.92 +/- 2.58). Thirteen different HPV genotypes were found using the INNO-LiPA kit. Single and multiple infections by HPV were found with prevalence of single infections (P = 0.029). Comparison between HPV genotype and simple or multiple infections was highly significant; it was observed more HPV 52 followed by HPV 16 in single infections (P < 0.001). p16 expression was predominantly diffuse, which was observed in 91.7% of lesions, whereas 8.3% were focal (P < 0.001). HPV 52, HPV 16 and 31 were the most prevalent HPV types in high-grade CIN in these indigenous women. Diffuse p16 expression in high-grade CIN was not influenced by the viral genotype; however, more studies are necessary to further our understanding of this restricted group.
C1 [Freitas, V. G.; Speck, N. M. G.; Ribalta, J. C.] Univ Fed Sao Paulo, Dept Ginecol, Nucleo Prevencao Doencas Ginecol, Sao Paulo, SP, Brazil.
   [Focchi, G. R.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Patol, Sao Paulo, SP, Brazil.
   [Pereira, E. R.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Med Prevent, Sao Paulo, SP, Brazil.
   [Levi, J. E.] Univ Sao Paulo, Inst Med Trop, Sao Paulo, SP, Brazil.
RP Freitas, VG (corresponding author), Univ Fed Sao Paulo, Dept Ginecol, Nucleo Prevencao Doencas Ginecol, Sao Paulo, SP, Brazil.
EM valgfreitas@yahoo.com.br
RI Ribalta, Julisa JCL/F-4287-2012
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
   grant
FX Research supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES) grant.
CR Bell MC, 2007, GYNECOL ONCOL, V107, P236, DOI 10.1016/j.ygyno.2007.06.007
   Bergeron C, 2010, AM J CLIN PATHOL, V133, P395, DOI 10.1309/AJCPXSVCDZ3D5MZM
   Brito EB, 2002, EPIDEMIOL INFECT, V128, P485, DOI 10.1017/S0950268802006908
   Ciapponi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025493
   Cunningham J, 2008, LANCET ONCOL, V9, P585, DOI 10.1016/S1470-2045(08)70150-5
   Dal Bello B, 2009, J CLIN MICROBIOL, V47, P2175, DOI 10.1128/JCM.00286-09
   Darragh TM, 2013, INT J GYNECOL PATHOL, V32, P76, DOI 10.1097/PGP.0b013e31826916c7
   Speck NMD, 2009, EUR J GYNAECOL ONCOL, V30, P415
   Del Rio-Ospina L, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1126-z
   Dijkstra MG, 2010, J CLIN PATHOL, V63, P972, DOI 10.1136/jcp.2010.078634
   Focchi Gustavo R A, 2007, J Low Genit Tract Dis, V11, P98, DOI 10.1097/01.lgt.0000245042.29847.dd
   Gracey M, 2009, LANCET, V374, P65, DOI 10.1016/S0140-6736(09)60914-4
   Hamid NA, 2009, CELL MOL LIFE SCI, V66, P1700, DOI 10.1007/s00018-009-8631-7
   Herrero R, 2015, LANCET ONCOL, V16, pE206, DOI 10.1016/S1470-2045(14)70481-4
   Kahn M, 2011, CHEM BIODIVERSITY, V1
   Kietpeerakool Chumnan, 2015, Asian Pac J Cancer Prev, V16, P5153
   Klaes R, 2002, AM J SURG PATHOL, V26, P1389, DOI 10.1097/00000478-200211000-00001
   Kleter B, 1999, J CLIN MICROBIOL, V37, P2508, DOI 10.1128/JCM.37.8.2508-2517.1999
   Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396
   Munagala R, 2009, INT J ONCOL, V34, P263, DOI 10.3892/ijo_00000148
   Peurala E, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3376
   Pitta DR, 2009, SAO PAULO MED J, V127, P122, DOI 10.1590/S1516-31802009000300003
   Plummer M, 2007, J INFECT DIS, V195, P1582, DOI 10.1086/516784
   Pereira ER, 2015, EUR J GYNAECOL ONCOL, V36, P376
   Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0
   Shwe MM, 2015, ACTA MED OKAYAMA, V69, P51
   Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527
   Taborda W C, 2000, Rev Panam Salud Publica, V7, P92, DOI 10.1590/S1020-49892000000200004
   Tonon SA, 2004, INT J INFECT DIS, V8, P13, DOI 10.1016/j.ijid.2003.03.001
   Torres M, 2012, Open Virol J, V6, P144, DOI 10.2174/1874357901206010144
   Trottier H, 2006, CANCER EPIDEM BIOMAR, V15, P1274, DOI 10.1158/1055-9965.EPI-06-0129
   Tsoumpou I, 2009, CANCER TREAT REV, V35, P210, DOI 10.1016/j.ctrv.2008.10.005
   van der Graaf Y, 2002, AM J EPIDEMIOL, V156, P158, DOI 10.1093/aje/kwf013
   WHO, 2015, HUM PAP HPV CERV CAN
   Xue H, 2015, J MED VIROL, V87, P1248, DOI 10.1002/jmv.24029
   Zhang G, 2015, INT J GYNECOL PATHOL, V34, P180, DOI 10.1097/PGP.0000000000000112
NR 36
TC 0
Z9 0
U1 0
U2 2
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
SN 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2016
VL 15
IS 3
AR 15036840
DI 10.4238/gmr.15036840
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA DY1UY
UT WOS:000384881100006
PM 27706717
OA Bronze
DA 2020-11-30
ER

PT J
AU Cambou, MC
   Levi, JE
   Lake, JE
   de Andrade, A
   Jalil, EM
   Russomano, F
   Derrico, M
   Veloso, VG
   Friedman, RK
   Luz, PM
   Grinsztejn, B
AF Cambou, Mary C.
   Levi, Jose Eduardo
   Lake, Jordan E.
   de Andrade, Angela
   Jalil, Emilia M.
   Russomano, Fabio
   Derrico, Monica
   Veloso, Valdilea G.
   Friedman, Ruth K.
   Luz, Paula M.
   Grinsztejn, Beatriz
TI Time trend analysis of cervical high-risk human papillomavirus (HPV) in
   HIV-infected women in an urban cohort from Rio de Janeiro, Brazil: the
   rise of non-16/18 HPV
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV; Women; Cervical HPV; High-risk HPV; HPV vaccine; Epidemiology
ID SQUAMOUS INTRAEPITHELIAL LESIONS; PREVALENCE
AB Objectives: HIV-infected women are at increased risk of human papillomavirus (HPV) infection. Time trends in annual prevalences of cervical high-risk human papillomavirus (HR-HPV) genotypes among a non-vaccinated, HIV-infected female cohort in urban Brazil were assessed for the period 2006-2012.
   Methods: Cervical specimens were collected for HPV genotyping yearly between January 2006 and December 2012 in a cross-sectional analysis of participants aged >= 18 years enrolled in the Women's HIV Cohort at Fiocruz in Rio de Janeiro, Brazil. Age-adjusted generalized estimating equation models with an exchangeable matrix were used to estimate odds ratios (OR) and 95% confidence intervals (CI) for annual HPV positivity (reference year: 2006).
   Results: Among the 590 participants, the median age across all study years ranged from 35.5 to 40.0 years. The prevalence of any HR-HPV was >= 53% every year; prevalences of HR-HPV 16, 58, 59, and 68 were >= 24% in at least 1 year. The odds of HPV 16 and 68 decreased in 2012. HPV 58 prevalence followed a U-shape, beginning and ending at >20%. HPV 59 prevalence followed a linear trend, with increased odds in 2012 (OR 16.0, 95% CI 3.8-67.3; Bonferroni-adjusted p-value <0.01).
   Conclusions: The prevalences of HR-HPV 58, 59, and 68 were high in this cohort. Given current HR-HPV vaccine coverage and availability, further investigations are needed to optimize vaccine recommendations for this population. (C) 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Cambou, Mary C.; Lake, Jordan E.] Univ Calif Los Angeles, David Geffen Sch Med, Program Global Hlth, Dept Med,Div Infect Dis, Los Angeles, CA 90095 USA.
   [Cambou, Mary C.] Montefiore Univ Hosp, Albert Einstein Coll Med, Dept Internal Med, Bronx, NY USA.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop, Virol Lab, Sao Paulo, SP, Brazil.
   [de Andrade, Angela; Jalil, Emilia M.; Derrico, Monica; Veloso, Valdilea G.; Friedman, Ruth K.; Luz, Paula M.; Grinsztejn, Beatriz] Fiocruz MS, Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas IPEC, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Russomano, Fabio] Fiocruz MS, Inst Fernandes Figueira, BR-21045900 Rio De Janeiro, RJ, Brazil.
RP Cambou, MC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Program Global Hlth, Dept Med,Div Infect Dis, 10833 Le Conte Ave,CHS 37-121, Los Angeles, CA 90095 USA.
EM mcambou@montefiore.org
OI Luz, Paula/0000-0001-9746-719X
FU South American Program in HIV Prevention Research (SAPHIR) [NIH R25
   MH087222]; Brazilian National Counsel of Technological and Scientific
   Development (CNPq)National Council for Scientific and Technological
   Development (CNPq); Research Funding Agency of the State of Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); Instituto de Pesquisa Clinica
   Evandro Chagas; Fundacao Oswaldo Cruz; Brazilian National STD/AIDS
   Program of the Brazilian Ministry of Health; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [K23AI110532]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069476,
   K23AI110532, UM1AI069476, UM1AI069476, K23AI110532, K23AI110532,
   UM1AI069476, K23AI110532, K23AI110532, UM1AI069476, UM1AI069476,
   K23AI110532, UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [R25MH087222, R25MH087222,
   R25MH087222, R25MH087222, R25MH087222, R25MH087222, R25MH087222,
   R25MH087222] Funding Source: NIH RePORTER
FX MCC, JEL, PML, and BG are supported by the South American Program in HIV
   Prevention Research (SAPHIR; NIH R25 MH087222). BG and PML acknowledge
   funding from the Brazilian National Counsel of Technological and
   Scientific Development (CNPq) and the Research Funding Agency of the
   State of Rio de Janeiro (FAPERJ). This study was funded by the Instituto
   de Pesquisa Clinica Evandro Chagas, Fundacao Oswaldo Cruz and the
   Brazilian National STD/AIDS Program of the Brazilian Ministry of Health.
   JEL has served as a consultant to Gilead Sciences and GSK. JEL is
   supported by the National Institutes of Health (K23AI110532). The
   authors would like to acknowledge the participants and Fiocruz staff who
   made the IPEC Women's HIV Cervical HPV Genotyping Study possible.
CR Cambou MC, 2015, AIDS PATIENT CARE ST, V29, P4, DOI 10.1089/apc.2014.0166
   Choi YH, 2012, VACCINE, V30, P3383, DOI 10.1016/j.vaccine.2012.03.065
   Drolet M, 2015, LANCET INFECT DIS, V15, P565, DOI 10.1016/S1473-3099(14)71073-4
   Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031
   Fernandes Jose V, 2010, BMC Res Notes, V3, P96, DOI 10.1186/1756-0500-3-96
   Grinsztejn B, 2009, INT J INFECT DIS, V13, P72, DOI 10.1016/j.ijid.2008.03.031
   Luz PM, 2012, INT J STD AIDS, V23, P12, DOI 10.1258/ijsa.2009.009409
   Malagon T, 2012, LANCET INFECT DIS, V12, P781, DOI 10.1016/S1473-3099(12)70187-1
   McKenzie ND, 2010, GYNECOL ONCOL, V116, P572, DOI 10.1016/j.ygyno.2009.10.058
   Paesi S, 2009, J MED VIROL, V81, P1270, DOI 10.1002/jmv.21410
NR 10
TC 4
Z9 4
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD DEC
PY 2015
VL 41
BP 17
EP 20
DI 10.1016/j.ijid.2015.10.017
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA DA8FI
UT WOS:000368040100006
PM 26518062
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-11-30
ER

PT J
AU Genta, MLND
   Anton, C
   Sadalla, JC
   Carvalho, JPM
   Levi, JE
   Oliveira, C
   Carvalho, JP
AF Genta, M. L. N. D.
   Anton, C.
   Sadalla, J. C.
   Carvalho, J. P. M.
   Levi, J. E.
   Oliveira, C.
   Carvalho, J. P.
TI IMPACT OF HPV 16 AND 18 ON INVASIVE CERVICAL CANCER SURVIVAL IN BRAZIL
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
LA English
DT Meeting Abstract
C1 [Genta, M. L. N. D.; Anton, C.; Sadalla, J. C.; Carvalho, J. P. M.; Carvalho, J. P.] Inst Canc Estado Sao Paulo, Gynecol Oncol, Sao Paulo, Brazil.
   [Levi, J. E.; Oliveira, C.] Inst Med Trop, Virol, Sao Paulo, Brazil.
RI CARVALHO, JESUS PAULA/G-8387-2018; Anton, Cristina/ABB-9783-2020;
   Oliveira, Cristina M/F-7193-2012; Anton, Cristina/AAS-7697-2020;
   Carvalho, Jesus Paula/O-7464-2019
OI CARVALHO, JESUS PAULA/0000-0003-4495-057X; Anton,
   Cristina/0000-0002-6259-2449; 
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1048-891X
EI 1525-1438
J9 INT J GYNECOL CANCER
JI Int. J. Gynecol. Cancer
PD OCT
PY 2015
VL 25
IS 9
SU 1
MA ESGO-1292
BP 793
EP 793
PG 1
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA DN5XT
UT WOS:000377145702090
DA 2020-11-30
ER

PT J
AU Lima, GF
   Sanchez, MCA
   Levi, JE
   Caramelo, LC
   Fujimori, M
   Sanchez, AR
   Inoue, J
   Costa-Nascimento, MJ
   Junior, AM
   Di Santi, SM
AF Lima, Giselle F.
   Sanchez, Maria Carmen A.
   Levi, Jose E.
   Caramelo, Luiza C.
   Fujimori, Mahyumi
   Sanchez, Arianni R.
   Inoue, Juliana
   Costa-Nascimento, Maria J.
   Junior, Alfredo M.
   Di Santi, Silvia M.
TI HIDDEN PLASMODIUM AND THE RISK OF TRANSFUSION TRANSMITTED MALARIA IN
   NON-ENDEMIC AREAS
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
C1 [Lima, Giselle F.; Inoue, Juliana; Di Santi, Silvia M.] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Sanchez, Maria Carmen A.; Caramelo, Luiza C.; Fujimori, Mahyumi; Sanchez, Arianni R.] Univ Sao Paulo, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   [Levi, Jose E.; Junior, Alfredo M.] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Costa-Nascimento, Maria J.] Superintendencia Controle Endemias Estado Sao Paul, Sao Paulo, Brazil.
RI Sanchez, Maria Carmen/D-8886-2012
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 2015
VL 93
IS 4
SU S
MA 844
BP 256
EP 256
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA VB0ZJ
UT WOS:000412844102585
DA 2020-11-30
ER

PT J
AU Luna, EJ
   Figueiredo, GM
   Levi, JE
   Figueiredo, WM
   Costa, AA
   Campos, SR
   Felix, AC
   Souza, AC
   Souza, NC
   Cardoso, MR
   Pannuti, CS
AF Luna, Expedito J.
   Figueiredo, Gerusa M.
   Levi, Jose E.
   Figueiredo, Walter M.
   Costa, Angela A.
   Campos, Sergio R.
   Felix, Alvina C.
   Souza, Ana C.
   Souza, Nathalia C.
   Cardoso, Maria R.
   Pannuti, Claudio S.
TI DENGUE COHORT STUDY, ARARAQUARA, BRAZIL, 2015, BASELINE SEROPREVALENCE
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Meeting Abstract
C1 [Luna, Expedito J.; Figueiredo, Gerusa M.; Levi, Jose E.; Campos, Sergio R.; Felix, Alvina C.; Souza, Ana C.; Souza, Nathalia C.; Cardoso, Maria R.; Pannuti, Claudio S.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Figueiredo, Walter M.; Costa, Angela A.] Univ Sao Paulo, Araraquara, Brazil.
RI Figueiredo, Gerusa M/B-6660-2014; Luna, Expedito J A/B-7948-2012
OI Figueiredo, Gerusa M/0000-0001-9657-9675; Luna, Expedito J
   A/0000-0002-1145-9672
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD OCT
PY 2015
VL 93
IS 4
SU S
MA 1413
BP 431
EP 432
PG 2
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA VB0ZJ
UT WOS:000412844103408
DA 2020-11-30
ER

PT J
AU Levi, J
   Lira, SC
   Polite, MB
   Farinha, MT
   Bianco, C
   Sakashita, A
   Kutner, JM
AF Levi, J.
   Lira, S. C.
   Polite, M. B.
   Farinha, M. T.
   Bianco, C.
   Sakashita, A.
   Kutner, J. M.
TI HIV Seroepidemiology in 10 Years of Blood DonorScreening
SO TRANSFUSION
LA English
DT Meeting Abstract
CT AABB Annual Meeting
CY OCT 24-27, 2015
CL Anaheim, CA
SP AABB
C1 [Levi, J.; Lira, S. C.; Polite, M. B.; Farinha, M. T.; Bianco, C.; Sakashita, A.; Kutner, J. M.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
RI Carranza-Lira, Sebastian/AAF-4886-2019
NR 0
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 2015
VL 55
SU 3
SI SI
MA SP329
BP 192A
EP 192A
PG 1
WC Hematology
SC Hematology
GA DD5GS
UT WOS:000369951500419
DA 2020-11-30
ER

PT J
AU Levi, JE
   Lira, SMD
   Polite, MBD
   Pereira, RAD
   Mota, M
   Bianco, C
   Kutner, JM
AF Levi, Jose Eduardo
   da Costa Lira, Sanny Marcele
   de Carvalho Polite, Marcia Bernardino
   d'Almeida Pereira, Ricardo Antonio
   Mota, Mariza
   Bianco, Celso
   Kutner, Jose Mauro
TI Simultaneous blood donor screening for abnormal hemoglobin levels and
   glycated hemoglobin (HbA(1c)) by high-performance liquid chromatography
SO TRANSFUSION
LA English
DT Letter
C1 [Levi, Jose Eduardo; da Costa Lira, Sanny Marcele; de Carvalho Polite, Marcia Bernardino; d'Almeida Pereira, Ricardo Antonio; Mota, Mariza; Bianco, Celso; Kutner, Jose Mauro] Hosp Israelita Albert Einstein, Hemotherapy & Cell Therapy Dept, Sao Paulo, Brazil.
RP Levi, JE (corresponding author), Hosp Israelita Albert Einstein, Hemotherapy & Cell Therapy Dept, Sao Paulo, Brazil.
EM jose.levi@einstein.br
OI Kutner, Jose/0000-0003-3784-6731
CR Amer Diabet Assoc, 2012, DIABETES CARE, V35, pS64, DOI [10.2337/dc12-s064, 10.2337/dc12-S064, 10.2337/dc09-S062, 10.2337/dc11-S062]
   Davey RJ, 2006, VOX SANG, V91, P206, DOI 10.1111/j.1423-0410.2006.00824.x
   Gore MO, 2014, DIABETES CARE, V37, pE3, DOI 10.2337/dc13-0908
   Kessler DA, 2012, TRANSFUSION, V52, P2174, DOI 10.1111/j.1537-2995.2011.03549.x
   Lenhard MJ, 2013, TRANSFUSION, V53, P2776, DOI 10.1111/trf.12135
NR 5
TC 1
Z9 1
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 2015
VL 55
IS 9
BP 2291
EP 2292
DI 10.1111/trf.13209
PG 2
WC Hematology
SC Hematology
GA CT6HO
UT WOS:000362914300029
PM 26372916
DA 2020-11-30
ER

PT J
AU Nishiya, AS
   de Almeida-Neto, C
   Romano, CM
   Alencar, CS
   Ferreira, SC
   Di-Lorenzo-Oliveira, C
   Levi, JE
   Salles, NA
   Mendrone, A
   Sabino, EC
AF Nishiya, Anna Shoko
   de Almeida-Neto, Cesar
   Romano, Camila Malta
   Alencar, Ceclia Salete
   Ferreira, Suzete Cleusa
   Di-Lorenzo-Oliveira, Claudia
   Levi, Jose Eduardo
   Salles, Nanci Alves
   Mendrone-Junior, Alfredo
   Sabino, Ester Cerdeira
TI Phylogenetic analysis of the emergence of main hepatitis C virus
   subtypes in Sao Paulo, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Growth rate; HCV; Phylogenetic analysis; Subtypes
ID BLOOD-DONORS; MOLECULAR EPIDEMIOLOGY; GENETIC DIVERSITY; SEROLOGIC
   MARKERS; VIRAL-HEPATITIS; PREVALENCE; INFECTION; GENOTYPES; RISK;
   TRANSMISSION
AB Background: It is recognized that hepatitis C virus subtypes (1a, 1b, 2a, 2b, 2c and 3a) originated in Africa and Asia and spread worldwide exponentially during the Second World War (1940) through the transfusion of contaminated blood products, invasive medical and dental procedures, and intravenous drug use. The entry of hepatitis C virus subtypes into different regions occurred at distinct times, presenting exponential growth rates of larger or smaller spread. Our study estimated the growth and spread of the most prevalent subtypes currently circulating in Sao Paulo.
   Methods: A total of 465 non-structural region 5B sequences of hepatitis C virus covering a 14-year time-span were used to reconstruct the population history and estimate the population dynamics and Time to Most Recent Common Ancestor of genotypes using the Bayesian Markov Chain Monte Carlo approach implemented in BEAST (Bayesian evolutionary analysis by sampling tree software/program).
   Results: Evolutionary analysis demonstrated that the different hepatitis C virus subtypes had distinct growth patterns. The introduction of hepatitis C virus-la and -3a were estimated to be circa 1979 and 1967, respectively, whereas hepatitis C virus-1b appears to have a more ancient entry, circa 1923. Hepatitis C virus-1b phylogenies suggest that different lineages circulate in Sao Paulo, and four well-supported groups (i.e., G1, G2, G3 and G4) were identified. Hepatitis C virus-la presented the highest growth rate (r=0.4), but its spread became less marked after the 2000s. Hepatitis C virus-3a grew exponentially until the 1990s and had an intermediate growth rate (r=0.32). An evident exponential growth (r=0.26) was found for hepatitis C virus-1b between 1980 and the mid-1990s.
   Conclusions: After an initial period of exponential growth, the expansion of the three main subtypes began to decrease. Hepatitis C virus-1b presented inflated genetic diversity, and its transmission may have been sustained by different generations and transmission routes other than blood transfusion. Hepatitis C virus-1a and -3a showed no group stratification, most likely due to their recent entry. (C) 2015 Elsevier Editora Ltda. All rights reserved.
C1 [Nishiya, Anna Shoko; de Almeida-Neto, Cesar; Ferreira, Suzete Cleusa; Levi, Jose Eduardo; Salles, Nanci Alves; Mendrone-Junior, Alfredo] Fundacao Prosangue Hemoctr Sao Paulo, BR-05403000 Sao Paulo, SP, Brazil.
   [Nishiya, Anna Shoko; Alencar, Ceclia Salete; Ferreira, Suzete Cleusa; Sabino, Ester Cerdeira] Univ Fed Sao Paulo UNIFESP, Infect Dis Div DIPA, Sao Paulo, SP, Brazil.
   [de Almeida-Neto, Cesar] Univ Sao Paulo, Fac Med, Discipline Med Sci, Sao Paulo, SP, Brazil.
   [Romano, Camila Malta] Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, Lab Virol,Dept Infect & Parasit Dis, Sao Paulo, SP, Brazil.
   [Alencar, Ceclia Salete] Univ Sao Paulo, Fac Med, Hosp Clin, Lim Med Res Lab 03, Sao Paulo, SP, Brazil.
   [Di-Lorenzo-Oliveira, Claudia] Univ Sao Joao Del Rei, Sao Joao Del Rei, MG, Brazil.
   [Sabino, Ester Cerdeira] Univ Sao Paulo, Fac Med, Dept Infect Dis, Sao Paulo, SP, Brazil.
RP Nishiya, AS (corresponding author), Fundacao Prosangue Hemoctr Sao Paulo, Dept Biol Mol, Av Dr Eneas Carvalho de Aguiar 155, BR-05403000 Sao Paulo, SP, Brazil.
EM a_nishiya@hotmail.com
RI de Almeida-Neto, Cesar/O-9224-2014; Romano, Camila M/C-8185-2013;
   Nishiya, Anna/Q-8156-2016; Romano, Camila/ABC-2883-2020; Ferreira,
   Suzete/K-1626-2016; Sabino, Ester Cerdeira/F-7750-2010
OI de Almeida-Neto, Cesar/0000-0002-8490-4634; Romano,
   Camila/0000-0003-4550-1987; Ferreira, Suzete/0000-0002-4190-0238;
   Sabino, Ester Cerdeira/0000-0003-2623-5126
FU CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) of
   Brazilian Ministry of EducationCAPES; Fundacao Pro-Sangue/Hemocentro de
   Sao Paulo
FX This study was supported by CAPES (Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior) of Brazilian Ministry of Education and by
   Fundacao Pro-Sangue/Hemocentro de Sao Paulo.
CR Oliveira MDA, 2009, J CLIN VIROL, V44, P200, DOI 10.1016/j.jcv.2008.12.008
   Brandao Ajacio B M, 2002, BMC Gastroenterol, V2, P18, DOI 10.1186/1471-230X-2-18
   Busch MP, 2003, JAMA-J AM MED ASSOC, V289, P959, DOI 10.1001/jama.289.8.959
   Candotti D, 2003, J VIROL, V77, P7914, DOI 10.1128/JVI.77.14.7914-7923.2003
   CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562
   Danta M, 2007, AIDS, V21, P983, DOI 10.1097/QAD.0b013e3281053a0c
   de Almeida-Neto C, 2013, TRANSFUSION, V53, P827, DOI 10.1111/j.1537-2995.2012.03840.x
   DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   FOCACCIA R, 1998, BRAZ J INFECT DIS, V2, P269
   Hauri AM, 2004, INT J STD AIDS, V15, P7, DOI 10.1258/095646204322637182
   Jeannel D, 1998, J MED VIROL, V55, P92, DOI 10.1002/(SICI)1096-9071(199806)55:2&lt;92::AID-JMV2&gt;3.0.CO;2-I
   JUNQUEIRA PC, 2005, REV BRAS HEMATOL HEM, V27, P201, DOI DOI 10.1590/S1516-84842005000300013
   Lampe E, 2010, INFECT GENET EVOL, V10, P886, DOI 10.1016/j.meegid.2010.05.010
   Lavanchy D, 1999, J VIRAL HEPATITIS, V6, P35
   Levi JE, 2002, J CLIN MICROBIOL, V40, P2645, DOI 10.1128/JCM.40.7.2645-2647.2002
   Lopes Carmen L R, 2009, Rev. Saúde Pública, V43, P43, DOI 10.1590/S0034-89102009000800008
   Magiorkinis G, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000198
   MELLOR J, 1995, J GEN VIROL, V76, P2493, DOI 10.1099/0022-1317-76-10-2493
   Mendes-Correa Maria Cassia J., 2001, Revista do Instituto de Medicina Tropical de Sao Paulo, V43, P15, DOI 10.1590/S0036-46652001000100003
   Miller ER, 2009, J INFECTION, V58, P375, DOI 10.1016/j.jinf.2009.02.014
   Morice Y, 2006, J MED VIROL, V78, P1296, DOI 10.1002/jmv.20692
   Nakano T, 2004, J INFECT DIS, V190, P1098, DOI 10.1086/422606
   Nascimento MC, 2008, J MED VIROL, V80, P53, DOI 10.1002/jmv.21046
   Ndjomou J, 2003, J GEN VIROL, V84, P2333, DOI 10.1099/vir.0.19240-0
   Nishiya AS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086413
   Noronha IL, 1997, NEPHROL DIAL TRANSPL, V12, P2234, DOI 10.1093/ndt/12.11.2234
   Oliveira Maria de Lourdes Aguiar, 2006, Cad. Saúde Pública, V22, P861, DOI 10.1590/S0102-311X2006000400024
   Oliveira MLA, 1999, BRAZ J MED BIOL RES, V32, P279, DOI 10.1590/S0100-879X1999000300005
   Pereira LMMB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-60
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Pybus OG, 2001, SCIENCE, V292, P2323, DOI 10.1126/science.1058321
   Pybus OG, 2007, INT J PARASITOL, V37, P839, DOI 10.1016/j.ijpara.2007.04.009
   Pybus Oliver G, 2005, Infect Genet Evol, V5, P131, DOI 10.1016/j.meegid.2004.08.001
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011170
   Rosini Nilton, 2003, Braz J Infect Dis, V7, P262, DOI 10.1590/S1413-86702003000400006
   Salles Nanci A., 2003, Rev Panam Salud Publica, V13, P111, DOI 10.1590/S1020-49892003000200011
   Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4
   Silva MBS, 2010, MEM I OSWALDO CRUZ, V105, P299, DOI 10.1590/S0074-02762010000300009
   Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819
   Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0
   SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661
   Simmonds P, 2013, CURR TOP MICROBIOL, V369, P1, DOI 10.1007/978-3-642-27340-7_1
   Smith DB, 1997, J GASTROEN HEPATOL, V12, P522, DOI 10.1111/j.1440-1746.1997.tb00477.x
   Tohme RA, 2010, HEPATOLOGY, V52, P1497, DOI 10.1002/hep.23808
   Valente VB, 2005, REV SOC BRAS MED TRO, V38, P488, DOI 10.1590/S0037-86822005000600008
   Wasley Annemarie, 2007, MMWR Surveill Summ, V56, P1
   WHO, 2012, HEP C N 164 FS, V2014
   Wolff FH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010494
   Zarife MAS, 2006, T ROY SOC TROP MED H, V100, P663, DOI 10.1016/j.trstmh.2005.09.009
NR 50
TC 5
Z9 6
U1 2
U2 8
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2015
VL 19
IS 5
BP 473
EP 478
DI 10.1016/j.bjid.2015.06.010
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA CS5FY
UT WOS:000362104000004
PM 26296325
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU de Oliveira, CM
   Bravo, IG
   Souza, NCSE
   Genta, MLND
   Fregnani, JHTG
   Tacla, M
   Carvalho, JP
   Longatto, A
   Levi, JE
AF de Oliveira, Cristina Mendes
   Bravo, Ignacio G.
   Santiago e Souza, Nathalia Caroline
   Nogueira Dias Genta, Maria Luiza
   Tavares Guerreiro Fregnani, Jose Humberto
   Tacla, Maricy
   Carvalho, Jesus Paula
   Longatto-Filho, Adhemar
   Levi, Jose Eduardo
TI High-level of viral genomic diversity in cervical cancers: A Brazilian
   study on human papillomavirus type 16
SO INFECTION GENETICS AND EVOLUTION
LA English
DT Article
DE HPV16 diversity; Intralesion; Cervical cancer
ID INTEGRATION SITES; INTRAEPITHELIAL NEOPLASIA; PRECANCEROUS LESIONS;
   DNA-REPLICATION; LIFE-CYCLE; CARCINOMA; PAPILLOMATOSIS; APOBEC3; WOMEN;
   HPV
AB Invasive cervical cancer (ICC) is the third most frequent cancer among women worldwide and is associated with persistent infection by carcinogenic human papillomaviruses (HPVs). The combination of large populations of viral progeny and decades of sustained infection may allow for the generation of intra-patient diversity, in spite of the assumedly low mutation rates of PVs. While the natural history of chronic HPVs infections has been comprehensively described, within-host viral diversity remains largely unexplored.
   In this study we have applied next generation sequencing to the analysis of intra-host genetic diversity in ten ICC and one condyloma cases associated to single HPV16 infection. We retrieved from all cases near full-length genomic sequences.
   All samples analyzed contained polymorphic sites, ranging from 3 to 125 polymorphic positions per genome, and the median probability of a viral genome picked at random to be identical to the consensus sequence in the lesion was only 40%. We have also identified two independent putative duplication events in two samples, spanning the L2 and the L1 gene, respectively. Finally, we have identified with good support a chimera of human and viral DNA.
   We propose that viral diversity generated during HPVs chronic infection may be fueled by innate and adaptive immune pressures. Further research will be needed to understand the dynamics of viral DNA variability, differentially in benign and malignant lesions, as well as in tissues with differential intensity of immune surveillance. Finally, the impact of intralesion viral diversity on the long-term oncogenic potential may deserve closer attention. (C) 2015 Elsevier B.V. All rights reserved.
C1 [de Oliveira, Cristina Mendes; Santiago e Souza, Nathalia Caroline; Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop, Lab Virol, Sao Paulo, Brazil.
   [de Oliveira, Cristina Mendes; Bravo, Ignacio G.] Catalan Inst Oncol, Infect & Canc Lab, Barcelona, Spain.
   [Nogueira Dias Genta, Maria Luiza; Carvalho, Jesus Paula] ICESP, Fac Med, Sao Paulo, Brazil.
   [Tavares Guerreiro Fregnani, Jose Humberto] Barretos Canc Hosp, Teaching & Res Inst, Sao Paulo, Brazil.
   [Tacla, Maricy] Univ Sao Paulo, Fac Med, Dept Gynecol, Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] Hosp Canc Barretos, Mol Oncol Res Ctr, Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] Univ Sao Paulo, Fac Med, Lab Med Invest LIM 14, Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal.
   [Longatto-Filho, Adhemar] PT Govt Associate Lab, ICVS 3Bs, Braga, Portugal.
RP de Oliveira, CM (corresponding author), Univ Sao Paulo, Inst Med Trop, Lab Virol, LIM 52, Rua Dr Eneas Carvalho Aguiar 470,2o Andar, BR-05403000 Sao Paulo, SP, Brazil.
EM cristina.oliveira1@gmail.com
RI Filho, Adhemar Longatto/A-2889-2016; Longatto-Filho,
   Adhemar/N-3397-2019; CARVALHO, JESUS PAULA/G-8387-2018; longatto-filho,
   adhemar/D-7039-2013; Fregnani, Jose H/H-4238-2012; Carvalho, Jesus
   Paula/O-7464-2019; Bravo, Ignacio G./A-2483-2009; Oliveira, Cristina
   M/F-7193-2012
OI Longatto-Filho, Adhemar/0000-0002-5779-9752; CARVALHO, JESUS
   PAULA/0000-0003-4495-057X; longatto-filho, adhemar/0000-0002-5779-9752;
   Fregnani, Jose H/0000-0002-5235-6469; Bravo, Ignacio
   G./0000-0003-3389-3389; 
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2011/24035-2, 2012/23290-1]
FX C.M.O. is funded by Grants # 2011/24035-2 and # 2012/23290-1, Sao Paulo
   Research Foundation (FAPESP).
CR Akagi K, 2014, GENOME RES, V24, P185, DOI 10.1101/gr.164806.113
   Antonsson A, 2000, J VIROL, V74, P11636, DOI 10.1128/JVI.74.24.11636-11641.2000
   Aromseree S, 2014, J MED VIROL, V86, P1911, DOI 10.1002/jmv.24034
   BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228
   Bernard HU, 2010, VIROLOGY, V401, P70, DOI 10.1016/j.virol.2010.02.002
   Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
   Bragg LM, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003031
   Bravo Ignacio G., 2015, Evolution Medicine and Public Health, P32, DOI 10.1093/emph/eov003
   Bravo IG, 2010, TRENDS MICROBIOL, V18, P432, DOI 10.1016/j.tim.2010.07.008
   Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321
   Burk RD, 2013, VIROLOGY, V445, P232, DOI 10.1016/j.virol.2013.07.018
   BYRNE JC, 1987, NEW ENGL J MED, V317, P873, DOI 10.1056/NEJM198710013171406
   Canadas MP, 2010, CLIN MICROBIOL INFEC, V16, P836, DOI 10.1111/j.1469-0691.2009.02964.x
   Chen ZG, 2005, J VIROL, V79, P7014, DOI 10.1128/JVI.79.11.7014-7023.2005
   Chen ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072565
   Chen Z, 2009, J VIROL, V83, P1443, DOI 10.1128/JVI.02068-08
   Cubie HA, 2013, VIROLOGY, V445, P21, DOI 10.1016/j.virol.2013.06.007
   Dall KL, 2008, CANCER RES, V68, P8249, DOI 10.1158/0008-5472.CAN-08-1741
   de Oliveira CM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-357
   de Sanjose S, 2014, PRESSE MED, V43, pE423, DOI 10.1016/j.lpm.2014.10.001
   de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8
   de Villiers EM, 2013, VIROLOGY, V445, P2, DOI 10.1016/j.virol.2013.04.023
   De Vuyst H, 2009, INT J CANCER, V124, P1626, DOI 10.1002/ijc.24116
   DILLNER J, 1990, INT J CANCER, V46, P703, DOI 10.1002/ijc.2910460426
   DILORENZO TP, 1992, J GEN VIROL, V73, P423, DOI 10.1099/0022-1317-73-2-423
   Doorbar J, 2006, CLIN SCI, V110, P525, DOI 10.1042/CS20050369
   Doorbar J, 2012, VACCINE, V30, pF55, DOI 10.1016/j.vaccine.2012.06.083
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Flores ER, 1997, J VIROL, V71, P7167, DOI 10.1128/JVI.71.10.7167-7179.1997
   Freitas LB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100746
   Gheit T, 2006, VIRAL IMMUNOL, V19, P340, DOI 10.1089/vim.2006.19.340
   Kukimoto I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080583
   Levi JE, 2014, OJOG, V4, P470, DOI DOI 10.4236/0J0G.2014.48068
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396
   Liu L, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/251364
   Loeb LA, 2008, NAT REV GENET, V9, P594, DOI 10.1038/nrg2345
   Munk C, 2012, BMC EVOL BIOL, V12, DOI 10.1186/1471-2148-12-71
   MURRAY RF, 1971, NATURE, V232, P51, DOI 10.1038/232051a0
   Orav M, 2013, J VIROL, V87, P12051, DOI 10.1128/JVI.01798-13
   Quint W, 2012, J PATHOL, V227, P62, DOI 10.1002/path.3970
   Rebollo A, 2001, J IMMUNOL, V167, P6366, DOI 10.4049/jimmunol.167.11.6366
   Smith B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021375
   Stamatakis A, 2005, BIOINFORMATICS, V21, P456, DOI 10.1093/bioinformatics/bti191
   Sun M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036577
   Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017
   Valmary-Degano S, 2013, HUM PATHOL, V44, P992, DOI 10.1016/j.humpath.2012.08.019
   Vartanian JP, 2008, SCIENCE, V320, P230, DOI 10.1126/science.1153201
   Walboomers JMM, 1997, J PATHOL, V181, P253, DOI 10.1002/(SICI)1096-9896(199703)181:3<253::AID-PATH755>3.0.CO;2-0
   Wang L, 2013, ASIAN PAC J CANCER P, V14, P3837, DOI 10.7314/APJCP.2013.14.6.3837
   Wang Z, 2014, J VIROL, V88, P1308, DOI 10.1128/JVI.03091-13
   Watts KJ, 2002, INT J CANCER, V97, P868, DOI 10.1002/ijc.10103
   Wentzensen N, 2004, CANCER RES, V64, P3878, DOI 10.1158/0008-5472.CAN-04-0009
   Xu B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066693
   Yuan H, 2012, NEW ENGL J MED, V367, P1220, DOI 10.1056/NEJMoa1203055
NR 55
TC 13
Z9 13
U1 0
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-1348
EI 1567-7257
J9 INFECT GENET EVOL
JI Infect. Genet. Evol.
PD AUG
PY 2015
VL 34
BP 44
EP 51
DI 10.1016/j.meegid.2015.07.002
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA CQ9AJ
UT WOS:000360902400007
PM 26160543
OA Green Published
DA 2020-11-30
ER

PT J
AU Veo, CAR
   Saad, SS
   Fregnani, JHTG
   Scapulatempo-Neto, C
   Tsunoda, AT
   Resende, JCP
   Lorenzi, AT
   Mafra, A
   Cinti, C
   Cotrim, ID
   Rosa, LAR
   de Oliveira, CM
   Martins, TR
   Centrone, C
   Levi, JE
   Longatto, A
AF Veo, Carlos A. R.
   Saad, Sarhan S.
   Fregnani, Jose Humberto T. G.
   Scapulatempo-Neto, Cristovam
   Tsunoda, Audrey Tieko
   Possati Resende, Julio Cesar
   Lorenzi, Adriana Tarla
   Mafra, Allini
   Cinti, Claudia
   Cotrim, Ismael Dale
   Reis Rosa, Luciana Albina
   de Oliveira, Cristina Mendes
   Martins, Toni Ricardo
   Centrone, Cristiane
   Levi, Jose Eduardo
   Longatto-Filho, Adhemar
TI Clinical characteristics of women diagnosed with carcinoma who tested
   positive for cervical and anal high-risk human papillomavirus DNA and E6
   RNA
SO TUMOR BIOLOGY
LA English
DT Article
DE HPV; Cervical cancer; Anus; HPV E6; HPV DNA; HPV RNA
ID INTRAEPITHELIAL NEOPLASIA; NATURAL-HISTORY; INFECTIONS; PREDICTORS;
   KNOWLEDGE; CANCERS; BURDEN; GAPS; MEN
AB High-risk human papillomavirus (hrHPV) is an essential cause of cervical carcinoma and is also strongly related to anal cancer development. The hrHPV E6 oncoprotein plays a major role in carcinogenesis. We aimed to evaluate the frequency of hrHPV DNA and E6 oncoprotein in the anuses of women with cervical carcinoma. We analyzed 117 women with cervical cancer and 103 controls for hrHPV and the E6 oncogene. Positive test results for a cervical carcinoma included 66.7 % with hrHPV-16 and 7.7 % with hrHPV-18. One case tested positive for both HPV variants (0.9 %). The samples from the anal canal were positive for HPV-16 in 59.8 % of the cases. Simultaneous presence of HPV in the cervix and anal canal was found in 53.8 % of the cases. Regarding expression of E6 RNA, positivity for HPV-16 in the anal canal was found in 21.2 % of the cases, positivity for HPV-16 in the cervix was found in 75.0 %, and positivity for HPV-18 in the cervix was found in 1.9 %. E6 expression in both the cervix and anal canal was found in 19.2 % of the cases. In the controls, 1 % tested positive for HPV-16 and 0 % for HPV-18. Anal samples from the controls showed a hrHPV frequency of 4.9 % (only HPV16). The presence of hrHPV in the anal canal of women with cervical cancer was detected at a high frequency. We also detected E6 RNA expression in the anal canal of women with cervical cancer, suggesting that these women are at risk for anal hrHPV infection.
C1 [Veo, Carlos A. R.; Fregnani, Jose Humberto T. G.; Scapulatempo-Neto, Cristovam; Tsunoda, Audrey Tieko; Possati Resende, Julio Cesar; Mafra, Allini] Pio XII Fdn, Barretos Canc Hosp, Barretos, Brazil.
   [Saad, Sarhan S.] Fed Univ Sao Paulo UNIFESP, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
   [Fregnani, Jose Humberto T. G.; Tsunoda, Audrey Tieko; Longatto-Filho, Adhemar] Pio XII Fdn, Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil.
   [Cinti, Claudia; Cotrim, Ismael Dale] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Reis Rosa, Luciana Albina; de Oliveira, Cristina Mendes; Martins, Toni Ricardo; Centrone, Cristiane; Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] Univ Sao Paulo, Fac Med, Lab Med Invest LIM 14, BR-1246903 Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal.
   [Longatto-Filho, Adhemar] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal.
RP Longatto, A (corresponding author), Univ Sao Paulo, Fac Med, Lab Med Invest LIM 14, BR-1246903 Sao Paulo, Brazil.
EM longatto16@hotmail.com
RI longatto-filho, adhemar/D-7039-2013; Saad, Sarhan Sydney/AAH-3350-2020;
   Oliveira, Cristina M/F-7193-2012; Longatto-Filho, Adhemar/N-3397-2019;
   Fregnani, Jose H/H-4238-2012; da Costa, Allini Mafra/AAQ-2091-2020;
   Saad, Sarhan S/G-1625-2012; Mafra, Allini/R-1360-2018; Lorenzi,
   Adriana/O-1098-2013; Possati-Resende, Julio Cesar/C-8575-2016
OI longatto-filho, adhemar/0000-0002-5779-9752; Saad, Sarhan
   Sydney/0000-0003-0395-6799; Longatto-Filho, Adhemar/0000-0002-5779-9752;
   Fregnani, Jose H/0000-0002-5235-6469; da Costa, Allini
   Mafra/0000-0002-2993-7919; Saad, Sarhan S/0000-0003-0395-6799; Mafra,
   Allini/0000-0002-2993-7919; Scapulatempo-Neto,
   Cristovam/0000-0002-8920-6579; Lorenzi, Adriana/0000-0001-7161-3961;
   Possati-Resende, Julio Cesar/0000-0002-7869-3885
FU Research Support Fund of the State of Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2010/16795-4]
FX We acknowledge the Research Support Fund of the State of Sao Paulo
   (FAPESP), process number 2010/16795-4), for the financial support
   grants. FAPESP had no other type of influence on this manuscript beyond
   the financial support.
CR Broccolo F, 2013, J MED VIROL, V85, P472, DOI 10.1002/jmv.23487
   Castle PE, 2013, CANCER EPIDEM BIOMAR, V22, P42, DOI 10.1158/1055-9965.EPI-12-0984
   Chaturvedi AK, 2010, J ADOLESCENT HEALTH, V46, pS20, DOI 10.1016/j.jadohealth.2010.01.016
   Cornall AM, 2013, INT J CANCER, V133, P2253, DOI 10.1002/ijc.28228
   Franco EL, 2012, VACCINE, V30, pF175, DOI 10.1016/j.vaccine.2012.06.092
   Gillison ML, 2014, INT J CANCER, V134, P497, DOI 10.1002/ijc.28201
   Guler T, 2013, ARCH GYNECOL OBSTET, V288, P667, DOI 10.1007/s00404-013-2821-0
   Hessol NA, 2013, AIDS, V27, P1743, DOI 10.1097/QAD.0b013e3283601b09
   Moscicki AB, 2012, VACCINE, V30, pF24, DOI 10.1016/j.vaccine.2012.05.089
   Palefsky JM, 2011, NEW ENGL J MED, V365, P1576, DOI 10.1056/NEJMoa1010971
   Preaud Emmanuelle, 2013, J Med Econ, V16, P763, DOI 10.3111/13696998.2013.793691
   SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
   Staff S, 2013, J CLIN PATHOL, V66, P807, DOI 10.1136/jclinpath-2012-201283
   Szarewski A, 2012, J CLIN MICROBIOL, V50, P1867, DOI 10.1128/JCM.00181-12
   Vaccarella S, 2013, EUR J CANCER, V49, P3262, DOI 10.1016/j.ejca.2013.04.024
   Valari O, 2011, GYNECOL ONCOL, V122, P505, DOI 10.1016/j.ygyno.2011.05.033
   Veo CAR, 2008, EUR J OBSTET GYN R B, V140, P103, DOI 10.1016/j.ejogrb.2008.02.024
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Waldstrom M, 2012, CYTOPATHOLOGY, V23, P389, DOI 10.1111/j.1365-2303.2011.00923.x
   Wheeler CM, 2013, OBSTET GYN CLIN N AM, V40, P165, DOI 10.1016/j.ogc.2013.02.004
NR 20
TC 7
Z9 7
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUL
PY 2015
VL 36
IS 7
BP 5399
EP 5405
DI 10.1007/s13277-015-3205-9
PG 7
WC Oncology
SC Oncology
GA CP0MI
UT WOS:000359569000065
PM 25677903
DA 2020-11-30
ER

PT J
AU Castilho, JL
   Levi, JE
   Luz, PM
   Cambou, MC
   Vanni, T
   de Andrade, A
   Derrico, M
   Veloso, VG
   Grinsztejn, B
   Friedman, RK
AF Castilho, Jessica L.
   Levi, Jose Eduardo
   Luz, Paula M.
   Cambou, Mary Catherine
   Vanni, Tazio
   de Andrade, Angela
   Derrico, Monica
   Veloso, Valdilea G.
   Grinsztejn, Beatriz
   Friedman, Ruth K.
TI A cross-sectional study of high-risk human papillomavirus clustering and
   cervical outcomes in HIV-infected women in Rio de Janeiro, Brazil
SO BMC CANCER
LA English
DT Article
DE HPV; Women; HIV; Cervical cancer; Epidemiology
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SQUAMOUS INTRAEPITHELIAL LESIONS;
   CYTOLOGICAL ABNORMALITIES; POSITIVE WOMEN; CELL COUNT; HPV TYPES;
   PREVALENCE; GENOTYPES; CANCER; VACCINE
AB Background: In Brazil, the rate of cervical cancer remains high despite the availability of screening programs. With ongoing vaccine development and implementation, information on the prevalence of specific HPV types is needed, particularly among high-risk populations, such as HIV-infected women.
   Methods: We performed a study of HIV-infected women in Rio de Janeiro, Brazil, who underwent cervical HPV genotype testing between 2005-2013. We examined the prevalence of high-risk HPV types and the patterns of high-risk HPV type clustering. Using logarithmic binomial regression, we estimated the risk of abnormal cytology by HPV genotype result.
   Results: Of the 562 women included, 498 (89 %) had at least one HPV type detected. 364 women (65 %) had at least one high-risk HPV type detected and 181 (32 %) had more than one high-risk type detected. HPV 58 was the most frequent HPV type detected overall (prevalence 19.8 % [95 % confidence interval 16.4-23.1]), followed by HPV 53 (prevalence 15.5 % [12.5-18.5]) and HPV 16 (prevalence 13 % [10.2-15.8]). Women infected with more than one high-risk HPV type were younger, had lower CD4+ lymphocyte counts, and were more likely to be infected with HPV 16 or 18. In adjusted analyses, presence of more than one high-risk HPV type was associated with a two-fold increased risk of abnormal cytology after adjusting for presence of individual high-risk type, age, and CD4+ lymphocyte count (adjusted prevalence ratios 1.88-2.07, all p < 0.001). No single high-risk HPV type was statistically associated with abnormal cytology after adjusting for the presence of more than one high-risk HPV type.
   Conclusions: In the largest study of cervical HPV genotypes among HIV-infected women in Latin America, infection by high-risk HPV types other than 16 or 18 and infection by more than one high-risk HPV types were common. Infection by more than one high-risk type was more strongly associated with abnormal cervical cytology than any individual high-risk HPV type, highlighting the need for multi-valent HPV vaccines.
C1 [Castilho, Jessica L.] Vanderbilt Univ, Div Infect Dis, Sch Med, Nashville, TN 37235 USA.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Luz, Paula M.; de Andrade, Angela; Derrico, Monica; Veloso, Valdilea G.; Grinsztejn, Beatriz; Friedman, Ruth K.] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, Brazil.
   [Cambou, Mary Catherine] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA.
   [Cambou, Mary Catherine] Univ Calif Los Angeles, David Geffen Sch Med, Program Global Hlth, Los Angeles, CA 90095 USA.
   [Vanni, Tazio] Minist Saude, Dept Ciencia & Tecnol, Brasilia, DF, Brazil.
RP Castilho, JL (corresponding author), Vanderbilt Univ, Div Infect Dis, Sch Med, 221 Kirkland Hall, Nashville, TN 37235 USA.
EM jessica.castilho@vanderbilt.edu
RI Vanni, Tazio P./B-7925-2018
OI Luz, Paula/0000-0001-9746-719X
FU National Institutes of Health (United States)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [T32
   AI007474, K24 AI65298, UO1 AI069923, R25 MH087222]; National Council of
   Technological and Scientific Development (Brazil)National Council for
   Scientific and Technological Development (CNPq); Research Agency of the
   State of Rio de Janeiro (Brazil); Brazilian National STD/AIDS Program
   (Brazil); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [T32AI007474, U01AI069923, U01AI069923, K24AI065298,
   T32AI007474, T32AI007474, UM1AI069476, U01AI069923, U01AI069923,
   U01AI069923, T32AI007474, U01AI069923, T32AI007474, U01AI069923,
   U01AI069923, K24AI065298, T32AI007474, U01AI069923, T32AI007474,
   K24AI065298, U01AI069923, U01AI069923, U01AI069923, UM1AI069476,
   T32AI007474, T32AI007474, K24AI065298, U01AI069923, T32AI007474,
   K24AI065298, UM1AI069476, T32AI007474, U01AI069923, T32AI007474,
   T32AI007474, U01AI069923, U01AI069923, T32AI007474, T32AI007474,
   T32AI007474, T32AI007474, K24AI065298, T32AI007474, U01AI069923,
   UM1AI069476, T32AI007474, U01AI069923, UM1AI069476, UM1AI069476,
   T32AI007474, T32AI007474, T32AI007474, T32AI007474, UM1AI069476,
   K24AI065298, UM1AI069476, U01AI069923, T32AI007474, U01AI069923,
   K24AI065298, K24AI065298, U01AI069923, K24AI065298, T32AI007474] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [R25MH087222,
   R25MH087222, R25MH087222, R25MH087222, R25MH087222, R25MH087222,
   R25MH087222, R25MH087222] Funding Source: NIH RePORTER
FX We would like to thank the patients of the Women's HIV Cohort at INI for
   their time and participation in our study. This work was supported by
   the National Institutes of Health (T32 AI007474 [JLC], K24 AI65298
   [JLC], UO1 AI069923 [JLC, BG, VGV, PML], and R25 MH087222 [MCC]) (United
   States). PML and BG were also supported by the National Council of
   Technological and Scientific Development (Brazil), Research Agency of
   the State of Rio de Janeiro (Brazil), and the Brazilian National
   STD/AIDS Program (Brazil).
CR Abraham AG, 2013, JAIDS-J ACQ IMM DEF, V62, P405, DOI 10.1097/QAI.0b013e31828177d7
   Brandao VDRAB, 2009, MEM I OSWALDO CRUZ, V104, P755, DOI 10.1590/S0074-02762009000500016
   Arbyn M, 2014, J PATHOL, V234, P431, DOI 10.1002/path.4424
   Ayres Andréia Rodrigues Gonçalves, 2010, Rev. Saúde Pública, V44, P963
   da Silva MFPTB, 2012, GENET MOL RES, V11, P462, DOI 10.4238/2012.March.1.3
   Boldrini NT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102169
   Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
   Camargo M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-451
   Carozzi F, 2012, EUR J CANCER, V48, P1633, DOI 10.1016/j.ejca.2011.10.010
   Chaturvedi AK, 2005, CANCER EPIDEM BIOMAR, V14, P2439, DOI 10.1158/1055-9965.EPI-05-0465
   Ciapponi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025493
   Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14
   Correa CM, 2011, REV ASSOC MED BRAS, V57, P425, DOI 10.1590/S0104-42302011000400017
   Dartell M, 2013, SEX TRANSM DIS, V40, P737, DOI 10.1097/OLQ.0000000000000005
   Resende LSDA, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-214
   de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033
   Fernandes Jose V, 2010, BMC Res Notes, V3, P96, DOI 10.1186/1756-0500-3-96
   Fife KH, 2009, JAIDS-J ACQ IMM DEF, V51, P274, DOI 10.1097/QAI.0b013e3181a97be5
   Franceschi S, 2007, CLIN INFECT DIS, V45, P510, DOI 10.1086/520022
   Goncalves MAG, 1999, INT J STD AIDS, V10, P803, DOI 10.1258/0956462991913583
   Grinsztejn B, 2009, INT J INFECT DIS, V13, P72, DOI 10.1016/j.ijid.2008.03.031
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Hanisch RA, 2013, J CLIN VIROL, V58, P696, DOI 10.1016/j.jcv.2013.10.012
   Kahn JA, 2013, CLIN INFECT DIS, V57, P735, DOI 10.1093/cid/cit319
   Kang M, 2012, HIV MED, V13, P372, DOI 10.1111/j.1468-1293.2011.00979.x
   Kiatpongsan S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048426
   Konopnicki D, 2013, J INFECT DIS, V207, P1723, DOI 10.1093/infdis/jit090
   Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396
   Luque AE, 2006, J INFECT DIS, V194, P428, DOI 10.1086/505876
   Luz PM, 2012, INT J STD AIDS, V23, P12, DOI 10.1258/ijsa.2009.009409
   MacLeod IJ, 2011, J MED VIROL, V83, P1689, DOI 10.1002/jmv.22178
   Mbulawa ZZA, 2013, J INFECTION, V67, P51, DOI 10.1016/j.jinf.2013.03.009
   MCDONALD AC, 2014, S AFRICA FRONT ONCOL, V4, P48
   McKenzie ND, 2010, GYNECOL ONCOL, V116, P572, DOI 10.1016/j.ygyno.2009.10.058
   Meyrelles ARI, 2013, GYNECOL ONCOL, V128, P107, DOI 10.1016/j.ygyno.2012.10.003
   Minkoff H, 2001, AIDS, V15, P2157, DOI 10.1097/00002030-200111090-00011
   Nicol AF, 2013, J CLIN VIROL, V57, P147, DOI 10.1016/j.jcv.2013.02.007
   Paesi S, 2009, J MED VIROL, V81, P1270, DOI 10.1002/jmv.21410
   Palefsky JM, 2003, CURR OPIN ONCOL, V15, P382, DOI 10.1097/00001622-200309000-00007
   Pista A, 2011, CLIN MICROBIOL INFEC, V17, P941, DOI 10.1111/j.1469-0691.2010.03387.x
   Powell SE, 2012, VACCINE, V31, P109, DOI 10.1016/j.vaccine.2012.10.092
   Rocha-Brischiliari SC, 2014, INFECT AGENTS CANCER, V9, DOI 10.1186/1750-9378-9-6
   Rositch AF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055383
   Sahasrabuddhe VV, 2007, BRIT J CANCER, V96, P1480, DOI 10.1038/sj.bjc.6603737
   Schiffman Mark, 2009, Infect Agent Cancer, V4, P8, DOI 10.1186/1750-9378-4-8
   Smelov V, 2015, INT J CANCER, V136, P1171, DOI 10.1002/ijc.29085
   Vaccarella S, 2013, INFECT AGENTS CANCER, V8, DOI 10.1186/1750-9378-8-50
   Vaccarella S, 2010, CANCER EPIDEM BIOMAR, V19, P503, DOI 10.1158/1055-9965.EPI-09-0983
   Vanni T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093376
   Vanni T, 2012, VACCINE, V30, P4866, DOI 10.1016/j.vaccine.2012.04.087
   de Andrade ACV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018297
   Villa LL, 2012, CANCER EPIDEM BIOMAR, V21, P1409, DOI 10.1158/1055-9965.EPI-12-0147
   Wentzensen N, 2014, J INFECT DIS, V209, P855, DOI 10.1093/infdis/jit577
NR 53
TC 9
Z9 9
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUN 23
PY 2015
VL 15
AR 478
DI 10.1186/s12885-015-1486-4
PG 10
WC Oncology
SC Oncology
GA CK9SQ
UT WOS:000356580200001
PM 26100400
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Levi, JE
   Nishiya, A
   Felix, AC
   Salles, NA
   Sampaio, LR
   Hangai, F
   Sabino, EC
   Mendrone, A
AF Levi, Jose Eduardo
   Nishiya, Anna
   Felix, Alvina Clara
   Salles, Nanci Alves
   Sampaio, Luciana Ribeiro
   Hangai, Fatima
   Sabino, Ester Cerdeira
   Mendrone, Alfredo, Jr.
TI Real-time symptomatic case of transfusion-transmitted dengue
SO TRANSFUSION
LA English
DT Article
ID WEST-NILE-VIRUS; UNITED-STATES; BLOOD-DONORS; TRANSMISSION; VIREMIA
AB BackgroundDengue virus transmission by blood transfusion is a rarely reported event.
   Case ReportDuring a dengue outbreak in SAo Paulo city, a regular plateletpheresis donor informed the blood bank of being diagnosed a few days after donation. The recipient was hospitalized and displayed symptoms and laboratory evidence of dengue after transfusion.
   ResultsThe donor was immunoglobulin (Ig)G, IgM, and polymerase chain reaction nonreactive on the index sample, seroconverting 20 days later. The platelet units were transfused into two patients. One of them developed fever 3 days after transfusion, with high viral load. His pretransfusion sample was negative for IgG, IgM, and dengue RNA, while the second recipient did not show any symptoms nor laboratory evidence of dengue infection.
   ConclusionsThis case brings additional evidence that dengue is indeed transmissible by blood transfusion and clinical manifestations, although rare, do occur.
C1 [Levi, Jose Eduardo; Nishiya, Anna; Salles, Nanci Alves; Sampaio, Luciana Ribeiro; Hangai, Fatima; Mendrone, Alfredo, Jr.] Fundacao Prosangue, Hemoctr Sao Paulo, Sao Paulo, SP, Brazil.
   [Levi, Jose Eduardo; Felix, Alvina Clara] Univ Sao Paulo, Virol Lab, Inst Med Trop, Sao Paulo, Brazil.
   [Sabino, Ester Cerdeira] Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
RP Levi, JE (corresponding author), Fundacao Prosangue, Hemoctr Sao Paulo, Dept Mol Biol, Rua Dr Eneas de Carvalho Aguiar 155,1o andar, Sao Paulo, SP, Brazil.
EM jelevi@prosangue.sp.gov.br
RI Nishiya, Anna/Q-8156-2016; Sabino, Ester Cerdeira/F-7750-2010
OI Sabino, Ester Cerdeira/0000-0003-2623-5126
CR Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Callahan JD, 2001, J CLIN MICROBIOL, V39, P4119, DOI 10.1128/JCM.39.11.4119-4124.2001
   Chuang Vivien W. M., 2008, Hong Kong Medical Journal, V14, P170
   Cox J, 2012, J VIROL, V86, P7637, DOI 10.1128/JVI.00534-12
   Dias LL, 2012, TRANSFUSION, V52, P1667, DOI 10.1111/j.1537-2995.2012.03729.x
   Johnson BW, 2004, AM J TROP MED HYG, V70, P89, DOI 10.4269/ajtmh.2004.70.89
   Lanteri MC, 2012, TRANSFUSION, V52, P1634, DOI 10.1111/j.1537-2995.2012.03747.x
   Linnen JM, 2008, TRANSFUSION, V48, P1355, DOI 10.1111/j.1537-2995.2008.01772.x
   Montgomery SP, 2006, TRANSFUSION, V46, P2038, DOI 10.1111/j.1537-2995.2006.01030.x
   Pealer LN, 2003, NEW ENGL J MED, V349, P1236, DOI 10.1056/NEJMoa030969
   Prefeitura de Sao Paulo Secretaria Municipal de Saude Coordenacao de Vigilancia da Saude, 2014, NO CAS AUT INC 10000
   Sabino E, 2013, VOX SANG S2, V105, P41
   Stramer SL, 2012, TRANSFUSION, V52, P1657, DOI 10.1111/j.1537-2995.2012.03566.x
   Tambyah PA, 2008, NEW ENGL J MED, V359, P1526, DOI 10.1056/NEJMc0708673
NR 14
TC 32
Z9 33
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD MAY
PY 2015
VL 55
IS 5
BP 961
EP 964
DI 10.1111/trf.12944
PG 4
WC Hematology
SC Hematology
GA CH8JB
UT WOS:000354281500008
PM 25605570
DA 2020-11-30
ER

PT J
AU de Matos, AM
   Carvalho, KI
   Rosa, DS
   Villas-Boas, LS
   da Silva, WC
   Rodrigues, CLDL
   Oliveira, OMNPF
   Levi, JE
   Araujo, ESA
   Pannuti, CS
   Luna, EJA
   Kallas, EG
AF de Matos, Andreia Manso
   Carvalho, Karina Inacio
   Rosa, Daniela Santoro
   Villas-Boas, Lucy Santos
   da Silva, Wanessa Cardoso
   de Lima Rodrigues, Celia Luiza
   Peel Furtado Oliveira, Olimpia Massae Nakasone
   Levi, Jose Eduardo
   Affonso Araujo, Evaldo Stanislau
   Pannuti, Claudio Sergio
   Albuquerque Luna, Expedito Jose
   Kallas, Esper George
TI CD8+T Lymphocyte Expansion, Proliferation and Activation in Dengue Fever
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID CD8(+) T-CELLS; HEMORRHAGIC-FEVER; VIRAL-INFECTIONS; VIRUS-INFECTION;
   MEMORY; SUBSETS; RESPONSES; DISEASE; DIFFERENTIATION; PATHOGENESIS
AB Dengue fever induces a robust immune response, including massive T cell activation. The level of T cell activation may, however, be associated with more severe disease. In this study, we explored the level of CD8+ T lymphocyte activation in the first six days after onset of symptoms during a DENV2 outbreak in early 2010 on the coast of Sao Paulo State, Brazil. Using flow cytometry we detected a progressive increase in the percentage of CD8+ T cells in 74 dengue fever cases. Peripheral blood mononuclear cells from 30 cases were thawed and evaluated using expanded phenotyping. The expansion of the CD8+ T cells was coupled with increased Ki67 expression. Cell activation was observed later in the course of disease, as determined by the expression of the activation markers CD38 and HLA-DR. This increased CD8+ T lymphocyte activation was observed in all memory subsets, but was more pronounced in the effector memory subset, as defined by higher CD38 expression. Our results show that most CD8+ T cell subsets are expanded during DENV2 infection and that the effector memory subset is the predominantly affected sub population.
C1 [de Matos, Andreia Manso; Carvalho, Karina Inacio; Rosa, Daniela Santoro; Kallas, Esper George] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM 60, Sao Paulo, Brazil.
   [Carvalho, Karina Inacio] Albert Einstein Hosp, Sao Paulo, Brazil.
   [Rosa, Daniela Santoro] Fed Univ Sao Paulo UNIFESP, Div Immunol, Sao Paulo, Brazil.
   [Villas-Boas, Lucy Santos; da Silva, Wanessa Cardoso; de Lima Rodrigues, Celia Luiza; Levi, Jose Eduardo; Pannuti, Claudio Sergio; Albuquerque Luna, Expedito Jose] Univ Sao Paulo, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   [Villas-Boas, Lucy Santos; da Silva, Wanessa Cardoso; de Lima Rodrigues, Celia Luiza; Levi, Jose Eduardo; Pannuti, Claudio Sergio; Albuquerque Luna, Expedito Jose] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias LIM 52, Sao Paulo, Brazil.
   [Peel Furtado Oliveira, Olimpia Massae Nakasone; Affonso Araujo, Evaldo Stanislau] Hosp Ana Costa, Sao Paulo, Brazil.
   [Affonso Araujo, Evaldo Stanislau] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias LIM 47, Sao Paulo, Brazil.
RP de Matos, AM (corresponding author), Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM 60, Sao Paulo, Brazil.
EM esper.kallas@usp.br
RI Carvalho, Karina IL/J-6789-2012; Rosa, Daniela S/D-2190-2012; Luna,
   Expedito J A/B-7948-2012; Silva, Wanessa/C-7837-2012
OI Carvalho, Karina IL/0000-0002-7763-8139; Rosa, Daniela
   S/0000-0003-4536-891X; Luna, Expedito J A/0000-0002-1145-9672; Kallas,
   Esper/0000-0003-2026-6925
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazilian
   Ministry of Science and Technology (CNPq)National Council for Scientific
   and Technological Development (CNPq) [476088/2009-7]; CNPqNational
   Council for Scientific and Technological Development (CNPq); Coordenacao
   de Aperfeicoamento de Pessoal de Nivel Superior, Brazilian Ministry of
   Education
FX The present work was supported by the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico, Brazilian Ministry of Science
   and Technology (CNPq, grant #476088/2009-7 to EGK). AMM and EGK's
   scholarships were supported by CNPq. KIC's scholarship was supported by
   the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior,
   Brazilian Ministry of Education. URL of CNPq: URL www.cnpq.br; URL of
   CAPES: www.capes.gov.br The funders had no role in study design, data
   collection and analysis, decision to publish; or preparation of the
   manuscript.
CR Appay V, 2008, CYTOM PART A, V73A, P975, DOI 10.1002/cyto.a.20643
   Azeredo EL, 2006, MEM I OSWALDO CRUZ, V101, P437, DOI 10.1590/S0074-02762006000400016
   Bashyam HS, 2006, J IMMUNOL, V176, P2817, DOI 10.4049/jimmunol.176.5.2817
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Chau Tran Nguyen Bich, 2008, J Infect Dis, V198, P516, DOI 10.1086/590117
   CORLEY RB, 1985, P NATL ACAD SCI USA, V82, P516, DOI 10.1073/pnas.82.2.516
   de Souza VAUF, 2004, J CLIN MICROBIOL, V42, P1782, DOI 10.1128/JCM.42.4.1782-1784.2004
   Durbin AP, 2008, VIROLOGY, V376, P429, DOI 10.1016/j.virol.2008.03.028
   Endy TP, 2004, J INFECT DIS, V189, P990, DOI 10.1086/382280
   Friberg H, 2011, IMMUNOL CELL BIOL, V89, P122, DOI 10.1038/icb.2010.61
   Geginat J, 2003, BLOOD, V101, P4260, DOI 10.1182/blood-2002-11-3577
   Goncalves RM, 2010, INFECT IMMUN, V78, P4763, DOI 10.1128/IAI.00578-10
   Green S, 1999, J INFECT DIS, V180, P1429, DOI 10.1086/315072
   Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65
   Guirakhoo F, 2001, J VIROL, V75, P7290, DOI 10.1128/JVI.75.16.7290-7304.2001
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Lai YL, 2007, J CLIN MICROBIOL, V45, P935, DOI 10.1128/JCM.01258-06
   Lanzavecchia A, 2005, CURR OPIN IMMUNOL, V17, P326, DOI 10.1016/j.coi.2005.04.010
   Levi JE, 2007, J CLIN MICROBIOL, V45, P1893, DOI 10.1128/JCM.00065-07
   Liu CC, 2002, J MED VIROL, V68, P241, DOI 10.1002/jmv.10198
   Malavige GN, 2004, POSTGRAD MED J, V80, P588, DOI 10.1136/pgmj.2004.019638
   Mathew A, 1999, J IMMUNOL, V162, P5609
   Mathew A, 2008, IMMUNOL REV, V225, P300, DOI 10.1111/j.1600-065X.2008.00678.x
   McMichael AJ, 2000, PHILOS T R SOC B, V355, P363, DOI 10.1098/rstb.2000.0575
   Messer WB, 2002, AM J TROP MED HYG, V66, P765, DOI 10.4269/ajtmh.2002.66.765
   Nguyen TPD, 2010, J IMMUNOL, V184, P7281, DOI 10.4049/jimmunol.0903262
   PAHO, 2008, NUMB REP CAS DENG DE
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011811
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   SARASOMBATH S, 1988, Southeast Asian Journal of Tropical Medicine and Public Health, V19, P649
   Schmid ML, 1999, BRIT MED J, V318, P1076, DOI 10.1136/bmj.318.7190.1076a
   Tomiyama H, 2002, J IMMUNOL, V168, P5538, DOI 10.4049/jimmunol.168.11.5538
   Villar L, 2014, NEW ENGL J MED, DOI [10. 1056/ NEJMsr1414226, DOI 10.1056/NEJMSR1414226]
   Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Zielinski CE, 2011, IMMUNOL REV, V240, P40, DOI 10.1111/j.1600-065X.2010.01000.x
NR 38
TC 16
Z9 16
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD FEB
PY 2015
VL 9
IS 2
AR e0003520
DI 10.1371/journal.pntd.0003520
PG 14
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CD3PW
UT WOS:000350992500048
PM 25675375
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Serravalle, K
   Levi, JE
   Oliveira, C
   Queiroz, C
   Dantas, A
   Studart, E
AF Serravalle, Karina
   Levi, Jose Eduardo
   Oliveira, Cristina
   Queiroz, Conceicao
   Dantas, Adila
   Studart, Eduardo
TI Comparison of two techniques for HPV genotyping in women with high-grade
   squamous intraepithelial lesion
SO REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA
LA Portuguese
DT Article
DE Cervix uteri/virology; Cervical intraepithelial neoplasia/virology;
   Papillomavirus infections/virology; Genotype; Papillomaviridae/isolation
   & purification; Papillomaviridae/genetics
ID INVASIVE CERVICAL-CANCER; HUMAN-PAPILLOMAVIRUS HPV; PREVALENCE;
   NEOPLASIA; PERFORMANCE
AB PURPOSE: The aim of this study was to compare the performance of two human papillomavirus (HPV) genotyping techniques, Linear Array and PapilloCheck, in women with high- grade squamous intraepithelial lesion (HSIL). METHODS: A total of 88 women with cytological diagnosis of HSIL were recruited at 2 reference centers in cervical pathology in Salvador, Bahia, Brazil, from July 2006 to January 2009. After the cytological diagnosis of HSIL, cervix cells were collected to determine the HPV genotype and a biopsy was obtained under colposcopic vision for histopathological analysis. After the confirmation of CIN2+ by histopathology, HPV genotyping was performed on 41 women by the Linear Array and PapilloCheck methods. RESULTS: Both tests showed an overall concordance rate for HPV detection of 97.2% (35/36). Of the 36 valid samples, 35 (97.2%) were positive in both tests and 1 (2.8%) was discordant, with the Linear Array indicating the presence of multiple types. The most prevalent HPV genotypes detected by the Linear Array technique were HPV 16, HPV 56, HPV 35, HPV 45, and HPV 70; and those detected by the PapilloCheck technique were HPV 16, HPV 56, HPV 11, HPV 35, and HPV 42. A similar rate of infection with multiple HPV types was observed with the two tests (72.5% with the Linear Array and 75.0% with the PapilloCheck). CONCLUSIONS: Linear Array genotyping assay and PapilloCheck showed equivalent performance for the detection of oncogenic HPV types in women with HSIL, with PapilloCheck having the advantage of being a method that avoids subjectivity when reading the HPV genotypes.
C1 [Serravalle, Karina; Queiroz, Conceicao; Dantas, Adila; Studart, Eduardo] Lab Anat Patol & Biol Mol Sludari & Sludari, Salvador, BA, Brazil.
   [Levi, Jose Eduardo; Oliveira, Cristina] Univ Sao Paulo, Inst Med Trop, Lab Virol, Sao Paulo, SP, Brazil.
RP Serravalle, K (corresponding author), Lab Anat Patol & Biol Mol Sludari & Sludari, Salvador, BA, Brazil.
CR Ayres Andréia Rodrigues Gonçalves, 2010, Rev. Saúde Pública, V44, P963
   Barra GB, 2012, CLIN CHEM S, V58, pA227
   Baseman JG, 2005, J CLIN VIROL, V32, pS16, DOI 10.1016/j.jcv.2004.12.008
   BOSCH FX, 1995, J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796
   Bruno A, 2014, REV BRAS GINECOL OBS, V36, P416, DOI 10.1590/SO100-720320140004995
   Dalstein V, 2009, J VIROL METHODS, V156, P77, DOI 10.1016/j.jviromet.2008.11.002
   de Oliveira CM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-357
   ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18
   Freitas Taíse Palmeiras, 2007, Rev. Inst. Med. trop. S. Paulo, V49, P297, DOI 10.1590/S0036-46652007000500005
   Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
   Halfon P, 2010, J CLIN VIROL, V47, P38, DOI 10.1016/j.jcv.2009.10.013
   Hesselink AT, 2006, J CLIN MICROBIOL, V44, P3680, DOI 10.1128/JCM.02078-05
   IARC, 2005, HDB CANC PREV CERV C
   Levi JE, 2014, OJOG, V4, P470, DOI DOI 10.4236/0J0G.2014.48068
   Lorenzato F, 2000, INT J GYNECOL CANCER, V10, P143, DOI 10.1046/j.1525-1438.2000.00007.x
   Ministerio da Saude. Instituto Nacional de Cancer Jose Alencar Gomes da Silva (INCA), 2014, COORD PREV VIG NCIA
   Monsonego J, 2005, GYNECOL ONCOL, V99, P160, DOI 10.1016/j.ygyno.2005.05.030
   Nakagawa JTT, 2010, REV BRAS ENFERM, V63, P307, DOI 10.1590/S0034-71672010000200021
   Noronha V, 1999, Rev Soc Bras Med Trop, V32, P235, DOI 10.1590/S0037-86821999000300003
   Rabelo-Santos SH, 2003, MEM I OSWALDO CRUZ, V98, P181, DOI 10.1590/S0074-02762003000200003
   Rama CH, 2008, REV SAUDE PUBL, V42, P123, DOI [10.1590/S0034-89102008000100016, 10.1590/s0034-89102008000100016]
   Rosa MI, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.06.033
   Villa LL, 2000, J GEN VIROL, V81, P2959, DOI 10.1099/0022-1317-81-12-2959
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Wentzensen N, 2014, J INFECT DIS, V209, P855, DOI 10.1093/infdis/jit577
   zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798
NR 26
TC 2
Z9 3
U1 0
U2 3
PU FEDERACAO BRASILEIRA SOC GINECOLOGIA & OBSTETRICIA-FEBRASGO
PI RIO DE JANEIRO RJ
PA AV DAS AMERICAS, 8445, SALA 711-BARRA DA TIJUCA, RIO DE JANEIRO RJ,
   22793-081, BRAZIL
SN 0100-7203
EI 1806-9339
J9 REV BRAS GINECOL OBS
JI Rev. Bras. Ginecol. Obstet.
PD FEB
PY 2015
VL 37
IS 2
BP 94
EP 99
DI 10.1590/SO100-720320150005206
PG 6
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA VA8YZ
UT WOS:000410566000008
PM 25760629
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Tso, FK
   Rodrigues, CLL
   Levi, JE
   Ferraz, MGMD
   Speck, NMG
   Ribalta, JCL
AF Tso, F. K.
   Rodrigues, C. L. L.
   Levi, J. E.
   Mattosinho de Castro Ferraz, M. G.
   Speck, N. M. G.
   Ribalta, J. C. L.
TI HPV infection-associated anogenital cyto-colpo-histological findings and
   molecular typing in HIV-positive women
SO GENETICS AND MOLECULAR RESEARCH
LA English
DT Article
DE HPV infection; HIV; Anal cancer; Anal cytology; E6/E7 mRNA
ID ANAL INTRAEPITHELIAL NEOPLASIA; IFCPC INTERNATIONAL FEDERATION; E6/E7
   MESSENGER-RNA; HUMAN-PAPILLOMAVIRUS; CLINICAL-PERFORMANCE; CERVICAL
   PATHOLOGY; UNINFECTED WOMEN; UTERINE CERVIX; RIO 2011; EXPRESSION
AB HIV and human papillomavirus (HPV) coinfection is increasing, especially in the anal canal (AC) and cervico-vaginal regions. We identified anal epithelium abnormalities related to high-risk HPV (HR-HPV) lesions in the lower genital tracts (LGTs) of HIV-positive women, described the HPV genotypes identified, and assessed the expression of E6/E7 oncogenes in coinfected patients. Ninety-eight women were enrolled in groups combining HIV status and presence or absence of HPV in the LGT. Anal and cervical smears were collected for cytology and HR-HPV assays using Cobas(R) and/or PapilloCheck(R). Samples with highly oncogenic HPV genotypes were confirmed by NucliSENS EasyQ(R). Forty-two HIV-positive (25-52; mean age 39.5) and 56 HIV-negative (18-58; mean age 35.7) patients were included. E2 and C1 groups presented AC alterations (P = 0.002); altered images for high-resolution anoscopy were higher in E1 and C2 (P < 0.001). Of the 29 women with alterations, 41.38% were HIV-negative and 58.62% were HIV-positive (P < 0.001). HIV-positive patients accounted for 29% of the anal high-grade squamous intraepithelial lesions (P = 0.015). The Cobas(R) positive result frequency was higher in three AC groups than in the other groups. There was variation in the number of HPV types in the cervicovaginal samples among the study groups (P < 0.001). Anal cytology and anoscopy showed more altered findings in HIV-positive patients with HPV in the LGT. HR-HPV anal infections by various genotypes are common and are associated with cervical infections in HIV-positive patients. E6/E7 expression is apparently more common in the AC of HIV-positive women.
C1 [Tso, F. K.; Speck, N. M. G.; Ribalta, J. C. L.] Univ Fed Sao Paulo, Dept Ginecol, Nucleo Prevencao Doencas Ginecol, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Rodrigues, C. L. L.; Levi, J. E.] Univ Sao Paulo, Inst Med Trop, Lab Virol, Sao Paulo, SP, Brazil.
   [Mattosinho de Castro Ferraz, M. G.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Patol, Sao Paulo, SP, Brazil.
RP Tso, FK (corresponding author), Univ Fed Sao Paulo, Dept Ginecol, Nucleo Prevencao Doencas Ginecol, Escola Paulista Med, Sao Paulo, SP, Brazil.
EM fernandaktso@gmail.com
RI Tso, Fernanda Kesselring/AAR-1767-2020
FU CAPESCAPES
FX Research supported by a CAPES grant.
CR Agorastos T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119755
   Andersson S, 2006, INT J ONCOL, V29, P705
   Cambou MC, 2015, AIDS PATIENT CARE ST, V29, P4, DOI 10.1089/apc.2014.0166
   Capaul SE, 2005, J CLIN VIROL, V32, P236, DOI 10.1016/j.jcv.2004.08.006
   Correa CM, 2011, REV ASSOC MED BRAS, V57, P425, DOI 10.1590/S0104-42302011000400017
   Cui M, 2014, J CLIN MICROBIOL, V52, P2210, DOI 10.1128/JCM.00883-14
   Dandapani SV, 2010, J GASTROINTEST ONCOL, V1, P34, DOI 10.3978/j.issn.2078-6891.2010.005
   Darragh TM, 2011, CANCER CYTOPATHOL, V119, P5, DOI 10.1002/cncy.20126
   Gage JC, 2012, J CLIN MICROBIOL, V50, P61, DOI 10.1128/JCM.05989-11
   Gimenez Felicidad, 2011, Arq. Gastroenterol., V48, P136, DOI 10.1590/S0004-28032011000200010
   Goodman MT, 2010, J INFECT DIS, V201, P1331, DOI 10.1086/651620
   Greco D., 2013, PROTOCOLO CLIN DIRET, P1
   Hessol NA, 2013, AIDS, V27, P1743, DOI 10.1097/QAD.0b013e3283601b09
   Hessol NA, 2009, AIDS, V23, P59, DOI 10.1097/QAD.0b013e32831cc101
   Kojic EM, 2011, SEX TRANSM DIS, V38, P253, DOI 10.1097/OLQ.0b013e3181f70253
   Kraus I, 2006, J CLIN MICROBIOL, V44, P1310, DOI 10.1128/JCM.44.4.1310-1317.2006
   Molden T, 2006, GYNECOL ONCOL, V100, P95, DOI 10.1016/j.ygyno.2005.07.108
   Molden T, 2007, J VIROL METHODS, V142, P204, DOI 10.1016/j.jviromet.2007.01.036
   Naucler P, 2009, JNCI-J NATL CANCER I, V101, P88, DOI 10.1093/jnci/djn444
   Palefsky JM, 2005, AIDS, V19, P1407, DOI 10.1097/01.aids.0000181012.62385.4a
   Palefsky J, 2009, CURR OPIN HIV AIDS, V4, P52, DOI 10.1097/COH.0b013e32831a7246
   Pantanowitz L, 2011, DIAGN CYTOPATHOL, V39, P65, DOI 10.1002/dc.21364
   Pimenta AV, 2011, FEMINA, V2011, P111
   Poggio Juan Lucas, 2011, Clin Colon Rectal Surg, V24, P177, DOI 10.1055/s-0031-1286002
   Quaas J, 2014, GEBURTSH FRAUENHEILK, V74, P1090, DOI 10.1055/s-0034-1383216
   Quaas J, 2013, GEBURTSH FRAUENHEILK, V73, P904, DOI 10.1055/s-0033-1350824
   Silling S, 2012, J CLIN VIROL, V53, P325, DOI 10.1016/j.jcv.2011.12.029
   Stanley MA, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-398
   Stier EA, 2015, AM J OBSTET GYNECOL, V213, P278, DOI 10.1016/j.ajog.2015.03.034
   Szarewski A, 2008, CANCER EPIDEM BIOMAR, V17, P3033, DOI 10.1158/1055-9965.EPI-08-0508
   Tornesello ML, 2008, J GEN VIROL, V89, P1380, DOI 10.1099/vir.0.83553-0
   Valari O, 2011, GYNECOL ONCOL, V122, P505, DOI 10.1016/j.ygyno.2011.05.033
   Wentzensen N, 2014, J CLIN MICROBIOL, V52, P2892, DOI 10.1128/JCM.03517-13
   Wentzensen N, 2012, AIDS, V26, P2185, DOI 10.1097/QAD.0b013e328359f255
NR 34
TC 4
Z9 4
U1 0
U2 2
PU FUNPEC-EDITORA
PI RIBEIRAO PRETO
PA RUA FLORIANO PEIXOTO 2444, ALTO DA BOA VISTA, RIBEIRAO PRETO, SP 00000,
   BRAZIL
SN 1676-5680
J9 GENET MOL RES
JI Genet. Mol. Res.
PY 2015
VL 14
IS 4
BP 17630
EP 17640
DI 10.4238/2015.December.21.36
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA DF8DN
UT WOS:000371587400036
PM 26782408
OA Bronze
DA 2020-11-30
ER

PT J
AU Cambou, MC
   Luz, PM
   Lake, JE
   Levi, JE
   Coutinho, JR
   de Andrade, A
   Heinke, T
   Derrico, M
   Veloso, VG
   Friedman, RK
   Grinsztejn, B
AF Cambou, Mary C.
   Luz, Paula M.
   Lake, Jordan E.
   Levi, Jose Eduardo
   Coutinho, Jose Ricardo
   de Andrade, Angela
   Heinke, Thais
   Derrico, Monica
   Veloso, Valdilea G.
   Friedman, Ruth K.
   Grinsztejn, Beatriz
TI Anal Human Papillomavirus (HPV) Prevalences and Factors Associated with
   Abnormal Anal Cytology in HIV-Infected Women in an Urban Cohort from Rio
   de Janeiro, Brazil
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID SQUAMOUS INTRAEPITHELIAL LESIONS; NEOPLASIA; CANCER; GUIDELINES;
   CARCINOMA; RISK
AB Identifying factors, including human papillomavirus (HPV) genotypes, associated with abnormal anal cytology in HIV-infected women have implications for anal squamous cell cancer (SCC) prevention in HIV-infected women. Anal and cervical samples were collected for cytology, and tested for high-(HR-HPV) and low-risk HPV (LR-HPV) genotypes in a cross-sectional analysis of the IPEC Women's HIV Cohort (Rio de Janeiro, Brazil). Multivariate log-binomial regression models estimated prevalence ratios for factors associated with abnormal anal cytology [>= atypical squamous cells of undetermined significance, (ASC-US)]. Characteristics of the 863 participants included: median age 42 years, 57% non-white, 79% current CD4+ T-cell count >350 cells/mm(3), 53% HIV-1 viral load <50 copies/mL, median ART duration 5.8 years. Fifty-one percent of anal specimens contained >= 1 HR-HPV genotype; 31% had abnormal anal cytology [14% ASC-US, 11% low-grade squamous intra-epithelial lesion, (LSIL); 2% atypical squamous cells-cannot exclude high-grade SIL (ASC-H); 4% high-grade SIL/cancer (HSIL+)]. In multivariate analysis, cervical LSIL+, nadir CD4+ T-cell count <= 50 cells/mm(3), HIV-1 viral load >= 50 copies/mL, and anal HPV 6, 11, 16, 18, 33, 45, 52, 56, and 58 were associated with >= anal ASC-US (p<0.05). Abnormal anal cytology and HR-HPV prevalences were high. HIV-infected women with cervical LSIL+, low nadir CD4+ counts, or detectable HIV-1 viral loads should be a particular focus for enhanced anal SCC screening efforts.
C1 [Cambou, Mary C.; Lake, Jordan E.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA.
   [Cambou, Mary C.; Lake, Jordan E.] Univ Calif Los Angeles, David Geffen Sch Med, Program Global Hlth, Los Angeles, CA 90095 USA.
   [Luz, Paula M.; Coutinho, Jose Ricardo; de Andrade, Angela; Derrico, Monica; Veloso, Valdilea G.; Friedman, Ruth K.; Grinsztejn, Beatriz] Fundacao Oswaldo Cruz, Evandro Chagas Clin Res Inst, Rio De Janeiro, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop, Sao Paulo, Brazil.
   [Heinke, Thais] SalomaoZoppi Diagnost, Sao Paulo, Brazil.
RP Cambou, MC (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM mcambou@mednet.ucla.edu
OI Luz, Paula/0000-0001-9746-719X; Heinke, Thais/0000-0002-2842-496X
FU South American Program in HIV Prevention Research (SAPHIR) [NIH R25
   MH087222]; Brazilian National Counsel of Technological and Scientific
   Development (CNPq)National Council for Scientific and Technological
   Development (CNPq); Research Funding Agency of the State of Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); Instituto de Pesquisa Clinica
   Evandro Chagas; Fundacao Oswaldo Cruz; Brazilian National STD/AIDS
   Program of the Brazilian Ministry of Health; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069476,
   UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476, UM1AI069476,
   UM1AI069476, UM1AI069476] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [K23MH084611, K23MH084611, K23MH084611,
   R25MH087222, R25MH087222, R25MH087222, R25MH087222, R25MH087222,
   R25MH087222, R25MH087222, K23MH084611, K23MH084611, R25MH087222] Funding
   Source: NIH RePORTER
FX MCC, JEL, PML, and BG are supported by the South American Program in HIV
   Prevention Research (SAPHIR; NIH R25 MH087222). BG and PML acknowledge
   funding from the Brazilian National Counsel of Technological and
   Scientific Development (CNPq) and the Research Funding Agency of the
   State of Rio de Janeiro (FAPERJ). This study was funded by the Instituto
   de Pesquisa Clinica Evandro Chagas, Fundacao Oswaldo Cruz and the
   Brazilian National STD/AIDS Program of the Brazilian Ministry of Health.
CR Abraham AG, 2013, JAIDS-J ACQ IMM DEF, V62, P405, DOI 10.1097/QAI.0b013e31828177d7
   Ahdieh L, 2001, J INFECT DIS, V184, P682, DOI 10.1086/323081
   [Anonymous], 2014, Cancer Discov, V4, pOF2, DOI 10.1158/2159-8290.CD-NB2013-168
   Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
   Boldrini NT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102169
   Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321
   Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14
   Daling JR, 2004, CANCER-AM CANCER SOC, V101, P270, DOI 10.1002/cncr.20365
   Darragh TM, 2011, CANCER CYTOPATHOL, V119, P5, DOI 10.1002/cncy.20126
   De Vuyst H, 2009, INT J CANCER, V124, P1626, DOI 10.1002/ijc.24116
   Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031
   Fernandes Jose V, 2010, BMC Res Notes, V3, P96, DOI 10.1186/1756-0500-3-96
   Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055
   Goncalves Maria Alice G, 2008, Infect Agent Cancer, V3, P5, DOI 10.1186/1750-9378-3-5
   Gravitt PE, 2011, J CLIN INVEST, V121, P4593, DOI 10.1172/JCI57149
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Hessol NA, 2013, AIDS, V27, P1743, DOI 10.1097/QAD.0b013e3283601b09
   Huh WK, 2009, OBSTET GYNECOL, V114, P139, DOI 10.1097/AOG.0b013e3181ab6878
   Institute NC, SEER STAT FACT SHEET
   Kojic EM, 2011, SEX TRANSM DIS, V38, P253, DOI 10.1097/OLQ.0b013e3181f70253
   Luz PM, 2012, INT J STD AIDS, V23, P12, DOI 10.1258/ijsa.2009.009409
   Machalek DA, 2012, LANCET ONCOL, V13, P487, DOI 10.1016/S1470-2045(12)70080-3
   Mani D, 2013, CURR OPIN ONCOL, V25, P518, DOI 10.1097/CCO.0b013e328363e04a
   Chaves EBM, 2012, J MED VIROL, V84, P1335, DOI 10.1002/jmv.23346
   McKenzie ND, 2010, GYNECOL ONCOL, V116, P572, DOI 10.1016/j.ygyno.2009.10.058
   Nagle Deborah, 2009, Clin Colon Rectal Surg, V22, P102, DOI 10.1055/s-0029-1223841
   Paesi S, 2009, J MED VIROL, V81, P1270, DOI 10.1002/jmv.21410
   Petersen MR, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-9
   Robbins HA, 2014, AIDS, V28, P881, DOI 10.1097/QAD.0000000000000163
   Saude Md, 2013, PROTOCOL CLINICO E D
   Sehnal B, 2014, J CLIN VIROL, V59, P18, DOI 10.1016/j.jcv.2013.11.004
   Silverberg MJ, 2012, CLIN INFECT DIS, V54, P1026, DOI 10.1093/cid/cir1012
   Stanley MA, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-398
   Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903
   Tandon R, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.01.010
   Tong WWY, 2014, HIV MED, V15, P65, DOI 10.1111/hiv.12080
   UCSF, AN CANC INF
   Wells JS, 2014, AIDS PATIENT CARE ST, V28, P350, DOI 10.1089/apc.2013.0358
   Bosch FX, 2013, VACCINE, V31, P1, DOI 10.1016/j.vaccine.2013.07.026
   Zbar AP, 2002, INT J COLORECTAL DIS, V17, P203, DOI 10.1007/s00384-001-0369-0
NR 40
TC 20
Z9 21
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
EI 1557-7449
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD JAN 1
PY 2015
VL 29
IS 1
BP 4
EP 12
DI 10.1089/apc.2014.0166
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AY0MI
UT WOS:000347290100002
PM 25361401
OA Green Published
DA 2020-11-30
ER

PT J
AU Longatto, A
   Levi, JE
   Martins, TR
   Cohen, D
   Cury, L
   Villa, LL
   Eluf-Neto, J
AF Longatto-Filho, Adhemar
   Levi, Jose Eduardo
   Martins, Toni Ricardo
   Cohen, Diane
   Cury, Lise
   Villa, Luisa Lina
   Eluf-Neto, Jose
TI Critical Analyses of the Introduction of Liquid-Based Cytology in a
   Public Health Service of the State of Sao Paulo, Brazil
SO ACTA CYTOLOGICA
LA English
DT Article
DE Cervical cancer screening; Cytology in low-resource settings;
   Gynecologic cytology; Liquid-based cytology; Public health
ID CERVICAL-CANCER; GYNECOLOGICAL CYTOLOGY; PAP TEST; PERFORMANCE; RODEO;
   STRATEGIES; COLLEGE; SMEARS; RATES
AB Objective: The aim of this study was to compare the performance of the current conventional Pap smear with liquidbased cytology (LBC) preparations. Study Design: Women routinely undergoing their cytopathological and histopathological examinations at Fundacao Oncocentro de Sao Paulo (FOSP) were recruited for LBC. Conventional smears were analyzed from women from other areas of the State of Sao Paulo with similar sociodemographic characteristics. Results: A total of 218,594 cases were analyzed, consisting of 206,999 conventional smears and 11,595 LBC. Among the conventional smears, 3.0% were of unsatisfactory preparation; conversely, unsatisfactory LBC preparations accounted for 0.3%. The ASC-H (atypical squamous cells -cannot exclude high-grade squamous intraepithelial lesion) frequency did not demonstrate any differences between the twomethods. In contrast, the incidence of ASC-US (atypical squamous cells of undetermined significance) was almost twice as frequent between LBC and conventional smears, at 2.9 versus 1.6%, respectively. An equal percentage of highgrade squamous intraepithelial lesions were observed for the two methods, but not for low-grade squamous intraepithelial lesions, which were more significantly observed in LBC preparations than in conventional smears (2.2 vs. 0.7%). The index of positivity was importantly enhanced from 3.0% (conventional smears) to 5.7% (LBC). Conclusions : LBC performed better than conventional smears, and we are truly confident that LBC can improve public health strategies aimed at reducing cervical lesions through prevention programs. (C) 2015 S. Karger AG, Basel
C1 [Longatto-Filho, Adhemar] Univ Sao Paulo, LIM 14, Sao Paulo, Brazil.
   [Eluf-Neto, Jose] Univ Sao Paulo, Dept Prevent Med, Sao Paulo, Brazil.
   [Villa, Luisa Lina] Univ Sao Paulo, Fac Med, Dept Radiol & Oncol, Sao Paulo, Brazil.
   [Levi, Jose Eduardo; Martins, Toni Ricardo] Univ Sao Paulo, Inst Med Trop, Lab Virol, Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar; Levi, Jose Eduardo; Villa, Luisa Lina] Inst Nacl Ciencia Tecnol Doencas Papilomavirus Hu, Sao Paulo, Brazil.
   [Cohen, Diane; Cury, Lise; Eluf-Neto, Jose] Fundacao Oncoctr Sao Paulo, Rua Oscar Freire 2396, BR-05409012 Sao Paulo, SP, Brazil.
   [Villa, Luisa Lina; Eluf-Neto, Jose] Inst Canc Estado Sao Paulo, Ctr Invest Translac Oncol, Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] Pio XII Fdn, Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil.
   [Longatto-Filho, Adhemar] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal.
   [Longatto-Filho, Adhemar] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal.
RP Eluf-Neto, J (corresponding author), Fundacao Oncoctr Sao Paulo, Rua Oscar Freire 2396, BR-05409012 Sao Paulo, SP, Brazil.
EM jelufnet@usp.br
RI Longatto-Filho, Adhemar/N-3397-2019; longatto-filho,
   adhemar/D-7039-2013; VILLA, LUISA/AAH-4761-2019; Eluf-Neto,
   Jose/B-2522-2009
OI Longatto-Filho, Adhemar/0000-0002-5779-9752; longatto-filho,
   adhemar/0000-0002-5779-9752; VILLA, LUISA/0000-0003-4074-2335;
   Eluf-Neto, Jose/0000-0001-7504-2115
CR Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9
   Arbyn M, 2011, ANN ONCOL, V22, P2675, DOI 10.1093/annonc/mdr015
   Arbyn M, 2008, OBSTET GYNECOL, V111, P167, DOI 10.1097/01.AOG.0000296488.85807.b3
   Cummings MC, 2015, CANCER CYTOPATHOL, V123, P108, DOI 10.1002/cncy.21498
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fregnani JHTG, 2013, ACTA CYTOL, V57, P69, DOI 10.1159/000343046
   INCA: ESTIMATIVA, 2014, ESTIMATIVA 2014 INC
   Isidean SD, 2014, LANCET, V383, P493, DOI 10.1016/S0140-6736(13)62028-0
   Longatto A, 2010, ACTA CYTOL, V54, P654, DOI 10.1159/000325196
   Longatto-Filho A, 2007, DIAGN CYTOPATHOL, V35, P672, DOI 10.1002/dc.20700
   Longatto A, 2012, VIRCHOWS ARCH, V460, P577, DOI 10.1007/s00428-012-1242-y
   Lynge E, 2009, EUR J CANCER, V45, P2714, DOI 10.1016/j.ejca.2009.07.024
   Monsonego J, 2012, GYNECOL ONCOL, V125, P175, DOI 10.1016/j.ygyno.2012.01.002
   Navarro C, 2015, REV SAUDE PUBL, V49, DOI 10.1590/S0034-8910.2015049005554
   Nygard JF, 2002, J MED SCREEN, V9, P86, DOI 10.1136/jms.9.2.86
   Renshaw AA, 2004, ARCH PATHOL LAB MED, V128, P17
   Ronco G, 2007, BRIT MED J, V335, P28, DOI 10.1136/bmj.39196.740995.BE
   Saieg MA, 2014, ACTA CYTOL, V58, P378, DOI 10.1159/000365944
   Scapulatempo C, 2013, ACTA CYTOL, V57, P489, DOI 10.1159/000351789
   Schmitt FC, 2008, J CLIN PATHOL, V61, P258, DOI 10.1136/jcp.2006.044347
   Siebers AG, 2014, CANCER CAUSE CONTROL, V25, P1141, DOI 10.1007/s10552-014-0414-2
   Stein MD, 2013, AM J CLIN PATHOL, V140, P567, DOI 10.1309/AJCPWL36JXMRESFH
   The NHS Information Centre, 2011, SCREEN IMM TEAM CERV
   Vanni T, 2011, INT J CANCER, V129, P671, DOI 10.1002/ijc.25708
   Wilbur DC, 2009, AM J CLIN PATHOL, V132, P767, DOI 10.1309/AJCP8VE7AWBZCVQT
   Zheng BW, 2015, ARCH PATHOL LAB MED, V139, P373, DOI 10.5858/arpa.2014-0070-OA
NR 26
TC 5
Z9 6
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0001-5547
EI 1938-2650
J9 ACTA CYTOL
JI Acta Cytol.
PY 2015
VL 59
IS 3
BP 273
EP 277
DI 10.1159/000435801
PG 5
WC Pathology
SC Pathology
GA V8F3G
UT WOS:000421583900009
PM 26279162
OA Green Published, Bronze
DA 2020-11-30
ER

PT J
AU Levi, JE
   Cabral, SPN
   Nishiya, A
   Ferreira, S
   Romano, CM
   Polite, MBC
   Pereira, RAA
   Mota, MA
   Kutner, JM
AF Levi, J. E.
   Cabral, S. P. N.
   Nishiya, A.
   Ferreira, S.
   Romano, C. M.
   Polite, M. B. C.
   Pereira, R. A. A.
   Mota, M. A.
   Kutner, J. M.
TI Absence of nonprimate hepacivirus-related genomes in blood donors
   seroreactive for hepatitis C virus displaying indeterminate blot
   patterns
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Article
DE blood donors; blot indeterminates; hepatitis C virus; nonprimate
   hepacivirus
ID INFECTION
AB Despite intensive search, no primate homologue to the Hepatitis C Virus (HCV) has ever been found. The search for a zoonotic origin for HCV has been renewed recently when a virus, now known as non-primate hepacivirus (NPHV), with a high homology to HCV was found in dogs. A variable proportion of anti-HCV reactive blood donors submitted to the immunoblot (IB) to confirm their HCV status, present indeterminate results. The degree of homology between HCV and NPHV suggests that humans may be infected by NPHV or NPHV-like viruses. Maximum similarity between NHPV and HCV is observed in the nonstructural regions 3 and 5. Peptides representing both domains are present in IB assays, so it is reasonable to suppose that blood donors harboring such viruses may display cross-reactivity to the HCV antigenic fractions. Fifty-nine plasma samples from blood donors found reactive for anti-HCV and presenting IB indeterminate results were submitted to five distinct PCR reactions under low-stringency conditions, employing primers targeting GBV-C 5'UTR and NS3, Flavivirus-genus NS5 and NPHV 5'UTR and NS3. No amplification was obtained with all primer pairs tested except for five samples that amplified both 5'UTR and NS3 fragments from GBV-C. Unbiased next-generation sequencing may prove or rule out the existence of HCV-related viruses in IB indeterminate samples.
C1 [Levi, J. E.; Cabral, S. P. N.; Polite, M. B. C.; Pereira, R. A. A.; Mota, M. A.; Kutner, J. M.] Hosp Israelita Albert Einstein, Blood Bank, BR-05652000 Sao Paulo, Brazil.
   [Levi, J. E.; Nishiya, A.; Ferreira, S.] Fundacao Pro Sangue, Hemoctr Sao Paulo, Dept Mol Biol, Sao Paulo, Brazil.
   [Levi, J. E.; Romano, C. M.] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Nishiya, A.; Ferreira, S.] Univ Fed Sao Paulo, Infect Dis Div DIPA, Sao Paulo, Brazil.
RP Levi, JE (corresponding author), Hosp Israelita Albert Einstein, Blood Bank, Ave Albert Einstein 627,4 Andar,Bloco A, BR-05652000 Sao Paulo, Brazil.
EM jose.levi@einstein.br
RI Ferreira, Suzete/K-1626-2016; Nishiya, Anna/Q-8156-2016; Romano, Camila
   M/C-8185-2013; Romano, Camila/ABC-2883-2020
OI Ferreira, Suzete/0000-0002-4190-0238; Romano,
   Camila/0000-0003-4550-1987; Kutner, Jose/0000-0003-3784-6731
CR Burbelo PD, 2012, J VIROL, V86, P6171, DOI 10.1128/JVI.00250-12
   Johnson N, 2010, VECTOR-BORNE ZOONOT, V10, P665, DOI 10.1089/vbz.2009.0210
   Kapoor A, 2013, MBIO, V4, DOI 10.1128/mBio.00216-13
   Kapoor A, 2011, P NATL ACAD SCI USA, V108, P11608, DOI 10.1073/pnas.1101794108
   Levi José Eduardo, 2003, Rev. Inst. Med. trop. S. Paulo, V45, P75, DOI 10.1590/S0036-46652003000200004
   Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   Makuria AT, 2012, TRANSFUSION, V52, P1940, DOI 10.1111/j.1537-2995.2011.03524.x
   Muerhoff AS, 1996, J VIROL METHODS, V62, P55, DOI 10.1016/0166-0934(96)02088-5
   Simmonds P, 2013, CURR TOP MICROBIOL, V369, P1, DOI 10.1007/978-3-642-27340-7_1
   Stapleton JT, 2011, J GEN VIROL, V92, P233, DOI 10.1099/vir.0.027490-0
NR 11
TC 5
Z9 5
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
EI 1365-2893
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD NOV
PY 2014
VL 21
IS 11
BP E164
EP E166
DI 10.1111/jvh.12252
PG 3
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA AQ5JT
UT WOS:000342844900003
PM 24689976
DA 2020-11-30
ER

PT J
AU Santos, APD
   Levi, JE
   Lemos, MF
   Calux, SJ
   Oba, IT
   Moreira, RC
AF de Torres Santos, Ana Paula
   Levi, Jose Eduardo
   Lemos, Marcilio Figueiredo
   Calux, Samira Julien
   Oba, Isabel Takano
   Moreira, Regina Celia
TI Identification of hepatitis B virus genotypes in the State of Sao Paulo
SO REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
LA Portuguese
DT Article
DE hepatitis B; polymerase chain reaction; genotype; Brazil
ID EPIDEMIOLOGY; PRECORE; INFECTION; MUTANTS; BRAZIL; RISK; DNA
AB Objective: The aim of this study was to identify HBV genotypes in serum samples from patients from the state of Sao Paulo, received by the viral hepatitis laboratory, at the Virology Centre of Instituto Adolfo Lutz, from various municipalities.
   Methods: a total of 94 serum samples were randomly analyzed. Genotyping was performed using nested PCR for amplification of S and Pol regions from viral genome. Genotypes were identified comparing the sequences obtained with the sequences deposited in GenBank.
   Results: we were able to determine the genotype of 91 (97%) samples, as follows: genotype A (55.3%), D (32%), F (5.3%), C (3.2%) and G (1%). There are few data on the epidemiology of genotype G. This genotype has been detected in restricted areas around the world. Frequently, the genotype G infection occurs in HIV-positive male patients. In our case, the sample identified as G was also positive for HIV but in a female patient, which is an uncommon finding in the scientific literature.
   Conclusion: in this work, we identified the most frequent genotypes in Sao Paulo as well as the genotype G, rare among the genotypes found in our environment.
C1 [de Torres Santos, Ana Paula; Levi, Jose Eduardo; Lemos, Marcilio Figueiredo; Calux, Samira Julien; Oba, Isabel Takano; Moreira, Regina Celia] Adolfo Lutz Inst, BR-01246902 Sao Paulo, Brazil.
RP Moreira, RC (corresponding author), Adolfo Lutz Inst, Av Dr Arnaldo 355, BR-01246902 Sao Paulo, Brazil.
EM regina.moreira7@gmail.com
RI Moreira, Regina C/B-1488-2016
OI Moreira, Regina C/0000-0002-8208-8776
CR Alcalde R, 2009, REV INST MED TROP SP, V51, P269, DOI 10.1590/S0036-46652009000500006
   Alvarado-Mora MV, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-415
   [Anonymous], 2003, J HEPATOL, V38, P533, DOI DOI 10.1016/S0168-8278(03)00083-7
   Bottecchia M, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-11
   Carrilho FJ, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-13
   Compri AP, 2012, REV SOC BRAS MED TRO, V45, P301, DOI 10.1590/S0037-86822012000300004
   da Silva AC, 2010, MEM I OSWALDO CRUZ, V105, P770, DOI 10.1590/S0074-02762010000600007
   IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007, IARC Monogr Eval Carcinog Risks Hum, V90, P1
   KANEKO S, 1989, J CLIN MICROBIOL, V27, P1930, DOI 10.1128/JCM.27.9.1930-1933.1989
   KANEKO S, 1989, P NATL ACAD SCI USA, V86, P312, DOI 10.1073/pnas.86.1.312
   Kao Jia-Horng, 2011, Korean Journal of Internal Medicine, V26, P255, DOI 10.3904/kjim.2011.26.3.255
   Kobayashi M, 2006, J MED VIROL, V78, P1276, DOI 10.1002/jmv.20701
   Mello FCA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-103
   Moraes MTB, 1996, ARCH VIROL, V141, P1767, DOI 10.1007/BF01718299
   Orito E, 2006, HEPATOL RES, V35, P127, DOI 10.1016/j.hepres.2006.03.005
   Osci C, 2010, CIENC SAUDE COLETIVA, V15, P1
   Osiowy C, 2008, J GEN VIROL, V89, P3009, DOI 10.1099/vir.0.2008/005124-0
   Ranjbar R, 2011, IRAN RED CRESCENT ME, V13, P855
   Rezende REF, 2005, J CLIN VIROL, V32, P53, DOI 10.1016/j.jcv.2004.08.001
   Sanchez LV, 2002, J MED VIROL, V68, P24, DOI 10.1002/jmv.10166
   Sitnik R, 2004, J CLIN MICROBIOL, V42, P2455, DOI 10.1128/JCM.42.6.2455-2460.2004
   Stuyver L, 2000, J GEN VIROL, V81, P67, DOI 10.1099/0022-1317-81-1-67
   Sunbul M, 2005, WORLD J GASTROENTERO, V11, P1976, DOI 10.3748/wjg.v11.i13.1976
   Teles SA, 1999, ARTIF ORGANS, V23, P1074, DOI 10.1046/j.1525-1594.1999.06310.x
   Viana S, 2005, AM J TROP MED HYG, V73, P808, DOI 10.4269/ajtmh.2005.73.808
   Vieth S, 2002, VIRUS GENES, V24, P153, DOI 10.1023/A:1014572600432
   Yang HI, 2008, JNCI-J NATL CANCER I, V100, P1134, DOI 10.1093/jnci/djn243
   Yu H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009297
NR 28
TC 0
Z9 0
U1 0
U2 2
PU ASSOC MEDICA BRASILEIRA
PI SAO PAULO
PA RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL
EI 1806-9282
J9 REV ASSOC MED BRAS
JI Rev. Assoc. Med. Bras.
PD SEP-OCT
PY 2014
VL 60
IS 5
BP 424
EP 427
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA AT9SK
UT WOS:000345266200007
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Mendrone, A
   Cerutti, C
   Levi, JE
   Boulos, M
   Sanchez, MCA
   Malafronte, RD
   Di Santi, SM
   Odone, V
AF Mendrone, Alfredo, Jr.
   Cerutti, Crispim, Jr.
   Levi, Jose Eduardo
   Boulos, Marcos
   Arroyo Sanchez, Maria Carmen
   Malafronte, Rosely dos Santos
   Di Santi, Silvia Maria
   Odone, Vicente, Jr.
TI Unexpected detection of Plasmodium vivax and Plasmodium falciparum DNA
   in asymptomatic blood donors: fact or artifact?
SO MALARIA JOURNAL
LA English
DT Editorial Material
ID REAL-TIME PCR; AUTOCHTHONOUS MALARIA; NATURAL INFECTION; ATLANTIC
   FOREST; AMAZON REGION; SAO-PAULO; BRAZIL; TRANSFUSION; DIAGNOSIS;
   ANOPHELINES
AB A study searching for Plasmodium vivax and Plasmodium falciparum DNA among blood donors from the non-endemic area in Brazil reported a rate of 7.41%. This number is at least three times higher than what has been observed in blood donors from the Amazon, an endemic area concentrating >99% of all malaria cases in Brazil. Moreover, the majority of the donors were supposedly infected by P. falciparum, a rare finding both in men and anophelines from the Atlantic forest. These findings shall be taken with caution since they disagree with several publications in the literature and possibly overestimate the actual risk of malaria transmission by blood transfusion in Sao Paulo city.
C1 [Mendrone, Alfredo, Jr.; Levi, Jose Eduardo; Odone, Vicente, Jr.] Hemoctr Sao Paulo, Fundacao Pro Sangue, Sao Paulo, Brazil.
   [Cerutti, Crispim, Jr.] Univ Fed Espirito Santo, Unidade Med Trop, Vitoria, Brazil.
   [Boulos, Marcos] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Levi, Jose Eduardo; Arroyo Sanchez, Maria Carmen; Malafronte, Rosely dos Santos; Di Santi, Silvia Maria] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   [Di Santi, Silvia Maria] Secretaria Estado Saude Sao Paulo, Superintendencia Controle Endemias, Sao Paulo, Brazil.
RP Levi, JE (corresponding author), Hemoctr Sao Paulo, Fundacao Pro Sangue, Sao Paulo, Brazil.
EM jelevi@prosangue.sp.gov.br
RI Cerutti, Crispim/C-4529-2011; Di Santi, Silvia/D-8973-2012; Sanchez,
   Maria Carmen/D-8886-2012
OI Di Santi, Silvia/0000-0001-8049-2014; Arroyo Sanchez, Maria
   Carmen/0000-0003-4055-5556
CR Achidi EA, 1995, ANN TROP MED PARASIT, V89, P601, DOI 10.1080/00034983.1995.11812994
   Sanchez MCA, 2011, TROP MED INT HEALTH, V16, P145
   Batista-dos-Santos S, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-345
   Cerutti C, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-33
   DEANE L M, 1969, Revista do Instituto de Medicina Tropical de Sao Paulo, V11, P71
   DEANE LM, 1992, MEM I OSWALDO CRUZ, V87, P1, DOI 10.1590/S0074-02761992000700001
   Di Santi SM, 2005, REV SOC BRAS MED TRO, V38, P333
   Duarte AMRC, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-58
   Fugikaha Érica, 2007, Rev. Inst. Med. trop. S. Paulo, V49, P1, DOI 10.1590/S0036-46652007000100001
   Gama BE, 2007, EXP PARASITOL, V116, P427, DOI 10.1016/j.exppara.2007.02.011
   Guimares AE, 2000, MEM I OSWALDO CRUZ, V95, P753, DOI 10.1590/S0074-02762000000600002
   Kirchgatter K, 2005, BMJ-BRIT MED J, V331, P576
   Lima GFMC, 2011, MEM I OSWALDO CRUZ, V106, P691, DOI 10.1590/S0074-02762011000600008
   Maselli LMF, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-224
   Neves A, 2013, ACTA TROP, V125, P102, DOI 10.1016/j.actatropica.2012.08.014
   Perandin F, 2004, J CLIN MICROBIOL, V42, P1214, DOI 10.1128/JCM.42.3.1214-1219.2004
   PINOTTI M, 1951, T ROY SOC TROP MED H, V44, P663, DOI 10.1016/0035-9203(51)90003-X
   Rezende HR, 2009, NEOTROP ENTOMOL, V38, P272, DOI 10.1590/S1519-566X2009000200017
   Duarte AMRD, 2008, ACTA TROP, V107, P179, DOI 10.1016/j.actatropica.2008.05.020
   Scuracchio P, 2011, REV INST MED TROP SP, V53, P55, DOI 10.1590/S0036-46652011000100010
   Yamasaki T, 2011, J MED PRIMATOL, V40, P392, DOI 10.1111/j.1600-0684.2011.00498.x
NR 21
TC 7
Z9 7
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD AUG 28
PY 2014
VL 13
AR 336
DI 10.1186/1475-2875-13-336
PG 3
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AO3GB
UT WOS:000341216100001
PM 25168246
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU van de Weg, CAM
   Pannuti, CS
   van den Ham, HJ
   de Araujo, ESA
   Boas, LSV
   Felix, AC
   Carvalho, KI
   Levi, JE
   Romano, CM
   Centrone, CC
   Rodrigues, CLD
   Luna, E
   van Gorp, ECM
   Osterhaus, ADME
   Kallas, EG
   Martina, BEE
AF van de Weg, Cornella A. M.
   Pannuti, Claudio S.
   van den Ham, Henk-Jan
   de Araujo, Evaldo S. A.
   Boas, Lucy S. V.
   Felix, Alvina C.
   Carvalho, Karina I.
   Levi, Jose E.
   Romano, Camila M.
   Centrone, Cristiane C.
   de Lima Rodrigues, Celia L.
   Luna, Expedito
   van Gorp, Eric C. M.
   Osterhaus, Albert D. M. E.
   Kallas, Esper G.
   Martina, Byron E. E.
TI Serum angiopoietin-2 and soluble VEGF receptor 2 are surrogate markers
   for plasma leakage in patients with acute dengue virus infection
SO JOURNAL OF CLINICAL VIROLOGY
LA English
DT Article
DE Dengue virus; Plasma leakage; Vascular permeability; Angiopoietin-2;
   Soluble VEGFR-2
ID TIE-2 LIGAND ANGIOPOIETIN-2; CELL-ADHESION MOLECULES; ENDOTHELIAL-CELLS;
   HEMORRHAGIC-FEVER; SHOCK SYNDROME; ACTIVATION; CHILDREN;
   METALLOPROTEINASES; PERMEABILITY; ASSOCIATION
AB Background: Endothelial cell dysfunction is believed to play an important role in the pathogenesis of plasma leakage in patients with acute dengue virus (DENV) infection. Several factors, produced by activated endothelial cells, have been associated with plasma leakage or severe disease in patients with infectious diseases.
   Objectives: The aim of this study was to investigate which of these markers could serve as a surrogate marker for the occurrence of plasma leakage in patients with acute DENV infection.
   Study design: A case-control study was performed in patients with acute DENV infection in Santos, Brazil. Plasma leakage was detected with X-ray and/or ultrasound examination at admission. Serum levels of soluble endoglin, endothelin-1, angiopoietin-2, VEGF, soluble VEGFR-2, MMP-2, MMP-9, TIMP-1 and TIMP2 were determined using commercially available ELISAs.
   Results: Increased levels of angiopoietin-2, endothelin-1 and MMP-2 and decreased levels of soluble VEGFR2 were significantly associated with the occurrence of plasma leakage. An unsupervised cluster analysis confirmed that angiopoietin-2 and soluble VEGFR-2 were strongly associated with clinical apparent vascular leakage.
   Conclusion: Angiopoietin-2 and soluble VEGFR-2 can serve as surrogate markers for the occurrence of plasma leakage in patients with acute DENV infection. (C) 2014 Elsevier B.V. All rights reserved.
C1 [van de Weg, Cornella A. M.; van den Ham, Henk-Jan; van Gorp, Eric C. M.; Osterhaus, Albert D. M. E.; Martina, Byron E. E.] Erasmus MC, Dept Virosci, NL-3000 CA Rotterdam, Netherlands.
   [Pannuti, Claudio S.; de Araujo, Evaldo S. A.; Boas, Lucy S. V.; Felix, Alvina C.; Levi, Jose E.; Romano, Camila M.; Centrone, Cristiane C.; de Lima Rodrigues, Celia L.; Luna, Expedito] Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, BR-05403000 Sao Paulo, Brazil.
   [de Araujo, Evaldo S. A.; Boas, Lucy S. V.; Felix, Alvina C.; Levi, Jose E.; Romano, Camila M.; Centrone, Cristiane C.; de Lima Rodrigues, Celia L.; Luna, Expedito] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias LIM 52, BR-05403000 Sao Paulo, Brazil.
   [de Araujo, Evaldo S. A.] Hosp Ana Costa, Dept Infect Dis, BR-11075400 Campo Grande, Santos, Brazil.
   [Carvalho, Karina I.] Hosp Albert Einstein, BR-05652000 Sao Paulo, Brazil.
   [Kallas, Esper G.] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM 60, BR-05403000 Sao Paulo, Brazil.
RP Martina, BEE (corresponding author), Erasmus MC, Dept Virosci, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM b.martina@erasmusmc.nl
RI Carvalho, Karina IL/J-6789-2012; Romano, Camila M/C-8185-2013; Romano,
   Camila/ABC-2883-2020; Luna, Expedito J A/B-7948-2012
OI Carvalho, Karina IL/0000-0002-7763-8139; Romano,
   Camila/0000-0003-4550-1987; Luna, Expedito J A/0000-0002-1145-9672;
   Kallas, Esper/0000-0003-2026-6925; van den Ham,
   Henk-Jan/0000-0001-8582-5404; Centrone, Cristiane/0000-0002-7452-5163
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazilian
   Ministry of Science and Technology (CNPq)National Council for Scientific
   and Technological Development (CNPq) [476088/2009-7, 301339/2009-0];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   Brazilian Ministry of EducationCAPES; European Union Seventh Framework
   Programme (FP7) under SILVEREuropean Union (EU) [260644]; Dutch
   government [FES0908]; Netherlands Genomics Initiative (NGI)
   [050-060-452]
FX This study was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico, Brazilian Ministry of Science and Technology
   (CNPq, grant #476088/2009-7 to EGK and 301339/2009-0 to CSP). KIC's
   scholarship was supported by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Brazilian Ministry of Education.; The
   research leading to these results has also received funding from the
   European Union Seventh Framework Programme (FP7/2007-2013) under SILVER
   grant agreement no. 260644.; Moreover, this study was supported by the
   Virgo consortium funded by the Dutch government, project number FES0908,
   and by the Netherlands Genomics Initiative (NGI) project number
   050-060-452.
CR Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5
   Bernardo MM, 2003, BIOCHEM J, V374, P739, DOI 10.1042/BJ20030557
   Bethell DB, 2001, CLIN INFECT DIS, V32, P243, DOI 10.1086/318453
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Cardier JE, 2006, ENDOTHELIUM-J ENDOTH, V13, P335, DOI 10.1080/10623320600972135
   Dalrymple NA, 2012, ADV VIROL, V2012, DOI 10.1155/2012/840654
   Dalrymple NA, 2012, J VIROL, V86, P6408, DOI 10.1128/JVI.00213-12
   de Souza VAUF, 2004, J CLIN MICROBIOL, V42, P1782, DOI 10.1128/JCM.42.4.1782-1784.2004
   Dewi BE, 2008, J GEN VIROL, V89, P642, DOI 10.1099/vir.0.83356-0
   Dietmann A, 2009, J INFECT DIS, V200, P1842, DOI 10.1086/648476
   Dietmann A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-253
   Felix AC, 2012, CLIN VACCINE IMMUNOL, V19, P1972, DOI 10.1128/CVI.00535-12
   Fiedler U, 2004, BLOOD, V103, P4150, DOI 10.1182/blood-2003-10-3685
   Furuta T, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001505
   Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486
   Harris E, 2000, AM J TROP MED HYG, V63, P5, DOI 10.4269/ajtmh.2000.63.5
   Harris E, 1998, J CLIN MICROBIOL, V36, P2634, DOI 10.1128/JCM.36.9.2634-2639.1998
   Jessie K, 2004, J INFECT DIS, V189, P1411, DOI 10.1086/383043
   Kelley JF, 2012, VIROLOGY, V422, P326, DOI 10.1016/j.virol.2011.10.030
   Khongphatthanayothin A, 2003, INTENS CARE MED, V29, P570, DOI 10.1007/s00134-003-1671-9
   Krishnamurti C, 2001, AM J TROP MED HYG, V65, P840, DOI 10.4269/ajtmh.2001.65.840
   Kubelka CF, 2010, J INFECTION, V61, P501, DOI 10.1016/j.jinf.2010.09.020
   Luplerdlop N, 2006, EMBO REP, V7, P1176, DOI 10.1038/sj.embor.7400814
   Luplertlop N, 2008, JPN J INFECT DIS, V61, P298
   Michels M, 2012, AM J TROP MED HYG, V87, P943, DOI 10.4269/ajtmh.2012.12-0020
   Nachman RL, 2008, NEW ENGL J MED, V359, P1261, DOI 10.1056/NEJMra0800887
   Neufeld G, 1999, FASEB J, V13, P9
   Huy NT, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002412
   Ong SP, 2013, MED MICROBIOL IMMUN, V202, P437, DOI 10.1007/s00430-013-0310-5
   Lam PK, 2013, CLIN INFECT DIS, V57, P1577, DOI 10.1093/cid/cit594
   PITTET JF, 1991, ANN SURG, V213, P261, DOI 10.1097/00000658-199103000-00014
   Rathakrishnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052215
   Romano CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070318
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011811
   Scharpfenecker M, 2005, J CELL SCI, V118, P771, DOI 10.1242/jcs.01653
   Seet RCS, 2009, INT J INFECT DIS, V13, pE248, DOI 10.1016/j.ijid.2008.11.028
   Srikiatkhachorn A, 2007, J VIROL, V81, P1592, DOI 10.1128/JVI.01642-06
   Taraboletti G, 2002, AM J PATHOL, V160, P673, DOI 10.1016/S0002-9440(10)64887-0
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   The TD, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001679
   Tseng CS, 2005, FEMS IMMUNOL MED MIC, V43, P99, DOI 10.1016/j.femsim.2004.10.004
   van de Weg CAM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002236
   van de Weg CAM, 2012, AM J TROP MED HYG, V86, P166, DOI 10.4269/ajtmh.2012.11-0491
   van den Ham HJ, 2009, RHEUMATOLOGY, V48, P899, DOI 10.1093/rheumatology/kep125
   Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215
   World Health Organization, 2009, DENG HEM FEV DIAGN T
   YANAGISAWA M, 1988, J HYPERTENS, V6, pS188, DOI 10.1097/00004872-198812040-00056
NR 47
TC 27
Z9 28
U1 0
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-6532
EI 1873-5967
J9 J CLIN VIROL
JI J. Clin. Virol.
PD AUG
PY 2014
VL 60
IS 4
BP 328
EP 335
DI 10.1016/j.jcv.2014.05.001
PG 8
WC Virology
SC Virology
GA AO5AS
UT WOS:000341353200002
PM 24928471
DA 2020-11-30
ER

PT J
AU Moresco, MND
   Virgolino, HD
   de Morais, MPE
   da Motta-Passos, I
   Gomes-Gouvea, MS
   de Assis, LMS
   Aguiar, KRD
   Lombardi, SCF
   Malheiro, A
   Cavalheiro, ND
   Levi, JE
   Torres, KL
AF Moresco, M. N. dos S.
   Virgolino, H. de A.
   de Morais, M. P. E.
   da Motta-Passos, I.
   Gomes-Gouvea, M. S.
   de Assis, L. M. S.
   Aguiar, K. R. de L.
   Lombardi, S. C. F.
   Malheiro, A.
   Cavalheiro, N. de P.
   Levi, J. E.
   Torres, K. L.
TI Occult hepatitis B virus infection among blood donors from the Brazilian
   Amazon: implications for transfusion policy
SO VOX SANGUINIS
LA English
DT Article
DE blood donors; Brazilian Amazon; HBV DNA; occult hepatitis B
ID GENOTYPE-F; MOLECULAR CHARACTERIZATION; PREVALENCE; RISK; VACCINATION
AB Background Brazil requires the performance of both a test for hepatitis B surface antigen (HBsAg) and a test for antibodies to the core of hepatitis B for blood donor screening. Blood centres in regions of high HBV endemicity struggle to maintain adequate stocks in face of the high discard rates due to anti-HBc reactivity. We evaluated the potential infectivity of donations positive for anti-HBc in search of a rational approach for the handling of these collections.
   Study Design and Methods We tested anti-HBc reactive blood donations from the state of Amazonas for the presence of HBV DNA and for titres of anti-HBs. The study population consists of village-based donors from the interior of Amazonas state.
   Results Among 3600 donations, 799 were anti-HBc reactive (22.2%). We were able to perform real-time PCR for the HBV S gene on specimens from 291 of these donors. Eight of these samples were negative for HBsAg and positive for HBV DNA and were defined as occult B virus infections (2.7%). Six of those eight specimens had anti-HBs titres above 100 mIU/ml, indicating the concomitant presence of the virus with high antibody titres.
   Conclusion A small proportion of anti-HBc reactive donors carry HBV DNA and anti-HBs testing is not useful for predicting viremia on them. This finding indicates the possibility of HBV transmission from asymptomatic donors, especially in areas of high HBV prevalence. Sensitive HBV DNA nucleic acid testing may provide another level of safety, allowing eventual use of anti-HBc reactive units in critical situations.
C1 [Moresco, M. N. dos S.; Virgolino, H. de A.; da Motta-Passos, I.; Malheiro, A.; Torres, K. L.] Univ Fed Amazonas, Programa Posgrad Imunol Basica & Aplicada, Manaus, Amazonas, Brazil.
   [de Morais, M. P. E.; de Assis, L. M. S.; Aguiar, K. R. de L.; Malheiro, A.; Torres, K. L.] Fundacao Hematol & Hemoterapia Amazonas, Manaus, Amazonas, Brazil.
   [Gomes-Gouvea, M. S.] Univ Sao Paulo, Fac Med, Dept Gastroenterol, Lab Gastroenterol & Hepatol Trop, Sao Paulo, Brazil.
   [Lombardi, S. C. F.; Levi, J. E.] Fundacao Prosangue, Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Lombardi, S. C. F.] Univ Fed Sao Paulo DIPA UNIFESP, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, Brazil.
   [Cavalheiro, N. de P.; Levi, J. E.] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Sao Paulo, Brazil.
RP Torres, KL (corresponding author), Fundacao CECON, Diretoria Ensino & Pesquisa, Rua Francisco Orellana 215, BR-69040010 Manaus, Amazonas, Brazil.
EM katialuztorres@hotmail.com
RI Ferreira, Suzete/K-1626-2016
OI Ferreira, Suzete/0000-0002-4190-0238
FU Fundacao de Amparo a Pesquisa do Estado do Amazonas [FAPEAM D.005-2009];
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [K24HL075036, K24HL075036,
   K24HL075036, K24HL075036, K24HL075036, K24HL075036, K24HL075036,
   K24HL075036, K24HL075036, K24HL075036] Funding Source: NIH RePORTER
FX Fundacao de Amparo a Pesquisa do Estado do Amazonas (FAPEAM D.005-2009).
CR Allain JP, 2013, TRANSFUSION, V53, P1405, DOI 10.1111/trf.12096
   Arraes Luiz C., 2003, Rev. Inst. Med. trop. S. Paulo, V45, P137, DOI 10.1590/S0036-46652003000300004
   Bertolini DA, 2012, INFECT GENET EVOL, V12, P1295, DOI 10.1016/j.meegid.2012.04.009
   Braga WSM, 2005, REV SOC BRAS MED TRO, V38, P218, DOI 10.1590/S0037-86822005000300002
   Candotti D, 2009, J HEPATOL, V51, P798, DOI 10.1016/j.jhep.2009.05.020
   Castilho MD, 2012, AM J TROP MED HYG, V87, P768, DOI 10.4269/ajtmh.2012.12-0083
   Ximenes RAD, 2010, CAD SAUDE PUBLICA, V26, P1693, DOI 10.1590/S0102-311X2010000900003
   Devesa M, 2008, J MED VIROL, V80, P20, DOI 10.1002/jmv.21024
   El Khouri Marcelo, 2010, Arq. Gastroenterol., V47, P35, DOI 10.1590/S0004-28032010000100007
   El-Zayadi AR, 2008, TRANSFUSION MED, V18, P55, DOI 10.1111/j.1365-3148.2007.00806.x
   Garson JA, 2005, J VIROL METHODS, V126, P207, DOI 10.1016/j.jviromet.2005.03.001
   Hanada D, 2011, VOX SANG, V101, P91
   IBGE - Instituto Brasileiro de Geografia e Estatistica, DAD CENS 2010 PUBL D
   Ismail AM, 2012, BLOOD TRANSFUS-ITALY, V10, P230, DOI 10.2450/2011.0046-11
   Levi Jose Eduardo, 2013, Rev. Bras. Hematol. Hemoter., V35, P167, DOI 10.5581/1516-8484.20130039
   Mello FCA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-103
   Braga WSM, 2012, REV SOC BRAS MED TRO, V45, P13, DOI 10.1590/S0037-86822012000100004
   Panigrahi R, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-204
   Pereira LMMB, 2010, ESTUDO PREVALENCIA B
   Silva CMD, 2005, J INFECTION, V51, P24, DOI 10.1016/j.jinf.2004.07.007
   Stramer SL, 2011, NEW ENGL J MED, V364, P236, DOI 10.1056/NEJMoa1007644
   SUSAM - Secretaria de Estado de Saude do Amazonas, 2010, MAP REG SAUD AM
   Tacke F, 2007, J CLIN VIROL, V38, P353, DOI 10.1016/j.jcv.2006.12.024
   Taira R, 2013, TRANSFUSION, V53, P1393, DOI 10.1111/j.1537-2995.2012.03909.x
   Torres C, 2011, MOL PHYLOGENET EVOL, V59, P114, DOI 10.1016/j.ympev.2011.01.010
   Vermeulen M, 2009, TRANSFUSION, V49, P1115, DOI 10.1111/j.1537-2995.2009.02110.x
NR 26
TC 9
Z9 10
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0042-9007
EI 1423-0410
J9 VOX SANG
JI Vox Sang.
PD JUL
PY 2014
VL 107
IS 1
BP 19
EP 25
DI 10.1111/vox.12125
PG 7
WC Hematology
SC Hematology
GA AN5YL
UT WOS:000340668900003
PM 24697276
OA Green Accepted
DA 2020-11-30
ER

PT J
AU Benvenuti, LA
   Roggeio, A
   Nishiya, AS
   Campos, SV
   Fiorelli, AI
   Levi, JE
AF Benvenuti, Luiz A.
   Roggerio, Alessandra
   Nishiya, Anna S.
   Campos, Silvia V.
   Fiorelli, Alfredo I.
   Levi, Jose E.
TI Trypanosoma cruzi persistence in the native heart is associated with
   high-grade myocarditis, but not with Chagas' disease reactivation after
   heart transplantation
SO JOURNAL OF HEART AND LUNG TRANSPLANTATION
LA English
DT Article
DE Chagas' disease; Trypanosoma cruzi; heart transplantation; myocarditis;
   polymerase chain reaction
ID POLYMERASE-CHAIN-REACTION; AMERICAN TRYPANOSOMIASIS; PARASITE
   PERSISTENCE; DNA; AMPLIFICATION; PATHOGENESIS; LESIONS
AB BACKGROUND: Chagas' disease reactivation (CDR) after heart transplantation (HTx) is characterized by relapse of the infectious disease, with direct detection of Trypanosoma cruzi parasites in blood, cerebrospinal fluid, or tissues. We investigated whether a detailed pathologic examination of the explanted heart at HTx with evaluation of myocarditis and parasitic persistence or load in the myocardium could be useful to identify patients at high risk of CDR.
   METHODS: The native hearts of 18 chagasic patients who presented CDR after HTx (CDR+ group) were compared with the native hearts of 16 chagasic patients who never presented CDR in a follow-up of at least 18 months after HTx (CDR- group). The intensity of myocarditis was evaluated semiquantitatively. Parasite persistence/load in the myocardium was investigated through immunohistochemistry for T cruzi antigens and by qualitative and quantitative real-time PCR for T cruzi DNA.
   RESULTS: The rate of high-grade myocarditis, parasite persistence, and the median of parasitic load and parasitic load/10(6) cells in the CDR+ group were 83.3%, 77.8%, 8.43 x 10(-3), and 9.890, respectively, whereas in the CDR- group the values were 87.5%, 50%, 7.49 x 10(-3), and 17.800. There was no statistical difference between the groups. High-grade myocarditis was present in all 22 samples (100%) with parasite persistence and in 7 of 12 samples (58.3%) with no parasite persistence (p = 0.003).
   CONCLUSIONS: Although associated with high-grade myocarditis, T cruzi parasite persistence in the myocardium of the native heart is not associated with the occurrence of CDR after HTx. (C) 2014 International Society for Heart and Lung Transplantation. All rights reserved.
C1 [Benvenuti, Luiz A.; Roggerio, Alessandra; Campos, Silvia V.; Fiorelli, Alfredo I.] Univ Sao Paulo, Sch Med, Inst Heart, BR-05403000 Sao Paulo, Brazil.
   [Nishiya, Anna S.; Levi, Jose E.] Univ Fed Sao Paulo, Fdn Pro Sangue, Hemocentro Sao Paulo, Dept Biol Mol, Sao Paulo, Brazil.
   [Nishiya, Anna S.] Univ Fed Sao Paulo, Div Infect Dis DIPA, Silo Paulo, Brazil.
RP Benvenuti, LA (corresponding author), Univ Sao Paulo, Sch Med, Inst Heart, Av Dr Eneas Carvalho Aguiar 44, BR-05403000 Sao Paulo, Brazil.
EM anpluiz@incor.usp.br
RI Benvenuti, Luiz/C-6614-2014; Nishiya, Anna/Q-8156-2016; Aiello,
   Vera/A-9495-2008
OI Aiello, Vera/0000-0002-4185-9423
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [11/51580-1]
FX This study was financially supported by grant 11/51580-1, sao Paulo
   Research Foundation (FAPESP).
CR ARETZ HT, 1987, HUM PATHOL, V18, P619
   Bacal F, 2010, CLIN TRANSPLANT, V24, pE29, DOI 10.1111/j.1399-0012.2009.01202.x
   Barbosa AA, 1984, REV SOC BRAS MED TRO, V17, P123, DOI DOI 10.1590/S0037-86821984000300003
   Marcon GEB, 2011, MEM I OSWALDO CRUZ, V106, P85, DOI 10.1590/S0074-02762011000100014
   Benvenuti LA, 2008, ANN TROP MED PARASIT, V102, P481, DOI 10.1179/136485908X311740
   Benvenuti LA, 2011, J HEART LUNG TRANSPL, V30, P799, DOI 10.1016/j.healun.2011.02.012
   Benvenuti LA, 2007, ARQ BRAS CARDIOL, V88, P496, DOI 10.1590/S0066-782X2007000400022
   Bocchi EA, 2001, ANN THORAC SURG, V71, P1833, DOI 10.1016/S0003-4975(01)02587-5
   Campos SV, 2008, J HEART LUNG TRANSPL, V27, P597, DOI 10.1016/j.healun.2008.02.017
   Cobo ED, 2012, J TROP MED-US, V2012, DOI 10.1155/2012/232646
   Fiorelli AI, 2011, TRANSPL P, V43, P220, DOI 10.1016/j.transproceed.2010.12.046
   Gault E, 2001, J CLIN MICROBIOL, V39, P772, DOI 10.1128/JCM.39.2.772-775.2001
   Godoy HL, 2010, J HEART LUNG TRANSPL, V29, P286, DOI 10.1016/j.healun.2009.08.006
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   Higuchi MD, 2003, CARDIOVASC RES, V60, P96, DOI 10.1016/S0008-6363(03)00361-4
   JONES EM, 1993, AM J TROP MED HYG, V48, P348, DOI 10.4269/ajtmh.1993.48.348
   Marin JA, 2007, CIRCULATION, V115, P1109, DOI 10.1161/CIRCULATIONAHA.106.624296
   Olivares-Villagomez D, 1998, AM J TROP MED HYG, V59, P563, DOI 10.4269/ajtmh.1998.59.563
   Piron M, 2007, ACTA TROP, V103, P195, DOI 10.1016/j.actatropica.2007.05.019
   Sartori AMC, 2007, ANN TROP MED PARASIT, V101, P31, DOI 10.1179/136485907X154629
   TEIXEIRA VDA, 1993, T ROY SOC TROP MED H, V87, P552
   Teixiera V. de P.A., 1991, Revista da Sociedade Brasileira de Medicina Tropical, V24, P73
NR 22
TC 10
Z9 10
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1053-2498
EI 1557-3117
J9 J HEART LUNG TRANSPL
JI J. Heart Lung Transplant.
PD JUL
PY 2014
VL 33
IS 7
BP 698
EP 703
DI 10.1016/j.healun.2014.01.920
PG 6
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery;
   Transplantation
SC Cardiovascular System & Cardiology; Respiratory System; Surgery;
   Transplantation
GA AM0JP
UT WOS:000339532100005
PM 24675024
DA 2020-11-30
ER

PT J
AU Ferreira, SC
   de Almeida-Neto, C
   Nishiya, AS
   Oliveira, CDL
   Ferreira, JE
   Alencar, CS
   Levi, JE
   Salles, NA
   Mendrone, A
   Sabino, EC
AF Ferreira, S. C.
   de Almeida-Neto, C.
   Nishiya, A. S.
   Oliveira, C. D. L.
   Ferreira, J. E.
   Alencar, C. S.
   Levi, J. E.
   Salles, N. A.
   Mendrone, A., Jr.
   Sabino, E. C.
TI Demographic, risk factors and motivations among blood donors with
   reactive serologic tests for syphilis in SAo Paulo, Brazil
SO TRANSFUSION MEDICINE
LA English
DT Article
DE blood donors; motivation; risk factors; risk-taking; syphilis
   serodiagnosis
ID MEN; SEX; DIAGNOSIS; CENTERS; PROFILE; COHORT; STATES
AB Objective To identify the demographic characteristics, risk factors and motivations for donating among blood donors with reactive serologic tests for syphilis. Background Post-donation interviews with syphilis seropositive blood donors improve recruitment and screening strategies. Methods This case-control study compares 75 Venereal Disease Research Laboratory (VDRL)>8, EIA+ (enzyme immunoassay) and FTA-ABS+ (fluorescent treponemal antibody); 80 VDRL-, EIA+ and FTA-ABS+; and 34 VDRL- and EIA- donors between 2004 and 2009. Donors were assessed by their demographic characteristics, sexual behaviour, history of alcohol and illicit drugs use, and motivations to donate. Results Donors with VDRL>8 were more likely to be divorced [AOR=12 center dot 53; 95% confidence interval (CI) 1 center dot 30-120 center dot 81], to have had more than six sexual partners (AOR=7 center dot 1; 95% CI 1 center dot 12-44 center dot 62) and to report male-male-sex in the past 12months (AOR=8 center dot 18; 95% CI 1 center dot 78-37 center dot 60). Donors with VDRL-, EIA+ and FTA-ABS+ were less likely to be female (AOR=0 center dot 26; 95% CI 0 center dot 07-0 center dot 96), more likely to be older (AOR=10 center dot 2; 95% CI 2 center dot 45-42 center dot 5839 and <60years old) and to have had more than six sexual partners in the past 12months (AOR=8 center dot 37; 95% CI 1 center dot 49-46 center dot 91). There was no significant difference among groups regarding illicit drugs use; 30 center dot 7% (VDRL>8) and 12 center dot 5% (VDRL-, EIA+ and FTA-ABS+) of donors reported that they had been at risk for HIV infection (P=0 center dot 004). One-third of donors came to the blood bank to help a friend or a relative who needed blood. Conclusion Although donors exposed to syphilis reported and recognised some high risk behaviour, most were motivated by direct appeal to donate blood. Monitoring the risk profile of blood donors can benefit public health and improve blood safety.
C1 [Ferreira, S. C.; Nishiya, A. S.; Alencar, C. S.; Sabino, E. C.] Univ Fed Sao Paulo, Infect Dis Div, Sao Paulo, Brazil.
   [Ferreira, S. C.; de Almeida-Neto, C.; Nishiya, A. S.; Levi, J. E.; Salles, N. A.; Mendrone, A., Jr.] Fundacao Prosangue Hemoctr Sao Paulo, Dept Mol Biol, BR-05403000 Sao Paulo, Brazil.
   [de Almeida-Neto, C.] Univ Sao Paulo, Fac Med, Discipline Med Sci, Sao Paulo, Brazil.
   [Oliveira, C. D. L.] Univ Fed Sao Joao del Rei, Dept Med, Sao Joao Del Rei, Brazil.
   [Ferreira, J. E.] Adolfo Lutz Inst, Pathol Ctr, Sao Paulo, Brazil.
   [Alencar, C. S.] Univ Sao Paulo, LIM Med Res Lab Fac Med 03, Sao Paulo, Brazil.
   [Sabino, E. C.] Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
RP de Almeida-Neto, C (corresponding author), Fundacao Prosangue Hemoctr Sao Paulo, Dept Apheresis, Ave Dr Eneas de Carvalho Aguiar,155 1 Andar, BR-05403000 Sao Paulo, Brazil.
EM cesarnt@uol.com.br
RI Ferreira, Suzete/K-1626-2016; Sabino, Ester Cerdeira/F-7750-2010;
   Nishiya, Anna/Q-8156-2016; Ferreira, Joao E/C-6025-2012; Oliveira,
   Claudia/O-2326-2019; Ferreira, Joao E/L-1287-2016; de Almeida-Neto,
   Cesar/O-9224-2014
OI Ferreira, Suzete/0000-0002-4190-0238; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Ferreira, Joao E/0000-0001-9607-2014;
   Oliveira, Claudia/0000-0001-8533-8155; de Almeida-Neto,
   Cesar/0000-0002-8490-4634
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [K24 HL075036] Funding Source: Medline; NATIONAL
   HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [K24HL075036, K24HL075036,
   K24HL075036, K24HL075036, K24HL075036, K24HL075036, K24HL075036,
   K24HL075036, K24HL075036, K24HL075036] Funding Source: NIH RePORTER
CR Blatyta PF, 2013, TRANSFUSION, V53, P2734, DOI 10.1111/trf.12166
   Boletim-Epidemiologico, 2004, B EP MIN SAUD, P5
   Botham SJ, 2013, SEX HEALTH, V10, P291, DOI 10.1071/SH12142
   Burchell AN, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-246
   Carneiro-Proietti AB, 2010, TRANSFUSION, V50, P918, DOI 10.1111/j.1537-2995.2009.02529.x
   CHAMBERS RW, 1969, TRANSFUSION, V9, P32, DOI 10.1111/j.1537-2995.1969.tb04909.x
   de Almeida C, 2009, TRANSFUSION, V49, P330, DOI 10.1111/j.1537-2995.2008.01977.x
   Cavalcante EGF, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-595
   Goncalez TT, 2013, TRANSFUSION, V53, P1291, DOI 10.1111/j.1537-2995.2012.03887.x
   LARSEN S, 1983, DIAGN IMMUNOL, P162
   Leichliter JS, 2013, JAIDS-J ACQ IMM DEF, V63, P254, DOI 10.1097/QAI.0b013e31828e0cfc
   McMillan A, 2008, INT J STD AIDS, V19, P620, DOI 10.1258/ijsa.2008.008103
   Owusu-Ofori AK, 2011, EMERG INFECT DIS, V17, P2080, DOI 10.3201/eid1711.110985
   Patavino GM, 2012, TRANSFUSION, V52, P151, DOI 10.1111/j.1537-2995.2011.03248.x
   Perkins HA, 2010, TRANSFUSION, V50, P2080, DOI 10.1111/j.1537-2995.2010.02851.x
   RISSEEUWAPPEL IM, 1983, SEX TRANSM DIS, V10, P200, DOI 10.1097/00007435-198311000-00009
   Singh AE, 1999, CLIN MICROBIOL REV, V12, P187, DOI 10.1128/CMR.12.2.187
   Spornraft-Ragaller P, 2013, INFECTION, V41, P1145, DOI 10.1007/s15010-013-0476-1
   Su JR, 2011, ANN INTERN MED, V155, P145, DOI 10.7326/0003-4819-155-3-201108020-00004
   Teles SA, 2008, REV PANAM SALUD PUBL, V24, P25, DOI 10.1590/S1020-49892008000700003
   Torrone E. A., 2008, J ACQ IMMUN DEF SYND, V58, P328
   WHO, 2001, WHO DEP HIV AIDS
NR 22
TC 3
Z9 3
U1 0
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0958-7578
EI 1365-3148
J9 TRANSFUSION MED
JI Transfus. Med.
PD JUN
PY 2014
VL 24
IS 3
BP 169
EP 175
DI 10.1111/tme.12124
PG 7
WC Hematology
SC Hematology
GA AJ3OK
UT WOS:000337576100007
PM 24779667
OA Green Accepted
DA 2020-11-30
ER

PT J
AU Ferreira, SC
   de Almeida-Neto, C
   Nishiya, AS
   Di-Lorenzo-Oliveira, C
   Ferreira, JE
   Alencar, CS
   Levi, JE
   Salles, NA
   Mendrone, A
   Sabino, EC
AF Ferreira, S. C.
   de Almeida-Neto, C.
   Nishiya, A. S.
   Di-Lorenzo-Oliveira, C.
   Ferreira, J. E.
   Alencar, C. S.
   Levi, J. E.
   Salles, N. A.
   Mendrone-Junior, A.
   Sabino, E. C.
TI Prevalence of Treponema pallidum DNA among blood donors with two
   different serologic tests profiles for syphilis in Sao Paulo, Brazil
SO VOX SANGUINIS
LA English
DT Article
DE risk factors; real-time polymerase chain reaction; blood donors;
   syphilis serodiagnosis
ID POLYMERASE-I GENE
AB The presence of Treponema pallidum DNA was assessed by real-time PCR in samples of blood donors with reactive serologic tests for syphilis. Treponema pallidum DNA was detected in two (1 center dot 02%) of 197 samples of VDRL>8, EIA+ and FTA-ABS+ donors, and in no sample from 80 VDRL-, EIA+ and FTA-ABS+ donors. Donors VDRL-, EIA+ and FTA-ABS+ lack demonstrable T.pallidum DNA in their blood and are unlike to transmit syphilis. Donors VDRL>8, EIA+ and FTA-ABS+ carry the risk of syphilis infectivity even in concomitance to antibodies detection. Serologic screening for syphilis may still play a role to prevent its transfusion transmission.
C1 [Ferreira, S. C.; Nishiya, A. S.; Alencar, C. S.; Sabino, E. C.] Univ Fed Sao Paulo, Infect Dis Div, Sao Paulo, Brazil.
   [Ferreira, S. C.; de Almeida-Neto, C.; Nishiya, A. S.; Levi, J. E.; Salles, N. A.; Mendrone-Junior, A.] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Di-Lorenzo-Oliveira, C.] Univ Fed Sao Joao del Rei, Sao Joao Del Rei, MG, Brazil.
   [Ferreira, J. E.] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Alencar, C. S.] HC FMUSP, Lab Medice Lab, LIM 03, Sao Paulo, Brazil.
   [Sabino, E. C.] Univ Sao Paulo, Dept Infect Dis, Sao Paulo, Brazil.
   [Sabino, E. C.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
RP de Almeida-Neto, C (corresponding author), Ave Dr Eneas de Carvalho Aguiar,155 1 Andar, BR-05403000 Sao Paulo, SP, Brazil.
EM cesarnt@uol.com.br
RI Ferreira, Joao E/L-1287-2016; Ferreira, Suzete/K-1626-2016; Nishiya,
   Anna/Q-8156-2016; Ferreira, Joao E/C-6025-2012; Sabino, Ester
   Cerdeira/F-7750-2010; de Almeida-Neto, Cesar/O-9224-2014
OI Ferreira, Suzete/0000-0002-4190-0238; Ferreira, Joao
   E/0000-0001-9607-2014; Sabino, Ester Cerdeira/0000-0003-2623-5126; de
   Almeida-Neto, Cesar/0000-0002-8490-4634
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [P50 AI098461] Funding Source: Medline
CR Blatyta PF, 2013, TRANSFUSION, V53, P2734, DOI 10.1111/trf.12166
   de Almeida C, 2009, TRANSFUSION, V49, P330, DOI 10.1111/j.1537-2995.2008.01977.x
   Dow BC, 2010, TRANSFUSION, V50, P737, DOI 10.1111/j.1537-2995.2009.02516.x
   LARSEN SA, 1995, CLIN MICROBIOL REV, V8, P1
   Liu H, 2001, J CLIN MICROBIOL, V39, P1941, DOI 10.1128/JCM.39.5.1941-1946.2001
   Marfin AA, 2001, DIAGN MICR INFEC DIS, V40, P163, DOI 10.1016/S0732-8893(01)00275-9
   Ministerio da Saude (BR), 2011, CAD INF SANG HEM PRO
   Orton S, 2001, TRANSFUS MED REV, V15, P282, DOI 10.1053/tm.2001.26956
   Otani MM, 2003, EXTERNAL EVALUATION, P201
   Owusu-Ofori AK, 2011, EMERG INFECT DIS, V17, P2080, DOI 10.3201/eid1711.110985
   Perkins HA, 2010, TRANSFUSION, V50, P2080, DOI 10.1111/j.1537-2995.2010.02851.x
   Singh AE, 1999, CLIN MICROBIOL REV, V12, P187, DOI 10.1128/CMR.12.2.187
   WHO, 2010, SCREENING DONATED BLOOD FOR TRANSFUSION: TRANSMISSIBLE INFECTIONS, P1
NR 13
TC 2
Z9 3
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0042-9007
EI 1423-0410
J9 VOX SANG
JI Vox Sang.
PD MAY
PY 2014
VL 106
IS 4
BP 376
EP 378
DI 10.1111/vox.12111
PG 3
WC Hematology
SC Hematology
GA AF5UJ
UT WOS:000334778400013
PM 24877236
DA 2020-11-30
ER

PT J
AU Lopez, RVM
   Levi, JE
   Eluf-Neto, J
   Koifman, RJ
   Koifman, S
   Curado, MP
   Michaluart, P
   Figueiredo, DLA
   Saggioro, FP
   de Carvalho, MB
   Kowalski, LP
   Abrahao, M
   de Gois, F
   Tajara, EH
   Waterboer, T
   Boffetta, P
   Brennan, P
   Wunsch, V
AF Mendoza Lopez, Rossana Veronica
   Levi, Jose Eduardo
   Eluf-Neto, Jose
   Koifman, Rosalina Jorge
   Koifman, Sergio
   Curado, Maria Paula
   Michaluart-Junior, Pedro
   Alves Figueiredo, David Livingstone
   Saggioro, Fabiano Pinto
   de Carvalho, Marcos Brasilino
   Kowalski, Luiz Paulo
   Abrahao, Marcio
   de Gois-Filho, Francisco
   Tajara, Eloiza Helena
   Waterboer, Tim
   Boffetta, Paolo
   Brennan, Paul
   Wuensch-Filho, Victor
TI Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer
   in a geographical region with a low prevalence of HPV infection
SO CANCER CAUSES & CONTROL
LA English
DT Article
DE Human papillomavirus; Serology; Prognosis; Head and neck cancer;
   Prevalence
ID GLUTATHIONE-S-TRANSFERASE; SQUAMOUS-CELL CARCINOMA; OROPHARYNGEAL
   CANCER; POSITIVE HEAD; SURVIVAL; IDENTIFICATION; BIOMARKERS; PROTEINS;
   SEROLOGY; RISK
AB The role of human papillomavirus (HPV) on head and neck squamous cell carcinoma (HNSCC) survival in regions with low HPV prevalence is not yet clear. We evaluated the HPV16 infection on survival of HNSCC Brazilian patient series.
   This cohort comprised 1,093 HNSCC cases recruited from 1998 to 2008 in four Brazilian cities and followed up until June 2009. HPV16 antibodies were analyzed by multiplex Luminex assay. In a subset of 398 fresh frozen or paraffin blocks of HNSCC specimens, we analyzed for HPV16 DNA by L1 generic primer polymerase chain reaction. HNSCC survival according to HPV16 antibodies was evaluated through Kaplan-Meier method and Cox regression.
   Prevalence of HPV16 E6 and E6/E7 antibodies was higher in oropharyngeal cancer than in other head and neck tumor sites. HPV16 DNA positive in tumor tissue was also higher in the oropharynx. Seropositivity for HPV16 E6 antibodies was correlated with improved HNSCC survival and oropharyngeal cancer. The presence of HPV16 E6/E7 antibodies was correlated with improved HNSCC survival and oropharyngeal cancer survival. The death risk of oropharyngeal squamous cell carcinoma patients HPV16 E6/E7 antibodies positive was 78 % lower than to those who test negative.
   Oropharyngeal squamous cell carcinoma is less aggressive in the HPV16 E6/E7 positive serology patients. HPV16 E6/E7 antibody is a clinically sensible surrogate prognostic marker of oropharyngeal squamous cell carcinoma.
C1 [Mendoza Lopez, Rossana Veronica; Wuensch-Filho, Victor] Univ Sao Paulo, Fac Saude Publ, BR-01246904 Sao Paulo, Brazil.
   [Mendoza Lopez, Rossana Veronica] Hosp Canc Barretos, Inst Ensino & Pesquisa, Barretos, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Med Trop, BR-01246904 Sao Paulo, Brazil.
   [Eluf-Neto, Jose] Univ Sao Paulo, Fac Med, BR-01246904 Sao Paulo, Brazil.
   [Koifman, Rosalina Jorge; Koifman, Sergio] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ, Rio De Janeiro, Brazil.
   [Curado, Maria Paula] Hosp Araujo Jorge, Goiania, Brazil.
   [Curado, Maria Paula; Boffetta, Paolo] Int Prevent Res Inst, Lyon, France.
   [Michaluart-Junior, Pedro] Univ Sao Paulo, Fac Med, Hosp Clin, BR-01246904 Sao Paulo, Brazil.
   [Alves Figueiredo, David Livingstone; Saggioro, Fabiano Pinto] Univ Sao Paulo, Fac Med Ribeirao Preto, Hosp Clin, BR-14049 Ribeirao Preto, Brazil.
   [de Carvalho, Marcos Brasilino] Hosp Heliopolis, Sao Paulo, Brazil.
   [Kowalski, Luiz Paulo] Hosp Canc AC Camargo, Sao Paulo, Brazil.
   [Abrahao, Marcio] Univ Fed Sao Paulo, Hosp Sao Paulo, Sao Paulo, Brazil.
   [de Gois-Filho, Francisco] Inst Canc Arnaldo Viera Carvalho, Sao Paulo, Brazil.
   [Tajara, Eloiza Helena] Fac Med Sao Jose Rio Preto, Sao Paulo, Brazil.
   [Waterboer, Tim] German Canc Res Ctr, Heidelberg, Germany.
   [Boffetta, Paolo] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA.
   [Brennan, Paul] Int Agcy Res Canc, F-69372 Lyon, France.
RP Lopez, RVM (corresponding author), Univ Sao Paulo, Fac Saude Publ, Av Dr Arnaldo 715, BR-01246904 Sao Paulo, Brazil.
EM rossana@usp.br
RI Tajara, Eloiza H/G-7586-2012; Waterboer, Tim/G-1252-2010; Mendoza Lopez,
   Rossana Veronica/X-3968-2018; Figueiredo, David Livingstone
   Alves/J-8474-2016; Kowalski, Luiz P/D-1701-2012; Abrahao,
   Marcio/AAX-7399-2020; Filho, Victor Wunsch/C-4475-2012; Eluf-Neto,
   Jose/B-2522-2009; Curado, Maria Paula/M-6200-2013
OI Tajara, Eloiza H/0000-0002-2603-2057; Mendoza Lopez, Rossana
   Veronica/0000-0001-7993-767X; Kowalski, Luiz P/0000-0002-0481-156X;
   Eluf-Neto, Jose/0000-0001-7504-2115; Curado, Maria
   Paula/0000-0001-8172-2483; Brasilino de Carvalho,
   Marcos/0000-0001-6854-2680; Figueiredo, David Livingstone
   Alves/0000-0002-5446-296X
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [10/50733-6,
   09/52031-1, 04/12054-9]; European CommissionEuropean CommissionEuropean
   Commission Joint Research Centre [IC18-CT97-0222]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [10/50733-6; 09/52031-1 and 04/12054-9] and by the
   European Commission [IC18-CT97-0222].
CR Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217
   [Anonymous], 2007, IARC MON EV CARC RIS
   Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X
   BERNARD HU, 1994, J INFECT DIS, V170, P1077, DOI 10.1093/infdis/170.5.1077
   Carvalho AL, 2004, ORAL ONCOL, V40, P71, DOI 10.1016/S1368-8375(03)00138-6
   Clifford GM, 2007, CANCER EPIDEM BIOMAR, V16, P1874, DOI 10.1158/1055-9965.EPI-07-0349
   Coutlee F, 2002, J CLIN MICROBIOL, V40, P902, DOI 10.1128/JCM.40.3.902-907.2002
   D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497
   Dayyani F, 2010, HEAD NECK ONCOL, V2, DOI 10.1186/1758-3284-2-15
   Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011
   Ferlay J., 2010, IARC CANCERBASE
   Hashibe M, 2007, J NATL CANCER I, V99, P777, DOI 10.1093/jnci/djk179
   Herrero R, 2003, JNCI-J NATL CANCER I, V95, P1772, DOI [10.1093/jnci/djg107, 10.1093/jnci/djg/107]
   Kleter B, 1999, J CLIN MICROBIOL, V37, P2508, DOI 10.1128/JCM.37.8.2508-2517.1999
   Kreimer AR, 2005, CANCER EPIDEM BIOMAR, V14, P467, DOI 10.1158/1055-9965.EPI-04-0551
   Liang CH, 2012, CANCER RES, V72, P5004, DOI 10.1158/0008-5472.CAN-11-3277
   Mendez E, 2012, CANCER RES, V72, P4896, DOI 10.1158/0008-5472.CAN-12-3285
   Nasman A, 2009, INT J CANCER, V125, P362, DOI 10.1002/ijc.24339
   Ribeiro KB, 2011, INT J EPIDEMIOL, V40, P489, DOI 10.1093/ije/dyq249
   Rotnaglova E, 2011, INT J CANCER, V129, P101, DOI 10.1002/ijc.25889
   Rubenstein LM, 2011, INFECT AGENTS CANCER, V6, DOI 10.1186/1750-9378-6-9
   Sehr P, 2001, J IMMUNOL METHODS, V253, P153, DOI 10.1016/S0022-1759(01)00376-3
   Smith EM, 2008, CANCER EPIDEM BIOMAR, V17, P2087, DOI 10.1158/1055-9965.EPI-08-0054
   Smith EM, 2007, INT J CANCER, V120, P825, DOI 10.1002/ijc.22330
   Smith EM, 2012, J ONCOL, V2012, DOI 10.1155/2012/571862
   Smith EM, 2010, INT J CANCER, V127, P111, DOI 10.1002/ijc.25015
   Sobin LH, 2002, TNM CLASSIFICATION M
   Szymanska K, 2011, CANCER CAUSE CONTROL, V22, P1037, DOI 10.1007/s10552-011-9779-7
   Waterboer T, 2005, CLIN CHEM, V51, P1845, DOI 10.1373/clinchem.2005.052381
   World Health Organization, 1992, INT STAT CLASS DIS R
NR 30
TC 41
Z9 43
U1 1
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-5243
EI 1573-7225
J9 CANCER CAUSE CONTROL
JI Cancer Causes Control
PD APR
PY 2014
VL 25
IS 4
BP 461
EP 471
DI 10.1007/s10552-014-0348-8
PG 11
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA AC6PY
UT WOS:000332647500006
PM 24474236
DA 2020-11-30
ER

PT J
AU Nishiya, AS
   de Almeida-Neto, C
   Ferreira, SC
   Alencar, CS
   Di-Lorenzo-Oliveira, C
   Levi, JE
   Salles, NA
   Mendrone, A
   Sabino, EC
AF Nishiya, Anna S.
   de Almeida-Neto, Cesar
   Ferreira, Suzete C.
   Alencar, Cecilia S.
   Di-Lorenzo-Oliveira, Claudia
   Levi, Jose E.
   Salles, Nanci A.
   Mendrone, Alfredo, Jr.
   Sabino, Ester C.
TI HCV Genotypes, Characterization of Mutations Conferring Drug Resistance
   to Protease Inhibitors, and Risk Factors among Blood Donors in Sao
   Paulo, Brazil
SO PLOS ONE
LA English
DT Article
ID HEPATITIS-C VIRUS; SPONTANEOUS VIRAL CLEARANCE; NS3 PROTEASE; DECREASED
   SENSITIVITY; SEROLOGIC MARKERS; GENETIC DIVERSITY; PLUS RIBAVIRIN;
   PREVALENCE; INFECTION; TELAPREVIR
AB Background: Hepatitis C virus (HCV) infection is a global health problem estimated to affect almost 200 million people worldwide. The aim of this study is to analyze the subtypes and existence of variants resistant to protease inhibitors and their association with potential HCV risk factors among blood donors in Brazil.
   Methods: Repeat anti-HCV reactive blood donors are systematically asked to return for retest, notification, and counseling in which they are interviewed for risk factors for transfusion-transmitted diseases. We analyzed 202 donors who returned for counseling from 2007 to 2010 and presented enzyme immunoassay-and immunoblot-reactive results. The HCV genotypes and resistance mutation analyses were determined by the direct sequencing of the NS5b and NS3 regions, respectively. The HCV viral load was determined using an in-house real-time PCR assay targeting the 5'-NCR.
   Results: HCV subtypes 1b, 1a, and 3a were found in 45.5%, 32.0%, and 18.0% of the donors, respectively. The mean viral load of genotype 1 was significantly higher than that of the genotype 3 isolates. Subtype 1a was more frequent among young donors and 3a was more frequent among older donors. Protease inhibitor-resistant variants were detected in 12.8% of the sequenced samples belonging to genotype 1, and a higher frequency was observed among subtype 1a (20%) in comparison to 1b (8%). There was no difference in the prevalence of HCV risk factors among the genotypes or drug-resistant variants.
   Conclusions: We found a predominance of subtype 1b, with an increase in the frequency of subtype 1a, in young subjects. Mutations conferring resistance to NS3 inhibitors were frequent in treatment-naive blood donors, particularly those infected with subtype 1a. These variants were detected in the major viral population of HCV quasispecies, have replicative capacities comparable to nonresistant strains, and could be important for predicting the response to antiviral triple therapy.
C1 [Nishiya, Anna S.; de Almeida-Neto, Cesar; Ferreira, Suzete C.; Levi, Jose E.; Salles, Nanci A.; Mendrone, Alfredo, Jr.] Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Nishiya, Anna S.; Ferreira, Suzete C.; Alencar, Cecilia S.; Sabino, Ester C.] Univ Fed Sao Paulo, Infect Dis Div DIPA, Sao Paulo, Brazil.
   [de Almeida-Neto, Cesar] Univ Sao Paulo, Fac Med, Discipline Med Sci, Sao Paulo, Brazil.
   [Alencar, Cecilia S.] HCFMUSP, Dept Pathol, LIM Lab Medice Lab 03, Sao Paulo, Brazil.
   [Di-Lorenzo-Oliveira, Claudia] Univ Sao Joao del Rei, Divinopolis, MG, Brazil.
   [Sabino, Ester C.] Univ Sao Paulo, Fac Med, Dept Infect Dis, Sao Paulo, Brazil.
RP Nishiya, AS (corresponding author), Fundacao Prosangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
EM a_nishiya@hotmail.com
RI de Almeida-Neto, Cesar/O-9224-2014; Ferreira, Suzete/K-1626-2016;
   Sabino, Ester Cerdeira/F-7750-2010; Nishiya, Anna/Q-8156-2016
OI de Almeida-Neto, Cesar/0000-0002-8490-4634; Ferreira,
   Suzete/0000-0002-4190-0238; Sabino, Ester Cerdeira/0000-0003-2623-5126; 
FU CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) of
   Brazilian Ministry of EducationCAPES; Fundacao Pro-Sangue/Hemocentro de
   Sao Paulo
FX This study was supported by CAPES (Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior) of Brazilian Ministry of Education and by
   Fundacao Pro-Sangue/Hemocentro de Sao Paulo. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Oliveira MDA, 2009, J CLIN VIROL, V44, P200, DOI 10.1016/j.jcv.2008.12.008
   [Anonymous], 2002, HEPATOLOGY, V36, pS3, DOI 10.1053/jhep.2002.37117
   Bacon BR, 2011, NEW ENGL J MED, V364, P1207, DOI 10.1056/NEJMoa1009482
   Bartels DJ, 2008, J INFECT DIS, V198, P800, DOI 10.1086/591141
   Bartels DJ, 2013, J VIROL, V87, P1544, DOI 10.1128/JVI.02294-12
   Berger A, 1996, J MED VIROL, V48, P339, DOI 10.1002/(SICI)1096-9071(199604)48:4&lt;339::AID-JMV7&gt;3.0.CO;2-8
   Besse B, 2012, J VIROL METHODS, V185, P94, DOI 10.1016/j.jviromet.2012.06.011
   Brandao Ajacio B M, 2002, BMC Gastroenterol, V2, P18, DOI 10.1186/1471-230X-2-18
   Calado RA, 2011, J MED VIROL, V83, P608, DOI 10.1002/jmv.21955
   Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
   CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562
   Curry S, 2008, J VIROL METHODS, V153, P156, DOI 10.1016/j.jviromet.2008.07.020
   Danta M, 2007, AIDS, V21, P983, DOI 10.1097/QAD.0b013e3281053a0c
   de Almeida-Neto C, 2013, TRANSFUSION, V53, P827, DOI 10.1111/j.1537-2995.2012.03840.x
   Dias PT, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-208
   Dienstag JL, 2006, GASTROENTEROLOGY, V130, P231, DOI 10.1053/j.gastro.2005.11.010
   DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601
   Duggal P, 2013, ANN INTERN MED, V158, P235, DOI 10.7326/0003-4819-158-4-201302190-00003
   ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8
   Felsenstein J, 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X
   Focaccia R., 2004, Braz J Infect Dis, V8, P348, DOI 10.1590/S1413-86702004000500003
   FOCACCIA R, 1998, BRAZ J INFECT DIS, V2, P269
   Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047
   Halfon P, 2011, J HEPATOL, V55, P192, DOI 10.1016/j.jhep.2011.01.011
   HALL TA, 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.5598/IMAFUNGUS.2011.02.02.06
   Hoffmann L, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-57
   Jacobson IM, 2011, NEW ENGL J MED, V364, P2405, DOI 10.1056/NEJMoa1012912
   Jensen DM, 2011, NEW ENGL J MED, V364, P1272, DOI 10.1056/NEJMe1100829
   Kieffer TL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034372
   Kuntzen T, 2008, HEPATOLOGY, V48, P1769, DOI 10.1002/hep.22549
   Lampe E, 2010, INFECT GENET EVOL, V10, P886, DOI 10.1016/j.meegid.2010.05.010
   Lavanchy D, 1999, J VIRAL HEPATITIS, V6, P35
   Lavanchy D, 2009, LIVER INT, V29, P74, DOI 10.1111/j.1478-3231.2008.01934.x
   Lopes Carmen L R, 2009, Rev. Saúde Pública, V43, P43, DOI 10.1590/S0034-89102009000800008
   Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
   McHutchison JG, 2009, NEW ENGL J MED, V360, P1827, DOI 10.1056/NEJMoa0806104
   Micallef JM, 2006, J VIRAL HEPATITIS, V13, P34, DOI 10.1111/j.1365-2893.2005.00651.x
   Nakano T, 2004, J INFECT DIS, V190, P1098, DOI 10.1086/422606
   Nakano T, 2012, LIVER INT, V32, P339, DOI 10.1111/j.1478-3231.2011.02684.x
   Nascimento MC, 2008, J MED VIROL, V80, P53, DOI 10.1002/jmv.21046
   Oliveira Maria de Lourdes Aguiar, 2006, Cad. Saúde Pública, V22, P861, DOI 10.1590/S0102-311X2006000400024
   Oliveira MLA, 1999, BRAZ J MED BIOL RES, V32, P279, DOI 10.1590/S0100-879X1999000300005
   Organization WH, 2012, N 164 FS
   Paolucci S, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-245
   Pawlotsky JM, 2011, HEPATOLOGY, V53, P1742, DOI 10.1002/hep.24262
   Penin F, 2004, HEPATOLOGY, V39, P5, DOI 10.1002/hep.20032
   Pereira LMMB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-60
   Peres-da-Silva A, 2012, MEM I OSWALDO CRUZ, V107, P254, DOI 10.1590/S0074-02762012000200016
   Peres-da-Silva A, 2010, ARCH VIROL, V155, P807, DOI 10.1007/s00705-010-0642-z
   Poordad F, 2011, NEW ENGL J MED, V364, P1195, DOI 10.1056/NEJMoa1010494
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011170
   Rong X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052467
   Rosini Nilton, 2003, Braz J Infect Dis, V7, P262, DOI 10.1590/S1413-86702003000400006
   Salles Nanci A., 2003, Rev Panam Salud Publica, V13, P111, DOI 10.1590/S1020-49892003000200011
   Sarrazin C, 2007, GASTROENTEROLOGY, V132, P1767, DOI 10.1053/j.gastro.2007.02.037
   Sarrazin C, 2007, GASTROENTEROLOGY, V132, P1270, DOI 10.1053/j.gastro.2007.01.041
   Sarrazin C, 2010, GASTROENTEROLOGY, V138, P447, DOI 10.1053/j.gastro.2009.11.055
   Schroter M, 2002, J CLIN MICROBIOL, V40, P1866, DOI 10.1128/JCM.40.5.1866-1868.2002
   Sherman KE, 2011, NEW ENGL J MED, V365, P1014, DOI 10.1056/NEJMoa1014463
   Shindo H, 2011, HEPATOL INT
   Simmonds P, 2004, J GEN VIROL, V85, P3173, DOI 10.1099/vir.0.80401-0
   SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661
   Simmonds P, 1996, J GEN VIROL, V77, P3013, DOI 10.1099/0022-1317-77-12-3013
   Soriano V, 2008, J INFECT DIS, V198, P1337, DOI 10.1086/592171
   Susser S, 2009, HEPATOLOGY, V50, P1709, DOI 10.1002/hep.23192
   Suzuki F, 2012, J CLIN VIROL, V54, P352, DOI 10.1016/j.jcv.2012.04.024
   Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463
   Tohme RA, 2010, HEPATOLOGY, V52, P1497, DOI 10.1002/hep.23808
   Torres KL, 2009, EMERG INFECT DIS, V15, P676, DOI 10.3201/eid1504.081288
   Valente VB, 2005, REV SOC BRAS MED TRO, V38, P488, DOI 10.1590/S0037-86822005000600008
   Vermehren J, 2012, J VIRAL HEPATITIS, V19, P120, DOI 10.1111/j.1365-2893.2011.01449.x
   Vicenti I, 2012, J ANTIMICROB CHEMOTH, V67, P984, DOI 10.1093/jac/dkr581
   Vigani AG, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-164
   Wasley Annemarie, 2007, MMWR Surveill Summ, V56, P1
   Welsch C, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r16
   Wyles David L, 2012, Top Antivir Med, V20, P139
   Zarife MAS, 2006, T ROY SOC TROP MED H, V100, P663, DOI 10.1016/j.trstmh.2005.09.009
   Zeminian LB, 2013, MEM I OSWALDO CRUZ, V108, P13, DOI 10.1590/S0074-02762013000100002
   Zeuzem S, 2011, NEW ENGL J MED, V364, P2417, DOI 10.1056/NEJMoa1013086
NR 79
TC 21
Z9 22
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 21
PY 2014
VL 9
IS 1
AR e86413
DI 10.1371/journal.pone.0086413
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 297GT
UT WOS:000330244500242
PM 24466079
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Ometto, T
   Durigon, EL
   de Araujo, J
   Aprelon, R
   de Aguiar, DM
   Cavalcante, GT
   Melo, RM
   Levi, JE
   de Azevedo, SM
   Petry, MV
   Neto, IS
   Serafini, P
   Villalobos, E
   Cunha, EMS
   Lara, MDCSH
   Nava, AFD
   Nardi, MS
   Hurtado, R
   Rodrigues, R
   Sherer, AL
   Sherer, JDM
   Geraldi, MP
   de Seixas, MMM
   Peterka, C
   Bandeira, DD
   Pradel, J
   Vachiery, N
   Labruna, MB
   de Camargo, LMA
   Lanciotti, R
   Lefrancois, T
AF Ometto, Tatiana
   Durigon, Edison Luiz
   de Araujo, Jansen
   Aprelon, Rosalie
   de Aguiar, Daniel Moura
   Cavalcante, Guacyara Tenorio
   Melo, Rosane Marini
   Levi, Jose Eduardo
   de Azevedo Junior, Severino Mendes
   Petry, Maria Virginia
   Neto, Isaac Simao
   Serafini, Patricia
   Villalobos, Eliana
   Sequetin Cunha, Elenice Maria
   Lara, Maria do Carmo Custodio S. H.
   Dales Nava, Alessandra Ferreira
   Nardi, Marcello Schiavo
   Hurtado, Renata
   Rodrigues, Roberta
   Sherer, Angelo Luis
   Martins Sherer, Janete de Fatima
   Geraldi, Marcelo Plaisant
   Moraes de Seixas, Marina Maria
   Peterka, Cassio
   Bandeira, Debora de Souza
   Pradel, Jennifer
   Vachiery, Nathalie
   Labruna, Marcelo Bahia
   Aranha de Camargo, Luiz Marcelo
   Lanciotti, Robert
   Lefrancois, Thierry
TI West Nile virus surveillance, Brazil, 2008-2010
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE West Nile virus; Serology; Molecular biology; Brazil; Equids; Migratory
   birds
ID LINKED IMMUNOSORBENT ASSAYS; SEROLOGIC EVIDENCE; ANTIBODIES; HORSES;
   INFECTION; STATE; BIRDS
AB Background: West Nile virus (WNV) is an emergent pathogen that is widely distributed in North and Central America. The recent introduction in South America has focused attention on the spread of WNV across Southern American countries. The transmission network involves mosquitoes, birds, horses and humans.
   Methods: The serological evaluation of sera from 678 equids and 478 birds was performed using a WNV-specific blocking ELISA, and only the positive results were confirmed by plaque reduction neutralisation tests (PRNTs). Molecular analysis was performed on sera from 992 healthy equids and on 63 macerates of brains from equids that died of encephalitis and had previously tested negative for other pathogens. We also tested swabs from 928 birds. The samples analysed were collected in different biomes of Brazil.
   Results: We identified WNV antibodies by ELISA in thirteen equids and five birds, and PRNT90 confirmed WNV positivity in four equid samples collected in 2009 in an area between the Amazon and the Pantanal. None of the ELISA positive bird samples were confirmed by PRNT90, and all samples tested by RT-PCR were negative.
   Conclusion: WNV circulation is confirmed by this large scale survey even in the absence of detection of clinical cases.
C1 [Ometto, Tatiana; Durigon, Edison Luiz; de Araujo, Jansen; Hurtado, Renata; Moraes de Seixas, Marina Maria] Univ Sao Paulo, Lab Virol Clin & Mol BSL3, ICB, BR-05508900 Sao Paulo, Brazil.
   [Aprelon, Rosalie; Pradel, Jennifer; Vachiery, Nathalie; Lefrancois, Thierry] CIRAD UMR CMAEE CIRAD INRA, F-97170 Petit Bourg, Guadeloupe, France.
   [de Aguiar, Daniel Moura] Univ Fed Mato Grosso UFMT, Dept Clin Med Vet, BR-78060900 Cuiaba, Brazil.
   [Cavalcante, Guacyara Tenorio] Univ Sao Paulo, Inst Fis, R-05508090 Sao Paulo, Brazil.
   [Melo, Rosane Marini] Inst Defesa Agr Estado Mato Gross INDEA, BR-78050970 Cuiaba, Brazil.
   [Levi, Jose Eduardo; Geraldi, Marcelo Plaisant] Univ Sao Paulo, Virol Lab, Inst Med Trop Sao Paulo, BR-05403000 Sao Paulo, Brazil.
   [de Azevedo Junior, Severino Mendes; Rodrigues, Roberta] Univ Fed Rural Pernambuco UFRPE, BR-52171900 Recife, PE, Brazil.
   [Petry, Maria Virginia; Sherer, Angelo Luis; Martins Sherer, Janete de Fatima] Univ Vale Rio Sinos UNISINOS, BR-93022000 Sao Leopoldo, Brazil.
   [Neto, Isaac Simao; Serafini, Patricia] Ctr Nacl Pesquisa & Conservacao Aves Silvestre CE, BR-88053700 Florianopolis, SC, Brazil.
   [Villalobos, Eliana; Sequetin Cunha, Elenice Maria; Lara, Maria do Carmo Custodio S. H.] Inst Biol, Ctr Pesquisa & Desenvolvimento Sanidade Anim, BR-04014002 Sao Paulo, Brazil.
   [Dales Nava, Alessandra Ferreira] EcoHlth Alliance, BR-05508270 Sao Paulo, Brazil.
   [Nardi, Marcello Schiavo; Peterka, Cassio; Bandeira, Debora de Souza] IPE, BR-19280000 Teodoro Sampaio, Brazil.
   [Hurtado, Renata; Labruna, Marcelo Bahia] Univ Sao Paulo, Fac Med Vet & Zootecnia, BR-05508270 Sao Paulo, Brazil.
   [Aranha de Camargo, Luiz Marcelo] Univ Sao Paulo, Inst Ciencias Biomed 5, BR-78965300 Monte Negro, Brazil.
   [Lanciotti, Robert] Ctr Dis Control & Prevent CDC, Ft Collins, CO 80521 USA.
RP Ometto, T (corresponding author), Univ Sao Paulo, Lab Virol Clin & Mol BSL3, ICB, BR-05508900 Sao Paulo, Brazil.
EM tatiometto@usp.br
RI Aguiar, Daniel M/F-1268-2013; Nava, Alessandra/AAH-2900-2019; Labruna,
   Marcelo B/B-6241-2013; lefrancois, thierry/C-5070-2011; Aguiar, Daniel
   Moura/G-9081-2012; Petry, Maria Virginia/K-8410-2013; Lara, Maria do
   Carmo/T-4646-2019
OI Aguiar, Daniel M/0000-0001-8631-522X; Labruna, Marcelo
   B/0000-0002-9675-3132; lefrancois, thierry/0000-0001-8793-5228; Petry,
   Maria Virginia/0000-0002-7870-7394; Araujo, Jansen/0000-0002-7250-3024;
   Durigon, Edison/0000-0003-4898-6553; Lara, Maria do
   Carmo/0000-0002-9705-6865
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [FAPESP 2009/05994-9]; Interreg
   IV Caraibe 'CaribVET' (Europe Project); FEDEREuropean Union (EU);
   Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [FAPESP 2009/05994-9]; Interreg
   IV Caraibe 'CaribVET' (Europe Project); FEDEREuropean Union (EU)
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP 2009/05994-9); Interreg IV Caraibe 'CaribVET'
   (Europe Project) and FEDER 2007-2013 'Risque en sante animale et
   vegetale'.
CR Diaz LA, 2008, EMERG INFECT DIS, V14, P689, DOI 10.3201/eid1404.071257
   Araujo FAA, 2004, B ELETRONICO EPIDEMI, V2, P1
   Araujo FAA, 2004, B ELETRON EPIDEMIOL, V5, P1
   Araujo FAA, 2003, B ELETRON EPIDEMIOL, V1, P3
   Beaty B.J., 1995, DIAGNOSTIC PROCEDURE, P189
   Blitvich BJ, 2003, EMERG INFECT DIS, V9, P853
   Blitvich BJ, 2003, J CLIN MICROBIOL, V41, P2676, DOI 10.1128/JCM.41.6.2676-2679.2003
   Blitvich BJ, 2003, J CLIN MICROBIOL, V41, P1041, DOI 10.1128/JCM.41.3.1041-1047.2003
   Bosch I, 2007, EMERG INFECT DIS, V13, P651, DOI 10.3201/eid1304.061383
   Alessi CAC, 2009, REV INST MED TROP SP, V51, P277, DOI 10.1590/S0036-46652009000500008
   Carmargo LMA, 2002, MEM I O CRUZ, V97, P193
   De Filette M, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-16
   Domingues RB, 2009, BRAZ J INFECT DIS, V13, P433, DOI 10.1590/S1413-86702009000600009
   Estrada-Franco JG, 2003, EMERG INFECT DIS, V9, P1604, DOI 10.3201/eid0912.030564
   Fernandez-Salas I, 2003, VECTOR-BORNE ZOONOT, V3, P209, DOI 10.1089/153036603322662192
   Komar N, 2006, REV PANAM SALUD PUBL, V19, P112, DOI 10.1590/S1020-49892006000200006
   Koopmans M, 2007, ECOL CONT VECTOR-BOR, V1, P123
   Lefrancois T, 2005, EMERG INFECT DIS, V11, P1100, DOI 10.3201/eid1107.050105
   Levi JE, 2011, REV BRAS HEMATOL HEM, V33, P399
   Lorono-Pino MA, 2003, EMERG INFECT DIS, V9, P857
   Martina BEE, 2010, CURR OPIN INVEST DR, V11, P139
   Mattar S, 2005, EMERG INFECT DIS, V11, P1497, DOI 10.3201/eid1109.050426
   McMullen AR, 2011, EMERG INFECT DIS, V17, P785, DOI 10.3201/eid1705.101707
   Melandri V, 2012, MEM I OSWALDO CRUZ, V107, P1073, DOI 10.1590/S0074-02762012000800020
   Ministerio do Agicultura Pecuaria e Abastecimento, EQ
   Ministerio do Meio Ambiente, BRAZ BIOM
   Morales MA, 2006, EMERG INFECT DIS, V12, P1559, DOI 10.3201/eid1210.060852
   Pai A, 2008, TRANSFUSION, V48, P2184, DOI 10.1111/j.1537-2995.2008.01861.x
   Pauvolid-Correa A, 2011, MEM I OSWALDO CRUZ, V106, P467, DOI 10.1590/S0074-02762011000400014
   Pesko KN, 2012, INFECT GENET EVOL, V12, P181, DOI 10.1016/j.meegid.2011.11.014
   Rodrigues RC, 2009, ZOOLOGIA-CURITIBA, V26, P386, DOI 10.1590/S1984-46702009000300002
   Stramer SL, 2005, NEW ENGL J MED, V353, P451, DOI 10.1056/NEJMoa044333
   Vasconcelos PFC, 1998, OVERVIEW ARBOVIROLOG, P19
NR 33
TC 25
Z9 25
U1 0
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0035-9203
EI 1878-3503
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD NOV
PY 2013
VL 107
IS 11
BP 723
EP 730
DI 10.1093/trstmh/trt081
PG 8
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 258LN
UT WOS:000327460900008
PM 24008895
DA 2020-11-30
ER

PT J
AU Salles, NA
   Levi, JE
   Barreto, CC
   Sampaio, LP
   Romano, CM
   Sabino, EC
   Mendrone, A
AF Salles, Nanci Alves
   Levi, Jose Eduardo
   Barreto, Claudia Cortese
   Sampaio, Luciana Pereira
   Romano, Camila Malta
   Sabino, Ester Cerdeira
   Mendrone Junior, Alfredo
TI Human immunodeficiency virus transfusion transmission despite nucleic
   acid testing
SO TRANSFUSION
LA English
DT Letter
ID BRAZIL; RISK
C1 [Romano, Camila Malta] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Sabino, Ester Cerdeira] Univ Sao Paulo, Sch Med, Dept Infect Dis, Sao Paulo, Brazil.
EM alfredo.mendrone@prosangue.sp.gov.br
RI Romano, Camila M/C-8185-2013; Romano, Camila/ABC-2883-2020; Sabino,
   Ester Cerdeira/F-7750-2010
OI Romano, Camila/0000-0003-4550-1987; Sabino, Ester
   Cerdeira/0000-0003-2623-5126
CR Allers K, 2011, BLOOD, V117, P2791, DOI 10.1182/blood-2010-09-309591
   Goncalez T, 2010, TRANSFUSION, V50, P1806, DOI 10.1111/j.1537-2995.2010.02650.x
   Kleinman SH, 2009, TRANSFUSION, V49, P2454, DOI 10.1111/j.1537-2995.2009.02322.x
   Sabino EC, 2012, TRANSFUSION, V52, P870, DOI 10.1111/j.1537-2995.2011.03344.x
NR 4
TC 12
Z9 12
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD OCT
PY 2013
VL 53
IS 10
SI SI
BP 2593
EP 2595
DI 10.1111/trf.12316
PN 2
PG 3
WC Hematology
SC Hematology
GA 238UY
UT WOS:000325978000026
PM 24099406
DA 2020-11-30
ER

PT J
AU Pereira, RA
   Polite, MB
   Cabral, SP
   Farinha, MT
   Lira, SC
   Mota, MA
   Levi, J
   Kutner, JM
AF Pereira, R. A.
   Polite, M. B.
   Cabral, S. P.
   Farinha, M. T.
   Lira, S. C.
   Mota, M. A.
   Levi, J.
   Kutner, J. M.
TI High-Performance Liquid Chromatography for Screening of Abnormal
   Hemoglobins in Blood Donors Allows the Identification of Diabetic
   Individuals through the Detection of A1C Hemoglobin
SO TRANSFUSION
LA English
DT Meeting Abstract
CT AABB Annual Meeting and CTTXPO
CY OCT 12-15, 2013
CL Denver, CO
SP AABB
C1 [Pereira, R. A.; Polite, M. B.; Cabral, S. P.; Farinha, M. T.; Lira, S. C.; Mota, M. A.; Levi, J.; Kutner, J. M.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
EM ricardoap@einstein.br
RI Carranza-Lira, Sebastian/AAF-4886-2019
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 2013
VL 53
SU 2
SI SI
BP 99A
EP 99A
PG 1
WC Hematology
SC Hematology
GA 218CA
UT WOS:000324409000206
DA 2020-11-30
ER

PT J
AU Mota, MA
   Dezan, MR
   Cruz, RO
   Costa, TH
   Conti, FM
   Aravechia, MG
   Levi, JE
   Castilho, L
   Kutner, JM
AF Mota, M. A.
   Dezan, M. R.
   Cruz, R. O.
   Costa, T. H.
   Conti, F. M.
   Aravechia, M. G.
   Levi, J. E.
   Castilho, L.
   Kutner, J. M.
TI Validation of a Protocol for Fetal RHD Genotyping from Maternal Plasma
   in a Multi-Ethnic Population
SO TRANSFUSION
LA English
DT Meeting Abstract
CT AABB Annual Meeting and CTTXPO
CY OCT 12-15, 2013
CL Denver, CO
SP AABB
C1 [Mota, M. A.; Dezan, M. R.; Cruz, R. O.; Costa, T. H.; Conti, F. M.; Aravechia, M. G.; Levi, J. E.; Kutner, J. M.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Castilho, L.] Univ Estadual Campinas, Hemoctr, Campinas, SP, Brazil.
EM marizamota@einstein.br
RI Castilho, Lilian/F-6123-2012
OI Castilho, Lilian/0000-0002-3104-647X
NR 0
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 2013
VL 53
SU 2
SI SI
BP 170A
EP 171A
PG 2
WC Hematology
SC Hematology
GA 218CA
UT WOS:000324409000392
DA 2020-11-30
ER

PT J
AU Levi, JE
   Cabral, SN
   Nishiya, AS
   Ferreira, SC
   Romano, CM
   Polite, MB
   Pereira, RA
   Mota, MA
   Kutner, JM
AF Levi, J. E.
   Cabral, S. N.
   Nishiya, A. S.
   Ferreira, S. C.
   Romano, C. M.
   Polite, M. B.
   Pereira, R. A.
   Mota, M. A.
   Kutner, J. M.
TI Searching for Non-Primate Hepacivirus (NHPV) Related Genomes in
   HCV-Reactive Donors with Indeterminate Blot Patterns
SO TRANSFUSION
LA English
DT Meeting Abstract
CT AABB Annual Meeting and CTTXPO
CY OCT 12-15, 2013
CL Denver, CO
SP AABB
C1 [Levi, J. E.; Cabral, S. N.; Polite, M. B.; Pereira, R. A.; Mota, M. A.; Kutner, J. M.] Hosp Israelita Albert Einstein, Blood Bank, Sao Paulo, Brazil.
   [Levi, J. E.; Nishiya, A. S.; Ferreira, S. C.] Fundacao Prosangue, Sao Paulo, Brazil.
   [Romano, C. M.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
EM dudilevi@usp.br
RI Romano, Camila M/C-8185-2013; Nishiya, Anna/Q-8156-2016; Romano,
   Camila/ABC-2883-2020
OI Romano, Camila/0000-0003-4550-1987
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 2013
VL 53
SU 2
SI SI
BP 214A
EP 214A
PG 1
WC Hematology
SC Hematology
GA 218CA
UT WOS:000324409000501
DA 2020-11-30
ER

PT J
AU Romano, CM
   Lauck, M
   Salvador, FS
   Lima, CR
   Villas-Boas, LS
   Araujo, ESA
   Levi, JE
   Pannuti, CS
   O'Connor, D
   Kallas, EG
AF Romano, Camila Malta
   Lauck, Michael
   Salvador, Felipe S.
   Lima, Celia Rodrigues
   Villas-Boas, Lucy S.
   Araujo, Evaldo Stanislau A.
   Levi, Jose Eduardo
   Pannuti, Claudio Sergio
   O'Connor, David
   Kallas, Esper Georges
TI Inter- and Intra-Host Viral Diversity in a Large Seasonal DENV2 Outbreak
SO PLOS ONE
LA English
DT Article
ID DENGUE VIRUS; EVOLUTIONARY DYNAMICS; ARBOVIRUS; SELECTION; PRESSURE;
   PATTERNS; MUTATION; TYPE-2; TIME
AB Background: High genetic diversity at both inter-and intra-host level are hallmarks of RNA viruses due to the error-prone nature of their genome replication. Several groups have evaluated the extent of viral variability using different RNA virus deep sequencing methods. Although much of this effort has been dedicated to pathogens that cause chronic infections in humans, few studies investigated arthropod-borne, acute viral infections. Methods and
   Principal Findings: We deep sequenced the complete genome of ten DENV2 isolates from representative classical and severe cases sampled in a large outbreak in Brazil using two different approaches. Analysis of the consensus genomes confirmed the larger extent of the 2010 epidemic in comparison to a previous epidemic caused by the same viruses in another city two years before (genetic distance = 0.002 and 0.0008 respectively). Analysis of viral populations within the host revealed a high level of conservation. After excluding homopolymer regions of 454/Roche generated sequences, we found 10 to 44 variable sites per genome population at a frequency of >1%, resulting in very low intra-host genetic diversity. While up to 60% of all variable sites at intra-host level were non-synonymous changes, only 10% of inter-host variability resulted from non-synonymous mutations, indicative of purifying selection at the population level.
   Conclusions and Significance: Despite the error-prone nature of RNA-dependent RNA-polymerase, dengue viruses maintain low levels of intra-host variability.
C1 [Romano, Camila Malta; Salvador, Felipe S.; Lima, Celia Rodrigues; Villas-Boas, Lucy S.; Levi, Jose Eduardo; Pannuti, Claudio Sergio] Univ Sao Paulo, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   [Romano, Camila Malta; Salvador, Felipe S.; Lima, Celia Rodrigues; Villas-Boas, Lucy S.; Levi, Jose Eduardo; Pannuti, Claudio Sergio] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias LIMHC, Sao Paulo, Brazil.
   [Lauck, Michael; O'Connor, David] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA.
   [Araujo, Evaldo Stanislau A.] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil.
   [Kallas, Esper Georges] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM 60, Sao Paulo, Brazil.
RP Romano, CM (corresponding author), Univ Sao Paulo, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
EM cmromano@usp.br
RI Romano, Camila/ABC-2883-2020; Romano, Camila M/C-8185-2013
OI Romano, Camila/0000-0003-4550-1987; Kallas, Esper/0000-0003-2026-6925;
   o'connor, david/0000-0003-2139-470X
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [10/12313-5]; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico, Brazilian Ministry
   of Science and Technology (CNPq)National Council for Scientific and
   Technological Development (CNPq) [476088/2009-7]; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 AI077376-04A1]; Research
   Facilities Improvement ProgramUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [RR15459-01, RR020141-01]; NATIONAL CENTER FOR
   RESEARCH RESOURCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Research Resources (NCRR) [C06RR020141, C06RR020141, C06RR020141,
   C06RR020141, C06RR020141, C06RR020141, C06RR015459] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01AI077376, R01AI077376, R01AI077376, R01AI077376,
   R01AI077376, R01AI077376, R01AI077376, R01AI077376] Funding Source: NIH
   RePORTER
FX The present work was supported by Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP grant #10/12313-5 to CMR) and by the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazilian
   Ministry of Science and Technology (CNPq, grant #476088/2009-7 to EGK).
   URL of FAPESP: www.fapesp.br; URL of CNPq: www.cnpq.br; URL of
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior:
   www.capes.gov.br. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. This work was also made possible in part by National
   Institutes of Health grant R01 AI077376-04A1. The research was
   conducted, in part, at a facility constructed with support from Research
   Facilities Improvement Program grants RR15459-01 and RR020141-01.
CR Aaskov J, 2006, SCIENCE, V311, P236, DOI 10.1126/science.1115030
   Becker EA, 2012, GENOME BIOL EVOL, V4, P457, DOI 10.1093/gbe/evs029
   Bimber BN, 2010, J VIROL, V84, P12087, DOI 10.1128/JVI.01378-10
   Brackney DE, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000856
   Coffey LL, 2008, P NATL ACAD SCI USA, V105, P6970, DOI 10.1073/pnas.0712130105
   CVE DdZ, 2010, DAD PROV CVE DENG
   de Souza VAUF, 2004, J CLIN MICROBIOL, V42, P1782, DOI 10.1128/JCM.42.4.1782-1784.2004
   Descloux E, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000493
   Santos Cecília Luiza Simões dos, 2003, Rev. Inst. Med. trop. S. Paulo, V45, P11, DOI 10.1590/S0036-46652003000100003
   Duffy S, 2008, NAT REV GENET, V9, P267, DOI 10.1038/nrg2323
   Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
   Farci P, 2000, SEMIN LIVER DIS, V20, P103
   Farci P, 2000, SCIENCE, V288, P339, DOI 10.1126/science.288.5464.339
   Gilles A, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-245
   Grenfell BT, 2004, SCIENCE, V303, P327, DOI 10.1126/science.1090727
   Guilarde AO, 2008, J INFECT DIS, V197, P817, DOI 10.1086/528805
   Henn MR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002529
   Hoper D, 2012, J VIROL, V86, P1394, DOI 10.1128/JVI.00797-11
   Holmes EC, 2003, J VIROL, V77, P11296, DOI 10.1128/JVI.77.20.11296-11298.2003
   Kanesa-thasan N, 1998, EMERG INFECT DIS, V4, P299, DOI 10.3201/eid0402.980220
   Kumar SRP, 2010, J GEN VIROL, V91, P707, DOI 10.1099/vir.0.017954-0
   Lai YL, 2007, J CLIN MICROBIOL, V45, P935, DOI 10.1128/JCM.01258-06
   Lauck M, 2012, J VIROL, V86, P3952, DOI 10.1128/JVI.06627-11
   Li DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019447
   MADDISON WP, 1989, FOLIA PRIMATOL, V53, P190, DOI 10.1159/000156416
   Murcia PR, 2010, J VIROL, V84, P6943, DOI 10.1128/JVI.00112-10
   Ninomiya M, 2012, J CLIN MICROBIOL, V50, P857, DOI 10.1128/JCM.05715-11
   Oliveira MF, 2010, EMERG INFECT DIS, V16, P576, DOI 10.3201/eid1603.090996
   PAHO, 2008, NUMB REP CAS DENG DE
   Parameswaran P, 2012, J VIROL
   Pond SLK, 2005, BIOINFORMATICS, V21, P2531, DOI 10.1093/bioinformatics/bti320
   Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083
   Rogozin IB, 2003, MUTAT RES-REV MUTAT, V544, P65, DOI 10.1016/S1383-5742(03)00032-2
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011811
   Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180
   Rozera G, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-15
   SABINO E, 1993, AIDS RES HUM RETROV, V9, P1265, DOI 10.1089/aid.1993.9.1265
   Strauss BS, 1999, MUTAT RES-REV MUTAT, V437, P195, DOI 10.1016/S1383-5742(99)00066-6
   Suzuki S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019534
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Temporao JG, 2011, EMERG INFECT DIS, V17, P938, DOI 10.3201/eid1705.101681
   Thai KTD, 2012, J VIROL, V86, P835, DOI 10.1128/JVI.05985-11
   VARTANIAN JP, 1992, AIDS, V6, P1095, DOI 10.1097/00002030-199210000-00005
   Vasilakis N, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000467
   Wang WK, 2002, VIROLOGY, V303, P181, DOI 10.1006/viro.2002.1635
   Wang WK, 2002, J VIROL, V76, P4662, DOI 10.1128/JVI.76.9.4662-4665.2002
   Weaver SC, 1999, J VIROL, V73, P4316, DOI 10.1128/JVI.73.5.4316-4326.1999
   World Health Organization, 2009, DENG GUID DIAGN TREA, P147
NR 48
TC 27
Z9 27
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 2
PY 2013
VL 8
IS 8
AR e70318
DI 10.1371/journal.pone.0070318
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 219XU
UT WOS:000324545800039
PM 23936406
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU de Oliveira, CM
   Fregnani, JHTG
   Carvalho, JP
   Longatto, A
   Levi, JE
AF de Oliveira, Cristina Mendes
   Tavares Guerreiro Fregnani, Jose Humberto
   Carvalho, Jesus Paula
   Longatto-Filho, Adhemar
   Levi, Jose Eduardo
TI Human papillomavirus genotypes distribution in 175 invasive cervical
   cancer cases from Brazil
SO BMC CANCER
LA English
DT Article
DE Human Papillomavirus (HPV); Invasive cervical cancer (ICC); Brazil
ID CLASSIFICATION; PREVALENCE; NEOPLASIA; DNA
AB Background: Invasive cervical cancer is the second most common malignant tumor affecting Brazilian women. Knowledge on Human Papillomavirus (HPV) genotypes in invasive cervical cancer cases is crucial to guide the introduction and further evaluate the impact of new preventive strategies based on HPV. We aimed to provide updated comprehensive data about the HPV types' distribution in patients with invasive cervical cancer.
   Methods: Fresh tumor tissue samples of histologically confirmed invasive cervical cancer were collected from 175 women attending two cancer reference hospitals from Sao Paulo State: ICESP and Hospital de Cancer de Barretos. HPV detection and genotyping were performed by the Linear Array HPV Genotyping Test (Roche Molecular Diagnostics, Pleasanton, USA).
   Results: 170 out of 172 valid samples (99%) were HPV DNA positive. The most frequent types were HPV16 (77.6%), HPV18 (12.3%), HPV31 (8.8%), HPV33 (7.1%) and HPV35 (5.9%). Most infections (75%) were caused by individual HPV types. Women with adenocarcinoma were not younger than those with squamous cell carcinoma, as well, as women infected with HPV33 were older than those infected by other HPV types. Some differences between results obtained in the two hospitals were observed: higher overall prevalence of HPV16, absence of single infection by HPV31 and HPV45 was verified in HC-Barretos in comparison to ICESP patients.
   Conclusions: To our knowledge, this is one of the largest studies made with fresh tumor tissues of invasive cervical cancer cases in Brazil. This study depicted a distinct HPV genotype distribution between two centers that may reflect the local epidemiology of HPV transmission among these populations. Due to the impact of these findings on cervical cancer preventive strategies, extension of this investigation to routine screening populations is warranted.
C1 [de Oliveira, Cristina Mendes; Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Tavares Guerreiro Fregnani, Jose Humberto] Hosp Canc Barretos, Fundacao Pio 12, Nucleo Apoio Ao Pesquisador, Sao Paulo, Brazil.
   [Carvalho, Jesus Paula] Univ Sao Paulo, Fac Med, ICESP, Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] Hosp Canc Barretos, Mol Oncol Res Ctr, Sao Paulo, Brazil.
   [Longatto-Filho, Adhemar] Univ Minho, PT Govt Associate Lab 2ICVS 3Bs, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal.
   [Longatto-Filho, Adhemar] Univ Sao Paulo, Fac Med, LIM 14, Sao Paulo, Brazil.
   [Levi, Jose Eduardo] INCT HPV, Sao Paulo, Brazil.
RP de Oliveira, CM (corresponding author), Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
EM cristina.oliveira1@gmail.com
RI Fregnani, Jose H/H-4238-2012; Carvalho, Jesus Paula/O-7464-2019;
   Longatto-Filho, Adhemar/N-3397-2019; Filho, Adhemar
   Longatto/A-2889-2016; Oliveira, Cristina M/F-7193-2012; longatto-filho,
   adhemar/D-7039-2013; CARVALHO, JESUS PAULA/G-8387-2018
OI Fregnani, Jose H/0000-0002-5235-6469; Longatto-Filho,
   Adhemar/0000-0002-5779-9752; longatto-filho,
   adhemar/0000-0002-5779-9752; CARVALHO, JESUS PAULA/0000-0003-4495-057X
CR Bernard HU, 2010, VIROLOGY, V401, P70, DOI 10.1016/j.virol.2010.02.002
   BOSCH FX, 1995, J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796
   Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244
   Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
   Brasil. Ministerio da Saude. Instituto Nacional de Cancer Jose Alencar Gomes da Silva, 2011, EST 2012 INC CANC NO
   Campbell CMP, 2012, INT J GYNECOL OBSTET, V116, P47, DOI 10.1016/j.ijgo.2011.08.008
   Castellsague X, 2006, JNCI-J NATL CANCER I, V98, P303, DOI 10.1093/jnci/djj067
   Dalstein V, 2009, J VIROL METHODS, V156, P77, DOI 10.1016/j.jviromet.2008.11.002
   de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8
   de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033
   ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18
   Ferlay J, 2010, GLOBOCAN 2008 V2 0 C
   Fernandes Jose V, 2010, BMC Res Notes, V3, P96, DOI 10.1186/1756-0500-3-96
   Greer C E, 1991, PCR Methods Appl, V1, P46
   Kasamatsu E, 2012, J MED VIROL, V84, P1628, DOI 10.1002/jmv.23373
   Levi JE, 1998, INT J CANCER, V76, P779, DOI 10.1002/(SICI)1097-0215(19980610)76:6<779::AID-IJC1>3.0.CO;2-V
   Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002/ijc.25396
   Lorenzato F, 2000, INT J GYNECOL CANCER, V10, P143, DOI 10.1046/j.1525-1438.2000.00007.x
   Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641
   Mutch DG, 2009, GYNECOL ONCOL, V115, P325, DOI DOI 10.1016/J.YGYN0.2009.10.050
   Noronha V, 1999, Rev Soc Bras Med Trop, V32, P235, DOI 10.1590/S0037-86821999000300003
   Oliveira CM, 2012, GYNECOL ONCOL, V2, P18
   Rabelo-Santos SH, 2003, MEM I OSWALDO CRUZ, V98, P181, DOI 10.1590/S0074-02762003000200003
   Schiffman Mark, 2003, J Natl Cancer Inst Monogr, P14
   Schiller JT, 2008, VACCINE, V26, pK53, DOI 10.1016/j.vaccine.2008.06.002
   Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527
   Vinokurova S, 2008, CANCER RES, V68, P307, DOI 10.1158/0008-5472.CAN-07-2754
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
NR 28
TC 19
Z9 19
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUL 24
PY 2013
VL 13
AR 357
DI 10.1186/1471-2407-13-357
PG 8
WC Oncology
SC Oncology
GA 190HS
UT WOS:000322330600001
PM 23883423
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Araujo, AR
   Peruhype-Magalhaes, V
   Coelho-dos-Reis, JGA
   Chaves, LPV
   de Lima, TA
   Pimentel, JPD
   de Paula, L
   de Almeida, CM
   Tarrago, AM
   Tateno, A
   Levi, JE
   Teixeira-Carvalho, A
   Martins, OD
   Lira, ED
   Torres, KL
   Talhari, S
   Malheiro, A
AF Araujo, Ana Ruth
   Peruhype-Magalhaes, Vanessa
   Alves Coelho-dos-Reis, Jordana Grazziela
   Viana Chaves, Laura Patricia
   de Lima, Tatiane Amabili
   Diniz Pimentel, Joao Paulo
   de Paula, Lucia
   de Almeida, Carlos Mauricio
   Tarrago, Andrea Monteiro
   Tateno, Adriana
   Levi, Jose Eduardo
   Teixeira-Carvalho, Andrea
   Martins-Filho, Olindo de Assis
   Lira, Edson da Fonseca
   Torres, Katia Luz
   Talhari, Sinesio
   Malheiro, Adriana
TI Dual role of IL-12 in the therapeutic efficacy or failure during
   combined PEG-Interferon-alpha 2A and ribavirin therapy in patients with
   chronic hepatitis C
SO IMMUNOLOGY LETTERS
LA English
DT Article
DE HCV; PEG-IFN-alpha 2A/ribavirin; Sustained virological response; Viral
   load; Cytokines
ID SUSTAINED VIROLOGICAL RESPONSE; INTERFERON-ALPHA THERAPY;
   VIRUS-INFECTION; PRETREATMENT PREDICTION; PEGYLATED-INTERFERON; PLUS
   RIBAVIRIN; HOST FACTORS; T-CELLS; PEGINTERFERON; POLYMORPHISMS
AB Several efforts have been made to establish novel biomarkers with relevant predictive values to monitor HCV-infected patients under pegilated Interferon-alpha 2A-(PEG-IFN-alpha 2A)/ribavirin therapy. The aim of this study was to monitor the kinetics of HCV viral load, serum levels of pro-inflammatory/regulatory cytokines and leukocyte activation status before and after PEG-IFN-alpha 2A/ribavirin therapy in 52 volunteers, including 12 chronic HCV patients and 40 controls. The HCV viral load, serum levels of cytokines (IL-8/IL-6/TNF-alpha/IL-12/IFN-gamma/IL-4/IL-10) and the phenotype of peripheral blood leukocytes were evaluated before and after 4, 12 and 24 weeks following the PEG-IFN-alpha 2A/ribavirin therapy. Our results demonstrated that sustained virological response-(SVR) is associated with early decrease in the viral load after 4 weeks of treatment. The presence of a modulated pro-inflammatory profile at baseline favors SVR, whereas a strong inflammatory response at baseline predisposes to therapeutic failure. Furthermore, a time-dependent increase on serum IL-12 levels in patients under treatment is critical to support the SVR, while the early predominance of IL-10 correlates to late virological relapse. On the other hand, a broad but unguided "cytokine storm" is observed in the non-responder HCV patients after 12 weeks of treatment. Corroborating these findings, monocyte/lymphocyte activation at baseline is associated with the non-responders to therapy whereas high CDS+ T-cell numbers associate with SVR. All in all, these data suggest that the baseline pattern of serum pro-inflammatory/regulatory cytokines and the immunological activation status of chronic HCV patients undergoing PEG-IFN-alpha 2A/ribavirin therapy are closely related with the therapeutic response. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Araujo, Ana Ruth; de Lima, Tatiane Amabili; de Almeida, Carlos Mauricio; Talhari, Sinesio] Fundacao Med Trop Amazonas, Manaus, Amazonas, Brazil.
   [Araujo, Ana Ruth; de Lima, Tatiane Amabili; Talhari, Sinesio] Univ Estado Amazonas, Manaus, Amazonas, Brazil.
   [Araujo, Ana Ruth; Viana Chaves, Laura Patricia; de Paula, Lucia; Tarrago, Andrea Monteiro; Malheiro, Adriana] Univ Fed Amazonas, Manaus, Amazonas, Brazil.
   [Peruhype-Magalhaes, Vanessa; Alves Coelho-dos-Reis, Jordana Grazziela; Teixeira-Carvalho, Andrea; Martins-Filho, Olindo de Assis] Fundacao Oswaldo Cruz, Lab Biomarcadores Diagnost & Monitoracao, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.
   [Viana Chaves, Laura Patricia; de Lima, Tatiane Amabili; Diniz Pimentel, Joao Paulo; Tarrago, Andrea Monteiro; Lira, Edson da Fonseca; Torres, Katia Luz; Malheiro, Adriana] Fundacao Hematol & Hemoterapia Amazonas Hemoam, Manaus, Amazonas, Brazil.
   [Tateno, Adriana; Levi, Jose Eduardo] Inst Med Trop Sao Paulo IMT, Sao Paulo, Brazil.
   [de Paula, Lucia] Fundacao Alfredo da Matta FUAM, Manaus, Amazonas, Brazil.
   [Diniz Pimentel, Joao Paulo] FIOCRUZ Amazonia, Ctr Pesquisas Leonidas & Maria Deane, Manaus, Amazonas, Brazil.
RP Peruhype-Magalhaes, V (corresponding author), FIOCRUZ Minas, Lab Biomarcadores Diagnost & Monitoracao, Ctr Pesquisas Rene Rachou, Av Augusto de Lima 1715, BR-30190002 Belo Horizonte, MG, Brazil.
EM vanessa@cpqrr.fiocurz.br
FU Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)Minas
   Gerais State Research Foundation (FAPEMIG); Fundacao de Amparo a
   Pesquisa do Estado do Amazonas (FAPEAM); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq)
FX This study was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Minas Gerais (FAPEMIG), the Fundacao de Amparo a Pesquisa do Estado
   do Amazonas (FAPEAM), the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq).
CR Aziz H, 2011, INFECT GENET EVOL, V11, P640, DOI 10.1016/j.meegid.2011.01.022
   Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444
   Bucci C, 2013, J GEN VIROL
   Cramp ME, 2000, GASTROENTEROLOGY, V118, P346, DOI 10.1016/S0016-5085(00)70217-4
   Dai CY, 2009, HEPATOLOGY, V49, P2125, DOI 10.1002/hep.22826
   Freeman AJ, 2001, HEPATOLOGY, V34, P809, DOI 10.1053/jhep.2001.27831
   Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047
   Fujita N, 2011, MOL MED, V17, P70, DOI 10.2119/molmed.2010.00124
   Gelderblom HC, 2007, LIVER INT, V27, P944, DOI 10.1111/j.1478-3231.2007.01507.x
   Golden-Mason L, 2007, J VIROL, V81, P9249, DOI 10.1128/JVI.00409-07
   Grandi T, 2013, MEM I OSWALDO CRUZ, V108, P48, DOI 10.1590/S0074-02762013000100008
   Guobuzaite A, 2008, MED LITH, V44, P510, DOI 10.3390/medicina44070066
   Hanafiah KM, 2013, HEPATOLOGY, V57, P1333, DOI 10.1002/hep.26141
   Hoofnagle JH, 2002, HEPATOLOGY, V36, pS21, DOI 10.1053/jhep.2002.36227
   Kamal SM, 2004, HEPATOLOGY, V39, P1721, DOI 10.1002/hep.20266
   Kamal SM, 2002, GASTROENTEROLOGY, V123, P1070, DOI 10.1053/gast.2002.36045
   Kurosaki M, 2011, J GASTROENTEROL, V46, P401, DOI 10.1007/s00535-010-0322-5
   Ma CJ, 2011, IMMUNOLOGY, V132, P421, DOI 10.1111/j.1365-2567.2010.03382.x
   Mangia A, 2013, J HEPATOL
   Martin-Carbonero L, 2008, AIDS, V22, P15, DOI 10.1097/QAD.0b013e3282f1da99
   Namikawa M, 2012, J GASTROEN HEPATOL, V27, P69, DOI 10.1111/j.1440-1746.2011.06802.x
   Nelson DR, 1998, HEPATOLOGY, V28, P225, DOI 10.1002/hep.510280129
   Sharafi H, 2012, HEPAT MON, V12, DOI 10.5812/hepatmon.8387
   Sharafi H, 2012, HEPAT MON, V12, P190, DOI 10.5812/hepatmon.849
   Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4
   Shirakawa H, 2008, HEPATOLOGY, V48, P1753, DOI 10.1002/hep.22543
   SMITH DB, 1995, J GEN VIROL, V76, P1749, DOI 10.1099/0022-1317-76-7-1749
   Umemura T, 2011, ANTIVIR THER, V16, P1073, DOI 10.3851/IMP1869
   Maia LPV, 2009, J MED VIROL, V81, P1220, DOI 10.1002/jmv.21521
   Waggoner SN, 2007, J LEUKOCYTE BIOL, V82, P1407, DOI 10.1189/jlb.0507268
   Wendel Silvano, 2007, Rev. Inst. Med. trop. S. Paulo, V49, P177, DOI 10.1590/S0036-46652007000300008
   Yoneda S, 2011, J INFECT DIS, V203, P1087, DOI 10.1093/infdis/jiq165
   Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019664
NR 33
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-2478
EI 1879-0542
J9 IMMUNOL LETT
JI Immunol. Lett.
PD JUL-AUG
PY 2013
VL 154
IS 1-2
BP 61
EP 69
DI 10.1016/j.imlet.2013.07.010
PG 9
WC Immunology
SC Immunology
GA 246SM
UT WOS:000326559400010
PM 23973662
DA 2020-11-30
ER

PT J
AU van de Weg, CAM
   Pannuti, CS
   de Araujo, ESA
   van den Ham, HJ
   Andeweg, AC
   Boas, LSV
   Felix, AC
   Carvalho, KI
   de Matos, AM
   Levi, JE
   Romano, CM
   Centrone, CC
   Rodrigues, CLD
   Luna, E
   van Gorp, ECM
   Osterhaus, ADME
   Martina, BEE
   Kallas, EG
AF van de Weg, Cornelia A. M.
   Pannuti, Claudio S.
   de Araujo, Evaldo S. A.
   van den Ham, Henk-Jan
   Andeweg, Arno C.
   Boas, Lucy S. V.
   Felix, Alvina C.
   Carvalho, Karina I.
   de Matos, Andreia M.
   Levi, Jose E.
   Romano, Camila M.
   Centrone, Cristiane C.
   de Lima Rodrigues, Celia L.
   Luna, Expedito
   van Gorp, Eric C. M.
   Osterhaus, Albert D. M. E.
   Martina, Byron E. E.
   Kallas, Esper G.
TI Microbial Translocation Is Associated with Extensive Immune Activation
   in Dengue Virus Infected Patients with Severe Disease
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID HEMORRHAGIC-FEVER; BACTERIAL LIPOPOLYSACCHARIDE; HUMAN
   MONOCYTES/MACROPHAGES; CYTOKINE PATTERNS; INTERFERON-GAMMA; PLASMA
   LEAKAGE; SHOCK SYNDROME; SEPTIC SHOCK; TNF-ALPHA; EXPRESSION
AB Background: Severe dengue virus (DENV) disease is associated with extensive immune activation, characterized by a cytokine storm. Previously, elevated lipopolysaccharide (LPS) levels in dengue were found to correlate with clinical disease severity. In the present cross-sectional study we identified markers of microbial translocation and immune activation, which are associated with severe manifestations of DENV infection.
   Methods: Serum samples from DENV-infected patients were collected during the outbreak in 2010 in the State of Sao Paulo, Brazil. Levels of LPS, lipopolysaccharide binding protein (LBP), soluble CD14 (sCD14) and IgM and IgG endotoxin core antibodies were determined by ELISA. Thirty cytokines were quantified using a multiplex luminex system. Patients were classified according to the 2009 WHO classification and the occurrence of plasma leakage/shock and hemorrhage. Moreover, a (non-supervised) cluster analysis based on the expression of the quantified cytokines was applied to identify groups of patients with similar cytokine profiles. Markers of microbial translocation were linked to groups with similar clinical disease severity and clusters with similar cytokine profiles.
   Results: Cluster analysis indicated that LPS levels were significantly increased in patients with a profound pro-inflammatory cytokine profile. LBP and sCD14 showed significantly increased levels in patients with severe disease in the clinical classification and in patients with severe inflammation in the cluster analysis. With both the clinical classification and the cluster analysis, levels of IL-6, IL-8, sIL-2R, MCP-1, RANTES, HGF, G-CSF and EGF were associated with severe disease.
   Conclusions: The present study provides evidence that both microbial translocation and extensive immune activation occur during severe DENV infection and may play an important role in the pathogenesis.
C1 [van de Weg, Cornelia A. M.; van den Ham, Henk-Jan; Andeweg, Arno C.; van Gorp, Eric C. M.; Osterhaus, Albert D. M. E.; Martina, Byron E. E.] Erasmus MC, Virosci Lab, Rotterdam, Netherlands.
   [Pannuti, Claudio S.; de Araujo, Evaldo S. A.; Boas, Lucy S. V.; Felix, Alvina C.; Levi, Jose E.; Romano, Camila M.; Centrone, Cristiane C.; de Lima Rodrigues, Celia L.; Luna, Expedito] Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   [Pannuti, Claudio S.; de Araujo, Evaldo S. A.; Boas, Lucy S. V.; Felix, Alvina C.; Levi, Jose E.; Romano, Camila M.; Centrone, Cristiane C.; de Lima Rodrigues, Celia L.; Luna, Expedito] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias LIM 52, Sao Paulo, Brazil.
   [de Araujo, Evaldo S. A.] Hosp Ana Costa, Dept Infect Dis, Santos, Brazil.
   [Carvalho, Karina I.; de Matos, Andreia M.; Kallas, Esper G.] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM 60, Sao Paulo, Brazil.
RP van de Weg, CAM (corresponding author), Erasmus MC, Virosci Lab, Rotterdam, Netherlands.
EM esper.kallas@usp.br
RI Romano, Camila M/C-8185-2013; Luna, Expedito J A/B-7948-2012; Romano,
   Camila/ABC-2883-2020; Carvalho, Karina IL/J-6789-2012
OI Luna, Expedito J A/0000-0002-1145-9672; Romano,
   Camila/0000-0003-4550-1987; Carvalho, Karina IL/0000-0002-7763-8139;
   Osterhaus, Albert/0000-0002-6074-1172; van den Ham,
   Henk-Jan/0000-0001-8582-5404; Kallas, Esper/0000-0003-2026-6925
FU "Conselho Nacional de Desenvolvimento Cientifico e Tecnologico,
   Brazilian Ministry of Science and Technology'' [CNPq] [476088/2009-7];
   CNPqNational Council for Scientific and Technological Development
   (CNPq); "Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior,
   Brazilian Ministry of Education''; "Virgo consortium''; Dutch government
   [FES0908]; Netherlands Genomics Initiative (NGI) [050-060-452]
FX This work was supported by the "Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico, Brazilian Ministry of Science and Technology''
   [CNPq, project number 476088/2009-7 to EGK]. AMdM and EGK's scholarships
   were supported by "CNPq.'' KIC's scholarship was supported by the
   "Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazilian
   Ministry of Education.'' Moreover, this study was also supported by the
   "Virgo consortium,'' funded by the Dutch government [project number
   FES0908] and by the "Netherlands Genomics Initiative (NGI)'' [project
   number 050-060-452]. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Azeredo EL, 2001, IMMUNOBIOLOGY, V204, P494, DOI 10.1078/0171-2985-00058
   Bethell DB, 1998, J INFECT DIS, V177, P778, DOI 10.1086/517807
   Bosisio D, 2002, BLOOD, V99, P3427, DOI 10.1182/blood.V99.9.3427
   Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Bukh AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021275
   CARUSO C, 1993, MEDIAT INFLAMM, V2, P3, DOI 10.1155/S0962935193000018
   Chen JP, 2006, J IMMUNOL, V177, P3185, DOI 10.4049/jimmunol.177.5.3185
   Chen YC, 1999, J VIROL, V73, P2650, DOI 10.1128/JVI.73.4.2650-2657.1999
   Chen YC, 2002, J VIROL, V76, P9877, DOI 10.1128/JVI.76.19.9877-9887.2002
   Crisostomo PR, 2008, AM J PHYSIOL-CELL PH, V294, pC675, DOI 10.1152/ajpcell.00437.2007
   de Souza VAUF, 2004, J CLIN MICROBIOL, V42, P1782, DOI 10.1128/JCM.42.4.1782-1784.2004
   Felix AC, 2012, CLIN VACCINE IMMUNOL, V19, P1972, DOI 10.1128/CVI.00535-12
   Green S, 1999, J INFECT DIS, V179, P755, DOI 10.1086/314680
   Green S, 1999, J MED VIROL, V59, P329, DOI 10.1002/(SICI)1096-9071(199911)59:3&lt;329::AID-JMV12&gt;3.0.CO;2-G
   Halstead SB, 2003, ADV VIRUS RES, V60, P421, DOI 10.1016/S0065-3527(03)60011-4
   Harris E, 1998, J CLIN MICROBIOL, V36, P2634, DOI 10.1128/JCM.36.9.2634-2639.1998
   HOBER D, 1993, AM J TROP MED HYG, V48, P324, DOI 10.4269/ajtmh.1993.48.324
   Hofer U, 2009, SEMIN IMMUNOPATHOL, V31, P257, DOI 10.1007/s00281-009-0158-3
   Hung NT, 2004, J INFECT DIS, V189, P221, DOI 10.1086/380762
   John CC, 2006, J INFECT DIS, V194, P837, DOI 10.1086/506623
   KURANE I, 1991, J CLIN INVEST, V88, P1473, DOI 10.1172/JCI115457
   LANDMANN R, 1995, J INFECT DIS, V171, P639, DOI 10.1093/infdis/171.3.639
   Lee YR, 2006, J GEN VIROL, V87, P3623, DOI 10.1099/vir.0.82093-0
   Libraty DH, 2002, J INFECT DIS, V185, P1213, DOI 10.1086/340365
   Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
   Murphy K.P., 2008, JANEWAYS IMMUNOBIOLO
   Opal SM, 1999, J INFECT DIS, V180, P1584, DOI 10.1086/315093
   Pacsa AS, 2000, FEMS IMMUNOL MED MIC, V28, P151, DOI 10.1111/j.1574-695X.2000.tb01470.x
   Perez AB, 2004, J MED VIROL, V73, P230, DOI 10.1002/jmv.20080
   Redd AD, 2009, P NATL ACAD SCI USA, V106, P6718, DOI 10.1073/pnas.0901983106
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011811
   Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
   Santos-Oliveira JR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001198
   Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711
   Sierra B, 2010, CYTOKINE, V52, P175, DOI 10.1016/j.cyto.2010.06.010
   Srikiatkhachorn A, 2007, J VIROL, V81, P1592, DOI 10.1128/JVI.01642-06
   Suharti C, 2003, EUR CYTOKINE NETW, V14, P172
   Tang YQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012644
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   van de Weg CAM, 2012, AM J TROP MED HYG, V86, P166, DOI 10.4269/ajtmh.2012.11-0491
   van de Weg CAM, 2012, J CLIN VIROL, V53, P38, DOI 10.1016/j.jcv.2011.09.028
   van den Ham HJ, 2009, RHEUMATOLOGY, V48, P899, DOI 10.1093/rheumatology/kep125
   Wang WM, 2011, INFLAMMATION, V34, P509, DOI 10.1007/s10753-010-9258-4
   World Health Organization, 2009, DENG HEM FEV DIAGN T
NR 45
TC 41
Z9 42
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD MAY
PY 2013
VL 7
IS 5
AR e2236
DI 10.1371/journal.pntd.0002236
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 158SW
UT WOS:000319994400038
PM 23717702
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Amaro, SM
   Golub, JE
   Nuovo, GJ
   Cunha, CB
   Levi, JE
   Villa, LL
   Andrade, CV
   Russomano, FB
   Tristao, A
   Pires, A
   Nicol, AF
AF Amaro-Filho, Sergio M.
   Golub, Jonathan E.
   Nuovo, Gerard J.
   Cunha, Cynthia B.
   Levi, Jose E.
   Villa, Luisa L.
   Andrade, Cecilia V.
   Russomano, Fabio B.
   Tristao, Aparecida
   Pires, Andrea
   Nicol, Alcina F.
TI A Comparative Analysis of Clinical and Molecular Factors with the Stage
   of Cervical Cancer in a Brazilian Cohort
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; HUMAN-PAPILLOMAVIRUS; INTRAEPITHELIAL
   NEOPLASIA; P16(INK4A) EXPRESSION; COMPUTED-TOMOGRAPHY; CYCLE REGULATORS;
   HPV; P53; MARKER; KI-67
AB Cell cycle protein expression plays an important role in the pathophysiology of cervical cancer. However, few studies have attempted to correlate the use of these biomarkers with the clinical progression of the tumor.
   Objectives: 1) To analyze the expression of Ki-67, p53 and p16(INK4a) in cervical cancer, 2) to correlate the relative expression of these proteins as well as clinical parameters with the stage of disease, and 3) to determine the HPV DNA prevalence and subtype distribution.
   Methods: Tissue Micro-Arrays (TMA) from patients with invasive cervical cancer (ICC) and controls were analyzed. HPV DNA detection was done by PCR and in situ hybridization. Ki-67, p53 and p16(INK4a) were analyzed by immunohistochemistry; clinical data was derived from the chart review.
   Results: Advanced tumor stage (III and IV) was strongly associated (p<0.005) with advanced age (>55 years old), with more than four pregnancies and with the lack of formal education. HPV DNA was found in 94.3% of cases with the most prevalent types being HPV16 (67.5%), followed by HPV33 (12.0%) and HPV35 (3.6%). High expression of Ki-67 and p16 was more common in the advanced FIGO stages (p = 0.023). Women with HPV16 tended to be younger (50.9 years; SE 1.9) compared to women with other types (59.9 years; SE 2.8).
   Conclusion: We found that Ki-67 and p16 expression were independently associated with the tumor stage. We also noted that about 1/3 of the cervical cancers in this Brazilian cohort were not associated with HPV types directly targeted by the current HPV vaccines.
C1 [Amaro-Filho, Sergio M.; Nicol, Alcina F.] Fiocruz MS, IOC, Lab Interdisciplinary Med Res LIPMED, BR-21045900 Rio De Janeiro, Brazil.
   [Golub, Jonathan E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol Infect Dis, Baltimore, MD USA.
   [Nuovo, Gerard J.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
   [Cunha, Cynthia B.] Fiocruz MS, IPEC, Evandro Chagas Clin Res Inst, Dept Infect Dis, BR-21045900 Rio De Janeiro, Brazil.
   [Levi, Jose E.] Univ Sao Paulo, Virol Lab, Inst Trop Med, BR-09500900 Sao Paulo, Brazil.
   [Villa, Luisa L.] Hosp Alemao Oswaldo Cruz, Ludwig Inst Canc Res, Sao Paulo, Brazil.
   [Andrade, Cecilia V.; Russomano, Fabio B.; Tristao, Aparecida] Fiocruz MS, Fernandes Figueira Inst, BR-21045900 Rio De Janeiro, Brazil.
   [Pires, Andrea] Fonte Med Diagnost Lab, Niteroi, RJ, Brazil.
   [Pires, Andrea] Univ Fed Fluminense, Niteroi, RJ, Brazil.
RP Nicol, AF (corresponding author), Fiocruz MS, IOC, Lab Interdisciplinary Med Res LIPMED, BR-21045900 Rio De Janeiro, Brazil.
EM nicol@ioc.fiocruz.br
RI VILLA, LUISA/AAH-4761-2019; Papilomavirus, Inct/I-2406-2013; USP,
   Oncologia/F-9053-2014; ANDRADE, CECILIA/B-5916-2017
OI VILLA, LUISA/0000-0003-4074-2335; ANDRADE, CECILIA/0000-0001-7980-4367;
   Amaro-Filho, Sergio/0000-0002-7374-4081
FU Fogarty International Center, National Institutes of Health (NIH)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Fogarty International Center (FIC) [2 D 43
   TW000010-23-AITRP]; LIPMED-IOCFiocruz, RJ, Brazil; Lewis Foundation
   (from Dr Gerard J Nuovo Laboratory); FOGARTY INTERNATIONAL CENTERUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010,
   D43TW000010, D43TW000010, D43TW000010, D43TW000010, D43TW000010] Funding
   Source: NIH RePORTER
FX Grant Support: AFN and SAF were scholars in the International AIDS
   Research and Training Program, supported by the Fogarty International
   Center, National Institutes of Health (NIH) Research Grant 2 D 43
   TW000010-23-AITRP. This work was supported in part by grants from
   LIPMED-IOCFiocruz, RJ, Brazil, and the Lewis Foundation (from Dr Gerard
   J Nuovo Laboratory). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ancuta E, 2009, ROM J MORPHOL EMBRYO, V50, P413
   Angeletti PC, 2008, ADV PHARMACOL, V56, P509, DOI 10.1016/S1054-3589(07)56016-3
   Bahnassy AA, 2007, BMC CLIN PATHOL, V7, DOI 10.1186/1472-6890-7-4
   Bidus MA, 2007, CERVICAL VAGINAL CAN
   BUCHWALD C, 1995, LARYNGOSCOPE, V105, P66, DOI 10.1288/00005537-199501000-00015
   Cheah PL, 2012, ASIAN PAC J CANCER P, V13, P469, DOI 10.7314/APJCP.2012.13.2.469
   Conesa-Zamora P, 2009, AM J CLIN PATHOL, V132, P378, DOI 10.1309/AJCPO0WY1VIFCYDC
   Pires ARC, 2006, DIAGN PATHOL, V1, DOI 10.1186/1746-1596-1-14
   Doorbar J, 2006, CLIN SCI, V110, P525, DOI 10.1042/CS20050369
   DRYJA TP, 1986, AM J HUM GENET, V38, P59
   FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0
   Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227
   FUJITA M, 1992, CANCER RES, V52, P5323
   Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090
   Galgano MT, 2010, AM J SURG PATHOL, V34, P1077, DOI 10.1097/PAS.0b013e3181e8b2c4
   Giarnieri E, 2000, CLIN CANCER RES, V6, P3600
   Giarre M, 2001, J VIROL, V75, P4705, DOI 10.1128/JVI.75.10.4705-4712.2001
   Goel MM, 2005, DIAGN CYTOPATHOL, V33, P15, DOI 10.1002/dc.20218
   Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
   Gupta N, 2010, DIAGN CYTOPATHOL, V38, P618, DOI 10.1002/dc.21270
   Hampl M, 2007, J CANCER RES CLIN, V133, P235, DOI 10.1007/s00432-006-0162-0
   Harima Y, 2002, INT J RADIAT ONCOL, V52, P1345, DOI 10.1016/S0360-3016(01)02796-1
   HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057
   Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115
   Kalof AN, 2006, ADV ANAT PATHOL, V13, P190, DOI 10.1097/00125480-200607000-00006
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Korenjak M, 2005, CURR OPIN GENET DEV, V15, P520, DOI 10.1016/j.gde.2005.07.001
   Ku JL, 1997, INT J CANCER, V72, P313, DOI 10.1002/(SICI)1097-0215(19970717)72:2<313::AID-IJC19>3.0.CO;2-G
   Kuo KT, 2006, BRIT J OPHTHALMOL, V90, P894, DOI 10.1136/bjo.2005.086314
   Mimica M, 2010, INT J GYNECOL CANCER, V20, P116, DOI 10.1111/IGC.0b013e3181bc8da7
   Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9
   Nicol AF, 2012, MEM I OSWALDO CRUZ, V107, P571, DOI 10.1590/S0074-02762012000500001
   Nicol AF, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-289
   Oka K, 2000, CANCER, V88, P2766, DOI 10.1002/1097-0142(20000615)88:12<2766::AID-CNCR15>3.0.CO;2-G
   OMIM, LI FRAUM SYNDR
   Otto TD, 2008, GENET MOL RES, V7, P861, DOI 10.4238/vol7-3X-Meeting04
   Queiroz C, 2006, PATHOL RES PRACT, V202, P77, DOI 10.1016/j.prp.2005.08.012
   Rajaram S, 2010, J CANCER RES THER, V6, P267, DOI 10.4103/0973-1482.73342
   Rajkumar T, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-80
   Skomedal H, 1999, GYNECOL ONCOL, V73, P223, DOI 10.1006/gyno.1999.5346
   SUBAK LL, 1995, OBSTET GYNECOL, V86, P43, DOI 10.1016/0029-7844(95)00109-5
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]
   Tan GC, 2008, ASIAN PAC J CANCER P, V9, P781
   Tjalma WA, 2001, EUR J OBSTET GYN R B, V97, P223, DOI 10.1016/S0301-2115(00)00541-8
   Tsuda H, 2003, GYNECOL ONCOL, V91, P476, DOI 10.1016/j.ygyno.2003.08.019
   Volgareva G, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-58
NR 46
TC 9
Z9 12
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 7
PY 2013
VL 8
IS 3
AR e57810
DI 10.1371/journal.pone.0057810
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 136BN
UT WOS:000318334500034
PM 23505442
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Felix, AC
   Romano, CM
   Centrone, CD
   Rodrigues, CL
   Villas-Boas, L
   Araujo, ES
   de Matos, AM
   Carvalho, KI
   Martelli, CMT
   Kallas, EG
   Pannuti, CS
   Levi, JE
AF Felix, Alvina Clara
   Romano, Camila Malta
   Centrone, Cristiane de Campos
   Rodrigues, Celia Lima
   Villas-Boas, Lucy
   Araujo, Evaldo Stanislau
   de Matos, Andreia Manso
   Carvalho, Karina Inacio
   Turchi Martelli, Celina Maria
   Kallas, Esper Georges
   Pannuti, Claudio Sergio
   Levi, Jose Eduardo
TI Low Sensitivity of NS1 Protein Tests Evidenced during a Dengue Type 2
   Virus Outbreak in Santos, Brazil, in 2010
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID HEMORRHAGIC-FEVER; ANTIGEN; DIAGNOSIS; VIREMIA; TRANSFUSION; INFECTIONS;
   BLOOD; ELISA; SPECIFICITY; DISEASE
AB In 2010, a large outbreak of dengue occurred in Santos, Brazil. The detection of the NS1 antigen was used for diagnosis in addition to the detection of IgG, IgM, and RNA. A large number of NS1 false-negative results were obtained. A total of 379 RNA-positive samples were selected for thorough evaluation. NS1 was reactive in 37.7% of cases. Most of the cases were characterized as a secondary infection by dengue 2 virus. Sequencing of NS1 positive and negative isolates did not reveal any mutation that could justify the diagnostic failure. Use of existing NS1 tests in the Brazilian population may present a low negative predictive value, and they should be used with caution, preferentially after performing a validation with samples freshly obtained during the ongoing epidemic.
C1 [Felix, Alvina Clara; Romano, Camila Malta; Centrone, Cristiane de Campos; Rodrigues, Celia Lima; Villas-Boas, Lucy; Araujo, Evaldo Stanislau; Pannuti, Claudio Sergio; Levi, Jose Eduardo] Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   [Felix, Alvina Clara; Romano, Camila Malta; Centrone, Cristiane de Campos; Rodrigues, Celia Lima; Villas-Boas, Lucy; Araujo, Evaldo Stanislau; Pannuti, Claudio Sergio; Levi, Jose Eduardo] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas Parasitarias LIMHC, Sao Paulo, Brazil.
   [Araujo, Evaldo Stanislau] Hosp Ana Costa, Santos, Brazil.
   [de Matos, Andreia Manso; Carvalho, Karina Inacio; Kallas, Esper Georges] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM 60, Sao Paulo, Brazil.
   [Turchi Martelli, Celina Maria] Univ Fed Goias, IPTSP, Goiania, Go, Brazil.
RP Levi, JE (corresponding author), Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
EM dudilevi@usp.br
RI Carvalho, Karina IL/J-6789-2012; Iats, Inct/K-2300-2013; Romano, Camila
   M/C-8185-2013; Romano, Camila/ABC-2883-2020
OI Carvalho, Karina IL/0000-0002-7763-8139; Romano,
   Camila/0000-0003-4550-1987; Turchi Martelli, Celina
   Maria/0000-0002-2491-0688; Kallas, Esper/0000-0003-2026-6925
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2010/12313-5]
FX This study was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP grant 2010/12313-5).
CR Alcon S, 2002, J CLIN MICROBIOL, V40, P376, DOI 10.1128/JCM.40.02.376-381.2002
   Barreto ML, 2011, LANCET, V377, P1877, DOI 10.1016/S0140-6736(11)60202-X
   Castro-Jorge LA, 2010, J MED VIROL, V82, P1400, DOI 10.1002/jmv.21814
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Coller BAG, 2011, CURR OPIN IMMUNOL, V23, P391, DOI 10.1016/j.coi.2011.03.005
   de Souza VAUF, 2004, J CLIN MICROBIOL, V42, P1782, DOI 10.1128/JCM.42.4.1782-1784.2004
   Duyen HTL, 2011, J INFECT DIS, V203, P1292, DOI 10.1093/infdis/jir014
   Guilarde AO, 2008, J INFECT DIS, V197, P817, DOI 10.1086/528805
   Guzman MG, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000811
   Hang VT, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000360
   Harris E, 1998, J CLIN MICROBIOL, V36, P2634, DOI 10.1128/JCM.36.9.2634-2639.1998
   Kao Chuan-Liang, 2005, Journal of Microbiology Immunology and Infection, V38, P5
   Koraka P, 2003, J CLIN MICROBIOL, V41, P4154, DOI 10.1128/JCM.41.9.4154-4159.2003
   Levi JE, 2007, J CLIN MICROBIOL, V45, P1893, DOI 10.1128/JCM.00065-07
   Libraty DH, 2002, J INFECT DIS, V186, P1165, DOI 10.1086/343813
   Lima MDQ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000738
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011811
   Secretaria da Saude do Estado de Sao Paulo, OFF DAT DENG EP STAT
   Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265
   Stramer SL, 2012, TRANSFUSION, V52, P1657, DOI 10.1111/j.1537-2995.2012.03566.x
   Stramer SL, 2009, TRANSFUSION, V49, p1S, DOI 10.1111/j.1537-2995.2009.02279.x
   Tambyah PA, 2008, NEW ENGL J MED, V359, P1526, DOI 10.1056/NEJMc0708673
   Teixeira MG, 2012, REV INST MED TROP SP, V54, pS1, DOI 10.1590/S0036-46652012000700002
   Teles FRR, 2005, REV MED VIROL, V15, P287, DOI 10.1002/rmv.461
   WHO, WORLD STAT DENG CAS
   Young PR, 2000, J CLIN MICROBIOL, V38, P1053, DOI 10.1128/JCM.38.3.1053-1057.2000
NR 26
TC 25
Z9 26
U1 0
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD DEC
PY 2012
VL 19
IS 12
BP 1972
EP 1976
DI 10.1128/CVI.00535-12
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 047NU
UT WOS:000311848400011
PM 23100478
OA Bronze, Green Published
DA 2020-11-30
ER

PT J
AU Amorim, JH
   Bizerra, RSP
   Alves, RPD
   Sbrogio-Almeida, ME
   Levi, JE
   Capurro, ML
   Ferreira, LCD
AF Amorim, Jaime Henrique
   Pereira Bizerra, Raiza Sales
   dos Santos Alves, Rubens Prince
   Sbrogio-Almeida, Maria Elisabete
   Levi, Jose Eduardo
   Capurro, Margareth Lara
   de Souza Ferreira, Luis Carlos
TI A Genetic and Pathologic Study of a DENV2 Clinical Isolate Capable of
   Inducing Encephalitis and Hematological Disturbances in Immunocompetent
   Mice
SO PLOS ONE
LA English
DT Article
ID DENGUE VIRUS-INFECTION; DOMAIN-III; HEMORRHAGIC-FEVER; NS1 PROTEIN;
   MOUSE MODEL; PATHOGENESIS; RECOMBINANT; MANIFESTATIONS; DETERMINANTS;
   REPLICATION
AB Dengue virus (DENV) is the causative agent of dengue fever (DF), a mosquito-borne illness endemic to tropical and subtropical regions. There is currently no effective drug or vaccine formulation for the prevention of DF and its more severe forms, i.e., dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). There are two generally available experimental models for the study of DENV pathogenicity as well as the evaluation of potential vaccine candidates. The first model consists of non-human primates, which do not develop symptoms but rather a transient viremia. Second, mouse-adapted virus strains or immunocompromised mouse lineages are utilized, which display some of the pathological features of the infection observed in humans but may not be relevant to the results with regard to the wild-type original virus strains or mouse lineages. In this study, we describe a genetic and pathological study of a DENV2 clinical isolate, named JHA1, which is naturally capable of infecting and killing Balb/c mice and reproduces some of the symptoms observed in DENV-infected subjects. Sequence analyses demonstrated that the JHA1 isolate belongs to the American genotype group and carries genetic markers previously associated with neurovirulence in mouse-adapted virus strains. The JHA1 strain was lethal to immunocompetent mice following intracranial (i.c.) inoculation with a LD50 of approximately 50 PFU. Mice infected with the JHA1 strain lost weight and exhibited general tissue damage and hematological disturbances, with similarity to those symptoms observed in infected humans. In addition, it was demonstrated that the JHA1 strain shares immunological determinants with the DENV2 NGC reference strain, as evaluated by cross-reactivity of anti-envelope glycoprotein (domain III) antibodies. The present results indicate that the JHA1 isolate may be a useful tool in the study of DENV pathogenicity and will help in the evaluation of anti-DENV vaccine formulations as well as potential therapeutic approaches.
C1 [Amorim, Jaime Henrique; Pereira Bizerra, Raiza Sales; dos Santos Alves, Rubens Prince; de Souza Ferreira, Luis Carlos] Univ Sao Paulo, Dept Microbiol, Vaccine Dev Lab, BR-05508 Sao Paulo, Brazil.
   [dos Santos Alves, Rubens Prince] Univ Estadual Santa Cruz, Ilheus, Brazil.
   [Sbrogio-Almeida, Maria Elisabete] Butantan Inst, Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, BR-05508 Sao Paulo, Brazil.
   [Capurro, Margareth Lara] Univ Sao Paulo, Dept Parasitol, BR-05508 Sao Paulo, Brazil.
RP Amorim, JH (corresponding author), Univ Sao Paulo, Dept Microbiol, Vaccine Dev Lab, BR-05508 Sao Paulo, Brazil.
EM lcsf@usp.br
RI Ferreira, Luis Carlos S/M-3954-2014; Amorim, Jaime Henrique/O-9222-2017;
   Capurro, Margareth/M-5286-2019; Capurro, Margareth/F-8679-2012
OI Ferreira, Luis Carlos S/0000-0002-4883-1693; Amorim, Jaime
   Henrique/0000-0002-0623-2879; Capurro, Margareth/0000-0002-7480-2116
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   grantFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/50033-7]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) grant process 2009/50033-7. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript
CR Amaral DC, 2011, J NEUROINFLAMM, V9, P8
   Amorim JH, 2012, VACCINE, V30, P837, DOI 10.1016/j.vaccine.2011.12.034
   Amorim JH, 2010, J VIROL METHODS, V167, P186, DOI 10.1016/j.jviromet.2010.04.003
   Atrasheuskaya A, 2003, FEMS IMMUNOL MED MIC, V35, P33, DOI 10.1111/j.1574-695X.2003.tb00646.x
   Azevedo AS, 2011, PLOS ONE, V7
   Bhardwaj S, 2001, J VIROL, V75, P4002, DOI 10.1128/JVI.75.8.4002-4007.2001
   Blaney JE, 2005, J VIROL, V79, P5516, DOI 10.1128/JVI.79.9.5516-5528.2005
   Bray M, 1998, J VIROL, V72, P1647, DOI 10.1128/JVI.72.2.1647-1651.1998
   Chang SF, 2010, J CLIN MICROBIOL, V48, P4586, DOI 10.1128/JCM.01228-10
   Chen MC, 2009, J IMMUNOL, V183, P1797, DOI 10.4049/jimmunol.0800672
   Chin JFL, 2007, MICROBES INFECT, V9, P1, DOI 10.1016/j.micinf.2006.09.009
   Chu JJH, 2005, J GEN VIROL, V86, P405, DOI 10.1099/vir.0.80411-0
   Clements DE, 2010, VACCINE, V28, P2705, DOI 10.1016/j.vaccine.2010.01.022
   Clyde K, 2006, J VIROL, V80, P11418, DOI 10.1128/JVI.01257-06
   COLE GA, 1969, AM J EPIDEMIOL, V89, P669, DOI 10.1093/oxfordjournals.aje.a120981
   Costa SM, 2006, VACCINE, V24, P195, DOI 10.1016/j.vaccine.2005.07.059
   de Miranda AS, 2012, BEHAV BRAIN RES, V230, P237, DOI 10.1016/j.bbr.2012.02.020
   Franca RFD, 2010, EXP MOL PATHOL, V89, P321, DOI 10.1016/j.yexmp.2010.07.007
   ERHARDT W, 1984, RES EXP MED, V184, P159, DOI 10.1007/BF01852390
   Fernandez-Mestre MT, 2004, TISSUE ANTIGENS, V64, P469, DOI 10.1111/j.1399-0039.2004.00304.x
   Ferreira GP, 2010, MICROBES INFECT, V12, P546, DOI 10.1016/j.micinf.2010.03.007
   Figueiredo LB, 2008, EMERG INFECT DIS, V14, P314, DOI 10.3201/eid1402.070278
   Gao GP, 2008, HUM GENE THER, V19, P927, DOI 10.1089/hum.2008.011
   Gualano RC, 1998, J GEN VIROL, V79, P437, DOI 10.1099/0022-1317-79-3-437
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Gulati S, 2007, TROP MED INT HEALTH, V12, P1087, DOI 10.1111/j.1365-3156.2007.01891.x
   Guzman MG, 2006, REV PANAM SALUD PUBL, V19
   Guzman MG, 2012, NAT REV MICROBIOL S, V12, pS7
   HALSTEAD SB, 1973, J INFECT DIS, V128, P7, DOI 10.1093/infdis/128.1.7
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   HENCHAL EA, 1988, J GEN VIROL, V69, P2101, DOI 10.1099/0022-1317-69-8-2101
   IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531
   IRIE K, 1989, GENE, V75, P197, DOI 10.1016/0378-1119(89)90266-7
   Jessie K, 2004, J INFECT DIS, V189, P1411, DOI 10.1086/383043
   KHO L K, 1981, Southeast Asian Journal of Tropical Medicine and Public Health, V12, P83
   Kumar SRP, 2010, J GEN VIROL, V91, P707, DOI 10.1099/vir.0.017954-0
   Kurosu T, 2007, BIOCHEM BIOPH RES CO, V362, P1051, DOI 10.1016/j.bbrc.2007.08.137
   Lan NTP, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000304
   Leitmeyer KC, 1999, J VIROL, V73, P4738, DOI 10.1128/JVI.73.6.4738-4747.1999
   Lin CF, 2002, J IMMUNOL, V169, P657, DOI 10.4049/jimmunol.169.2.657
   Lin CF, 2006, VIRAL IMMUNOL, V19, P127, DOI 10.1089/vim.2006.19.127
   Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
   Pandey Basu Dev, 2000, Southeast Asian Journal of Tropical Medicine and Public Health, V31, P266
   PATEY O, 1993, AM J TROP MED HYG, V48, P793, DOI 10.4269/ajtmh.1993.48.793
   Pham TB, 2009, J CLIN VIROL, V45, P276, DOI 10.1016/j.jcv.2009.04.004
   Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595
   Row D, 1996, AM J TROP MED HYG, V54, P253, DOI 10.4269/ajtmh.1996.54.253
   RUSSELL PK, 1967, J IMMUNOL, V99, P285
   SABIN ALBERT B., 1952, AMER JOUR TROP MED AND HYG, V1, P30
   Sambrook J, 1989, MOL CLONING LAB MANU, P1527
   Serufo JC, 2006, REV SOC BRASILEIRA M, V5, P465
   Solomon T, 2000, LANCET, V355, P1053, DOI 10.1016/S0140-6736(00)02036-5
   Sun W, 2006, J INFECT DIS, V193, P1658, DOI 10.1086/503372
   TAMURA K, 2011, MOL BIOL EVOL, V28, P2731, DOI [DOI 10.1093/molbev/msr121, DOI 10.1093/MOLBEV/MSR121]
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092
   Tan GK, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000672
   Tan GK, 2009, CURR OPIN INFECT DIS, V22, P302, DOI 10.1097/QCO.0b013e328329ae32
   Tanner L, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000196
   Thomas L, 2010, AM J TROP MED HYG, V83, P696, DOI 10.4269/ajtmh.2010.10-0138
   Velandia-Romero ML, 2012, J NEUROVIROL
   Verrastro T, 1996, HEMATOLOGIA HEMOTERA, P1
   Whitehead SS, 2007, NAT REV MICROBIOL, V5, P518, DOI 10.1038/nrmicro1690
   Williams KL, 2009, ANN NY ACAD SCI, V1171, pE12, DOI 10.1111/j.1749-6632.2009.05057.x
   Yauch LE, 2008, ANTIVIR RES, V80, P87, DOI 10.1016/j.antiviral.2008.06.010
   Zhang GL, 2005, NUCLEIC ACIDS RES, V33, pW180, DOI 10.1093/nar/gki479
   Zhang ZS, 2007, J VIROL METHODS, V143, P125, DOI 10.1016/j.jviromet.2007.02.012
NR 66
TC 14
Z9 16
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 13
PY 2012
VL 7
IS 9
AR e44984
DI 10.1371/journal.pone.0044984
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 005ZK
UT WOS:000308788700070
PM 23028722
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Romao, RM
   Levi, JE
   De Carvalho, MHB
   Francisco, RPV
   De Amorim, AG
   Zugaib, M
AF Romao, Renata Moscolini
   Levi, Jose Eduardo
   Burlacchini De Carvalho, Mario Henrique
   Vieira Francisco, Rossana Pulcineli
   De Amorim Filho, Antonio Gomes
   Zugaib, Marcelo
TI Use of cell-free fetal nucleic acids in maternal blood for prenatal
   diagnosis: the reality of this scenario in Brazil
SO REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
LA Portuguese
DT Review
DE Noninvasive diagnosis; prenatal care; free nucleic acids; fetal DNA;
   maternal plasma; Brazil
ID HORMONE MESSENGER-RNA; PREGNANT-WOMEN; FREE DNA; NONINVASIVE
   DETERMINATION; QUANTITATIVE-ANALYSIS; GENDER DETERMINATION;
   HUNTINGTON-DISEASE; RHESUS-D; PLASMA; SERUM
AB The discovery of cell-free fetal nucleic acids in the plasma of pregnant women has allowed the development of new, noninvasive prenatal diagnostic tests for the determination of fetal gender and Rh. These tests have been implemented in the public health system in several countries of Europe for over five years. The new possibilities for diagnostic use of these technologies are the detection of fetal chromosomal aneuploidies, monogenic fetal disorders, and placental-related disorders, subjects that have been intensively studied by several groups around the world. The aim of this review was to assess the Brazilian research and clinical scenarios regarding the utilization of commercially available tests that use these plasma markers, stressing the advantages, both economic and safety-related, that non-invasive tests have when compared to those currently used in the Brazilian public health system.
C1 [Romao, Renata Moscolini] Univ Sao Paulo, Ciencias Fac Med, Sao Paulo, Brazil.
   [Romao, Renata Moscolini] FMUSP, Dept Obstet & Ginecol, Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab,Dept Biol Mol, Fdn Pro Sangue Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Pesquisa Banco Sangue Hosp Albert Einstein, Sao Paulo, Brazil.
   [Burlacchini De Carvalho, Mario Henrique; Vieira Francisco, Rossana Pulcineli; Zugaib, Marcelo] Univ Sao Paulo, Dept Obstetr & Ginecol, BR-09500900 Sao Paulo, Brazil.
   [De Amorim Filho, Antonio Gomes] Univ Sao Paulo, Clin Obstetr Hosp Clin, BR-09500900 Sao Paulo, Brazil.
RP Romao, RM (corresponding author), Univ Sao Paulo, Fac Med, Dept Obstet & Ginecol, Av Dr Eneas Carvalho Aguiar,255 Inst Cent,100 And, Sao Paulo, Brazil.
EM renata.romao@usp.br
RI Francisco, Rossana PV/C-5648-2012; Zugaib, Marcelo/A-5724-2013; HCFMUSP,
   Pos-Graduacao DOG -/F-1162-2013; Burlacchini de Carvalho, Mario
   Henrique/E-7217-2013; Francisco, Rossana Pulcineli Vieira/AAG-7461-2020
OI Francisco, Rossana PV/0000-0002-9981-8069; Zugaib,
   Marcelo/0000-0003-1155-2671; Burlacchini de Carvalho, Mario
   Henrique/0000-0003-0599-0739; Francisco, Rossana Pulcineli
   Vieira/0000-0002-9981-8069
CR Amaral DRT, 2011, J CLIN LAB ANAL, V25, P100, DOI 10.1002/jcla.20440
   Amicucci P, 2000, CLIN CHEM, V46, P301
   Au PKC, 2011, PRENATAL DIAG, V31, P218, DOI 10.1002/pd.2672
   Benachi A, 2012, EUR J OBSTET GYN R B, V162, P28, DOI 10.1016/j.ejogrb.2012.02.001
   Bianchi DW, 2012, OBSTET GYNECOL, V119, P890, DOI 10.1097/AOG.0b013e31824fb482
   Bischoff FZ, 2005, HUM REPROD UPDATE, V11, P59, DOI 10.1093/humupd/dmh053
   Bowman J, 2003, TRANSFUSION, V43, P1661, DOI 10.1111/j.0041-1132.2003.00632.x
   Bustamante-Aragones A, 2008, EUR J NEUROL, V15, P1338, DOI 10.1111/j.1468-1331.2008.02312.x
   Bustamante-Aragones A, 2008, J CYST FIBROS, V7, P505, DOI 10.1016/j.jcf.2008.05.006
   Chim SSC, 2008, CLIN CHEM, V54, P482, DOI 10.1373/clinchem.2007.097972
   Chinen PA, 2010, AM J PERINAT, V27, P759, DOI 10.1055/s-0030-1253560
   Chitty LS, 2011, ULTRASOUND OBST GYN, V37, P283, DOI 10.1002/uog.8893
   Chiu RWK, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7401
   Chiu RWK, 2011, SEMIN FETAL NEONAT M, V16, P88, DOI 10.1016/j.siny.2010.10.003
   Chiu RWK, 2009, TRENDS GENET, V25, P324, DOI 10.1016/j.tig.2009.05.004
   Chiu RWK, 2008, P NATL ACAD SCI USA, V105, P20458, DOI 10.1073/pnas.0810641105
   Chiu RWK, 2002, LANCET, V360, P998, DOI 10.1016/S0140-6736(02)11086-5
   Chiu RWK, 2002, CLIN CHEM, V48, P778
   Gonzalez-Gonzalez MC, 2008, J ASSIST REPROD GEN, V25, P477, DOI 10.1007/s10815-008-9256-8
   Deng YH, 2011, CLIN CHEM LAB MED, V49, P641, DOI 10.1515/CCLM.2011.099
   Deng ZH, 2006, PRENATAL DIAG, V26, P362, DOI 10.1002/pd.1422
   Ehrich M, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.12.060
   Fan HC, 2008, P NATL ACAD SCI USA, V105, P16266, DOI 10.1073/pnas.0808319105
   Farina A, 2005, AM J OBSTET GYNECOL, V193, P421, DOI 10.1016/j.ajog.2004.12.023
   Farina A, 2004, CLIN CHEM, V50, P1851, DOI 10.1373/clinchem.2004.037713
   Flori E, 2004, HUM REPROD, V19, P723, DOI 10.1093/humrep/deh117
   Gonzalez-Gonzalez MC, 2003, PRENATAL DIAG, V23, P232, DOI 10.1002/pd.570
   Gonzalez-Gonzalez MC, 2002, PRENATAL DIAG, V22, P946, DOI 10.1002/pd.439
   Hill M, 2011, CLIN GENET, V80, P68, DOI 10.1111/j.1399-0004.2010.01533.x
   Hill M, 2011, PRENATAL DIAG, V31, P267, DOI 10.1002/pd.2680
   Honda H, 2002, HUM GENET, V110, P75, DOI 10.1007/s00439-001-0649-3
   Honda H, 2001, CLIN CHEM, V47, P41
   Hyett JA, 2005, PRENATAL DIAG, V25, P1111, DOI 10.1002/pd.1284
   Jimbo M, 2003, CLIN CHEM, V49, P1540, DOI 10.1373/49.9.1540
   Leung TN, 1998, LANCET, V352, P1904, DOI 10.1016/S0140-6736(05)60395-9
   Levi José Eduardo, 2003, Rev. Bras. Ginecol. Obstet., V25, P687, DOI 10.1590/S0100-72032003000900011
   Levine RJ, 2004, AM J OBSTET GYNECOL, V190, P707, DOI 10.1016/j.ajog.2003.12.019
   Li Y, 2004, PRENATAL DIAG, V24, P896, DOI 10.1002/pd.1030
   Li Y, 2007, PRENATAL DIAG, V27, P11, DOI 10.1002/pd.1608
   Lichtenstein AV, 2001, ANN NY ACAD SCI, V945, P239
   Lo YMD, 2007, P NATL ACAD SCI USA, V104, P13116, DOI 10.1073/pnas.0705765104
   Lo YMD, 2007, NAT MED, V13, P218, DOI 10.1038/nm1530
   Lo YMD, 1999, AM J HUM GENET, V64, P218, DOI 10.1086/302205
   Lo YMD, 1998, AM J HUM GENET, V62, P768, DOI 10.1086/301800
   Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0
   Lo YMD, 1999, CLIN CHEM, V45, P184
   Lo YMD, 1998, NEW ENGL J MED, V339, P1734, DOI 10.1056/NEJM199812103392402
   Machado Isabela Nelly, 2006, Rev. Assoc. Med. Bras., V52, P232, DOI 10.1590/S0104-42302006000400022
   Macher HC, 2012, CLIN CHIM ACTA, V413, P490, DOI 10.1016/j.cca.2011.11.004
   Nasis O, 2004, CLIN CHEM, V50, P694, DOI 10.1373/clinchem.2003.025981
   Newson AJ, 2008, SEMIN FETAL NEONAT M, V13, P103, DOI 10.1016/j.siny.2007.12.004
   Ng EKO, 2003, CLIN CHEM, V49, P727, DOI 10.1373/49.5.727
   Poon LLM, 2000, CLIN CHEM, V46, P1832
   Rijnders RJP, 2001, OBSTET GYNECOL, V98, P374, DOI 10.1016/S0029-7844(01)01480-6
   Scheffer PG, 2011, BJOG-INT J OBSTET GY, V118, P1340, DOI 10.1111/j.1471-0528.2011.03028.x
   Sehnert AJ, 2011, CLIN CHEM, V57, P1042, DOI 10.1373/clinchem.2011.165910
   Sekizawa A, 2001, Am J Pharmacogenomics, V1, P111, DOI 10.2165/00129785-200101020-00004
   Sekizawa A, 2003, AM J OBSTET GYNECOL, V188, P480, DOI 10.1067/mob.2003.27
   Sekizawa A, 2002, CLIN CHEM, V48, P353
   Sekizawa A, 2001, CLIN CHEM, V47, P1856
   Sirichotiyakul S, 2012, PRENATAL DIAG, V32, P45, DOI 10.1002/pd.2892
   Smid M, 2006, PRENATAL DIAG, V26, P785, DOI 10.1002/pd.1504
   Stanghellini I, 2006, MOL HUM REPROD, V12, P587, DOI 10.1093/molehr/gal052
   Sugito Y, 2003, CLIN CHEM, V49, P1667, DOI 10.1373/49.10.1667
   Swinkels DW, 2002, CLIN CHEM, V48, P650
   Tsui NBY, 2011, BLOOD, V117, P3684, DOI 10.1182/blood-2010-10-310789
   Tsui NBY, 2010, CLIN CHEM, V56, P73, DOI 10.1373/clinchem.2009.132662
   Tsui NBY, 2009, PRENATAL DIAG, V29, P1031, DOI 10.1002/pd.2340
   van der Schoot CE, 2008, SEMIN FETAL NEONAT M, V13, P63, DOI 10.1016/j.siny.2007.12.012
   Zhong XY, 2000, PRENATAL DIAG, V20, P838
   Zhong XY, 2002, HYPERTENS PREGNANCY, V21, P77, DOI 10.1081/PRG-120002911
   Zimmermann B, 2005, CLIN CHEM, V51, P1598, DOI 10.1373/clinchem.2005.051235
NR 72
TC 3
Z9 3
U1 0
U2 7
PU ASSOC MEDICA BRASILEIRA
PI SAO PAULO
PA RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL
EI 1806-9282
J9 REV ASSOC MED BRAS
JI Rev. Assoc. Med. Bras.
PD SEP-OCT
PY 2012
VL 58
IS 5
BP 615
EP 619
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 024NO
UT WOS:000310116100020
PM 23090235
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Cavalheiro, N
   Santos, A
   Melo, C
   Tengan, F
   Levi, J
AF Cavalheiro, N.
   Santos, A.
   Melo, C.
   Tengan, F.
   Levi, J.
TI Serial dilution of semen samples and better results in HCV-PCR in
   patients with hepatitis C infection
SO JOURNAL OF VIRAL HEPATITIS
LA English
DT Meeting Abstract
CT Congress on Viral Hepatitis
CY SEP 07-09, 2012
CL Frankfurt, GERMANY
C1 [Cavalheiro, N.; Santos, A.; Melo, C.; Tengan, F.; Levi, J.] Univ Sao Paulo, BR-05508 Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1352-0504
J9 J VIRAL HEPATITIS
JI J. Viral Hepatitis
PD SEP
PY 2012
VL 19
SU 3
SI SI
BP 6
EP 6
PG 1
WC Gastroenterology & Hepatology; Infectious Diseases; Virology
SC Gastroenterology & Hepatology; Infectious Diseases; Virology
GA 003BZ
UT WOS:000308584500010
DA 2020-11-30
ER

PT J
AU Ferreira, SC
   de Almeida-Neto, C
   Nishiya, AS
   Di-Lorenzo-Oliveira, C
   Ferreira, JE
   Alencar, CS
   Levi, JE
   Salles, NA
   Mendrone, A
   Sabino, EC
AF Ferreira, S. C.
   de Almeida-Neto, C.
   Nishiya, A. S.
   Di-Lorenzo-Oliveira, C.
   Ferreira, J. E.
   Alencar, C. S.
   Levi, J. E.
   Salles, N. A.
   Mendrone, A.
   Sabino, E. C.
TI Case-Control Study of Risk Factors for Syphilis Among Blood Donors in
   Sao Paulo, Brazil
SO TRANSFUSION
LA English
DT Meeting Abstract
CT AABB Annual Meeting and CTTXPO
CY OCT 06-09, 2012
CL Boston, MA
SP AABB, CTTXPO
C1 [Ferreira, S. C.; de Almeida-Neto, C.; Nishiya, A. S.; Levi, J. E.; Salles, N. A.; Mendrone, A.] Fundacao Prosangue Hemctr Sao Paulo, Dept Mol Biol, Sao Pulo, Brazil.
   [Alencar, C. S.; Sabino, E. C.] Univ Sao Paulo, Fac Med, Dept Infect & Parasit Dis, Sao Paulo, Brazil.
   [Ferreira, J. E.] Adolfo Lutz Inst, Dept Clin Pathol, Sao Paulo, Brazil.
EM lom.suzy@gmail.com
RI Sabino, Ester Cerdeira/F-7750-2010; Ferreira, Joao E/L-1287-2016;
   Nishiya, Anna/Q-8156-2016; Ferreira, Suzete/K-1626-2016; Ferreira, Joao
   E/C-6025-2012; de Almeida-Neto, Cesar/O-9224-2014
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; Ferreira,
   Suzete/0000-0002-4190-0238; Ferreira, Joao E/0000-0001-9607-2014; de
   Almeida-Neto, Cesar/0000-0002-8490-4634
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 2012
VL 52
SU 3
SI SI
BP 213A
EP 213A
PG 1
WC Hematology
SC Hematology
GA 000PH
UT WOS:000308398600525
DA 2020-11-30
ER

PT J
AU Nishiya, AS
   de Almeida-Neto, C
   Ferreira, SC
   Alencar, CS
   Oliveira, CD
   Alvarado-Mora, MV
   Levi, JE
   Salles, NA
   Mendrone, A
   Sabino, EC
AF Nishiya, A. S.
   de Almeida-Neto, C.
   Ferreira, S. C.
   Alencar, C. S.
   Oliveira, C. D.
   Alvarado-Mora, M. V.
   Levi, J. E.
   Salles, N. A.
   Mendrone, A.
   Sabino, E. C.
TI HCV Genotype and Risk Factors Among Blood Donors in Sao Paulo, Brazil
SO TRANSFUSION
LA English
DT Meeting Abstract
CT AABB Annual Meeting and CTTXPO
CY OCT 06-09, 2012
CL Boston, MA
SP AABB, CTTXPO
C1 [Nishiya, A. S.; de Almeida-Neto, C.; Ferreira, S. C.; Levi, J. E.; Salles, N. A.; Mendrone, A.] Fundacao Prosangue, Hemoctr Sao Paulo, Sao Paulo, Brazil.
   [Alencar, C. S.; Sabino, E. C.] Univ Sao Paulo, Fac Med, Dept Infect Dis, Sao Paulo, Brazil.
   [Oliveira, C. D.] Univ Sao Joao del Rei, Divinopolis, Brazil.
   [Alvarado-Mora, M. V.] Sao Paulo Inst Trop Med, Lab Gastroenterol & Hepatol, Sao Paulo, Brazil.
   [Alvarado-Mora, M. V.] Univ Sao Paulo, Sch Med, Dept Gastroenterol, Sao Paulo, Brazil.
EM a_nishiya@hotmail.com
RI Sabino, Ester Cerdeira/F-7750-2010; Alvarado-Mora, Monica/I-3180-2012;
   de Almeida-Neto, Cesar/O-9224-2014; Nishiya, Anna/Q-8156-2016; Ferreira,
   Suzete/K-1626-2016
OI Sabino, Ester Cerdeira/0000-0003-2623-5126; de Almeida-Neto,
   Cesar/0000-0002-8490-4634; Ferreira, Suzete/0000-0002-4190-0238
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 2012
VL 52
SU 3
SI SI
BP 215A
EP 215A
PG 1
WC Hematology
SC Hematology
GA 000PH
UT WOS:000308398600531
DA 2020-11-30
ER

PT J
AU da Siva, LVRF
   Zerbinati, RM
   Tateno, AF
   Boas, LV
   de Almeida, MB
   Levi, JE
   Drexler, JF
   Drosten, C
   Pannuti, CS
AF Ferreira da Silva Filho, Luiz Vicente Ribeiro
   Zerbinati, Rodrigo Melim
   Tateno, Adriana Fumie
   Boas, Lucy Vilas
   de Almeida, Marina Buarque
   Levi, Jose Eduardo
   Drexler, Jan Felix
   Drosten, Christian
   Pannuti, Claudio Sergio
TI The Differential Clinical Impact of Human Coronavirus Species in
   Children With Cystic Fibrosis
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID RESPIRATORY-TRACT DISEASE; IDENTIFICATION; PNEUMONIA; HKU1; NL63
AB We investigated the clinical impact of human coronaviruses (HCoV) OC43, 229E, HKU1 and NL63 in pediatric patients with cystic fibrosis (CF) during routine and exacerbation visits. A total of 408 nasopharyngeal aspirate samples were obtained from 103 patients over a 1-year period. Samples positive for HCoV were submitted for nucleotide sequencing to determine the species. Nineteen samples (4.65%) were positive for HCoV, of which 8 were positive for NL63, 6 for OC43, 4 for HKU1, and 1 for 229E. Identification of HCoV was not associated with an increased rate of respiratory exacerbations, but NL63-positive patients had higher exacerbation rates than patients who were positive for other HCoV species.
C1 [Ferreira da Silva Filho, Luiz Vicente Ribeiro; Zerbinati, Rodrigo Melim; Tateno, Adriana Fumie; Boas, Lucy Vilas; Levi, Jose Eduardo; Pannuti, Claudio Sergio] Univ Sao Paulo, Inst Med Trop Sao Paulo, Lab Virol LIMHC FMUSP, BR-05508 Sao Paulo, Brazil.
   [Ferreira da Silva Filho, Luiz Vicente Ribeiro; de Almeida, Marina Buarque] Hosp Clin FMUSP, Inst Crianca, Sao Paulo, Brazil.
   [Drexler, Jan Felix; Drosten, Christian] Univ Bonn, Med Ctr, Inst Virol, Bonn, Germany.
RP da Siva, LVRF (corresponding author), Rua Gregorio Paes de Almeida 1231, BR-05450001 Sao Paulo, Brazil.
EM vicres@usp.br
RI da Silva Filho, Luiz Vicente R F/A-6957-2011; de Almeida, Marina
   Buarque/L-2052-2013; Silva Filho, Luiz Vicente/R-3984-2016; Drexler, Jan
   Felix/C-1004-2014
OI da Silva Filho, Luiz Vicente R F/0000-0001-8431-1997; de Almeida, Marina
   Buarque/0000-0003-4623-5940; Drexler, Jan Felix/0000-0002-3509-0232;
   Melim Zerbinati, Rodrigo/0000-0001-9936-9139
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [05/01625-8]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (grant 05/01625-8).
CR Arden KE, 2005, J MED VIROL, V75, P455, DOI 10.1002/jmv.20288
   Arkwright PD, 2003, AM J RESP CRIT CARE, V167, P384, DOI 10.1164/rccm.200204-364OC
   de Almeida MB, 2010, EMERG INFECT DIS, V16, P996, DOI 10.3201/eid1606.100063
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Fielding BC, 2011, FUTURE MICROBIOL, V6, P153, DOI [10.2217/fmb.10.166, 10.2217/FMB.10.166]
   Gaunt ER, 2010, J CLIN MICROBIOL, V48, P2940, DOI 10.1128/JCM.00636-10
   Kupfer B, 2007, EUR J MED RES, V12, P134
   MCINTOSH K, 1974, J INFECT DIS, V130, P502, DOI 10.1093/infdis/130.5.502
   Olesen HV, 2006, PEDIATR PULM, V41, P1197, DOI 10.1002/ppul.20517
   Ratjen F, 2003, LANCET, V361, P681, DOI 10.1016/S0140-6736(03)12567-6
   Talbot HK, 2009, PEDIATR INFECT DIS J, V28, P682, DOI 10.1097/INF.0b013e31819d0d27
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Wat D, 2008, J CYST FIBROS, V7, P320, DOI 10.1016/j.jcf.2007.12.002
   Wevers BA, 2010, FUTURE VIROL, V5, P145, DOI 10.2217/FVL.10.4
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
NR 15
TC 15
Z9 15
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD AUG 1
PY 2012
VL 206
IS 3
BP 384
EP 388
DI 10.1093/infdis/jis274
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 973OI
UT WOS:000306369100011
PM 22459737
OA Green Published, Bronze
DA 2020-11-30
ER

PT J
AU Levi, JE
   Pereira, RAD
   Polite, MBC
   Nunez, SP
   Kutner, JM
AF Levi, J. E.
   D'Almeida Pereira, R. A.
   Carvalho Polite, M. B.
   Nunez, S. P.
   Kutner, J. M.
TI A WINDOW-PERIOD HBV NAT DONATION FROM A VACCINATED DONOR
SO VOX SANGUINIS
LA English
DT Meeting Abstract
C1 [Levi, J. E.; D'Almeida Pereira, R. A.; Carvalho Polite, M. B.; Nunez, S. P.; Kutner, J. M.] Hosp Albert Einstein, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0042-9007
J9 VOX SANG
JI Vox Sang.
PD JUL
PY 2012
VL 103
SU 1
SI SI
BP 167
EP 167
PG 1
WC Hematology
SC Hematology
GA 960SP
UT WOS:000305410601092
DA 2020-11-30
ER

PT J
AU Machado, CM
   Levi, JE
AF Machado, Clarisse Martins
   Levi, Jose Eduardo
TI Transplant-Associated and Blood Transfusion-Associated Tropical and
   Parasitic Infections
SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
LA English
DT Article
DE Transplantation; Blood transfusion; Tropical diseases; Parasites;
   Transmission; Donors
ID HEPATITIS-C VIRUS; MYCOBACTERIUM-TUBERCULOSIS INFECTION;
   HUMAN-IMMUNODEFICIENCY-VIRUS; OF-THE-LITERATURE; CHAGAS-DISEASE;
   SOLID-ORGAN; LIVER-TRANSPLANTATION; UNITED-STATES; TRANSMISSION;
   RECIPIENTS
AB Blood transfusion and transplantation may represent efficient mechanisms of spreading infectious agents to naive populations. In the developed countries, as a consequence of globalization, several factors such as international commerce, tourism, and immigration have acted as important features for the emergence or reemergence of infectious diseases previously referred to as tropical. This article reviews the relevant bacterial, protozoan and viral infections that are more frequently associated with blood transfusion and/or solid organ or marrow transplantation and may affect susceptible populations worldwide.
C1 [Machado, Clarisse Martins; Levi, Jose Eduardo] Univ Sao Paulo, Virol Lab, Inst Trop Med, BR-05403000 Sao Paulo, Brazil.
   [Machado, Clarisse Martins] Amaral Carvalho Fdn, Hematopoiet Stem Cell Transplantat Program, BR-17210080 Sao Paulo, Brazil.
RP Machado, CM (corresponding author), Univ Sao Paulo, Virol Lab, Inst Trop Med, Av Dr Eneas de Carvalho Aguiar 470, BR-05403000 Sao Paulo, Brazil.
EM clarimm@usp.br
CR Aguado JM, 1997, TRANSPLANTATION, V63, P1278, DOI 10.1097/00007890-199705150-00015
   Al-Anazi Khalid A, 2009, Cases J, V2, P91, DOI 10.1186/1757-1626-2-91
   Alter HJ, 2008, BLOOD, V112, P2617, DOI 10.1182/blood-2008-07-077370
   Antinori S, 2008, LANCET INFECT DIS, V8, P191, DOI 10.1016/S1473-3099(08)70043-4
   Aregawi M, 2011, WORLD MALARIA REPORT
   Bacal F, 2010, CLIN TRANSPLANT, V24, pE29, DOI 10.1111/j.1399-0012.2009.01202.x
   Basset D, 2005, MICROBES INFECT, V7, P1370, DOI 10.1016/j.micinf.2005.06.002
   Batista MV, 2011, TROP MED INT HEALTH, V16, P1134, DOI 10.1111/j.1365-3156.2011.02816.x
   Bern C, 2007, JAMA-J AM MED ASSOC, V298, P2171, DOI 10.1001/jama.298.18.2171
   Bocchi EA, 2001, ANN THORAC SURG, V71, P1833, DOI 10.1016/S0003-4975(01)02587-5
   Bronnert J, 2007, J TRAVEL MED, V14, P177, DOI 10.1111/j.1708-8305.2006.00095.x
   Candotti D, 2009, J HEPATOL, V51, P798, DOI 10.1016/j.jhep.2009.05.020
   Centers for Disease Control and Prevention (CDC), 2008, MMWR Morb Mortal Wkly Rep, V57, P333
   Chiche L, 2003, TRANSPLANTATION, V75, P166, DOI 10.1097/00007890-200301150-00031
   Chin-Hong PV, 2011, AM J TRANSPLANT, V11, P672, DOI 10.1111/j.1600-6143.2011.03444.x
   Chocair P R, 1981, Rev Inst Med Trop Sao Paulo, V23, P280
   CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562
   Cohn DL, 2000, AM J RESP CRIT CARE, V161, pS221
   Cruz I, 2002, LANCET, V359, P1124, DOI 10.1016/S0140-6736(02)08160-6
   D'Albuquerque LAC, 2007, AM J TRANSPLANT, V7, P680, DOI 10.1111/j.1600-6143.2007.01663.x
   De Serres G, 2008, CLIN INFECT DIS, V46, P1329, DOI 10.1086/586745
   Dey A, 2006, Indian J Med Microbiol, V24, P165
   Dias JP, 2008, REV SOC BRAS MED TRO, V41, P296, DOI 10.1590/S0037-86822008000300014
   Fischer L, 1999, CLIN TRANSPLANT, V13, P491, DOI 10.1034/j.1399-0012.1999.130609.x
   Frank C, 2000, LANCET, V355, P887, DOI 10.1016/S0140-6736(99)06527-7
   Freitas J., 1952, REV PAULIST MED, V40, P36
   Gerlich WH, 2007, J MED VIROL, V79, pS32, DOI 10.1002/jmv.20963
   Humar A, 2010, AM J TRANSPLANT, V10, P889, DOI 10.1111/j.1600-6143.2009.02992.x
   Ison MG, 2011, AM J TRANSPLANT, V11, P1218, DOI 10.1111/j.1600-6143.2011.03597.x
   Koseoglu F, 2001, TRANSPLANT P, V33, P1782, DOI 10.1016/S0041-1345(00)02678-6
   Kotton CN, 2007, CLIN INFECT DIS, V44, P857, DOI 10.1086/511859
   Levi JE, 2011, ISBT SCI SER, V6, P116
   Linnen JM, 2008, TRANSFUSION, V48, P1355, DOI 10.1111/j.1537-2995.2008.01772.x
   Machado CM, 2009, REV INST MED TROP SP, V51, P309, DOI 10.1590/S0036-46652009000600002
   Machado CM, 2010, TRANSPLANT INFECT, P90
   Manning Susan E., 2008, Morbidity and Mortality Weekly Report, V57, P1
   Martin-Davila P, 2008, CLIN MICROBIOL REV, V21, P60, DOI 10.1128/CMR.00021-07
   Mascola L., 2006, Morbidity and Mortality Weekly Report, V55, P798
   Menichetti F, 2006, LIVER TRANSPLANT, V12, P674, DOI 10.1002/lt.20730
   Morris MI, 2010, INFECT DIS CLIN N AM, V24, P497, DOI 10.1016/j.idc.2010.02.002
   Munoz P, 2005, CLIN INFECT DIS, V40, P581, DOI 10.1086/427692
   Negro F, 2011, LIVER INT, V31, P1, DOI 10.1111/j.1478-3231.2011.02537.x
   Owusu-Ofori AK, 2010, CLIN INFECT DIS, V51, P1192, DOI 10.1086/656806
   Pinazo MJ, 2011, TRANSPLANT REV-ORLAN, V25, P91, DOI 10.1016/j.trre.2010.12.002
   Pruss A, 2010, TRANSPL INFECT DIS, V12, P375, DOI 10.1111/j.1399-3062.2010.00505.x
   QUARTO M, 1989, NEW ENGL J MED, V320, P1754
   Reesink HW, 2010, VOX SANG, V98, P468, DOI 10.1111/j.1423-0410.2009.01301.x
   Rigau-Perez Jose G., 2001, American Journal of Tropical Medicine and Hygiene, V64, P67
   Rose DN, 2000, ARCH INTERN MED, V160, P1513, DOI 10.1001/archinte.160.10.1513
   Roth WK, 2012, VOX SANG, V102, P82, DOI 10.1111/j.1423-0410.2011.01506.x
   Rupprecht CE, 2002, LANCET INFECT DIS, V2, P327, DOI 10.1016/S1473-3099(02)00287-6
   Scarlata F, 2008, T ROY SOC TROP MED H, V102, P394, DOI 10.1016/j.trstmh.2008.01.011
   Schmunis GA, 2005, CLIN MICROBIOL REV, V18, P12, DOI 10.1128/CMR.18.1.12-29.2005
   Schofield CJ, 2006, TRENDS PARASITOL, V22, P583, DOI 10.1016/j.pt.2006.09.011
   Singh N, 1998, CLIN INFECT DIS, V27, P1266, DOI 10.1086/514993
   Stramer S. L., 2007, Morbidity and Mortality Weekly Report, V56, P141
   Stramer SL, 2011, NEW ENGL J MED, V364, P236, DOI 10.1056/NEJMoa1007644
   Subramanian A, 2009, AM J TRANSPLANT, V9, pS57, DOI 10.1111/j.1600-6143.2009.02894.x
   Tan FLS, 2005, NEPHROL DIAL TRANSPL, V20, P447, DOI 10.1093/ndt/gfh601
   Tomblyn M, 2009, BIOL BLOOD MARROW TR, V15, P1143, DOI 10.1016/j.bbmt.2009.06.019
   Vermeulen M, 2009, TRANSFUSION, V49, P1115, DOI 10.1111/j.1537-2995.2009.02110.x
   Wendel S, 2010, ACTA TROP, V115, P28, DOI 10.1016/j.actatropica.2009.12.006
   WHO Expert Committee on the Control of Leishmaniases, 2010, WHO TECHN SER
   Wiwanitkit V, 2010, J INFECT DEV COUNTR, V4, P51, DOI 10.3855/jidc.145
   World Health Organization, 2011, GLOB TUB CONTR
   Zayas CF, 2002, JAMA-J AM MED ASSOC, V287, P1795
   Zou SM, 2012, TRANSFUS MED REV, V26, P119, DOI 10.1016/j.tmrv.2011.07.007
   Zou SM, 2004, NEW ENGL J MED, V351, P751, DOI 10.1056/NEJMoa032510
NR 68
TC 5
Z9 5
U1 0
U2 7
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0891-5520
EI 1557-9824
J9 INFECT DIS CLIN N AM
JI Infect. Dis. Clin. North Am.
PD JUN
PY 2012
VL 26
IS 2
BP 225
EP +
DI 10.1016/j.idc.2012.02.008
PG 18
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 966QS
UT WOS:000305853100004
PM 22632636
OA Green Published
DA 2020-11-30
ER

PT J
AU Machado, IN
   Levi, JE
   Lima, SBS
   Barini, R
AF Machado, Isabela N.
   Levi, Jose E.
   Lima, Simone B. S.
   Barini, Ricardo
TI Identification of Sex-Determining Region Y (SRY) in Maternal Plasma
   after Paternal Lymphocyte Immunization: Is it Possible?
SO AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY
LA English
DT Article
DE Fetal gender determination; immunotherapy; infertility; maternal plasma;
   prenatal diagnosis
ID RECURRENT SPONTANEOUS-ABORTION; RANDOMIZED-TRIAL; FETAL DNA;
   IMMUNOTHERAPY; CELLS; WOMEN; SERUM
AB Problem Women treated with allogeneic immunization using paternal lymphocytes often request laboratory molecular tests using cell-free fetal DNA in maternal plasma. There is concern whether the treatment can interfere with its results. This study evaluated the applicability of fetal sex determination using fragments of sex-determining region Y (SRY) in the plasma of women submitted to paternal lymphocyte immunization.
   Method of study Non-pregnant women blood samples were collected at two different moments: prior to paternal lymphocyte immunization and after three doses of the immunotherapy, in a prospective study. For women who became pregnant, another sample was collect during the first trimester. Amplification of the fragment of the Y chromosome (SRY) was performed using real-time PCR.
   Results The SRY gene was not identified in any of the plasma samples of the 50 non-pregnant women submitted to paternal lymphocyte immunization at either of the two moments evaluated. For the 26 pregnant women, the results of the identification of sex -determining in maternal plasma were completely in agreement with the infant sex.
   Conclusion Paternal lymphocyte immunization does not affect the results of SRY fragment investigation in the plasma of women submitted to paternal lymphocyte immunization therapy.
C1 [Machado, Isabela N.; Lima, Simone B. S.; Barini, Ricardo] Allovita Reprod Immunol Lab, Campinas, SP, Brazil.
   [Levi, Jose E.] SirioLibanes Hosp Blood Bank, Sao Paulo, Brazil.
RP Machado, IN (corresponding author), Rua Antonio Lapa 280,Sl 110 Cambui, BR-13025240 Campinas, SP, Brazil.
EM imachado@fcm.unicamp.br
RI Barini, Ricardo/U-8446-2019; BARINI, RICARDO/B-9920-2019
OI BARINI, RICARDO/0000-0002-4138-6945
CR [Anonymous], 2002, LYMPH IMM THER LIT L
   BEER AE, 1981, AM J OBSTET GYNECOL, V141, P987
   Caetano Marcos Roberto, 2006, Sao Paulo Med. J., V124, P181, DOI 10.1590/S1516-31802006000400002
   Check J H, 2005, Clin Exp Obstet Gynecol, V32, P85
   Flori E, 2004, HUM REPROD, V19, P723, DOI 10.1093/humrep/deh117
   Gharesi-Fard Behrouz, 2007, Iran J Immunol, V4, P173
   Kling C, 2006, HUM REPROD, V21, P429, DOI 10.1093/humrep/dei316
   Levi José Eduardo, 2003, Rev. Bras. Ginecol. Obstet., V25, P687, DOI 10.1590/S0100-72032003000900011
   Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0
   Machado Isabela Nelly, 2006, Rev. Assoc. Med. Bras., V52, P232, DOI 10.1590/S0104-42302006000400022
   Nonaka T, 2007, AM J REPROD IMMUNOL, V58, P530, DOI 10.1111/j.1600-0897.2007.00536.x
   Ober C, 1999, LANCET, V354, P365, DOI 10.1016/S0140-6736(98)12055-X
   Pandey Manoj Kumar, 2004, Archives of Gynecology and Obstetrics, V269, P161, DOI 10.1007/s00404-003-0560-3
   Pandey MK, 2004, INT IMMUNOPHARMACOL, V4, P289, DOI 10.1016/j.intimp.2004.01.001
   Perricone R, 2006, AM J REPROD IMMUNOL, V55, P232, DOI 10.1111/j.1600-0897.2005.00356.x
   Porter TF, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000112.pub2
   Wegener S, 2006, TRANSFUS MED HEMOTH, V33, P501, DOI 10.1159/000096125
NR 17
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1046-7408
J9 AM J REPROD IMMUNOL
JI Am. J. Reprod. Immunol.
PD MAR
PY 2012
VL 67
IS 3
BP 231
EP 234
DI 10.1111/j.1600-0897.2011.01082.x
PG 4
WC Immunology; Reproductive Biology
SC Immunology; Reproductive Biology
GA 883DZ
UT WOS:000299615500007
PM 22032865
DA 2020-11-30
ER

PT J
AU Silva, SA
   Rodrigues, CL
   Campos, AF
   Levi, JE
AF Silva, Synara Araujo
   Rodrigues, Celia Lima
   Campos, Aleia Faustino
   Levi, Jose Eduardo
TI EVALUATION OF GBV-C/HGV VIREMIA IN HIV-INFECTED WOMEN
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE GBV-C; Real-Time PCR; Viral load; Anti-HGenv; AIDS
ID HEPATITIS-G VIRUS; POLYMERASE-CHAIN-REACTION; C/HEPATITIS-G-VIRUS; C
   INFECTION; BLOOD-DONORS; RNA; COINFECTION; SURVIVAL; DISEASE;
   PROGRESSION
AB The present study aimed at standardizing a real-time quantitative polymerase chain reaction assay to evaluate the presence of GBV-C/HGV RNA. A "TaqMan" assay using primers and probe derived from the 5' NCR region was developed and validated. Two hundred and fifty-three plasma samples from HIV-infected women were tested for GBV-C viremia and antibody against the envelope protein 2. GBV-C RNA was detected in 22.5% of the patients whereas the antibody was identified in 25.3% of the cohort. Detection of viral RNA and of antibodies was mutually exclusive. Viral loads showed a mean of 1,777 arbitrary units/mL, being 1.1 and 13,625 arbitrary units/mL respectively the lowest and highest values measured. We conclude that the real-time quantitative polymerase chain reaction method developed is appropriate for the investigation of GBV-C RNA since it was shown to be highly specific and sensitive, as well as requiring few steps, preventing contamination and providing additional information as to the relative viremia of carriers, a parameter that must be included in studies evaluating the co-factors influencing the clinical outcome of HIV/AIDS.
C1 [Rodrigues, Celia Lima; Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, BR-05403000 Sao Paulo, Brazil.
   [Silva, Synara Araujo; Rodrigues, Celia Lima; Campos, Aleia Faustino; Levi, Jose Eduardo] Univ Sao Paulo, Sch Med, Dept Infect Dis, BR-05403000 Sao Paulo, Brazil.
RP Levi, JE (corresponding author), Univ Sao Paulo, Inst Trop Med, Virol Lab, Av Dr Eneas de Carvalho Aguiar 470,2 Andar, BR-05403000 Sao Paulo, Brazil.
EM synaraalexandre@yahoo.com; cllrodrigues@hotmail.com; aleia@usp.br;
   dudilevi@usp.br
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [05/01072-9]
FX This study was funded by the Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP), grant number 05/01072-9.
CR Andonov A, 1998, J CLIN MICROBIOL, V36, P286, DOI 10.1128/JCM.36.1.286-289.1998
   Bassit L, 1998, VOX SANG, V74, P83, DOI 10.1046/j.1423-0410.1998.7420083.x
   Bortolin MT, 2004, INTERVIROLOGY, V47, P314, DOI 10.1159/000080874
   Castelain S, 2004, J MED VIROL, V73, P596, DOI 10.1002/jmv.20131
   Fan XF, 1999, J MED VIROL, V58, P160, DOI 10.1002/(SICI)1096-9071(199906)58:2&lt;160::AID-JMV10&gt;3.0.CO;2-9
   Heringlake S, 1998, J INFECT DIS, V177, P1723, DOI 10.1086/517431
   Lefrere JJ, 1999, J INFECT DIS, V179, P783, DOI 10.1086/314671
   Lefrere JJ, 2000, J VIROL METHODS, V85, P117, DOI 10.1016/S0166-0934(99)00160-3
   Lefrere JJ, 1997, BLOOD, V90, P3776, DOI 10.1182/blood.V90.9.3776
   Levi JE, 2004, GYNECOL ONCOL, V92, P225, DOI 10.1016/j.ygyno.2003.10.004
   Levi José Eduardo, 2003, Rev. Inst. Med. trop. S. Paulo, V45, P75, DOI 10.1590/S0036-46652003000200004
   Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
   Linnen JM, 1997, J VIRAL HEPATITIS, V4, P293, DOI 10.1046/j.1365-2893.1997.00064.x
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   Mohr EL, 2009, J VIRAL HEPATITIS, V16, P757, DOI 10.1111/j.1365-2893.2009.01194.x
   Reshetnyak VI, 2008, WORLD J GASTROENTERO, V14, P4725, DOI 10.3748/wjg.14.4725
   Simmons JN, 1995, NAT MED, V1, P564
   Souza IE, 2006, J CLIN MICROBIOL, V44, P3105, DOI 10.1128/JCM.02663-05
   Tacke M, 1997, LANCET, V349, P318, DOI 10.1016/S0140-6736(96)06461-6
   Tacke M, 1997, LANCET, V349, P736
   Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398
   Toyoda H, 1998, J ACQ IMMUN DEF SYND, V17, P209, DOI 10.1097/00042560-199803010-00004
   Van der Bij AK, 2005, J INFECT DIS, V191, P678, DOI 10.1086/427559
   Williams CF, 2004, NEW ENGL J MED, V350, P981, DOI 10.1056/NEJMoa030107
   Xiang JH, 2004, LANCET, V363, P2040, DOI 10.1016/S0140-6736(04)16453-2
   Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364
   Zhang W, 2006, HIV MED, V7, P173, DOI 10.1111/j.1468-1293.2006.00366.x
NR 27
TC 2
Z9 2
U1 0
U2 0
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PD JAN-FEB
PY 2012
VL 54
IS 1
BP 31
EP 35
DI 10.1590/S0036-46652012000100006
PG 5
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 899DT
UT WOS:000300796100006
PM 22370751
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Roth, WK
   Busch, MP
   Schuller, A
   Ismay, S
   Cheng, A
   Seed, CR
   Jungbauer, C
   Minsk, PM
   Sondag-Thull, D
   Wendel, S
   Levi, JE
   Fearon, M
   Delage, G
   Xie, Y
   Jukic', I
   Turek, P
   Ullum, H
   Tefanova, V
   Tilk, M
   Reimal, R
   Castren, J
   Naukkarinen, M
   Assal, A
   Jork, C
   Hourfar, MK
   Michel, P
   Offergeld, R
   Pichl, L
   Schmidt, M
   Schottstedt, V
   Seifried, E
   Wagner, F
   Weber-Schehl, M
   Politis, C
   Lin, CK
   Tsoi, WC
   O'Riordan, J
   Gottreich, A
   Shinar, E
   Yahalom, V
   Velati, C
   Satake, M
   Sanad, N
   Sisene, I
   Bon, AH
   Koppelmann, M
   Flanagan, P
   Flesland, O
   Brojer, E
   Letowska, M
   Nascimento, F
   Zhiburt, E
   Chua, SS
   Teo, D
   Stezinar, SL
   Vermeulen, M
   Reddy, R
   Park, Q
   Castro, E
   Eiras, A
   Fraile, IG
   Torres, P
   Ekermo, B
   Niederhauser, C
   Chen, H
   Oota, S
   Brant, LJ
   Eglin, R
   Jarvis, L
   Mohabir, L
   Brodsky, J
   Foster, G
   Jennings, C
   Notari, E
   Stramer, S
   Kessler, D
   Hillyer, C
   Kamel, H
   Katz, L
   Taylor, C
   Panzer, S
   Reesink, HW
AF Roth, W. K.
   Busch, M. P.
   Schuller, A.
   Ismay, S.
   Cheng, A.
   Seed, C. R.
   Jungbauer, C.
   Minsk, P. M.
   Sondag-Thull, D.
   Wendel, S.
   Levi, J. E.
   Fearon, M.
   Delage, G.
   Xie, Y.
   Jukic', I.
   Turek, P.
   Ullum, H.
   Tefanova, V.
   Tilk, M.
   Reimal, R.
   Castren, J.
   Naukkarinen, M.
   Assal, A.
   Jork, C.
   Hourfar, M. K.
   Michel, P.
   Offergeld, R.
   Pichl, L.
   Schmidt, M.
   Schottstedt, V.
   Seifried, E.
   Wagner, F.
   Weber-Schehl, M.
   Politis, C.
   Lin, C. K.
   Tsoi, W. C.
   O'Riordan, J.
   Gottreich, A.
   Shinar, E.
   Yahalom, V.
   Velati, C.
   Satake, M.
   Sanad, N.
   Sisene, I.
   Bon, A. H.
   Koppelmann, M.
   Flanagan, P.
   Flesland, O.
   Brojer, E.
   Letowska, M.
   Nascimento, F.
   Zhiburt, E.
   Chua, S. S.
   Teo, D.
   Stezinar, S. Levicnik
   Vermeulen, M.
   Reddy, R.
   Park, Q.
   Castro, E.
   Eiras, A.
   Gonzales Fraile, I.
   Torres, P.
   Ekermo, B.
   Niederhauser, C.
   Chen, H.
   Oota, S.
   Brant, L. J.
   Eglin, R.
   Jarvis, L.
   Mohabir, L.
   Brodsky, J.
   Foster, G.
   Jennings, C.
   Notari, E.
   Stramer, S.
   Kessler, D.
   Hillyer, C.
   Kamel, H.
   Katz, L.
   Taylor, C.
   Panzer, S.
   Reesink, H. W.
TI International survey on NAT testing of blood donations: expanding
   implementation and yield from 1999 to 2009
SO VOX SANGUINIS
LA English
DT Article
ID NUCLEIC-ACID TECHNOLOGY; TRANSFUSION SERVICE; EXPERIENCES; HIV-1; HCV;
   PCR
C1 [Roth, W. K.; Schuller, A.] GFE Blut mbH, D-60438 Frankfurt, Germany.
   [Busch, M. P.] Univ Calif San Francisco, Blood Syst Res Inst, San Francisco, CA 94143 USA.
   [Reesink, H. W.] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands.
   [Panzer, S.] Univ Vienna, Univ Klin Blutgrp Serol & Transfus Med, Klin Abt Blutgrp Serol, A-1090 Vienna, Austria.
RP Roth, WK (corresponding author), GFE Blut mbH, Altenhoferallee 3, D-60438 Frankfurt, Germany.
EM kurt.roth@gfeblut.de; mbusch@bloodsystems.org; annetteschuller@aol.com;
   simon.panzer@meduniwien.ac.at; h.w.reesink@amc.nl
RI Selerski, Marcin/A-7594-2012; Brojer, Ewa/V-6860-2018; Letowska,
   Magdalena/V-5037-2018; Wendel, S/AAQ-9048-2020
OI Brojer, Ewa/0000-0003-1947-6888; Letowska,
   Magdalena/0000-0002-3951-280X; Schmidt, Michael/0000-0001-9338-0900;
   Ullum, Henrik/0000-0001-7306-9058; Vermeulen,
   Marion/0000-0003-4383-4526; Jukic, Irena/0000-0003-2778-8400
FU WHOWorld Health Organization; EUEuropean Union (EU); NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA; CDCCentre National de la Recherche Scientifique (CNRS)United
   States Department of Health & Human ServicesCenters for Disease Control
   & Prevention - USA
FX The ISBT WP-TTID believes that collection and analysis of NAT and
   serological infectious disease donor screening data should be performed
   on a more regular basis in the future, given the expanded number of
   countries performing NAT, changing epidemiology of infectious diseases
   and donor selection practices and the likely evolution of NAT testing to
   target additional agents. Although this task is an appropriate one for
   the ISBT TTID working group, ongoing funding will be required to execute
   electronic surveys and rigorously analyse compiled data on a regular
   basis (every 3-5 years). The authors of this International Forum are
   grateful to the companies who have supported the working party to date
   and encourage their ongoing support, as well as funding from other
   sources (WHO, EU, NIH or CDC). Finally, we thank all of the experts and
   the national blood transfusion services for their participation in
   completing the survey and reviewing the manuscript.
CR Cardoso MS, 1999, BIOLOGICALS, V27, P281, DOI 10.1006/biol.1999.0221
   Coste J, 2005, VOX SANG, V88, P289, DOI 10.1111/j.1423-0410.2005.00636_1.x
   Engelfriet CP, 2002, VOX SANG, V82, P87, DOI 10.1046/j.0042-9007.2001.00147_1.x
   McCullough J, 2000, TRANSFUSION, V40, P143
   McCullough J, 1998, TRANSFUSION, V38, P903, DOI 10.1046/j.1537-2995.1998.381098440852.x
   Roth WK, 1999, LANCET, V353, P359, DOI 10.1016/S0140-6736(98)06318-1
   Schottstedt V, 1998, BIOLOGICALS, V26, P101, DOI 10.1006/biol.1998.0144
NR 7
TC 109
Z9 126
U1 0
U2 20
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0042-9007
J9 VOX SANG
JI Vox Sang.
PD JAN
PY 2012
VL 102
IS 1
BP 82
EP 90
DI 10.1111/j.1423-0410.2011.01506.x
PG 9
WC Hematology
SC Hematology
GA 869MO
UT WOS:000298602400012
PM 21933190
DA 2020-11-30
ER

PT J
AU Araujo, AR
   de Almeida, CM
   Fraporti, L
   Garcia, N
   de Lima, TA
   Maia, LPV
   Torres, KL
   Tarrago, AM
   Victoria, F
   Victoria, M
   Tateno, A
   Levi, JE
   Talhari, S
   Malheiro, A
AF Araujo, Ana Ruth
   de Almeida, Carlos Maurico
   Fraporti, Liziara
   Garcia, Nadja
   de Lima, Tatiane Amabili
   Viana Maia, Laura Patricia
   Torres, Katia Luz
   Tarrago, Andrea Monteiro
   Victoria, Flamir
   Victoria, Marilu
   Tateno, Adriana
   Levi, Jose Eduardo
   Talhari, Sinesio
   Malheiro, Adriana
TI Characterization of hepatitis C virus in chronic hepatitis patients:
   genotypes in the State of Amazonas, Brazil
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA Portuguese
DT Article
DE Hepatitis C virus; Genotyping; Hepatitis
AB Introduction: In the State of Amazonas, data regarding the prevalence of different genotypes of hepatitis C virus remains scarce. Methods: The genotype of 69 HCV positive patients was determined. An in-house standardized nested-PCR was used to detect HCV RNA. Genotype assignment was based on type-specific motifs on the sequenced amplicons delimited by primers HC11/HC18 from the 5' untranslated region. Results: Of the 69 patients studied, 65.2% were male and 34.8% were female. Genotype 1 showed the greatest prevalence, followed by 3 and 2. Conclusions: These data suggesting that Manaus is the point of arrival of HCV in the State of Amazonas.
C1 [Fraporti, Liziara; Garcia, Nadja; de Lima, Tatiane Amabili; Viana Maia, Laura Patricia; Torres, Katia Luz; Tarrago, Andrea Monteiro] Fundacao Hematol & Hemoterapia Amazonas, Lab Imunol, Diretoria Ensino & Pesquisa, Manaus, Amazonas, Brazil.
   [Tateno, Adriana; Levi, Jose Eduardo] Inst Med Trop Sao Paulo, Virol Lab, Sao Paulo, Brazil.
   [Malheiro, Adriana] Fundacao Med Trop Amazonas, Ambulatorio Virol, HEMOAM, BR-69050002 Manaus, Amazonas, Brazil.
   [Araujo, Ana Ruth; Fraporti, Liziara; Garcia, Nadja; Viana Maia, Laura Patricia; Malheiro, Adriana] Univ Fed Amazonas, Dept Parasitol, Inst Ciencias Biol, Manaus, Amazonas, Brazil.
RP Malheiro, A (corresponding author), Fundacao Med Trop Amazonas, Ambulatorio Virol, HEMOAM, Av Constantino Nery 4397, BR-69050002 Manaus, Amazonas, Brazil.
EM malheiroadriana@yahoo.com.br
CR Bezerra CS, 2007, BRAZ J MICROBIOL, V38, P656, DOI 10.1590/S1517-83822007000400014
   Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
   Gale M, 2005, NATURE, V436, P939, DOI 10.1038/nature04078
   Gonzaga RMS, 2008, BRAZ J MICROBIOL, V39, P644, DOI 10.1590/S1517-83822008000400008
   HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9
   Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107
   Ministerio da Saude, 2006, PROGR NAC HEP VIR
   Pavio N, 2003, J BIOSCIENCES, V28, P287, DOI 10.1007/BF02970148
   Poynard T, 2003, LANCET, V362, P2095, DOI 10.1016/S0140-6736(03)15109-4
   Saez-Alquezar A, 2001, DIAGNOSTICO LAB PRIN, P37
   Strauss E, 2001, Rev Soc Bras Med Trop, V34, P69, DOI 10.1590/S0037-86822001000100011
   Torres KL, 2009, EMERG INFECT DIS, V15, P676, DOI 10.3201/eid1504.081288
NR 12
TC 4
Z9 6
U1 0
U2 3
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD SEP-OCT
PY 2011
VL 44
IS 5
BP 638
EP 640
DI 10.1590/S0037-86822011000500024
PG 3
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 849CF
UT WOS:000297102400024
PM 22031084
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Levi, JE
   Foglieto, M
   Romano, C
   Granato, CH
   Wendel, S
AF Levi, J. E.
   Foglieto, M.
   Romano, C.
   Granato, C. H.
   Wendel, S.
TI A High Viral Load HIV-1 Isolate Missed by NAT Screening
SO TRANSFUSION
LA English
DT Meeting Abstract
CT AABB Annual Meeting and CTTXPO
CY OCT 22-25, 2011
CL San Diego, CA
SP AABB
C1 [Levi, J. E.; Wendel, S.] Hosp Sirio Libanes, Blood Bank, Sao Paulo, Brazil.
   [Romano, C.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   [Levi, J. E.; Foglieto, M.; Wendel, S.] Ctr Imunol & Imunogenet, NAT, Sao Paulo, Brazil.
   [Granato, C. H.] Doencas Infecciosas Fleury Med & Saude, Sao Paulo, Brazil.
EM biologia@cii-laboratorio.com.br
RI Wendel, S/AAQ-9048-2020
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 2011
VL 51
SU 3
SI SI
BP 205A
EP 205A
PG 1
WC Hematology
SC Hematology
GA 822YC
UT WOS:000295085500526
DA 2020-11-30
ER

PT J
AU Lima, GFMC
   Levi, JE
   Geraldi, MP
   Sanchez, MCA
   Segurado, AAC
   Hristov, AD
   Inoue, J
   Costa-Nascimento, MD
   Di Santi, SM
AF Lima, Giselle F. M. C.
   Levi, Jose E.
   Geraldi, Marcelo P.
   Sanchez, Maria Carmen A.
   Segurado, Aluisio A. C.
   Hristov, Angelica D.
   Inoue, Juliana
   Costa-Nascimento, Maria de Jesus
   Di Santi, Silvia M.
TI Malaria diagnosis from pooled blood samples: comparative analysis of
   real-time PCR, nested PCR and immunoassay as a platform for the
   molecular and serological diagnosis of malaria on a large-scale
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE malaria; real-time PCR; nested PCR; Plasmodium; diagnosis
ID PLASMODIUM-VIVAX; IMPORTED MALARIA; SAO-PAULO; ASSAY; TRANSFUSION;
   AMPLIFICATION; SENSITIVITY; MICROSCOPY; FALCIPARUM; INFECTION
AB Malaria diagnoses has traditionally been made using thick blood smears, but more sensitive and faster techniques are required to process large numbers of samples in clinical and epidemiological studies and in blood donor screening. Here, we evaluated molecular and serological tools to build a screening platform for pooled samples aimed at reducing both the time and the cost of these diagnoses. Positive and negative samples were analysed in individual and pooled experiments using real-time polymerase chain reaction (PCR), nested PCR and an immunochromatographic test. For the individual tests, 46/49 samples were positive by real-time PCR, 46/49 were positive by nested PCR and 32/46 were positive by immunochromatographic test. For the assays performed using pooled samples, 13/15 samples were positive by real-time PCR and nested PCR and 11/15 were positive by immunochromatographic test. These molecular methods demonstrated sensitivity and specificity for both the individual and pooled samples. Due to the advantages of the real-time PCR, such as the fast processing and the closed system, this method should be indicated as the first choice for use in large-scale diagnosis and the nested PCR should be used for species differentiation. However, additional field isolates should be tested to confirm the results achieved using cultured parasites and the serological test should only be adopted as a complementary method for malaria diagnosis.
C1 [Lima, Giselle F. M. C.; Hristov, Angelica D.; Inoue, Juliana; Costa-Nascimento, Maria de Jesus; Di Santi, Silvia M.] Secretaria Estado Saude Sao Paulo, Nucleo Estudos Malaria, Sao Paulo, Brazil.
   [Levi, Jose E.] Banco Sangue Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Levi, Jose E.; Geraldi, Marcelo P.] Univ Sao Paulo, Fac Med, Virol Lab, BR-05403000 Sao Paulo, Brazil.
   [Sanchez, Maria Carmen A.] Univ Sao Paulo, Fac Med, Lab Soroepidemiol & Imunobiol, Inst Med Trop Sao Paulo, BR-05403000 Sao Paulo, Brazil.
   [Segurado, Aluisio A. C.; Inoue, Juliana; Di Santi, Silvia M.] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas Parasitarias, BR-05403000 Sao Paulo, Brazil.
RP Lima, GFMC (corresponding author), Secretaria Estado Saude Sao Paulo, Nucleo Estudos Malaria, Sao Paulo, Brazil.
EM giselledecastro@usp.br
RI Sanchez, Maria Carmen/D-8886-2012; Lima, Giselle/M-8335-2014; Hristov,
   Angelica/G-9801-2011; Inoue, Juliana/J-3314-2014; Segurado, Aluisio
   C/K-2229-2012; Di Santi, Silvia/D-8973-2012
OI Segurado, Aluisio C/0000-0002-6311-8036; Di Santi,
   Silvia/0000-0001-8049-2014; Arroyo Sanchez, Maria
   Carmen/0000-0003-4055-5556
FU SUCEN/Health Secretariat of the state of Sao Paulo; Tropical Medicine
   Institute of Sao Paulo/USP
FX Financial support: SUCEN/Health Secretariat of the state of Sao Paulo,
   Post-Graduation Program in Infectious and Parasitic Diseases/Tropical
   Medicine Institute of Sao Paulo/USP
CR Alves FP, 2002, AM J TROP MED HYG, V66, P641, DOI 10.4269/ajtmh.2002.66.641
   [Anonymous], 1988, B WORLD HEALTH ORGAN, V66, P575
   [Anonymous], 2010, SIST INF AGR NOT SIN
   AVILA Priscilla Elisangela, 2002, Rev. Inst. Med. trop. S. Paulo, V44, P293, DOI 10.1590/S0036-46652002000500012
   BARKER RH, 1994, EXP PARASITOL, V79, P41, DOI 10.1006/expr.1994.1057
   Belizario V. Y., 2005, Southeast Asian Journal of Tropical Medicine and Public Health, V36, P552
   Bharti AR, 2009, AM J TROP MED HYG, V81, P754, DOI 10.4269/ajtmh.2009.09-0274
   Boonma P, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-124
   Coleman RE, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-121
   Costa-Nascimento MJ, 2007, REV SOC BRAS MED TRO, V40, P147
   Couto RD, 2010, REV SOC BRAS MED TRO, V43, P52, DOI 10.1590/S0037-86822010000100012
   Di Santi Silvia Maria, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P183, DOI 10.1590/S0036-46652004000400002
   Dorfman R, 1943, ANN MATH STAT, V14, P436, DOI 10.1214/aoms/1177731363
   Farcas GA, 2004, J CLIN MICROBIOL, V42, P636, DOI 10.1128/JCM.42.2.636-638.2004
   Fugikaha Érica, 2007, Rev. Inst. Med. trop. S. Paulo, V49, P1, DOI 10.1590/S0036-46652007000100001
   Gama BE, 2007, EXP PARASITOL, V116, P427, DOI 10.1016/j.exppara.2007.02.011
   Greiner M, 2000, PREV VET MED, V45, P23, DOI 10.1016/S0167-5877(00)00115-X
   Han ET, 2007, J CLIN MICROBIOL, V45, P2521, DOI 10.1128/JCM.02117-06
   Huong NM, 2002, TROP MED INT HEALTH, V7, P304, DOI 10.1046/j.1365-3156.2002.00869.x
   Jeremiah Z. A., 2007, Research Journal of Parasitology, V2, P39
   Kain KC, 1998, CLIN INFECT DIS, V27, P142, DOI 10.1086/514616
   Khairnar K, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-284
   Kimura Masatsugu, 1997, Parasitology International, V46, P91, DOI 10.1016/S1383-5769(97)00013-5
   Kirchgatter K, 2005, BMJ-BRIT MED J, V331, P576
   Kitchen AD, 2006, VOX SANG, V90, P77, DOI 10.1111/j.1423-0410.2006.00733.x
   Lee MA, 2002, J CLIN MICROBIOL, V40, P4343, DOI 10.1128/JCM.40.11.4343-4345.2002
   Melana SM, 2001, CLIN CANCER RES, V7, P283
   Moody A, 2002, CLIN MICROBIOL REV, V15, P66, DOI 10.1128/CMR.15.1.66-78.2002
   Murray CK, 2003, TROP MED INT HEALTH, V8, P876, DOI 10.1046/j.1365-3156.2003.01115.x
   Oh JS, 2008, MEM I OSWALDO CRUZ, V103, P75, DOI 10.1590/S0074-02762008005000008
   Oliveira JPA, 1995, CLIN INFEC DIS, V20, P15
   OPAS-Organizacao Pan- Americana da Saude/Organizacao Pan-Americana da Saude, 1975, MAN DIAGN MICR MAL
   Park SK, 2003, YONSEI MED J, V44, P747, DOI 10.3349/ymj.2003.44.4.747
   Perandin F, 2004, J CLIN MICROBIOL, V42, P1214, DOI 10.1128/JCM.42.3.1214-1219.2004
   Pereira MG, 1995, EPIDEMIOLOGIA TEORIA
   Ross R, 1903, LANCET, V1, P86
   Rubio JM, 1999, J CLIN MICROBIOL, V37, P3260, DOI 10.1128/JCM.37.10.3260-3264.1999
   Saez-Alquezar A, 1998, Rev Soc Bras Med Trop, V31, P27, DOI 10.1590/S0037-86821998000100004
   Scuracchio PS, 2009, TRANSFUSION, V49, p233A
   Seed CR, 2005, TRANSFUS MED REV, V19, P229, DOI 10.1016/j.tmrv.2005.02.004
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B
   Swan H, 2005, AM J TROP MED HYG, V73, P850, DOI 10.4269/ajtmh.2005.73.850
   Taylor SM, 2010, J CLIN MICROBIOL, V48, P512, DOI 10.1128/JCM.01800-09
   Veron V, 2009, EXP PARASITOL, V121, P346, DOI 10.1016/j.exppara.2008.12.012
   Westreich DJ, 2008, J CLIN MICROBIOL, V46, P1785, DOI 10.1128/JCM.00787-07
   Zicker F, 1997, METODOS INVESTIGACAO, P33
NR 46
TC 24
Z9 25
U1 0
U2 7
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD SEP
PY 2011
VL 106
IS 6
BP 691
EP 700
DI 10.1590/S0074-02762011000600008
PG 10
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 835FY
UT WOS:000296022400008
PM 22012223
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Levi, JE
   Nascimento, MC
   Sumita, LM
   de Souza, VAUF
   Freire, WS
   Mayaud, P
   Pannuti, CS
AF Levi, Jose Eduardo
   Nascimento, Maria Claudia
   Sumita, Laura Masami
   Ueda Fick de Souza, Vanda Akico
   Freire, Wilton S.
   Mayaud, Philippe
   Pannuti, Claudio S.
TI Non-Detection of Human Herpesvirus 8 (HHV-8) DNA in HHV-8-Seropositive
   Blood Donors from Three Brazilian Regions
SO PLOS ONE
LA English
DT Article
ID HUMAN-HERPESVIRUS TYPE-8; LATENT CLASS ANALYSIS; KAPOSIS-SARCOMA;
   MONONUCLEAR-CELLS; RISK-FACTORS; VIRAL LOAD; TRANSMISSION; TRANSFUSION;
   PREVALENCE; INFECTION
AB Human herpesvirus 8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus (KSHV), is the etiologic agent of all forms of Kaposi's sarcoma, primary effusion lymphoma and the plasmablastic cell variant of multicentric Castleman disease. In endemic areas of sub-Saharan Africa, blood transfusions have been associated with a substantial risk of HHV-8 transmission. By contrast, several studies among healthy blood donors from North America have failed to detect HHV-8 DNA in samples of seropositive individuals. In this study, using a real-time PCR assay, we investigated the presence of HHV-8 DNA in whole-blood samples of 803 HHV-8 blood donors from three Brazilian states (Sao Paulo, Amazon, Bahia) who tested positive for HHV-8 antibodies, in a previous multicenter study. HHV-8 DNA was not detected in any sample. Our findings do not support the introduction of routine HHV-8 screening among healthy blood donors in Brazil. (WC = 140).
C1 [Levi, Jose Eduardo; Nascimento, Maria Claudia; Sumita, Laura Masami; Ueda Fick de Souza, Vanda Akico; Freire, Wilton S.; Pannuti, Claudio S.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
   [Ueda Fick de Souza, Vanda Akico; Pannuti, Claudio S.] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias LIM HC, Sao Paulo, Brazil.
   [Nascimento, Maria Claudia; Mayaud, Philippe] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England.
RP Levi, JE (corresponding author), Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
EM cpannuti@usp.br
RI Pannuti, Claudio/B-7649-2012
OI MAYAUD, Philippe/0000-0001-5730-947X
FU Conselho Nacional de Desenvolvimento Cientifico e Technologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); agency of the Brazilian Ministry of Science and Technology
   [304879/2003-7, 305258/2006-0, 473867/2006-0]; UK's Department for
   International Development (DFID); HIV in Developing Countries of the
   LSHTM
FX The study was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Technologico (CNPq), an agency of the Brazilian Ministry of
   Science and Technology (Grants 304879/2003-7, 305258/2006-0 and
   473867/2006-0). Additional financial support was provided by the UK's
   Department for International Development (DFID)-funded Research
   Programme Consortium on Research and Capacity Building on Sexual and
   Reproductive Health and HIV in Developing Countries of the LSHTM. The
   funders had no role in study design, data collection and analysis,
   decision to publish and preparation of the manuscript. The views
   expressed herein do not necessarily represent the views and policies of
   CNPq and DFID.
CR Belec L, 1998, TRANSFUSION, V38, P771, DOI 10.1046/j.1537-2995.1998.38898375517.x
   Bigoni B, 1996, J INFECT DIS, V173, P542, DOI 10.1093/infdis/173.3.542
   Blackbourn DJ, 1997, LANCET, V349, P609, DOI 10.1016/S0140-6736(96)10004-0
   Brown EE, 2005, INT J EPIDEMIOL, V34, P1110, DOI 10.1093/ije/dyi131
   Brown EE, 2006, CANCER, V107, P2282, DOI 10.1002/cncr.22236
   Cannon MJ, 2009, J INFECT DIS, V199, P1592, DOI 10.1086/598859
   Dedicoat M, 2003, BRIT J CANCER, V88, P1, DOI 10.1038/sj.bjc.6600745
   Enbom M, 2002, J MED VIROL, V68, P264, DOI 10.1002/jmv.10183
   Engels EA, 1999, J NATL CANCER I, V91, P1773, DOI 10.1093/jnci/91.20.1773
   Engels EA, 2000, INT J CANCER, V88, P1003, DOI 10.1002/1097-0215(20001215)88:6&lt;1003::AID-IJC26&gt;3.0.CO;2-9
   Ferreira S, 2003, TRANSFUSION, V43, P1764, DOI 10.1111/j.0041-1132.2003.00602.x
   Hladik W, 2006, NEW ENGL J MED, V355, P1331, DOI 10.1056/NEJMoa055009
   Hudnall SD, 2008, TRANSFUSION, V48, P1180, DOI 10.1111/j.1537-2995.2008.01685.x
   Hudnall SD, 2003, TRANSFUSION, V43, P85, DOI 10.1046/j.1537-2995.2003.00272.x
   Krishnan HH, 2004, J VIROL, V78, P3601, DOI 10.1128/JVI.78.7.3601-3620.2004
   Lam LL, 2002, J CLIN MICROBIOL, V40, P325, DOI 10.1128/JCM.40.02.325-329.2002
   Martro E, 2004, J VIROL, V78, P11707, DOI 10.1128/JVI.78.21.11707-11714.2004
   Mbulaiteye SM, 2003, J NATL CANCER I, V95, P1330, DOI 10.1093/jnci/djg039
   Nascimento MC, 2008, J MED VIROL, V80, P1202, DOI 10.1002/jmv.21188
   Nascimento MC, 2007, J CLIN MICROBIOL, V45, P715, DOI 10.1128/JCM.01264-06
   Pellett PE, 2003, TRANSFUSION, V43, P1260, DOI 10.1046/j.1537-2995.2003.00490.x
   Polstra AM, 2003, J CLIN MICROBIOL, V41, P5488, DOI 10.1128/JCM.41.12.5488-5491.2003
   Qu L, 2011, VOX SANG, V100, P267, DOI 10.1111/j.1423-0410.2010.01404.x
   Qu LR, 2010, TRANSFUSION, V50, P1050, DOI 10.1111/j.1537-2995.2009.02559.x
   Stramer SL, 2009, TRANSFUSION, V49, p1S, DOI 10.1111/j.1537-2995.2009.02279.x
   Uldrick TS, 2011, CANCER LETT, V305, P150, DOI 10.1016/j.canlet.2011.02.006
   Vitale F, 2000, EPIDEMIOL INFECT, V125, P671, DOI 10.1017/S0950268800004726
NR 27
TC 12
Z9 12
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 8
PY 2011
VL 6
IS 8
AR e23546
DI 10.1371/journal.pone.0023546
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 806AM
UT WOS:000293773300032
PM 21858163
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-11-30
ER

PT J
AU Giret, MTM
   Miraglia, JL
   Sucupira, MCA
   Nishiya, A
   Levi, JE
   Diaz, RS
   Sabino, EC
   Kallas, EG
AF Giret, Maria Teresa M.
   Miraglia, Joao Luiz
   Araripe Sucupira, Maria Cecilia
   Nishiya, Anna
   Levi, Jose Eduardo
   Diaz, Ricardo S.
   Sabino, Ester C.
   Kallas, Esper G.
TI Prevalence, Incidence Density, and Genotype Distribution of GB Virus C
   Infection in a Cohort of Recently HIV-1-Infected Subjects in Sao Paulo,
   Brazil
SO PLOS ONE
LA English
DT Article
ID HEPATITIS-G VIRUS; C/HEPATITIS-G-VIRUS; EARLY HIV-1 INFECTION;
   ANTIRETROVIRAL THERAPY; PHYLOGENETIC ANALYSIS; DISEASE PROGRESSION;
   REGION SEQUENCES; NONCODING REGION; BLOOD-DONORS; NO INFLUENCE
AB Background: The results of previous studies elsewhere have indicated that GB virus C (GBV-C) infection is frequent in patients infected with the human immunodeficiency virus type 1 (HIV-1) due to similar transmission routes of both viruses. The aim of this study was to determine the prevalence, incidence density and genotypic characteristics of GBV-C in this population.
   Methodology/Principal Findings: The study population included 233 patients from a cohort primarily comprised of homosexual men recently infected with HIV-1 in Sao Paulo, Brazil. The presence of GBV-C RNA was determined in plasma samples by reverse transcriptase-nested polymerase chain reaction and quantified by real-time PCR. GBV-C genotypes were determined by direct sequencing. HIV viral load, CD4+ T lymphocyte and CD8+ T lymphocyte count were also tested in all patients. The overall prevalence of GBV-C infection was 0.23 (95% CI: 0.18 to 0.29) in the study group. There was no significant difference between patients with and without GBV-C infection and Glycoprotein E2 antibody presence regarding age, sex, HIV-1 viral load, CD4+ and CD8+ T cell counts and treatment with antiretroviral drugs. An inverse correlation was observed between GBV-C and HIV-1 loads at enrollment and after one year. Also, a positive but not significant correlation was observed between GBV-C load and CD4+ T lymphocyte. Phylogenetic analysis of the GBV-C isolates revealed the presence of genotype 1 and genotype 2, these sub classified into subtype 2a and 2b.
   Conclusion/Significance: GBV-C infection is common in recently HIV -1 infected patients in Sao Paulo, Brazil and the predominant genotype is 2b. This study provides the first report of the GBV-C prevalence at the time of diagnosis of HIV-1 and the incidence density of GBV-C infection in one year.
C1 [Giret, Maria Teresa M.; Miraglia, Joao Luiz; Kallas, Esper G.] Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Araripe Sucupira, Maria Cecilia; Diaz, Ricardo S.] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   [Nishiya, Anna; Sabino, Ester C.] Sao Paulo Blood Bank, Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
RP Giret, MTM (corresponding author), Univ Sao Paulo, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
EM esper.kallas@gmail.com
RI Kallas, Esper G/C-9539-2012; Miraglia, Joao/H-5294-2013; Araripe
   Sucupira, Maria Cecilia/K-1931-2012; Diaz, Ricardo/K-3978-2012; Sabino,
   Ester Cerdeira/F-7750-2010; Nishiya, Anna/Q-8156-2016
OI Araripe Sucupira, Maria Cecilia/0000-0002-1114-5382; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Kallas, Esper/0000-0003-2026-6925;
   Miraglia, Joao Luiz/0000-0002-4788-6254
FU Ministry of HealthMinistry of Health - Turkey
   [914/BRA/3014-UNESCO/Kallas]; Sao Paulo City Health Department
   [2004-0.168.922-7/Kallas]; Fundacao de Amparo a Pesquisa do Estado de
   Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15856-9/Diaz, Sabino Kallas, 05/01072-9/Levi]; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazilian Ministry
   of EducationCAPES
FX This study was supported with funding from the Brazilian Program for STD
   and AIDS, Ministry of Health (914/BRA/3014-UNESCO/Kallas), the Sao Paulo
   City Health Department (2004-0.168.922-7/Kallas), and the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (04/15856-9/Diaz, Sabino &
   Kallas; and 05/01072-9/Levi). T.M.G. was supported by the Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazilian Ministry
   of Education. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Alter MJ, 1997, NEW ENGL J MED, V336, P741, DOI 10.1056/NEJM199703133361101
   Barbosa AD, 2009, REV SOC BRAS MED TRO, V42, P591, DOI 10.1590/S0037-86822009000500021
   Barbour JD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001080
   Berzsenyi MD, 2007, GASTROENTEROLOGY, V133, P1821, DOI 10.1053/j.gastro.2007.08.076
   Berzsenyi MD, 2005, J CLIN VIROL, V33, P257, DOI 10.1016/j.jcv.2005.04.002
   Birk M, 2002, AIDS, V16, P2482, DOI 10.1097/00002030-200212060-00017
   Bjorkman P, 2004, AIDS, V18, P877, DOI [10.1097/01.aids.0000125908.52357.4c, 10.1097/00002030-200404090-00005]
   Branco C, 2010, J MED VIROL, V82, P452, DOI 10.1002/jmv.21703
   Brumme ZL, 2002, AIDS, V16, P1929, DOI 10.1097/00002030-200209270-00010
   Compston LI, 2009, J MED VIROL, V81, P1860, DOI 10.1002/jmv.21614
   Gallian P, 1998, J MED VIROL, V56, P310, DOI 10.1002/(SICI)1096-9071(199812)56:4&lt;310::AID-JMV4&gt;3.0.CO;2-4
   George SL, 2006, J INFECT DIS, V193, P451, DOI 10.1086/499435
   Hammad AM, 2009, ANN CLIN MICROB ANTI, V8, DOI 10.1186/1476-0711-8-36
   Handajani R, 2000, J CLIN MICROBIOL, V38, P662, DOI 10.1128/JCM.38.2.662-668.2000
   Heringlake S, 1998, J INFECT DIS, V177, P1723, DOI 10.1086/517431
   Hosseini-Moghaddam SM, 2008, J MED VIROL, V80, P1260, DOI 10.1002/jmv.21161
   Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42
   Jarvis LM, 1996, LANCET, V348, P1352, DOI 10.1016/S0140-6736(96)04041-X
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Katayama K, 1998, ARCH VIROL, V143, P1063, DOI 10.1007/s007050050356
   Lampe E, 1998, J MED VIROL, V56, P39, DOI 10.1002/(SICI)1096-9071(199809)56:1&lt;39::AID-JMV7&gt;3.0.CO;2-O
   Lampe E, 1997, J MED VIROL, V52, P61, DOI 10.1002/(SICI)1096-9071(199705)52:1&lt;61::AID-JMV10&gt;3.0.CO;2-3
   Lau DTY, 1999, J INFECT DIS, V180, P1334, DOI 10.1086/315031
   Leao GC, 2007, JPN J CLIN ONCOL, V37, P632, DOI 10.1093/jjco/hym063
   Levi José Eduardo, 2003, Rev. Inst. Med. trop. S. Paulo, V45, P75, DOI 10.1590/S0036-46652003000200004
   Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
   Loureiro CL, 2002, J MED VIROL, V68, P357, DOI 10.1002/jmv.10211
   Lyra AC, 2005, BRAZ J MED BIOL RES, V38, P767, DOI 10.1590/S0100-879X2005000500015
   Maidana Maria Teresa, 2005, Braz J Infect Dis, V9, P122, DOI 10.1590/S1413-86702005000200001
   Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11
   Massud I, 2002, MEDICINA-BUENOS AIRE, V62, P173
   *MIN SAUD SECR VIG, ANT THER REC HIV INF
   Muerhoff AS, 2006, J MED VIROL, V78, P105, DOI 10.1002/jmv.20510
   Muerhoff AS, 2003, J MED VIROL, V70, P141, DOI 10.1002/jmv.10375
   MUERHOFF AS, 1995, J VIROL, V69, P5621, DOI 10.1128/JVI.69.9.5621-5630.1995
   Muerhoff AS, 1996, J HEPATOL, V25, P379, DOI 10.1016/S0168-8278(96)80125-5
   Muerhoff AS, 1997, J VIROL, V71, P6501, DOI 10.1128/JVI.71.9.6501-6508.1997
   Mukaide M, 1997, FEBS LETT, V407, P51, DOI 10.1016/S0014-5793(97)00136-1
   Naito H, 1999, J CLIN MICROBIOL, V37, P1217, DOI 10.1128/JCM.37.4.1217-1220.1999
   Naito H, 2001, J VIROL METHODS, V91, P3, DOI 10.1016/S0166-0934(00)00207-X
   Nishiya Anna S., 2003, Rev. Inst. Med. trop. S. Paulo, V45, P213, DOI 10.1590/S0036-46652003000400007
   Okamoto H, 1997, J GEN VIROL, V78, P737, DOI 10.1099/0022-1317-78-4-737
   Oliveira LA, 2002, MEM I OSWALDO CRUZ, V97, P953, DOI 10.1590/S0074-02762002000700005
   Pereira LMMB, 2002, J MED VIROL, V67, P27, DOI 10.1002/jmv.2188
   Pinho J. R. R., 1996, Revista do Instituto de Medicina Tropical de Sao Paulo, V38, P243, DOI 10.1590/S0036-46651996000300016
   Pinho Joao Renato Rebello, 1996, Revista do Instituto de Medicina Tropical de Sao Paulo, V38, P441, DOI 10.1590/S0036-46651996000600010
   Pinho JRR, 1999, J CLIN MICROBIOL, V37, P1634, DOI 10.1128/JCM.37.5.1634-1637.1999
   Quiros-Roldan E, 2002, AIDS, V16, P1430, DOI 10.1097/00002030-200207050-00019
   Ramezani A, 2008, J GASTROINTEST LIVER, V17, P269
   Ramezani A, 2008, INT J INFECT DIS, V12, P57, DOI 10.1016/j.ijid.2007.04.010
   Ramos R, 2004, MEM I OSWALDO CRUZ, V99, P639, DOI 10.1590/S0074-02762004000600019
   Rey D, 2000, EUR J CLIN MICROBIOL, V19, P721, DOI 10.1007/s100960000352
   Ribeiro-dos-Santos G, 2002, EUR J CLIN MICROBIOL, V21, P438, DOI 10.1007/s10096-002-0752-y
   Ryt-Hansen R, 2006, AIDS RES HUM RETROV, V22, P496, DOI 10.1089/aid.2006.22.496
   Sa D, 2007, AIDS RES HUM RETROV, V23, P1087, DOI 10.1089/aid.2006.0173
   Sathar MA, 2004, CLIN INFECT DIS, V38, P405, DOI 10.1086/381092
   SCHLAUDER GG, 1995, LANCET, V346, P447, DOI 10.1016/S0140-6736(95)92821-9
   Schwarze-Zander C, 2006, J INFECT DIS, V194, P410, DOI 10.1086/505713
   SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401
   SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564
   Smith DB, 1997, J GEN VIROL, V78, P1533, DOI 10.1099/0022-1317-78-7-1533
   Souza IE, 2006, HIV MED, V7, P25, DOI 10.1111/j.1468-1293.2005.00339.x
   STAPLETON JT, 2010, J GEN VIROL
   Supapol WB, 2008, J INFECT DIS, V197, P1369, DOI 10.1086/587488
   Supapol WB, 2011, J MED VIROL, V83, P33, DOI 10.1002/jmv.21946
   Thomas DL, 1998, J INFECT DIS, V177, P539, DOI 10.1086/514245
   Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398
   Tucker TJ, 1999, J MED VIROL, V59, P52, DOI 10.1002/(SICI)1096-9071(199909)59:1&lt;52::AID-JMV9&gt;3.0.CO;2-D
   Van der Bij AK, 2005, J INFECT DIS, V191, P678, DOI 10.1086/427559
   Watanabe MAE, 2003, RENAL FAILURE, V25, P67, DOI 10.1081/JDI-120017469
   Weng HY, 2009, AM J EPIDEMIOL, V169, P1182, DOI 10.1093/aje/kwp035
   Williams CF, 2004, NEW ENGL J MED, V350, P981, DOI 10.1056/NEJMoa030107
   Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364
   Xiang JH, 2000, J VIROL, V74, P9125, DOI 10.1128/JVI.74.19.9125-9133.2000
NR 74
TC 25
Z9 26
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 5
PY 2011
VL 6
IS 4
AR e18407
DI 10.1371/journal.pone.0018407
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 745UD
UT WOS:000289191300021
PM 21483671
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Ribeiro, KB
   Levi, JE
   Pawlita, M
   Koifman, S
   Matos, E
   Eluf-Neto, J
   Wunsch, V
   Curado, MP
   Shangina, O
   Zaridze, D
   Szeszenia-Dabrowska, N
   Lissowska, J
   Daudt, A
   Menezes, A
   Bencko, V
   Mates, D
   Fernandez, L
   Fabianova, E
   Gheit, T
   Tommasino, M
   Boffetta, P
   Brennan, P
   Waterboer, T
AF Ribeiro, Karina Braga
   Levi, Jose Eduardo
   Pawlita, Michael
   Koifman, Sergio
   Matos, Elena
   Eluf-Neto, Jose
   Wunsch-Filho, Victor
   Curado, Maria Paula
   Shangina, Oxana
   Zaridze, David
   Szeszenia-Dabrowska, Neonila
   Lissowska, Jolanta
   Daudt, Alexander
   Menezes, Ana
   Bencko, Vladimir
   Mates, Dana
   Fernandez, Leticia
   Fabianova, Eleonora
   Gheit, Tarik
   Tommasino, Massimo
   Boffetta, Paolo
   Brennan, Paul
   Waterboer, Tim
TI Low human papillomavirus prevalence in head and neck cancer: results
   from two large case-control studies in high-incidence regions
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE Head and neck cancer; human papillomavirus (HPV); Central Europe; Latin
   America
ID SQUAMOUS-CELL CARCINOMAS; GLUTATHIONE-S-TRANSFERASE; ONCOGENIC
   HUMAN-PAPILLOMAVIRUS; POLYMERASE-CHAIN-REACTION; INVASIVE
   CERVICAL-CANCER; ORAL-CANCER; OROPHARYNGEAL CANCER; PARTICLE VACCINE;
   ONCOPROTEINS E6; UNITED-STATES
AB Background Recent studies support an important role for human papillomavirus (HPV) in a subgroup of head and neck squamous cell carcinomas (HNSCC). We have evaluated the HPV deoxyribonucleic acid (DNA) prevalence as well as the association between serological response to HPV infection and HNSCC in two distinct populations from Central Europe (CE) and Latin America (LA).
   Methods Cases (n = 2214) and controls (n = 3319) were recruited from 1998 to 2003, using a similar protocol including questionnaire and blood sample collection. Tumour DNA from 196 fresh tissue biopsies was analysed for multiple HPV types followed by an HPV type-specific polymerase chain reaction (PCR) protocol towards the E7 gene from HPV 16. Using multiplex serology, serum samples were analysed for antibodies to 17 HPV types. Statistical analysis included the estimation of adjusted odds ratios (ORs) and the respective 95% confidence intervals (CIs).
   Results HPV16 E7 DNA prevalence among cases was 3.1% (6/196), including 4.4% in the oropharynx (3/68), 3.8% in the hypopharynx/larynx (3/78) and 0% among 50 cases of oral cavity carcinomas. Positivity for both HPV16 E6 and E7 antibodies was associated with a very high risk of oropharyngeal cancer (OR = 179, 95% CI 35.8-899) and hypopharyngeal/laryngeal cancer (OR = 14.9, 95% CI 2.92-76.1).
   Conclusions A very low prevalence of HPV DNA and serum antibodies was observed among cases in both CE and LA. The proportion of head and neck cancer caused by HPV may vary substantially between different geographical regions and studies that are designed to evaluate the impact of HPV vaccination on HNSCC need to consider this heterogeneity.
C1 [Ribeiro, Karina Braga; Curado, Maria Paula; Gheit, Tarik; Tommasino, Massimo; Boffetta, Paolo; Brennan, Paul] Int Agcy Res Canc, F-69008 Lyon, France.
   [Ribeiro, Karina Braga] Fac Ciencias Med Santa Casa Sao Paulo, Dept Social Med, Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Unit, Sao Paulo, Brazil.
   [Pawlita, Michael; Waterboer, Tim] German Canc Res Ctr, Infect & Canc Program, Heidelberg, Germany.
   [Koifman, Sergio] Fiocruz MS, Natl Sch Publ Hlth, BR-21045900 Rio De Janeiro, Brazil.
   [Matos, Elena] Univ Buenos Aires, Angel H Roffo Oncol Inst, Buenos Aires, DF, Argentina.
   [Eluf-Neto, Jose] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Wunsch-Filho, Victor] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Curado, Maria Paula] Associacao Combate Ao Canc Goias, Goiania, Go, Brazil.
   [Shangina, Oxana; Zaridze, David] NN Blokhin Canc Res Ctr, Dept Epidemiol & Prevent, Moscow, Russia.
   [Szeszenia-Dabrowska, Neonila] Inst Occupat Med, Lodz, Poland.
   [Lissowska, Jolanta] Ctr Canc, Dept Epidemiol & Canc Prevent, Warsaw, Poland.
   [Lissowska, Jolanta] M Sklodowska Curie Inst Oncol, Warsaw, Poland.
   [Daudt, Alexander] Hosp Clin Porto, Oncol Unit, Porto Alegre, RS, Brazil.
   [Menezes, Ana] Univ Fed Pelotas, Sch Med, Dept Internal Med, Pelotas, Brazil.
   [Bencko, Vladimir] Charles Univ Prague, Gen Univ Hosp, Prague, Czech Republic.
   [Bencko, Vladimir] Charles Univ Prague, Fac Med 1, Inst Hyg & Epidemiol, Prague, Czech Republic.
   [Mates, Dana] Inst Hyg Publ Hlth Hlth Serv & Management, Bucharest, Romania.
   [Fernandez, Leticia] Inst Nacl Oncol & Radiobiol, Havana, Cuba.
   [Fabianova, Eleonora] Specialized Inst Hyg & Epidemiol, Banska Bystrica, Slovakia.
   [Boffetta, Paolo] Int Prevent Res Inst, F-69006 Lyon, France.
   [Boffetta, Paolo] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY 10029 USA.
RP Brennan, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.
EM brennan@iarc.fr
RI Curado, Maria Paula/M-6200-2013; Waterboer, Tim/G-1252-2010;
   Szeszenia-Dabrowska, Neonila/F-7190-2010; Filho, Victor
   Wunsch/C-4475-2012; de Cassia Braga Ribeiro, Karina/F-1626-2010;
   Zaridze, David/K-5605-2013; Pawlita, Labor/C-9720-2011; Lissowska,
   Jolanta/AAH-3252-2020; Bencko, Vladimir/H-8598-2017; Eluf-Neto,
   Jose/B-2522-2009; Menezes, Ana MB/G-7266-2012
OI Curado, Maria Paula/0000-0001-8172-2483; de Cassia Braga Ribeiro,
   Karina/0000-0002-8095-5979; Lissowska, Jolanta/0000-0003-2695-5799;
   Bencko, Vladimir/0000-0003-1935-2228; Eluf-Neto,
   Jose/0000-0001-7504-2115; mates, dana/0000-0002-6219-9807; Pawlita,
   Michael/0000-0002-4720-8306
FU International Agency for Research on Cancer; INCO Copernicus program
   [ERBIC15-CT96-0313, IC18-CT97-0222]; Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2001/01768-2]
FX Karina Braga Ribeiro was supported by a Fellowship from the
   International Agency for Research on Cancer. These studies were
   supported by grants from the INCO Copernicus program (contract
   ERBIC15-CT96-0313 (central Europe) and contract IC18-CT97-0222 (Latin
   America)) and the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) (contract 2001/01768-2).
CR ABURAD ATT, 2006, THESIS U SAO PAULO
   Andl T, 1998, CANCER RES, V58, P5
   Annertz K, 2002, INT J CANCER, V101, P95, DOI 10.1002/ijc.10577
   Applebaum KM, 2007, JNCI-J NATL CANCER I, V99, P1801, DOI 10.1093/jnci/djm233
   BERNARD HU, 1994, J INFECT DIS, V170, P1077, DOI 10.1093/infdis/170.5.1077
   Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8
   Chaturvedi AK, 2008, J CLIN ONCOL, V26, P612, DOI 10.1200/JCO.2007.14.1713
   Clifford GM, 2007, CANCER EPIDEM BIOMAR, V16, P1874, DOI 10.1158/1055-9965.EPI-07-0349
   Coutlee F, 2002, J CLIN MICROBIOL, V40, P902, DOI 10.1128/JCM.40.3.902-907.2002
   Curado MP, 2009, CURR OPIN ONCOL, V21, P194, DOI 10.1097/CCO.0b013e32832a68ca
   D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497
   D'Souza G, 2009, J INFECT DIS, V199, P1263, DOI 10.1086/597755
   Dahlstrom KR, 2003, CLIN CANCER RES, V9, P2620
   Dillner J, 1999, SEMIN CANCER BIOL, V9, P423, DOI 10.1006/scbi.1999.0146
   FERLAY J, 2004, GLOBOCAN 2002
   Furniss CS, 2007, INT J CANCER, V120, P2386, DOI 10.1002/ijc.22633
   Gillison ML, 2008, CANCER-AM CANCER SOC, V113, P3036, DOI 10.1002/cncr.23764
   Gillison ML, 2008, JNCI-J NATL CANCER I, V100, P407, DOI 10.1093/jnci/djn025
   Gillison ML, 2004, SEMIN ONCOL, V31, P744, DOI 10.1053/j.seminoncol.2004.09.011
   Gillison ML, 2001, CURR OPIN ONCOL, V13, P183, DOI 10.1097/00001622-200105000-00009
   Golas SM, 2007, COMMUNITY DENT ORAL, V35, P98, DOI 10.1111/j.1600-0528.2007.00299.x
   Guha N, 2007, AM J EPIDEMIOL, V166, P1159, DOI 10.1093/aje/kwm193
   Habeck M, 2000, MOL MED TODAY, V6, P297, DOI 10.1016/S1357-4310(00)01752-4
   Herrero R, 2003, JNCI-J NATL CANCER I, V95, P1772, DOI [10.1093/jnci/djg107, 10.1093/jnci/djg/107]
   Hobbs CGL, 2006, CLIN OTOLARYNGOL, V31, P259, DOI 10.1111/j.1749-4486.2006.01246.x
   Huang SX, 1997, INT J CANCER, V70, P408, DOI 10.1002/(SICI)1097-0215(19970207)70:4&lt;408::AID-IJC6&gt;3.0.CO;2-#
   Kolker JL, 2007, COMMUNITY DENT ORAL, V35, P489, DOI 10.1111/j.1600-0528.2007.00371.x
   Kreimer AR, 2005, INT J CANCER, V115, P329, DOI 10.1002/ijc.20872
   Kreimer AR, 2005, CANCER EPIDEM BIOMAR, V14, P467, DOI 10.1158/1055-9965.EPI-04-0551
   LEVI JE, 1989, AM J PATHOL, V135, P1179
   Meschede W, 1998, J CLIN MICROBIOL, V36, P475, DOI 10.1128/JCM.36.2.475-480.1998
   Michael KM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000091
   Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5
   Pintos J, 2008, ORAL ONCOL, V44, P242, DOI 10.1016/j.oraloncology.2007.02.005
   Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619
   Rivero Elena Riet Correa, 2006, Braz. oral res., V20, P21, DOI 10.1590/S1806-83242006000100005
   Schwartz SM, 1998, JNCI-J NATL CANCER I, V90, P1626, DOI 10.1093/jnci/90.21.1626
   Sehr P, 2002, J VIROL METHODS, V106, P61, DOI 10.1016/S0166-0934(02)00134-9
   Sehr P, 2001, J IMMUNOL METHODS, V253, P153, DOI 10.1016/S0022-1759(01)00376-3
   Shiboski CH, 2005, CANCER-AM CANCER SOC, V103, P1843, DOI 10.1002/cncr.20998
   Smith EM, 2008, CANCER EPIDEM BIOMAR, V17, P2087, DOI 10.1158/1055-9965.EPI-08-0054
   Smith EM, 2007, INT J CANCER, V120, P825, DOI 10.1002/ijc.22330
   Smith EM, 1998, LARYNGOSCOPE, V108, P1098, DOI 10.1097/00005537-199807000-00027
   Smith EM, 2000, ANN OTO RHINOL LARYN, V109, P1069, DOI 10.1177/000348940010901114
   Smith EM, 2004, INT J CANCER, V108, P766, DOI 10.1002/ijc.11633
   SNIJDERS PJF, 1994, J GEN VIROL, V75, P2769, DOI 10.1099/0022-1317-75-10-2769
   Snijders PJF, 1997, CLIN DERMATOL, V15, P415, DOI 10.1016/S0738-081X(96)00156-3
   Snijders PJF, 1996, INT J CANCER, V66, P464, DOI 10.1002/(SICI)1097-0215(19960516)66:4<464::AID-IJC9>3.0.CO;2-U
   Stanley M, 2003, AM J OBSTET GYNECOL, V188, P3, DOI 10.1067/mob.2003.97
   Szymanska K, 2010, CARCINOGENESIS, V31, P1054, DOI 10.1093/carcin/bgp212
   Tachezy R, 2009, J MED VIROL, V81, P878, DOI 10.1002/jmv.21470
   Torrente MC, 2007, ACTA OTO-LARYNGOL, V127, P900, DOI 10.1080/00016480601110238
   van Houten VMM, 2001, INT J CANCER, V93, P232, DOI 10.1002/ijc.1313
   Villa LL, 2005, LANCET ONCOL, V6, P271, DOI 10.1016/S1470-2045(05)70101-7
   Waterboer T, 2006, J IMMUNOL METHODS, V309, P200, DOI 10.1016/j.jim.2005.11.008
   Waterboer T, 2005, CLIN CHEM, V51, P1845, DOI 10.1373/clinchem.2005.052381
   WHO/ICO Information Centre on HPV and Cervical Cancer, 2007, Vaccine, V25 Suppl 3, pC1
   Wiest T, 2002, ONCOGENE, V21, P1510, DOI 10.1038/sj.onc.1205214
   Zumbach K, 2000, INT J CANCER, V85, P815, DOI 10.1002/(SICI)1097-0215(20000315)85:6&lt;815::AID-IJC14&gt;3.0.CO;2-X
   Zumbach K, 2000, INT J CANCER, V85, P313, DOI 10.1002/(SICI)1097-0215(20000201)85:3&lt;313::AID-IJC3&gt;3.0.CO;2-W
NR 60
TC 117
Z9 122
U1 1
U2 31
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD APR
PY 2011
VL 40
IS 2
BP 489
EP 502
DI 10.1093/ije/dyq249
PG 14
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 745LB
UT WOS:000289165800030
PM 21224273
OA Bronze
DA 2020-11-30
ER

PT J
AU Campos, AF
   Tengan, FM
   Silva, SAA
   Levi, JE
AF Campos, A. F.
   Tengan, F. M.
   Silva, S. A. A.
   Levi, J. E.
TI Influence of hepatitis G virus (GB virus C) on the prognosis of
   HIV-infected women
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE GB virus C; prevalence; HIV; co-infection; antiretroviral therapy (ART);
   hepatitis
ID C/HEPATITIS-G VIRUS; A-E HEPATITIS; DISEASE; PROGRESSION; COINFECTION;
   PREVALENCE; SURVIVAL; SEQUENCE; BRAZIL; AGENT
AB This study was undertaken to evaluate the prevalence of GB virus C (GBV-C) viraemia and anti-E2 antibody, and to assess the effect of co-infection with GBV-C and HIV during a 10-year follow-up of a cohort of 248 HIV-infected women. Laboratory variables (mean and median CD4 counts, and HIV and GBV-C viral loads) and clinical parameters were investigated. At baseline, 115 women had past exposure to GBV-C: 57 (23%) were GBV-C RNA positive and 58 (23%) were anti-E2 positive. There was no statistical difference between the groups (GBV-C RNA + /anti-E2 -, GBV-C RNA - /anti-E2 + and GBV-C RNA - /anti-E2 -) regarding baseline CD4 counts or HIV viral loads (P = 0.360 and 0.713, respectively). Relative risk of death for the GBV-C RNA + /anti-E2 - group was 63% lower than that for the GBV-C RNA - /anti-E2 - group. Multivariate analysis demonstrated that only HIV loads >= 100,000 copies/mL and AIDS-defining illness during follow-up were associated with shorter survival after AIDS development. It is likely that antiretroviral therapy (ART) use in our cohort blurred a putative protective effect related to the presence of GBV-C RNA.
C1 [Campos, A. F.; Tengan, F. M.] Univ Sao Paulo, Dept Infect Dis, Sch Med, BR-05403000 Sao Paulo, Brazil.
   [Silva, S. A. A.; Levi, J. E.] Univ Sao Paulo, Inst Trop Med, Virol Lab, BR-05403000 Sao Paulo, Brazil.
RP Campos, AF (corresponding author), Univ Sao Paulo, Dept Infect Dis, Sch Med, Rua Dr Eneas de Carvalho Aguiar 470 20 Andar, BR-05403000 Sao Paulo, Brazil.
EM aleia@usp.br
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [05/01072-9]
FX This study was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP), Grant number 05/01072-9.
CR Alter MJ, 1997, NEW ENGL J MED, V336, P741, DOI 10.1056/NEJM199703133361101
   Andonov A, 1998, J CLIN MICROBIOL, V36, P286, DOI 10.1128/JCM.36.1.286-289.1998
   DEINHARDT F, 1967, J EXP MED, V125, P673, DOI 10.1084/jem.125.4.673
   GIRET MTM, 2009, AIDS, V23, P1
   Heringlake S, 1998, J INFECT DIS, V177, P1723, DOI 10.1086/517431
   Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A
   Lefrere JJ, 1999, J INFECT DIS, V179, P783, DOI 10.1086/314671
   Levi José E., 2002, Braz J Infect Dis, V6, P129, DOI 10.1590/S1413-86702002000300005
   Levi José Eduardo, 2003, Rev. Inst. Med. trop. S. Paulo, V45, P75, DOI 10.1590/S0036-46652003000200004
   Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
   Linnen JM, 1997, J VIRAL HEPATITIS, V4, P293, DOI 10.1046/j.1365-2893.1997.00064.x
   *MIN SAUD, 2008, B EP
   Mohr EL, 2009, J VIRAL HEPATITIS, V16, P757, DOI 10.1111/j.1365-2893.2009.01194.x
   Nunnari G, 2003, ANN INTERN MED, V139, P26, DOI 10.7326/0003-4819-139-1-200307010-00009
   Oliveira LA, 2002, MEM I OSWALDO CRUZ, V97, P953, DOI 10.1590/S0074-02762002000700005
   Polgreen PM, 2003, MICROBES INFECT, V5, P1255, DOI 10.1016/j.micinf.2003.08.006
   Ribeiro-dos-Santos G, 2002, EUR J CLIN MICROBIOL, V21, P438, DOI 10.1007/s10096-002-0752-y
   Sabin CA, 1998, J ACQ IMMUN DEF SYND, V19, P546, DOI 10.1097/00042560-199812150-00016
   SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401
   Souza IE, 2006, HIV MED, V7, P25, DOI 10.1111/j.1468-1293.2005.00339.x
   Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398
   Toyoda H, 1998, J ACQ IMMUN DEF SYND, V17, P209, DOI 10.1097/00042560-199803010-00004
   Tucker TJ, 2000, J MED VIROL, V61, P52, DOI 10.1002/(SICI)1096-9071(200005)61:1&lt;52::AID-JMV8&gt;3.0.CO;2-L
   Williams CF, 2004, NEW ENGL J MED, V350, P981, DOI 10.1056/NEJMoa030107
NR 24
TC 5
Z9 5
U1 0
U2 2
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND
SN 0956-4624
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD APR
PY 2011
VL 22
IS 4
BP 209
EP 213
DI 10.1258/ijsa.2011.010283
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 773FK
UT WOS:000291292200007
PM 21515753
DA 2020-11-30
ER

PT J
AU de Andrade, ACV
   Luz, PM
   Velasque, L
   Veloso, VG
   Moreira, RI
   Russomano, F
   Chicarino-Coelho, J
   Pires, E
   Levi, JE
   Grinsztejn, B
   Friedman, RK
AF Vasconcelos de Andrade, Angela Cristina
   Luz, Paula Mendes
   Velasque, Luciane
   Veloso, Valdilea Goncalves
   Moreira, Ronaldo I.
   Russomano, Fabio
   Chicarino-Coelho, Janice
   Pires, Elaine
   Levi, Jose Eduardo
   Grinsztejn, Beatriz
   Friedman, Ruth Khalili
TI Factors Associated with Colposcopy-Histopathology Confirmed Cervical
   Intraepithelial Neoplasia among HIV-Infected Women from Rio De Janeiro,
   Brazil
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY;
   HUMAN-PAPILLOMAVIRUS; CANCER-RISK; AIDS; PREVALENCE; TERMINOLOGY;
   PREDICTORS; MANAGEMENT; PEOPLE
AB Introduction: Despite the availability of preventive strategies (screening tests and vaccines), cervical cancer continues to impose a significant health burden in low- and medium-resourced countries. HIV-infected women are at increased risk for infection with human papillomavirus (HPV) and thus development of cervical squamous intraepithelial neoplasia (CIN).
   Methods: Study participants included HIV-infected women enrolling the prospective open cohort of Evandro Chagas Clinical Research Institute, Oswaldo Cruz Foundation (IPEC/FIOCRUZ). At cohort entry, women were subjected to conventional Papanicolaou test, HPV-DNA test and colposcopy; lesions suspicious for CIN were biopsied. Histopathology report was based on directed biopsy or on specimens obtained by excision of the transformation zone or cervical conization. Poisson regression modeling was used to assess factors associated with CIN2+ diagnosis.
   Results: The median age of the 366 HIV-infected women included in the study was 34 years (interquartile range: 28-41 years). The prevalence of CIN1, CIN2 and CIN3 were 20.0%, 3.5%, and 2.2%, respectively. One woman was found to have cervical cancer. The prevalence of CIN2+ was 6.0%. Factors associated with CIN2+ diagnosis in the multivariate model were age < years compared to >= 35 years (aPR = 3.22 95% CI 1.23-8.39), current tobacco use (aPR = 3.69 95% CI 1.54-8.78), nadir CD4 T-cell count < 350 cells/mm3 when compared to >= 350 cells/mm3 (aPR = 6.03 95% CI 1.50-24.3) and concomitant diagnosis of vulvar and/or vaginal intraepithelial lesion (aPR = 2.68 95% CI 0.99-7.24).
   Discussion: Increased survival through wide-spread use of highly active antiretroviral therapy might allow for the development of cervical cancer. In Brazil, limited cytology screening and gynecological care adds further complexity to the HIV-HPV co-infection problem. Integrated HIV care and cervical cancer prevention programs are needed for the prevention of cervical cancer mortality in this group of women.
C1 [Vasconcelos de Andrade, Angela Cristina; Luz, Paula Mendes; Velasque, Luciane; Veloso, Valdilea Goncalves; Moreira, Ronaldo I.; Chicarino-Coelho, Janice; Pires, Elaine; Grinsztejn, Beatriz; Friedman, Ruth Khalili] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
   [Velasque, Luciane] Univ Fed Estado Rio de Janeiro, Dept Matemat & Estat, Rio De Janeiro, Brazil.
   [Russomano, Fabio] Fundacao Oswaldo Cruz, Inst Fernandes Figueira, Rio De Janeiro, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
RP de Andrade, ACV (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
EM gbeatriz@ipec.fiocruz.br
RI Veloso, Valdilea Goncalves/J-6189-2012
OI Luz, Paula/0000-0001-9746-719X
CR Anastos K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013525
   Arrossi S, 2003, SALUD PUBLICA MEXICO, V45, pS306
   Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
   Behrens T, 2004, METHOD INFORM MED, V43, P505
   Bollen LJM, 2006, SEX TRANSM DIS, V33, P259
   Brasil. Ministerio da Saude (MS). Secretaria de Vigilancia em Saude. Programa Nacional de DST/Aids, 2006, MAN CONTR DOENC SEX
   Campos DP, 2005, AIDS, V19, pS22, DOI 10.1097/01.aids.0000191486.92285.1c
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   Conley LJ, 2002, LANCET, V359, P108, DOI 10.1016/S0140-6736(02)07368-3
   Dexeus S, 2002, EUR J GYNAECOL ONCOL, V23, P269
   Engels EA, 2006, AIDS, V20, P1645, DOI 10.1097/01.aids.0000238411.75324.59
   Franceschi S, 2003, JAIDS-J ACQ IMM DEF, V34, P84, DOI 10.1097/00126334-200309010-00013
   Franceschi S, 2007, CLIN INFECT DIS, V45, P510, DOI 10.1086/520022
   Heard I, 2002, AIDS, V16, P1799, DOI 10.1097/00002030-200209060-00013
   *INCA, 2009, EST 2010 INC CANC BR
   INCA, 2006, NOM BRAS LAUD CERV C
   Jamieson DJ, 2006, OBSTET GYNECOL, V107, P1023, DOI 10.1097/01.AOG.0000210237.80211.ff
   Massad LS, 1999, J ACQ IMMUN DEF SYND, V21, P33, DOI 10.1097/00126334-199905010-00005
   Massad LS, 2004, AM J OBSTET GYNECOL, V190, P1241, DOI 10.1016/j.ajog.2003.12.037
   Orem J, 2004, CURR OPIN ONCOL, V16, P468, DOI 10.1097/00001622-200409000-00010
   Palefsky JM, 2003, CURR OPIN ONCOL, V15, P382, DOI 10.1097/00001622-200309000-00007
   Parham GP, 2006, GYNECOL ONCOL, V103, P1017, DOI 10.1016/j.ygyno.2006.06.015
   Petersen MR, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-9
   PRENDIVILLE W, 1989, BRIT J OBSTET GYNAEC, V96, P1054, DOI 10.1111/j.1471-0528.1989.tb03380.x
   RICHART RM, 1990, OBSTET GYNECOL, V75, P131
   Sahasrabuddhe VV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008634
   Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(07)61416-0
   Solomon D, 2001, J NATL CANCER I, V93, P293, DOI 10.1093/jnci/93.4.293
   Strickler HD, 2005, J NATL CANCER I, V97, P577, DOI 10.1093/jnci/dji073
   UNAIDS, 2010, AIDS EP UPD 2009
   Walker P, 2003, OBSTET GYNECOL, V101, P175, DOI 10.1016/S0029-7844(02)02581-4
   Yang BH, 2004, INT J CANCER, V109, P418, DOI 10.1002/ijc.11719
   Zimmermmann JB, 2006, REV BRAS GINECOL OBS, V28, P345, DOI 10.1590/S0100-72032006000600005
NR 33
TC 15
Z9 15
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 30
PY 2011
VL 6
IS 3
AR e18297
DI 10.1371/journal.pone.0018297
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 743YK
UT WOS:000289055700045
PM 21479179
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Freitas, RS
   Dantas, KC
   Pereira, CN
   Levi, JE
   Martins, JEC
AF Freitas, Roseli Santos
   Dantas, Katia Cristina
   Pereira, Cristiane Neves
   Levi, Jose Eduardo
   Costa Martins, Jose Eduardo
TI Preservation methods of fungi in 35 years old stock culture storages: A
   comparative study
SO AFRICAN JOURNAL OF MICROBIOLOGY RESEARCH
LA English
DT Article
DE Polymorphism; genotypic characteristics; lyophilization; random
   amplified polymorphism DNA
ID UNITED-STATES; LONG PERIODS; MORTALITY; STRAINS; TRENDS
AB The maintenance of fungi isolates and the development of methodologies were available from their phenotypic and genotypic characteristics. Alterations of Histoplasma capsulatum and Candida spp. Strains preserved by continuous subculturing on fungal collection and by lyophilization for 35 years were evaluated. Candida isolates maintained by lyophilized methodology were viable and preserved by the typical characteristics of each species. Only one lyophilized isolate from H. capsulatum was viable and demonstrated typical morphology. Both genus, which were preserved by continuous subculturing, revealed morphologic alterations and lost their sporulation capacity. The DNA from these isolates was sequenced (conserved 28S rDNA) in order to confirm their identity. Random amplified polymorphism DNA (RAPD)-based comparative analysis of the two preservation methods revealed alterations in the band profiles in 28 and 33% in Candida spp. and Histoplasma capsulatum strains respectively. The RAPD-based results confirm that the subculturing method alters phenotypic and genotypic characteristics by deleting or inserting nucleotides. Otherwise, the lyophilization was effective to yeasts, but it was not effective for dimorphic fungi.
C1 [Freitas, Roseli Santos; Dantas, Katia Cristina; Pereira, Cristiane Neves; Costa Martins, Jose Eduardo] Inst Med Trop Sao Paulo, Lab Micol Med, Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Inst Med Trop Sao Paulo, Virol Lab, Sao Paulo, Brazil.
RP Freitas, RS (corresponding author), Inst Med Trop Sao Paulo, Lab Micol Med, Sao Paulo, Brazil.
EM roselsf32@yahoo.com
RI Freitas, Roseli/F-5952-2013
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [02/12903-00]
FX We would like to thank FAPESP (Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo) for the financial support (process no 02/12903-00). We are
   also grateful to Assistant Professor Dra. Maria Helena Matte
   (Departamento de Microbiologia da Faculdade de Saude Publica da
   Universidade de Sao Paulo) for her assistance in the dendrograms
   analyses.
CR American Type Culture Collection, 1991, PRES METH FREEZ FREE
   Armstrong GL, 1999, JAMA-J AM MED ASSOC, V281, P61, DOI 10.1001/jama.281.1.61
   Beattie GM, 1997, DIABETES, V46, P519, DOI 10.2337/diabetes.46.3.519
   Binelli CA, 2006, CLIN MICROBIOL INFEC, V12, P538, DOI 10.1111/j.1469-0691.2006.01435.x
   Borba CD, 2008, MEM I OSWALDO CRUZ, V103, P306, DOI 10.1590/S0074-02762008005000013
   Cavalcante SC, 2007, MEM I OSWALDO CRUZ, V102, P41, DOI 10.1590/S0074-02762007000100006
   Cavalcanti MS, 1994, B MICOLOGICO, V9, P19
   DASILVA AMM, 1994, MYCOSES, V37, P165, DOI 10.1111/j.1439-0507.1994.tb00295.x
   De Hoog GS, 2000, ATLAS CLIN FUNGI, P180
   de Moraes-Borba C, 2000, Rev Iberoam Micol, V17, P142
   Dobzhansky T, 1973, GENETIC DIVERSITY HU, P20
   Ferreti de Lima Renata, 2001, Revista Iberoamericana de Micologia, V18, P191
   Franzot SP, 1998, INFECT IMMUN, V66, P89, DOI 10.1128/IAI.66.1.89-97.1998
   Kauffman CA, 2007, CLIN MICROBIOL REV, V20, P115, DOI 10.1128/CMR.00027-06
   KERSULYTE D, 1992, J BACTERIOL, V174, P7075, DOI 10.1128/jb.174.22.7075-7079.1992
   Kwon-Chung KJ, 1992, MED MYCOL, P143
   Lacaz C. S., 2002, TRATADO MICOLOGIA ME, P416
   Leung WK, 2000, J CLIN MICROBIOL, V38, P2219
   McNeil MM, 2001, CLIN INFECT DIS, V33, P641, DOI 10.1086/322606
   Nobre Vandack, 2003, Rev. Inst. Med. trop. S. Paulo, V45, P69, DOI 10.1590/S0036-46652003000200003
   Pfaller MA, 2007, CLIN MICROBIOL REV, V20, P133, DOI 10.1128/CMR.00029-06
   Rees JR, 1998, CLIN INFECT DIS, V27, P1138, DOI 10.1093/clinids/27.5.1138
   SANDHU GS, 1995, J CLIN MICROBIOL, V33, P2913, DOI 10.1128/JCM.33.11.2913-2919.1995
   Wheat LJ, 2003, INFECT DIS CLIN N AM, V17, P1, DOI 10.1016/S0891-5520(02)00039-9
   WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531
NR 25
TC 1
Z9 2
U1 0
U2 2
PU ACADEMIC JOURNALS
PI VICTORIA ISLAND
PA P O BOX 5170-00200 NAIROBI, VICTORIA ISLAND, LAGOS 73023, NIGERIA
SN 1996-0808
J9 AFR J MICROBIOL RES
JI Afr. J. Microbiol. Res.
PD MAR 4
PY 2011
VL 5
IS 5
BP 555
EP 561
PG 7
WC Microbiology
SC Microbiology
GA 804ZJ
UT WOS:000293694900015
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Schijman, AG
   Bisio, M
   Orellana, L
   Sued, M
   Duffy, T
   Jaramillo, AMM
   Cura, C
   Auter, F
   Veron, V
   Qvarnstrom, Y
   Deborggraeve, S
   Hijar, G
   Zulantay, I
   Lucero, RH
   Velazquez, E
   Tellez, T
   Leon, ZS
   Galvao, L
   Nolder, D
   Rumi, MM
   Levi, JE
   Ramirez, JD
   Zorrilla, P
   Flores, M
   Jercic, MI
   Crisante, G
   Anez, N
   Castro, AM
   Gonzalez, CI
   Viana, KA
   Yachelini, P
   Torrico, F
   Robello, C
   Diosque, P
   Chavez, OT
   Aznar, C
   Russomando, G
   Buscher, P
   Assal, A
   Guhl, F
   Estani, SS
   DaSilva, A
   Britto, C
   Luquetti, A
   Ladzins, J
AF Schijman, Alejandro G.
   Bisio, Margarita
   Orellana, Liliana
   Sued, Mariela
   Duffy, Tomas
   Mejia Jaramillo, Ana M.
   Cura, Carolina
   Auter, Frederic
   Veron, Vincent
   Qvarnstrom, Yvonne
   Deborggraeve, Stijn
   Hijar, Gisely
   Zulantay, Ines
   Horacio Lucero, Raul
   Velazquez, Elsa
   Tellez, Tatiana
   Sanchez Leon, Zunilda
   Galvao, Lucia
   Nolder, Debbie
   Monje Rumi, Maria
   Levi, Jose E.
   Ramirez, Juan D.
   Zorrilla, Pilar
   Flores, Maria
   Jercic, Maria I.
   Crisante, Gladys
   Anez, Nestor
   De Castro, Ana M.
   Gonzalez, Clara I.
   Viana, Karla Acosta
   Yachelini, Pedro
   Torrico, Faustino
   Robello, Carlos
   Diosque, Patricio
   Triana Chavez, Omar
   Aznar, Christine
   Russomando, Graciela
   Buscher, Philippe
   Assal, Azzedine
   Guhl, Felipe
   Sosa Estani, Sergio
   DaSilva, Alexandre
   Britto, Constanca
   Luquetti, Alejandro
   Ladzins, Janis
TI International Study to Evaluate PCR Methods for Detection of Trypanosoma
   cruzi DNA in Blood Samples from Chagas Disease Patients
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; KINETOPLAST MINICIRCLE DNA; FOLLOW-UP;
   REACTION AMPLIFICATION; HEART-TRANSPLANTATION; SATELLITE DNA; DIAGNOSIS;
   IDENTIFICATION; XENODIAGNOSIS; ASSAYS
AB Background: A century after its discovery, Chagas disease still represents a major neglected tropical threat. Accurate diagnostics tools as well as surrogate markers of parasitological response to treatment are research priorities in the field. The purpose of this study was to evaluate the performance of PCR methods in detection of Trypanosoma cruzi DNA by an external quality evaluation.
   Methodology/Findings: An international collaborative study was launched by expert PCR laboratories from 16 countries. Currently used strategies were challenged against serial dilutions of purified DNA from stocks representing T. cruzi discrete typing units (DTU) I, IV and VI (set A), human blood spiked with parasite cells (set B) and Guanidine Hidrochloride-EDTA blood samples from 32 seropositive and 10 seronegative patients from Southern Cone countries (set C). Forty eight PCR tests were reported for set A and 44 for sets B and C; 28 targeted minicircle DNA (kDNA), 13 satellite DNA (Sat-DNA) and the remainder low copy number sequences. In set A, commercial master mixes and Sat-DNA Real Time PCR showed better specificity, but kDNA-PCR was more sensitive to detect DTU I DNA. In set B, commercial DNA extraction kits presented better specificity than solvent extraction protocols. Sat-DNA PCR tests had higher specificity, with sensitivities of 0.05-0.5 parasites/mL whereas specific kDNA tests detected 5.10(-3) par/mL. Sixteen specific and coherent methods had a Good Performance in both sets A and B (10 fg/mu l of DNA from all stocks, 5 par/mL spiked blood). The median values of sensitivities, specificities and accuracies obtained in testing the Set C samples with the 16 tests determined to be good performing by analyzing Sets A and B samples varied considerably. Out of them, four methods depicted the best performing parameters in all three sets of samples, detecting at least 10 fg/mu l for each DNA stock, 0.5 par/mL and a sensitivity between 83.3-94.4%, specificity of 85-95%, accuracy of 86.8-89.5% and kappa index of 0.7-0.8 compared to consensus PCR reports of the 16 good performing tests and 63-69%, 100%, 71.4-76.2% and 0.4-0.5, respectively compared to serodiagnosis. Method LbD2 used solvent extraction followed by Sybr-Green based Real time PCR targeted to Sat-DNA; method LbD3 used solvent DNA extraction followed by conventional PCR targeted to Sat-DNA. The third method (LbF1) used glass fiber column based DNA extraction followed by TaqMan Real Time PCR targeted to Sat-DNA (cruzi 1/cruzi 2 and cruzi 3 TaqMan probe) and the fourth method (LbQ) used solvent DNA extraction followed by conventional hot-start PCR targeted to kDNA (primer pairs 121/122). These four methods were further evaluated at the coordinating laboratory in a subset of human blood samples, confirming the performance obtained by the participating laboratories.
   Conclusion/Significance: This study represents a first crucial step towards international validation of PCR procedures for detection of T. cruzi in human blood samples.
C1 [Schijman, Alejandro G.; Bisio, Margarita; Duffy, Tomas; Cura, Carolina] Inst Invest Ingn Genet & Biol Mol INGEBI CONICET, Lab Biol Mol Enfermedad Chagas LabMECH, Buenos Aires, DF, Argentina.
   [Orellana, Liliana; Sued, Mariela] Univ Buenos Aires, Inst Calculo, Buenos Aires, DF, Argentina.
   [Mejia Jaramillo, Ana M.; Triana Chavez, Omar] Univ Antioquia, Grp Chagas, Medellin, Colombia.
   [Auter, Frederic; Assal, Azzedine] French Blood Serv, Paris, France.
   [Veron, Vincent; Aznar, Christine] Univ Parasitol, Lab Hosp, Cayene, French Guiana.
   [Qvarnstrom, Yvonne] Ctr Dis Control, Dept Parasit Dis, Atlanta, GA 30333 USA.
   [Deborggraeve, Stijn; Buscher, Philippe] Inst Trop Med, Antwerp, Belgium.
   [Hijar, Gisely] Inst Nacl Salud, Lima, Peru.
   [Horacio Lucero, Raul] Univ Nacl Nordeste, Chaco, Argentina.
   [Velazquez, Elsa] Inst Nacl Chagas, Buenos Aires, DF, Argentina.
   [Tellez, Tatiana; Torrico, Faustino] Univ Mayor San Simon, Ctr Univ Med Trop, Fac Med, Cochabamba, Bolivia.
   [Sanchez Leon, Zunilda; Russomando, Graciela] Univ Nacl Asuncion, Inst Invest Ciencias Salud, Asuncion, Paraguay.
   [Galvao, Lucia] Fac Farm, Natal, RN, Brazil.
   [Nolder, Debbie] Univ London London Sch Hyg & Trop Med, Hosp Trop Dis, Dept Clin Parasitol, London WC1E 7HT, England.
   [Monje Rumi, Maria] Univ Nacl Salta, Lab Patol Expt, Salta, Argentina.
   [Levi, Jose E.] Hosp Sirio Libanes, Blood Bank, Sao Paulo, Brazil.
   [Ramirez, Juan D.] Univ Los Andes, Ctr Invest Microbiol & Parasitol Trop, Bogota, Colombia.
   [Zorrilla, Pilar] Inst Pasteur, Montevideo, Uruguay.
   [Flores, Maria] Inst Salud Carlos III, Ctr Nacl Microbiol, Ctr Mahahonda, Madrid, Spain.
   [Jercic, Maria I.] Inst Nacl Salud, Secc Parasitol, Santiago, Chile.
   [Crisante, Gladys] Univ Los Andes, Ctr Invest Parasitol JF Torrealba, Merida, Venezuela.
   [De Castro, Ana M.] Univ Fed Goias, IPTSP, Goiania, Go, Brazil.
   [Gonzalez, Clara I.] Univ Ind Santander, Fac Salud, GIEM, Bucaramanga, Colombia.
   [Viana, Karla Acosta] Univ Autonoma Yucatan, Dept Biomed Enfermedades Infecciosas & Parasitari, Lab Biol Celular, Ctr Invest Reg CIR Dr Hideyo Noguchi, Yucatan, Mexico.
   [Yachelini, Pedro] Univ Catolica Santiago Estero, Inst Biomed, Santiago Del Estero, Argentina.
   [Sosa Estani, Sergio] CeNDIE ANLIS Dr Carlos G Malbran, Buenos Aires, DF, Argentina.
   [Britto, Constanca] Fiocruz MS, Inst Oswaldo Cruz, Lab Biol Mol & Doencas Endem, BR-21045900 Rio De Janeiro, Brazil.
   [Luquetti, Alejandro] Lab Pesquisa Doenca Chagas, Goiania, Go, Brazil.
   [Ladzins, Janis] WHO, Special Programme Res & Training Trop Dis TDR, CH-1211 Geneva, Switzerland.
RP Schijman, AG (corresponding author), Inst Invest Ingn Genet & Biol Mol INGEBI CONICET, Lab Biol Mol Enfermedad Chagas LabMECH, Buenos Aires, DF, Argentina.
EM schijman@dna.uba.ar
RI Viana, Karla Y. Acosta/AAF-2514-2020; Duffy, Tomas/S-6045-2017; ROBELLO,
   CARLOS/M-5609-2019; Ramirez, Juan David/F-3524-2016; FLORES-CHAVEZ,
   MARIA/M-5918-2015; Buscher, Philippe/B-9956-2012; ZULANTAY,
   INES/I-1042-2013; Orellana, Liliana/I-5249-2013; Britto,
   Constanca/L-7658-2016
OI Viana, Karla Y. Acosta/0000-0001-7311-0858; ROBELLO,
   CARLOS/0000-0001-6985-6171; Ramirez, Juan David/0000-0002-1344-9312;
   FLORES-CHAVEZ, MARIA/0000-0003-2597-3100; Buscher,
   Philippe/0000-0002-1926-7472; Deborggraeve, Stijn/0000-0003-1501-5355;
   Guhl, Felipe/0000-0001-7180-7125; Galvao, Lucia/0000-0002-6207-4502;
   ZULANTAY, INES/0000-0002-6426-0413; Orellana,
   Liliana/0000-0003-3736-4337; Mejia-jaramillo, Ana/0000-0003-2125-9858;
   Britto, Constanca/0000-0003-0788-7030
FU World Health Organization-Tropical Diseases Research, Panamerican Health
   Organization (WHO-TDR-PAHO); Universidad de las Naciones
   Unidas/Biotecnologia para America Latina y el Caribe (UNU-BIOLAC);
   Consejo Nacional de Ciencias y Tecnologia (CONICET)Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (CONICET) [PIP 112-200801-09215];
   National Agency of Science and Technology, Buenos Aires, Argentina [PICT
   33955]
FX Funding was provided by World Health Organization-Tropical Diseases
   Research, Panamerican Health Organization (WHO-TDR-PAHO), Universidad de
   las Naciones Unidas/Biotecnologia para America Latina y el Caribe
   (UNU-BIOLAC), Consejo Nacional de Ciencias y Tecnologia (CONICET) PIP
   112-200801-09215, National Agency of Science and Technology, PICT 33955,
   Buenos Aires, Argentina. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR de Noya BA, 2010, J INFECT DIS, V201, P1308, DOI 10.1086/651608
   AVILA HA, 1991, MOL BIOCHEM PARASIT, V48, P211, DOI 10.1016/0166-6851(91)90116-N
   AVILA HA, 1993, J CLIN MICROBIOL, V31, P2421, DOI 10.1128/JCM.31.9.2421-2426.1993
   Bisio M, 2009, REV BIOMED, V20, P166
   Brener Z., 1962, REV INST MED TROP SP, V4, P389
   Brisse S, 2001, INT J PARASITOL, V31, P1218, DOI 10.1016/S0020-7519(01)00238-7
   BRITTO C, 1995, PARASITOLOGY, V110, P241, DOI 10.1017/S0031182000080823
   BRITTO C, 1993, MEM I OSWALDO CRUZ, V88, P171, DOI 10.1590/S0074-02761993000100030
   Britto CC, 2009, MEM I OSWALDO CRUZ, V104, P122, DOI 10.1590/S0074-02762009000900018
   Burgos JM, 2007, INT J PARASITOL, V37, P1319, DOI 10.1016/j.ijpara.2007.04.015
   Burgos JM, 2010, CLIN INFECT DIS, V51, P485, DOI 10.1086/655680
   CARDINAL MV, 2008, INT J PARASITOL
   Carolina M, 2003, MOL BIOCHEM PARASIT, V129, P1, DOI 10.1016/S0166-6851(03)00054-9
   Castro AM, 2002, PARASITOL RES, V88, P894, DOI 10.1007/s00436-002-0679-3
   Chagas C., 1909, MEM I OSWALDO CRUZ, V1, P159, DOI DOI 10.1590/S0074-02761909000200008
   Claes F, 2007, J CLIN MICROBIOL, V45, P3785, DOI 10.1128/JCM.01244-07
   Coura JR, 2009, MEM I OSWALDO CRUZ, V104, P31, DOI 10.1590/S0074-02762009000900006
   Cura C, 2010, INT J PARASITOL, DOI 10 1016/jupari 2010 06 006
   Ramirez JD, 2009, J CLIN MICROBIOL, V47, P3945, DOI 10.1128/JCM.01601-09
   de Freitas Jorge M., 2006, PLoS Pathogens, V2, P226, DOI 10.1371/journal.ppat.0020024
   de Souza W., 2003, P13
   Deborggraeve S, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000450
   Diez M, 2007, AM J TRANSPLANT, V7, P1633, DOI 10.1111/j.1600-6143.2007.01820.x
   Duffy T, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000419
   EHRLICH GD, 1994, PCR BASED DIAGNOSTIC
   Galvao LMC, 2003, J CLIN MICROBIOL, V41, P5066, DOI 10.1128/JCM.41.11.5066-5070.2003
   Gomes YM, 2009, MEM I OSWALDO CRUZ, V104, P115, DOI 10.1590/S0074-02762009000900017
   Herrera C, 2007, INFECT GENET EVOL, V7, P535, DOI 10.1016/j.meegid.2006.12.003
   Hoorfar J, 2004, LETT APPL MICROBIOL, V38, P79, DOI 10.1046/j.1472-765X.2003.01456.x
   Ienne S, 2010, INFECT GENET EVOL, V10, P601, DOI 10.1016/j.meegid.2010.04.007
   Kirchhoff LV, 1996, J CLIN MICROBIOL, V34, P1171, DOI 10.1128/JCM.34.5.1171-1175.1996
   Lewis MD, 2009, AM J TROP MED HYG, V81, P1041, DOI 10.4269/ajtmh.2009.09-0305
   Lewis MD, 2009, INT J PARASITOL, V39, P1305, DOI 10.1016/j.ijpara.2009.04.001
   Malorny B, 2003, APPL ENVIRON MICROB, V69, P290, DOI 10.1128/AEM.69.1.290-296.2003
   Marcet PL, 2006, PARASITOLOGY, V132, P57, DOI 10.1017/S0031182005008772
   Miyamoto CT, 2008, EXP PARASITOL, V120, P45, DOI 10.1016/j.exppara.2008.04.018
   MOSER DR, 1989, J CLIN MICROBIOL, V27, P1477, DOI 10.1128/JCM.27.7.1477-1482.1989
   Piron M, 2007, ACTA TROP, V103, P195, DOI 10.1016/j.actatropica.2007.05.019
   Portela-Lindoso AAB, 2003, REV SAUDE PUBL, V37, P107, DOI 10.1590/S0034-89102003000100016
   Russomando G, 1998, AM J TROP MED HYG, V59, P487, DOI 10.4269/ajtmh.1998.59.487
   Sambrook J., 2001, MOL CLONING LAB MANU
   Schijman AG, 2003, J ANTIMICROB CHEMOTH, V52, P441, DOI 10.1093/jac/dkg338
   Solari A, 2001, J ANTIMICROB CHEMOTH, V48, P515, DOI 10.1093/jac/48.4.515
   STURM NR, 1989, MOL BIOCHEM PARASIT, V33, P205, DOI 10.1016/0166-6851(89)90082-0
   Taha MK, 2005, J CLIN MICROBIOL, V43, P144, DOI 10.1128/JCM.43.1.144-149.2005
   Telleria J, 2006, EXP PARASITOL, V114, P279, DOI 10.1016/j.exppara.2006.04.005
   Vargas N, 2004, MOL BIOCHEM PARASIT, V138, P131, DOI 10.1016/j.molbiopara.2004.08.005
   Virreira M, 2003, AM J TROP MED HYG, V68, P574, DOI 10.4269/ajtmh.2003.68.574
   Wincker P, 1997, PARASITOLOGY, V114, P367, DOI 10.1017/S0031182096008554
   World Health Organization, 2007, TDRGTC06 WHO
   Zingales B, 2009, MEM I OSWALDO CRUZ, V104, P1051, DOI 10.1590/S0074-02762009000700021
   Zulantay I, 2007, ANN TROP MED PARASIT, V101, P673, DOI 10.1179/136485907X241415
   Zulantay I, 2004, DIAGN MICR INFEC DIS, V48, P253, DOI 10.1016/j.diagmicrobio.2003.10.011
   2002, 22174 ISODIS
NR 54
TC 206
Z9 212
U1 1
U2 48
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD JAN
PY 2011
VL 5
IS 1
AR e931
DI 10.1371/journal.pntd.0000931
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 711MP
UT WOS:000286596000009
PM 21264349
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-11-30
ER

PT J
AU Araujo, AR
   Levi, JE
   de Almeida, CM
   de Lima, TA
   Maia, LPV
   Torres, KL
   Tarrago, AM
   Victoria, F
   Victoria, M
   Talhari, S
   Malheiro, A
AF Araujo, Ana Ruth
   Levi, Jose Eduardo
   de Almeida, Carlos Maurico
   de Lima, Tatiane Amabili
   Patricia Viana Maia, Laura
   Torres, Katia Luz
   Tarrago, Andrea Monteiro
   Victoria, Flamir
   Victoria, Marilu
   Talhari, Sinesio
   Malheiro, Adriana
TI Sustained virological response in patients with coinfection by hepatitis
   C virus genotypes 1 and 2, after just nine weeks of antiviral therapy:
   case report
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA Portuguese
DT Article
DE Hepatite C virus; Co-infection; SRV
ID INFECTION; RIBAVIRIN
AB A report of a 67 year-old male patient with positive serology for HCV. PCR revealed the presence of HCV RNA, viral load of 2,000 copies/mL and genotypes 1 and 2. The pacient was treated with peginterferon alfa-2a at 180mcg/week and ribavirin at 1,000mg/day. In week four of treatment, HCV viral load was undetectable. In week nine, the patient developed hematemesis, worsening of asthenia, anorexia and impaired general condition, so the treatment was discontinued. The PCR was negative six months and one year after the cessation of treatment. The patient remains asymptomatic.
C1 [Araujo, Ana Ruth; de Almeida, Carlos Maurico; de Lima, Tatiane Amabili; Victoria, Flamir; Victoria, Marilu; Talhari, Sinesio] Fundacao Med Trop Amazonas, Manaus, Amazonas, Brazil.
   [Araujo, Ana Ruth; Patricia Viana Maia, Laura; Malheiro, Adriana] Univ Fed Amazonas, Manaus, Amazonas, Brazil.
   [de Lima, Tatiane Amabili; Patricia Viana Maia, Laura; Torres, Katia Luz; Tarrago, Andrea Monteiro; Malheiro, Adriana] Fundacao Hematol & Hemoterapia Amazonas, Manaus, Amazonas, Brazil.
   [Levi, Jose Eduardo] Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
RP Malheiro, A (corresponding author), HEMOAM, Av Constantino Nery 4397, BR-69050002 Manaus, Amazonas, Brazil.
EM malheiroadriana@yahoo.com.br
CR Bowen DG, 2005, NATURE, V436, P946, DOI 10.1038/nature04079
   Gale M, 2005, NATURE, V436, P939, DOI 10.1038/nature04078
   HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9
   Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107
   Mangia A, 2005, NEW ENGL J MED, V352, P2609, DOI 10.1056/NEJMoa042608
   Pavio N, 2003, J BIOSCIENCES, V28, P287, DOI 10.1007/BF02970148
   Rumi MG, 2010, GASTROENTEROLOGY, V138, P108, DOI [10.1053/j.gastro.2009.08.071, 10.1053/j.gastro.2010.04.037]
   Strauss E, 2001, Rev Soc Bras Med Trop, V34, P69, DOI 10.1590/S0037-86822001000100011
   Torres KL, 2009, EMERG INFECT DIS, V15, P676, DOI 10.3201/eid1504.081288
NR 9
TC 1
Z9 1
U1 0
U2 3
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PD SEP-OCT
PY 2010
VL 43
IS 5
BP 605
EP 607
DI 10.1590/S0037-86822010000500030
PG 3
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 684XX
UT WOS:000284589700030
PM 21085882
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Romano, CM
   de Matos, AM
   Araujo, ESA
   Villas-Boas, LS
   da Silva, WC
   Oliveira, OMNPF
   Carvalho, KI
   de Souza, ACM
   Rodrigues, CL
   Levi, JE
   Kallas, EG
   Pannuti, CS
AF Romano, Camila Malta
   de Matos, Andreia Manso
   Araujo, Evaldo Stanislau A.
   Villas-Boas, Lucy Santos
   da Silva, Wanessa Cardoso
   Oliveira, Olimpia M. N. P. F.
   Carvalho, Karina I.
   Mamana de Souza, Ana Carolina
   Rodrigues, Celia L.
   Levi, Jose Eduardo
   Kallas, Esper G.
   Pannuti, Claudio Sergio
TI Characterization of Dengue Virus Type 2: New Insights on the 2010
   Brazilian Epidemic
SO PLOS ONE
LA English
DT Article
ID HEMORRHAGIC-FEVER; SEROTYPES; OUTBREAK; AMERICA; STATE
AB Dengue viruses (DENV) serotypes 1, 2, and 3 have been causing yearly outbreaks in Brazil. In this study, we report the reintroduction of DENV2 in the coast of Sao Paulo State. Partial envelope viral genes were sequenced from eighteen patients with dengue fever during the 2010 epidemic. Phylogenetic analysis showed this strain belongs to the American/Asian genotype and was closely related to the virus that circulated in Rio de Janeiro in 2007 and 2008. The phylogeny also showed no clustering by clinical presentation, suggesting that the disease severity could not be explained by distinct variants or genotypes. The time of the most recent common ancestor of American/Asian genotype and the Sao Paulo and Rio de Janeiro (SP/RJ) monophyletic cluster was estimated to be around 40 and 10 years, respectively. Since this virus was first identified in Brazil in 2007, we suggest that it was already circulating in the country before causing the first documented outbreak. This is the first description of the 2010 outbreak in the State of Sao Paulo, Brazil, and should contribute to efforts to control and monitor the spread of DENVs in endemic areas.
C1 [Romano, Camila Malta; Villas-Boas, Lucy Santos; da Silva, Wanessa Cardoso; Mamana de Souza, Ana Carolina; Rodrigues, Celia L.; Levi, Jose Eduardo; Pannuti, Claudio Sergio] Univ Sao Paulo, Dept Molestias Infecciosas & Parasitarias, LIMHC, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
   [de Matos, Andreia Manso; Carvalho, Karina I.; Kallas, Esper G.] Univ Sao Paulo, Fac Med, Disciplina Imunol Clin & Alergia LIM 60, Sao Paulo, Brazil.
   [Araujo, Evaldo Stanislau A.; Oliveira, Olimpia M. N. P. F.] Hosp Ana Costa, Santos, Brazil.
RP Romano, CM (corresponding author), Univ Sao Paulo, Dept Molestias Infecciosas & Parasitarias, LIMHC, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
EM cmromano@usp.br
RI Romano, Camila/ABC-2883-2020; Pannuti, Claudio/B-7649-2012; Kallas,
   Esper G/C-9539-2012; Romano, Camila M/C-8185-2013; Carvalho, Karina
   IL/J-6789-2012
OI Romano, Camila/0000-0003-4550-1987; Carvalho, Karina
   IL/0000-0002-7763-8139; Kallas, Esper/0000-0003-2026-6925
FU Conselho Nacional de Desenvolvimento Cientifico e TecnologicoNational
   Council for Scientific and Technological Development (CNPq); Coordenacao
   de Aperfeicoamento de Pessoal de Ni-vel Superior, Brazilian Ministry of
   Education; Brazilian Ministry of Science and Technology (CNPq)National
   Council for Scientific and Technological Development (CNPq)
   [476088/2009-7]
FX The present work was supported by the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico, Brazilian Ministry of Science
   and Technology (CNPq, grant #476088/2009-7 to EGK). AMM and EGK's
   scholarships were supported by CNPq. KIC's scholarship was supported by
   the Coordenacao de Aperfeicoamento de Pessoal de Ni-vel Superior,
   Brazilian Ministry of Education. URL of CNPq: URL www.cnpq.br; URL of
   CAPES: www.capes.gov.br. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Adams B, 2006, P NATL ACAD SCI USA, V103, P14234, DOI 10.1073/pnas.0602768103
   Araujo JMG, 2009, INFECT GENET EVOL, V9, P716, DOI 10.1016/j.meegid.2008.10.005
   Carrington CVF, 2005, J VIROL, V79, P14680, DOI 10.1128/JVI.79.23.14680-14687.2005
   de Melo FL, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000390
   DESOUZA RV, 1995, MEM I OSWALDO CRUZ, V90, P345, DOI 10.1590/S0074-02761995000300006
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Endy TP, 2004, J INFECT DIS, V189, P990, DOI 10.1086/382280
   HALSTEAD SB, 1980, B WORLD HEALTH ORGAN, V58, P1
   HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268
   Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0
   Holmes EC, 2003, INFECT GENET EVOL, V3, P19, DOI 10.1016/S1567-1348(03)00004-2
   Kumar SRP, 2010, J GEN VIROL, V91, P707, DOI 10.1099/vir.0.017954-0
   Malavige GN, 2004, POSTGRAD MED J, V80, P588, DOI 10.1136/pgmj.2004.019638
   Messer WB, 2002, AM J TROP MED HYG, V66, P765, DOI 10.4269/ajtmh.2002.66.765
   Miagostovich MP, 1998, MEM I OSWALDO CRUZ, V93, P625, DOI 10.1590/S0074-02761998000500011
   Mondini A, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000448
   NOGUEIRA RMR, 1993, EPIDEMIOL INFECT, V111, P163, DOI 10.1017/S0950268800056788
   Oliveira MF, 2010, EMERG INFECT DIS, V16, P576, DOI 10.3201/eid1603.090996
   PAHO, 2008, NUMB REP CAS DENG DE
   de Figueiredo RMP, 2008, EMERG INFECT DIS, V14, P667, DOI 10.3201/eid1404.071185
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Nogueira RMR, 2007, REV PANAM SALUD PUBL, V22, P358, DOI 10.1590/S1020-49892007001000009
   RICOHESSE R, 1990, VIROLOGY, V174, P479, DOI 10.1016/0042-6822(90)90102-W
   RicoHesse R, 1997, VIROLOGY, V230, P244, DOI 10.1006/viro.1997.8504
   Siqueira JB, 2005, EMERG INFECT DIS, V11, P48, DOI 10.3201/eid1101.031091
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Vasconcelos Pedro F. Da C., 1995, Revista do Instituto de Medicina Tropical de Sao Paulo, V37, P253
   Zanotto PMD, 1996, P NATL ACAD SCI USA, V93, P548, DOI 10.1073/pnas.93.2.548
   Zhang CL, 2005, J VIROL, V79, P15123, DOI 10.1128/JVI.79.24.15123-15130.2005
NR 29
TC 31
Z9 31
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 28
PY 2010
VL 5
IS 7
AR e11811
DI 10.1371/journal.pone.0011811
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 633QX
UT WOS:000280520100005
PM 20676363
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Levi, JE
   Wendel, S
   Takaoka, DT
   Foglietto, M
AF Levi, J. E.
   Wendel, S.
   Takaoka, D. T.
   Foglietto, M.
TI RESULTS OF ROUTINE SCREENING OF BRAZILIAN BLOOD DONORS WITH THE ROCHE
   COBAS S 201/TAQSCREEN MPX SYSTEM
SO VOX SANGUINIS
LA English
DT Meeting Abstract
C1 [Levi, J. E.; Wendel, S.] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Takaoka, D. T.; Foglietto, M.] Ctr Imunol and Imunogenet, Sao Paulo, Brazil.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0042-9007
J9 VOX SANG
JI Vox Sang.
PD JUL
PY 2010
VL 99
SU 1
BP 88
EP 88
PG 1
WC Hematology
SC Hematology
GA 625DE
UT WOS:000279872500220
DA 2020-11-30
ER

PT J
AU Torres, KL
   Tateno, A
   Lima, TA
   Malheiro, A
   Morais, MPE
   Levi, JE
AF Torres, K. L.
   Tateno, A.
   Lima, T. A.
   Malheiro, A.
   Morais, M. P. E.
   Levi, J. E.
TI CHARACTERIZATION OF HEPATITIS C VIRUS INFECTION IN AMAZON BLOOD DONORS,
   BRAZIL
SO VOX SANGUINIS
LA English
DT Meeting Abstract
C1 [Torres, K. L.; Lima, T. A.; Malheiro, A.; Morais, M. P. E.] Hemoam Foudat, Manaus, Amazonas, Brazil.
   [Tateno, A.; Levi, J. E.] Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0042-9007
J9 VOX SANG
JI Vox Sang.
PD JUL
PY 2010
VL 99
SU 1
BP 297
EP 297
PG 1
WC Hematology
SC Hematology
GA 625DE
UT WOS:000279872501339
DA 2020-11-30
ER

PT J
AU Szymanska, K
   Levi, JE
   Menezes, A
   Wunsch, V
   Eluf-Neto, J
   Koifman, S
   Matos, E
   Daudt, AW
   Curado, MP
   Villar, S
   Pawlita, M
   Waterboer, T
   Boffetta, P
   Hainaut, P
   Brennan, P
AF Szymanska, K.
   Levi, J. E.
   Menezes, A.
   Wuensch-Filho, V.
   Eluf-Neto, J.
   Koifman, S.
   Matos, E.
   Daudt, A. W.
   Curado, M. P.
   Villar, S.
   Pawlita, M.
   Waterboer, T.
   Boffetta, P.
   Hainaut, P.
   Brennan, P.
TI TP53 and EGFR mutations in combination with lifestyle risk factors in
   tumours of the upper aerodigestive tract from South America
SO CARCINOGENESIS
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMAS; LUNG CANCERS; P53 GENE; HEAD; NECK; PATTERNS;
   EXPRESSION; SMOKERS; BRAZIL; NEVER
AB Cancers of the upper aerodigestive tract [(UADT): oral cavity, pharynx, larynx and oesophagus] have high incidence rates in some parts of South America. Alterations in the TP53 gene are common in these cancers. In our study, we have estimated the prevalence and patterns of TP53 mutations (exons 4-10) in 236 UADT tumours from South America in relation to lifestyle risk factors, such as tobacco smoking and alcohol drinking. Moreover, we have conducted a pilot study of EGFR mutations (exons 18-21) in 45 tumours from the same population. TP53 mutation prevalence was high: 59% of tumours were found to carry mutant TP53. We found an association between TP53 mutations and tobacco smoking and alcohol drinking. The mutation rate increased from 38% in never-smokers to 66% in current smokers (P-value for trend = 0.09). G:C > T:A transversions were found only in smokers (15%). Alcohol drinkers carried more G:C > A:T transitions (P = 0.08). Non-exposed individuals were more probable to carry G:C > A:T transitions at CpG sites (P = 0.01 for never-smokers and P < 0.001 for never-drinkers). EGFR mutations were found in 4% of cases. Inactivation of TP53 by mutations is a crucial molecular event in the UADT carcinogenesis and it is closely related to exposure to lifestyle risk factors. EGFR mutations do not appear to be a common event in UADT carcinogenesis in this population.
C1 [Brennan, P.] Int Agcy Res Canc, Genet Sect, F-69008 Lyon, France.
   [Levi, J. E.; Wuensch-Filho, V.; Eluf-Neto, J.] Univ Sao Paulo, BR-01246904 Sao Paulo, Brazil.
   [Menezes, A.] Univ Fed Pelotas, BR-96020220 Pelotas, Brazil.
   [Koifman, S.] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ, BR-21041210 Rio De Janeiro, Brazil.
   [Matos, E.] Univ Buenos Aires, Dept Carcinogenesis Quim, RA-1417 Buenos Aires, DF, Argentina.
   [Daudt, A. W.] Hosp Clin Porto Alegre, BR-90035903 Porto Alegre, RS, Brazil.
   [Curado, M. P.] Goiania Canc Registry, Goiania, Go, Brazil.
   [Pawlita, M.; Waterboer, T.] German Canc Res Ctr, Infect & Canc F020, D-69120 Heidelberg, Germany.
RP Brennan, P (corresponding author), Int Agcy Res Canc, Genet Sect, 150 Cours Albert Thomas, F-69008 Lyon, France.
EM gep@iarc.fr
RI Menezes, Ana MB/G-7266-2012; Pawlita, Labor/C-9720-2011; Eluf-Neto,
   Jose/B-2522-2009; Curado, Maria Paula/M-6200-2013; Filho, Victor
   Wunsch/C-4475-2012; Hainaut, Pierre/B-6018-2012; Waterboer,
   Tim/G-1252-2010
OI Eluf-Neto, Jose/0000-0001-7504-2115; Curado, Maria
   Paula/0000-0001-8172-2483; Hainaut, Pierre/0000-0002-1303-1610; Pawlita,
   Michael/0000-0002-4720-8306
FU European Commission International Cooperation with Developing Countries
   [IC18-CT97-0222]; Fondo para la Investigacion Cientifica y Tecnologica
   (Argentina)ANPCyT; Fundacao de Amparo a Pesquisa no Estado de Sao
   PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [01/01768-2]; International Agency for Research on Cancer
FX European Commission International Cooperation with Developing Countries
   programme (IC18-CT97-0222); Fondo para la Investigacion Cientifica y
   Tecnologica (Argentina); Fundacao de Amparo a Pesquisa no Estado de Sao
   Paulo (01/01768-2).; The authors thank Ms Helene Renard for invaluable
   help in creating databases for managing the laboratory data and Dr
   Magali Olivier for fruitful discussions on TP53 mutation spectra.
   Katarzyna Szymanska undertook the work reported in this paper during the
   tenure of a Postdoctoral Fellowship awarded by the International Agency
   for Research on Cancer.
CR Breton J, 2003, MUTAGENESIS, V18, P299, DOI 10.1093/mutage/18.3.299
   Castellsague X, 2000, INT J CANCER, V88, P658, DOI 10.1002/1097-0215(20001115)88:4&lt;658::AID-IJC22&gt;3.0.CO;2-T
   Chaves ACM, 2004, INT J ONCOL, V24, P295
   Clifford GM, 2007, CANCER EPIDEM BIOMAR, V16, P1874, DOI 10.1158/1055-9965.EPI-07-0349
   Dai M, 2004, CANCER RES, V64, P468, DOI 10.1158/0008-5472.CAN-03-3284
   FERLAY J, 2004, 5 IARC
   Goldenberg D, 2003, HEAD NECK-J SCI SPEC, V25, P595, DOI 10.1002/hed.10288
   HOLLSTEIN MC, 1991, CANCER RES, V51, P4102
   IARC, 2004, IARC MON EV CARC RIS, V83
   IARC, 1988, IARC MON EV CARC RIS, V44
   Le Calvez F, 2005, CANCER RES, V65, P5076, DOI 10.1158/0008-5472.CAN-05-0551
   Le Calvez F, 2005, CLIN CHEM, V51, P1284, DOI 10.1373/clinchem.2005.048348
   Lee JW, 2005, CLIN CANCER RES, V11, P2879, DOI 10.1158/1078-0432.CCR-04-2029
   Loeffler-Ragy J, 2006, EUR J CANCER, V42, P109, DOI 10.1016/j.ejca.2005.08.034
   Mounawar M, 2007, CANCER RES, V67, P5667, DOI 10.1158/0008-5472.CAN-06-4229
   Nagai MA, 1998, INT J CANCER, V76, P13, DOI 10.1002/(SICI)1097-0215(19980330)76:1<13::AID-IJC3>3.0.CO;2-0
   Noori P, 2001, CARCINOGENESIS, V22, P1825, DOI 10.1093/carcin/22.11.1825
   Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101
   Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495
   Putz A, 2002, INT J CANCER, V98, P99, DOI 10.1002/ijc.10128
   Sankaranarayanan R, 1998, ANTICANCER RES, V18, P4779
   van Heerden WFP, 1998, ANTICANCER RES, V18, P237
   Waterboer T, 2005, CLIN CHEM, V51, P1845, DOI 10.1373/clinchem.2005.052381
   Willmore-Payne C, 2006, MODERN PATHOL, V19, P634, DOI 10.1038/modpathol.3800552
NR 24
TC 14
Z9 14
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD JUN
PY 2010
VL 31
IS 6
BP 1054
EP 1059
DI 10.1093/carcin/bgp212
PG 6
WC Oncology
SC Oncology
GA 603OS
UT WOS:000278218500013
PM 19955396
OA Bronze
DA 2020-11-30
ER

PT J
AU Malheiro, A
   Fraporti, LS
   Victoria, F
   Torres, KL
   Pimentel, JPD
   Tarrago, A
   Maia, LPV
   Vasquez, F
   Levi, JE
   Victoria, M
AF Malheiro, Adriana
   Fraporti, Liziara Silva
   Victoria, Flamir
   Torres, Katia Luz
   Diniz Pimentel, Joao Paulo
   Tarrago, Andrea
   Viana Maia, Laura Patricia
   Vasquez, Felicien
   Levi, Jose Eduardo
   Victoria, Marilu
TI Immune response characterization in HIV/HCV co-infected patients of
   medicine tropical foundation
SO RETROVIROLOGY
LA English
DT Meeting Abstract
C1 [Malheiro, Adriana; Fraporti, Liziara Silva; Torres, Katia Luz; Diniz Pimentel, Joao Paulo; Tarrago, Andrea; Viana Maia, Laura Patricia; Vasquez, Felicien] Fundacao Hematol Hemoterapia Amazonas, Manaus, Brazil.
   [Victoria, Flamir] Fundacao Med Trop Amazonas, Manaus, Brazil.
   [Malheiro, Adriana; Fraporti, Liziara Silva; Vasquez, Felicien] Univ Fed Amazonas, Manaus, Brazil.
   [Victoria, Marilu] Univ Estadual Sao Paulo, Sao Paulo, Brazil.
EM elisadleon@yahoo.com.br
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD MAY 11
PY 2010
VL 7
SU 1
BP 40
EP 40
AR P80
DI 10.1186/1742-4690-7-S1-P80
PG 1
WC Virology
SC Virology
GA 605EF
UT WOS:000278329600125
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Reesink, HW
   Panzer, S
   Wendel, S
   Levi, JE
   Ullum, H
   Ekblom-Kullberg, S
   Seifried, E
   Schmidt, M
   Shinar, E
   Prati, D
   Berzuini, A
   Ghosh, S
   Flesland, O
   Jeansson, S
   Zhiburt, E
   Piron, M
   Sauleda, S
   Ekermo, B
   Eglin, R
   Kitchen, A
   Dodd, RY
   Leiby, DA
   Katz, LM
   Kleinman, S
AF Reesink, H. W.
   Panzer, S.
   Wendel, S.
   Levi, J. E.
   Ullum, H.
   Ekblom-Kullberg, S.
   Seifried, E.
   Schmidt, M.
   Shinar, E.
   Prati, D.
   Berzuini, A.
   Ghosh, S.
   Flesland, O.
   Jeansson, S.
   Zhiburt, E.
   Piron, M.
   Sauleda, S.
   Ekermo, B.
   Eglin, R.
   Kitchen, A.
   Dodd, R. Y.
   Leiby, D. A.
   Katz, L. M.
   Kleinman, S.
TI The use of malaria antibody tests in the prevention of
   transfusion-transmitted malaria
SO VOX SANGUINIS
LA English
DT Article
ID BLOOD
C1 [Reesink, H. W.] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands.
   [Panzer, S.] Med Univ Vienna, Clin Blood Grp Serol & Transfus Med, Dept Blood Grp Serol, A-1090 Vienna, Austria.
   [Wendel, S.] Hosp Sirio Libanes, Blood Bank, BR-01308050 Sao Paulo, Brazil.
   [Levi, J. E.] Ctr Imunol & Imunogenet, BR-01409001 Sao Paulo, Brazil.
   [Ullum, H.] Copenhagen Univ Hosp, Dept Clin Immunol 2031, Ctr Clin Invest, Rigshosp, DK-2100 Copenhagen, Denmark.
   [Ekblom-Kullberg, S.] Finnish Red Cross Blood Serv, FI-00310 Helsinki, Finland.
   [Seifried, E.; Schmidt, M.] German Red Cross, Inst Transfus Med & Immunohematol, D-60528 Frankfurt, Germany.
   [Prati, D.; Berzuini, A.] Osped A Manzoni, Dept Transfus Med, I-23900 Lecce, Italy.
   [Ghosh, S.] New Zealand Blood Serv, Hamilton 3240, New Zealand.
   [Flesland, O.] Asker & Baerum Hosp, Lab Ctr, NO-1309 Rud, Norway.
   [Jeansson, S.] Oslo Univ Hosp Ulleval, Dept Microbiol, Oslo, Norway.
   [Jeansson, S.] Univ Oslo, Fac Med, Oslo, Norway.
   [Zhiburt, E.] Pirogov Russian Natl Med Surg Ctr, Moscow 105203, Russia.
   [Zhiburt, E.] Russian Transfusionist Assoc, Moscow 105203, Russia.
   [Piron, M.; Sauleda, S.] Blood & Tissue Bank Catalonia, Transfus Safety Lab, Barcelona 08035, Spain.
   [Ekermo, B.] Linkoping Univ Hosp, Dept Clin Immunol & Transfus Med, SE-58185 Linkoping, Sweden.
   [Eglin, R.; Kitchen, A.] NHSBT, London NW9 5BG, England.
   [Dodd, R. Y.] Amer Red Cross, Res & Dev, Holland Lab, Rockville, MD 20855 USA.
   [Leiby, D. A.] Amer Red Cross, Transmissible Dis Dept, Holland Lab, Rockville, MD 20855 USA.
   [Katz, L. M.] Mississippi Valley Reg Blood Ctr, Davenport, IA 52772 USA.
   [Kleinman, S.] Univ British Columbia, Victoria, BC V9A 4W4, Canada.
RP Reesink, HW (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM internationalforum@kpnplanet.nl; internationalforum@kpnplanet.nl;
   snwendel@terra.com.br; biologia@cii-laboratorio.com.br;
   henrik.ullum@rh.regionh.dk; susanne.ekblom-kullberg@bts.redcross.fi;
   e.seifried@blutspende.de; m.schmidt@blutspende.de; eilats@mdais.co.il;
   d.prati@ospedale.lecco.it; a.berzuini@ospedale.lecco.it;
   susanta.ghosh@nzblood.co.nz; oystein.flesland@vestreviken.no;
   stig.jeansson@ulleval.no; ezhiburt@yandex.ru; ssauleda@bstcat.net;
   bengt.ekermo@lio.se; roger.eglin@nhsbt.nhs.uk;
   alan.kitchen@nhsbt.nhs.uk; dodd@usa.redcross.org;
   leibyd@usa.redcross.org; lkatz@mvrbc.org; skleinman@shaw.ca
RI Prati, Daniele/P-8215-2019; Wendel, S/AAQ-9048-2020
OI Prati, Daniele/0000-0002-2281-7498; Schmidt,
   Michael/0000-0001-9338-0900; Ullum, Henrik/0000-0001-7306-9058
CR [Anonymous], OFFICIAL J EUROPEAN
   Arafat R., 2003, Morbidity and Mortality Weekly Report, V52, P1075
   ARAFAT R, 2003, MMWR-MORBID MORTAL W, V52, P1161
   Boccolini D., 2007, Notiziario dell'Istituto Superiore di Sanita, V20, P3
   Cardo LJ, 2009, TRANSFUSION, V49, P337, DOI 10.1111/j.1537-2995.2008.01974.x
   *COUNC EUR, GUID PREP US QUAL AS
   Doderer C, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-19
   *FDA, 2006, FDA WORKSH TEST MAL
   Grijalva C. G., 2009, Morbidity and Mortality Weekly Report, V58, P1
   KIRCHGATTER K, 2005, LETHAL MALARIA CAUSE
   Kitchen AD, 2004, VOX SANG, V87, P150, DOI 10.1111/j.1423-0410.2004.00561.x
   Kruger A, 2001, TROP MED INT HEALTH, V6, P983, DOI 10.1046/j.1365-3156.2001.00816.x
   Leiby D, 2008, VOX SANG, V95, P39
   Leiby DA, 2008, TRANSFUSION, V48, P2222, DOI 10.1111/j.1537-2995.2008.01825.x
   PRATI D, 2004, VOX SANG, V87, P132
   Reesink HW, 2004, VOX SANG, V87, P125
   Romi R, 2001, J TRAVEL MED, V8, P6, DOI 10.2310/7060.2001.5140
   Rougemont M, 2004, J CLIN MICROBIOL, V42, P5636, DOI 10.1128/JCM.42.12.5636-5643.2004
   SANTI SM, 2005, REV SOC BRAS MED TRO, V38, P333
   Spencer B, 2009, TRANSFUSION, V49, P2335, DOI 10.1111/j.1537-2995.2009.02290.x
   2006, FDA WORKSH TEST MAL
NR 21
TC 21
Z9 21
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0042-9007
EI 1423-0410
J9 VOX SANG
JI Vox Sang.
PD APR
PY 2010
VL 98
IS 3
BP 468
EP 478
DI 10.1111/j.1423-0410.2009.01301.x
PN 2
PG 11
WC Hematology
SC Hematology
GA 568OA
UT WOS:000275530800011
PM 20136789
DA 2020-11-30
ER

PT J
AU Maidana-Giret, MT
   Silva, TM
   Sauer, MM
   Tomiyama, H
   Levi, JE
   Bassichetto, KC
   Nishiya, A
   Diaz, RS
   Sabino, EC
   Palacios, R
   Kallas, EG
AF Maidana-Giret, Maria Teresa
   Silva, Tania M.
   Sauer, Mariana M.
   Tomiyama, Helena
   Levi, Jose Eduardo
   Bassichetto, Katia C.
   Nishiya, Anna
   Diaz, Ricardo S.
   Sabino, Ester C.
   Palacios, Ricardo
   Kallas, Esper Georges
TI GB virus type C infection modulates T-cell activation independently of
   HIV-1 viral load
SO AIDS
LA English
DT Article
DE activation; CD38; coinfection; GB virus type C; HIV-1; T lymphocyte
ID HEPATITIS-G VIRUS; BLOOD MONONUCLEAR-CELLS; IMMUNE ACTIVATION;
   ANTIRETROVIRAL THERAPY; LYMPHOCYTE ACTIVATION; SET-POINT; COINFECTION;
   RNA; PROGRESSION; INDIVIDUALS
AB Background: Many clinical studies have suggested a beneficial effect of GB virus type C (GBV-C) on the course of HIV-1 infection, but the mechanisms involved in such amelioration are not clear. As recent evidence has implicated cellular activation in HIV-1 pathogenesis, we investigated the effect of GBV-C viremia on T-cell activation in early HIV-1 infection.
   Methods: Forty-eight recently infected HIV-1 patients (23 GBV-C viremic) were evaluated for T-cell counts, expanded immunophenotyping GBV-C RNA detection, and HIV-1 viral load. Nonparametric univariate and multivariate analyses were carried out to identify variables associated with cellular activation, including GBV-C status, HIV-1 viral load, T lymphocyte counts, and CD38 and chemokine (C-C motif) receptor 5 (CCR5) surface expression.
   Finding: We not only confirmed the positive correlation between HIV-1 viral load and the percentage of T cells positive for CD38(+)CD8(+) but also observed that GBV-C viremic patients had a lower percentage of T cells positive for CD38(+)CD4(+), CD38(+)CD8(+), CCR5(+)CD4(+), and CCR5(+)CD8(+) compared with HIV-1-infected patients who were not GBV-C viremic. In regression models, GBV-C RNA(+) status was associated with a reduction in the CD38 on CD4(+) or CD8(+) T cells and CCR5(+) on CD8(+) T cells, independent of the HIV-1 viral load or CD4(+) and CD8(+) T-cell counts. These results were also supported by the lower expression of CD69 and CD25 in GBV-C viremic patients.
   Interpretation: The association between GBV-C replication and lower T-cell activation may be a key mechanism involved in the protection conferred by this virus against HIV-1 disease progression to immunodeficiency in HIV-1-infected patients. (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
C1 [Kallas, Esper Georges] Univ Sao Paulo, Lab Invest Med 60, Div Clin Immunol & Allergy, BR-01246903 Sao Paulo, Brazil.
   [Maidana-Giret, Maria Teresa; Silva, Tania M.; Sauer, Mariana M.; Tomiyama, Helena; Diaz, Ricardo S.; Palacios, Ricardo; Kallas, Esper Georges] Univ Fed Sao Paulo, Div Infect Dis, Sao Paulo, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, BR-01246903 Sao Paulo, Brazil.
   [Bassichetto, Katia C.] Publ Hlth Dept Sao Paulo, Sao Paulo, Brazil.
   [Nishiya, Anna; Sabino, Ester C.] Fundacao Prosangue, Hemoctr, Sao Paulo, Brazil.
RP Kallas, EG (corresponding author), Univ Sao Paulo, Lab Invest Med 60, Div Clin Immunol & Allergy, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM esper.kallas@gmail.com
RI Palacios, Ricardo/AAN-7606-2020; Sabino, Ester Cerdeira/F-7750-2010;
   Diaz, Ricardo/K-3978-2012; Kallas, Esper G/C-9539-2012; Nishiya,
   Anna/Q-8156-2016; Palacios, Ricardo/B-7248-2018
OI Palacios, Ricardo/0000-0002-1410-8579; Sabino, Ester
   Cerdeira/0000-0003-2623-5126; Palacios, Ricardo/0000-0002-1410-8579;
   Kallas, Esper/0000-0003-2026-6925
FU Brazilian Program for STD and AIDS, Ministry of Health
   [914/BRA/3014-UNESCO/Kallas]; Sao Paulo City Health Department
   [2004-0.168.922-7/Kallas]; Fundacao de Amparo a Pesquisa do Estado de
   Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [04/15856-9/Diaz, 05/01072-9/Levi)]; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Brazilian Ministry of EducationCAPES
FX This study was supported with funding from the Brazilian Program for STD
   and AIDS, Ministry of Health (914/BRA/3014-UNESCO/Kallas), the Sao Paulo
   City Health Department (2004-0.168.922-7/Kallas), and the Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (04/15856-9/Diaz, Sabino &
   Kallas; 05/01072-9/Levi). M.T.M.G. and M.M.S. were supported by the
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   Brazilian Ministry of Education.
CR Barbour JD, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001080
   Berzsenyi MD, 2007, GASTROENTEROLOGY, V133, P1821, DOI 10.1053/j.gastro.2007.08.076
   Bisson GP, 2005, AIDS, V19, P1910, DOI 10.1097/01.aids.0000188427.25657.e7
   Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
   Chun TW, 2004, P NATL ACAD SCI USA, V101, P2464, DOI 10.1073/pnas.0307328101
   Cocchi F, 2000, P NATL ACAD SCI USA, V97, P13812, DOI 10.1073/pnas.240469997
   Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333
   Doisne JM, 2004, J IMMUNOL, V173, P2410, DOI 10.4049/jimmunol.173.4.2410
   Eggena MP, 2005, J IMMUNOL, V174, P4407, DOI 10.4049/jimmunol.174.7.4407
   Fogeda M, 1999, J VIROL, V73, P4052, DOI 10.1128/JVI.73.5.4052-4061.1999
   George SL, 2006, J INFECT DIS, V193, P451, DOI 10.1086/499435
   Giorgi JV, 2002, J ACQ IMMUN DEF SYND, V29, P346, DOI 10.1097/00126334-200204010-00004
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660
   Grossman Z, 2006, NAT MED, V12, P289, DOI 10.1038/nm1380
   Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255
   Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772
   Heringlake S, 1998, J INFECT DIS, V177, P1723, DOI 10.1086/517431
   Jarvis LM, 1996, LANCET, V348, P1352, DOI 10.1016/S0140-6736(96)04041-X
   Kallas Esper Georges, 2004, Braz J Infect Dis, V8, P399, DOI 10.1590/S1413-86702004000600003
   Kao JH, 1998, ARCH VIROL, V143, P797, DOI 10.1007/s007050050331
   Kaufman TM, 2007, AIDS, V21, P1045, DOI 10.1097/QAD.0b013e3280f77412
   LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803
   Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A
   Lefrere JJ, 1999, J MED VIROL, V59, P32, DOI 10.1002/(SICI)1096-9071(199909)59:1&lt;32::AID-JMV6&gt;3.0.CO;2-O
   Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505
   Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003
   Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501
   Nattermann J, 2003, AIDS, V17, P1457, DOI 10.1097/00002030-200307040-00006
   Nunnari G, 2003, ANN INTERN MED, V139, P26, DOI 10.7326/0003-4819-139-1-200307010-00009
   Papagno L, 2004, PLOS BIOL, V2, P173, DOI 10.1371/journal.pbio.0020020
   Reimann KA, 2000, CLIN DIAGN LAB IMMUN, V7, P352, DOI 10.1128/CDLI.7.3.352-359.2000
   Rey D, 2000, EUR J CLIN MICROBIOL, V19, P721, DOI 10.1007/s100960000352
   Rodriguez B, 2003, J INFECT DIS, V187, P504, DOI 10.1086/368206
   Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104
   Savarino A, 2000, AIDS, V14, P1079, DOI 10.1097/00002030-200006160-00004
   Schlueter V, 1996, J CLIN MICROBIOL, V34, P2660, DOI 10.1128/JCM.34.11.2660-2664.1996
   Silvestri G, 2003, J CLIN INVEST, V112, P821, DOI 10.1172/JCI200319799
   SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564
   Souza IE, 2006, HIV MED, V7, P25, DOI 10.1111/j.1468-1293.2005.00339.x
   Thomas DL, 1998, J INFECT DIS, V177, P539, DOI 10.1086/514245
   Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398
   Tucker TJ, 1999, J MED VIROL, V59, P52, DOI 10.1002/(SICI)1096-9071(199909)59:1&lt;52::AID-JMV9&gt;3.0.CO;2-D
   Valdez H, 1997, AIDS Clin Rev, P187
   Williams CF, 2004, NEW ENGL J MED, V350, P981, DOI 10.1056/NEJMoa030107
   Xiang JH, 2004, LANCET, V363, P2040, DOI 10.1016/S0140-6736(04)16453-2
   Xiang JH, 2000, J VIROL, V74, P9125, DOI 10.1128/JVI.74.19.9125-9133.2000
NR 46
TC 39
Z9 40
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0269-9370
EI 1473-5571
J9 AIDS
JI Aids
PD NOV 13
PY 2009
VL 23
IS 17
BP 2277
EP 2287
DI 10.1097/QAD.0b013e32832d7a11
PG 11
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 517CF
UT WOS:000271589700005
PM 19773635
DA 2020-11-30
ER

PT J
AU Grinsztejn, B
   Veloso, VG
   Levi, JE
   Velasque, L
   Luz, PM
   Friedman, RK
   Andrade, AC
   Moreira, RI
   Russomano, F
   Pilotto, JH
   Bastos, FI
   Palefsky, J
AF Grinsztejn, Beatriz
   Veloso, Valdilea Goncalves
   Levi, Jose Eduardo
   Velasque, Luciane
   Luz, Paula Mendes
   Friedman, Ruth Khalili
   Andrade, Angela Cristina
   Moreira, Ronaldo Ismerio
   Russomano, Fabio
   Pilotto, Jose Henrique
   Bastos, Francisco Inacio
   Palefsky, Joel
TI Factors associated with increased prevalence of human papillomavirus
   infection in a cohort of HIV-infected Brazilian women (vol 13, pg 72,
   2009)
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Correction
C1 [Grinsztejn, Beatriz; Veloso, Valdilea Goncalves; Velasque, Luciane; Luz, Paula Mendes; Friedman, Ruth Khalili; Andrade, Angela Cristina; Moreira, Ronaldo Ismerio; Pilotto, Jose Henrique] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas IPEC, BR-21045900 Rio De Janeiro, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Russomano, Fabio] Fundacao Oswaldo Cruz, IFF, BR-21045900 Rio De Janeiro, Brazil.
   [Bastos, Francisco Inacio] Fundacao Oswaldo Cruz, ICICT, BR-21045900 Rio De Janeiro, Brazil.
   [Palefsky, Joel] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas IPEC, Av Brasil,4365 Manguinhos, BR-21045900 Rio De Janeiro, Brazil.
RI Veloso, Valdilea Goncalves/J-6189-2012; Pilotto, Jose
   Henrique/AAD-9773-2019
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Bastos,
   Francisco/0000-0001-5970-8896
CR Grinsztejn B, 2009, INT J INFECT DIS, V13, P72, DOI 10.1016/j.ijid.2008.03.031
NR 1
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD SEP
PY 2009
VL 13
IS 5
BP 655
EP 656
DI 10.1016/j.ijid.2009.04.001
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA 498HB
UT WOS:000270126900020
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Meneghini, BC
   Poll, MC
   Ramos, PG
   Andrade, RA
   Levi, JE
   Colella, R
AF Meneghini, B. C.
   Poll, M. C.
   Ramos, P. G.
   Andrade, R. A.
   Levi, J. E.
   Colella, R.
TI Screening For Hemoglobinopathies in Blood Donors Living in Sao Paulo,
   Brazil
SO TRANSFUSION
LA English
DT Meeting Abstract
CT 62nd Annual Meeting of the American-Association-of-Blood-Banks
CY OCT 24-27, 2009
CL New Orleans, LA
SP Amer Assoc Blood Banks
C1 [Meneghini, B. C.; Poll, M. C.; Ramos, P. G.; Andrade, R. A.; Colella, R.] Banco Sangue Sao Paulo, Blood Bank, Sao Paulo, Brazil.
   [Levi, J. E.] Ctr Imunol & Imunogenet, Sao Paulo, Brazil.
EM bcmeneghini@bssp.com.br
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 2009
VL 49
BP 61A
EP 61A
PG 1
WC Hematology
SC Hematology
GA 490XU
UT WOS:000269542200152
DA 2020-11-30
ER

PT J
AU Ribeiro, K
   Waterboer, T
   Pawlita, M
   Levi, JE
   Boffetta, P
   Brennan, P
AF Ribeiro, Karina
   Waterboer, Tim
   Pawlita, Michael
   Levi, Jose Eduardo
   Boffetta, Paolo
   Brennan, Paul
CA Dy Grp Latin Amer Head Neck Stu
   Dy Grp Cent Europe Head Neck Stu
TI HPV and p53 antibodies are associated with the risk of head and neck
   cancer in multiple high-risk populations
SO CANCER RESEARCH
LA English
DT Meeting Abstract
C1 IARC, Lyon, France.
   DKFZ, Heidelberg, Germany.
   Univ Sao Paulo, Sao Paulo, Brazil.
RI Waterboer, Tim/G-1252-2010; de Cassia Braga Ribeiro, Karina/F-1626-2010
OI de Cassia Braga Ribeiro, Karina/0000-0002-8095-5979
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAY 1
PY 2009
VL 69
SU 9
MA 2153
PG 1
WC Oncology
SC Oncology
GA V43TC
UT WOS:000209702704096
DA 2020-11-30
ER

PT J
AU Torres, KL
   Malheiro, A
   Tateno, A
   de Lima, TA
   Maia, LPV
   Pimentel, JPD
   de Morais, MPE
   Usui, CSD
   Braga, FD
   Igor, ASF
   Vasquez, F
   Levi, JE
AF Torres, Katia Luz
   Malheiro, Adriana
   Tateno, Adriana
   de Lima, Tatiane Amabile
   Viana Maia, Laura Patricia
   Diniz Pimentel, Joao Paulo
   Encarnacao de Morais, Marcia Poinho
   de Melo Usui, Christiane Santana
   Braga, Flavia de Oliveira
   Ferreira Silva, Igor Araujo
   Vasquez, Felicien
   Levi, Jose Eduardo
TI Hepatitis C Virus in Blood Donors, Brazil
SO EMERGING INFECTIOUS DISEASES
LA English
DT Letter
ID ALGORITHMS; INFECTION; GENOTYPES; RNA
C1 [Torres, Katia Luz] Fundacao Hematol & Hemoterapia Amazonas, Div Res, BR-4397 Manaus, Amazonas, Brazil.
   [Malheiro, Adriana; Braga, Flavia de Oliveira; Ferreira Silva, Igor Araujo] Univ Fed Amazonas, Manaus, Amazonas, Brazil.
   [Levi, Jose Eduardo] Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
RP Torres, KL (corresponding author), Fundacao Hematol & Hemoterapia Amazonas, Div Res, Av Constantino Nery, BR-4397 Manaus, Amazonas, Brazil.
EM torres@hemoam.am.gov.br
CR Amorim RMS, 2004, MEM I OSWALDO CRUZ, V99, P895, DOI 10.1590/S0074-02762004000800019
   Andrade AFB, 2006, MEM I OSWALDO CRUZ, V101, P673, DOI 10.1590/S0074-02762006000600016
   Barreto AMEC, 2008, BRAZ J MED BIOL RES, V41, P126, DOI 10.1590/S0100-879X2008005000004
   Bernardin F, 2008, HEPATOLOGY, V47, P1446, DOI 10.1002/hep.22184
   Campiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007
   Goncales Neiva S. L., 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P263, DOI 10.1590/S0036-46652000000500005
   Kleinman SH, 2006, TRANSFUSION, V46, P695, DOI 10.1111/j.1537-2995.2006.00787.x
   Lefrere JJ, 2004, TRANSFUSION, V44, P343, DOI 10.1111/j.1537-2995.2004.00656.x
   SMITH DB, 1995, J GEN VIROL, V76, P1749, DOI 10.1099/0022-1317-76-7-1749
   Wendel Silvano, 2007, Rev. Inst. Med. trop. S. Paulo, V49, P177, DOI 10.1590/S0036-46652007000300008
NR 10
TC 14
Z9 15
U1 0
U2 0
PU CENTERS  DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1080-6040
J9 EMERG INFECT DIS
JI Emerg. Infect. Dis
PD APR
PY 2009
VL 15
IS 4
BP 676
EP 678
DI 10.3201/eid1504.081288
PG 3
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 425NR
UT WOS:000264644900046
PM 19331773
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU de Souza, ACMF
   de Oliveira, CM
   Marques, HHS
   Levi, JE
AF Mamana Fernandes de Souza, Ana Carolina
   de Oliveira, Cristina Mendes
   Marques, Heloisa H. S.
   Levi, Jose Eduardo
TI Description of an HIV-1 BC Recombinant Virus Identified in a Pediatric
   Patient in the City of Sao Paulo
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1; AIDS; children; circulating recombinant forms
ID SUBTYPE-C; TYPE-1; RESISTANCE; PREVALENCE; CHILDREN; STRAINS; BRAZIL
AB This case report refers to a 10-year-old HIV-1 infected patient, who was found to harbor a BC recombinant virus. This child lives in Sao Paulo and was infected by the mother-to-child route. Phylogenetic analyses revealed that this mosaic virus shares common breakpoints in the polymerase region with the recently published CRF31_BC.
C1 [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, LIM 52, BR-05403000 Sao Paulo, Brazil.
   [Marques, Heloisa H. S.] Univ Sao Paulo, Sch Med, Clin Hosp, Children Inst,ICR HC FMUSP, BR-05403000 Sao Paulo, Brazil.
RP Levi, JE (corresponding author), Univ Sao Paulo, Inst Trop Med, Virol Lab, LIM 52, Rua Dr Eneas Carvalho Aguiar 470,2O Andar, BR-05403000 Sao Paulo, Brazil.
EM dudilevi@usp.br
RI Oliveira, Cristina M/F-7193-2012
CR Bello G, 2008, AIDS, V22, P1993, DOI 10.1097/QAD.0b013e328315e0aa
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   Brigido LFM, 2005, AIDS RES HUM RETROV, V21, P673, DOI 10.1089/aid.2005.21.673
   Brigido LFM, 2007, AIDS RES HUM RETROV, V23, P1579, DOI 10.1089/aid.2007.0102
   Brindeiro PA, 2002, J CLIN MICROBIOL, V40, P4512, DOI 10.1128/JCM.40.12.4512-4519.2002
   Brindeiro RM, 2003, AIDS, V17, P1063, DOI 10.1097/00002030-200305020-00016
   CSILLAG C, 1994, LANCET, V344, P1354
   de Oliveira T, 2005, BIOINFORMATICS, V21, P3797, DOI 10.1093/bioinformatics/bti607
   Machado ES, 2004, J CLIN VIROL, V30, P24, DOI 10.1016/j.jcv.2003.08.001
   *MIN SAUD SECR VIG, 2007, PROGR NAC DST AIDS
   MORGADO MG, 1994, AIDS RES HUM RETROV, V10, P569, DOI 10.1089/aid.1994.10.569
   Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817
   Rhodes T, 2003, J VIROL, V77, P11193, DOI 10.1128/JVI.77.20.11193-11200.2003
   Robertson DL, 2000, SCIENCE, V288, P55, DOI 10.1126/science.288.5463.55d
   SABINO EC, 1994, J VIROL, V68, P6340, DOI 10.1128/JVI.68.10.6340-6346.1994
   SALMINEN MO, 1995, AIDS RES HUM RETROV, V11, P1423, DOI 10.1089/aid.1995.11.1423
   Santos AF, 2006, AIDS, V20, P2011
   Soares MA, 2003, AIDS, V17, P11, DOI 10.1097/00002030-200301030-00004
   SWOFFORD DL, 1999, PHYLOGENETIC ANAL PA
   *UNAIDS WHO, 2007, JOINT UN PROGR HIV A
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD FEB
PY 2009
VL 13
IS 1
BP 67
EP 69
DI 10.1590/S1413-86702009000100014
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA 466ZB
UT WOS:000267703200014
PM 19578633
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Grinsztejn, B
   Veloso, VG
   Levi, JE
   Velasque, L
   Luz, PM
   Friedman, RK
   Andrade, AC
   Moreira, RI
   Russomano, F
   Pilotto, JH
   Bastos, FI
   Palefsky, J
AF Grinsztejn, Beatriz
   Veloso, Valdilea Goncalves
   Levi, Jose Eduardo
   Velasque, Luciane
   Luz, Paula Mendes
   Friedman, Ruth Khalili
   Andrade, Angela Cristina
   Moreira, Ronaldo Ismerio
   Russomano, Fabio
   Pilotto, Jose Henrique
   Bastos, Francisco Inacio
   Palefsky, Joel
TI Factors associated with increased prevalence of human papillomavirus
   infection in a cohort of HIV-Infected Brazilian women
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Human papillomavirus; Human immunodeficiency virus; Evandro Chagas
   Research Institute cohort; Prevalence ratio; Brazil
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA;
   RIO-DE-JANEIRO; RISK-FACTORS; GENITAL WARTS; HPV INFECTION; DNA
   DETECTION; CANCER; ABNORMALITIES; EPIDEMIOLOGY
AB Objectives: Human papillomavirus (HPV) infection is a major risk factor for cervical disease. Using baseline data from the HIV-infected cohort of Evandro Chagas Clinical Research Institute at Fiocruz, Rio de Janeiro, Brazil, factors associated with an increased prevalence of HPV were assessed.
   Methods: Samples from 634 HIV-infected women were tested for the presence of HPV infection using hybrid capture 11 and polymerase chain reaction. Prevalence ratios (PR) were estimated using Poisson regression analysis with robust variance.
   Results: The overall prevalence of HPV infection was 48%, of which 94% were infected with a high-risk HPV. In multivariate analysis, factors independently associated with infection with high-risk HPV type were: younger age (<30 years of age; PR 1.5, 95% confidence interval (CI) 1.1-2.1), current or prior drug use (PR 1.3, 95% CI 1.0-1.6), self-reported history of HPV infection (PR 1.2, 95% CI 0.96-1.6), condom use in the last sexual intercourse (PR 1.3, 95% CI 1.1-1.7), and nadir CD4+ T-cell count <100 cells/mm(3) (PR 1.6, 95% CI 1.2-2.1).
   Conclusions: The estimated prevalence of high-risk HPV-infection among HIV-infected women from Rio de Janeiro, Brazil, was high. Close monitoring of HPV-related effects is warranted in all HIV-infected women, in particular those of younger age and advanced immunosuppression. (C) 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
C1 [Grinsztejn, Beatriz; Veloso, Valdilea Goncalves; Velasque, Luciane; Luz, Paula Mendes; Friedman, Ruth Khalili; Andrade, Angela Cristina; Moreira, Ronaldo Ismerio; Pilotto, Jose Henrique] Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Russomano, Fabio] Fundacao Oswaldo Cruz, IFF, BR-21045900 Rio De Janeiro, Brazil.
   [Bastos, Francisco Inacio] Fundacao Oswaldo Cruz, ICICT, BR-21045900 Rio De Janeiro, Brazil.
   [Palefsky, Joel] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisas Clin Evandro Chagas, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM gbeatriz@ipec.flocruz.br
RI Veloso, Valdilea Goncalves/J-6189-2012; Pilotto, Jose
   Henrique/AAD-9773-2019; Palefsky, Joel/A-7128-2009
OI Pilotto, Jose Henrique/0000-0003-0521-8597; Luz,
   Paula/0000-0001-9746-719X; Bastos, Francisco/0000-0001-5970-8896
FU Digene Inc., Brazilian branch; Brazilian National AIDS Program
FX Thanks are due to Digene Inc., Brazilian branch, for partially
   supporting HPV testing and to the Brazilian National AIDS Program for
   financial support to the project.
CR Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
   Bower M, 2006, CURR OPIN INFECT DIS, V19, P14, DOI 10.1097/01.qco.0000200295.30285.13
   BROWN D, 2007, 24 INT PAP C CLIN WO
   Burk RD, 1996, J INFECT DIS, V174, P679, DOI 10.1093/infdis/174.4.679
   Campos DP, 2005, AIDS, V19, pS22, DOI 10.1097/01.aids.0000191486.92285.1c
   CANTONI E, 2004, J STAT SOFTW, V10, P1
   Clifford GM, 2006, AIDS, V20, P2337, DOI 10.1097/01.aids.0000253361.63578.14
   Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072
   de Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016/S1473-3099(07)70158-5
   de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033
   Dolei A, 1999, J GEN VIROL, V80, P2937, DOI 10.1099/0022-1317-80-11-2937
   Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031
   Franco EL, 1999, J INFECT DIS, V180, P1415, DOI 10.1086/315086
   Goedert JJ, 1998, LANCET, V351, P1833, DOI 10.1016/S0140-6736(97)09028-4
   Goncalves MAG, 1999, INT J STD AIDS, V10, P803, DOI 10.1258/0956462991913583
   Goncalves MAG, 2003, TUMORI, V89, P9
   Grinsztejn B, 2006, INT J STD AIDS, V17, P473, DOI 10.1258/095646206777689071
   Heard I, 2000, OBSTET GYNECOL, V96, P403, DOI 10.1016/S0029-7844(00)00948-0
   *INCA, 2006, EST 2006 CANC INC BR, P96
   Kjaer SK, 1997, CANCER EPIDEM BIOMAR, V6, P799
   Levi JE, 2002, J CLIN MICROBIOL, V40, P3341, DOI 10.1128/JCM.40.9.3341-3345.2002
   Levi JE, 2004, GYNECOL ONCOL, V92, P225, DOI 10.1016/j.ygyno.2003.10.004
   MAIMAN M, 1990, GYNECOL ONCOL, V38, P377, DOI 10.1016/0090-8258(90)90077-X
   Manhart LE, 2002, SEX TRANSM DIS, V29, P725, DOI 10.1097/00007435-200211000-00018
   Manhart LE, 2006, SEX TRANSM DIS, V33, P502, DOI 10.1097/01.olq.0000204545.89516.0a
   Massad LS, 1999, J ACQ IMMUN DEF SYND, V21, P33, DOI 10.1097/00126334-199905010-00005
   Minkoff H, 1998, AM J OBSTET GYNECOL, V178, P982, DOI 10.1016/S0002-9378(98)70535-6
   Miotti PG, 1996, J INFECT DIS, V173, P714, DOI 10.1093/infdis/173.3.714
   Munoz N, 1996, SEX TRANSM DIS, V23, P504, DOI 10.1097/00007435-199611000-00012
   Orem J, 2004, CURR OPIN ONCOL, V16, P468, DOI 10.1097/00001622-200409000-00010
   Palefsky JM, 1999, JNCI-J NATL CANCER I, V91, P226, DOI 10.1093/jnci/91.3.226
   Palefsky JM, 2003, CURR OPIN ONCOL, V15, P382, DOI 10.1097/00001622-200309000-00007
   Palefsky Joel M, 2003, J Natl Cancer Inst Monogr, P41
   REEVES WC, 1994, J INFECT DIS, V170, P753, DOI 10.1093/infdis/170.4.753
   Rezza G, 1998, EPIDEMIOL INFECT, V121, P173, DOI 10.1017/S0950268898008954
   Richardson H, 2000, SEX TRANSM DIS, V27, P79, DOI 10.1097/00007435-200002000-00005
   Serwadda D, 1999, J INFECT DIS, V180, P1316, DOI 10.1086/315026
   Shah KV, 1997, J CLIN MICROBIOL, V35, P517, DOI 10.1128/JCM.35.2.517-519.1997
   Sirera G, 2005, MED CLIN-BARCELONA, V125, P127, DOI 10.1157/13076944
   Skov T, 1998, INT J EPIDEMIOL, V27, P91, DOI 10.1093/ije/27.1.91
   Smith JS, 2007, INT J CANCER, V121, P621, DOI 10.1002/ijc.22527
   STONE KM, 1999, SEXUALLY TRANSMITTED, P1307
   Strickler HD, 2005, J NATL CANCER I, V97, P577, DOI 10.1093/jnci/dji073
   Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903
   Trottier H, 2006, VACCINE, V24, P4, DOI 10.1016/j.vaccine.2005.09.054
   VERNON SD, 1994, J INFECT DIS, V169, P1108, DOI 10.1093/infdis/169.5.1108
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Winer RL, 2006, NEW ENGL J MED, V354, P2645, DOI 10.1056/NEJMoa053284
   WRIGHT TC, 1994, OBSTET GYNECOL, V84, P591
NR 49
TC 36
Z9 37
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD JAN
PY 2009
VL 13
IS 1
BP 72
EP 80
DI 10.1016/j.ijid.2008.03.031
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA 398CY
UT WOS:000262711400011
PM 18632296
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU de Souza, ACMF
   de Oliveira, CM
   Rodrigues, CLD
   Silva, SAA
   Levi, JE
AF Mamana Fernandes de Souza, Ana Carolina
   de Oliveira, Cristina Mendes
   de Lima Rodrigues, Celia Luiza
   Araujo Silva, Synara Alexandre
   Levi, Jose Eduardo
TI Short Communication Molecular Characterization of HIV Type 1 BF Pol
   Recombinants from Sao Paulo, Brazil
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID ANTIRETROVIRAL DRUG-RESISTANCE; BLOOD-DONORS; SUBTYPE-B; DIVERSITY;
   IDENTIFICATION; STRAINS; VIRUSES; SPREAD; COHORT
AB In the Brazilian HIV-1 epidemic, subtypes B, C, and F1 are cocirculating in the population. Sequences of the partial pol gene from 463 HIV-1-infected patients were obtained from plasma samples and viral subtype was characterized. BF recombinants were found in 8% of the samples. Fifteen different patterns were observed. A CRF28_BF and CRF29_BF structure was found in 29.7% of the samples, CRF12_BF in 13.5%, and CRF39_BF in 2.7%. Two other patterns were identified in each of three samples. These findings could indicate a new CRF description, but to determine this a full length study is required.
C1 [Mamana Fernandes de Souza, Ana Carolina; de Oliveira, Cristina Mendes; de Lima Rodrigues, Celia Luiza; Araujo Silva, Synara Alexandre; Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, LIM 52, BR-05403000 Sao Paulo, Brazil.
RP Levi, JE (corresponding author), Univ Sao Paulo, Inst Trop Med, Virol Lab, LIM 52, Rua Dr Eneas de Carvalho Aguiar,470 2 Andar, BR-05403000 Sao Paulo, Brazil.
EM dudilevi@usp.br
RI Oliveira, Cristina M/F-7193-2012
CR Aulicino PC, 2007, J VIROL, V81, P427, DOI 10.1128/JVI.01403-06
   Barreto CC, 2006, JAIDS-J ACQ IMM DEF, V41, P338
   Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
   Brennan CA, 2007, AIDS RES HUM RETROV, V23, P1434, DOI 10.1089/aid.2007.0121
   Brigido LFM, 2005, AIDS RES HUM RETROV, V21, P673, DOI 10.1089/aid.2005.21.673
   Carr JK, 2001, AIDS, V15, pF41, DOI 10.1097/00002030-200110190-00002
   Couto-Fernandez JC, 1999, J ACQ IMMUN DEF SYND, V22, P288
   De Sa DJ, 2005, AIDS RES HUM RETROV, V21, P145, DOI 10.1089/aid.2005.21.145
   De Sa DJ, 2006, AIDS RES HUM RETROV, V22, P1
   de Sa DJ, 2008, AIDS RES HUM RETROV, V24, P347, DOI 10.1089/aid.2007.0203
   Gotte M, 1999, ARCH BIOCHEM BIOPHYS, V365, P199, DOI 10.1006/abbi.1999.1209
   Guimaraes ML, 2008, AIDS, V22, P433, DOI 10.1097/QAD.0b013e3282f47ad0
   Machado ES, 2004, J CLIN VIROL, V30, P24, DOI 10.1016/j.jcv.2003.08.001
   *MIN SAUD SECR VIG, 2007, B EP DST AIDS
   Rios M, 2007, J MED VIROL, V79, P647, DOI 10.1002/jmv.20881
   Robertson DL, 2000, SCIENCE, V288, P55, DOI 10.1126/science.288.5463.55d
   SABINO EC, 1994, J VIROL, V68, P6340, DOI 10.1128/JVI.68.10.6340-6346.1994
   Sanabani S, 2006, INFECT GENET EVOL, V6, P368, DOI 10.1016/j.meegid.2006.01.003
   *SECR MUN SAUD PMS, 2008, B EP AIDS DST HEP B
   Sierra Maria, 2005, Infection Genetics and Evolution, V5, P209, DOI 10.1016/j.meegid.2004.07.010
   Thomson MM, 2004, AIDS RES HUM RETROV, V20, P1126, DOI 10.1089/aid.2004.20.1126
   Thomson MM, 2002, J GEN VIROL, V83, P107, DOI 10.1099/0022-1317-83-1-107
   Veras NMC, 2007, AIDS RES HUM RETROV, V23, P1481, DOI 10.1089/aid.2007.0145
   Vicente ACP, 2000, J ACQ IMMUN DEF SYND, V23, P327
   Vinoles J, 2005, AM J TROP MED HYG, V72, P495, DOI 10.4269/ajtmh.2005.72.495
NR 25
TC 13
Z9 13
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD DEC
PY 2008
VL 24
IS 12
BP 1521
EP 1525
DI 10.1089/aid.2008.0089
PG 5
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 386UG
UT WOS:000261907500006
PM 19025398
DA 2020-11-30
ER

PT J
AU Scuracchio, P
   Poli, M
   Dourado, D
   Scuotto, R
   Matutani, M
   Kayano, S
   Vieira, S
   Colella, R
   Levi, JE
AF Scuracchio, P.
   Poli, M.
   Dourado, D.
   Scuotto, R.
   Matutani, M.
   Kayano, S.
   Vieira, S.
   Colella, R.
   Levi, J. E.
TI Seroconversion for anti-HBc: What should we do?
SO TRANSFUSION
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the American-Association-of-Blood-Banks and TXPO
CY OCT 04-07, 2008
CL Montreal, CANADA
SP Amer Assoc Blood Banks
C1 [Scuracchio, P.; Poli, M.; Dourado, D.; Scuotto, R.; Matutani, M.; Vieira, S.; Colella, R.] Banco Sangue Sao Paulo, Sao Paulo, Brazil.
   [Levi, J. E.] Hosp Sirio Libanes Blood Bank, Sao Paulo, Brazil.
EM biologia@cii-laboratorio.com.br
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 2008
VL 48
IS 2
SU S
BP 102A
EP 102A
PG 1
WC Hematology
SC Hematology
GA 347CO
UT WOS:000259118400299
DA 2020-11-30
ER

PT J
AU Wendel, S
   Levi, JE
   Candotti, D
   Biagini, S
   Attain, JP
AF Wendel, S.
   Levi, J. E.
   Candotti, D.
   Biagini, S.
   Attain, J. -P
TI A case of HBV transfusion-transmission revealed after a 13 month-long
   window period
SO TRANSFUSION
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the American-Association-of-Blood-Banks and TXPO
CY OCT 04-07, 2008
CL Montreal, CANADA
SP Amer Assoc Blood Banks
C1 [Levi, J. E.] Hosp Sirio Libanes Blood Bank, Sao Paulo, Brazil.
   [Candotti, D.] Natl Hlth Serv Blood & Transplant, Cambridge, England.
   [Attain, J. -P] Univ Cambridge, Cambridge, England.
EM jpa1000@cam.ac.uk
RI Wendel, S/AAQ-9048-2020
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 2008
VL 48
IS 2
SU S
BP 104A
EP 104A
PG 1
WC Hematology
SC Hematology
GA 347CO
UT WOS:000259118400304
DA 2020-11-30
ER

PT J
AU Wendel, S
   Levi, JE
   Biagini, S
   Candotti, D
   Allain, JP
AF Wendel, Silvano
   Levi, Jose E.
   Biagini, Silvana
   Candotti, Daniel
   Allain, Jean-Pierre
TI A probable case of hepatitis B virus transfusion transmission revealed
   after a 13-month-long window period
SO TRANSFUSION
LA English
DT Article
ID BLOOD-DONORS; HBV INFECTION; ANTI-HBC; C VIRUS; HBSAG; NAT; DNA; SAFETY;
   RISK; RNA
AB BACKGROUND: Transfusion-transmitted hepatitis B virus (HBV) infection in recipients with drug-related immunodeficiency is rarely described in endemic areas. Hepatitis B surface antigen (HBsAg)-negative infectious donor blood can be identified by sensitive nucleic acid testing (NAT). Two immunodeficient patients who received blood components from a single seronegative blood donor subsequently found to contain HBV DNA are described.
   MATERIALS AND METHODS: Multiple samples from the implicated donor and the two recipients were tested for HBV serologic and molecular markers. HBV genome fragments were amplified, sequenced, and phylogenetically analyzed.
   RESULTS: The implicated donation had low-level HBV DNA due to the donor being in the window period before the donor's seroconversion. Recipient 1 had been vaccinated to HBV and carried anti-HBs but remained negative for all other HBV markers until she developed acute hepatitis B (viral load 2.7 x 10(8) IU/mL and alanine aminotransferase [ALT] level 1744 IU/L) 13 months after transfusion of red cells. Identical HBV sequences from both donor and recipient provided evidence of transfusion-related infection. Recipient 2, who received platelets from the same donation while receiving major chemotherapy, remained uninfected.
   CONCLUSIONS: In unusual circumstances, HBV incubation time can be considerably prolonged. Both active and passive neutralizing antibodies to HBV likely delayed, but did not prevent, acute infection when the immune system was impaired. HBV NAT may have interdicted the infectious unit, although the donation viral load could not be quantified and odds of detection calculated.
C1 [Wendel, Silvano] Hosp Sirio Libanes, Blood Bank, BR-01308050 Sao Paulo, Brazil.
   Univ Cambridge, Cambridge Blood Ctr, Natl Hlth Serv Blood & Tissue, Cambridge, England.
RP Wendel, S (corresponding author), Hosp Sirio Libanes, Blood Bank, Rua Adma Jafet 91, BR-01308050 Sao Paulo, Brazil.
EM snwendel@uninet.com.br
RI Wendel, S/AAQ-9048-2020
CR Allain JP, 2003, BLOOD, V101, P2419, DOI 10.1182/blood-2002-04-1084
   Araujo NM, 2004, ARCH VIROL, V149, P1383, DOI 10.1007/s00705-003-0269-4
   BARKER LF, 1972, AM J MED SCI, V263, P27, DOI 10.1097/00000441-197201000-00005
   Biswas R, 2003, TRANSFUSION, V43, P788, DOI 10.1046/j.1537-2995.2003.00424.x
   Brojer E, 2006, HEPATOLOGY, V44, P1666, DOI 10.1002/hep.21413
   Candotti D, 2006, J VIRAL HEPATITIS, V13, P715, DOI 10.1111/j.1365-2893.2006.00741.x
   Gerlich WH, 2007, J MED VIROL, V79, pS32, DOI 10.1002/jmv.20963
   HYAMS KC, 1995, CLIN INFECT DIS, V20, P992, DOI 10.1093/clinids/20.4.992
   Kuhns MC, 2004, TRANSFUSION, V44, P1332, DOI 10.1111/j.1537-2995.2004.04055.x
   Meng Q, 2001, J CLIN MICROBIOL, V39, P2937, DOI 10.1128/JCM.39.8.2937-2945.2001
   MIMMS LT, 1993, BRIT MED J, V307, P1095, DOI 10.1136/bmj.307.6912.1095
   Motta-Castro ARC, 2005, J MED VIROL, V77, P188, DOI 10.1002/jmv.20435
   Owusu-Ofori S, 2005, TRANSFUSION, V45, P133, DOI 10.1111/j.1537-2995.2004.04279.x
   Prince AM, 2001, TRANSFUSION, V41, P329, DOI 10.1046/j.1537-2995.2001.41030329.x
   Roche B, 1997, J HEPATOL, V26, P517, DOI 10.1016/S0168-8278(97)80416-3
   Roth WK, 2002, TRANSFUSION, V42, P869, DOI 10.1046/j.1537-2995.2002.00128.x
   Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601
   Tabor E, 2006, J MED VIROL, V78, pS43, DOI 10.1002/jmv.20606
   Wendel Silvano, 2007, Rev. Inst. Med. trop. S. Paulo, V49, P177, DOI 10.1590/S0036-46652007000300008
   YOKOSUKA O, 1993, DIAGNOSTIC MOL MICRO, P2
   Yoshikawa A, 2005, VOX SANG, V88, P77, DOI 10.1111/j.1423-0410.2005.00602.x
   Yoshikawa A, 2007, TRANSFUSION, V47, P1162, DOI 10.1111/j.1537-2995.2007.01234.x
NR 22
TC 19
Z9 20
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD AUG
PY 2008
VL 48
IS 8
BP 1602
EP 1608
DI 10.1111/j.1537-2995.2008.01723.x
PG 7
WC Hematology
SC Hematology
GA 332IX
UT WOS:000258077800013
PM 18466175
DA 2020-11-30
ER

PT J
AU Ribeiro, KB
   Levi, JE
   Curado, MP
   Eluf-Neto, J
   Koifman, S
   Wunsch, V
   Menezes, A
   Daudt, AW
   Matos, E
   Fernandez, L
   Boffetta, P
   Brennan, P
AF Ribeiro, K. B.
   Levi, J. E.
   Curado, M. P.
   Eluf-Neto, J.
   Koifman, S.
   Wunsch Filho, V.
   Menezes, A.
   Daudt, A. W.
   Matos, E.
   Fernandez, L.
   Boffetta, P.
   Brennan, P.
TI Serologic response to HPV and the risk of head and neck cancer
SO EJC SUPPLEMENTS
LA English
DT Meeting Abstract
CT 20th Meeting of the European-Association-for-Cancer-Research
CY JUL 05-08, 2008
CL Lyon, FRANCE
SP European Assoc Canc Res
C1 [Ribeiro, K. B.; Levi, J. E.; Curado, M. P.; Eluf-Neto, J.; Koifman, S.; Wunsch Filho, V.; Menezes, A.; Daudt, A. W.; Matos, E.; Fernandez, L.; Boffetta, P.; Brennan, P.] IARC, Genet Epidemiol Grp, Lyon, France.
RI Eluf-Neto, Jose/B-2522-2009; Filho, Victor Wunsch/C-4475-2012; de Cassia
   Braga Ribeiro, Karina/F-1626-2010
OI Eluf-Neto, Jose/0000-0001-7504-2115; de Cassia Braga Ribeiro,
   Karina/0000-0002-8095-5979
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-6349
J9 EJC SUPPL
JI EJC Suppl.
PD JUL
PY 2008
VL 6
IS 9
BP 188
EP 189
DI 10.1016/S1359-6349(08)71848-2
PG 2
WC Oncology
SC Oncology
GA 330DF
UT WOS:000257919000668
DA 2020-11-30
ER

PT J
AU Szymanska, K
   Levi, JE
   Daudt, AW
   Wunsch, V
   Eluf-Neto, J
   Curado', MP
   Koifman, S
   Menezes, A
   Matos, E
   Fernandez, L
   Boffetta, P
   Tommassino, M
   Gheit, T
   Hainaut, P
   Brennan, P
AF Szymanska, K.
   Levi, J. E.
   Daudt, A. W.
   Wuensch-Filho, V.
   Eluf-Neto, J.
   Curado', M. P.
   Koifman, S.
   Menezes, A.
   Matos, E.
   Fernandez, L.
   Boffetta, P.
   Tommassino, M.
   Gheit, T.
   Hainaut, P.
   Brennan, P.
TI TP53 mutations and HPV infections in tumours of the upper aerodigestive
   tract from Latin America
SO EJC SUPPLEMENTS
LA English
DT Meeting Abstract
CT 20th Meeting of the European-Association-for-Cancer-Research
CY JUL 05-08, 2008
CL Lyon, FRANCE
SP European Assoc Canc Res
C1 [Szymanska, K.; Curado', M. P.; Boffetta, P.; Tommassino, M.; Gheit, T.; Hainaut, P.; Brennan, P.] Int Agcy Res Canc, F-69372 Lyon, France.
   [Levi, J. E.; Wuensch-Filho, V.; Eluf-Neto, J.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Daudt, A. W.] Clin Hosp Porto Alegre, Porto Alegre, RS, Brazil.
   [Curado', M. P.] Canc Registry Goiania, Goiania, Go, Brazil.
   [Koifman, S.] Natl Sch Publ Helath, Rio de Janeiro, Brazil.
   [Menezes, A.] Univ Fed Pelotas, Pelotas, Brazil.
   [Matos, E.] Univ Buenos Aires, Buenos Aires, DF, Argentina.
   [Fernandez, L.] Inst Oncol & Radiobiol, Havana, Cuba.
RI Hainaut, Pierre/B-6018-2012; Menezes, Ana MB/G-7266-2012; Filho, Victor
   Wunsch/C-4475-2012; Eluf-Neto, Jose/B-2522-2009
OI Hainaut, Pierre/0000-0002-1303-1610; Eluf-Neto, Jose/0000-0001-7504-2115
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-6349
J9 EJC SUPPL
JI EJC Suppl.
PD JUL
PY 2008
VL 6
IS 9
BP 196
EP 196
DI 10.1016/S1359-6349(08)71871-8
PG 1
WC Oncology
SC Oncology
GA 330DF
UT WOS:000257919000691
DA 2020-11-30
ER

PT J
AU Lopez, RVM
   Zago, MA
   Eluf-Neto, J
   Silva, WA
   Zanette, DL
   Levi, JE
   Carvalho, MB
   Curado, MP
   Boffetta, P
   Wunsch, V
AF Lopez, R. V. M.
   Zago, M. A.
   Eluf-Neto, J.
   Silva, W. A., Jr.
   Zanette, D. L.
   Levi, J. E.
   Carvalho, M. B.
   Curado, M. P.
   Boffetta, P.
   Wunsch-Filho, V.
TI Prognostic significance of matrix metalloproteinases 1 and 3
   polymorphisms in squamous cell carcinoma of the head and neck
SO EJC SUPPLEMENTS
LA English
DT Meeting Abstract
CT International Conference on Integrative Molecular Cancer Epidemiology
CY JUL 03-05, 2008
CL Lyon, FRANCE
SP Int Acgy Res Canc, European Assoc Canc Res, Amer Assoc Canc Res, Network Excellence Canc, Nutr & Individual Susceptibil
C1 [Lopez, R. V. M.; Wunsch-Filho, V.] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Sao Paulo, Brazil.
   [Zago, M. A.; Silva, W. A., Jr.; Zanette, D. L.] Univ Sao Paulo, Sch Med, Mol Genet Lab, BR-14049 Ribeirao Preto, Brazil.
   [Eluf-Neto, J.] Univ Sao Paulo, Sch Med, Dept Prevent Med, Sao Paulo, Brazil.
   [Levi, J. E.] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   [Carvalho, M. B.] Heliopolis Hosp, Dept Head & Neck, Sao Paulo, Brazil.
   [Curado, M. P.] Araujo Jorge Hosp, Goiania, Go, Brazil.
   [Curado, M. P.] Canc Registry Goiania, Goiania, Go, Brazil.
   [Curado, M. P.; Boffetta, P.] Int Agcy Res Canc, F-69372 Lyon, France.
RI Filho, Victor Wunsch/C-4475-2012; ZAGO, MARCO A/E-9442-2017; Eluf-Neto,
   Jose/B-2522-2009; Silva, Wilson Araujo/E-9487-2011; ZANETTE,
   DALILA/Q-3541-2016
OI Eluf-Neto, Jose/0000-0001-7504-2115; Silva, Wilson
   Araujo/0000-0001-9364-2886; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1359-6349
J9 EJC SUPPL
JI EJC Suppl.
PD JUL
PY 2008
VL 6
IS 9
BP 207
EP 207
DI 10.1016/S1359-6349(08)71911-6
PG 1
WC Oncology
SC Oncology
GA 330DF
UT WOS:000257919000731
DA 2020-11-30
ER

PT J
AU Hashibe, M
   Mckay, JD
   Curado, MP
   Oliveira, JC
   Koifman, S
   Koifman, R
   Zaridze, D
   Shangina, O
   Wunsch, V
   Eluf, J
   Levi, JE
   Matos, E
   Lagiou, P
   Lagiou, A
   Benhamou, S
   Bouchardy, C
   Szeszenia-Dabrowska, N
   Menezes, A
   Dall'Agnol, MM
   Merletti, F
   Richiardi, L
   Fernandez, L
   Lence, J
   Talamini, R
   Barzan, L
   Mates, D
   Mates, IN
   Kjaerheim, K
   Macfarlane, GJ
   Macfarlane, TV
   Simonato, L
   Canova, C
   Holcatova, I
   Agudo, A
   Castellsague, X
   Lowry, R
   Janout, V
   Kollarova, H
   Conway, DI
   McKinney, PA
   Znaor, A
   Fabianova, E
   Bencko, V
   Lissowska, J
   Chabrier, A
   Hung, RJ
   Gaborieau, V
   Boffetta, P
   Brennan, P
AF Hashibe, Mia
   Mckay, James D.
   Curado, Maria Paula
   Oliveira, Jose Carlos
   Koifman, Sergio
   Koifman, Rosalina
   Zaridze, David
   Shangina, Oxana
   Wuensch-Filho, Victor
   Eluf-Neto, Jose
   Levi, Jose Eduardo
   Matos, Elena
   Lagiou, Pagona
   Lagiou, Areti
   Benhamou, Simone
   Bouchardy, Christine
   Szeszenia-Dabrowska, Neonilia
   Menezes, Ana
   Dall'Agnol, Marinel Mor
   Merletti, Franco
   Richiardi, Lorenzo
   Fernandez, Leticia
   Lence, Juan
   Talamini, Renato
   Barzan, Luigi
   Mates, Dana
   Mates, Ioan Nicolae
   Kjaerheim, Kristina
   Macfarlane, Gary J.
   Macfarlane, Tatiana V.
   Simonato, Lorenzo
   Canova, Cristina
   Holcatova, Ivana
   Agudo, Antonio
   Castellsague, Xavier
   Lowry, Ray
   Janout, Vladimir
   Kollarova, Helena
   Conway, David I.
   McKinney, Patricia A.
   Znaor, Ariana
   Fabianova, Eleonora
   Bencko, Vladimir
   Lissowska, Jolanta
   Chabrier, Amelie
   Hung, Rayjean J.
   Gaborieau, Valerie
   Boffetta, Paolo
   Brennan, Paul
TI Multiple ADH genes are associated with upper aerodigestive cancers
SO NATURE GENETICS
LA English
DT Article
ID ALCOHOL-DEHYDROGENASE
AB Alcohol is an important risk factor for upper aerodigestive cancers and is principally metabolized by alcohol dehydrogenase (ADH) enzymes. We have investigated six ADH genetic variants in over 3,800 aerodigestive cancer cases and 5,200 controls from three individual studies. Gene variants rs1229984 (ADH1B) and rs1573496 (ADH7) were significantly protective against aerodigestive cancer in each individual study and overall (P = 10(-10) and 10(-9), respectively). These effects became more apparent with increasing alcohol consumption (P for trend = 0.0002 and 0.065, respectively). Both gene effects were independent of each other, implying that multiple ADH genes may be involved in upper aerodigestive cancer etiology.
C1 [Hashibe, Mia; Mckay, James D.; Curado, Maria Paula; Chabrier, Amelie; Hung, Rayjean J.; Gaborieau, Valerie; Boffetta, Paolo; Brennan, Paul] Int Agcy Res Canc, F-69372 Lyon, France.
   [Curado, Maria Paula; Oliveira, Jose Carlos] Hosp Araujo Jorge, Goiania, Go, Brazil.
   [Curado, Maria Paula; Oliveira, Jose Carlos] Populat Canc Register Goiania, Goiania, Go, Brazil.
   [Koifman, Sergio; Koifman, Rosalina] Escola Nacl Suade Publ, Rio De Janeiro, Brazil.
   [Zaridze, David; Shangina, Oxana] Russian Acad Med Sci, Canc Res Ctr, Moscow, Russia.
   [Wuensch-Filho, Victor; Eluf-Neto, Jose; Levi, Jose Eduardo] Univ Sao Paulo, Sao Paulo, Brazil.
   [Matos, Elena] Univ Buenos Aires, Inst Oncol Angel H Roffo, RA-1053 Buenos Aires, DF, Argentina.
   [Lagiou, Areti; Benhamou, Simone] Univ Athens, Sch Med, GR-11527 Athens, Greece.
   [Benhamou, Simone] Inst Natl Sante & Rech Med, U794, Evry, France.
   [Bouchardy, Christine] Geneva Canc Registry, Geneva, Switzerland.
   [Szeszenia-Dabrowska, Neonilia] Inst Occupat Med, Lodz, Poland.
   [Menezes, Ana; Dall'Agnol, Marinel Mor] Univ Fed Pelotas, Pelotas, Brazil.
   [Merletti, Franco; Richiardi, Lorenzo] CeRMS, Canc Epidemiol Unit, Turin, Italy.
   [Merletti, Franco; Richiardi, Lorenzo] Univ Turin, Turin, Italy.
   [Fernandez, Leticia; Lence, Juan] Inst Oncol & Radiobiol, Havana, Cuba.
   [Talamini, Renato] Aviano Canc Ctr, I-33081 Aviano, Italy.
   [Barzan, Luigi] Gen Hosp, Pordenone, Italy.
   [Mates, Dana] Inst Publ Hlth, Bucharest, Romania.
   [Mates, Ioan Nicolae] Univ Med & Pharm Carol Davila, Bucharest, Romania.
   [Kjaerheim, Kristina] Canc Registry Norway, Oslo, Norway.
   [Macfarlane, Gary J.; Macfarlane, Tatiana V.] Univ Aberdeen, Sch Med, Aberdeen AB9 2ZD, Scotland.
   [Simonato, Lorenzo; Canova, Cristina] Univ Padua, Padua, Italy.
   [Holcatova, Ivana; Bencko, Vladimir] Inst Hyg & Epidemiol, CR-10042 Prague, Czech Republic.
   [Agudo, Antonio; Castellsague, Xavier] Inst Catala Oncol, Barcelona, Spain.
   [Lowry, Ray] Univ Newcastle, Sch Dent, Newcastle Upon Tyne, Tyne & Wear, England.
   [Janout, Vladimir; Kollarova, Helena] Palacky Univ, CR-77147 Olomouc, Czech Republic.
   [Conway, David I.] Univ Glasgow, Sch Dent, Glasgow, Lanark, Scotland.
   [McKinney, Patricia A.] Univ Leeds, Ctr Biostat & Epidemiol, Leeds, W Yorkshire, England.
   [McKinney, Patricia A.] NHS Natl Serv Scotland, Informat Serv Div, Edinburgh, Midlothian, Scotland.
   [Znaor, Ariana] Croatian Natl Canc Registry, Zagreb, Croatia.
   [Fabianova, Eleonora] Specialized State Hlth Inst, Banska Bystrica, Slovakia.
   [Lissowska, Jolanta] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland.
   [Lissowska, Jolanta] Inst Oncol, Warsaw, Poland.
   [Hung, Rayjean J.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.
RP Brennan, P (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69372 Lyon, France.
EM Brennan@iarc.fr
RI Eluf-Neto, Jose/B-2522-2009; Holcatova, Ivana/C-8327-2017; Curado, Maria
   Paula/M-6200-2013; Szeszenia-Dabrowska, Neonila/F-7190-2010; Hung,
   Rayjean J/A-7439-2013; Znaor, A/H-6718-2019; Menezes, Ana
   MB/G-7266-2012; Benhamou, Simone/K-6554-2015; Bencko,
   Vladimir/H-8598-2017; Mates, Ioan Nicolae/E-9255-2017; Pique, Xavier
   Castellsague/N-5795-2014; Macfarlane, Gary J/I-9521-2014; Zaridze,
   David/K-5605-2013; Filho, Victor Wunsch/C-4475-2012; Janout,
   Vladimir/M-5133-2014; Lissowska, Jolanta/AAH-3252-2020; Benhamou,
   Simone/ABD-2590-2020; Agudo, Antonio/J-1805-2016; richiardi,
   lorenzo/J-3480-2018
OI Eluf-Neto, Jose/0000-0001-7504-2115; Holcatova,
   Ivana/0000-0002-1366-0337; Curado, Maria Paula/0000-0001-8172-2483;
   Bencko, Vladimir/0000-0003-1935-2228; Pique, Xavier
   Castellsague/0000-0002-0802-3595; Macfarlane, Gary
   J/0000-0003-2322-3314; Lissowska, Jolanta/0000-0003-2695-5799; Agudo,
   Antonio/0000-0001-9900-5677; Ioan Nicoale, Mates/0000-0001-7210-0615;
   Kjaerheim, Kristina/0000-0003-0691-3735; Macfarlane,
   Tatiana/0000-0002-9392-0812; mates, dana/0000-0002-6219-9807; Conway,
   David/0000-0001-7762-4063; richiardi, lorenzo/0000-0003-0316-9402;
   BENHAMOU, Simone/0000-0001-5853-8047; SIMONATO,
   LORENZO/0000-0002-9914-1000; CANOVA, CRISTINA/0000-0001-7027-7935;
   Kollarova, Helena/0000-0001-6951-6716
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01
   CA 092039-01A2] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA092039,
   R01CA092039, R01CA092039, R01CA092039, R01CA092039, R01CA092039,
   R01CA092039, R01CA092039] Funding Source: NIH RePORTER
CR Birley AJ, 2008, HUM MOL GENET, V17, P179, DOI 10.1093/hmg/ddm295
   Brennan P, 2004, AM J EPIDEMIOL, V159, P1, DOI 10.1093/aje/kwh003
   CARR LG, 1989, ALCOHOL CLIN EXP RES, V13, P594, DOI 10.1111/j.1530-0277.1989.tb00383.x
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Hashibe M, 2006, CANCER EPIDEM BIOMAR, V15, P696, DOI 10.1158/1055-9965.EPI-05-0710
   HOOG JO, 1986, EUR J BIOCHEM, V159, P215, DOI 10.1111/j.1432-1033.1986.tb09855.x
   Smigielski EM, 2000, NUCLEIC ACIDS RES, V28, P352, DOI 10.1093/nar/28.1.352
   SMITH M, 1986, ADV HUM GENET, V15, P249
NR 8
TC 124
Z9 127
U1 1
U2 17
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
J9 NAT GENET
JI Nature Genet.
PD JUN
PY 2008
VL 40
IS 6
BP 707
EP 709
DI 10.1038/ng.151
PG 3
WC Genetics & Heredity
SC Genetics & Heredity
GA 305XV
UT WOS:000256212000009
PM 18500343
OA Green Published
DA 2020-11-30
ER

PT J
AU Domingues, RB
   Kuster, GW
   Onuki-Castro, FL
   Souza, VA
   Levi, JE
   Pannuti, CS
AF Domingues, Renan B.
   Kuster, Gustavo W.
   Onuki-Castro, Fabio L.
   Souza, Vanda A.
   Levi, Jose E.
   Pannuti, Claudio S.
TI Involvement of the central nervous system in patients with dengue virus
   infection
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE dengue virus; neurological manifestations; CSF; PCR
ID NEUROLOGICAL MANIFESTATIONS; ENCEPHALITIS; FEVER
AB The findings of a neurological evaluation in 85 patients with confirmed, acute, dengue virus infection are described. Signs of central nervous system involvement were present in IS patients (21.2%). The most frequent neurological symptom was mental confusion. The frequency of neurological involvement did not differ between patients with primary and secondary dengue infection, and the prevalence of central nervous system involvement in dengue fever and dengue hemorrhagic fever also did not differ significantly. The presence of CNS involvement did not influence the prognosis of dengue infection. Dengue viral CSF RNA was found in 7 of 13 patients submitted to a spinal tap, the CSF viral load being less than 1000 copies/ml. PCR was negative in serum samples obtained from three patients on the same day as the CSF samples, suggesting that the dengue virus actively enters the CNS and that the presence of the virus in the CNS does not result from passive crossing of the blood-brain barrier. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Domingues, Renan B.; Kuster, Gustavo W.; Onuki-Castro, Fabio L.] EMESCAM, Dept Pathol, Vitoria, Brazil.
   [Domingues, Renan B.; Kuster, Gustavo W.] Hosp Merid, Ctr Integrado Neurol, Espirito Santo, Brazil.
   [Souza, Vanda A.; Levi, Jose E.; Pannuti, Claudio S.] Univ Sao Paulo, Inst Trop Med, Fac Med,Dept Molestias Infecciosas & Parasitarias, Virol Lab, Sao Paulo, Brazil.
RP Domingues, RB (corresponding author), EMESCAM, Dept Pathol, Vitoria, Brazil.
EM renan-domingues@uol.com.br
RI Domingues, Renan B/H-1351-2012; Domingues, Renan/N-6003-2019; Pannuti,
   Claudio/B-7649-2012
OI Domingues, Renan B/0000-0002-6058-7937; Domingues,
   Renan/0000-0002-6058-7937; 
CR da Fonseca BAL, 2002, CURR OPIN PEDIATR, V14, P67
   Domingues RB, 2006, CEPHALALGIA, V26, P879, DOI 10.1111/j.1468-2982.2006.01100.x
   Domingues RB, 1997, CLIN INFECT DIS, V25, P86, DOI 10.1086/514494
   Ferreira MLB, 2005, ARQ NEURO-PSIQUIAT, V63, P488, DOI 10.1590/S0004-282X2005000300023
   George R., 1997, Annals Academy of Medicine Singapore, V26, P815
   Harris E, 1998, J CLIN MICROBIOL, V36, P2634, DOI 10.1128/JCM.36.9.2634-2639.1998
   Hommel D, 1998, RES VIROLOGY, V149, P235, DOI 10.1016/S0923-2516(98)80005-8
   Kalita J, 2005, Electromyogr Clin Neurophysiol, V45, P357
   Kankirawatana P, 2000, J CHILD NEUROL, V15, P544, DOI 10.1177/088307380001500809
   Laue T, 1999, J CLIN MICROBIOL, V37, P2543, DOI 10.1128/JCM.37.8.2543-2547.1999
   Lum LCS, 1996, AM J TROP MED HYG, V54, P256, DOI 10.4269/ajtmh.1996.54.256
   Miagostovich MP, 1997, CLIN NEUROPATHOL, V16, P204
   Misra UK, 2006, J NEUROL SCI, V244, P117, DOI 10.1016/j.jns.2006.01.011
   Palma-da Cunha-Matta A, 2004, REV NEUROLOGIA, V39, P233
   Pancharoen Chitsanu, 2001, Southeast Asian Journal of Tropical Medicine and Public Health, V32, P341
   Ramos C, 1998, J NEUROVIROL, V4, P465, DOI 10.3109/13550289809114548
   Row D, 1996, AM J TROP MED HYG, V54, P253, DOI 10.4269/ajtmh.1996.54.253
   Solomon T, 2000, LANCET, V355, P1053, DOI 10.1016/S0140-6736(00)02036-5
   Solomon T, 2001, J INFECTION, V42, P104, DOI 10.1053/jinf.2001.0802
   SOUZA RV, 1998, NEUROINFECCAO, V98, P33
   SOUZA VAU, 2004, J CLIN MICROBIOL, V42, P1782
   Strobel M, 1999, ANN MED INTERNE, V150, P79
   Vasconcelos Pedro F. C., 1998, Revista do Instituto de Medicina Tropical de Sao Paulo, V40, P35, DOI 10.1590/S0036-46651998000100008
   Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215
   Vaughn DW, 1999, AM J TROP MED HYG, V60, P693, DOI 10.4269/ajtmh.1999.60.693
   *WHO, 1999, GUID TREATM DENG DEV
   Witayathawornwong Prasonk, 2005, Southeast Asian Journal of Tropical Medicine and Public Health, V36, P200
   World Health Organization, 1997, DENG HAEM FEV DIAGN
   Yeo P. S. D., 2005, SMJ Singapore Medical Journal, V46, P647
NR 29
TC 75
Z9 82
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD APR 15
PY 2008
VL 267
IS 1-2
BP 36
EP 40
DI 10.1016/j.jns.2007.09.040
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 276YW
UT WOS:000254180600006
PM 17959198
DA 2020-11-30
ER

PT J
AU Guilarde, AO
   Turchi, MD
   Siqueira, JB
   Feres, VCR
   Rocha, B
   Levi, JE
   Souza, VAUF
   Boas, LSV
   Pannuti, CS
   Martelli, CMT
AF Guilarde, Adriana O.
   Turchi, Marilia D.
   Siqueira, Joao Bosco, Jr.
   Feres, Valeria C. R.
   Rocha, Benigno
   Levi, Jose E.
   Souza, Vanda A. U. F.
   Boas, Lucy Santos Vilas
   Pannuti, Claudio S.
   Martelli, Celina M. T.
TI Dengue and dengue hemorrhagic fever among adults: Clinical outcomes
   related to viremia, serotypes, and antibody response
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID RIO-DE-JANEIRO; CENTRAL BRAZIL; RISK-FACTORS; VIROLOGICAL FEATURES;
   IMMUNE-COMPLEXES; DISEASE SEVERITY; VIRUS-INFECTION; CLASSIFICATION;
   EPIDEMIC; SURVEILLANCE
AB Background. Clinical manifestations of dengue vary in different areas of endemicity and between specific age groups, whereas predictors of outcome have remained controversial. In Brazil, the disease burden predominantly affects adults, with an increasing trend toward progression to dengue hemorrhagic fever (DHF) noted.
   Methods. A cohort of adults with confirmed cases of dengue was recruited in central Brazil in 2005. Patients were classified according to the severity of their disease. Associations of antibody responses, viremia levels (as determined by real-time polymerase chain reaction [PCR]), and serotypes (as determined by multiplex PCR) with disease severity were evaluated.
   Results. Of the 185 symptomatic patients > 14 years of age who had a confirmed case of dengue, 26.5% and 23.2% were classified as having intermediate dengue fever (DF)/ DHF (defined as internal hemorrhage, plasma leakage, manifested signs of shock, and/ or thrombocytopenia [platelet count, <= 50,000 platelets/mm(3)]) and DHF, respectively. The onset of intermediate DF/ DHF and DHF occurred at a late stage of disease, around the period of defervescence. Patients with DHF had abnormal liver enzyme levels, with a > 3-fold increase in aspartate aminotransferase level, compared with the range of values considered to be normal. Overall, 65% of patients presented with secondary infections with dengue virus, with such infection occurring in similar proportions of patients in each of the 3 disease category groups. Dengue virus serotype 3 (DV3) was the predominant serotype, and viremia was detected during and after defervescence among patients with DHF or intermediate DF/ DHF.
   Conclusions. Viremia was detected after defervescence in adult patients classified as having DHF or intermediate DF/ DHF. Secondary infection was not a predictor of severe clinical manifestation in adults with infected with the DV3 serotype.
C1 [Guilarde, Adriana O.; Turchi, Marilia D.; Siqueira, Joao Bosco, Jr.; Rocha, Benigno; Martelli, Celina M. T.] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, BR-74605050 Goiania, Go, Brazil.
   [Feres, Valeria C. R.] Secretaria Estado Saude de Goias, Lab Cent Saude Publ Goias, Goiania, Go, Brazil.
   [Pannuti, Claudio S.] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Virol Lab, Sao Paulo, Brazil.
   [Pannuti, Claudio S.] Univ Sao Paulo, Inst Med Trop Sao Paulo, Sao Paulo, Brazil.
RP Martelli, CMT (corresponding author), Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Rua 235,S-N Setor Univ, BR-74605050 Goiania, Go, Brazil.
EM celina@iptsp.ufg.br
RI Pannuti, Claudio/B-7649-2012
OI Turchi Martelli, Celina Maria/0000-0002-2491-0688
CR Anantapreecha S, 2005, EPIDEMIOL INFECT, V133, P503, DOI 10.1017/S0950268804003541
   Balmaseda A, 2006, AM J TROP MED HYG, V74, P449, DOI 10.4269/ajtmh.2006.74.449
   Balmaseda A, 2005, AM J TROP MED HYG, V73, P1059, DOI 10.4269/ajtmh.2005.73.1059
   Bandyopadhyay S, 2006, TROP MED INT HEALTH, V11, P1238, DOI 10.1111/j.1365-3156.2006.01678.x
   *BRAZ MIN HLTH, 2006, EP DENG DEC 2006, P1
   Clyde K, 2006, J VIROL, V80, P11418, DOI 10.1128/JVI.01257-06
   De Simone TS, 2004, T ROY SOC TROP MED H, V98, P553, DOI 10.1016/j.trstmh.2003.09.003
   de Souza VAUF, 2004, J CLIN MICROBIOL, V42, P1782, DOI 10.1128/JCM.42.4.1782-1784.2004
   Deen JL, 2006, LANCET, V368, P170, DOI 10.1016/S0140-6736(06)69006-5
   Endy TP, 2004, J INFECT DIS, V189, P990, DOI 10.1086/382280
   Gibbons RV, 2002, BRIT MED J, V324, P1563, DOI 10.1136/bmj.324.7353.1563
   Gubler DJ, 2001, DENGUE DENGUE HEMORR
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Guzman MG, 2000, AM J EPIDEMIOL, V152, P793, DOI 10.1093/aje/152.9.793
   HALSTEAD SB, 1970, YALE J BIOL MED, V42, P311
   Halstead SB, 2006, REV PANAM SALUD PUBL, V20, P407, DOI 10.1590/S1020-49892006001100007
   Hammond SN, 2005, AM J TROP MED HYG, V73, P1063
   Harris E, 2000, AM J TROP MED HYG, V63, P5, DOI 10.4269/ajtmh.2000.63.5
   Harris E, 1998, J CLIN MICROBIOL, V36, P2634, DOI 10.1128/JCM.36.9.2634-2639.1998
   Hung NT, 2005, AM J TROP MED HYG, V72, P370
   IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531
   KUNO G, 1987, AM J TROP MED HYG, V36, P153, DOI 10.4269/ajtmh.1987.36.153
   Lee Min-Sheng, 2006, Journal of Microbiology Immunology and Infection, V39, P121
   Levi JE, 2007, J CLIN MICROBIOL, V45, P1893, DOI 10.1128/JCM.00065-07
   Libraty DH, 2002, J INFECT DIS, V185, P1213, DOI 10.1086/340365
   Matheus S, 2005, J CLIN MICROBIOL, V43, P5784, DOI 10.1128/JCM.43.11.5784-5786.2005
   *MIN SAUD, 2005, DENG DIAGN CLIN HAND
   Montenegro D, 2006, REV SOC BRAS MED TRO, V39, P9, DOI 10.1590/S0037-86822006000100002
   Nogueira RMR, 2005, EMERG INFECT DIS, V11, P1376
   Nogueira RMR, 1999, T ROY SOC TROP MED H, V93, P418, DOI 10.1016/S0035-9203(99)90142-6
   Feres VCR, 2006, J CLIN VIROL, V37, P179, DOI 10.1016/j.jcv.2006.07.004
   Rigau-Perez JG, 2006, LANCET INFECT DIS, V6, P297, DOI 10.1016/S1473-3099(06)70465-0
   ROSEN L, 1989, REV INFECT DIS, V11, pS840
   Siqueira JB, 2005, EMERG INFECT DIS, V11, P48, DOI 10.3201/eid1101.031091
   Siqueira JB, 2004, AM J TROP MED HYG, V71, P646, DOI 10.4269/ajtmh.2004.71.646
   Souza Luiz José de, 2004, Braz J Infect Dis, V8, P156, DOI 10.1590/S1413-86702004000200006
   Stephenson JR, 2005, B WORLD HEALTH ORGAN, V83, P308
   de Souza VAUF, 2007, J CLIN VIROL, V39, P230, DOI 10.1016/j.jcv.2007.04.005
   Uehara PM, 2006, REV SOC BRAS MED TRO, V39, P544, DOI 10.1590/S0037-86822006000600006
   Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215
   Vaughn DW, 1999, AM J TROP MED HYG, V60, P693, DOI 10.4269/ajtmh.1999.60.693
   Wang WK, 2006, CLIN INFECT DIS, V43, P1023, DOI 10.1086/507635
   WHO, 1997, DENG HAEM FEV DIAGN, P1
   Wichmann O, 2004, TROP MED INT HEALTH, V9, P1022, DOI 10.1111/j.1365-3156.2004.01295.x
   Wichmann O, 2007, J INFECT DIS, V195, P1089, DOI 10.1086/512680
   World Health Organization, 2006, DEF DIAGN DIAB MELL, P1
   Yeh WT, 2006, FEMS IMMUNOL MED MIC, V48, P84, DOI 10.1111/j.1574-695X.2006.00127.x
   ZAGNE SMO, 1994, T ROY SOC TROP MED H, V88, P677, DOI 10.1016/0035-9203(94)90225-9
NR 48
TC 117
Z9 126
U1 1
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAR 15
PY 2008
VL 197
IS 6
BP 817
EP 824
DI 10.1086/528805
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 271FI
UT WOS:000253773900007
PM 18269315
OA Bronze, Green Published
DA 2020-11-30
ER

PT J
AU Campos, EA
   Simoes, JA
   Rabelo-Santos, SH
   Sarian, LO
   Pitta, DR
   Levi, JE
   Derchain, S
AF Campos, Elisabete A.
   Simoes, Jose Antonio
   Rabelo-Santos, Silvia H.
   Sarian, Luis Otavio
   Pitta, Denise Rocha
   Levi, Jose Eduardo
   Derchain, Sophie
TI Recovery of DNA for the detection and genotyping of human papillomavirus
   from clinical cervical specimens stored for up to 2 years in a universal
   collection medium with denaturing reagent
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE HPV DNA; universal collection medium; denaturing reagent; detection;
   storage; cervical cancer; genotype
ID HYBRID-CAPTURE-II; HYBRID-CAPTURE-2 ASSAY; TRANSPORT-MEDIUM; HPV
   INFECTIONS; ROCHE AMPLICOR; SAMPLES; AMPLIFICATION; WOMEN; EXTRACTION;
   FIXATION
AB The recovery and stability of DNA for the detection and genotyping of HPV in UCM-containing specimens, after exposure to denaturing reagents and stored for up to 2 years were evaluated. Samples were collected from 60 women who had cervical cytology specimens harboring cervical intraepithelial neoplasia (CIN) 2 or 3. All samples were stored in UCM and had been frozen at -20 degrees C following the addition of the denaturing reagent (sodium hydroxide) and the removal of the aliquot required for Hybrid Capture 2 testing for the identification of HPV DNA. The samples had been stored for 6, 12 and 24 months (20 samples for each storage time). HPV DNA extraction was performed according to a protocol designed specifically and the presence and quality of DNA was confirmed by human P-globin detection using the consensus primers G73 and G74. HPV DNA was amplified using the consensus primers PGMY09 and PGMY11, and reverse line-blot hybridization was used to detect type-specific amplicons for 37 HPV types. The DNA extracted from the denatured specimen was recovered in 57/60 (95%) of the samples. HPV DNA was detected in 56/57 (98%) of the recovered samples. Twenty-six of the 56 samples recovered (48%) were genotyped successfully. (c) 2007 Elsevier B.V. All rights reserved.
C1 [Campos, Elisabete A.; Simoes, Jose Antonio; Sarian, Luis Otavio; Pitta, Denise Rocha; Derchain, Sophie] Univ Estadual Campinas, Dept Obstet & Gynecol, Sao Paulo, Brazil.
   [Rabelo-Santos, Silvia H.] Univ Fed Goias, Sch Pharm, Goiania, Go, Brazil.
   [Levi, Jose Eduardo] Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
RP Simoes, JA (corresponding author), Caixa Postal 6181,Cidade Univ Zeferino Vaz, BR-13083970 Campinas, SP, Brazil.
EM jsimoes@caism.unicamp.br
RI Derchain, Sophie FM/I-9500-2014; Sarian, Luis/AAA-2722-2020; Sarian,
   Luis O/C-4150-2013; Rabelo-Santos, Silvia/F-9574-2012
OI Derchain, Sophie FM/0000-0003-1029-9993; Sarian, Luis
   O/0000-0002-9554-6131; moraes, denise/0000-0001-5103-7629; Campos,
   Elisabete Aparecida/0000-0001-8226-1105
CR ARBYN A, 2006, VACCINE, P79
   BENEZRA J, 1991, J HISTOCHEM CYTOCHEM, V39, P351, DOI 10.1177/39.3.1704393
   Carozzi FM, 2005, AM J CLIN PATHOL, V124, P716, DOI 10.1309/84E5WHJQHK83BGQD
   Carozzi F, 2007, J CLIN MICROBIOL, V45, P364, DOI 10.1128/JCM.00706-06
   CASTEL PE, 2003, J CLIN MICROBIOL, P4022
   Castellsague X, 2006, JNCI-J NATL CANCER I, V98, P303, DOI 10.1093/jnci/djj067
   Clavel C, 1999, BRIT J CANCER, V80, P1306, DOI 10.1038/sj.bjc.6690523
   Clifford G, 2006, VACCINE, V24, P26, DOI 10.1016/j.vaccine.2006.05.026
   Dunn ST, 2007, J VIROL METHODS, V143, P45, DOI 10.1016/j.jviromet.2007.02.006
   Giuliani L, 2006, ANTICANCER RES, V26, P3939
   Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
   GREER CE, 1991, AM J CLIN PATHOL, V95, P117, DOI 10.1093/ajcp/95.2.117
   Levi JE, 2002, J CLIN MICROBIOL, V40, P3341, DOI 10.1128/JCM.40.9.3341-3345.2002
   Melo A, 2005, REV MED CHILE, V133, P639, DOI 10.4067/S0034-98872005000600003
   Mesquita R A, 2001, Pesqui Odontol Bras, V15, P314
   Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641
   Munoz N, 2006, VACCINE, V24, P1, DOI 10.1016/j.vaccine.2006.05.115
   Nonogaki S, 2004, ACTA CYTOL, V48, P514, DOI 10.1159/000326413
   Perrons C, 2002, J MED VIROL, V67, P246, DOI 10.1002/jmv.2214
   Poljak M, 2002, J CLIN VIROL, V25, pS89
   Rabelo-Santos SH, 2005, J VIROL METHODS, V126, P197, DOI 10.1016/j.jviromet.2005.02.009
   Schiffman M, 2007, CANCER CYTOPATHOL, V111, P145, DOI 10.1002/cncr.22751
   Stevens MP, 2007, J CLIN MICROBIOL, V45, P2130, DOI 10.1128/JCM.02438-06
   Stevens MP, 2006, J CLIN MICROBIOL, V44, P2428, DOI 10.1128/JCM.02608-05
   Taha NSA, 2006, J CLIN VIROL, V36, P32, DOI 10.1016/j.jcv.2005.12.011
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Woo YL, 2007, J VIROL METHODS, V142, P226, DOI 10.1016/j.jviromet.2007.01.029
NR 27
TC 6
Z9 7
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD FEB
PY 2008
VL 147
IS 2
BP 333
EP 337
DI 10.1016/j.jviromet.2007.09.014
PG 5
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 260IP
UT WOS:000253004300020
PM 17976831
DA 2020-11-30
ER

PT J
AU Campos, A
   Amaral, E
   Levi, JE
   Portugal, P
   Villarroel, M
   Bezerra, KC
   Nousco, MT
   Morais, SS
AF Campos, Angela
   Amaral, Eliana
   Levi, Jose Eduardo
   Portugal, Priscila
   Villarroel, Marina
   Bezerra, Karina C.
   Nousco da Silva, Marcos T.
   Morais, Sirlei Siani
TI Hiv vaginal viral load in Brazilian HIV-infected women
SO REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
LA Portuguese
DT Article
DE HIV; vagina; viral load; horizontal disease transmission;
   heterosexuality; prevalence
ID IMMUNODEFICIENCY-VIRUS TYPE-1; FEMALE GENITAL-TRACT; ACTIVE
   ANTIRETROVIRAL THERAPY; CERVICOVAGINAL SECRETIONS; HETEROSEXUAL
   TRANSMISSION; RNA LEVELS; CELL-FREE; PLASMA; BLOOD; ASSOCIATIONS
AB OBJECTIVE. To evaluate factors associated to presence of free RNA-HIV in the vagina. Methods. Cross-sectional study with HIV-infected women, excluding those who had undergone histerectomy, had used vaginal medication within the last 48 hours, had had unprotected sex less than 72 hours before, were pregnant, or had genital bleeding. After signing an informed consent, blood samples were obtained for T CD4 lymphocytes count and plasmatic viral load, in addition to cervico-vaginal lavage using 10mL of sterile normal saline, later centrifuged, aliquoted and stored at -70 degrees C to quantify free HIV-RNA. Plasmatic and vaginal viral load were measured using the kit HIV v1.5 Cobas Amplicor, Roche. Hybrid Capture test Digene was utilized for HPV (high and low risk), clamydia trachomatis and N. gonorrhoae detection from an endocervical sample. Vaginal swab for bacterioscopy by the Gram method, evaluated according to Nugent criteria was obtained.
   RESULTS. Among 200 women evaluated, 73.5% were using HAART The RNA-HIV was detectable in the vaginal lavage of 18 (9%), but in only one of those who had undetectable plasma viral load (0.5%). The vaginal prevalence of HIV was 24 tunes higher among those with detectable plasmatic HIV. Plasma viral load >= 1500 copies/mL, no HAART use, reduced CD4 and bacterial vaginosis had Increased prevalence of vaginal HIV-RNA, butin the adjusted statistical analysis, only the former remained significant
   CONCLUSION. Prevalence of vaginal HIV-RNA was low(9%). Plasmatic viral load:? 1500 copies/mL, was the only risk factor for free vaginal HIV-RNA.
C1 [Campos, Angela; Amaral, Eliana; Levi, Jose Eduardo; Portugal, Priscila; Villarroel, Marina; Bezerra, Karina C.; Nousco da Silva, Marcos T.; Morais, Sirlei Siani] Univ Estadual Campinas, BR-13083881 Campinas, SP, Brazil.
RP Amaral, E (corresponding author), Univ Estadual Campinas, Caixa Postal 6081, BR-13083881 Campinas, SP, Brazil.
EM elianaa@unicamp.br
CR Andreoletti L, 2003, J INFECT DIS, V188, P549, DOI 10.1086/377104
   Benki S, 2004, J INFECT DIS, V189, P2192, DOI 10.1086/421298
   Castilla J, 2005, JAIDS-J ACQ IMM DEF, V40, P96, DOI 10.1097/01.qai.0000157389.78374.45
   Coombs RW, 2003, AIDS, V17, P455, DOI 10.1097/00002030-200303070-00001
   Coutlee F, 2006, J CLIN MICROBIOL, V44, P1998, DOI 10.1128/JCM.00104-06
   Cu-Uvin S, 2006, JAIDS-J ACQ IMM DEF, V42, P584, DOI 10.1097/01.qai.0000229997.52246.95
   Cummins JE, 2006, AIDS RES HUM RETROV, V22, P788, DOI 10.1089/aid.2006.22.788
   Debiaggi M, 2001, EUR J CLIN MICROBIOL, V20, P91, DOI 10.1007/s10096-001-8055-2
   Garcia-Bujalance S, 2004, EUR J CLIN MICROBIOL, V23, P111, DOI 10.1007/s10096-003-1058-4
   Ghys PD, 1997, AIDS, V11, pF85, DOI 10.1097/00002030-199712000-00001
   Graham SM, 2007, AIDS, V21, P501, DOI 10.1097/QAD.0b013e32801424bd
   Hart CE, 1999, J INFECT DIS, V179, P871, DOI 10.1086/314656
   Kovacs A, 1999, J ACQ IMMUN DEF SYND, V22, P124
   Kovacs A, 2001, LANCET, V358, P1593, DOI 10.1016/S0140-6736(01)06653-3
   Levi G, 2005, J OBSTET GYNAECOL RE, V31, P178, DOI 10.1111/j.1341-8076.2005.00267.x
   Levi JE, 2004, GYNECOL ONCOL, V92, P225, DOI 10.1016/j.ygyno.2003.10.004
   Malamba SS, 2005, JAIDS-J ACQ IMM DEF, V39, P576
   Neely MN, 2007, JAIDS-J ACQ IMM DEF, V44, P38, DOI 10.1097/01.qai.0000248352.18007.1f
   NICOL AF, 2007, J CLIN PATHOL
   *PER HIV GUID WORK, 2006, PUBL HLTH SERV TASK, P1
   *PROGR NAC DST AID, 2006, CONS REC PROF TRANSM
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   Spinillo A, 2001, OBSTET GYNECOL, V97, P999, DOI 10.1016/S0029-7844(01)01130-9
   Sullivan ST, 2005, J VIROL, V79, P9799, DOI 10.1128/JVI.79.15.9799-9809.2005
   Wang CC, 2004, AIDS, V18, P205, DOI 10.1097/00002030-200401230-00009
   Wright TC, 2001, AM J OBSTET GYNECOL, V184, P279, DOI 10.1067/mob.2001.108999
   Zara F, 2004, SEX TRANSM INFECT, V80, P108, DOI 10.1136/sti.2003.005157
NR 27
TC 3
Z9 3
U1 0
U2 4
PU ASSOC MEDICA BRASILEIRA
PI SAO PAULO
PA RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL
SN 0104-4230
J9 REV ASSOC MED BRAS
JI Rev. Assoc. Med. Bras.
PD JAN-FEB
PY 2008
VL 54
IS 1
BP 67
EP 71
DI 10.1590/S0104-42302008000100023
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 301UF
UT WOS:000255920400022
PM 18392489
OA DOAJ Gold, Green Published
DA 2020-11-30
ER

PT J
AU Nahas, SC
   Nahas, CSR
   da Silva, EV
   Levi, JE
   Alui, FC
   Marques, CFS
AF Nahas, Sergio Carlos
   Rizkallah Nahas, Caio Sergio
   da Silva Filho, Edesio Vieira
   Levi, Jose Eduardo
   Alui, Fabio Cesar
   Sparapan Marques, Carlos Frederico
TI Perianal squamous cell carcinoma with high-grade anal intraepithelial
   neoplasia in an HIV-positive patient using highly active antiretroviral
   therapy: case report
SO SAO PAULO MEDICAL JOURNAL
LA English
DT Article
DE carcinoma in situ; anal cancer; anus neoplasms; AIDS serodiagnosis;
   human papillomavirus 16
ID HUMAN-PAPILLOMAVIRUS INFECTION; LESIONS; MEN; SEX
AB CONTEXT. Highly active antiretroviral therapy (HAART) has turned human immunodeficiency virus (HIV) infection into a chronic condition, and this has led to increased incidence of anal dysplasia among HIV-positive patients. Routine anal evaluation including the anal canal and perianal area is recommended for this population, especially for patients infected by oncogenic human papillomavirus (HPV) types.
   CASE REPORT. A 54-year-old homosexual HIV-positive man presented with a six-year history of recurrent perianal and anal warts. He had previously undergone incomplete surgical excision and fulguration in another institution on two occasions. He had been using HAART over the past two years. He presented some condylomatous spreading lesions occupying Part of the anal canal and the perianal skin, and also a well-demarcated slightly painful perianal plaque of dimensions 1.0 x 1.0 cm. Both anal canal Pap smears and biopsies guided by high-resolution anoscopy revealed high-grade squamous intraepithelial lesion. Biopsies of the border of the perianal plaque also revealed high-grade squamous intraepithelial lesion. HPV DNA testing of the anus defected the presence of HPV-16 type. The patient underwent local full-thickness excision of the lesion. Histological analysis on the excised tissue revealed high-grade squamous intrarepithelial lesion with one focus of microinvasive squamous cell cancer measuring I mm. No lymph vessel or perineural invasion was detected. The patient showed pathological evidence of recurrent anal and perianal high-grade squamous intraepithelial lesions at the sixth-month follow-up and required further ablation of those lesions. However no invasive squamous cell carcinoma recurrence has been defected so far.
C1 [Nahas, Sergio Carlos; Rizkallah Nahas, Caio Sergio; da Silva Filho, Edesio Vieira; Levi, Jose Eduardo; Alui, Fabio Cesar; Sparapan Marques, Carlos Frederico] Univ Sao Paulo, Fac Med, Hosp Clin, Dept Gastroenterol,Surg Div, Sao Paulo, Brazil.
RP Nahas, SC (corresponding author), Rua Jabebira,136 Jardim Everest, BR-05602020 Sao Paulo, Brazil.
EM sergionahas@uol.com.br
RI Nahas, Caio/A-3065-2013; MARQUES, CARLOS/A-4809-2013; NAHAS,
   SERGIO/A-4799-2013
OI Nahas, Caio/0000-0001-8036-512X; MARQUES, CARLOS/0000-0003-4293-6301;
   NAHAS, SERGIO/0000-0002-2268-4146
CR BECKMANN AM, 1989, INT J CANCER, V43, P1042, DOI 10.1002/ijc.2910430615
   Cleary RK, 1999, DIS COLON RECTUM, V42, P945, DOI 10.1007/BF02237107
   Frisch M, 2000, JNCI-J NATL CANCER I, V92, P1500, DOI 10.1093/jnci/92.18.1500
   Goldstone SE, 2001, DIS COLON RECTUM, V44, P690, DOI 10.1007/BF02234568
   Heard I, 2004, ANTIVIR THER, V9, P13
   Jay N, 1997, DIS COLON RECTUM, V40, P919, DOI 10.1007/BF02051199
   MELBYE M, 1990, INT J CANCER, V46, P203, DOI 10.1002/ijc.2910460210
   Palefsky JM, 2005, AIDS, V19, P1407, DOI 10.1097/01.aids.0000181012.62385.4a
   Palefsky JM, 1998, AIDS, V12, P495, DOI 10.1097/00002030-199805000-00011
   Palefsky JM, 2001, J ACQ IMMUN DEF SYND, V28, P422, DOI 10.1097/00042560-200112150-00003
NR 10
TC 3
Z9 3
U1 0
U2 5
PU ASSOCIACAO PAULISTA MEDICINA
PI SAO PAULO
PA AV BRIG LUIS ANTONIO, 278-7 ANDAR, SAO PAULO, CEP01318-901, BRAZIL
SN 1516-3180
J9 SAO PAULO MED J
JI Sao Paulo Med. J.
PD SEP 6
PY 2007
VL 125
IS 5
BP 292
EP 294
DI 10.1590/S1516-31802007000500009
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 338KT
UT WOS:000258507300009
PM 18094898
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Levi, JE
   Tateno, AF
   Machado, AF
   Ramalho, DC
   de Souza, VAUF
   Guilarde, AO
   Feres, VCD
   Martelli, CMT
   Turchi, MD
   Siqueira, JB
   Pannuti, CS
AF Levi, Jose Eduardo
   Tateno, Adriana Fumie
   Machado, Adriana Freire
   Ramalho, Dbora Camillo
   Akico Ueda Fick de Souza, Vanda
   Guilarde, Adriana Oliveira
   de Rezende Feres, Valria Christina
   Martelli, Celina Maria Turchi
   Turchi, Marilia Dalva
   Siqueira, Joao Bosco, Jr.
   Pannuti, Claudio Sergio
TI Evaluation of a commercial real-time PCR kit for detection of dengue
   virus in samples collected during an outbreak in Goiania, central
   Brazil, in 2005
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID HEMORRHAGIC-FEVER; SURVEILLANCE; INFECTIONS; DISEASE
AB In the past 2 decades, dengue has reemerged in Brazil as a significant public health problem. Clinicians demand a diagnostic test with high sensitivity that is applicable during the early symptomatic phase. We aimed to test two distinct molecular methods on samples from suspected dengue cases during an outbreak in Central Brazil. Acute-phase serum specimens from 254 patients suspected of having dengue were collected during 2005 in the city of Goiania, Central Brazil. Samples were blindly evaluated by real-time and multiplex PCR in addition to routine immunoglobulin M serology and virus culture. Overall, acute dengue was confirmed by serology, multiplex PCR, or virus isolation for 80% of patients (203/254). Another four patients presented real-time PCR-positive results as the unique marker of dengue. Higher real-time PCR positivity levels and viral loads were observed in the early symptomatic phase of disease (<= 5 days) than after this period. Multiplex and real-time PCR assays presented a high kappa agreement (0.85). According to multiplex PCR, 60 samples harbored dengue virus type 3 (DEN-3), 4 samples harbored DEN-2, and 1 sample displayed a pattern compatible with a double infection with DEN-2 and -3. The dengue virus real-time kit was found to be practical and adjustable for high throughput, to display the best performance in the early symptomatic phase of dengue cases, and to be valuable for confirming dengue diagnosis in a timely manner.
C1 Univ Sao Paulo, Inst Trop Med, Virol Lab, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, FMUSP, Virol Lab, LIM HC, BR-05403000 Sao Paulo, Brazil.
   Univ Fed Goias, IPTSP, Goiania, Go, Brazil.
   Secretaria Estado Saude Goias, LACEN Go, Goiania, Go, Brazil.
RP Levi, JE (corresponding author), Univ Sao Paulo, Inst Trop Med, Virol Lab, Rua Dr Eneas de Caarvalho Aguiar 470,2 Andar, BR-05403000 Sao Paulo, Brazil.
EM dudilevi@usp.br
RI Pannuti, Claudio/B-7649-2012
OI Turchi Martelli, Celina Maria/0000-0002-2491-0688
CR Barkham TM, 2006, T ROY SOC TROP MED H, V100, P142, DOI 10.1016/j.trstmh.2005.05.015
   GUBLER DJ, 1984, AM J TROP MED HYG, V33, P158, DOI 10.4269/ajtmh.1984.33.158
   Harris E, 1998, J CLIN MICROBIOL, V36, P2634, DOI 10.1128/JCM.36.9.2634-2639.1998
   IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531
   KUNO G, 1991, J VIROL METHODS, V33, P101, DOI 10.1016/0166-0934(91)90011-N
   Montenegro D, 2006, REV SOC BRAS MED TRO, V39, P9, DOI 10.1590/S0037-86822006000100002
   Nogueira RMR, 2005, EMERG INFECT DIS, V11, P1376
   Poersch CD, 2005, J CLIN VIROL, V32, P272, DOI 10.1016/j.jcv.2004.08.008
   Feres VCR, 2006, J CLIN VIROL, V37, P179, DOI 10.1016/j.jcv.2006.07.004
   Siqueira JB, 2005, EMERG INFECT DIS, V11, P48, DOI 10.3201/eid1101.031091
   Sudiro TM, 2001, J MED VIROL, V63, P29, DOI 10.1002/1096-9071(200101)63:1&lt;29::AID-JMV1004&gt;3.0.CO;2-S
   Vaughn DW, 2000, J INFECT DIS, V181, P2, DOI 10.1086/315215
   Wang WK, 2003, VIROLOGY, V305, P330, DOI 10.1006/viro.2002.1704
   World Health Organization, 1997, DENG HAEM FEV DIAGN, P34
NR 14
TC 18
Z9 19
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUN
PY 2007
VL 45
IS 6
BP 1893
EP 1897
DI 10.1128/JCM.00065-07
PG 5
WC Microbiology
SC Microbiology
GA 179JT
UT WOS:000247286500034
PM 17409201
OA Bronze, Green Published
DA 2020-11-30
ER

PT J
AU Mauad, LQ
   Tateno, AF
   Levi, JE
   Mauad, MA
   Souza, M
   Colturado, VR
   Ikoma, MV
   Machado, CM
AF Mauad, L. Q.
   Tateno, A. F.
   Levi, J. E.
   Mauad, M. A.
   Souza, M.
   Colturado, V. R.
   Ikoma, M. V.
   Machado, C. M.
TI Prospective study of the dynamics of human papillomavirus infection in
   female HSCT recipients: Preliminary results
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the
   European-Group-for-Blood-and-Marrow-Transplantation
CY MAR 25-28, 2007
CL Lyon, FRANCE
SP European Grp Blood & Marrow Transplantat
C1 Amaral Carvalho Fdn, Jau, Brazil.
   Univ Sao Paulo, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD APR
PY 2007
VL 39
SU 1
BP S161
EP S161
PG 1
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 150HU
UT WOS:000245207400432
DA 2020-11-30
ER

PT J
AU Oliveira, RR
   Tateno, AF
   Levi, JE
   Boas, LSV
   Pannuti, CS
   Machado, CM
AF Oliveira, R. R.
   Tateno, A. F.
   Levi, J. E.
   Boas, L. S. Vilas
   Pannuti, C. S.
   Machado, C. M.
TI Human metapneumovirus infection in haematopoietic stem cell transplant
   recipients from Sao Paulo, Brazil
SO BONE MARROW TRANSPLANTATION
LA English
DT Meeting Abstract
CT 33rd Annual Meeting of the
   European-Group-for-Blood-and-Marrow-Transplantation
CY MAR 25-28, 2007
CL Lyon, FRANCE
SP European Grp Blood & Marrow Transplantat
C1 Univ Sao Paulo, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD APR
PY 2007
VL 39
SU 1
BP S160
EP S160
PG 1
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA 150HU
UT WOS:000245207400430
DA 2020-11-30
ER

PT J
AU Cavalcante, SC
   Freitas, RS
   Vidal, MSM
   Dantas, KC
   Levi, JE
   Martins, JEC
AF Cavalcante, Sonia Cristina
   Freitas, Roseli Santos
   Martinelli Vidal, Monica Scarpelli
   Dantas, Katia Cristina
   Levi, Jose Eduardo
   Costa Martins, Jose Eduardo
TI Evaluation of phenotypic and genotypic alterations induced by long
   periods of subculturing of Cryptococcus neoformans strains
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Cryptococcus neoforms; random amplified polymorphic DNA technique;
   freeze drying
ID GATTII SEROTYPE-B; PATHOGENIC FUNGI; MOLECULAR EPIDEMIOLOGY; DISTILLED
   WATER; AIDS; MENINGITIS; CULTIVATION; MAINTENANCE; INFECTIONS
AB Cryptococcus neoformans is an encapsulated fungal organism that can cause disease in apparently immunocompetent, as well as immunocompromised, hosts. Since 1930, successive subculture has been used to preserve C. neoformans isolates in our Fungus Collection. In the 1970s, some of these Fungus Collection samples were selected to be subjected to a different methods of maintenance - that of lyophilized. Our objective was to analyze C. neoformans isolates in order to make a comparative evaluation between these two methods of preservation. The overall aim of this study was to qualify the preservation technique used in our mycology laboratory since the technique used might affect the survival, stability and purity of the primary isolates in culture.
   The samples were analyzed using classical mycology methods and using the randomly amplified polymorphic DNA technique. In the analysis of phenotypes and genotypes, the typical characteristics of C. neoformans were found to differ in relation to the different methods of preservation employed.
   The aim of this study was to demonstrate the importance of selecting the appropriate method of preservation for fungus collections. This selection can affect the survival and purity of the cultures, and preserve the stability of their physiological, biochemical, and genetic characteristics.
C1 Inst Med Trop Sao Paulo, Lab Micol Med, BR-05403000 Sao Paulo, Brazil.
   Inst Med Trop Sao Paulo, Virol Lab, BR-05403000 Sao Paulo, Brazil.
RP Cavalcante, SC (corresponding author), Inst Med Trop Sao Paulo, Lab Micol Med, LIM 53-52,Rua Dr Eneas Carvalho Aguiar 500, BR-05403000 Sao Paulo, Brazil.
EM soniamicologia@yahoo.com
RI Freitas, Roseli/F-5952-2013
OI Freitas, Roseli/0000-0001-5811-5255
CR BENNETT JE, 1978, SABOURAUDIA, V16, P167
   Borba Cintia de Moraes, 2000, Revista Iberoamericana de Micologia, V17, P142
   BOSMANS J, 1974, MYCOPATH MYCOL APPL, V53, P13, DOI 10.1007/BF02127195
   CASTELLA.A, 1967, J TROP MED HYG, V70, P181
   CASTELLANI A, 1963, J TROP MED HYG, V66, P283
   Cavalcanti MS, 1994, B MICOLOGICO, V9, P19
   Chen S, 2000, CLIN INFECT DIS, V31, P499, DOI 10.1086/313992
   Cherniak R, 1988, Curr Top Med Mycol, V2, P40
   Chiapello LS, 2003, MED MYCOL, V41, P347, DOI 10.1080/1369378031000137260
   DASILVA AMM, 1994, MYCOSES, V37, P165, DOI 10.1111/j.1439-0507.1994.tb00295.x
   Diaz MR, 2000, SYST APPL MICROBIOL, V23, P535, DOI 10.1016/S0723-2020(00)80028-4
   DISMUKES WE, 1988, J INFECT DIS, V157, P624, DOI 10.1093/infdis/157.4.624
   Ellerbroek PM, 2004, CURR MED CHEM, V11, P253, DOI 10.2174/0929867043456188
   Ferreti de Lima Renata, 2001, Revista Iberoamericana de Micologia, V18, P191
   Franzot SP, 1999, J CLIN MICROBIOL, V37, P838, DOI 10.1128/JCM.37.3.838-840.1999
   Hoang LMN, 2004, J MED MICROBIOL, V53, P935, DOI 10.1099/jmm.0.05427-0
   Horta JA, 2002, MED MYCOL, V40, P565
   Igreja RP, 2004, MED MYCOL, V42, P229, DOI 10.1080/13693780310001644743
   Jain N, 2005, J CLIN MICROBIOL, V43, P5733, DOI 10.1128/JCM.43.11.5733-5742.2005
   Kurtzman C, 1998, YEASTS TAXONOMIC STU
   KWONCHUNG KJ, 1982, J CLIN MICROBIOL, V15, P535, DOI 10.1128/JCM.15.3.535-537.1982
   KWONCHUNG KJ, 1992, MED MYCOL, P397
   LACAZ CD, 1983, REV BRAS MED, V40, P297
   Lacaz CS, 2002, TRATADO MICOLOGIA ME
   Litvintseva AP, 2005, J INFECT DIS, V192, P888, DOI 10.1086/432486
   MCGINNIS MR, 1980, LAB HDB MED MYCOLOGY
   Nakamura Y, 2001, Nihon Ishinkin Gakkai Zasshi, V42, P69
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Piot P, 2001, NATURE, V410, P968, DOI 10.1038/35073639
   POWDERLY WG, 1993, CLIN INFECT DIS, V17, P837, DOI 10.1093/clinids/17.5.837
   RODRIGUES EG, 1992, REV I MED TROP, V34, P159, DOI 10.1590/S0036-46651992000200012
   SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202
   SANDHU GS, 1995, J CLIN MICROBIOL, V33, P2913, DOI 10.1128/JCM.33.11.2913-2919.1995
   Spencer J F, 1996, Methods Mol Biol, V53, P5
   URDANETA SM, 1965, REV INST MED TROP SP, V71, P24
   vanderHorst CM, 1997, NEW ENGL J MED, V337, P15, DOI 10.1056/NEJM199707033370103
   Velegraki A, 2001, MED MYCOL, V39, P419, DOI 10.1080/mmy.39.5.419.422
   WILLIAMS JGK, 1990, NUCLEIC ACIDS RES, V18, P6531, DOI 10.1093/nar/18.22.6531
NR 38
TC 8
Z9 9
U1 0
U2 2
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD FEB
PY 2007
VL 102
IS 1
BP 41
EP 47
DI 10.1590/S0074-02762007000100006
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 134RG
UT WOS:000244101000006
PM 17293997
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Domingues, RB
   Kuster, GW
   de Castro, FLO
   Souza, VA
   Levi, JE
   Pannuti, CS
AF Domingues, R. B.
   Kuster, G. W.
   de Castro, F. L. Onuki
   Souza, V. A.
   Levi, J. E.
   Pannuti, C. S.
TI Headache features in patients with dengue virus infection
SO CEPHALALGIA
LA English
DT Article
DE dengue; dengue fever; dengue haemorrhagic fever; headache
ID ENCEPHALITIS; FEVER
AB The aim of this study was to describe the frequency and features of headache among patients with confirmed dengue virus infection and to compare the headache features in patients with dengue fever and dengue haemorrhagic fever, primary and secondary dengue infection, and patients with and without neurological involvement. Patients with classic dengue fever had a more intense headache than those with the more severe form of the disease, dengue haemorrhagic fever.
C1 EMESCAM, Escola Med Santa Casa Misericordia Vitoria, Vitoria, ES, Brazil.
   Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, SP, Brazil.
RP Domingues, RB (corresponding author), EMESCAM, Escola Med Santa Casa Misericordia Vitoria, Vitoria, ES, Brazil.
EM renan-domingues@uol.com.br
RI Domingues, Renan/N-6003-2019; Domingues, Renan B/H-1351-2012; Pannuti,
   Claudio/B-7649-2012
OI Domingues, Renan/0000-0002-6058-7937; Domingues, Renan
   B/0000-0002-6058-7937; 
CR Casali Clarisse Guimarães, 2004, Rev. Soc. Bras. Med. Trop., V37, P296, DOI 10.1590/S0037-86822004000400002
   da Fonseca BAL, 2002, CURR OPIN PEDIATR, V14, P67
   Domingues RB, 1997, CLIN INFECT DIS, V25, P86, DOI 10.1086/514494
   George R., 1997, Annals Academy of Medicine Singapore, V26, P815
   Harris E, 1998, J CLIN MICROBIOL, V36, P2634, DOI 10.1128/JCM.36.9.2634-2639.1998
   Hommel D, 1998, RES VIROLOGY, V149, P235, DOI 10.1016/S0923-2516(98)80005-8
   Kankirawatana P, 2000, J CHILD NEUROL, V15, P544, DOI 10.1177/088307380001500809
   Pancharoen Chitsanu, 2001, Southeast Asian Journal of Tropical Medicine and Public Health, V32, P341
   Rigau-Perez JG, 1998, LANCET, V352, P971, DOI 10.1016/S0140-6736(97)12483-7
   Row D, 1996, AM J TROP MED HYG, V54, P253, DOI 10.4269/ajtmh.1996.54.253
   Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x
   Solomon T, 2000, LANCET, V355, P1053, DOI 10.1016/S0140-6736(00)02036-5
   Solomon T, 2001, J INFECTION, V42, P104, DOI 10.1053/jinf.2001.0802
   SOUZA RV, 1998, NEUROINFECCAO 98, P33
   SOUZA VAU, 2004, J CLIN MICROBIOL, V42, P1782
   Strobel M, 1999, ANN MED INTERNE, V150, P79
   World Health Organization, 1999, GUID TREATM DENG FEV
NR 17
TC 11
Z9 14
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0333-1024
EI 1468-2982
J9 CEPHALALGIA
JI Cephalalgia
PD JUL
PY 2006
VL 26
IS 7
BP 879
EP 882
DI 10.1111/j.1468-2982.2006.01100.x
PG 4
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 052SD
UT WOS:000238253300017
PM 16776706
DA 2020-11-30
ER

PT J
AU Charbel, CE
   Levi, JE
   Martins, JEC
AF Charbel, CE
   Levi, JE
   Martins, JEC
TI Evaluation of polymerase chain reaction for the detection of
   Paracoccidioides brasiliensis DNA on serum samples from patients with
   paracoccidioidomycosis
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE paracoccidioidomycosis; Paracoccidioides brasiliensis; molecular
   diagnosis; serum; polymerase chain reaction
ID DIAGNOSIS; PCR
AB The aim of this study was to demonstrate the DNA of Paracoccidioides brasiliensis in human serum samples of patients with paracoccidioidomycosis using the polymerase chain reaction (PCR). The diagnosis of paracoccidioidomycosis (PCM was defined by microscopic observation of the fungus on direct exam or histopatholog) culture, and serological positivity. DNA from serum of 33 patients with PCM was extracted and submitted to nested-PCR using primers from the gp 43 gene. Only one sample was positive on nested-PCR. We conclude that the prevalence of fungemia in patients with different clinical forms of PCM is low, limiting the use of serum DNA detection as an alternative diagnostic tool.
C1 Inst Med Trop Sao Paulo, BR-05403000 Sao Paulo, Brazil.
   Lab Virol, LIM 52, BR-05403000 Sao Paulo, Brazil.
   Lab Micol Med, LIM 53, BR-05403000 Sao Paulo, Brazil.
RP Charbel, CE (corresponding author), Inst Med Trop Sao Paulo, Rua Dr Eneas de Carvalho Aguiar 500, BR-05403000 Sao Paulo, Brazil.
EM eucharbel@usp.br
CR Bialek R, 2000, J CLIN MICROBIOL, V38, P2940, DOI 10.1128/JCM.38.8.2940-2942.2000
   Cano MIN, 1998, J CLIN MICROBIOL, V36, P742
   da Silva SHM, 2004, J CLIN MICROBIOL, V42, P2419, DOI 10.1128/JCM.42.6.2419-2424.2004
   Goldani LZ, 1998, AM J TROP MED HYG, V58, P152, DOI 10.4269/ajtmh.1998.58.152
   Gomes GM, 2000, J CLIN MICROBIOL, V38, P3478, DOI 10.1128/JCM.38.9.3478-3480.2000
   Itano E. N., 2002, Japanese Journal of Medical Mycology, V43, P29, DOI 10.3314/jjmm.43.29
   Lacaz CS, 1994, PARACOCCIDIOIDOMYCOS, P13
   Mendes-Giannini MJS, 1994, PARACOCCIDIOIDOMYCOS, P345
   Meyer O, 1999, TRANSFUSION, V39, P1256, DOI 10.1046/j.1537-2995.1999.39111256.x
   Nishikaku AS, 2003, J CLIN MICROBIOL, V41, P3419, DOI 10.1128/JCM.41.7.3419-3422.2003
   Reiss E, 1998, MED MYCOL, V36, P249
   SINGERVERMES LM, 1993, CLIN EXP IMMUNOL, V94, P75, DOI 10.1111/j.1365-2249.1993.tb05980.x
NR 12
TC 4
Z9 4
U1 0
U2 1
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD MAR
PY 2006
VL 101
IS 2
BP 219
EP 221
DI 10.1590/S0074-02762006000200015
PG 3
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 038DF
UT WOS:000237198000015
PM 16830716
OA DOAJ Gold
DA 2020-11-30
ER

PT J
AU Rabelo-Santos, SH
   Levi, JE
   Derchain, SFM
   Sarian, LOZ
   Zeferino, LC
   Messias, S
   de Moraes, DL
   Campos, EA
   Syrjanen, KJ
AF Rabelo-Santos, SH
   Levi, JE
   Derchain, SFM
   Sarian, LOZ
   Zeferino, LC
   Messias, S
   de Moraes, DL
   Campos, EA
   Syrjanen, KJ
TI DNA recovery from Hybrid Capture II samples stored in specimen transport
   medium with denaturing reagent, for the detection of human
   papillomavirus by PCR
SO JOURNAL OF VIROLOGICAL METHODS
LA English
DT Article
DE DNA extraction; HPV; hybrid capture II; specimen transporting medium;
   polymerase chain reaction
ID PREVALENCE; CELLS; WOMEN
AB The purpose of this Study was to examine the quality of DNA recovered for human papillomavirus (HPV) detection using polymerase chain reaction (PCR) in samples that had been collected for Hybrid Capture II (HCII), testing and stored in specimen transport medium (STM) with denaturing reagent at -20 degrees C for 18 months. Endocervical tissue was collected from 92 women for HCII assay using the Digene STM, and a Papanicolaou smear was carried out in all cases. Seven women had normal colposcopy results. The remaining 85 patients underwent colposcopy-directed biopsy or cervical conization for histological investigation. Of the 92 samples tested, 84 were HCII-positive and 8 were negative. Quality control for amplification was carried out with beta-globin primers G73 and G74, and HPV was tested using PGMY09 and PGMY11. DNA was recovered from 83 of the 92 samples (90%). Among the 84 samples HCII-positive initially, HPV was detected by PCR in 56 (67%). PCR did not detect HPV DNA in the eight samples that were HCII-negative, although five of them were positive for beta-globin. This paper describes a novel DNA extraction technique that may permit exact HPV typing in stored samples collected originally for HCII testing, making it possible to carry out retrospective investigations to retrieve information on specific HPV types in large HCII series. (c) 2005 Elsevier B.V. All rights reserved.
C1 Univ Estadual Campinas, Dept Obstet & Gynecol, Campinas, SP, Brazil.
   Univ Sao Paulo, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   Univ Fed Goias, Goiania, Go, Brazil.
   Turku Univ, Cent Hosp Savitehtaankatu, Dept Radiotherapy & Oncol, Turku, Finland.
RP Derchain, SFM (corresponding author), Rua Antonio Hossri,629 Cidade Univ, BR-13083370 Campinas, SP, Brazil.
EM derchain@lem.unicarnp.br
RI Zeferino, Luiz Carlos/F-9851-2012; Derchain, Sophie FM/I-9500-2014;
   Sarian, Luis O/C-4150-2013; Sarian, Luis/AAA-2722-2020; Rabelo-Santos,
   Silvia/F-9574-2012; Zeferino, Luiz Carlos/AAQ-2140-2020
OI Derchain, Sophie FM/0000-0003-1029-9993; Sarian, Luis
   O/0000-0002-9554-6131; Campos, Elisabete Aparecida/0000-0001-8226-1105
CR BOSCH FX, 1995, J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796
   Cuzick J, 2000, BRIT J CANCER, V83, P561, DOI 10.1054/bjoc.2000.1375
   Davies P, 2001, BEST PRACT RES CL OB, V15, P677, DOI 10.1053/beog.2001.0214
   Dillner J, 2001, BEST PRACT RES CL OB, V15, P743, DOI 10.1053/beog.2001.0217
   Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
   Hubbard RA, 2003, ARCH PATHOL LAB MED, V127, P940
   Levi JE, 2002, J CLIN MICROBIOL, V40, P3341, DOI 10.1128/JCM.40.9.3341-3345.2002
   Lorincz A T, 1996, J Obstet Gynaecol Res, V22, P629
   Perrons C, 2002, J MED VIROL, V67, P246, DOI 10.1002/jmv.2214
   Peyton CL, 1998, J CLIN MICROBIOL, V36, P3248, DOI 10.1128/JCM.36.11.3248-3254.1998
   Poljak M, 2002, J CLIN VIROL, V25, pS89
   R Development Core Team, 2004, R LANG ENV STAT COMP
   Solomon D, 2001, J NATL CANCER I, V93, P293, DOI 10.1093/jnci/93.4.293
   SYRJANEN K, 2000, HUM PATHOL, P1
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Zehbe I, 1998, CANCER RES, V58, P829
   zurHausen H, 1996, BBA-REV CANCER, V1288, pF55
NR 17
TC 10
Z9 14
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-0934
EI 1879-0984
J9 J VIROL METHODS
JI J. Virol. Methods
PD JUN
PY 2005
VL 126
IS 1-2
BP 197
EP 201
DI 10.1016/j.jviromet.2005.02.009
PG 5
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Virology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Virology
GA 924TJ
UT WOS:000229003000025
PM 15847937
DA 2020-11-30
ER

PT J
AU Wendel, S
   Fontao-Wendel, R
   Levi, JE
   Aravechia, MG
   Bordokan, RFS
   Russo, D
   Haddad, MS
AF Wendel, S
   Fontao-Wendel, R
   Levi, JE
   Aravechia, MG
   Bordokan, RFS
   Russo, D
   Haddad, MS
TI A McLeod phenotype detected by random screening for K :-4 [Kp(b-)] blood
   donors in Brazil
SO TRANSFUSION
LA English
DT Article
ID CHRONIC GRANULOMATOUS-DISEASE; SYNDROME GENE; XK GENE; JAPANESE FAMILY;
   GROUP SYSTEM; KX-ANTIGEN; RED-CELLS; MUTATION; NEUROACANTHOCYTOSIS;
   DELETION
AB BACKGROUND: The red blood cells of the McLeod phenotype have weak expression of Kell System antigens due to no expression of XK protein.
   STUDY DESIGN AND METHODS: One blood donor reacted as K:-4 [Kp(b-)] during a screening assay. Subsequent serologic studies demonstrated weak expression of K:4 and all other high-incidence Kell system antigens tested; however, no expression of Kx antigen was observed.
   RESULTS: One apparently healthy blood donor demonstrated low expression of K:2, K:4, K:5, K:7, K:14, K:22, and no Kx antigen in his red blood cells. His brother and mother showed the same weak expression, and his father showed normal expression of antigens tested. Flow cytometry studies confirmed the mother's status as a McLeod carrier female. Genotyping determined the presence of KEL2 and KEL4 alleles in mother and siblings. Southern blot with an exon-1 probe showed fragments shorter than predicted for the siblings and the mother, suggesting a deletion. Polymerase chain reaction with primers spanning exon 1 and flanking regions displayed a similar pattern. Deoxyribonucleic acid sequence allowed the precise characterization of a deletion of 392 bp, beginning at the 5' of the coding region up to nucleotide 201 of exon 1, which putatively abrogates the production of XK protein.
   CONCLUSION: Two brothers with McLeod phenotype in a Brazilian blood-donor population were identified. The molecular basis for this phenotype is a 392-bp deletion spanning from 5' of the coding region to exon 1 of the XK gene, never described before.
C1 Univ Sao Paulo, Hosp Clin, Hosp Sirio Libanes Blood Bank, Ctr Imunol & Imunogenet,Fac Med, BR-09500900 Sao Paulo, Brazil.
   New York Blood Ctr, New York, NY 10021 USA.
RP Wendel, S (corresponding author), Rua Dona Adma Jafet 91-3SS, BR-01308050 Sao Paulo, Brazil.
EM snwendel@uninet.com.br
RI Wendel, S/AAQ-9048-2020
FU NHLBI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL54459] Funding Source: Medline; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [P50HL054459, P50HL054459, P50HL054459,
   P50HL054459, P50HL054459, P50HL054459, P50HL054459, P50HL054459,
   P50HL054459, P50HL054459, P50HL054459, P50HL054459, P50HL054459,
   P50HL054459, P50HL054459, P50HL054459, P50HL054459, P50HL054459,
   P50HL054459, P50HL054459, P50HL054459, P50HL054459, P50HL054459,
   P50HL054459, P50HL054459, P50HL054459, P50HL054459, P50HL054459,
   P50HL054459, P50HL054459, P50HL054459, P50HL054459, P50HL054459,
   P50HL054459, P50HL054459, P50HL054459, P50HL054459, P50HL054459,
   P50HL054459, P50HL054459, P50HL054459, P50HL054459, P50HL054459,
   P50HL054459, P50HL054459, P50HL054459, P50HL054459, P50HL054459,
   P50HL054459, P50HL054459, P50HL054459, P50HL054459, P50HL054459,
   P50HL054459, P50HL054459, P50HL054459, P50HL054459, P50HL054459,
   P50HL054459, P50HL054459, P50HL054459, P50HL054459, P50HL054459] Funding
   Source: NIH RePORTER
CR ALLEN FH, 1961, VOX SANG, V6, P555, DOI 10.1111/j.1423-0410.1961.tb03203.x
   *AM ASS BLOOD BANK, 1993, TECHN MAN, P612
   BERTELSON CJ, 1988, AM J HUM GENET, V42, P703
   BRANCH DR, 1985, BRIT J HAEMATOL, V59, P505, DOI 10.1111/j.1365-2141.1985.tb07337.x
   BRIDGES RA, 1959, AMA J DIS CHILD, V97, P387, DOI 10.1001/archpedi.1959.02070010389004
   Danek A, 2001, ANN NEUROL, V50, P755, DOI 10.1002/ana.10035
   Daniels GL, 1996, BLOOD, V88, P4045, DOI 10.1182/blood.V88.10.4045.bloodjournal88104045
   DESTBASILE G, 1988, HUM GENET, V80, P85, DOI 10.1007/BF00451463
   DIRETRIZES E, 1997, NORMAS REGULAMENTADO
   Dotti MT, 2000, MOVEMENT DISORD, V15, P1282, DOI 10.1002/1531-8257(200011)15:6<1282::AID-MDS1042>3.0.CO;2-2
   FRANCKE U, 1985, AM J HUM GENET, V37, P250
   FREY D, 1988, BLOOD, V71, P252
   Hanaoka N, 1999, J NEUROL SCI, V165, P6, DOI 10.1016/S0022-510X(99)00028-3
   HARDIE RJ, 1991, BRAIN, V114, P13
   HO MF, 1994, CELL, V77, P869, DOI 10.1016/0092-8674(94)90136-8
   Ho MF, 1996, ANN NEUROL, V39, P672, DOI 10.1002/ana.410390518
   ISSITT PD, 1998, APPL BLOOD GROUP SER, P609
   Jung HH, 2003, TRANSFUSION, V43, P928, DOI 10.1046/j.1537-2995.2003.t01-1-00434.x
   Jung HH, 2001, ANN NEUROL, V49, P384, DOI 10.1002/ana.76
   KHAMLICHI S, 1995, EUR J BIOCHEM, V228, P931, DOI 10.1111/j.1432-1033.1995.tb20342.x
   LEE S, 1993, BLOOD, V81, P2804
   Lee S, 1996, TRANSFUSION, V36, P490, DOI 10.1046/j.1537-2995.1996.36696269505.x
   LEE SH, 1995, BLOOD, V85, P912, DOI 10.1182/blood.V85.4.912.bloodjournal854912
   LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0
   MARSH WL, 1975, BRIT J HAEMATOL, V29, P247, DOI 10.1111/j.1365-2141.1975.tb01819.x
   MARSH WL, 1983, BLOOD GROUP ANTIGENS, P165
   NEMER WE, 2000, EUR J IMMUNOGENET, V27, P29
   Oyen R, 1996, Immunohematology, V12, P160
   Oyen R, 1997, Immunohematology, V13, P75
   REDMAN CM, 1986, J BIOL CHEM, V261, P9521
   REDMAN CM, 1988, BRIT J HAEMATOL, V68, P131, DOI 10.1111/j.1365-2141.1988.tb04191.x
   Russo D, 1998, J BIOL CHEM, V273, P13950, DOI 10.1074/jbc.273.22.13950
   Russo DC, 2000, TRANSFUSION, V40, P1371, DOI 10.1046/j.1537-2995.2000.40111371.x
   Russo DCW, 2002, TRANSFUSION, V42, P287, DOI 10.1046/j.1537-2995.2002.00049.x
   Supple SG, 2001, BRIT J HAEMATOL, V115, P369, DOI 10.1046/j.1365-2141.2001.03121.x
   Ueyama H, 2000, J NEUROL SCI, V176, P151, DOI 10.1016/S0022-510X(00)00307-5
   WALPOLE H, 1937, H WALPOLES CORRESPON
   WENDEL S, 1992, BRAZIL REV PAUL ME S, V110, P31
   WHITE W, 1980, REV FR TRANSFUS IMMU, V23, P305, DOI 10.1016/S0338-4535(80)80134-6
   WIMER BM, 1977, BRIT J HAEMATOL, V36, P219, DOI 10.1111/j.1365-2141.1977.tb00642.x
   WITT TN, 1992, J NEUROL, V239, P302, DOI 10.1007/BF00867584
NR 41
TC 7
Z9 7
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD NOV
PY 2004
VL 44
IS 11
BP 1579
EP 1587
DI 10.1111/j.1537-2995.2004.03259.x
PG 9
WC Hematology
SC Hematology
GA 866HA
UT WOS:000224763400008
PM 15504163
DA 2020-11-30
ER

PT J
AU Wendel, S
   Fontao-Wendel, R
   Levi, JE
   Aravecchia, MG
   Bordokan, R
   David, R
   Haddad, M
AF Wendel, S
   Fontao-Wendel, R
   Levi, JE
   Aravecchia, MG
   Bordokan, R
   David, R
   Haddad, M
TI A novel mutation at XK gene responsible for a McLeod phenotype
SO TRANSFUSION
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the American-Association-of-Blood-Banks
CY OCT 23-26, 2004
CL Baltimore, MD
SP Amer Assoc Blood Banks
C1 Hosp Sirio Libanes Blood Bank, Sao Paulo, Brazil.
   New York Blood Ctr, New York, NY 10021 USA.
   Hosp Clin Sao Paulo, Sao Paulo, Brazil.
RI Wendel, S/AAQ-9048-2020
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BLACKWELL PUBLISHING INC
PI MALDEN
PA 350 MAIN ST, MALDEN, MA 02148 USA
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 2004
VL 44
IS 9
SU S
BP 117A
EP 117A
PG 1
WC Hematology
SC Hematology
GA 849XS
UT WOS:000223575600402
DA 2020-11-30
ER

PT J
AU da Silva, LVF
   Tateno, AF
   Velloso, LD
   Levi, JE
   Fernandes, S
   Bento, CNO
   Rodrigues, JC
   Ramos, SRTS
AF da Silva, LVF
   Tateno, AF
   Velloso, LD
   Levi, JE
   Fernandes, S
   Bento, CNO
   Rodrigues, JC
   Ramos, SRTS
TI Identification of Pseudomonas aeruginosa, Burkholderia cepacia complex,
   and Stenotrophomonas maltophilia in respiratory samples from cystic
   fibrosis patients using multiplex PCR
SO PEDIATRIC PULMONOLOGY
LA English
DT Article
DE Burkholderia cepacia; Stenotrophomonas maltophilia; Pseudomonas
   aeruginosa; cystic fibrosis; infections; diagnostic methods; polymerase
   chain reaction
ID OROPHARYNGEAL CULTURES; XANTHOMONAS-MALTOPHILIA; YOUNG-CHILDREN;
   GENOMOVARS I; SPUTUM; INFECTION; BACTERIA; MULTIVORANS; VIETNAMIENSIS;
   MICROBIOLOGY
AB A multiplex PCR method was developed to identify P. aeruginosa, B. cepacia complex, and S. maltophilia directly in sputum and oropharyngeal samples from CF patients. One hundred and six patients (53 male, and 53 female) attending our pulmonology clinic were studied from September 2000-April 2001. Two hundred and fifty-seven samples were cultured in selective media and submitted to multiplex PCR reactions, using three primer pairs targeting specific genomic sequences of each species, with an additional primer pair targeting a stretch of ribosomal 16S DNA, universal for bacteria, to act as a control. P. aeruginosa was isolated by culture in 56% of samples, B. cepacia complex in 4.3%, and S. maltophilia in 2.7%, while multiplex PCR identified P. aeruginosa in 78.7%, B. cepacia complex in 3.9%, and S. maltophilia in 3.1 % of samples. Multiplex PCR results were verified by PCR reactions using different species-specific primers described in the literature and DNA sequencing of amplicons from a few samples. Comparing to culture results, the sensitivity and specificity values of multiplex PCR for bacterial identification were, respectively, 97.2% and 45.5% for P. aeruginosa, 45.5% and 97.9% for B. cepaciacomplex, and 40% and 97.6 for S. maltophilia. All 10 multiplex PCR-positive results for B. cepacia complex were confirmed using other species-specific primers described in the literature, while this approach confirmed results for S. maltophilia identification in 7/8 samples (87.5%). Sequencing of amplicons from samples culture-negative but multiplex PCR-positive for P. aeruginosa and B. cepacia complex confirmed their identity, while minor nucleotide differences among amplicons ruled out the hypothesis of PCR contamination. (C) 2004 Wiley-Liss, Inc.
C1 Univ Sao Paulo, Hosp Clin, Fac Med, Inst Crianca,Med Sch, BR-05404001 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Hosp Clin, Microbiol Sect Cent Lab, Sao Paulo, Brazil.
RP da Silva, LVF (corresponding author), Univ Sao Paulo, Hosp Clin, Fac Med, Inst Crianca,Med Sch, Rua Gregorio Paes Almeida,1148 Vica Madelena, BR-05404001 Sao Paulo, Brazil.
EM vicres@usp.br
RI da Silva Filho, Luiz Vicente R F/A-6957-2011
OI da Silva Filho, Luiz Vicente R F/0000-0001-8431-1997
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   AMAN L, 2003, INFECT CONT HOSP E S, V24, P6
   Armstrong DS, 1996, PEDIATR PULM, V21, P267, DOI 10.1002/(SICI)1099-0496(199605)21:5<267::AID-PPUL1>3.3.CO;2-G
   Bauernfeind A, 1999, J CLIN MICROBIOL, V37, P1335, DOI 10.1128/JCM.37.5.1335-1339.1999
   Beringer P M, 2000, Curr Opin Pulm Med, V6, P545, DOI 10.1097/00063198-200011000-00015
   BURDGE DR, 1995, CLIN INFECT DIS, V20, P445, DOI 10.1093/clinids/20.2.445
   Burns JL, 2001, J INFECT DIS, V183, P444, DOI 10.1086/318075
   Burns JL, 1998, CLIN INFECT DIS, V27, P158, DOI 10.1086/514631
   CAMPBELL PW, 1995, PEDIATR PULM, V20, P44, DOI 10.1002/ppul.1950200109
   COENYE T, 2003, J CYSTIC FIBROSIS S, V2, P42
   *CYST FIBR FDN, 1994, CONS C MICR INF DIS, P1
   SILVA FILHO Luiz V.F. da, 2002, Rev. Inst. Med. trop. S. Paulo, V44, P203, DOI 10.1590/S0036-46652002000400004
   DAWSONSAUNDERS B, 1994, BASIC CLIN BIOSTATIS, P234
   Demko CA, 1998, PEDIATR PULM, V25, P304, DOI 10.1002/(SICI)1099-0496(199805)25:5<304::AID-PPUL3>3.3.CO;2-K
   Denton M, 1998, CLIN MICROBIOL REV, V11, P57, DOI 10.1128/CMR.11.1.57
   Drevinek P, 2002, J CLIN MICROBIOL, V40, P3485, DOI 10.1128/JCM.40.9.3485-3488.2002
   Frederiksen B, 1997, PEDIATR PULM, V23, P330, DOI 10.1002/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O
   Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996
   Govan JRW, 2000, J ROY SOC MED, V93, P40
   Henegariu O, 1997, BIOTECHNIQUES, V23, P504, DOI 10.2144/97233rr01
   Henry DA, 2001, J CLIN MICROBIOL, V39, P1073, DOI 10.1128/JCM.39.3.1073-1078.2001
   HUDSON VL, 1993, J PEDIATR-US, V122, P854, DOI 10.1016/S0022-3476(09)90007-5
   ISLES A, 1984, J PEDIATR-US, V104, P206, DOI 10.1016/S0022-3476(84)80993-2
   Karpati F, 1996, MOL CELL PROBE, V10, P397, DOI 10.1006/mcpr.1996.0055
   KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0
   LiPuma JJ, 1998, CLIN CHEST MED, V19, P473, DOI 10.1016/S0272-5231(05)70094-0
   Mahenthiralingam E, 2000, J CLIN MICROBIOL, V38, P3165, DOI 10.1128/JCM.38.9.3165-3173.2000
   McDowell A, 2001, J CLIN MICROBIOL, V39, P4247, DOI 10.1128/JCM.39.12.4247-4255.2001
   MCINTOSH I, 1992, MOL CELL PROBE, V6, P299, DOI 10.1016/0890-8508(92)90005-I
   McMenamin JD, 2000, CHEST, V117, P1661, DOI 10.1378/chest.117.6.1661
   Moller LVM, 1998, AM J RESP CRIT CARE, V157, P950
   Nixon GM, 2002, ARCH DIS CHILD, V87, P306, DOI 10.1136/adc.87.4.306
   Nixon GM, 2001, J PEDIATR-US, V138, P699, DOI 10.1067/mpd.2001.112897
   OCALLAGHAN EM, 1994, J CLIN PATHOL, V47, P222, DOI 10.1136/jcp.47.3.222
   RAMSEY BW, 1991, AM REV RESPIR DIS, V144, P331, DOI 10.1164/ajrccm/144.2.331
   RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301
   Rosenfeld M, 1999, PEDIATR PULM, V28, P321, DOI 10.1002/(SICI)1099-0496(199911)28:5<321::AID-PPUL3>3.0.CO;2-V
   Rosenstein BJ, 1998, J PEDIATR-US, V132, P589, DOI 10.1016/S0022-3476(98)70344-0
   Shreve MR, 1999, J CLIN MICROBIOL, V37, P753, DOI 10.1128/JCM.37.3.753-757.1999
   SILVA LV, 1999, J MED MICROBIOL, V48, P357
   SPENCER RC, 1995, J HOSP INFECT, V30, P453, DOI 10.1016/0195-6701(95)90049-7
   THOMASSEN MJ, 1984, J PEDIATR-US, V104, P352, DOI 10.1016/S0022-3476(84)81094-X
   VALERIUS NH, 1991, LANCET, V338, P725, DOI 10.1016/0140-6736(91)91446-2
   Vandamme P, 1997, INT J SYST BACTERIOL, V47, P1188, DOI 10.1099/00207713-47-4-1188
   Vandamme P, 2002, FEMS IMMUNOL MED MIC, V33, P143, DOI 10.1111/j.1574-695X.2002.tb00584.x
   Whitby PW, 2000, J CLIN MICROBIOL, V38, P2962, DOI 10.1128/JCM.38.8.2962-2965.2000
   Whitby PW, 2000, J CLIN MICROBIOL, V38, P4305, DOI 10.1128/JCM.38.12.4305-4309.2000
   WONG K, 1984, J MED MICROBIOL, V17, P113, DOI 10.1099/00222615-17-2-113
   Yolken RH, 2002, J PEDIATR-US, V140, P290, DOI 10.1067/mpd.2002.123701
NR 49
TC 23
Z9 23
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-6863
EI 1099-0496
J9 PEDIATR PULM
JI Pediatr. Pulmonol.
PD JUN
PY 2004
VL 37
IS 6
BP 537
EP 547
DI 10.1002/ppul.20016
PG 11
WC Pediatrics; Respiratory System
SC Pediatrics; Respiratory System
GA 823QZ
UT WOS:000221629400010
PM 15114555
DA 2020-11-30
ER

PT J
AU Levi, JE
   Fernandes, S
   Tateno, AF
   Motta, E
   Lima, LP
   Eluf-Neto, J
   Pannuti, CS
AF Levi, JE
   Fernandes, S
   Tateno, AF
   Motta, E
   Lima, LP
   Eluf-Neto, J
   Pannuti, CS
TI Presence of multiple human papillomavirus types in cervical samples from
   HIV-infected women
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE HPV; PCR; genotyping; viral load; cervical intraepithelial neoplasia;
   multiple infections
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SQUAMOUS INTRAEPITHELIAL LESIONS;
   POLYMERASE-CHAIN-REACTION; NEGATIVE WOMEN; HPV GENOTYPES; RISK-FACTORS;
   NEOPLASIA; PREVALENCE; HYBRIDIZATION; PERSISTENCE
AB Objectives. The aim of this study was to detect and identify human papillomavirus (HPV) genotypes on a population of women infected by the human immunodeficiency virus (HIV) and to investigate the role of multiple infections on cervical dysplasia.
   Methods. Two hundred and fifty-five HIV-infected women were enrolled on a study to evaluate the prevalence of HPV and cervical intra-epithelial neoplasia (CIN). A group of HIV-negative women with confirmed CIN diagnosis was included for comparison. A polymerase chain reaction (PCR)-reverse hybridization method was applied to detect and precisely identify HPV types, specifically multiple infections.
   Results. On HIV patients, an altered Pap smear confirmed by biopsy was observed on 45 (18%); HPV-DNA prevalence was 87% (223/ 255), with 45% (116/255) infected by more than two types. In contrast, HPV-DNA was detected in all 36 women of the control group but only 3 were infected by more than two types. Cervical dysplasia was associated with low CD4 counts and elevated high-risk HPV viral load. However, the presence of multiple HPV types did not correlate with the degree of immune suppression or the presence of cervical lesions.
   Conclusions. Infection with multiple HPV types is a rather frequent finding on Brazilian HIV-infected women. On this population, concomitant infection with three or more HPV types does not seem to confer an additional risk of cervical dysplasia in comparison to single/ double infections, nor to be related to more severe immunesuppresion. (C) 2003 Elsevier Inc. All rights reserved.
C1 Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, Virol Lab,Dept Doencas Infecciosas & Parasitarias, BR-05403000 Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Obstet & Ginecol, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Prevent Med, Sao Paulo, Brazil.
RP Levi, JE (corresponding author), Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, Virol Lab,Dept Doencas Infecciosas & Parasitarias, Rua Dr Eneas de Carvalho Aguiar 470,2 Andar, BR-05403000 Sao Paulo, Brazil.
EM dudilevi@usp.br
RI Pannuti, Claudio/B-7649-2012; Eluf-Neto, Jose/B-2522-2009
OI Eluf-Neto, Jose/0000-0001-7504-2115
CR Ahdieh L, 2000, AM J EPIDEMIOL, V151, P1148, DOI 10.1093/oxfordjournals.aje.a010165
   Ahdieh L, 2001, J INFECT DIS, V184, P682, DOI 10.1086/323081
   An HJ, 2003, CANCER-AM CANCER SOC, V97, P1672, DOI 10.1002/cncr.11235
   BERNARD HU, 1994, J INFECT DIS, V170, P1077, DOI 10.1093/infdis/170.5.1077
   BRADSHAW BR, 1992, ARCH DERMATOL, V128, P949, DOI 10.1001/archderm.128.7.949
   Brown DR, 1999, J CLIN MICROBIOL, V37, P3316, DOI 10.1128/JCM.37.10.3316-3322.1999
   Chang DY, 1997, J MED MICROBIOL, V46, P54, DOI 10.1099/00222615-46-1-54
   Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031
   Fife KH, 2001, J MED VIROL, V64, P550, DOI 10.1002/jmv.1085
   Franco EL, 1999, J INFECT DIS, V180, P1415, DOI 10.1086/315086
   Goncalves MAG, 1999, INT J STD AIDS, V10, P803, DOI 10.1258/0956462991913583
   Gravitt PE, 1998, J CLIN MICROBIOL, V36, P3020, DOI 10.1128/JCM.36.10.3020-3027.1998
   Herrero R, 2000, JNCI-J NATL CANCER I, V92, P464, DOI 10.1093/jnci/92.6.464
   Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703
   HO GYF, 1994, INT J CANCER, V56, P788, DOI 10.1002/ijc.2910560605
   KLEIN RS, 1994, J INFECT DIS, V170, P1404, DOI 10.1093/infdis/170.6.1404
   Kleter B, 1999, J CLIN MICROBIOL, V37, P2508, DOI 10.1128/JCM.37.8.2508-2517.1999
   Lazcano-Ponce E, 2001, INT J CANCER, V91, P412, DOI 10.1002/1097-0215(20010201)91:3&lt;412::AID-IJC1071&gt;3.0.CO;2-M
   Levi JE, 2002, J CLIN MICROBIOL, V40, P3341, DOI 10.1128/JCM.40.9.3341-3345.2002
   Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641
   NUOVO GJ, 1991, MODERN PATHOL, V4, P632
   NUOVO GJ, 1991, AM J PATHOL, V138, P53
   Palefsky JM, 2001, J INFECT DIS, V183, P383, DOI 10.1086/318071
   Palefsky JM, 1999, JNCI-J NATL CANCER I, V91, P226, DOI 10.1093/jnci/91.3.226
   Palefsky JM, 1999, J ACQ IMMUN DEF SYND, V21, pS42
   Peyton CL, 2001, J INFECT DIS, V183, P1554, DOI 10.1086/320696
   RICHART RM, 1990, OBSTET GYNECOL, V75, P131
   RODAHUSMAN AM, 1995, J GEN VIROL, V76, P1057
   Rousseau MC, 2001, J INFECT DIS, V184, P1508, DOI 10.1086/324579
   Spitzer M, 1999, Obstet Gynecol Surv, V54, P131, DOI 10.1097/00006254-199902000-00023
   Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903
   Wallin KL, 1999, NEW ENGL J MED, V341, P1633, DOI 10.1056/NEJM199911253412201
NR 32
TC 74
Z9 79
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD JAN
PY 2004
VL 92
IS 1
BP 225
EP 231
DI 10.1016/j.ygyno.2003.10.004
PG 7
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA 777DK
UT WOS:000189159600035
PM 14751163
DA 2020-11-30
ER

PT J
AU Wendel, S
   Fachini, RM
   Levi, JE
   Ghaname, JN
   Mendonca, MC
   Neto, CD
   Braga, MD
   Di Pietro, AE
AF Wendel, S
   Fachini, RM
   Levi, JE
   Ghaname, JN
   Mendonca, MC
   Neto, CD
   Braga, MD
   Di Pietro, AE
TI A single window-period donation detected by human immunodeficiency virus
   p24 antigen after 5 years of routine screening in a group of Brazilian
   blood banks
SO VOX SANGUINIS
LA English
DT Article
DE blood donors; HIV; p24Ag
ID RISK; DONORS; HIV
AB Background and Objectives The purpose of this article was to describe the experience of screening for human immunodeficiency virus (HIV) p24 antigen (p24Ag) in blood donors, in four Brazilian Blood Banks, and to report the detection of the first window-period donation.
   Materials and Methods During 61 months (May 96 to June 01), 103 470 consecutive donations were screened for HIV p24Ag using commercially available enzyme-linked immunosorbent assay (ELISA) kits. Testing was carried out in accordance with the instructions supplied with the kits.
   Results Fifty-eight repeatedly reactive samples were identified [0.056% of the total; 95% confidence interval (95% Q: 0.042-0.070]. Ten of the 58 were confirmed as p24Ag positive after neutralization (0.010%; 95% Cl: 0.004-0.016), nine of the 10 (0.009%; 95% Cl: 0.003-0.014) were also HIV antibody positive and only one (0.001%; 95% Cl: 0.-0.003) was HIV antibody negative.
   Conclusions In this setting the rate of sole p24Ag-positive donations was one in 103 740. This figure corresponds closely with the previously estimated yield of one in 87 796 donations. The yield of HIV p24Ag(+) : Ab(-) has been previously estimated in our centres to be 1 : 87 796 donations, a value similar to that observed in actual practice.
C1 Hosp Sirio Libanes, Blood Bank, Sao Paulo, Brazil.
   Ctr Imunol & Imunogenet, Sao Paulo, Brazil.
   Hosp Nove Julho, Blood Bank, Sao Paulo, Brazil.
   Hosp Cruz Azul, Blood Bank, Sao Paulo, Brazil.
   Hosp VITA, Blood Bank, Curitiba, Parana, Brazil.
RP Wendel, S (corresponding author), Rua Adma Jafet, BR-01308050 Sao Paulo, Brazil.
RI de Almeida-Neto, Cesar/O-9224-2014
OI de Almeida-Neto, Cesar/0000-0002-8490-4634
CR BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x
   Korelitz JJ, 1996, TRANSFUSION, V36, P203, DOI 10.1046/j.1537-2995.1996.36396182135.x
   LINDEN JV, 2001, BLOOD SAFETY SURVEIL, P267
   NUCHPRAYOON C, 1994, VOX SANG S2, V67, P13
   Sabino EC, 1999, TRANSFUSION, V39, P1152, DOI 10.1046/j.1537-2995.1999.t01-2-39101150.x
   Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601
   Stramer SL, 1997, TRANSFUSION, V37, pS1
   Stramer SL, 2001, TRANSFUSION, V41, p29S
NR 8
TC 5
Z9 6
U1 0
U2 0
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0042-9007
J9 VOX SANG
JI Vox Sang.
PD NOV
PY 2002
VL 83
IS 4
BP 309
EP 312
DI 10.1046/j.1423-0410.2002.00226.x
PG 4
WC Hematology
SC Hematology
GA 615ZZ
UT WOS:000179278400004
PM 12437517
DA 2020-11-30
ER

PT J
AU Levi, JE
   Kleter, B
   Quint, WGV
   Fink, MCS
   Canto, CLM
   Matsubara, R
   Linhares, I
   Segurado, A
   Vanderborght, B
   Neto, JE
   van Doorn, LJ
AF Levi, JE
   Kleter, B
   Quint, WGV
   Fink, MCS
   Canto, CLM
   Matsubara, R
   Linhares, I
   Segurado, A
   Vanderborght, B
   Neto, JE
   van Doorn, LJ
TI High prevalence of human papillomavirus (HPV) infections and high
   frequency of multiple HPV genotypes in human immunodeficiency
   virus-infected women in Brazil
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID SQUAMOUS INTRAEPITHELIAL LESIONS; LINE PROBE ASSAY; HIGH-RISK;
   CLINICAL-EVALUATION; CERVICAL NEOPLASIA; BROAD-SPECTRUM; HYBRIDIZATION;
   DISEASE; CANCER
AB A group of 208 human immunodeficiency virus (HIV)-infected women in Brazil were studied for the presence of human papillomavirus with the general SPF10 PCR primer set. Virtually all (98%) women were found positive for human papillomavirus (HPV) DNA. Genotyping by the reverse hybridization line probe assay (HPV-LiPA) revealed a high prevalence of multiple genotypes (78.9% of the cases), with an average of 3.1 genotypes per patient (range, I to 10 genotypes). HPV 6 was the most prevalent genotype and was observed in 80 (39.2%) patients, followed by types 51 (31.9%), 11 (26.0%), 18 (24.0%), and 16 (22.5%). Of the genotypes detected, 40.9% were low-risk genotypes. Twenty-two (10.5%) patients showed normal (Pap I) cytology, 149 (71.6%) patients had inflammation (Pap I), and 28 patients (13.4%) had a Pap III score. The prevalence of high-risk genotypes increased with the cytological classification. There were no significant associations between the number of HPV genotypes detected and the cytological classification, HIV viral load, and CD4 count in these patients. In conclusion, the highly sensitive SPF10 LiPA system shows that a very high proportion of HIV-infected women in Brazil are infected with HPV and often carry multiple HPV genotypes.
C1 Delft Diagnost Lab, NL-2625 AD Delft, Netherlands.
   Univ Sao Paulo, Fac Med, Inst Infectol Emilio Ribas, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Inst Trop Med, Virol Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Doencas Infecc & Parasitarias, Nucl Extensao Atendimento Paciente HIV & AIDS, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dpto Med Preventiva, Sao Paulo, Brazil.
   Univ Fed Rio de Janeiro, Hosp Univ Clementina Frago Filho, Rio De Janeiro, Brazil.
   Innogenetics, Ghent, Belgium.
RP van Doorn, LJ (corresponding author), Delft Diagnost Lab, NL-2625 AD Delft, Netherlands.
EM L.J.van.Doorn@ddl.nl
RI Linhares, Iara/E-2060-2012; Eluf-Neto, Jose/B-2522-2009; Vanderborght,
   Bram/A-1599-2008; Segurado, Aluisio C/K-2229-2012
OI Eluf-Neto, Jose/0000-0001-7504-2115; Vanderborght,
   Bram/0000-0003-4881-9341; Segurado, Aluisio C/0000-0002-6311-8036;
   Linhares, Iara/0000-0002-7846-6885
CR Ahdieh L, 2000, AM J EPIDEMIOL, V151, P1148, DOI 10.1093/oxfordjournals.aje.a010165
   BOSCH FX, 1995, J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796
   Brown DR, 1999, J CLIN MICROBIOL, V37, P3316, DOI 10.1128/JCM.37.10.3316-3322.1999
   CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7
   Delmas MC, 2000, AIDS, V14, P1775, DOI 10.1097/00002030-200008180-00013
   Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031
   Goncalves MAG, 1999, INT J STD AIDS, V10, P803, DOI 10.1258/0956462991913583
   Gravitt PE, 1998, J CLIN MICROBIOL, V36, P3020, DOI 10.1128/JCM.36.10.3020-3027.1998
   Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
   Heard I, 2000, OBSTET GYNECOL, V96, P403, DOI 10.1016/S0029-7844(00)00948-0
   Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791, DOI 10.1128/JCM.35.3.791-795.1997
   Kjaer SK, 1996, INT J CANCER, V65, P601, DOI 10.1002/(SICI)1097-0215(19960301)65:5<601::AID-IJC8>3.0.CO;2-6
   Kleter B, 1998, AM J PATHOL, V153, P1731, DOI 10.1016/S0002-9440(10)65688-X
   Kleter B, 1999, J CLIN MICROBIOL, V37, P2508, DOI 10.1128/JCM.37.8.2508-2517.1999
   MANDELBLATT JS, 1992, AIDS, V6, P173, DOI 10.1097/00002030-199202000-00005
   Melchers WJG, 1999, AM J PATHOL, V155, P1473, DOI 10.1016/S0002-9440(10)65462-4
   Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X
   Palefsky JM, 1999, JNCI-J NATL CANCER I, V91, P226, DOI 10.1093/jnci/91.3.226
   Pirog EC, 2000, AM J PATHOL, V157, P1055, DOI 10.1016/S0002-9440(10)64619-6
   Quint WGV, 2001, J PATHOL, V194, P51, DOI 10.1002/path.855
   REMMINK AJ, 1995, INT J CANCER, V61, P306, DOI 10.1002/ijc.2910610305
   SCHIFFMAN MH, 1993, J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958
   van Doorn LJ, 2002, J CLIN MICROBIOL, V40, P979, DOI 10.1128/JCM.40.3.979-983.2002
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
NR 24
TC 141
Z9 146
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD SEP
PY 2002
VL 40
IS 9
BP 3341
EP 3345
DI 10.1128/JCM.40.9.3341-3345.2002
PG 5
WC Microbiology
SC Microbiology
GA 590NX
UT WOS:000177829900037
PM 12202576
OA Green Published, Bronze
DA 2020-11-30
ER

PT J
AU Levi, JE
   Takaoka, DT
   Garrini, RH
   Fachini, RM
   Focaccia, R
   Santos, ED
   Mitre, HP
   de Mendonca, JS
   Cavalheiro, ND
   Barone, AA
   Wendel, S
AF Levi, JE
   Takaoka, DT
   Garrini, RH
   Fachini, RM
   Focaccia, R
   Santos, ED
   Mitre, HP
   de Mendonca, JS
   Cavalheiro, ND
   Barone, AA
   Wendel, S
TI Three cases of infection with hepatitis C virus genotype 5 among
   Brazilian hepatitis patients
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID HCV RNA; POOL
AB During the course of routine genotyping of hepatitis C virus isolates by 5' noncoding region sequencing, three samples were found to bear genotype 5-specific nucleotides. A serotyping method was subsequently applied and confirmed the finding. This is the first report of the occurrence of genotype 5 in Brazil.
C1 Ctr Imunol & Imunogenet, Mol Biol Lab, BR-01409001 Sao Paulo, Brazil.
   Inst Unfectol Emilio Ribas, Sao Paulo, Brazil.
   Hosp Serv Publ Estadual, Serv Molestias Infecciosas, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Dept Molesitas Infecciosas & Parasitarias, Lab Hepatites, Sao Paulo, Brazil.
   Hosp Sirio Libanes, Banco Sangue, Sao Paulo, Brazil.
RP Levi, JE (corresponding author), Ctr Imunol & Imunogenet, Mol Biol Lab, Rua Peixoto Gomide 515,12 Andar, BR-01409001 Sao Paulo, Brazil.
RI Barone, Antonio A/C-5531-2013; FOCACCIA, ROBERTO/I-3970-2013
OI Barone, Antonio A/0000-0001-9895-3886; 
CR Bassit L, 1999, HEPATOLOGY, V29, P994, DOI 10.1002/hep.510290313
   Bernier L, 1996, J CLIN MICROBIOL, V34, P2815, DOI 10.1128/JCM.34.11.2815-2818.1996
   Blatt LM, 2000, J VIRAL HEPATITIS, V7, P196
   Bukh J, 1998, J INFECT DIS, V178, P1193, DOI 10.1086/515683
   FOCACCIA R, 1998, BRAZ J INFECT DIS, V2, P269
   Kedda M A, 1997, Trop Gastroenterol, V18, P153
   KLETER GEM, 1994, J CLIN MICROBIOL, V32, P306, DOI 10.1128/JCM.32.2.306-310.1994
   McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101
   Murphy DG, 1996, J HEPATOL, V24, P109, DOI 10.1016/S0168-8278(96)80194-2
   SALDANHA J, 1994, J MED VIROL, V43, P72, DOI 10.1002/jmv.1890430114
   Shobokshi OA, 1999, J MED VIROL, V58, P44, DOI 10.1002/(SICI)1096-9071(199905)58:1&lt;44::AID-JMV6&gt;3.0.CO;2-U
   SMITH DB, 1995, J GEN VIROL, V76, P1749, DOI 10.1099/0022-1317-76-7-1749
   Thomas I, 2000, VOX SANG, V79, P69
NR 13
TC 29
Z9 29
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD JUL
PY 2002
VL 40
IS 7
BP 2645
EP 2647
DI 10.1128/JCM.40.7.2645-2647.2002
PG 3
WC Microbiology
SC Microbiology
GA 569MH
UT WOS:000176605800057
PM 12089297
OA Bronze, Green Published
DA 2020-11-30
ER

PT J
AU Da Silva, LVF
   Levi, JE
   Bento, CNO
   Rodrigues, JC
   Ramos, SRTD
AF Da Silva, LVF
   Levi, JE
   Bento, CNO
   Rodrigues, JC
   Ramos, SRTD
TI Molecular epidemiology of Pseudomonas aeruginosa infections in a cystic
   fibrosis outpatient clinic
SO JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Article
ID RESPIRATORY-TRACT BACTERIOLOGY; FIELD GEL-ELECTROPHORESIS; OROPHARYNGEAL
   CULTURES; BURKHOLDERIA-CEPACIA; CROSS-INFECTION; COLONIZATION; PCR;
   TRANSMISSION; CARE; AMPLIFICATION
AB Chronic respiratory infection by Pseudomonas aeruginosa is a significant determinant in the prognosis of cystic fibrosis patients. Cross-infection between cystic fibrosis patients and the prevalence of P. aeruginosa among them were investigated by microbiological surveillance and RAPD typing of the isolates. A total of 748 samples was cultured, including specimens from the respiratory tract (sputum or throat swabs) and hands of patients and medical staff, resulting in the collection of 86 isolates of P. aeruginosa from 65 samples. prevalence of P. aeruginosa was 39.3% in respiratory samples, 0.2% on patients' hands and none in the medical staff's hand samples, RAPD typing characterised 51 genotypes and clonal persistence was observed in the majority of patients, These results suggest that cross-infection is not common in the outpatient clinic studied and a common source of acquisition is unlikely.
C1 Univ Sao Paulo, Sch Med, Hosp Clin, Inst Crianca, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Inst Med Trop Sao Paulo, Virol Lab, Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Hosp Clin, Cent Lab,Microbiol Sect, Sao Paulo, Brazil.
RP Da Silva, LVF (corresponding author), Univ Sao Paulo, Sch Med, Hosp Clin, Inst Crianca, Sao Paulo, Brazil.
EM vicres@usp.br
RI da Silva Filho, Luiz Vicente R F/A-6957-2011; Silva Filho, Luiz
   Vicente/R-3984-2016
OI da Silva Filho, Luiz Vicente R F/0000-0001-8431-1997; 
CR Adams C, 1998, J INFECTION, V37, P151, DOI 10.1016/S0163-4453(98)80170-9
   Armstrong DS, 1996, PEDIATR PULM, V21, P267, DOI 10.1002/(SICI)1099-0496(199605)21:5<267::AID-PPUL1>3.3.CO;2-G
   Ballmann M, 1998, THORAX, V53, P732, DOI 10.1136/thx.53.9.732
   Cheng K, 1996, LANCET, V348, P639, DOI 10.1016/S0140-6736(96)05169-0
   Da Silva LVF, 1999, J MED MICROBIOL, V48, P357, DOI 10.1099/00222615-48-4-357
   Doring G, 1996, PEDIATR PULM, V21, P90, DOI 10.1002/(SICI)1099-0496(199602)21:2<90::AID-PPUL5>3.0.CO;2-T
   Frederiksen B, 1999, PEDIATR PULM, V28, P159, DOI 10.1002/(SICI)1099-0496(199909)28:3<159::AID-PPUL1>3.0.CO;2-1
   GOVAN JRW, 1993, LANCET, V342, P15, DOI 10.1016/0140-6736(93)91881-L
   Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996
   GROTHUES D, 1988, J CLIN MICROBIOL, V26, P1973, DOI 10.1128/JCM.26.10.1973-1977.1988
   HOIBY N, 1974, ACTA PATH MICRO IM B, VB 82, P541
   HOIBY N, 1982, ACTA PAEDIATR SC   S, V301, P33
   HOOGKAMPKORSTANJE JAA, 1995, J CLIN MICROBIOL, V33, P572, DOI 10.1128/JCM.33.3.572-575.1995
   IACOCCA VF, 1963, AM J DIS CHILD, V106, P315, DOI 10.1001/archpedi.1963.02080050317012
   Johansen HK, 1998, PEDIATR PULM, V26, P89, DOI 10.1002/(SICI)1099-0496(199808)26:2<89::AID-PPUL3>3.0.CO;2-C
   Karpati F, 1996, MOL CELL PROBE, V10, P397, DOI 10.1006/mcpr.1996.0055
   KELLY NM, 1982, LANCET, V2, P688
   KERR JR, 1995, J HOSP INFECT, V30, P125, DOI 10.1016/0195-6701(95)90152-3
   KERSULYTE D, 1995, J CLIN MICROBIOL, V33, P2216, DOI 10.1128/JCM.33.8.2216-2219.1995
   LIPUMA JJ, 1990, LANCET, V336, P1094, DOI 10.1016/0140-6736(90)92571-X
   Mahadeva R, 1998, BMJ-BRIT MED J, V316, P1771, DOI 10.1136/bmj.316.7147.1771
   Mahenthiralingam E, 1996, J CLIN MICROBIOL, V34, P1129, DOI 10.1128/JCM.34.5.1129-1135.1996
   Microbiology and Infectious Disease in Cystic Fibrosis, 1994, CONS C CONC CAR, VV
   National Cancer Institute, 1993, METH DIL ANT SUSC TE, P1
   OCALLAGHAN EM, 1994, J CLIN PATHOL, V47, P222, DOI 10.1136/jcp.47.3.222
   ORSI GB, 1994, J HOSP INFECT, V27, P49, DOI 10.1016/0195-6701(94)90068-X
   PEDERSEN SS, 1986, J ANTIMICROB CHEMOTH, V17, P505, DOI 10.1093/jac/17.4.505
   PEDERSEN SS, 1986, ACTA PAEDIATR SCAND, V75, P840, DOI 10.1111/j.1651-2227.1986.tb10299.x
   RAMSEY BW, 1991, AM REV RESPIR DIS, V144, P331, DOI 10.1164/ajrccm/144.2.331
   RAMSEY BW, 1994, J PEDIATR-US, V124, P177, DOI 10.1016/S0022-3476(94)70301-9
   ROMLING U, 1994, J INFECT DIS, V170, P1616, DOI 10.1093/infdis/170.6.1616
   Rosenfeld M, 1999, PEDIATR PULM, V28, P321, DOI 10.1002/(SICI)1099-0496(199911)28:5<321::AID-PPUL3>3.0.CO;2-V
   Saiman L, 1996, CLIN INFECT DIS, V23, P532, DOI 10.1093/clinids/23.3.532
   Sambrook J., 1989, MOL CLONING LAB MANU
   SEIBERT KM, 1998, PEDIATR PULM, V17, P306
   SPEERT D, 1994, J INFECT DIS, V169, P134
   SPEERT DP, 1987, J HOSP INFECT, V9, P11, DOI 10.1016/0195-6701(87)90089-2
   SPEERT DP, 1982, J PEDIATR-US, V101, P227, DOI 10.1016/S0022-3476(82)80127-3
   Spencer D, 1999, BRIT MED J, V318, P58
   Talon D, 1996, J HOSP INFECT, V32, P135, DOI 10.1016/S0195-6701(96)90055-9
   Thomassen M J, 1985, Pediatr Pulmonol, V1, P40, DOI 10.1002/ppul.1950010110
   TUMMLER B, 1991, J CLIN MICROBIOL, V29, P1265
   Tyler KD, 1997, J CLIN MICROBIOL, V35, P339, DOI 10.1128/JCM.35.2.339-346.1997
   VALERIUS NH, 1991, LANCET, V338, P725, DOI 10.1016/0140-6736(91)91446-2
   VAZQUEZ C, 1993, ACTA PAEDIATR, V82, P308, DOI 10.1111/j.1651-2227.1993.tb12668.x
   WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213
   ZACH MS, 1990, PEDIATR PULM, V8, P188, DOI 10.1002/ppul.1950080311
   ZEMBRZUSKASADKOWSKA E, 1995, J HOSP INFECT, V29, P1, DOI 10.1016/0195-6701(95)90288-0
NR 48
TC 15
Z9 15
U1 0
U2 1
PU MICROBIOLOGY SOC
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER ST, LONDON WC1N 2JU, ERKS, ENGLAND
SN 0022-2615
EI 1473-5644
J9 J MED MICROBIOL
JI J. Med. Microbiol.
PD MAR
PY 2001
VL 50
IS 3
BP 261
EP 267
DI 10.1099/0022-1317-50-3-261
PG 9
WC Microbiology
SC Microbiology
GA 403MM
UT WOS:000167047100011
PM 11232773
OA Bronze
DA 2020-11-30
ER

PT J
AU Wendel, S
   Fachini, RM
   Levi, JE
   Ghaname, J
   Di Pietro, A
   Mendonca, MC
   Almeida, C
   Foschi, NM
   Braga, M
AF Wendel, S
   Fachini, RM
   Levi, JE
   Ghaname, J
   Di Pietro, A
   Mendonca, MC
   Almeida, C
   Foschi, NM
   Braga, M
TI A single window period donation detected by HIV p24Ag in Brazil after 3
   years of routine screening
SO TRANSFUSION
LA English
DT Meeting Abstract
C1 Sirio Libanes Hosp, Blood Bank, Sao Paulo, Brazil.
   Nove Julho Hosp, Blood Bank, Sao Paulo, Brazil.
   Vita Hosp, Blood Bank, Curitiba, Parana, Brazil.
   Cruz Azul Hosp, Sao Paulo, Brazil.
RI DE ALMEIDA, CARLOS CAETANO/K-4265-2016; Wendel, S/AAQ-9048-2020
OI DE ALMEIDA, CARLOS CAETANO/0000-0002-3215-5731; 
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC BLOOD BANKS
PI BETHESDA
PA 8101 GLENBROOK RD, BETHESDA, MD 20814-2749 USA
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD OCT
PY 2000
VL 40
IS 10
SU S
BP 85S
EP 85S
PG 1
WC Hematology
SC Hematology
GA 364CN
UT WOS:000089874600347
DA 2020-11-30
ER

PT J
AU Da Silva, LVF
   Levi, JE
   Bento, CNO
   Ramos, SRTD
   Rozov, T
AF Da Silva, LVF
   Levi, JE
   Bento, CNO
   Ramos, SRTD
   Rozov, T
TI PCR identification of Pseudomonas aeruginosa and direct detection in
   clinical samples from cystic fibrosis patients
SO JOURNAL OF MEDICAL MICROBIOLOGY
LA English
DT Article
ID BURKHOLDERIA-CEPACIA; COLONIZATION; INFECTION
AB This report describes a PCR primer pair that targets the algD GDP mannose gene of Pseudomonas aeruginosa and produces a specific 520-bp PCR product useful for P. aeruginosa identification. This PCR assay was tested with 182 isolates of I! aeruginosa and 20 isolates of other bacterial species, and demonstrated 100% specificity and sensitivity. The test was also able to detect I! aeruginosa directly in clinical samples such as sputum or throat swabs obtained from cystic fibrosis patients. The combination of this primer with a universal bacterial primer, acting as a control to assess DNA quality in the sample, resulted in a robust PCR method that can be used for rapid P. aeruginosa detection.
C1 Univ Sao Paulo, Sch Med, Hosp Clin, Inst Crianca, BR-05403900 Sao Paulo, Brazil.
   FMUSP, Hosp Clin, Cent Lab, Microbiol Sect, Sao Paulo, Brazil.
RP Da Silva, LVF (corresponding author), Univ Sao Paulo, Sch Med, Hosp Clin, Inst Crianca, Av Dr Eneas Carvalho de Aguiar,647 Cerqueira Cesa, BR-05403900 Sao Paulo, Brazil.
RI da Silva Filho, Luiz Vicente R F/A-6957-2011
OI da Silva Filho, Luiz Vicente R F/0000-0001-8431-1997
CR CAMPBELL PW, 1995, PEDIATR PULM, V20, P44, DOI 10.1002/ppul.1950200109
   DERETIC V, 1987, NUCLEIC ACIDS RES, V15, P4567, DOI 10.1093/nar/15.11.4567
   DeVos D, 1997, J CLIN MICROBIOL, V35, P1295, DOI 10.1128/JCM.35.6.1295-1299.1997
   Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996
   HOIBY N, 1982, ACTA PAEDIATR SC   S, V301, P33
   HOLLOWAY BW, 1990, BACTERIAL CHROMOSOME, P97
   MCINTOSH I, 1992, MOL CELL PROBE, V6, P299, DOI 10.1016/0890-8508(92)90005-I
   OCALLAGHAN EM, 1994, J CLIN PATHOL, V47, P222, DOI 10.1136/jcp.47.3.222
   PEDERSEN SS, 1992, THORAX, V47, P6, DOI 10.1136/thx.47.1.6
   PEDERSEN SS, 1992, APMIS S28, V100, P21
   Relman David A., 1993, P489
   Sambrook J, 1989, MOL CLONING LAB MANU
   SHAK S, 1995, CHEST S, V107, P65
   VALERIUS NH, 1991, LANCET, V338, P725, DOI 10.1016/0140-6736(91)91446-2
   VAZQUEZ C, 1993, ACTA PAEDIATR, V82, P308, DOI 10.1111/j.1651-2227.1993.tb12668.x
   WOOD RE, 1976, AM REV RESPIR DIS, V113, P833
   ZACH MS, 1990, PEDIATR PULM, V8, P188, DOI 10.1002/ppul.1950080311
NR 17
TC 41
Z9 42
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-2615
J9 J MED MICROBIOL
JI J. Med. Microbiol.
PD APR
PY 1999
VL 48
IS 4
BP 357
EP 361
DI 10.1099/00222615-48-4-357
PG 5
WC Microbiology
SC Microbiology
GA 237DL
UT WOS:000082640000006
PM 10509477
OA Bronze
DA 2020-11-30
ER

PT J
AU Wendel, S
   Fachini, RM
   Oliveira, LC
   Levi, JE
   Lima, LP
   Hamada, GS
   Ghaname, J
   Braga, M
   Paula, G
   DiPietro, A
AF Wendel, S
   Fachini, RM
   Oliveira, LC
   Levi, JE
   Lima, LP
   Hamada, GS
   Ghaname, J
   Braga, M
   Paula, G
   DiPietro, A
TI Blood donor screening with p24 antigen (Ag) in Brazilian blood banks.
SO TRANSFUSION
LA English
DT Meeting Abstract
C1 Hosp Sirio Libanes, Sao Paulo, Brazil.
RI Wendel, S/AAQ-9048-2020
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC BLOOD BANKS
PI BETHESDA
PA 8101 GLENBROOK RD, BETHESDA, MD 20814-2749 USA
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD OCT
PY 1998
VL 38
IS 10
SU S
MA S196
BP 54S
EP 54S
PG 1
WC Hematology
SC Hematology
GA 124FM
UT WOS:000076171800216
DA 2020-11-30
ER

PT J
AU Levi, JE
   Contri, DG
   Takaoka, DT
   Fachini, R
   Wendel, S
AF Levi, JE
   Contri, DG
   Takaoka, DT
   Fachini, R
   Wendel, S
TI PCR as a tool for primary screening of blood donors.
SO TRANSFUSION
LA English
DT Meeting Abstract
C1 Hosp Sirio Libanes, Blood Bank, Sao Paulo, Brazil.
   Ctr Imunol & Imunogenet, Div Mol Biol, Sao Paulo, Brazil.
RI Wendel, S/AAQ-9048-2020
NR 0
TC 0
Z9 2
U1 0
U2 0
PU AMER ASSOC BLOOD BANKS
PI BETHESDA
PA 8101 GLENBROOK RD, BETHESDA, MD 20814-2749 USA
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD OCT
PY 1998
VL 38
IS 10
SU S
MA S207
BP 57S
EP 57S
PG 1
WC Hematology
SC Hematology
GA 124FM
UT WOS:000076171800227
DA 2020-11-30
ER

PT J
AU Levi, JE
   Rahal, P
   Sarkis, AS
   Villa, LL
AF Levi, JE
   Rahal, P
   Sarkis, AS
   Villa, LL
TI Human papillomavirus DNA and p53 status in penile carcinomas
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; CERVICAL-CARCINOMA; PROTEIN; CANCER; GENE;
   MUTATIONS; PREVALENCE; INFECTION; TYPE-18; ASSOCIATION
AB Our study aimed at evaluating the presence of human papillomavirus (HPV) DNA in a series of 84 paraffin-embedded (PET) penile carcinomas. We have also investigated the presence of p53 mutations in these tumors by immunohistochemistry (IHC), single-stranded conformational polymorphism (SSCP) and DNA sequencing. Tissues weve submitted to amplification of a 268 bp fragment from the beta-globin gene and a fragment of the E6 gene of HPV types 6, 11, 16 and is. Twenty samples (18 fixed in Bouin's solution and 2 in buffered formalin) were found inadequate and were excluded from the analysis. In the remaining 64 tumors, HPV DNA was found in 26% of the samples. The prevalence of HPV in fresh samples of the same tumors was 56%. The most prevalent type was HPV 16 in both fresh samples and PET. Isotopic in situ hybridization was performed in ail PET samples, but only 2 cases were positive, I for HPV 16 and I for HPV 18. Immunohistochemistry with anti-p53 pAb1801 antibody showed a positive nuclear reaction over more than 5% of tumor cells in 26% of the cases. SSCP of exons 5-8 of the p53 gene was performed on 9 HPV-positive and 12 HPV-negative specimens. Abnormal mobility was found in 26% of the tumors, of which 2 were HPV positive and 5 HPV negative. Point mutations were detected in p53 exons 6 (1 case), 7 (1 case) and 8 (5 cases), showing that high-risk type HPVs and mutated p53 may coexist in these tumors. Our data indicate that a subset of penile carcinomas ave etiologically related to HPV and that an overlapping subset may arise from mutational events in the p53 gene. (C) 1998 Wiley-Liss, Inc.
C1 Inst Ludwig de Pesquisa Canc, BR-01509010 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Surg, Div Urol, Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Quim, Dept Biochem, Sao Paulo, Brazil.
RP Villa, LL (corresponding author), Inst Ludwig de Pesquisa Canc, Rua Prof Antonio Prudente 109-4O Andar, BR-01509010 Sao Paulo, Brazil.
EM Ludwig2@eu.ansp.br
RI Rahal, Paula/D-3871-2012; VILLA, LUISA/AAH-4761-2019
OI Rahal, Paula/0000-0001-5693-6148; VILLA, LUISA/0000-0003-4074-2335
CR Baay MFD, 1996, J CLIN MICROBIOL, V34, P745, DOI 10.1128/JCM.34.3.745-747.1996
   BORRESEN AL, 1992, LANCET, V339, P1350
   BUTZ K, 1995, ONCOGENE, V10, P927
   CHAN KW, 1994, J CLIN PATHOL, V47, P823, DOI 10.1136/jcp.47.9.823
   CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549
   CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M
   FUJITA M, 1992, CANCER RES, V52, P5323
   GRAHAM S, 1979, CANCER, V44, P1870, DOI 10.1002/1097-0142(197911)44:5<1870::AID-CNCR2820440546>3.0.CO;2-E
   GREGOIRE L, 1995, J NATL CANCER I, V87, P1705, DOI 10.1093/jnci/87.22.1705
   HELLAND A, 1993, J PATHOL, V171, P105, DOI 10.1002/path.1711710207
   HIGGINS GD, 1992, AM J CLIN PATHOL, V97, P272, DOI 10.1093/ajcp/97.2.272
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141
   IARC, 1995, MON EV CARC RISKS HU, V64
   Lam K Y, 1995, Eur J Surg Oncol, V21, P613, DOI 10.1016/S0748-7983(95)95262-4
   LEVI JE, 1989, AM J PATHOL, V135, P1179
   Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804
   MADEN C, 1993, JNCI-J NATL CANCER I, V85, P19, DOI 10.1093/jnci/85.1.19
   MANOS MM, 1989, CANCER CEL, V7, P209
   MCCANCE DJ, 1986, INT J CANCER, V37, P55, DOI 10.1002/ijc.2910370110
   PAQUETTE RL, 1993, CANCER-AM CANCER SOC, V72, P1272, DOI 10.1002/1097-0142(19930815)72:4<1272::AID-CNCR2820720420>3.0.CO;2-Q
   PARK DJ, 1994, ONCOGENE, V9, P205
   Parkin D, 1992, IARC SCI PUBLICATION, VVI
   SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0
   SARKAR FH, 1992, J UROLOGY, V147, P389, DOI 10.1016/S0022-5347(17)37245-2
   SUZUKI H, 1994, JPN J CLIN ONCOL, V24, P1
   TERVAHAUTA AI, 1994, CYTOPATHOLOGY, V5, P282, DOI 10.1111/j.1365-2303.1994.tb00432.x
   TORNESELLO ML, 1992, INT J CANCER, V51, P587, DOI 10.1002/ijc.2910510414
   Villa LL, 1997, NEW DEVELOPMENTS IN CERVICAL CANCER SCREENING AND PREVENTION, P379
   VILLA LL, 1986, INT J CANCER, V37, P853, DOI 10.1002/ijc.2910370610
   WIENER JS, 1992, INT J CANCER, V50, P694, DOI 10.1002/ijc.2910500505
NR 31
TC 50
Z9 51
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD JUN 10
PY 1998
VL 76
IS 6
BP 779
EP 783
DI 10.1002/(SICI)1097-0215(19980610)76:6<779::AID-IJC1>3.0.CO;2-V
PG 5
WC Oncology
SC Oncology
GA ZR537
UT WOS:000073987500001
PM 9626339
OA Bronze
DA 2020-11-30
ER

PT J
AU Wendel, S
   Fachini, R
   Campos, LC
   Levi, JE
   Hamada, G
   Lima, LP
AF Wendel, S
   Fachini, R
   Campos, LC
   Levi, JE
   Hamada, G
   Lima, LP
TI HCV ELISA donor screening tests performance from seven different kits.
SO TRANSFUSION
LA English
DT Meeting Abstract
C1 HOSP SIRIO LIBANES,BLOOD BANK,SAO PAULO,BRAZIL.
RI Wendel, S/AAQ-9048-2020
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC BLOOD BANKS
PI BETHESDA
PA 8101 GLENBROOK RD, BETHESDA, MD 20814-2749
SN 0041-1132
J9 TRANSFUSION
JI Transfusion
PD SEP
PY 1997
VL 37
IS 9
SU S
BP S201
EP S201
PG 1
WC Hematology
SC Hematology
GA XW275
UT WOS:A1997XW27500201
DA 2020-11-30
ER

PT J
AU VILLA, LL
   CABALLERO, OL
   LEVI, JE
   PENA, SDJ
   SIMPSON, AJG
AF VILLA, LL
   CABALLERO, OL
   LEVI, JE
   PENA, SDJ
   SIMPSON, AJG
TI AN APPROACH TO HUMAN PAPILLOMAVIRUS IDENTIFICATION USING LOW STRINGENCY
   SINGLE SPECIFIC PRIMER PCR
SO MOLECULAR AND CELLULAR PROBES
LA English
DT Article
DE GENITAL HUMAN PAPILLOMAVIRUS (HPV); LOW STRINGENCY SINGLE SPECIFIC
   PRIMER-PCR (LSSP-PCR)
ID TYPE-16; VARIANTS; SPREAD
AB A new PCR-based technique, low stringency single specific primer-PCR (LSSP-PCR), has been adapted to produce gene signatures capable of distinguishing human papillomaviruses (HPVs) in clinical specimens. This approach potentially offers a sensitive, inexpensive and high-throughput methodology for precise clinical diagnosis of HPV infections.
C1 FDN OSWALDO CRUZ, CTR PESQUISAS RENE RACHOU, BR-31090002 BELO HORIZONTE, MG, BRAZIL.
   GENE MG, BR-30130909 BELO HORIZONTE, MG, BRAZIL.
RP VILLA, LL (corresponding author), LUDWIG INST CANC RES, R PROF ANTONIO PRUDENTE 109-4TH FLOOR, BR-01509010 SAO PAULO, BRAZIL.
RI VILLA, LUISA/AAH-4761-2019
OI VILLA, LUISA/0000-0003-4074-2335
CR BERNARD HU, 1994, J INFECT DIS, V170, P1077, DOI 10.1093/infdis/170.5.1077
   CHAN SY, 1992, J VIROL, V66, P2057, DOI 10.1128/JVI.66.4.2057-2066.1992
   DEVILLIERS EM, 1989, J VIROL, V63, P4898, DOI 10.1128/JVI.63.11.4898-4903.1989
   GRAVITT PE, 1992, IARC SCI PUBL, V119, P111
   HAUSEN HZ, 1989, CANCER RES, V49, P4677
   HO L, 1991, J CLIN MICROBIOL, V29, P1765, DOI 10.1128/JCM.29.9.1765-1772.1991
   HO L, 1993, J VIROL, V67, P6413, DOI 10.1128/JVI.67.11.6413-6423.1993
   LONG FX, 1993, J INFECT DIS, V168, P610, DOI 10.1093/infdis/168.3.610
   MANOS MM, 1989, CANCER CEL, V7, P209
   PENA SDJ, 1994, P NATL ACAD SCI USA, V91, P1946, DOI 10.1073/pnas.91.5.1946
   RADY PL, 1993, J VIROL METHODS, V43, P335, DOI 10.1016/0166-0934(93)90151-G
NR 11
TC 12
Z9 14
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0890-8508
J9 MOL CELL PROBE
JI Mol. Cell. Probes
PD FEB
PY 1995
VL 9
IS 1
BP 45
EP 48
DI 10.1016/S0890-8508(95)90992-3
PG 4
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biotechnology & Applied Microbiology; Cell Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Cell Biology
GA QJ528
UT WOS:A1995QJ52800007
PM 7760859
DA 2020-11-30
ER

PT J
AU PASQUALINI, R
   LEVI, JE
   AZUL, MIS
   FARIA, M
   DESOUZA, SJ
   BRENTANI, R
AF PASQUALINI, R
   LEVI, JE
   AZUL, MIS
   FARIA, M
   DESOUZA, SJ
   BRENTANI, R
TI A MONOCLONAL-ANTIBODY (IID510G52) FOR THE DETERMINATION OF FUNCTIONAL
   DOMAINS WITHIN INTEGRIN CELL-SURFACE RECEPTORS
SO HYBRIDOMA
LA English
DT Article
ID IIB-IIIA COMPLEX; PLATELET GLYCOPROTEIN-IIB; FIBRONECTIN RECEPTOR;
   EXTRACELLULAR-MATRIX; CYTOPLASMIC DOMAIN; BETA-SUBUNIT; BINDING-SITE;
   GPIIB-IIIA; ALPHA-V; ADHESION
AB Monoclonal antibodies against cell surface receptors can be useful for the study of structural and biochemical features involved in protein interactions underlying platelet adhesion and aggregation. We report here the characterization of a monoclonal antibody, IID510g52 (hereafter referred to as IID5), which has been selected based on its specific binding properties against the platelet membrane glycoprotein IIIa. Characterization of the reactive epitope, including evolutionary conservation and identification of related IID5 target antigens in tumor cells, suggest that the IID5 epitope is implicated in the ligand-binding function of integrin receptors. Indeed, we show that this MoAb acts as a potent inhibitor of platelet aggregation and cell adhesion. Taken together, these results indicate that such a monoclonal may bc a strategic tool for better understanding multiple integrin-mediated adhesive reactions, as well as the determination of interacting recognition sites.
C1 UNIV SAO PAULO, HOSP CLIN, INST CORACAO, SAO PAULO, BRAZIL.
   LUDWIG INST CANC RES, SAO PAULO, BRAZIL.
RI de Souza, Sandro Jose/AAG-6270-2020
CR ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175
   BEER J, 1989, J BIOL CHEM, V264, P17564
   BOBBIT JM, 1987, ADV CARBOHYD CHEM, V11, P1
   BROWER DL, 1989, NATURE, V342, P285, DOI 10.1038/342285a0
   BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785
   BUCK CA, 1987, ANNU REV CELL BIOL, V3, P179, DOI 10.1146/annurev.cellbio.3.1.179
   CHARO IF, 1986, P NATL ACAD SCI USA, V83, P8351, DOI 10.1073/pnas.83.21.8351
   CHARONIS AS, 1985, J CELL BIOL, V100, P1848, DOI 10.1083/jcb.100.6.1848
   CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4
   CUMMINGS RD, 1989, METHOD CELL BIOL, V32, P141
   DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922
   DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B
   DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0
   ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102
   FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x
   FRELINGER AL, 1990, J BIOL CHEM, V265, P6346
   GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1
   GINSBERG MH, 1987, J BIOL CHEM, V262, P5437
   GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1
   HEMLER ME, 1987, J BIOL CHEM, V262, P3300
   HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053
   HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0
   HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9
   HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369
   KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x
   KARCZEWSKI J, 1989, J BIOL CHEM, V264, P21322
   LAM SCT, 1987, J BIOL CHEM, V262, P947
   LAWLER J, 1989, BLOOD, V74, P2022
   MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765
   MCEVER RP, 1983, J BIOL CHEM, V258, P5269
   MCGREGOR JL, 1983, EUR J BIOCHEM, V131, P427, DOI 10.1111/j.1432-1033.1983.tb07281.x
   MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364
   MISHELL BB, 1980, SELECTED METHODS CEL, P351
   NURDEN AT, 1987, THROMBOSIS HAEMOSTAS
   PARISE LV, 1986, J BIOL CHEM, V261, P14011
   PASQUALINI R, 1989, J BIOL CHEM, V264, P14566
   PHILLIPS DR, 1988, BLOOD, V71, P831
   PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002
   PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8
   RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119
   RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619
   SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3
   SCHLAGE WK, 1988, EUR J CELL BIOL, V47, P395
   SINAKOS Z, 1967, THROMB DIATH HAEMOST, V17, P99, DOI 10.1055/s-0038-1654085
   SOLOWSKA J, 1991, J CELL BIOL, V114, P1079, DOI 10.1083/jcb.114.5.1079
   TAKUN JW, 1986, CELL, V42, P271
   VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415
   WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881
   WOODWARD MP, 1985, J IMMUNOL METHODS, V78, P143, DOI 10.1016/0022-1759(85)90337-0
   YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040
NR 50
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1554-0014
EI 1557-8348
J9 HYBRIDOMA
JI Hybridoma
PD DEC
PY 1992
VL 11
IS 6
BP 741
EP 755
DI 10.1089/hyb.1992.11.741
PG 15
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Immunology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Immunology
GA KD722
UT WOS:A1992KD72200006
PM 1284122
DA 2020-11-30
ER

PT J
AU LEVI, JE
   DELCELO, R
   ALBERTI, VN
   TORLONI, H
   VILLA, LL
AF LEVI, JE
   DELCELO, R
   ALBERTI, VN
   TORLONI, H
   VILLA, LL
TI HUMAN PAPILLOMAVIRUS DNA IN RESPIRATORY PAPILLOMATOSIS DETECTED BY
   INSITU HYBRIDIZATION AND THE POLYMERASE CHAIN-REACTION
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
C1 LUDWIG INST CANC RES,DEPT VIROL,SAO PAULO BRANCH,R PROF ANTONIO PRUDENTE 109,4 ANDAR,BR-01509 SAO PAULO,BRAZIL.
   ESCOLA PAULISTA MED SCH,DEPT PATHOL,BR-04023 SAO PAULO,SP,BRAZIL.
CR BRANDSMA JL, 1986, CANCER RES, V46, P2185
   BURNS J, 1987, J CLIN PATHOL, V40, P858, DOI 10.1136/jcp.40.8.858
   BYRNE JC, 1987, NEW ENGL J MED, V317, P873, DOI 10.1056/NEJM198710013171406
   COSTA J, 1981, AM J CLIN PATHOL, V75, P194
   GISSMANN L, 1983, P NATL ACAD SCI-BIOL, V80, P560, DOI 10.1073/pnas.80.2.560
   GUPTA J, 1987, AM J PATHOL, V127, P206
   KASHIMA H, 1986, ANN OTO RHINOL LARYN, V95, P603, DOI 10.1177/000348948609500613
   KASHIMA H, 1988, LARYNGOSCOPE, V98, P619
   KASHIMA H, 1987, PAPILLOMAVIRUSES HUM, P138
   MANOS MM, 1989, CANCER CEL, V7, P209
   MOUNTS P, 1982, P NATL ACAD SCI-BIOL, V79, P5425, DOI 10.1073/pnas.79.17.5425
   MOUNTS P, 1984, PROG MED VIROL, V29, P90
   SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225
   Steinberg B M, 1985, Clin Dermatol, V3, P130, DOI 10.1016/0738-081X(85)90057-4
   STEINBERG BM, 1987, CANCER CELLS PAPILLO, V5, P403
   TERRY RM, 1987, J PATHOL, V153, P245, DOI 10.1002/path.1711530308
   TSUTSUMI K, 1989, LARYNGOSCOPE, V99, P80
   WARD P, 1988, J GEN VIROL, V69, P1671, DOI 10.1099/0022-1317-69-7-1671
   WINDER EL, 1976, CANCER, V38, P1591
NR 19
TC 46
Z9 46
U1 0
U2 0
PU AMER SOC INVESTIGATIVE PATHOLOGY, INC
PI BALTIMORE
PA 428 EAST PRESTON ST, BALTIMORE, MD 21202-3993
SN 0002-9440
J9 AM J PATHOL
JI Am. J. Pathol.
PD DEC
PY 1989
VL 135
IS 6
BP 1179
EP 1184
PG 6
WC Pathology
SC Pathology
GA CE323
UT WOS:A1989CE32300022
PM 2556927
DA 2020-11-30
ER

PT J
AU JUNQUEIRA, LCU
   KAMINSKAS, R
   LEVI, JE
   JOAZEIRO, PP
   MONTES, GS
AF JUNQUEIRA, LCU
   KAMINSKAS, R
   LEVI, JE
   JOAZEIRO, PP
   MONTES, GS
TI MORPHOLOGIC EVIDENCE THAT DISRUPTION OF THE GOLGI-APPARATUS IN PFHR
   9-TUMOR CELLS CAUSES DISTURBANCE IN THE TRAFFIC THROUGH THIS ORGANELLE
SO JOURNAL OF SUBMICROSCOPIC CYTOLOGY AND PATHOLOGY
LA English
DT Article
C1 ADOLFO LUTZ INST,SAO PAULO,BRAZIL.
   UNIV SAO PAULO,INST BIOMED SCI,DEPT HISTOL & EMBRYOL,BR-05508 SAO PAULO,BRAZIL.
RP JUNQUEIRA, LCU (corresponding author), LUDWIG INST CANC RES,SAO PAULO,BRAZIL.
RI JOAZEIRO, PAULO/C-6733-2014
CR CECCHELLI R, 1986, BIOSCIENCE REP, V6, P227, DOI 10.1007/BF01115011
   CHUNG AE, 1977, CANCER RES, V37, P2072
   ENGVALL E, 1984, EXP CELL RES, V150, P258, DOI 10.1016/0014-4827(84)90721-3
   FARQUHAR MG, 1981, J CELL BIOL, V91, pS77, DOI 10.1083/jcb.91.3.77s
   FRIEND DS, 1969, J CELL BIOL, V41, P269, DOI 10.1083/jcb.41.1.269
   GHADIALLY FN, 1982, ULTRASTRUCTURAL PATH, P276
   JUNQUEIRA LCU, 1984, J SUBMICR CYTOL PATH, V16, P643
   ROTHMAN JE, 1985, SCI AM, V253, P84
   TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6
   TARTAKOFF AM, 1983, INT REV CYTOL, V85, P221, DOI 10.1016/S0074-7696(08)62374-8
   Weibel E R, 1969, Int Rev Cytol, V26, P235, DOI 10.1016/S0074-7696(08)61637-X
NR 11
TC 2
Z9 2
U1 0
U2 0
PU EDITRICE COMPOSITORI BOLOGNA
PI BOLOGNA
PA VIA STALINGRADO 97/2, I-40128 BOLOGNA, ITALY
SN 1122-9497
J9 J SUBMICR CYTOL PATH
JI J. Submicrosc. Cytol. Pathol.
PD APR
PY 1988
VL 20
IS 2
BP 263
EP 268
PG 6
WC Pathology
SC Pathology
GA N1891
UT WOS:A1988N189100002
PM 3395965
DA 2020-11-30
ER

PT J
AU LEWISON, EF
   LEVI, JE
   JONES, GS
   JONES, HW
   SILBERSTEIN, HE
AF LEWISON, EF
   LEVI, JE
   JONES, GS
   JONES, HW
   SILBERSTEIN, HE
TI TRACER STUDIES OF RADIOACTIVE SODIUM ESTRONE SULFATE (S-35) IN CASES OF
   ADVANCED BREAST CANCER
SO CANCER
LA English
DT Article
CR ALBERT S, 1949, J BIOL CHEM, V177, P247
   Beatson G., 1896, LANCET, V148, P162, DOI DOI 10.1016/S0140-6736(01)72384-7
   Beatson G., 1896, LANCET, V148, P104, DOI [DOI 10.1016/S0140-6736(01)72307-0, 10.1016/s0140-6736(01)72307-0]
   BERGER M, CITED INDIRECTLY
   BISCHOFF F, 1947, AM J PHYSIOL, V150, P444
   Borsook H, 1937, SCIENCE, V86, P525, DOI 10.1126/science.86.2240.525
   BOYD S, 1900, BMJ-BRIT MED J, V2, P1161
   DAVIS ME, 1950, P SOC EXP BIOL MED, V74, P501
   DZIEWIATKOWSKI DD, 1949, J BIOL CHEM, V178, P197
   HEARD RDH, 1949, RECENT PROG HORM RES, V4, P43
   HEARD RDH, 1949, RECENT PROGR HORMONE, V4, P55
   HENRIQUES FC, 1946, IND ENG CHEM, V18, P349
   LIPSCHUTZ A, 1950, STEROID HORMONES TUM
   MYERS WG, 1950, CANCER RES, V10, P234
   Pirie NW, 1932, BIOCHEM J, V26, P2041, DOI 10.1042/bj0262041
   PULLINGER BD, 1949, LANCET, V257, P823
   SINGHER HO, 1945, SCIENCE, V101, P414, DOI 10.1126/science.101.2625.414
   TWOMBLY GH, 1950, CANCER, V3, P601, DOI 10.1002/1097-0142(1950)3:4<601::AID-CNCR2820030405>3.0.CO;2-Y
   TWOMBLY GH, 1948, AM J OBSTET GYNECOL, V56, P260, DOI 10.1016/0002-9378(48)90268-3
   WALPOLE AL, 1949, LANCET, V257, P783
NR 20
TC 18
Z9 18
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PY 1951
VL 4
IS 3
BP 537
EP 548
DI 10.1002/1097-0142(195105)4:3<537::AID-CNCR2820040307>3.0.CO;2-T
PG 12
WC Oncology
SC Oncology
GA UN996
UT WOS:A1951UN99600005
PM 14839610
OA Bronze
DA 2020-11-30
ER

PT J
AU LEWISON, EF
   JONES, GS
   JONES, HW
   LEVI, JE
   SILBERSTEIN, HE
AF LEWISON, EF
   JONES, GS
   JONES, HW
   LEVI, JE
   SILBERSTEIN, HE
TI TRACER STUDIES OF RADIOACTIVE SODIUM ESTRONE SULFATE (S-35) IN CASES OF
   ADVANCED BREAST CANCER
SO CANCER RESEARCH
LA English
DT Meeting Abstract
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI BIRMINGHAM
PA PO BOX 11806, BIRMINGHAM, AL 35202
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PY 1951
VL 11
IS 4
BP 266
EP 267
PG 2
WC Oncology
SC Oncology
GA UF402
UT WOS:A1951UF40200099
DA 2020-11-30
ER

PT J
AU LEVI, JE
   LEWISON, EF
AF LEVI, JE
   LEWISON, EF
TI VENOUS VELOCITY IN THE LEG MEASURED WITH RADIOACTIVE SODIUM
SO BULLETIN OF THE JOHNS HOPKINS HOSPITAL
LA English
DT Article
CR AEBERSOLD PC, 1948, JUN AM MED ASS M CHI
   ALLEN AW, 1949, SURGERY, V26, P1
   Aschoff L, 1913, ARCH INTERN MED, V12, P503
   ASCHOFF L, 1892, VIRCHOWS ARCH PATH A, V130, P93
   Belt TH, 1934, AM J PATHOL, V10, P129
   Blumgart HL, 1927, J CLIN INVEST, V4, P15, DOI 10.1172/JCI100110
   Blumgart HL, 1927, J CLIN INVEST, V4, P149, DOI 10.1172/JCI100116
   Blumgart HL, 1927, J CLIN INVEST, V4, P199, DOI 10.1172/JCI100118
   CARLOTTI J, 1947, AM HEART J, V33, P737
   HOMANS J, 1947, NEW ENGL J MED, V236, P196, DOI 10.1056/NEJM194702062360602
   Kvale WF, 1940, ARCH SURG-CHICAGO, V40, P344, DOI 10.1001/archsurg.1940.04240010184013
   LAWRENCE JH, 1947, JAMA-J AM MED ASSOC, V134, P219, DOI 10.1001/jama.1947.02880200001001
   MARINELLI LD, 1948, AM J ROENTGENOL, V59, P260
   MENEELY GR, 1947, AM J MED SCI, V214, P176, DOI 10.1097/00000441-194708000-00012
   MOORE FD, 1948, SURG GYNECOL OBSTET, V86, P129
   OCHSNER A, 1949, JAMA-J AM MED ASSOC, V139, P423, DOI 10.1001/jama.1949.02900240001001
   Patey DH, 1930, BRIT J SURG, V17, P487, DOI 10.1002/bjs.1800176714
   QUIMBY EH, 1947, AM J ROENTGENOL, V58, P741
   SMITH LA, 1941, P STAFF M MAYO CLIN, V16, P53
   Spier LC, 1936, AM HEART J, V12, P511, DOI 10.1016/S0002-8703(36)90817-7
   VIRCHOW R, 1856, GESEMMELTE ABHANDL F
   VIRCHOW R, 1856, ARCH PATH BERLIN
   WARREN S, 1948, NEW ENGL J MED, V239, P763, DOI 10.1056/NEJM194811182392101
   WELCH WH, 1899, THROMBOSIS EMBOLISM, P155
   WELCH WH, 1909, SYSTEM MED, V6, P691
   WRIGHT HP, 1948, LANCET, V252, P767, DOI 10.1016/S0140-6736(48)91332-4
   WRIGHT HP, 1949, BRIT J RADIOLOGY, V22
NR 27
TC 3
Z9 3
U1 0
U2 0
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
   21218-4363 USA
J9 B JOHNS HOPKINS HOSP
JI Bull. Johns Hopkins. Hosp.
PY 1950
VL 86
IS 6
BP 370
EP 382
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA UL461
UT WOS:A1950UL46100003
PM 15420549
DA 2020-11-30
ER

PT J
AU LEWISON, EF
   JONES, GS
   LEVI, JE
   JONES, HW
   SILBERSTEIN, H
AF LEWISON, EF
   JONES, GS
   LEVI, JE
   JONES, HW
   SILBERSTEIN, H
TI TRACER STUDIES OF RADIOACTIVE SODIUM ESTRONE SULFATE IN CASES OF
   ADVANCED BREAST CANCER
SO SURGICAL FORUM
LA English
DT Meeting Abstract
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER COLL SURGEONS
PI CHICAGO
PA 633 N SAINT CLAIR ST, CHICAGO, IL 60611-3211
SN 0071-8041
J9 SURG FORUM
JI Surg. Forum
PY 1950
VL 1
BP 578
EP 578
PG 1
WC Surgery
SC Surgery
GA XT827
UT WOS:A1950XT82700151
DA 2020-11-30
ER

EF